0	They developed ENTD nephrotic syndrome ENTDEND and finally renal failure. The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, ENTC PS ENTCEND alone or saline injected
1	They developed ENTD nephrotic syndrome ENTDEND  and finally renal failure. The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, ENTC AMNS ENTCEND alone, PS alone or saline injected
0	They developed ENTD nephrotic syndrome ENTDEND  and finally renal failure. The time-course curve of ENTC creatinine ENTCEND clearance dropped and showed significant difference (P less than 0
0	They developed ENTD nephrotic syndrome ENTDEND  and finally renal failure. The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENTC ruthenium ENTCEND red on the lamina rara externa and marked changes in epithelial cell cytoplasm
0	The enhancement of aminonucleoside ENTD nephrosis ENTDEND  by the co-administration of protamine.An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and ENTC protamine sulfate ENTCEND (PS)
0	The enhancement of ENTC aminonucleoside ENTCEND ENTD nephrosis ENTDEND by the co-administration of protamine
0	The enhancement of aminonucleoside ENTD nephrosis ENTDEND  by the co-administration of protamine.An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS). Male Sprague-Dawley rats, uninephrectomized three weeks before, received daily injections of subcutaneous AMNS (1 mg/100 g body wt) and intravenous PS (2 separated doses of 2.5 mg/100 g body wt) for four days. The series of injections were repeated another three times at 10 day intervals. The animals were sacrificed on days 24, 52, and 80. They developed nephrotic syndrome and finally renal failure. The time-course curve of ENTC creatinine ENTCEND clearance dropped and showed significant difference (P less than 0
0	Therefore, it is suggested that the administration of ENTC PS ENTCEND enhances the ENTD toxicity ENTDEND of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	Therefore, it is suggested that the administration of PS enhances the ENTD toxicity ENTDEND  of ENTC AMNS ENTCEND on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	The time-course curve of ENTC creatinine ENTCEND  clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the ENTD toxicity ENTDEND of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENTC ruthenium ENTCEND  red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the ENTD toxicity ENTDEND of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease
0	They developed nephrotic syndrome and finally ENTD renal failure ENTDEND  The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, ENTC PS ENTCEND alone or saline injected
0	They developed nephrotic syndrome and finally ENTD renal failure ENTDEND . The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, ENTC AMNS ENTCEND alone, PS alone or saline injected
0	They developed nephrotic syndrome and finally ENTD renal failure ENTDEND . The time-course curve of ENTC creatinine ENTCEND clearance dropped and showed significant difference (P less than 0
0	They developed nephrotic syndrome and finally ENTD renal failure ENTDEND . The time-course curve of creatinine clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENTC ruthenium ENTCEND red on the lamina rara externa and marked changes in epithelial cell cytoplasm
0	Therefore, it is suggested that the administration of ENTC PS ENTCEND  enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the ENTD end-stage renal disease ENTDEND
1	Therefore, it is suggested that the administration of PS enhances the toxicity of ENTC AMNS ENTCEND  on the glomerulus and readily produces progressive FSGS in rats resulting in the ENTD end-stage renal disease ENTDEND
0	The time-course curve of ENTC creatinine ENTCEND  clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive FSGS. The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ruthenium red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the ENTD end-stage renal disease ENTDEND
0	The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENTC ruthenium ENTCEND  red on the lamina rara externa and marked changes in epithelial cell cytoplasm. Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the ENTD end-stage renal disease ENTDEND
0	01) from that of each control group, such as, AMNS alone, ENTC PS ENTCEND  alone or saline injected. Their glomeruli showed changes of progressive ENTD FSGS ENTDEND
1	Therefore, it is suggested that the administration of PS enhances the toxicity of ENTC AMNS ENTCEND  on the glomerulus and readily produces progressive ENTD FSGS ENTDEND in rats resulting in the end-stage renal disease
0	The time-course curve of ENTC creatinine ENTCEND  clearance dropped and showed significant difference (P less than 0.01) from that of each control group, such as, AMNS alone, PS alone or saline injected. Their glomeruli showed changes of progressive ENTD FSGS ENTDEND
0	Their glomeruli showed changes of progressive ENTD FSGS ENTDEND . The ultrastructural studies in the initial stage revealed significant lack of particles of perfused ENTC ruthenium ENTCEND red on the lamina rara externa and marked changes in epithelial cell cytoplasm
0	Conversion to ENTC SRL ENTCEND prevented CsA-induced ENTD renal damage ENTDEND evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL
1	Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent ENTC CsA ENTCEND induced ENTD nephropathy ENTDEND , but the molecular mechanisms underlying these protocols remain nuclear
0	ENTD Renal lesions ENTDEND were analyzed in ENTC hematoxylin ENTCEND and eosin, periodic acid-Schiff, and Masson's trichrome stains
0	ENTD Renal lesions ENTDEND  were analyzed in hematoxylin and ENTC eosin ENTCEND , periodic acid-Schiff, and Masson's trichrome stains
1	ENTC SRL ENTCEND treated rats presented ENTD proteinuria ENTDEND and NGAL (serum and urinary) as the best markers of renal impairment
0	SRL-treated rats presented ENTD proteinuria ENTDEND  and NGAL (serum and urinary) as the best markers of renal impairment. Short ENTC CsA ENTCEND treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes
0	Renal lesions were analyzed in ENTC hematoxylin ENTCEND  and eosin, periodic acid-Schiff, and Masson's trichrome stains. SRL-treated rats presented ENTD proteinuria ENTDEND and NGAL (serum and urinary) as the best markers of renal impairment
0	Renal lesions were analyzed in hematoxylin and ENTC eosin ENTCEND , periodic acid-Schiff, and Masson's trichrome stains. SRL-treated rats presented ENTD proteinuria ENTDEND and NGAL (serum and urinary) as the best markers of renal impairment
1	ENTD LV hypertrophy ENTDEND induced by ENTC Iso ENTCEND treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0
0	The greater ENTD LV hypertrophy ENTDEND in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist ENTC metoprolol ENTCEND in conscious rats was significantly attenuated in TGR compared with SD rats (-9
0	The greater ENTD LV hypertrophy ENTDEND  in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by ENTC atropine ENTCEND on HR was similar in both strains
0	Enhanced isoproterenol-induced ENTD cardiac hypertrophy ENTDEND  in transgenic rats with low brain angiotensinogen.We have previously shown that a permanent deficiency in the brain renin- ENTC angiotensin ENTCEND system (RAS) may increase the sensitivity of the baroreflex control of heart rate
0	LV hypertrophy induced by ENTC Iso ENTCEND  treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively). The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced ENTD cardiac inotropic ENTDEND response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart
0	The decrease in the heart rate (HR) induced by the beta-AR antagonist ENTC metoprolol ENTCEND  in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced ENTD cardiac inotropic ENTDEND response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart
0	5%), whereas the effect of parasympathetic blockade by ENTC atropine ENTCEND  on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced ENTD cardiac inotropic ENTDEND response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart
0	LV hypertrophy induced by ENTC Iso ENTCEND  treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs. 0.24 +/- 0.004, respectively). The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats. The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and ENTD hypertrophy ENTDEND , possibly due to chronically low sympathetic outflow directed to the heart
0	The decrease in the heart rate (HR) induced by the beta-AR antagonist ENTC metoprolol ENTCEND  in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs. -18.1 +/- 1.5%), whereas the effect of parasympathetic blockade by atropine on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and ENTD hypertrophy ENTDEND , possibly due to chronically low sympathetic outflow directed to the heart
0	5%), whereas the effect of parasympathetic blockade by ENTC atropine ENTCEND  on HR was similar in both strains. These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and ENTD hypertrophy ENTDEND , possibly due to chronically low sympathetic outflow directed to the heart
0	Histopathological examination of the kidney showed ENTD tubular necrosis ENTDEND in D-AmB-treated rats but no change in NS-718-treated rats. ENTC Amphotericin B ENTCEND concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats
0	Serum blood urea and ENTC creatinine ENTCEND concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed ENTD tubular necrosis ENTDEND in D-AmB-treated rats but no change in NS-718-treated rats
0	Serum blood ENTC urea ENTCEND and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed ENTD tubular necrosis ENTDEND in D-AmB-treated rats but no change in NS-718-treated rats
1	Histopathological examination of the kidney showed ENTD tubular necrosis ENTDEND  in ENTC D-AmB ENTCEND -treated rats but no change in NS-718-treated rats
0	We compared the ENTD toxicity ENTDEND of NS-718 with that of ENTC Fungizone ENTCEND (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats
0	We compared the ENTD toxicity ENTDEND  of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats. Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and ENTC creatinine ENTCEND concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718
0	We compared the ENTD toxicity ENTDEND  of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats. Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood ENTC urea ENTCEND and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718
0	We compared the ENTD toxicity ENTDEND  of NS-718 with that of Fungizone ( ENTC amphotericin B-sodium deoxycholate ENTCEND ; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats
0	Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENTD nephrotoxicity ENTDEND of ENTC amphotericin B ENTCEND
0	Serum blood urea and ENTC creatinine ENTCEND  concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats. Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats. Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENTD nephrotoxicity ENTDEND of amphotericin B
0	Serum blood ENTC urea ENTCEND  and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718. Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats. Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats. Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENTD nephrotoxicity ENTDEND of amphotericin B
0	Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in ENTC D-AmB ENTCEND treated rats. Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the ENTD nephrotoxicity ENTDEND of amphotericin B
0	Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting ( ENTC ropivacaine ENTCEND  and short-acting (prilocaine) anesthetic. RESULTS: All patients had normal vocal cord function preoperatively. Twelve patients (43%) were found to have intraoperative ipsilateral ENTD vocal cord paralysis ENTDEND
1	Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting (ropivacaine) and short-acting ( ENTC prilocaine ENTCEND  anesthetic. RESULTS: All patients had normal vocal cord function preoperatively. Twelve patients (43%) were found to have intraoperative ipsilateral ENTD vocal cord paralysis ENTDEND
0	Such complications are most important in situations where there is a pre-existing contralateral ENTD paralysis ENTDEND  We therefore examined the effect of local anesthesia on vocal cord function to better understand its possible consequences. METHODS: This prospective study included 28 patients undergoing carotid endarterectomy under local anesthesia. Vocal cord function was evaluated before, during, and after surgery (postoperative day 1) using flexible laryngoscopy. Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting ENTC ropivacaine ENTCEND ) and short-acting (prilocaine) anesthetic
0	Such complications are most important in situations where there is a pre-existing contralateral ENTD paralysis ENTDEND . We therefore examined the effect of local anesthesia on vocal cord function to better understand its possible consequences. METHODS: This prospective study included 28 patients undergoing carotid endarterectomy under local anesthesia. Vocal cord function was evaluated before, during, and after surgery (postoperative day 1) using flexible laryngoscopy. Anesthesia was performed by injecting 20 to 40 mL of a mixture of long-acting (ropivacaine) and short-acting ENTC prilocaine ENTCEND ) anesthetic
0	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and ENTC tiapride ENTCEND  in a Japanese patient with ENTD Huntington's disease ENTDEND at the terminal stage of recurrent breast cancer
0	5 mg/day) for ENTD Huntington's disease ENTDEND  The patient had been treated with tiapride or tetrabenazine alone without any adverse effects before the administration of the combination therapy. She also had advanced breast cancer when the combination therapy was initiated. To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other ENTC neuroleptic drugs ENTCEND , particularly in patients with a worsening general condition
0	We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and ENTC tetrabenazine ENTCEND (12.5 mg/day) for ENTD Huntington's disease ENTDEND
1	To the best of our knowledge, the occurrence of ENTD neuroleptic malignant syndrome ENTDEND due to combination therapy with tetrabenazine and ENTC tiapride ENTCEND has not been previously reported
0	To the best of our knowledge, the occurrence of ENTD neuroleptic malignant syndrome ENTDEND  due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other ENTC neuroleptic drugs ENTCEND , particularly in patients with a worsening general condition
1	To the best of our knowledge, the occurrence of ENTD neuroleptic malignant syndrome ENTDEND  due to combination therapy with ENTC tetrabenazine ENTCEND and tiapride has not been previously reported
0	Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and ENTC tiapride ENTCEND  in a Japanese patient with Huntington's disease at the terminal stage of recurrent ENTD breast cancer ENTDEND
0	She also had advanced ENTD breast cancer ENTDEND when the combination therapy was initiated. To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported. Tetrabenazine should be administered very carefully in combination with other ENTC neuroleptic drugs ENTCEND , particularly in patients with a worsening general condition
0	Neuroleptic malignant syndrome induced by combination therapy with ENTC tetrabenazine ENTCEND  and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent ENTD breast cancer ENTDEND
1	CONCLUSION: Among non-users of aspirin, ENTC naproxen ENTCEND seemed to carry the highest risk for ENTD AMI ENTDEND /GI bleeding
1	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) ENTC non-steroidal anti-inflammatory drugs ENTCEND (NSAIDs). We aimed to compare the risks of hospitalization for ENTD AMI ENTDEND and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENTD AMI ENTDEND GI vs the acetaminophen (with no ENTC aspirin ENTCEND ) group were: rofecoxib 1
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENTD AMI ENTDEND /GI vs the ENTC acetaminophen ENTCEND (with no aspirin) group were: rofecoxib 1
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENTD AMI ENTDEND /GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ENTC ibuprofen ENTCEND 1
1	OBJECTIVES: The risk of acute myocardial infarction ( ENTD AMI ENTDEND  with ENTC COX-2 inhibitors ENTCEND may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs)
0	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENTD AMI ENTDEND /GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), ENTC diclofenac ENTCEND 1
0	The ENTD AMI ENTDEND GI toxicity of ENTC celecoxib ENTCEND was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
1	Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for ENTD AMI ENTDEND /GI vs the acetaminophen (with no aspirin) group were: ENTC rofecoxib ENTCEND 1
0	CONCLUSION: Among non-users of aspirin, ENTC naproxen ENTCEND  seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENTD toxicity ENTDEND of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	CONCLUSION: Among non-users of ENTC aspirin ENTCEND  naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENTD toxicity ENTDEND of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	The AMI/GI ENTD toxicity ENTDEND  of celecoxib was similar to that of ENTC acetaminophen ENTCEND and seemed to be better than those of rofecoxib and NS-NSAIDs
0	52), ENTC ibuprofen ENTCEND 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENTD toxicity ENTDEND of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	41), ENTC diclofenac ENTCEND 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding. The AMI/GI ENTD toxicity ENTDEND of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	The AMI/GI ENTD toxicity ENTDEND  of ENTC celecoxib ENTCEND was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
0	The AMI/GI ENTD toxicity ENTDEND  of celecoxib was similar to that of acetaminophen and seemed to be better than those of ENTC rofecoxib ENTCEND and NS-NSAIDs
1	CONCLUSION: Among non-users of aspirin, ENTC naproxen ENTCEND  seemed to carry the highest risk for AMI/ ENTD GI bleeding ENTDEND
1	OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) ENTC non-steroidal anti-inflammatory drugs ENTCEND  (NSAIDs). We aimed to compare the risks of hospitalization for AMI and ENTD GI bleeding ENTDEND among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen
0	CONCLUSION: Among non-users of ENTC aspirin ENTCEND , naproxen seemed to carry the highest risk for AMI ENTD GI bleeding ENTDEND
0	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/ ENTD GI bleeding ENTDEND . The AMI/GI toxicity of celecoxib was similar to that of ENTC acetaminophen ENTCEND and seemed to be better than those of rofecoxib and NS-NSAIDs
0	52), ENTC ibuprofen ENTCEND  1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI ENTD GI bleeding ENTDEND
0	We aimed to compare the risks of hospitalization for AMI and ENTD GI bleeding ENTDEND  among elderly patients using ENTC COX-2 inhibitors ENTCEND , NS-NSAIDs and acetaminophen
0	41), ENTC diclofenac ENTCEND  1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI ENTD GI bleeding ENTDEND
0	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/ ENTD GI bleeding ENTDEND . The AMI/GI toxicity of ENTC celecoxib ENTCEND was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs
1	CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/ ENTD GI bleeding ENTDEND . The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of ENTC rofecoxib ENTCEND and NS-NSAIDs
1	Abnormalities of the pupil and visual-evoked potential in ENTC quinine ENTCEND  amblyopia.Total blindness with a transient ENTD tonic pupillary ENTDEND response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps
1	Abnormalities of the pupil and visual-evoked potential in ENTC quinine ENTCEND  amblyopia.Total ENTD blindness ENTDEND with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps
0	A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in ENTC quinine ENTCEND ENTD toxicity ENTDEND , to our knowledge, have not been previously reported
1	Abnormalities of the pupil and visual-evoked potential in ENTC quinine ENTCEND ENTD amblyopia ENTDEND
0	Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of ENTC quinine sulfate ENTCEND for ENTD leg cramps ENTDEND
1	ENTC Doxorubicin ENTCEND -induced ENTD cardiotoxicity ENTDEND monitored by ECG in freely moving mice
0	These findings result in a model that allows the testing of protectors against doxorubicin-induced ENTD cardiotoxicity ENTDEND as demonstrated by the protection provided by ENTC ICRF-187 ENTCEND
0	As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general ENTD toxicity ENTDEND (6 weekly doses of 4 mg/kg ENTC doxorubicin ENTCEND given i
0	As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ENTC ICRF-187 ENTCEND was determined using a dose schedule with lower general ENTD toxicity ENTDEND (6 weekly doses of 4 mg/kg doxorubicin given i
0	After sacrifice the hearts of ENTC doxorubicin ENTCEND treated animals were enlarged and the atria were ENTD hypertrophic ENTDEND
0	After sacrifice the hearts of doxorubicin-treated animals were enlarged and the atria were ENTD hypertrophic ENTDEND . As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ENTC ICRF-187 ENTCEND was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i
0	ENTC Nifedipine ENTCEND  induced bradycardia in a patient with autonomic neuropathy.An 80 year old diabetic male with evidence of ENTD peripheral and autonomic neuropathy ENTDEND was admitted with chest pain
0	ENTC Nifedipine ENTCEND  induced bradycardia in a patient with ENTD autonomic neuropathy ENTDEND
0	ENTC Nifedipine ENTCEND  induced bradycardia in a patient with autonomic neuropathy.An 80 year old ENTD diabetic ENTDEND male with evidence of peripheral and autonomic neuropathy was admitted with chest pain
1	ENTC Nifedipine ENTCEND  induced ENTD bradycardia ENTDEND in a patient with autonomic neuropathy
0	He was found to have ENTD atrial flutter ENTDEND at a ventricular rate of 70/min which slowed down to 30-40/min when ENTC nifedipine ENTCEND (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min
1	This is inconsistent with the well-established finding that ENTC nifedipine ENTCEND induces ENTD tachycardia ENTDEND in normally innervated hearts
0	An 80 year old diabetic male with evidence of peripheral and autonomic neuropathy was admitted with ENTD chest pain ENTDEND  He was found to have atrial flutter at a ventricular rate of 70/min which slowed down to 30-40/min when ENTC nifedipine ENTCEND (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min
1	ENTC Penicillin ENTCEND ENTD anaphylaxis ENTDEND
0	Switching the immunosuppressive regimen from tacrolimus to ENTC cyclosporine ENTCEND did not improve the clinical situation. The termination of treatment with any calcineurin inhibitor resulted in a complete resolution of that complication. CONCLUSIONS: ENTD Posterior reversible encephalopathy syndrome ENTDEND after liver transplant is rare
1	Switching the immunosuppressive regimen from ENTC tacrolimus ENTCEND to cyclosporine did not improve the clinical situation. The termination of treatment with any calcineurin inhibitor resulted in a complete resolution of that complication. CONCLUSIONS: ENTD Posterior reversible encephalopathy syndrome ENTDEND after liver transplant is rare
0	OBJECTIVES: Posterior leukoencephalopathy due to calcineurin-inhibitor-related ENTD neurotoxicity ENTDEND is a rare but severe complication that results from treatment with immunosuppressive agents (primarily those administered after a liver or kidney transplant). The pathophysiologic mechanisms of that disorder remain unknown. CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for alcoholic cirrhosis and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from tacrolimus to ENTC cyclosporine ENTCEND did not improve the clinical situation
0	OBJECTIVES: Posterior leukoencephalopathy due to calcineurin-inhibitor-related ENTD neurotoxicity ENTDEND  is a rare but severe complication that results from treatment with immunosuppressive agents (primarily those administered after a liver or kidney transplant). The pathophysiologic mechanisms of that disorder remain unknown. CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for alcoholic cirrhosis and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from ENTC tacrolimus ENTCEND to cyclosporine did not improve the clinical situation
0	CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for ENTD alcoholic cirrhosis ENTDEND and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from tacrolimus to ENTC cyclosporine ENTCEND did not improve the clinical situation
0	CASE: We report the case of a 46-year-old woman who received a liver transplant in our center as treatment for ENTD alcoholic cirrhosis ENTDEND  and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant. After an initially uneventful course after the transplant, the patient rapidly fell into deep coma. RESULTS: Cerebral MRI scan showed typical signs of enhancement in the pontine and posterior regions. Switching the immunosuppressive regimen from ENTC tacrolimus ENTCEND to cyclosporine did not improve the clinical situation
1	ENTD Hypertensive ENTDEND  response during ENTC dobutamine ENTCEND stress echocardiography
0	CONCLUSIONS: Initiating treatment of ENTD type 2 diabetes ENTDEND with ENTC glibenclamide ENTCEND or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride
0	CONCLUSIONS: Initiating treatment of ENTD type 2 diabetes ENTDEND  with glibenclamide or ENTC glipizide ENTCEND is associated with increased risk of CAD in comparison to gliclazide or glimepiride
0	000) with either, and was unchanged with ENTC metformin ENTCEND  The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with glimepiride, 0.4-fold (0.7-1.3, P=0.192) with gliclazide, and 0.4-fold (0.7-1.1, P=0.09) with either. CONCLUSIONS: Initiating treatment of ENTD type 2 diabetes ENTDEND with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride
0	CONCLUSIONS: Initiating treatment of ENTD type 2 diabetes ENTDEND  with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or ENTC glimepiride ENTCEND
0	192) with ENTC gliclazide ENTCEND  and 0.4-fold (0.7-1.1, P=0.09) with either. CONCLUSIONS: Initiating treatment of ENTD type 2 diabetes ENTDEND with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride
1	CONCLUSIONS: Initiating treatment of type 2 diabetes with ENTC glibenclamide ENTCEND  or glipizide is associated with increased risk of ENTD CAD ENTDEND in comparison to gliclazide or glimepiride
0	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or ENTC glipizide ENTCEND  is associated with increased risk of ENTD CAD ENTDEND in comparison to gliclazide or glimepiride
0	The hazard of developing ENTD CAD ENTDEND (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with ENTC metformin ENTCEND
0	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of ENTD CAD ENTDEND  in comparison to gliclazide or ENTC glimepiride ENTCEND
0	CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of ENTD CAD ENTDEND  in comparison to ENTC gliclazide ENTCEND or glimepiride
0	The 20-year risk of CAD at diagnosis of ENTD diabetes ENTDEND  using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with ENTC glibenclamide ENTCEND ; 2-fold (0
0	The 20-year risk of CAD at diagnosis of ENTD diabetes ENTDEND , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with ENTC glipizide ENTCEND ; 2
0	The 20-year risk of CAD at diagnosis of ENTD diabetes ENTDEND , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with ENTC metformin ENTCEND
0	The 20-year risk of CAD at diagnosis of ENTD diabetes ENTDEND , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin. The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with ENTC glimepiride ENTCEND , 0
0	The 20-year risk of CAD at diagnosis of ENTD diabetes ENTDEND , using the UKPDS risk engine, was used to match cases with controls. RESULTS: The 76 cases of CAD were compared with 152 controls. The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin. The hazard decreased 0.3-fold (0.7-1.7, P=0.385) with glimepiride, 0.4-fold (0.7-1.3, P=0.192) with ENTC gliclazide ENTCEND , and 0
1	Posttransplant ENTD anemia ENTDEND : the role of ENTC sirolimus ENTCEND
1	Losartan reduced ENTD uraemia ENTDEND and increased urea clearance in advanced ENTC ADR ENTCEND nephropathy in SHR
0	Losartan reduced ENTD uraemia ENTDEND  and increased ENTC urea ENTCEND clearance in advanced ADR nephropathy in SHR
0	ENTC Losartan ENTCEND reduced ENTD uraemia ENTDEND and increased urea clearance in advanced ADR nephropathy in SHR
0	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously ENTD hypertensive ENTDEND rats (SHR) with ENTC adriamycin ENTCEND (ADR) nephropathy
0	Reduced progression of adriamycin nephropathy in spontaneously ENTD hypertensive ENTDEND  rats treated by ENTC losartan ENTCEND
0	Reduced progression of adriamycin nephropathy in spontaneously ENTD hypertensive ENTDEND  rats treated by losartan.BACKGROUND: The aim of the study was to investigate the antihypertensive effects of ENTC angiotensin II ENTCEND type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy
0	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and ENTD fibrosis ENTDEND in ENTC ADR ENTCEND nephropathy
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and ENTD interstitial fibrosis ENTDEND  thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased ENTC urea ENTCEND clearance in advanced ADR nephropathy in SHR
0	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and ENTD fibrosis ENTDEND  in ADR nephropathy. CONCLUSION: ENTC Losartan ENTCEND reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR
1	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy ENTD proteinuria ENTDEND and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ENTC ADR ENTCEND nephropathy in SHR
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy ENTD proteinuria ENTDEND  and chronic renal failure. Losartan reduced uraemia and increased ENTC urea ENTCEND clearance in advanced ADR nephropathy in SHR
0	RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased ENTD proteinuria ENTDEND  Prolonged treatment with ENTC losartan ENTCEND showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure
0	Losartan reduced uraemia and increased urea clearance in advanced ENTC ADR ENTCEND  ENTD nephropathy ENTDEND in SHR
0	Losartan reduced uraemia and increased ENTC urea ENTCEND  clearance in advanced ADR ENTD nephropathy ENTDEND in SHR
0	Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR ENTD nephropathy ENTDEND  CONCLUSION: ENTC Losartan ENTCEND reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR
0	BACKGROUND: The aim of the study was to investigate the antihypertensive effects of ENTC angiotensin II ENTCEND  type-1 receptor blocker, losartan, and its potential in slowing down ENTD renal disease ENTDEND progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy
0	Histological examination showed that losartan could prevent tubular ENTD atrophy ENTDEND  interstitial infiltration and fibrosis in ENTC ADR ENTCEND nephropathy
0	Losartan reduced uraemia and increased ENTC urea ENTCEND  clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular ENTD atrophy ENTDEND , interstitial infiltration and fibrosis in ADR nephropathy
0	Histological examination showed that ENTC losartan ENTCEND could prevent tubular ENTD atrophy ENTDEND , interstitial infiltration and fibrosis in ADR nephropathy
0	CONCLUSION: Losartan reduces the rate of progression of ENTC ADR ENTCEND induced focal segmental glomerulosclerosis to ENTD end-stage renal disease ENTDEND in SHR
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and ENTD chronic renal failure ENTDEND  Losartan reduced uraemia and increased ENTC urea ENTCEND clearance in advanced ADR nephropathy in SHR
0	Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and ENTD chronic renal failure ENTDEND . ENTC Losartan ENTCEND reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR
1	CONCLUSION: Losartan reduces the rate of progression of ENTC ADR ENTCEND -induced ENTD focal segmental glomerulosclerosis ENTDEND to end-stage renal disease in SHR
0	Losartan reduced uraemia and increased ENTC urea ENTCEND  clearance in advanced ADR nephropathy in SHR. Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy. CONCLUSION: Losartan reduces the rate of progression of ADR-induced ENTD focal segmental glomerulosclerosis ENTDEND to end-stage renal disease in SHR
0	CONCLUSION: ENTC Losartan ENTCEND  reduces the rate of progression of ADR-induced ENTD focal segmental glomerulosclerosis ENTDEND to end-stage renal disease in SHR
0	Prolonged treatment with losartan showed further reduction of ENTD glomerulosclerosis ENTDEND associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased urea clearance in advanced ENTC ADR ENTCEND nephropathy in SHR
0	Prolonged treatment with losartan showed further reduction of ENTD glomerulosclerosis ENTDEND  associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure. Losartan reduced uraemia and increased ENTC urea ENTCEND clearance in advanced ADR nephropathy in SHR
0	Prolonged treatment with ENTC losartan ENTCEND  showed further reduction of ENTD glomerulosclerosis ENTDEND associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure
0	Neuroleptic drugs such as haloperidol, which block ENTC dopamine ENTCEND receptors, also cause ENTD catalepsy ENTDEND in rodents
0	RESULTS: L-NOARG sub-chronic administration produced tolerance of ENTC L-NOARG ENTCEND and of haloperidol-induced ENTD catalepsy ENTDEND
1	Sub-chronic inhibition of nitric-oxide synthesis modifies ENTC haloperidol ENTCEND -induced ENTD catalepsy ENTDEND and the number of NADPH-diaphorase neurons in mice
0	RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of ENTC nitric-oxide ENTCEND synthase (NOS), induces ENTD catalepsy ENTDEND in mice
0	Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced ENTD catalepsy ENTDEND  and the number of ENTC NADPH ENTCEND -diaphorase neurons in mice
1	Chemical ENTD cystitis ENTDEND was induced by ENTC cyclophosphamide ENTCEND (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Chemical ENTD cystitis ENTDEND  was induced by cyclophosphamide (CYP) which is metabolized to ENTC acrolein ENTCEND , an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal ENTC nitric oxide ENTCEND synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat. Chemical ENTD cystitis ENTDEND was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic ENTD irritation of the urinary tract ENTDEND of the rat. Chemical cystitis was induced by ENTC cyclophosphamide ENTCEND (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic ENTD irritation of the urinary tract ENTDEND  of the rat. Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to ENTC acrolein ENTCEND , an irritant eliminated in the urine
0	Immunocytochemical techniques were used to examine alterations in the expression of neuronal ENTC nitric oxide ENTCEND  synthase (NOS) in bladder pathways following acute and chronic ENTD irritation of the urinary tract ENTDEND of the rat
0	Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic ENTD bladder irritation ENTDEND .Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat. Chemical cystitis was induced by ENTC cyclophosphamide ENTCEND (CYP) which is metabolized to acrolein, an irritant eliminated in the urine
0	Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic ENTD bladder irritation ENTDEND .Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase (NOS) in bladder pathways following acute and chronic irritation of the urinary tract of the rat. Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to ENTC acrolein ENTCEND , an irritant eliminated in the urine
0	Increased expression of neuronal ENTC nitric oxide ENTCEND  synthase in bladder afferent pathways following chronic ENTD bladder irritation ENTDEND
0	The plasticity of primary motor cortex (M1) in patients with Parkinson's disease ( ENTD PD ENTDEND  and ENTC levodopa ENTCEND -induced dyskinesias (LIDs) is severely impaired
1	The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and ENTC levodopa ENTCEND -induced ENTD dyskinesias ENTDEND (LIDs) is severely impaired
0	Safety of ENTC celecoxib ENTCEND  in patients with adverse ENTD skin reactions ENTDEND to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs
1	OBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse ENTD cutaneous reactions ENTDEND to ENTC P ENTCEND and N associated or not to classic NSAIDs
1	The diagnosis of P and ENTC N ENTCEND induced ENTD skin reactions ENTDEND was based in vivo challenge
0	The challenge was considered positive if one or more of the following appeared: ENTD erythema ENTDEND  rush or urticaria-angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated ENTC CE ENTCEND
0	The challenge was considered positive if one or more of the following appeared: ENTD erythema ENTDEND , rush or urticaria-angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 ENTC P ENTCEND and N-highly NSAIDs intolerant patients
0	The challenge was considered positive if one or more of the following appeared: ENTD erythema ENTDEND , rush or urticaria-angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and ENTC N ENTCEND -highly NSAIDs intolerant patients
0	CONCLUSION: Only one ENTD hypersensitivity ENTDEND reaction to ENTC CE ENTCEND was documented among 9 P and N-highly NSAIDs intolerant patients
0	METHODS: We studied 9 patients with ENTD hypersensitivity ENTDEND to ENTC P ENTCEND and N with or without associated reactions to classic NSAIDs
0	METHODS: We studied 9 patients with ENTD hypersensitivity ENTDEND  to P and ENTC N ENTCEND with or without associated reactions to classic NSAIDs
1	8%) tolerated ENTC CE ENTCEND . Only one patient developed a moderate ENTD angioedema ENTDEND of the lips
0	Only one patient developed a moderate ENTD angioedema ENTDEND  of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 ENTC P ENTCEND and N-highly NSAIDs intolerant patients
0	Only one patient developed a moderate ENTD angioedema ENTDEND  of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and ENTC N ENTCEND -highly NSAIDs intolerant patients
0	The challenge was considered positive if one or more of the following appeared: erythema, rush or ENTD urticaria ENTDEND angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated ENTC CE ENTCEND
0	The challenge was considered positive if one or more of the following appeared: erythema, rush or ENTD urticaria ENTDEND -angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 ENTC P ENTCEND and N-highly NSAIDs intolerant patients
0	The challenge was considered positive if one or more of the following appeared: erythema, rush or ENTD urticaria ENTDEND -angioedema. RESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips. CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and ENTC N ENTCEND -highly NSAIDs intolerant patients
1	ENTC Fluconazole ENTCEND  associated ENTD agranulocytosis ENTDEND and thrombocytopenia
1	ENTC Fluconazole ENTCEND  associated agranulocytosis and ENTD thrombocytopenia ENTDEND
0	In particular the temporal relationship of ENTD bone marrow suppression ENTDEND to the initiation of ENTC fluconazole ENTCEND and the abatement of symptoms that rapidly reversed immediately following discontinuation
0	The patient began to have changes in white blood cells and platelets within 48 h of administration of ENTC fluconazole ENTCEND and began to recover with 48 h of discontinuation. This case highlights that drug-induced ENTD blood dyscrasias ENTDEND can occur unexpectedly as a result of treatment with a commonly used drug thought to be "safe"
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENTC heparin ENTCEND associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, ENTD hyperkalemia ENTDEND , hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, ENTD hypoaldosteronism ENTDEND  and priapism. These side effects are relatively rare in a given individual, but given the extremely widespread use of ENTC heparin ENTCEND , some are quite common, particularly HITT and osteoporosis
1	However, additional important untoward effects of heparin therapy include heparin-induced ENTD thrombocytopenia ENTDEND ENTC heparin ENTCEND -associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, ENTD alopecia ENTDEND , transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated ENTD osteoporosis ENTDEND , eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and ENTD priapism ENTDEND  These side effects are relatively rare in a given individual, but given the extremely widespread use of ENTC heparin ENTCEND , some are quite common, particularly HITT and osteoporosis
0	Clinical aspects of heparin-induced thrombocytopenia and ENTD thrombosis ENTDEND  and other side effects of ENTC heparin ENTCEND therapy
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated osteoporosis, ENTD eosinophilia ENTDEND , skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated osteoporosis, eosinophilia, ENTD skin reactions ENTDEND , allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
1	However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated osteoporosis, eosinophilia, skin reactions, ENTD allergic reactions ENTDEND other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism
0	Bleeding is the primary untoward effect of ENTC heparin ENTCEND  Major ENTD bleeding ENTDEND is of primary concern in patients receiving heparin therapy
1	Spontaneous ENTD pain ENTDEND behaviors following the administration of ENTC CYP ENTCEND were observed
0	injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, ENTC Suramin ENTCEND and GR 82334. Spontaneous ENTD pain ENTDEND behaviors following the administration of CYP were observed
0	injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, Suramin and ENTC GR 82334 ENTCEND  Spontaneous ENTD pain ENTDEND behaviors following the administration of CYP were observed
1	Histological changes evident in model and intervention groups rats' bladder included ENTD edema ENTDEND  vasodilation, and infiltration of inflammatory cells. In model group, the expression of P2X3 receptor increased in urothelium and suburothelium, and NK1 receptor increased in suburothelium, while the expression of them in intervention group was lower. CONCLUSIONS: In ENTC CYP ENTCEND -induced cystitis, the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium
1	CONCLUSIONS: In ENTC CYP ENTCEND -induced ENTD cystitis ENTDEND , the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium
0	PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced ENTD cystitis ENTDEND in rats. METHODS: Sixty female Sprague-Dawley (SD) rats were randomly divided into three groups. The rats in the control group were intraperitoneally (i.p.) injected with 0.9% saline (4 ml/kg); the rats in the model group were i.p. injected with CYP (150 mg/kg); and the rats in the intervention group were i.p. injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, ENTC Suramin ENTCEND and GR 82334
0	PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced ENTD cystitis ENTDEND  in rats. METHODS: Sixty female Sprague-Dawley (SD) rats were randomly divided into three groups. The rats in the control group were intraperitoneally (i.p.) injected with 0.9% saline (4 ml/kg); the rats in the model group were i.p. injected with CYP (150 mg/kg); and the rats in the intervention group were i.p. injected with CYP with subsequently perfusion of bladder with P2X3 and NK1 receptors' antagonists, Suramin and ENTC GR 82334 ENTCEND
0	On the other hand, induction of metallothionein (MT) by ENTC ZnSO(4) ENTCEND and its role in neuroprotection has been documented. The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal ENTD cognitive dysfunction ENTDEND in rats
1	The present study aimed to explore the effect of MT induction on carmustine ( ENTC BCNU ENTCEND -induced hippocampal ENTD cognitive dysfunction ENTDEND in rats
0	The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal ENTD cognitive dysfunction ENTDEND  in rats. A total of 60 male Wistar albino rats were randomly divided into four groups (15/group): The control group injected with single doses of normal saline (i.c.v) followed 24 h later by BCNU solvent (i.v). The second group administered ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v, once) then BCNU solvent (i.v) after 24 h. Third group received BCNU (20 mg/kg, i.v, once) 24 h after injection with normal saline (i.c.v). Fourth group received a single dose of ZnSO(4) (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal ENTC glutathione ENTCEND reductase (GR) activity and reduced glutathione (GSH) content
0	The present study aimed to explore the effect of ENTC MT ENTCEND induction on carmustine (BCNU)-induced hippocampal ENTD cognitive dysfunction ENTDEND in rats
0	Also, BCNU administration increased serum ENTD tumor ENTDEND necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations. ENTC ZnSO(4) ENTCEND pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3
0	Also, ENTC BCNU ENTCEND administration increased serum ENTD tumor ENTDEND necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione ( ENTC GSH ENTCEND  content. Also, BCNU administration increased serum ENTD tumor ENTDEND necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum ENTD tumor ENTDEND  necrosis factor-alpha (TNFalpha), hippocampal MT and ENTC malondialdehyde ENTCEND (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum ENTD tumor ENTDEND  necrosis factor-alpha (TNFalpha), hippocampal ENTC MT ENTCEND and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The histological features were improved in hippocampus of rats treated with ENTC ZnSO(4) ENTCEND + BCNU compared to only BCNU-treated animals. In conclusion, MT induction halts BCNU-induced hippocampal ENTD toxicity ENTDEND as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, MT induction halts ENTC BCNU ENTCEND induced hippocampal ENTD toxicity ENTDEND as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, MT induction halts BCNU-induced hippocampal ENTD toxicity ENTDEND  as it prevented GR inhibition and ENTC GSH ENTCEND depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, MT induction halts BCNU-induced hippocampal ENTD toxicity ENTDEND  as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, ENTC MDA ENTCEND and caspase-3 activity with subsequent preservation of cognition
0	In conclusion, ENTC MT ENTCEND induction halts BCNU-induced hippocampal ENTD toxicity ENTDEND as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition
0	Fourth group received a single dose of ENTC ZnSO(4) ENTCEND (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
1	The obtained data revealed that ENTC BCNU ENTCEND administration resulted in ENTD deterioration of learning and short-term memory ENTDEND (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal ENTC glutathione ENTCEND reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and ENTC malondialdehyde ENTCEND (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal ENTC MT ENTCEND and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum tumor ENTD necrosis ENTDEND factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations. ENTC ZnSO(4) ENTCEND pretreatment counteracted BCNU-induced inhibition of GR and depletion of GSH and resulted in significant reduction in the levels of MDA and TNFalpha as well as the activity of caspase-3
0	Also, ENTC BCNU ENTCEND  administration increased serum tumor ENTD necrosis ENTDEND factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in deterioration of learning and short-term memory (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione ( ENTC GSH ENTCEND ) content. Also, BCNU administration increased serum tumor ENTD necrosis ENTDEND factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum tumor ENTD necrosis ENTDEND  factor-alpha (TNFalpha), hippocampal MT and ENTC malondialdehyde ENTCEND (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Also, BCNU administration increased serum tumor ENTD necrosis ENTDEND  factor-alpha (TNFalpha), hippocampal ENTC MT ENTCEND and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Fourth group received a single dose of ENTC ZnSO(4) ENTCEND  (0.1 micromol/10 microl normal saline, i.c.v) then BCNU (20 mg/kg, i.v, once) after 24 h. The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
1	The obtained data revealed that ENTC BCNU ENTCEND  administration resulted in ENTD deterioration of learning and short-term memory ENTDEND (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal ENTC glutathione ENTCEND reductase (GR) activity and reduced glutathione (GSH) content
0	The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and ENTC malondialdehyde ENTCEND (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	The obtained data revealed that BCNU administration resulted in ENTD deterioration of learning and short-term memory ENTDEND  (STM), as measured by using radial arm water maze, accompanied with decreased hippocampal glutathione reductase (GR) activity and reduced glutathione (GSH) content. Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal ENTC MT ENTCEND and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations
0	Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with ENTD hypertension ENTDEND are at the greatest risk of nephrotoxicity and would benefit from the addition of ENTC mannitol ENTCEND
0	Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) ENTC cisplatin ENTCEND every 3 weeks and those with ENTD hypertension ENTDEND are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol
0	2% of patients had head and neck cancer as their primary ENTD malignancy ENTDEND  Patients who did not receive ENTC mannitol ENTCEND were more likely to develop nephrotoxicity: odds ratio [OR] = 2
0	Rates of Renal Toxicity in ENTD Cancer ENTDEND  Patients Receiving ENTC Cisplatin ENTCEND With and Without Mannitol
0	There are many strategies to prevent this ENTD toxicity ENTDEND  including the use of ENTC mannitol ENTCEND as a nephroprotectant in combination with hydration
0	One of the major complications of ENTC cisplatin ENTCEND use is dose-limiting nephrotoxicity. There are many strategies to prevent this ENTD toxicity ENTDEND , including the use of mannitol as a nephroprotectant in combination with hydration
0	Patients who did not receive ENTC mannitol ENTCEND  were more likely to develop ENTD nephrotoxicity ENTDEND : odds ratio [OR] = 2
0	OBJECTIVE: We aimed to evaluate the rates of ENTC cisplatin ENTCEND induced ENTD nephrotoxicity ENTDEND in cancer patients receiving single-agent cisplatin with and without mannitol
0	METHODS: This single-center retrospective analysis was a quasi experiment created by the national ENTC mannitol ENTCEND shortage. Data were collected on adult cancer patients receiving single-agent cisplatin as an outpatient from January 2011 to September 2012. The primary outcome was ENTD acute kidney injury ENTDEND (AKI)
1	The primary outcome was acute kidney injury ( ENTD AKI ENTDEND . RESULTS: We evaluated 143 patients who received single-agent ENTC cisplatin ENTCEND ; 97
0	2% of patients had ENTD head and neck cancer ENTDEND as their primary malignancy. Patients who did not receive ENTC mannitol ENTCEND were more likely to develop nephrotoxicity: odds ratio [OR] = 2
0	RESULTS: We evaluated 143 patients who received single-agent ENTC cisplatin ENTCEND ; 97.2% of patients had ENTD head and neck cancer ENTDEND as their primary malignancy
0	Peak ENTC CE ENTCEND levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) decrease in cardiac output (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025). ENTD Ventricular arrhythmias ENTDEND were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia
0	ENTD Ventricular arrhythmias ENTDEND  were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia. CONCLUSIONS: ENTC Cocaine ENTCEND and ethanol in combination were more toxic than either substance alone
0	ENTD Ventricular arrhythmias ENTDEND  were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia. CONCLUSIONS: Cocaine and ENTC ethanol ENTCEND in combination were more toxic than either substance alone
0	Cocaine, ethanol, and ENTC cocaethylene ENTCEND ENTD cardiotoxity ENTDEND in an animal model of cocaine and ethanol abuse
0	The purpose of this study was to delineate the role of CE in the combined ENTD cardiotoxicity ENTDEND of ENTC cocaine ENTCEND and ethanol in a model simulating their abuse
0	The purpose of this study was to delineate the role of CE in the combined ENTD cardiotoxicity ENTDEND  of cocaine and ENTC ethanol ENTCEND in a model simulating their abuse
0	Cocaine, ethanol, and ENTC cocaethylene ENTCEND  cardiotoxity in an animal model of ENTD cocaine and ethanol abuse ENTDEND
0	ENTC Cocaine ENTCEND , ethanol, and cocaethylene cardiotoxity in an animal model of ENTD cocaine and ethanol abuse ENTDEND
0	Cocaine, ENTC ethanol ENTCEND , and cocaethylene cardiotoxity in an animal model of ENTD cocaine and ethanol abuse ENTDEND
0	Cocaine, ethanol, and ENTC cocaethylene ENTCEND  cardiotoxity in an animal model of ENTD cocaine and ethanol abuse ENTDEND
0	ENTC Cocaine ENTCEND , ethanol, and cocaethylene cardiotoxity in an animal model of ENTD cocaine and ethanol abuse ENTDEND
0	Cocaine, ENTC ethanol ENTCEND , and cocaethylene cardiotoxity in an animal model of ENTD cocaine and ethanol abuse ENTDEND
0	Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ENTD ventricular tachycardia ENTDEND  CONCLUSIONS: Cocaine and ethanol in combination were more toxic than either substance alone. Co-administration resulted in prolonged cardiac toxicity and was dysrhythmogenic. Peak serum ENTC cocaethylene ENTCEND concentrations were associated with prolonged myocardial depression
1	Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ENTD ventricular tachycardia ENTDEND . CONCLUSIONS: ENTC Cocaine ENTCEND and ethanol in combination were more toxic than either substance alone
1	Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ENTD ventricular tachycardia ENTDEND . CONCLUSIONS: Cocaine and ENTC ethanol ENTCEND in combination were more toxic than either substance alone
0	Peak serum ENTC cocaethylene ENTCEND  concentrations were associated with prolonged ENTD myocardial depression ENTDEND
0	CONCLUSIONS: ENTC Cocaine ENTCEND  and ethanol in combination were more toxic than either substance alone. Co-administration resulted in prolonged cardiac toxicity and was dysrhythmogenic. Peak serum cocaethylene concentrations were associated with prolonged ENTD myocardial depression ENTDEND
0	CONCLUSIONS: Cocaine and ENTC ethanol ENTCEND  in combination were more toxic than either substance alone. Co-administration resulted in prolonged cardiac toxicity and was dysrhythmogenic. Peak serum cocaethylene concentrations were associated with prolonged ENTD myocardial depression ENTDEND
1	Peak ENTC CE ENTCEND  levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) ENTD decrease in cardiac output ENTDEND (p < 0
0	The most dramatic hemodynamic changes occurred after each ENTC cocaine ENTCEND bolus in the C+E and C only groups; however, persistent hemodynamic changes occurred in the C+E group. Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) ENTD decrease in cardiac output ENTDEND (p < 0
0	Peak CE levels were associated with a 45% (SD +/- 22%, 95% CI = 22% to 69%) ENTD decrease in cardiac output ENTDEND  (p < 0.05), a 56% (SD +/- 23%, 95% CI = 32% to 80%) decrease in dP/dt(max) (p <.006), and a 23% (SD +/- 15%, 95% CI = 7% to 49%) decrease in SVO(2) (p < 0.025). Ventricular arrhythmias were primarily observed in the C+E group, in which four of eight dogs experienced ventricular tachycardia. CONCLUSIONS: Cocaine and ENTC ethanol ENTCEND in combination were more toxic than either substance alone
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti- ENTD arrhythmic ENTDEND property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	ENTC Quinine ENTCEND -induced ENTD arrhythmia ENTDEND in a patient with severe malaria
0	He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti ENTD arrhythmic ENTDEND property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	It was reported that there was a case of severe malaria patient with jaundice who presented with ENTD arrhythmia ENTDEND (premature ventricular contraction) while getting quinine infusion was reported. A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENTC bilirubin ENTCEND 8
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENTC potassium ENTCEND level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti ENTD arrhythmic ENTDEND property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENTC dextrose ENTCEND 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti ENTD arrhythmic ENTDEND property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	Quinine, like ENTC quinidine ENTCEND  is a chincona alkaloid that has anti ENTD arrhythmic ENTDEND property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	A man, 25 years old, was admitted to hospital with high ENTD fever ENTDEND  chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting ENTC quinine ENTCEND infusion was reported. A man, 25 years old, was admitted to hospital with high ENTD fever ENTDEND , chill, vomiting, jaundice
0	A man, 25 years old, was admitted to hospital with high ENTD fever ENTDEND , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	A man, 25 years old, was admitted to hospital with high ENTD fever ENTDEND , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENTC bilirubin ENTCEND 8
0	A man, 25 years old, was admitted to hospital with high ENTD fever ENTDEND , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, ENTC potassium ENTCEND 3
0	A man, 25 years old, was admitted to hospital with high ENTD fever ENTDEND , chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENTC dextrose ENTCEND 5% 500 mg/8 hour
0	On the second day the patient had vomitus, diarrhea, ENTD tinnitus ENTDEND  loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	On the second day the patient had vomitus, diarrhea, ENTD tinnitus ENTDEND , loss of hearing. After 30 hours of ENTC quinine ENTCEND infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had vomitus, diarrhea, ENTD tinnitus ENTDEND , loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENTC bilirubin ENTCEND 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, ENTD tinnitus ENTDEND , loss of hearing
0	89 mg/dL, ENTC potassium ENTCEND  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, ENTD tinnitus ENTDEND , loss of hearing
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENTC dextrose ENTCEND  5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, ENTD tinnitus ENTDEND , loss of hearing
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ( ENTD hypokalemia ENTDEND ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Administration of parenteral ENTC quinine ENTCEND must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENTD hypokalemia ENTDEND ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with ENTC lidocaine ENTCEND  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENTD hypokalemia ENTDEND ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENTC potassium ENTCEND  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENTD hypokalemia ENTDEND ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENTC dextrose ENTCEND  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENTD hypokalemia ENTDEND ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder ENTD hypokalemia ENTDEND ) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	On the second day the patient had ENTD vomitus ENTDEND  diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	On the second day the patient had ENTD vomitus ENTDEND , diarrhea, tinnitus, loss of hearing. After 30 hours of ENTC quinine ENTCEND infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had ENTD vomitus ENTDEND , diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENTC bilirubin ENTCEND  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had ENTD vomitus ENTDEND , diarrhea, tinnitus, loss of hearing
0	89 mg/dL, ENTC potassium ENTCEND  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had ENTD vomitus ENTDEND , diarrhea, tinnitus, loss of hearing
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENTC dextrose ENTCEND  5% 500 mg/8 hour. On the second day the patient had ENTD vomitus ENTDEND , diarrhea, tinnitus, loss of hearing
0	Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to ENTD vomiting ENTDEND and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENTD malaria ENTDEND cases
0	Administration of parenteral ENTC quinine ENTCEND  must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENTD malaria ENTDEND cases
0	He was treated with ENTC lidocaine ENTCEND  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENTD malaria ENTDEND cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENTC potassium ENTCEND  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENTD malaria ENTDEND cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENTC dextrose ENTCEND  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENTD malaria ENTDEND cases
0	Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in ENTD malaria ENTDEND cases
0	On the second day the patient had vomitus, diarrhea, tinnitus, ENTD loss of hearing ENTDEND  After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	On the second day the patient had vomitus, diarrhea, tinnitus, ENTD loss of hearing ENTDEND . After 30 hours of ENTC quinine ENTCEND infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had vomitus, diarrhea, tinnitus, ENTD loss of hearing ENTDEND . After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENTC bilirubin ENTCEND  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, ENTD loss of hearing ENTDEND
0	89 mg/dL, ENTC potassium ENTCEND  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, ENTD loss of hearing ENTDEND
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENTC dextrose ENTCEND  5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, ENTD loss of hearing ENTDEND
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENTD electrolyte disorder ENTDEND (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Administration of parenteral ENTC quinine ENTCEND  must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENTD electrolyte disorder ENTDEND (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with ENTC lidocaine ENTCEND  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENTD electrolyte disorder ENTDEND (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENTC potassium ENTCEND  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENTD electrolyte disorder ENTDEND (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENTC dextrose ENTCEND  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENTD electrolyte disorder ENTDEND (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with ENTD electrolyte disorder ENTDEND (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENTD sinoatrial block ENTDEND  positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENTD sinoatrial block ENTDEND , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. ENTC Quinine ENTCEND infusion was discontinued and changed with sulfate quinine tablets
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENTD sinoatrial block ENTDEND , positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENTC bilirubin ENTCEND  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type- ENTD sinoatrial block ENTDEND , positive U wave
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENTD sinoatrial block ENTDEND , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENTC potassium ENTCEND level was 3
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENTD sinoatrial block ENTDEND , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENTC dextrose ENTCEND 5%/24 hour and potassium aspartate tablet
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type-- ENTD sinoatrial block ENTDEND , positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	On the second day the patient had vomitus, ENTD diarrhea ENTDEND  tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	On the second day the patient had vomitus, ENTD diarrhea ENTDEND , tinnitus, loss of hearing. After 30 hours of ENTC quinine ENTCEND infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave
0	On the second day the patient had vomitus, ENTD diarrhea ENTDEND , tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENTC bilirubin ENTCEND  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, ENTD diarrhea ENTDEND , tinnitus, loss of hearing
0	89 mg/dL, ENTC potassium ENTCEND  3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, ENTD diarrhea ENTDEND , tinnitus, loss of hearing
0	52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENTC dextrose ENTCEND  5% 500 mg/8 hour. On the second day the patient had vomitus, ENTD diarrhea ENTDEND , tinnitus, loss of hearing
0	Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or ENTD diarrhea ENTDEND in malaria cases
0	52 meq/L Patient was diagnosed as ENTD severe malaria ENTDEND with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	52 meq/L Patient was diagnosed as ENTD severe malaria ENTDEND  with jaundice and got ENTC quinine ENTCEND infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as ENTD severe malaria ENTDEND  with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENTC bilirubin ENTCEND  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as ENTD severe malaria ENTDEND with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour
0	89 mg/dL, ENTC potassium ENTCEND  3.52 meq/L Patient was diagnosed as ENTD severe malaria ENTDEND with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as ENTD severe malaria ENTDEND  with jaundice and got quinine infusion in ENTC dextrose ENTCEND 5% 500 mg/8 hour
0	A man, 25 years old, was admitted to hospital with high fever, ENTD chill ENTDEND  vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting ENTC quinine ENTCEND  infusion was reported. A man, 25 years old, was admitted to hospital with high fever, ENTD chill ENTDEND , vomiting, jaundice
0	A man, 25 years old, was admitted to hospital with high fever, ENTD chill ENTDEND , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	A man, 25 years old, was admitted to hospital with high fever, ENTD chill ENTDEND , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENTC bilirubin ENTCEND 8
0	A man, 25 years old, was admitted to hospital with high fever, ENTD chill ENTDEND , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, ENTC potassium ENTCEND 3
0	A man, 25 years old, was admitted to hospital with high fever, ENTD chill ENTDEND , vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in ENTC dextrose ENTCEND 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as severe malaria with ENTD jaundice ENTDEND and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND tablet
0	52 meq/L Patient was diagnosed as severe malaria with ENTD jaundice ENTDEND  and got ENTC quinine ENTCEND infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as severe malaria with ENTD jaundice ENTDEND  and got quinine infusion in dextrose 5% 500 mg/8 hour. On the second day the patient had vomitus, diarrhea, tinnitus, loss of hearing. After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	36 mg/dL, unconjugated ENTC bilirubin ENTCEND  3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with ENTD jaundice ENTDEND and got quinine infusion in dextrose 5% 500 mg/8 hour
0	89 mg/dL, ENTC potassium ENTCEND  3.52 meq/L Patient was diagnosed as severe malaria with ENTD jaundice ENTDEND and got quinine infusion in dextrose 5% 500 mg/8 hour
0	52 meq/L Patient was diagnosed as severe malaria with ENTD jaundice ENTDEND  and got quinine infusion in ENTC dextrose ENTCEND 5% 500 mg/8 hour
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENTD heart diseases ENTDEND or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Administration of parenteral ENTC quinine ENTCEND  must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENTD heart diseases ENTDEND or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with ENTC lidocaine ENTCEND  50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENTD heart diseases ENTDEND or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, ENTC potassium ENTCEND  level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENTD heart diseases ENTDEND or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENTC dextrose ENTCEND  5%/24 hour and potassium aspartate tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENTD heart diseases ENTDEND or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC. Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have ENTD heart diseases ENTDEND or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases
0	He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and ENTC potassium aspartate ENTCEND  tablet. Quinine infusion was discontinued and changed with sulfate quinine tablets. Three hours later the patient felt better, the frequency of ENTD PVC ENTDEND reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3
1	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( ENTD premature ventricular contraction ENTDEND  while getting ENTC quinine ENTCEND infusion was reported
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction ( ENTD PVC ENTDEND  > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with ENTC lidocaine ENTCEND 50 mg intravenously followed by infusion 1500 mg in dextrose 5%/24 hour and potassium aspartate tablet
0	It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( ENTD premature ventricular contraction ENTDEND ) while getting quinine infusion was reported. A man, 25 years old, was admitted to hospital with high fever, chill, vomiting, jaundice. The patient was fully conscious, blood pressure 120/80 mmHg, pulse rate 100 x/minute, regular. On admission, laboratory examination showed Plasmodium falciparum (++++), total ENTC bilirubin ENTCEND 8
0	Three hours later the patient felt better, the frequency of ENTD PVC ENTDEND  reduced to 4 - 5 x/minute and on the third day ECG was normal, ENTC potassium ENTCEND level was 3
0	After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction ( ENTD PVC ENTDEND ) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave. He was treated with lidocaine 50 mg intravenously followed by infusion 1500 mg in ENTC dextrose ENTCEND 5%/24 hour and potassium aspartate tablet
0	Three hours later the patient felt better, the frequency of ENTD PVC ENTDEND  reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition. Quinine, like ENTC quinidine ENTCEND , is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC
0	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the ENTD neurotoxic ENTDEND action of ENTC DSP4 ENTCEND
0	The hyperactivity induced by ENTC D-amphetamine ENTCEND (10 mumol/kg) was significantly reduced by DSP4 pretreatment. However, the increased rearings and the amphetamine-induced stereotypies were not blocked by pretreatment with DSP4. The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the ENTD neurotoxic ENTDEND action of DSP4
0	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, ENTC desipramine ENTCEND  which prevents the ENTD neurotoxic ENTDEND action of DSP4
0	The reduction of ENTC amphetamine ENTCEND hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the ENTD neurotoxic ENTDEND action of DSP4
0	The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the ENTC noradrenaline ENTCEND uptake blocking agent, desipramine, which prevents the ENTD neurotoxic ENTDEND action of DSP4
0	The reduction of amphetamine ENTD hyperactivity ENTDEND induced by ENTC DSP4 ENTCEND was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
1	The ENTD hyperactivity ENTDEND induced by ENTC D-amphetamine ENTCEND (10 mumol/kg) was significantly reduced by DSP4 pretreatment
0	The reduction of amphetamine ENTD hyperactivity ENTDEND  induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, ENTC desipramine ENTCEND , which prevents the neurotoxic action of DSP4
0	The reduction of ENTC amphetamine ENTCEND ENTD hyperactivity ENTDEND induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
0	The reduction of amphetamine ENTD hyperactivity ENTDEND  induced by DSP4 was blocked by pretreatment with the ENTC noradrenaline ENTCEND -uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
0	However, the increased rearings and the amphetamine-induced ENTD stereotypies ENTDEND were not blocked by pretreatment with ENTC DSP4 ENTCEND
0	The hyperactivity induced by ENTC D-amphetamine ENTCEND  (10 mumol/kg) was significantly reduced by DSP4 pretreatment. However, the increased rearings and the amphetamine-induced ENTD stereotypies ENTDEND were not blocked by pretreatment with DSP4
0	However, the increased rearings and the amphetamine-induced ENTD stereotypies ENTDEND  were not blocked by pretreatment with DSP4. The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, ENTC desipramine ENTCEND , which prevents the neurotoxic action of DSP4
0	However, the increased rearings and the ENTC amphetamine ENTCEND induced ENTD stereotypies ENTDEND were not blocked by pretreatment with DSP4
0	However, the increased rearings and the amphetamine-induced ENTD stereotypies ENTDEND  were not blocked by pretreatment with DSP4. The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the ENTC noradrenaline ENTCEND -uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4
1	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and ENTC verapamil ENTCEND resulting in ENTD atrioventricular (AV) block ENTDEND in both patients and severe hypotension in one patient
1	After the addition of ENTC clonidine ENTCEND 0.15 mg bid she developed complete ENTD AV block ENTDEND , which resolved after all therapy was stopped
0	CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and ENTC spironolactone ENTCEND 100 mg/d. After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete ENTD AV block ENTDEND and severe hypotension, which resolved upon cessation of all medications
0	CASE SUMMARIES: A 54-year-old woman with ENTD hyperaldosteronism ENTDEND was treated with ENTC verapamil ENTCEND 480 mg/d and spironolactone 100 mg/d
0	CASE SUMMARIES: A 54-year-old woman with ENTD hyperaldosteronism ENTDEND  was treated with verapamil 480 mg/d and spironolactone 100 mg/d. After the addition of a minimal dose of ENTC clonidine ENTCEND (0
0	CASE SUMMARIES: A 54-year-old woman with ENTD hyperaldosteronism ENTDEND  was treated with verapamil 480 mg/d and ENTC spironolactone ENTCEND 100 mg/d
1	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and ENTC verapamil ENTCEND  resulting in atrioventricular (AV) block in both patients and severe ENTD hypotension ENTDEND in one patient
1	After the addition of a minimal dose of ENTC clonidine ENTCEND  (0.15 mg bid), she developed complete AV block and severe ENTD hypotension ENTDEND , which resolved upon cessation of all medications
0	OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe ENTD hypotension ENTDEND  in one patient. CASE SUMMARIES: A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and ENTC spironolactone ENTCEND 100 mg/d
0	The ENTD infections ENTDEND responded to antibiotic treatment. Two patients needed a lateral tarsorrhaphy for persistent epithelial defects. CONCLUSIONS: Aerosolized ENTC crack cocaine ENTCEND use can be associated with the development of corneal ulcers
0	Corneal ulcers associated with aerosolized ENTC crack cocaine ENTCEND  use.PURPOSE: We report 4 cases of corneal ulcers associated with drug abuse. The pathogenesis of these ENTD ulcers ENTDEND and management of these patients are also reviewed
0	CONCLUSIONS: Aerosolized ENTC crack cocaine ENTCEND  use can be associated with the development of corneal ulcers. ENTD Drug abuse ENTDEND provides additional challenges for management
1	RESULTS: Four patients with ENTD corneal ulcers ENTDEND associated with ENTC crack cocaine ENTCEND use were reviewed
1	Effects of exercise on the severity of ENTC isoproterenol ENTCEND -induced ENTD myocardial infarction ENTDEND
0	The results indicated that exercise reduced the mortality associated with the effects of large dosages of ENTC isoproterenol ENTCEND but had little on the severity of the ENTD infarction ENTDEND
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENTD cancer ENTDEND were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, ENTC anthracyclines ENTCEND , gemcitabine (GEM) em leader ]
0	Randomized clinical trials comparing ENTC VNR ENTCEND with other drugs in the treatment of ENTD cancer ENTDEND were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENTD cancer ENTDEND  were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to ENTC vindesine ENTCEND (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENTD cancer ENTDEND  were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [ ENTC fluorouracil ENTCEND , anthracyclines, gemcitabine (GEM) em leader ]
0	Randomized clinical trials comparing VNR with other drugs in the treatment of ENTD cancer ENTDEND  were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002. Outcomes of interest were severe cardiac events, toxic deaths and cardiac event-related deaths reported in each publication. We found 19 trials, involving 2441 patients treated by VNR and 2050 control patients. The incidence of cardiac events with VNR was 1.19% [95% confidence interval (CI) (0.75; 1.67)]. There was no difference in the risk of cardiac events between VNR and other drugs [odds ratio: 0.92, 95% CI (0.54; 1.55)]. The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, ENTC gemcitabine ENTCEND (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other ENTD cardiotoxic ENTDEND drugs [fluorouracil, ENTC anthracyclines ENTCEND , gemcitabine (GEM) em leader ]
1	The risk of ENTC VNR ENTCEND cardiac events was similar to vindesine (VDS) and other ENTD cardiotoxic ENTDEND drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine ( ENTC VDS ENTCEND  and other ENTD cardiotoxic ENTDEND drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other ENTD cardiotoxic ENTDEND  drugs ENTC fluorouracil ENTCEND , anthracyclines, gemcitabine (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other ENTD cardiotoxic ENTDEND  drugs [fluorouracil, anthracyclines, ENTC gemcitabine ENTCEND (GEM) em leader ]
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, ENTC anthracyclines ENTCEND , gemcitabine (GEM) em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENTD cardiac diseases ENTDEND
0	Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENTD cardiac diseases ENTDEND . ENTC Vinorelbine ENTCEND -related cardiac events concern about 1% of treated patients in clinical trials
0	The risk of VNR cardiac events was similar to vindesine ( ENTC VDS ENTCEND ) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENTD cardiac diseases ENTDEND
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [ ENTC fluorouracil ENTCEND , anthracyclines, gemcitabine (GEM) em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENTD cardiac diseases ENTDEND
0	The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine ( ENTC GEM ENTCEND  em leader ]. Even if it did not reach statistical significance because of a few number of cases, the risk was lower in trials excluding patients with cardiac history, and seemed to be higher in trials including patients with pre-existing ENTD cardiac diseases ENTDEND
1	ENTC Morphine ENTCEND -induced ENTD seizures ENTDEND in newborn infants
0	BACKGROUND: Most patients presenting to emergency departments (EDs) with ENTC cocaine ENTCEND associated chest pain are admitted for at least 12 hours and receive a "rule out ENTD acute coronary syndrome ENTDEND " protocol, often with noninvasive testing prior to discharge
0	Six patients had ENTD coronary stenosis ENTDEND >or=50%. During the 30-day follow-up period, no patients died of a cardiovascular event (0%; 95% CI, 0-6.1%) and no patient sustained a nonfatal myocardial infarction (0%; 95% CI, 0-6.1%). CONCLUSIONS: Although ENTC cocaine ENTCEND -associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events
0	CONCLUSIONS: Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with ENTC cocaine ENTCEND associated chest pain, a non- ENTD ischemic ENTDEND ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events
1	CONCLUSIONS: Although ENTC cocaine ENTCEND -associated ENTD myocardial ischemia ENTDEND can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events
0	The main outcome was 30-day cardiovascular death or ENTD myocardial infarction ENTDEND  RESULTS: A total of 59 patients with ENTC cocaine ENTCEND -associated chest pain were evaluated
1	Coronary computerized tomography angiography for rapid discharge of low-risk patients with ENTC cocaine ENTCEND -associated ENTD chest pain ENTDEND
0	It is unclear whether a coronary CTA strategy would be efficacious in ENTC cocaine ENTCEND associated chest pain, as ENTD coronary vasospasm ENTDEND may account for some of the ischemia
0	Patients with negative coronary CTA (maximal ENTD stenosis ENTDEND less than 50%) were discharged. The main outcome was 30-day cardiovascular death or myocardial infarction. RESULTS: A total of 59 patients with ENTC cocaine ENTCEND -associated chest pain were evaluated
0	An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL ENTD amyloidosis ENTDEND .Proteinuria is an expected complication in transplant patients treated with mammalian target of ENTC rapamycin ENTCEND inhibitors (mTOR-i)
0	In this case we report the unexpected diagnosis of ENTD amyloidosis ENTDEND in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENTC tacrolimus ENTCEND to everolimus
1	An unexpected diagnosis in a renal-transplant patient with proteinuria treated with ENTC everolimus ENTCEND : ENTD AL ENTDEND amyloidosis
0	Proteinuria is an expected complication in transplant patients treated with mammalian target of ENTC rapamycin ENTCEND  inhibitors (mTOR-i). However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular atrophy, or recurrent or de novo ENTD glomerulopathy ENTDEND
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular atrophy, or recurrent or de novo ENTD glomerulopathy ENTDEND . In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENTC tacrolimus ENTCEND to everolimus
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular atrophy, or recurrent or de novo ENTD glomerulopathy ENTDEND . In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to ENTC everolimus ENTCEND
0	Proteinuria is an expected complication in transplant patients treated with mammalian target of ENTC rapamycin ENTCEND  inhibitors (mTOR-i). However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial ENTD fibrosis ENTDEND and tubular atrophy, or recurrent or de novo glomerulopathy
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial ENTD fibrosis ENTDEND  and tubular atrophy, or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENTC tacrolimus ENTCEND to everolimus
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial ENTD fibrosis ENTDEND  and tubular atrophy, or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to ENTC everolimus ENTCEND
0	Proteinuria is an expected complication in transplant patients treated with mammalian target of ENTC rapamycin ENTCEND  inhibitors (mTOR-i). However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular ENTD atrophy ENTDEND , or recurrent or de novo glomerulopathy
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular ENTD atrophy ENTDEND , or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from ENTC tacrolimus ENTCEND to everolimus
0	However, clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection, interstitial fibrosis and tubular ENTD atrophy ENTDEND , or recurrent or de novo glomerulopathy. In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to ENTC everolimus ENTCEND
0	ENTD Proteinuria ENTDEND is an expected complication in transplant patients treated with mammalian target of ENTC rapamycin ENTCEND inhibitors (mTOR-i)
0	In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed ENTD proteinuria ENTDEND after conversion from ENTC tacrolimus ENTCEND to everolimus
1	An unexpected diagnosis in a renal-transplant patient with ENTD proteinuria ENTDEND  treated with ENTC everolimus ENTCEND : AL amyloidosis
0	Dehydrated rats regularly develop ENTD acute renal failure ENTDEND following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENTC TCA ENTCEND cycle and other acidic compounds
0	Dehydrated rats regularly develop ENTD acute renal failure ENTDEND  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENTC sugar alcohols ENTCEND , substances inthe TCA cycle and other acidic compounds
0	Dehydrated rats regularly develop ENTD acute renal failure ENTDEND  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of ENTC 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone ENTCEND protected rats against renal failure induced by kanamycin-dextran
1	Dehydrated rats regularly develop ENTD acute renal failure ENTDEND  following single injection of ENTC aminoglycoside ENTCEND antibiotics combined with dextran or of antibiotics only
1	Dehydrated rats regularly develop ENTD acute renal failure ENTDEND  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by ENTC kanamycin ENTCEND -dextran
0	Dehydrated rats regularly develop ENTD acute renal failure ENTDEND  following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENTC hexauronic acids ENTCEND and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	Effect of ENTC D-Glucarates ENTCEND  on basic antibiotic-induced renal damage in rats.Dehydrated rats regularly develop ENTD acute renal failure ENTDEND following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENTD renal failure ENTDEND induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENTC TCA ENTCEND cycle and other acidic compounds
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENTD renal failure ENTDEND  induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENTC sugar alcohols ENTCEND , substances inthe TCA cycle and other acidic compounds
0	Oral administration of ENTC 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone ENTCEND  protected rats against ENTD renal failure ENTDEND induced by kanamycin-dextran
0	Dehydrated rats regularly develop acute renal failure following single injection of ENTC aminoglycoside ENTCEND  antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENTD renal failure ENTDEND induced by kanamycin-dextran
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENTD renal failure ENTDEND  induced by ENTC kanamycin ENTCEND -dextran
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENTD renal failure ENTDEND  induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENTC hexauronic acids ENTCEND and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against ENTD renal failure ENTDEND  induced by kanamycin-dextran. The protective effect was prevalent among ENTC D-glucarates ENTCEND , and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENTC TCA ENTCEND  cycle and other acidic compounds. D-Glucarates were effective against ENTD renal damage ENTDEND induced by peptide antibiotics as well as various aminoglycoside antibitocis
0	The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENTC sugar alcohols ENTCEND , substances inthe TCA cycle and other acidic compounds. D-Glucarates were effective against ENTD renal damage ENTDEND induced by peptide antibiotics as well as various aminoglycoside antibitocis
0	Effect of D-Glucarates on basic antibiotic-induced ENTD renal damage ENTDEND  in rats.Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of ENTC 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone ENTCEND protected rats against renal failure induced by kanamycin-dextran
0	Rats excreted acidic urine when they were spared from ENTD renal lesions ENTDEND by ENTC monosaccharides ENTCEND
0	D-Glucarates were effective against ENTD renal damage ENTDEND  induced by peptide antibiotics as well as various ENTC aminoglycoside ENTCEND antibitocis
0	Effect of D-Glucarates on basic antibiotic-induced ENTD renal damage ENTDEND  in rats.Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by ENTC kanamycin ENTCEND -dextran
0	The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENTC hexauronic acids ENTCEND  and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds. D-Glucarates were effective against ENTD renal damage ENTDEND induced by peptide antibiotics as well as various aminoglycoside antibitocis
0	The reduction effect of ENTC D-glucarates ENTCEND against ENTD nephrotoxicity ENTDEND of basic antibiotics was discussed
0	ENTD Dehydrated ENTDEND rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe ENTC TCA ENTCEND cycle and other acidic compounds
0	ENTD Dehydrated ENTDEND  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, hexauronic acids and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, ENTC sugar alcohols ENTCEND , substances inthe TCA cycle and other acidic compounds
0	ENTD Dehydrated ENTDEND  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of ENTC 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone ENTCEND protected rats against renal failure induced by kanamycin-dextran
0	ENTD Dehydrated ENTDEND  rats regularly develop acute renal failure following single injection of ENTC aminoglycoside ENTCEND antibiotics combined with dextran or of antibiotics only
0	ENTD Dehydrated ENTDEND  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by ENTC kanamycin ENTCEND -dextran
0	ENTD Dehydrated ENTDEND  rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only. Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran. The protective effect was prevalent among D-glucarates, and also to other saccharic acid, ENTC hexauronic acids ENTCEND and hexaaldonic acids, although to a lesser degree, but not to a hexaaldose, sugar alcohols, substances inthe TCA cycle and other acidic compounds
0	Effect of ENTC D-Glucarates ENTCEND  on basic antibiotic-induced renal damage in rats ENTD Dehydrated ENTDEND rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only
0	Codeine ENTD catalepsy ENTDEND was increased by clonidine and decreased by naphazoline and xylometazoline. The brain concentration of NA was not changed by morphine and fentanyl, but one of the doses of codeine (45 mg/kg) slightly enhanced it. Pentazocine dose-dependently decreased the brain level of NA. The rate of NA turnover was not altered by analgesics except for the higher dose of fentanyl (0.2 mg/kg) following which the disappearance of NA from the brain was diminished. The results are discussed in the light of various and non-uniform data from the literature. It is suggested that in rats the brain NA plays a less important function than the other ENTC monoamines ENTCEND in the behavioural activity of potent analgesics
1	ENTC Codeine ENTCEND ENTD catalepsy ENTDEND was increased by clonidine and decreased by naphazoline and xylometazoline
0	It was found that three drugs stimulating central ENTC NA ENTCEND receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced ENTD catalepsy ENTDEND induced by morphine and fentanyl
1	The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on ENTD cataleptic ENTDEND effect of ENTC morphine ENTCEND , codine and fentanyl was studied in rats
1	Codeine ENTD catalepsy ENTDEND  was increased by clonidine and decreased by naphazoline and ENTC xylometazoline ENTCEND
1	It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and ENTC fentanyl ENTCEND  Codeine ENTD catalepsy ENTDEND was increased by clonidine and decreased by naphazoline and xylometazoline
1	Codeine ENTD catalepsy ENTDEND  was increased by clonidine and decreased by ENTC naphazoline ENTCEND and xylometazoline
1	Codeine ENTD catalepsy ENTDEND  was increased by ENTC clonidine ENTCEND and decreased by naphazoline and xylometazoline
0	The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and ENTC pentazocine ENTCEND  and on ENTD cataleptic ENTDEND effect of morphine, codine and fentanyl was studied in rats
1	After the end of fenoterol-hydrobromide infusion, ENTD tremor ENTDEND amplitudes decreased significantly faster than those following ENTC ritodrin-HCl ENTCEND infusion
1	After the end of ENTC fenoterol-hydrobromide ENTCEND infusion, ENTD tremor ENTDEND amplitudes decreased significantly faster than those following ritodrin-HCl infusion
0	Changes in serum ENTC creatinine ENTCEND after intervention (after-before) were significantly different between the PTRA and PCI groups (-0.12+/-0.5 vs. 0.13+/-0.3, P=0.014). This difference was not related to either a different clinical risk profile or to the volume of CM administered. CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients. The effectiveness of PTRA on renal function seems to be barely influenced by CM ENTD toxicity ENTDEND
0	The effectiveness of PTRA on renal function seems to be barely influenced by ENTC CM ENTCEND ENTD toxicity ENTDEND
0	PURPOSE: To compare the susceptibility to ENTD nephrotoxic ENTDEND effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI). MATERIAL AND METHODS: A total of 33 patients successfully treated with PTRA (PTRA group, mean age 70+/-12 years, 23 female, basal ENTC creatinine ENTCEND 1
1	ENTC Contrast medium ENTCEND ENTD nephrotoxicity ENTDEND after renal artery and coronary angioplasty
0	CB1 KO mice exhibited higher ENTC MDA ENTCEND levels and iNOS protein expression in the CPu and Cg compared to WT mice. Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe ENTD dyskinesias ENTDEND in CB1 KO than in WT mice
0	Increased vulnerability to 6-hydroxydopamine lesion and reduced development of ENTD dyskinesias ENTDEND  in mice lacking CB1 cannabinoid receptors.Motor impairment, dopamine (DA) neuronal activity and ENTC proenkephalin ENTCEND (PENK) gene expression in the caudate-putamen (CPu) were measured in 6-OHDA-lesioned and treated (L-DOPA+benserazide) CB1 KO and WT mice
0	Treatment with ENTC L-DOPA+benserazide ENTCEND (12 weeks) resulted in less severe ENTD dyskinesias ENTDEND in CB1 KO than in WT mice
1	The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced ENTC L-DOPA ENTCEND induced ENTD dyskinesias ENTDEND
0	The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and ENTC DA ENTCEND lesion, and reduced L-DOPA-induced ENTD dyskinesias ENTDEND
0	Increased vulnerability to ENTC 6-hydroxydopamine ENTCEND  lesion and reduced development of ENTD dyskinesias ENTDEND in mice lacking CB1 cannabinoid receptors
1	Central cardiovascular effects of ENTC AVP ENTCEND  and ANP in normotensive and spontaneously ENTD hypertensive ENTDEND rats
0	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced ENTD hypertension ENTDEND and ENTC sodium nitroprusside ENTCEND (SN)-induced hypotension
1	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine ( ENTC Phe ENTCEND -induced ENTD hypertension ENTDEND and sodium nitroprusside (SN)-induced hypotension
0	CCB was reduced in WKY and SHR after LV administration of ENTC AVP ENTCEND during SN-induced ENTD hypotension ENTDEND
1	CCB was reduced in WKY and SHR after LV administration of AVP during ENTC SN ENTCEND induced ENTD hypotension ENTDEND
0	Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine ( ENTC Phe ENTCEND )-induced hypertension and sodium nitroprusside (SN)-induced ENTD hypotension ENTDEND
0	We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial ENTD fibrosis ENTDEND independently of microalbuminuria in mice with ENTC streptozotocin ENTCEND (STZ)-induced diabetes
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENTC angiotensin ENTCEND system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy). We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial ENTD fibrosis ENTDEND independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes
0	We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin ( ENTC STZ ENTCEND -induced ENTD diabetes ENTDEND
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENTC angiotensin ENTCEND  system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy). We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced ENTD diabetes ENTDEND
0	Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of ENTC streptozotocin ENTCEND -induced diabetic nephropathy.OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with ENTD type 1 diabetes ENTDEND and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENTC angiotensin ENTCEND  system in patients with ENTD type 1 diabetes ENTDEND and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in ENTC STZ ENTCEND induced diabetic nephropathy. Confocal microscopy and real-time PCR further demonstrated that SIS3 abrogated EndoMT, reduced renal fibrosis, and retarded progression of ENTD nephropathy ENTDEND
0	OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin- ENTC angiotensin ENTCEND  system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of ENTD nephropathy ENTDEND , suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in ENTC STZ ENTCEND -induced diabetic nephropathy. Confocal microscopy and real-time PCR further demonstrated that SIS3 abrogated EndoMT, reduced renal fibrosis, and retarded progression of nephropathy. CONCLUSIONS: EndoMT is a novel pathway leading to early development of diabetic nephropathy. Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other ENTD diabetes complications ENTDEND
1	Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in ENTC STZ ENTCEND induced ENTD diabetic nephropathy ENTDEND in Tie2-Cre;Loxp-EGFP mice
0	Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced ENTD diabetic nephropathy ENTDEND .OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin ENTC angiotensin ENTCEND system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy)
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENTD QT prolongation ENTDEND induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers ENTC Amiodarone ENTCEND , Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENTD QT prolongation ENTDEND  induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, ENTC Paroxetine ENTCEND , Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner
0	Field potential duration (FPD) in human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), which can express QT interval in an electrocardiogram, is reported to be a useful tool to predict K(+) channel and ENTC Ca ENTCEND 2+) channel blocker effects on QT interval. However, there is no report showing that this technique can be used to predict multichannel blocker potential for ENTD QT prolongation ENTDEND
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENTD QT prolongation ENTDEND  induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and ENTC Citalopram ENTCEND prolonged FPDc in a concentration dependent manner
0	Field potential duration (FPD) in human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs), which can express QT interval in an electrocardiogram, is reported to be a useful tool to predict ENTC K ENTCEND +) channel and Ca(2+) channel blocker effects on QT interval. However, there is no report showing that this technique can be used to predict multichannel blocker potential for ENTD QT prolongation ENTDEND
0	The aim of this study is to show that FPD from MEA (Multielectrode array) of hiPS-CMs can detect ENTD QT prolongation ENTDEND  induced by multichannel blockers. hiPS-CMs were seeded onto MEA and FPD was measured for 2min every 10min for 30min after drug exposure for the vehicle and each drug concentration. IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas Ca(2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, Paroxetine, ENTC Terfenadine ENTCEND and Citalopram prolonged FPDc in a concentration dependent manner
0	Also, the multichannel blockers ENTC Amiodarone ENTCEND , Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner. Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause ENTD Torsade de Pointes ENTDEND (TdP) in clinical practice, produced early afterdepolarization (EAD)
0	Also, the multichannel blockers Amiodarone, ENTC Paroxetine ENTCEND , Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner. Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause ENTD Torsade de Pointes ENTDEND (TdP) in clinical practice, produced early afterdepolarization (EAD)
0	IKr and IKs blockers concentration-dependently prolonged corrected FPD (FPDc), whereas ENTC Ca ENTCEND 2+) channel blockers concentration-dependently shortened FPDc. Also, the multichannel blockers Amiodarone, Paroxetine, Terfenadine and Citalopram prolonged FPDc in a concentration dependent manner. Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause ENTD Torsade de Pointes ENTDEND (TdP) in clinical practice, produced early afterdepolarization (EAD)
1	Finally, the IKr blockers, Terfenadine and ENTC Citalopram ENTCEND  which are reported to cause ENTD Torsade de Pointes ENTDEND (TdP) in clinical practice, produced early afterdepolarization (EAD)
1	Finally, the IKr blockers, ENTC Terfenadine ENTCEND and Citalopram, which are reported to cause ENTD Torsade de Pointes ENTDEND (TdP) in clinical practice, produced early afterdepolarization (EAD)
0	In a random fashion, they received cimetidine 200 mg iv on one day, and on the other, a pretreatment of ENTC diphenhydramine ENTCEND 40 mg iv with cimetidine 200 mg iv. In the non-pretreatment group, mean arterial pressure (MAP) decreased from 107.4 +/- 8.4 mmHg to 86.7 +/- 11.4 mmHg (P less than 0.01) two minutes after cimetidine. Also, systemic vascular resistance (SVR) decreased during the eight-minute observation period (P less than 0.01). In contrast, in the pretreatment group, little haemodynamic change was seen. We conclude that an H1 antagonist may be useful in preventing ENTD hypotension ENTDEND caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor
1	We conclude that an H1 antagonist may be useful in preventing ENTD hypotension ENTDEND  caused by iv ENTC cimetidine ENTCEND , since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor
1	In the control group implants contained no ENTC PDN ENTCEND  ENTD Anxiety ENTDEND was assessed using an open field and elevated plus-maze devices
0	ENTC Misoprostol ENTCEND has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and ENTD headache ENTDEND
1	Her ENTD delirium ENTDEND significantly improved after ENTC misoprostol ENTCEND was discontinued and her mental status returned to normal within a week
0	We report a case of acute renal failure after HD- ENTC MTX ENTCEND therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital ENTD biliary atresia ENTDEND
0	High-dose methotrexate (HD- ENTC MTX ENTCEND  is an important treatment for Burkitt lymphoma, but can cause ENTD hepatic and renal toxicity ENTDEND when its clearance is delayed
0	High-dose methotrexate (HD- ENTC MTX ENTCEND ) is an important treatment for ENTD Burkitt lymphoma ENTDEND , but can cause hepatic and renal toxicity when its clearance is delayed
0	Subsequent HD- ENTC MTX ENTCEND therapy caused acute renal failure that required continuous hemodialysis. We supposed that intravascular ENTD hypovolemia ENTDEND due to substantial drainage from the ileostoma caused acute prerenal failure
1	We report a case of ENTD acute renal failure ENTDEND after HD ENTC MTX ENTCEND therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia
0	High-dose methotrexate (HD- ENTC MTX ENTCEND ) is an important treatment for Burkitt lymphoma, but can cause ENTD hepatic and renal toxicity ENTDEND when its clearance is delayed
0	At day 833 after the transplantation, he was diagnosed with PTLD ( ENTD post-transplantation lymphoproliferative disorder ENTDEND  Burkitt-type malignant lymphoma). During induction therapy, he suffered ileal perforation and ileostomy was performed. Subsequent HD ENTC MTX ENTCEND therapy caused acute renal failure that required continuous hemodialysis
1	ENTD Downbeat nystagmus ENTDEND  associated with intravenous patient-controlled administration of ENTC morphine ENTCEND
1	Downbeat nystagmus associated with intravenous patient-controlled administration of ENTC morphine ENTCEND .IMPLICATIONS: This case documents a patient who developed ENTD dizziness ENTDEND with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine
0	Anticholinesterases were administered in an attempt to antagonize prolonged ENTD neuromuscular blockade ENTDEND following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase. ENTC Edrophonium ENTCEND 10 mg, given 74 min after succinylcholine, when train-of-four stimulation was characteristic of phase II block, produced partial antagonism which was not sustained
0	Anticholinesterases were administered in an attempt to antagonize prolonged ENTD neuromuscular blockade ENTDEND  following the administration of ENTC succinylcholine ENTCEND in a patient later found to be homozygous for atypical plasma cholinesterase
0	Anticholinesterases were administered in an attempt to antagonize prolonged ENTD neuromuscular blockade ENTDEND  following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase. Edrophonium 10 mg, given 74 min after succinylcholine, when train-of-four stimulation was characteristic of phase II block, produced partial antagonism which was not sustained. Repeated doses of edrophonium to 70 mg and ENTC neostigmine ENTCEND to 2
0	Succinylcholine ENTD apnoea ENTDEND : attempted reversal with anticholinesterases.Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase. ENTC Edrophonium ENTCEND 10 mg, given 74 min after succinylcholine, when train-of-four stimulation was characteristic of phase II block, produced partial antagonism which was not sustained
1	ENTC Succinylcholine ENTCEND ENTD apnoea ENTDEND : attempted reversal with anticholinesterases
0	Repeated doses of edrophonium to 70 mg and ENTC neostigmine ENTCEND  to 2.5 mg did not antagonize or augment the block. Spontaneous respiration recommenced 200 min after succinylcholine administration. It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine ENTD apnoea ENTDEND despite muscle twitch activity typical of phase II block
0	ENTD Cancer ENTDEND  incidence and ENTC metolachlor ENTCEND use in the Agricultural Health Study: An update
0	An earlier suggestion of increased ENTD lung cancer ENTDEND risk at high levels of ENTC metolachlor ENTCEND use in this cohort was not confirmed in this update
1	A similar pattern was observed for ENTD follicular cell lymphoma ENTDEND  but no other lymphoma subtypes. An earlier suggestion of increased lung cancer risk at high levels of ENTC metolachlor ENTCEND use in this cohort was not confirmed in this update
0	However, our findings for both liver cancer and follicular cell ENTD lymphoma ENTDEND warrant follow-up to better differentiate effects of ENTC metolachlor ENTCEND use from other factors
1	This suggestion of an association between ENTC metolachlor ENTCEND and ENTD liver cancer ENTDEND among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies
0	ENTC Topotecan ENTCEND is an attractive option as it exhibits growth inhibition of human ENTD glioma ENTDEND as well as brain penetration
0	The present study assessed the combination of radiotherapy (60 Gy/30 fractions/40 days) and ENTC topotecan ENTCEND (0.9 mg/m(2)/day on days 1-5 on weeks 1, 3 and 5) in 50 adults with histologically proven and untreated GBM. The incidence of non-hematological ENTD toxicities ENTDEND was low and grade 3-4 hematological toxicities were reported in 20 patients (mainly lymphopenia and neutropenia)
0	ENTC Topotecan ENTCEND  in combination with radiotherapy in unresectable ENTD glioblastoma ENTDEND : a phase 2 study
1	The incidence of non-hematological toxicities was low and grade 3-4 hematological toxicities were reported in 20 patients (mainly ENTD lymphopenia ENTDEND and neutropenia). Partial response and stabilization rates were 2% and 32%, respectively, with an overall time to progression of 12 weeks. One-year overall survival (OS) rate was 42%, with a median OS of 40 weeks. ENTC Topotecan ENTCEND in combination with radiotherapy was well tolerated
1	The incidence of non-hematological toxicities was low and grade 3-4 hematological toxicities were reported in 20 patients (mainly lymphopenia and ENTD neutropenia ENTDEND . Partial response and stabilization rates were 2% and 32%, respectively, with an overall time to progression of 12 weeks. One-year overall survival (OS) rate was 42%, with a median OS of 40 weeks. ENTC Topotecan ENTCEND in combination with radiotherapy was well tolerated
0	CONCLUSIONS: The increases in ENTD anxiety ENTDEND and depression are in line with previous observations in recreational ENTC ecstasy ENTCEND -polydrug users
0	Significant between group differences were also observed in afternoon cortisol levels and in overall ENTC cortisol ENTCEND secretion across the day. CONCLUSIONS: The increases in ENTD anxiety ENTDEND and depression are in line with previous observations in recreational ecstasy-polydrug users
1	CONCLUSIONS: The increases in anxiety and ENTD depression ENTDEND are in line with previous observations in recreational ENTC ecstasy ENTCEND -polydrug users
0	RESULTS: Both user groups exhibited significantly greater levels of anxiety and ENTD depression ENTDEND than nonusers. On day 1, all participants exhibited a typical ENTC cortisol ENTCEND profile, though light users had significantly elevated levels pre-bed
0	RATIONALE: Ecstasy ( ENTC MDMA ENTCEND  is a psychostimulant drug which is increasingly associated with ENTD psychobiological dysfunction ENTDEND
0	RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with ENTD psychobiological dysfunction ENTDEND . While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users. OBJECTIVES: The current study is the first to explore the effects of ecstasy-polydrug use on psychological distress and basal functioning of the HPA axis through assessing the secretion of ENTC cortisol ENTCEND across the diurnal period
0	Hypokalemia, sometimes severe, was observed in some L-dopa-treated ENTD parkinsonian ENTDEND patients. The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and ENTC aldosterone ENTCEND
0	Hypokalemia, sometimes severe, was observed in some L-dopa-treated ENTD parkinsonian ENTDEND  patients. The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and ENTC sodium ENTCEND as well as urinary excretion of potassium, sodium and aldosterone
0	Hypokalemia, sometimes severe, was observed in some L-dopa-treated ENTD parkinsonian ENTDEND  patients. The influence of L-dopa on the renal excretion of ENTC potassium ENTCEND was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone
0	Hypokalemia, sometimes severe, was observed in some ENTC L-dopa ENTCEND treated ENTD parkinsonian ENTDEND patients
0	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with ENTD hypokalemia ENTDEND and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and ENTC aldosterone ENTCEND
0	The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with ENTD hypokalemia ENTDEND  and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and ENTC sodium ENTCEND as well as urinary excretion of potassium, sodium and aldosterone
0	The influence of L-dopa on the renal excretion of ENTC potassium ENTCEND  was studied in 3 patients with ENTD hypokalemia ENTDEND and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone
1	Kaliuretic effect of ENTC L-dopa ENTCEND  treatment in parkinsonian patients. ENTD Hypokalemia ENTDEND , sometimes severe, was observed in some L-dopa-treated parkinsonian patients
0	METHODS: This is a cross-sectional study involving 95 patients with ENTD PD ENTDEND on uninterrupted ENTC levodopa ENTCEND therapy for at least 6 months
1	Risk factors and predictors of ENTC levodopa ENTCEND -induced ENTD dyskinesia ENTDEND among multiethnic Malaysians with Parkinson's disease
1	Peri-operative ENTD atrioventricular block ENTDEND  as a result of chemotherapy with epirubicin and ENTC paclitaxel ENTCEND
1	Peri-operative ENTD atrioventricular block ENTDEND  as a result of chemotherapy with ENTC epirubicin ENTCEND and paclitaxel
1	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENTC cyclophosphamide ENTCEND  This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II ENTD atrioventricular block ENTDEND was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel ( ENTC Taxol ENTCEND  and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period. We discuss how evidence-based guidelines would not have been helpful in this case, and how chemotherapy can exhibit substantial ENTD cardiotoxicity ENTDEND that may develop over many years
0	In the preceding months she had received neo-adjuvant chemotherapy with ENTC epirubicin ENTCEND  paclitaxel (Taxol) and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period. We discuss how evidence-based guidelines would not have been helpful in this case, and how chemotherapy can exhibit substantial ENTD cardiotoxicity ENTDEND that may develop over many years
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENTC cyclophosphamide ENTCEND . This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be bradycardic at pre-operative assessment but had no cardiac symptoms. Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram, and temporary transvenous ventricular pacing instituted in the peri-operative period. We discuss how evidence-based guidelines would not have been helpful in this case, and how chemotherapy can exhibit substantial ENTD cardiotoxicity ENTDEND that may develop over many years
0	A 47-year-old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with ENTD carcinoma of the breast ENTDEND 6 months previously. In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, ENTC paclitaxel ENTCEND (Taxol) and cyclophosphamide
0	A 47-year-old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with ENTD carcinoma of the breast ENTDEND  6 months previously. In the preceding months she had received neo-adjuvant chemotherapy with ENTC epirubicin ENTCEND , paclitaxel (Taxol) and cyclophosphamide
0	A 47-year-old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with ENTD carcinoma of the breast ENTDEND  6 months previously. In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENTC cyclophosphamide ENTCEND
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel ( ENTC Taxol ENTCEND ) and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be ENTD bradycardic ENTDEND at pre-operative assessment but had no cardiac symptoms
0	In the preceding months she had received neo-adjuvant chemotherapy with ENTC epirubicin ENTCEND , paclitaxel (Taxol) and cyclophosphamide. This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be ENTD bradycardic ENTDEND at pre-operative assessment but had no cardiac symptoms
0	In the preceding months she had received neo-adjuvant chemotherapy with epirubicin, paclitaxel (Taxol) and ENTC cyclophosphamide ENTCEND . This had been apparently uncomplicated and she had maintained a remarkably high level of physical activity. She was found to be ENTD bradycardic ENTDEND at pre-operative assessment but had no cardiac symptoms
0	AIMS: Doxorubicin ( ENTC DOX ENTCEND  is an effective anti- ENTD cancer ENTDEND therapeutic, but is associated with both acute and late-stage cardiotoxicity
0	P53 inhibition exacerbates late-stage ENTC anthracycline ENTCEND  cardiotoxicity.AIMS: Doxorubicin (DOX) is an effective anti ENTD cancer ENTDEND therapeutic, but is associated with both acute and late-stage cardiotoxicity
1	Children are particularly sensitive to ENTC DOX ENTCEND induced ENTD heart failure ENTDEND
0	P53 inhibition exacerbates late-stage ENTC anthracycline ENTCEND  cardiotoxicity.AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity. Children are particularly sensitive to DOX-induced ENTD heart failure ENTDEND
0	late-stage ENTC DOX ENTCEND ENTD cardiotoxicity ENTDEND was examined in a juvenile model
0	P53 inhibition exacerbates late-stage ENTC anthracycline ENTCEND ENTD cardiotoxicity ENTDEND
0	People aged over 75 in ENTD atrial fibrillation ENTDEND  on ENTC warfarin ENTCEND : the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up
1	People aged over 75 in atrial fibrillation on ENTC warfarin ENTCEND : the rate of major ENTD hemorrhage ENTDEND and stroke in more than 500 patient-years of follow-up
0	MEASUREMENTS: Information regarding major bleeding episodes, ENTD strokes ENTDEND  and ENTC warfarin ENTCEND use was obtained from patients, relatives, primary physicians, and medical records
0	On the contrary, among primary coronary artery bypass surgery patients, there were more acute ENTD myocardial infarctions ENTDEND and renal dysfunction in Group A (5.8% vs 2.0%, P = 0.027; 22.5% vs 15.2%, P = 0.036, respectively). The 1-yr mortality was significantly higher after aprotinin treatment in the high risk surgery group (17.7% vs 9.8%, P = 0.034). CONCLUSION: Both antifibrinolytic drugs bear the risk of adverse outcome depending on the type of cardiac surgery. Administration of aprotinin should be avoided in coronary artery bypass graft and high risk patients, whereas administration of ENTC tranexamic acid ENTCEND is not recommended in valve surgery
1	During the first 5 mo, 596 patients received aprotinin (Group A); in the next 5 mo, 592 patients were treated with ENTC tranexamic acid ENTCEND (Group T). Except for antifibrinolytic therapy, the anesthetic and surgical protocols remained unchanged. RESULTS: The pre- and intraoperative variables were comparable between the treatment groups. Postoperatively, a significantly higher incidence of ENTD seizures ENTDEND was found in Group T (4
0	On the contrary, among primary coronary artery bypass surgery patients, there were more acute myocardial infarctions and ENTD renal dysfunction ENTDEND in Group A (5.8% vs 2.0%, P = 0.027; 22.5% vs 15.2%, P = 0.036, respectively). The 1-yr mortality was significantly higher after aprotinin treatment in the high risk surgery group (17.7% vs 9.8%, P = 0.034). CONCLUSION: Both antifibrinolytic drugs bear the risk of adverse outcome depending on the type of cardiac surgery. Administration of aprotinin should be avoided in coronary artery bypass graft and high risk patients, whereas administration of ENTC tranexamic acid ENTCEND is not recommended in valve surgery
1	During the first 5 mo, 596 patients received aprotinin (Group A); in the next 5 mo, 592 patients were treated with ENTC tranexamic acid ENTCEND  (Group T). Except for antifibrinolytic therapy, the anesthetic and surgical protocols remained unchanged. RESULTS: The pre- and intraoperative variables were comparable between the treatment groups. Postoperatively, a significantly higher incidence of seizures was found in Group T (4.6% vs 1.2%, P < 0.001). This difference was also significant in the primary valve surgery and the high risk surgery subgroups (7.9% vs 1.2%, P = 0.003; 7.3% vs 2.4%, P = 0.035, respectively). Persistent atrial fibrillation (7.9% vs 2.3%, P = 0.020) and ENTD renal failure ENTDEND (9
1	During ENTD hypotension ENTDEND produced by ENTC SNP ENTCEND similar decreases were observed in mean pulmonary arterial pressure (p less than 0
0	001), total body ENTC oxygen ENTCEND consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped. Cardiac output did not change. During ENTD hypotension ENTDEND produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0
1	ENTD Hypotension ENTDEND induced by ENTC ATP ENTCEND was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0
1	A total of 675 patients were included; 163 of these had therapy with vancomycin, ENTC gentamicin ENTCEND  or tobramycin; were >18 years; and treated in the ICU for >24 hours. Patients with an adherence to SOP >70% were classified into the high adherence group (HAG) and patients with an adherence of <70% into the low adherence group (LAG). ENTD AKI ENTDEND was defined according to RIFLE criteria
1	A total of 675 patients were included; 163 of these had therapy with ENTC vancomycin ENTCEND  gentamicin, or tobramycin; were >18 years; and treated in the ICU for >24 hours. Patients with an adherence to SOP >70% were classified into the high adherence group (HAG) and patients with an adherence of <70% into the low adherence group (LAG). ENTD AKI ENTDEND was defined according to RIFLE criteria
1	A total of 675 patients were included; 163 of these had therapy with vancomycin, gentamicin, or ENTC tobramycin ENTCEND  were >18 years; and treated in the ICU for >24 hours. Patients with an adherence to SOP >70% were classified into the high adherence group (HAG) and patients with an adherence of <70% into the low adherence group (LAG). ENTD AKI ENTDEND was defined according to RIFLE criteria
0	The aim of this study was to investigate, whether there is an association between adherence to guidelines (standard operating procedures (SOP)) for potentially ENTD nephrotoxic ENTDEND antibiotics and the occurrence of AKI. METHODS: This study was carried out as a prospective, clinical, non-interventional, observational study. Data collection was performed over a total of 170 days in three ICUs at Charite - Universitaetsmedizin Berlin. A total of 675 patients were included; 163 of these had therapy with vancomycin, ENTC gentamicin ENTCEND , or tobramycin; were >18 years; and treated in the ICU for >24 hours
0	The aim of this study was to investigate, whether there is an association between adherence to guidelines (standard operating procedures (SOP)) for potentially ENTD nephrotoxic ENTDEND  antibiotics and the occurrence of AKI. METHODS: This study was carried out as a prospective, clinical, non-interventional, observational study. Data collection was performed over a total of 170 days in three ICUs at Charite - Universitaetsmedizin Berlin. A total of 675 patients were included; 163 of these had therapy with ENTC vancomycin ENTCEND , gentamicin, or tobramycin; were >18 years; and treated in the ICU for >24 hours
0	The aim of this study was to investigate, whether there is an association between adherence to guidelines (standard operating procedures (SOP)) for potentially ENTD nephrotoxic ENTDEND  antibiotics and the occurrence of AKI. METHODS: This study was carried out as a prospective, clinical, non-interventional, observational study. Data collection was performed over a total of 170 days in three ICUs at Charite - Universitaetsmedizin Berlin. A total of 675 patients were included; 163 of these had therapy with vancomycin, gentamicin, or ENTC tobramycin ENTCEND ; were >18 years; and treated in the ICU for >24 hours
0	We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated ENTD AKI ENTDEND who underwent intraoperative dialytic support during liver transplantation anticoagulated with ENTC citrate ENTCEND dialysate during the entire procedure
1	We report a case of a 40-year-old female with ENTC acetaminophen ENTCEND induced fulminant liver failure with associated ENTD AKI ENTDEND who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate ENTC heparin ENTCEND or regional citrate. We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated ENTD AKI ENTDEND who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of ENTC citrate ENTCEND ENTD toxicity ENTDEND
0	Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate ENTD toxicity ENTDEND . Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate heparin or regional citrate. We report a case of a 40-year-old female with ENTC acetaminophen ENTCEND -induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate ENTD toxicity ENTDEND . Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate ENTC heparin ENTCEND or regional citrate
0	Intraoperative dialysis during liver transplantation with ENTC citrate ENTCEND  dialysate.Liver transplantation for acutely ill patients with ENTD fulminant liver failure ENTDEND carries high intraoperative and immediate postoperative risks
1	We report a case of a 40-year-old female with ENTC acetaminophen ENTCEND -induced ENTD fulminant liver failure ENTDEND with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	Citrate dialysate, a new dialysate with citric acid can be used for anticoagulation in patients who cannot tolerate ENTC heparin ENTCEND  or regional citrate. We report a case of a 40-year-old female with acetaminophen-induced ENTD fulminant liver failure ENTDEND with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure
0	METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related ENTD cirrhotic diseases ENTDEND between June 2002 and December 2004 who had survived more than 3 months. HBIg was administered intravenously during the first week and intramuscularly thereafter. RESULTS: At a median follow-up of 14.1 months, the overall recurrence rate in the 51 patients was 3.9% (2/51). The overall patient survival was 88.3%, and 82.4% after 1 and 2 years, respectively. A daily oral dose of 100 mg ENTC lamivudine ENTCEND for 2 weeks before transplantation for 10 patients enabled 57
0	BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of ENTC HBsAg ENTCEND positive patients. This study was undertaken to evaluate the outcomes of liver transplantation for patients with hepatitis B virus (HBV). METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related ENTD cirrhotic diseases ENTDEND between June 2002 and December 2004 who had survived more than 3 months
0	METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related ENTD cirrhotic diseases ENTDEND  between June 2002 and December 2004 who had survived more than 3 months. HBIg was administered intravenously during the first week and intramuscularly thereafter. RESULTS: At a median follow-up of 14.1 months, the overall recurrence rate in the 51 patients was 3.9% (2/51). The overall patient survival was 88.3%, and 82.4% after 1 and 2 years, respectively. A daily oral dose of 100 mg lamivudine for 2 weeks before transplantation for 10 patients enabled 57.1% (4/7) and 62.5% (5/8) of HBV-DNA and ENTC HBeAg ENTCEND positive patients respectively to convert to be negative
0	Intramuscular hepatitis B immune globulin combined with ENTC lamivudine ENTCEND  in prevention of ENTD hepatitis B ENTDEND recurrence after liver transplantation
0	BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of ENTD hepatitis B ENTDEND after liver transplantation has significantly improved the survival of ENTC HBsAg ENTCEND positive patients
1	This study was undertaken to evaluate the outcomes of liver transplantation for patients with ENTD hepatitis B ENTDEND virus (HBV). METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related cirrhotic diseases between June 2002 and December 2004 who had survived more than 3 months. HBIg was administered intravenously during the first week and intramuscularly thereafter. RESULTS: At a median follow-up of 14.1 months, the overall recurrence rate in the 51 patients was 3.9% (2/51). The overall patient survival was 88.3%, and 82.4% after 1 and 2 years, respectively. A daily oral dose of 100 mg lamivudine for 2 weeks before transplantation for 10 patients enabled 57.1% (4/7) and 62.5% (5/8) of HBV-DNA and ENTC HBeAg ENTCEND positive patients respectively to convert to be negative
0	An F1 hybrid of F344 and BN exhibited significant pituitary growth after 10 weeks of ENTC DES ENTCEND treatment with an average mass of 26.3 +/- 0.7 mg compared with 8.6 +/- 0.9 mg for untreated rats. Surprisingly, the F1 hybrid ENTD tumors ENTDEND were not hemorrhagic and had hemoglobin content and outward appearance identical to that of BN
0	Genetic separation of tumor growth and hemorrhagic phenotypes in an ENTC estrogen ENTCEND -induced ENTD tumor ENTDEND
1	Chronic administration of estrogen to the Fischer 344 (F344) rat induces growth of large, hemorrhagic ENTD pituitary tumors ENTDEND  Ten weeks of ENTC diethylstilbestrol ENTCEND (DES) treatment caused female F344 rat pituitaries to grow to an average of 109
0	Chronic administration of ENTC estrogen ENTCEND to the Fischer 344 (F344) rat induces growth of large, hemorrhagic ENTD pituitary tumors ENTDEND
0	4 mg for untreated rats, and to become highly ENTD hemorrhagic ENTDEND  The same ENTC DES ENTCEND treatment produced no significant growth (8
0	Genetic separation of tumor growth and ENTD hemorrhagic ENTDEND  phenotypes in an ENTC estrogen ENTCEND -induced tumor
0	Hodgkin lymphoma (HL) is a relatively chemosensitive ENTD malignancy ENTDEND  However, for those who relapse, high-dose chemotherapy with autologous stem cell transplant is the treatment of choice which relies on adequate disease control with salvage chemotherapy. Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity. Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting. In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; ENTC methylprednisolone ENTCEND 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included
0	ENTC GEM ENTCEND -P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Hodgkin lymphoma (HL) is a relatively chemosensitive ENTD malignancy ENTDEND
0	Hodgkin lymphoma (HL) is a relatively chemosensitive ENTD malignancy ENTDEND . However, for those who relapse, high-dose chemotherapy with autologous stem cell transplant is the treatment of choice which relies on adequate disease control with salvage chemotherapy. Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity. Gemcitabine and ENTC cisplatin ENTCEND have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
1	The most common grade 3/4 toxicities were haematological: neutropenia 54 % and ENTD thrombocytopenia ENTDEND 51 %. Median follow-up from the start of ENTC GEM ENTCEND -P was 4
0	In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; ENTC methylprednisolone ENTCEND  1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included. Demographic, survival, response and ENTD toxicity ENTDEND data were recorded
0	Regimens commonly used often require inpatient administration and can be difficult to deliver due to ENTD toxicity ENTDEND  ENTC Gemcitabine ENTCEND and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
0	Regimens commonly used often require inpatient administration and can be difficult to deliver due to ENTD toxicity ENTDEND . Gemcitabine and ENTC cisplatin ENTCEND have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
1	The most common grade 3/4 toxicities were haematological: ENTD neutropenia ENTDEND 54 % and thrombocytopenia 51 %. Median follow-up from the start of ENTC GEM ENTCEND -P was 4
0	In this retrospective single-centre analysis, patients with relapsed or refractory ENTD HL ENTDEND treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; ENTC methylprednisolone ENTCEND 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included
0	In this retrospective single-centre analysis, patients with relapsed or refractory ENTD HL ENTDEND  treated with ENTC gemcitabine ENTCEND 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100 mg/m(2) D15, every 28 days (GEM-P) were included
0	Gemcitabine and ENTC cisplatin ENTCEND  have activity in ENTD HL ENTDEND , non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting
1	BACKGROUND: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension ( ENTD PPH ENTDEND . Recently, ENTC fenfluramine ENTCEND appetite suppressants became widely used in the United States but were withdrawn in September 1997 because of concerns over adverse effects
0	A history of drug exposure also was taken with special attention on the use of antidepressants, anorexigens, and ENTC amphetamines ENTCEND  RESULTS: Five hundred seventy-nine patients were studied, 205 with ENTD PPH ENTDEND and 374 with pulmonary hypertension from other causes (secondary pulmonary hypertension [SPH])
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENTD status epilepticus ENTDEND followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, ENTC sodium salicylate ENTCEND , phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENTD status epilepticus ENTDEND  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and ENTC mefenamic acid ENTCEND , on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENTD status epilepticus ENTDEND  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, ENTC phenylbutazone ENTCEND , indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENTD status epilepticus ENTDEND  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ENTC ibuprofen ENTCEND and mefenamic acid, on seizures produced by pilocarpine
0	The muscarinic cholinergic agonist pilocarpine induces in rats seizures and ENTD status epilepticus ENTDEND  followed by widespread damage to the forebrain. The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, ENTC indomethacin ENTCEND , ibuprofen and mefenamic acid, on seizures produced by pilocarpine
1	The muscarinic cholinergic agonist ENTC pilocarpine ENTCEND induces in rats seizures and ENTD status epilepticus ENTDEND followed by widespread damage to the forebrain
1	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on ENTD seizures ENTDEND produced by pilocarpine. Pretreatment of rats with ENTC sodium salicylate ENTCEND , ED50 103 mg/kg (60-174), and phenylbutazone, 59 mg/kg (50-70) converted the non-convulsant dose of pilocarpine, 200 mg/kg, to a convulsant one
0	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and ENTC mefenamic acid ENTCEND , on ENTD seizures ENTDEND produced by pilocarpine
1	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, ENTC phenylbutazone ENTCEND , indomethacin, ibuprofen and mefenamic acid, on ENTD seizures ENTDEND produced by pilocarpine
0	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ENTC ibuprofen ENTCEND  and mefenamic acid, on ENTD seizures ENTDEND produced by pilocarpine
0	The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, ENTC indomethacin ENTCEND , ibuprofen and mefenamic acid, on ENTD seizures ENTDEND produced by pilocarpine
1	These results indicate that non-steroidal anti-inflammatory drugs differentially modulate the threshold for ENTC pilocarpine ENTCEND induced ENTD seizures ENTDEND
0	Pretreatment of rats with ENTC sodium salicylate ENTCEND , ED50 103 mg/kg (60-174), and phenylbutazone, 59 mg/kg (50-70) converted the non-convulsant dose of pilocarpine, 200 mg/kg, to a convulsant one. Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENTD brain damage ENTDEND induced by pilocarpine, 380 mg/kg
0	ENTC Mefenamic acid ENTCEND  26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENTD brain damage ENTDEND induced by pilocarpine, 380 mg/kg
0	Pretreatment of rats with sodium salicylate, ED50 103 mg/kg (60-174), and ENTC phenylbutazone ENTCEND  59 mg/kg (50-70) converted the non-convulsant dose of pilocarpine, 200 mg/kg, to a convulsant one. Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENTD brain damage ENTDEND induced by pilocarpine, 380 mg/kg
0	Indomethacin, 1-10 mg/kg, and ENTC ibuprofen ENTCEND  10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENTD brain damage ENTDEND induced by pilocarpine, 380 mg/kg
0	ENTC Indomethacin ENTCEND  1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine. Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENTD brain damage ENTDEND induced by pilocarpine, 380 mg/kg
0	Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related ENTD brain damage ENTDEND  induced by ENTC pilocarpine ENTCEND , 380 mg/kg
0	Despite popular use of piperacillin, the dire ENTD neurotoxicity ENTDEND associated with piperacillin still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
0	ENTC Piperacillin/tazobactam ENTCEND -induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.Despite popular use of piperacillin, the dire ENTD neurotoxicity ENTDEND associated with piperacillin still goes unrecognized, leading to a delay in appropriate management
0	Despite popular use of ENTC piperacillin ENTCEND  the dire ENTD neurotoxicity ENTDEND associated with piperacillin still goes unrecognized, leading to a delay in appropriate management
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for ENTD bronchiectasis ENTDEND with secondary infection. The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENTC piperacillin/tazobactam ENTCEND (2 g/250 mg) were given for ENTD bronchiectasis ENTDEND with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENTC piperacillin ENTCEND still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for ENTD bronchiectasis ENTDEND with secondary infection
0	Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of ENTC piperacillin/tazobactam ENTCEND  Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. Piperacillin-induced ENTD encephalopathy ENTDEND should be considered in any uremic patients with unexplained neurological manifestations
0	ENTC Piperacillin ENTCEND induced ENTD encephalopathy ENTDEND should be considered in any uremic patients with unexplained neurological manifestations
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental ENTD confusion ENTDEND  and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
1	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental ENTD confusion ENTDEND , and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENTC piperacillin/tazobactam ENTCEND (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENTC piperacillin ENTCEND  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental ENTD confusion ENTDEND , and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection
0	The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND  levels but leukocytosis. Neurologic examinations showed dysarthria and bilateral Babinski sign. Computed tomography of brain and electroencephalogram were unremarkable. Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam. Brain magnetic resonance imaging did not demonstrate acute ENTD infarction ENTDEND and organic brain lesions
0	Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of ENTC piperacillin/tazobactam ENTCEND . Brain magnetic resonance imaging did not demonstrate acute ENTD infarction ENTDEND and organic brain lesions
0	Brain magnetic resonance imaging did not demonstrate acute ENTD infarction ENTDEND  and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. ENTC Piperacillin ENTCEND -induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations
0	Piperacillin/tazobactam-induced ENTD seizure ENTDEND  rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
0	ENTC Piperacillin/tazobactam ENTCEND -induced ENTD seizure ENTDEND rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis
0	Piperacillin/tazobactam-induced ENTD seizure ENTDEND  rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.Despite popular use of ENTC piperacillin ENTCEND , the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, ENTD tremor ENTDEND  bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
1	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, ENTD tremor ENTDEND , bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENTC piperacillin/tazobactam ENTCEND (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENTC piperacillin ENTCEND  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, ENTD tremor ENTDEND , bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection
0	We report a 57-year-old woman with ENTD end-stage renal disease ENTDEND receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
0	We report a 57-year-old woman with ENTD end-stage renal disease ENTDEND  receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENTC piperacillin/tazobactam ENTCEND (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENTC piperacillin ENTCEND  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with ENTD end-stage renal disease ENTDEND receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with ENTD secondary infection ENTDEND  The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENTC piperacillin/tazobactam ENTCEND  (2 g/250 mg) were given for bronchiectasis with ENTD secondary infection ENTDEND
0	Despite popular use of piperacillin, the dire neurotoxicity associated with ENTC piperacillin ENTCEND  still goes unrecognized, leading to a delay in appropriate management. We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with ENTD secondary infection ENTDEND
0	The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND  levels but ENTD leukocytosis ENTDEND
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENTC piperacillin/tazobactam ENTCEND  (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ammonia levels but ENTD leukocytosis ENTDEND
0	The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND  levels but leukocytosis. Neurologic examinations showed ENTD dysarthria ENTDEND and bilateral Babinski sign
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of ENTC piperacillin/tazobactam ENTCEND  (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis. Neurologic examinations showed ENTD dysarthria ENTDEND and bilateral Babinski sign
0	Neurologic examinations showed ENTD dysarthria ENTDEND  and bilateral Babinski sign. Computed tomography of brain and electroencephalogram were unremarkable. Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of piperacillin/tazobactam. Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. ENTC Piperacillin ENTCEND -induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations
0	Despite the use of antiepileptic agents, another GTCS episode recurred after the sixth dose of ENTC piperacillin/tazobactam ENTCEND . Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. Piperacillin-induced encephalopathy should be considered in any ENTD uremic ENTDEND patients with unexplained neurological manifestations
0	ENTC Piperacillin ENTCEND -induced encephalopathy should be considered in any ENTD uremic ENTDEND patients with unexplained neurological manifestations
0	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure ( ENTD GTCS ENTDEND  after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection. The laboratory data revealed normal plasma electrolyte and ENTC ammonia ENTCEND levels but leukocytosis
1	We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure ( ENTD GTCS ENTDEND ) after 5 doses of ENTC piperacillin/tazobactam ENTCEND (2 g/250 mg) were given for bronchiectasis with secondary infection
0	Despite the use of antiepileptic agents, another ENTD GTCS ENTDEND episode recurred after the sixth dose of piperacillin/tazobactam. Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions. Initiation of high-flux hemodialysis rapidly reversed the neurologic symptoms within 4 hours. ENTC Piperacillin ENTCEND -induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations
1	Acute ENTD heart failure ENTDEND was induced by ENTC propranolol ENTCEND and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography
0	Acute heart failure was induced by ENTC propranolol ENTCEND  and volume loading after weaning from cardiopulmonary bypass; an absence of ENTD MR ENTDEND was confirmed by echocardiography
0	Sumatriptan succinate, a serotonin-1 ( ENTC 5-hydroxytryptamine ENTCEND 1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, myocardial ischemia, and ENTD myocardial infarction ENTDEND occurring after sumatriptan use
0	Cases have been published of coronary vasospasm, myocardial ischemia, and ENTD myocardial infarction ENTDEND  occurring after ENTC sumatriptan ENTCEND use
0	Sumatriptan succinate, a serotonin-1 ( ENTC 5-hydroxytryptamine ENTCEND -1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use. We report on the development of 8 serious cases of ischemic colitis in patients with ENTD migraine ENTDEND treated with sumatriptan
0	We report on the development of 8 serious cases of ischemic colitis in patients with ENTD migraine ENTDEND  treated with ENTC sumatriptan ENTCEND
0	ENTD Ischemic colitis ENTDEND  and sumatriptan use.Sumatriptan succinate, a ENTC serotonin ENTCEND -1 (5-hydroxytryptamine-1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries
1	ENTD Ischemic colitis ENTDEND  and ENTC sumatriptan ENTCEND use
0	Sumatriptan succinate, a serotonin-1 ( ENTC 5-hydroxytryptamine ENTCEND -1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of ENTD coronary vasospasm ENTDEND , myocardial ischemia, and myocardial infarction occurring after sumatriptan use
0	Cases have been published of ENTD coronary vasospasm ENTDEND , myocardial ischemia, and myocardial infarction occurring after ENTC sumatriptan ENTCEND use
0	Sumatriptan succinate, a serotonin-1 ( ENTC 5-hydroxytryptamine ENTCEND -1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, ENTD myocardial ischemia ENTDEND , and myocardial infarction occurring after sumatriptan use
0	Cases have been published of coronary vasospasm, ENTD myocardial ischemia ENTDEND , and myocardial infarction occurring after ENTC sumatriptan ENTCEND use
0	An adverse drug interaction with ENTC piroxicam ENTCEND  which she took occasionally, may have exacerbated the ENTD coagulopathy ENTDEND
0	A case of intercerebral hematoma due to ENTC warfarin ENTCEND induced ENTD coagulopathy ENTDEND is presented
0	A case of intercerebral ENTD hematoma ENTDEND due to warfarin-induced coagulopathy is presented. The 39-year-old woman had spread a warfarin-type rat poison around her house weekly using her bare hands, with no washing post application. Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used. An adverse drug interaction with ENTC piroxicam ENTCEND , which she took occasionally, may have exacerbated the coagulopathy
0	A case of intercerebral ENTD hematoma ENTDEND  due to ENTC warfarin ENTCEND -induced coagulopathy is presented
0	Cutaneous exposure to warfarin-like anticoagulant causing an ENTD intracerebral hemorrhage ENTDEND : a case report.A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented. The 39-year-old woman had spread a warfarin-type rat poison around her house weekly using her bare hands, with no washing post application. Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used. An adverse drug interaction with ENTC piroxicam ENTCEND , which she took occasionally, may have exacerbated the coagulopathy
1	Cutaneous exposure to ENTC warfarin ENTCEND -like anticoagulant causing an ENTD intracerebral hemorrhage ENTDEND : a case report
1	Fatal ENTD myeloencephalopathy ENTDEND  due to intrathecal ENTC vincristine ENTCEND administration
1	Vincristine was accidentally given intrathecally to a child with leukaemia, producing ENTD sensory and motor dysfunction ENTDEND followed by encephalopathy and death. Separate times for administering ENTC vincristine ENTCEND and intrathecal therapy is recommended
0	ENTC Vincristine ENTCEND was accidentally given intrathecally to a child with ENTD leukaemia ENTDEND , producing sensory and motor dysfunction followed by encephalopathy and death
1	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENTC danazol ENTCEND for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. ENTD Menstrual abnormalities ENTDEND (79%), weight gain (60%), muscle cramps/myalgias (40%), and transaminase elevations (40%) were the most common adverse reactions
1	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENTC danazol ENTCEND  for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. Menstrual abnormalities (79%), ENTD weight gain ENTDEND (60%), muscle cramps/myalgias (40%), and transaminase elevations (40%) were the most common adverse reactions
1	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENTC danazol ENTCEND  for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. Menstrual abnormalities (79%), weight gain (60%), ENTD muscle cramps ENTDEND /myalgias (40%), and transaminase elevations (40%) were the most common adverse reactions
0	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with ENTC danazol ENTCEND  for a continuous period of 6 months or longer. The mean age of the patients was 35.2 years and the mean duration of therapy was 59.7 months. Virtually all patients experienced one or more adverse reactions. Menstrual abnormalities (79%), weight gain (60%), muscle cramps/ ENTD myalgias ENTDEND (40%), and transaminase elevations (40%) were the most common adverse reactions
0	We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with ENTD hereditary angioedema ENTDEND treated with ENTC danazol ENTCEND for a continuous period of 6 months or longer
0	Glomeruli of ENTC PAN ENTCEND rats contained significantly more CC than glomeruli of controls. Glomeruli with ENTD sclerosis ENTDEND contained significantly more CC than non-sclerotic glomeruli in the same kidneys
0	After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal ENTC carbon ENTCEND (CC) intravenously. At 5 months glomerular sclerosis was found in 7.6 +/- 3.4% of the glomeruli of PAN rats; glomeruli of the controls were normal. Glomeruli of PAN rats contained significantly more CC than glomeruli of controls. Glomeruli with ENTD sclerosis ENTDEND contained significantly more CC than non-sclerotic glomeruli in the same kidneys
1	After 4 weeks the ENTC PAN ENTCEND rats were severely ENTD proteinuric ENTDEND (190 +/- 80 mg/24 hr), and all rats were given colloidal carbon (CC) intravenously
0	After 4 weeks the PAN rats were severely ENTD proteinuric ENTDEND  (190 +/- 80 mg/24 hr), and all rats were given colloidal ENTC carbon ENTCEND (CC) intravenously
0	Mesangial function and ENTD glomerular sclerosis ENTDEND  in rats with ENTC aminonucleoside ENTCEND nephrosis
0	After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal ENTC carbon ENTCEND  (CC) intravenously. At 5 months ENTD glomerular sclerosis ENTDEND was found in 7
0	Similar to the remnant kidney model in ENTC PAN ENTCEND ENTD nephrosis ENTDEND the development of glomerular sclerosis may be related to "mesangial overloading
0	Mesangial function and glomerular sclerosis in rats with aminonucleoside ENTD nephrosis ENTDEND .The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model. Five male Wistar rats received repeated subcutaneous PAN injections; five controls received saline only. After 4 weeks the PAN rats were severely proteinuric (190 +/- 80 mg/24 hr), and all rats were given colloidal ENTC carbon ENTCEND (CC) intravenously
0	Early ENTC CY ENTCEND ENTD toxicity ENTDEND caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days
1	Early ENTC CY ENTCEND  toxicity caused a typical ENTD haemorrhagic ENTDEND cystitis in both strains that was completely repaired in about 7-10 days
1	Early ENTC CY ENTCEND  toxicity caused a typical haemorrhagic ENTD cystitis ENTDEND in both strains that was completely repaired in about 7-10 days
0	These results indicate that delayed toxicity of ENTC CY ENTCEND in female DBA/2 mice causes a bladder pathology that is not observed in C57BL/6 mice. This pathology resembles ENTD interstitial cystitis ENTDEND in humans and could perhaps be used as an animal model for studies on the disease
1	Cardiac work was significantly reduced during ENTC SNP ENTCEND ENTD hypotension ENTDEND
1	Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, ENTC trimetaphan ENTCEND ENTD hypotension ENTDEND to 20% mean blood pressure decrease
0	Cardiac work was significantly reduced during SNP ENTD hypotension ENTDEND . Myocardial ENTC O2 ENTCEND consumption and O2 availability were directly dependent on the coronary perfusion
1	Relationship between ENTC nicotine ENTCEND -induced ENTD seizures ENTDEND and hippocampal nicotinic receptors
0	The binding sites from seizure sensitive and resistant mice were equally affected by treatment with ENTC dithiothreitol ENTCEND  trypsin or heat. Thus it appears that the difference between ENTD seizure ENTDEND sensitive and insensitive animals may be due to a difference in hippocampal nicotinic receptor concentration as measured with alpha-bungarotoxin binding
0	Levodopa (15 mg/kg and ENTC benserazide ENTCEND  3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and ENTD neuropsychiatric-like behaviors ENTDEND on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	These symptoms may be due to 'sensitisation' following repeated levodopa treatment or a direct effect of ENTC dopamine ENTCEND on the disease state. The levodopa-treated MPTP-lesioned marmoset was used as a model of ENTD neuropsychiatric symptoms ENTDEND in PD patients
0	The levodopa-treated ENTC MPTP ENTCEND lesioned marmoset was used as a model of ENTD neuropsychiatric symptoms ENTDEND in PD patients
0	In contrast, ENTC levodopa ENTCEND induced ENTD neuropsychiatric-like behaviors ENTDEND were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment
0	Levodopa (15 mg/kg and ENTC benserazide ENTCEND , 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for parkinsonian disability, ENTD dyskinesia ENTDEND and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	METHODS: Marmosets were administered ENTC 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ENTCEND (2.0 mg/kg s.c.) for five days, resulting in stable parkinsonism. Levodopa (15 mg/kg and benserazide, 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for parkinsonian disability, ENTD dyskinesia ENTDEND and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
1	As anticipated, animals exhibited a progressive increase in ENTC levodopa ENTCEND induced motor fluctuations, ENTD dyskinesia ENTDEND and wearing-off, that correlated with the duration of levodopa therapy
0	) for five days, resulting in stable ENTD parkinsonism ENTDEND  Levodopa (15 mg/kg and ENTC benserazide ENTCEND , 3
0	OBJECTIVES: Neuropsychiatric symptoms are increasingly recognised as a significant problem in patients with Parkinson's disease ( ENTD PD ENTDEND . These symptoms may be due to 'sensitisation' following repeated levodopa treatment or a direct effect of ENTC dopamine ENTCEND on the disease state
0	Neuropsychiatric behaviors in the ENTC MPTP ENTCEND  marmoset model of ENTD Parkinson's disease ENTDEND
0	) for five days, resulting in stable ENTD parkinsonism ENTDEND . ENTC Levodopa ENTCEND (15 mg/kg and benserazide, 3
0	Levodopa (15 mg/kg and ENTC benserazide ENTCEND , 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for ENTD parkinsonian disability ENTDEND , dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
1	METHODS: Marmosets were administered ENTC 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ENTCEND  (2.0 mg/kg s.c.) for five days, resulting in stable parkinsonism. Levodopa (15 mg/kg and benserazide, 3.75 mg/kg) p.o. b.i.d, was administered for 30 days. Animals were evaluated for ENTD parkinsonian disability ENTDEND , dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	Animals were evaluated for ENTD parkinsonian disability ENTDEND , dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to ENTC levodopa ENTCEND ) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day
0	We conclude that previously reported hypoglycemia, hyperbilirubinemia, ENTD polycythemia ENTDEND  neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENTC propranolol ENTCEND therapy
0	We conclude that previously reported ENTD hypoglycemia ENTDEND  hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENTC propranolol ENTCEND therapy
0	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and ENTD bradycardia ENTDEND are not invariable and cannot be statistically correlated with chronic ENTC propranolol ENTCEND therapy
0	We conclude that previously reported hypoglycemia, ENTD hyperbilirubinemia ENTDEND  polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENTC propranolol ENTCEND therapy
1	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic ENTC propranolol ENTCEND  therapy. ENTD Growth retardation ENTDEND , however, appears to be significant in both of our series
0	We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, ENTD neonatal apnea ENTDEND  and bradycardia are not invariable and cannot be statistically correlated with chronic ENTC propranolol ENTCEND therapy
0	Thus, dronedarone and ENTC amiodarone ENTCEND displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function. Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical ENTD arrhythmias ENTDEND , without compromising the left ventricular function
0	Consequently, ENTC dronedarone ENTCEND might be particularly suitable for the treatment and prevention of various clinical ENTD arrhythmias ENTDEND , without compromising the left ventricular function
0	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the ENTC isoproterenol ENTCEND induced tachycardia. Thus, dronedarone and amiodarone displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function. Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical ENTD arrhythmias ENTDEND , without compromising the left ventricular function
0	Hemodynamic and antiadrenergic effects of dronedarone and ENTC amiodarone ENTCEND  in animals with a healed ENTD myocardial infarction ENTDEND
0	Hemodynamic and antiadrenergic effects of ENTC dronedarone ENTCEND  and amiodarone in animals with a healed ENTD myocardial infarction ENTDEND
0	The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed ENTD myocardial infarction ENTDEND  All dogs (n = 6) randomly received orally dronedarone (10 and 30 mg/kg), amiodarone (10 and 30 mg/kg), and placebo twice daily for 7 days, with a 3-week washout between consecutive treatments. Heart rate (HR), mean arterial pressure (MBP), positive rate of increase of left ventricular pressure (+LVdP/dt), echocardiographically assessed left ventricular ejection fraction (LVEF), and fractional shortening (FS), as well as chronotropic response to ENTC isoproterenol ENTCEND and exercise-induced sympathetic stimulation were evaluated under baseline and posttreatment conditions
0	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced ENTD tachycardia ENTDEND  Thus, dronedarone and ENTC amiodarone ENTCEND displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function
0	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced ENTD tachycardia ENTDEND . Thus, ENTC dronedarone ENTCEND and amiodarone displayed a similar level of antiadrenergic effect and did not impair the resting left ventricular function
1	Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the ENTC isoproterenol ENTCEND -induced ENTD tachycardia ENTDEND
0	The ENTD QT prolongation ENTDEND appeared to respond to administration of i.v. ENTC calcium gluconate ENTCEND
1	Two cases of ENTC amisulpride ENTCEND  overdose: a cause for ENTD prolonged QT syndrome ENTDEND
0	Two cases of deliberate self- ENTD poisoning ENTDEND with 5 g and 3.6 g of amisulpride, respectively, are reported. In both cases, QT prolongation and hypocalcaemia were noted. The QT prolongation appeared to respond to administration of i.v. ENTC calcium gluconate ENTCEND
0	Two cases of deliberate self- ENTD poisoning ENTDEND  with 5 g and 3.6 g of ENTC amisulpride ENTCEND , respectively, are reported
0	Two cases of amisulpride ENTD overdose ENTDEND : a cause for prolonged QT syndrome.Two cases of deliberate self-poisoning with 5 g and 3.6 g of amisulpride, respectively, are reported. In both cases, QT prolongation and hypocalcaemia were noted. The QT prolongation appeared to respond to administration of i.v. ENTC calcium gluconate ENTCEND
0	Two cases of ENTC amisulpride ENTCEND ENTD overdose ENTDEND : a cause for prolonged QT syndrome
0	In both cases, QT prolongation and ENTD hypocalcaemia ENTDEND were noted. The QT prolongation appeared to respond to administration of i.v. ENTC calcium gluconate ENTCEND
1	6 g of ENTC amisulpride ENTCEND , respectively, are reported. In both cases, QT prolongation and ENTD hypocalcaemia ENTDEND were noted
1	Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible ENTD cardiomyopathy ENTDEND caused by ENTC doxorubicin ENTCEND
0	ENTC Carvedilol ENTCEND  protects against doxorubicin-induced mitochondrial ENTD cardiomyopathy ENTDEND
0	Carvedilol also prevented the decrease in mitochondrial ENTC Ca ENTCEND 2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin. Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria. It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and ENTD cardiomyopathy ENTDEND that accompanies long-term doxorubicin therapy in cancer patients
0	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term ENTC doxorubicin ENTCEND therapy in ENTD cancer ENTDEND patients
0	It is concluded that this protection by ENTC carvedilol ENTCEND against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in ENTD cancer ENTDEND patients
0	Carvedilol also prevented the decrease in mitochondrial ENTC Ca ENTCEND (2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin. Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria. It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in ENTD cancer ENTDEND patients
0	The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic ENTC doxorubicin ENTCEND ENTD toxicity ENTDEND
0	The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin ENTD toxicity ENTDEND . Heart and liver mitochondria were isolated from rats treated for 7 weeks with doxorubicin (2 mg/kg sc/week), ENTC carvedilol ENTCEND (1 mg/kg ip/week), or the combination of the two drugs
0	The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin ENTD toxicity ENTDEND . Heart and liver mitochondria were isolated from rats treated for 7 weeks with doxorubicin (2 mg/kg sc/week), carvedilol (1 mg/kg ip/week), or the combination of the two drugs. Heart mitochondria isolated from doxorubicin-treated rats exhibited depressed rates for state 3 respiration (336 +/- 26 versus 425 +/- 53 natom O/min/mg protein) and a lower respiratory control ratio (RCR) (4.3 +/- 0.6 versus 5.8 +/- 0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial ENTC calcium ENTCEND -loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats
0	It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting ENTD mitochondrial dysfunction ENTDEND and cardiomyopathy that accompanies long-term ENTC doxorubicin ENTCEND therapy in cancer patients
0	Recent evidence indicates that oxidative stress and ENTD mitochondrial dysfunction ENTDEND are key factors in the pathogenic process. The objective of this investigation was to test the hypothesis that ENTC carvedilol ENTCEND , a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity
0	Carvedilol also prevented the decrease in mitochondrial ENTC Ca ENTCEND (2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin. Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria. It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting ENTD mitochondrial dysfunction ENTDEND and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients
0	ENTC Bortezomib ENTCEND and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell ENTD malignancies ENTDEND
0	Bortezomib and high-dose ENTC dexamethasone ENTCEND containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell ENTD malignancies ENTDEND
0	Physicians should recognise the possibility of fatal ENTD bacterial infections ENTDEND related to ENTC bortezomib ENTCEND plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation
0	Physicians should recognise the possibility of fatal ENTD bacterial infections ENTDEND  related to bortezomib plus high-dose ENTC dexamethasone ENTCEND in elderly patients, and we believe this case warrants further investigation
1	ENTD Necrotising fasciitis ENTDEND  after ENTC bortezomib ENTCEND and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia
1	ENTD Necrotising fasciitis ENTDEND  after bortezomib and ENTC dexamethasone ENTCEND -containing regimen in an elderly patient of Waldenstrom macroglobulinaemia
0	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of ENTD Waldenstrom macroglobulinaemia ENTDEND ENTC Bortezomib ENTCEND and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies
0	Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of ENTD Waldenstrom macroglobulinaemia ENTDEND .Bortezomib and high-dose ENTC dexamethasone ENTCEND -containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies
0	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without ENTD neutropenia ENTDEND after the combination treatment with ENTC bortezomib ENTCEND , high-dose dexamethasone and rituximab
0	We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without ENTD neutropenia ENTDEND  after the combination treatment with bortezomib, high-dose ENTC dexamethasone ENTCEND and rituximab
1	Pure red cell aplasia, ENTD toxic dermatitis ENTDEND  and lymphadenopathy in a patient taking ENTC diphenylhydantoin ENTCEND
1	ENTD Pure red cell aplasia ENTDEND associated with ENTC diphenylhydantoin ENTCEND medication has been reported in 3 patients
0	In this patient the time relation between the ingestion of ENTC diphenylhydantoin ENTCEND and the occurrence of the ENTD skin rash ENTDEND , lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection
1	Pure red cell aplasia, toxic dermatitis and ENTD lymphadenopathy ENTDEND  in a patient taking ENTC diphenylhydantoin ENTCEND
0	PURPOSE: Apnea is known to occur during ENTD seizures ENTDEND  but systematic studies of ictal respiratory changes in adults are few. Data regarding respiratory pattern defects during interictal periods also are scarce. Here we sought to generate information with regard to the interictal period in animals with ENTC pilocarpine ENTCEND -induced epilepsy
0	PURPOSE: ENTD Apnea ENTDEND is known to occur during seizures, but systematic studies of ictal respiratory changes in adults are few. Data regarding respiratory pattern defects during interictal periods also are scarce. Here we sought to generate information with regard to the interictal period in animals with ENTC pilocarpine ENTCEND -induced epilepsy
1	Here we sought to generate information with regard to the interictal period in animals with ENTC pilocarpine ENTCEND -induced ENTD epilepsy ENTDEND
0	RESULTS: The ENTD hyperventilation ENTDEND maneuver caused a decrease in spontaneous ventilation in ENTC pilocarpine ENTCEND -treated and control rats
1	Furthermore, ENTC dexamethasone ENTCEND induced ENTD ocular hypertension ENTDEND was associated with chronic ER stress of the trabecular meshwork (TM)
0	Furthermore, reduction of ER stress in the TM with ENTC sodium 4-phenylbutyrate ENTCEND prevented dexamethasone-induced ENTD ocular hypertension ENTDEND in WT mice
0	1% ENTC dexamethasone ENTCEND led to elevation of intraocular pressure (IOP), functional and structural loss of ENTD retinal ganglion ENTDEND cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients
0	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of ENTD retinal ganglion ENTDEND  cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients. Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM). Similar to patients, withdrawal of dexamethasone treatment reduced elevated IOP and ER stress in this animal model. Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension. Furthermore, reduction of ER stress in the TM with ENTC sodium 4-phenylbutyrate ENTCEND prevented dexamethasone-induced ocular hypertension in WT mice
0	If untreated, these patients can develop a secondary glaucoma that resembles primary open-angle glaucoma ( ENTD POAG ENTDEND . The underlying pathology of glucocorticoid-induced glaucoma is not fully understood, due in part to lack of an appropriate animal model. Here, we developed a murine model of glucocorticoid-induced glaucoma that exhibits glaucoma features that are observed in patients. Treatment of WT mice with topical ocular 0.1% ENTC dexamethasone ENTCEND led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients
1	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced ENTD glaucoma ENTDEND in human patients. Furthermore, ENTC dexamethasone ENTCEND -induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM)
0	Furthermore, reduction of ER stress in the TM with ENTC sodium 4-phenylbutyrate ENTCEND  prevented dexamethasone-induced ocular hypertension in WT mice. Our data indicate that ER stress contributes to glucocorticoid-induced ocular hypertension and suggest that reducing ER stress has potential as a therapeutic strategy for treating glucocorticoid-induced ENTD glaucoma ENTDEND
1	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and ENTD axonal degeneration ENTDEND  resembling glucocorticoid-induced glaucoma in human patients. Furthermore, ENTC dexamethasone ENTCEND -induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM)
0	1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and ENTD axonal degeneration ENTDEND , resembling glucocorticoid-induced glaucoma in human patients. Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM). Similar to patients, withdrawal of dexamethasone treatment reduced elevated IOP and ER stress in this animal model. Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension. Furthermore, reduction of ER stress in the TM with ENTC sodium 4-phenylbutyrate ENTCEND prevented dexamethasone-induced ocular hypertension in WT mice
0	Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of ENTD hyperthyroidism ENTDEND  One should be aware of the side effects of ENTC antithyroid medications ENTCEND
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND  are commonly prescribed for the treatment of ENTD hyperthyroidism ENTDEND
0	Anti-thyroid drugs, like ENTC carbimazole ENTCEND and propylthiouracil (PTU) are commonly prescribed for the treatment of ENTD hyperthyroidism ENTDEND
0	The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENTD parotiditis ENTDEND but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENTC methimazole ENTCEND have a lower incidence of reported ANCA positive side effects than PUT
1	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENTC antithyroidmedications ENTCEND  We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENTD parotiditis ENTDEND but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENTD parotiditis ENTDEND but no renal or pulmonary involvement
1	We report a patient with Graves' disease who developed ANCA positive ENTC carbimazole ENTCEND induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and ENTD parotiditis ENTDEND but no renal or pulmonary involvement
0	The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENTD pyrexia ENTDEND and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENTC methimazole ENTCEND have a lower incidence of reported ANCA positive side effects than PUT
1	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENTC antithyroidmedications ENTCEND . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENTD pyrexia ENTDEND and parotiditis but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENTD pyrexia ENTDEND and parotiditis but no renal or pulmonary involvement
1	We report a patient with Graves' disease who developed ANCA positive ENTC carbimazole ENTCEND  induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, ENTD pyrexia ENTDEND and parotiditis but no renal or pulmonary involvement
0	The episode was characterized by a vasculitic ENTD skin rash ENTDEND associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENTC methimazole ENTCEND have a lower incidence of reported ANCA positive side effects than PUT
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENTC antithyroidmedications ENTCEND . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic ENTD skin rash ENTDEND associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic ENTD skin rash ENTDEND associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement
0	We report a patient with Graves' disease who developed ANCA positive ENTC carbimazole ENTCEND  induced vasculitis. The episode was characterized by a vasculitic ENTD skin rash ENTDEND associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement
0	He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENTD myositis ENTDEND  Carbimazole and ENTC methimazole ENTCEND have a lower incidence of reported ANCA positive side effects than PUT
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENTC antithyroidmedications ENTCEND . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENTD myositis ENTDEND
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENTD myositis ENTDEND
0	He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have ENTD myositis ENTDEND . ENTC Carbimazole ENTCEND and methimazole have a lower incidence of reported ANCA positive side effects than PUT
0	We report a patient with ENTD Graves' disease ENTDEND who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENTC methimazole ENTCEND have a lower incidence of reported ANCA positive side effects than PUT
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENTC antithyroidmedications ENTCEND . We report a patient with ENTD Graves' disease ENTDEND who developed ANCA positive carbimazole induced vasculitis
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with ENTD Graves' disease ENTDEND who developed ANCA positive carbimazole induced vasculitis
0	We report a patient with ENTD Graves' disease ENTDEND  who developed ANCA positive ENTC carbimazole ENTCEND induced vasculitis
0	Carbimazole and ENTC methimazole ENTCEND  have a lower incidence of reported ANCA positive side effects than PUT. To the best of our knowledge this is the first ANCA positive carbimazole induced ENTD vasculitis ENTDEND case reported from India
0	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENTC antithyroidmedications ENTCEND . We report a patient with Graves' disease who developed ANCA positive carbimazole induced ENTD vasculitis ENTDEND
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced ENTD vasculitis ENTDEND
0	We report a patient with Graves' disease who developed ANCA positive ENTC carbimazole ENTCEND  induced ENTD vasculitis ENTDEND
0	ENTD Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis ENTDEND is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint arthritis, pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENTC methimazole ENTCEND have a lower incidence of reported ANCA positive side effects than PUT
1	Carbimazole induced ENTD ANCA positive vasculitis ENTDEND . ENTC Anti-thyroid drugs ENTCEND , like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism
0	Carbimazole induced ENTD ANCA positive vasculitis ENTDEND .Anti-thyroid drugs, like carbimazole and ENTC propylthiouracil ENTCEND (PTU) are commonly prescribed for the treatment of hyperthyroidism
1	ENTC Carbimazole ENTCEND  induced ENTD ANCA positive vasculitis ENTDEND
0	The episode was characterized by a vasculitic skin rash associated with large joint ENTD arthritis ENTDEND  pyrexia and parotiditis but no renal or pulmonary involvement. He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis. Carbimazole and ENTC methimazole ENTCEND have a lower incidence of reported ANCA positive side effects than PUT
1	Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of ENTC antithyroidmedications ENTCEND . We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint ENTD arthritis ENTDEND , pyrexia and parotiditis but no renal or pulmonary involvement
0	Anti-thyroid drugs, like carbimazole and propylthiouracil ( ENTC PTU ENTCEND ) are commonly prescribed for the treatment of hyperthyroidism. One should be aware of the side effects of antithyroid medications. Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis is a potentially life-threatening adverse effect of antithyroidmedications. We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint ENTD arthritis ENTDEND , pyrexia and parotiditis but no renal or pulmonary involvement
1	We report a patient with Graves' disease who developed ANCA positive ENTC carbimazole ENTCEND  induced vasculitis. The episode was characterized by a vasculitic skin rash associated with large joint ENTD arthritis ENTDEND , pyrexia and parotiditis but no renal or pulmonary involvement
1	A case of phenytoin ( ENTC DPH ENTCEND  ENTD encephalopathy ENTDEND with increasing seizures and EEG and mental changes is described
0	A case of phenytoin ( ENTC DPH ENTCEND ) encephalopathy with increasing ENTD seizures ENTDEND and EEG and mental changes is described
0	In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform ENTD rash ENTDEND during ENTC DPH ENTCEND treatment, the protidogram was normal, and an intradermic DPH injection had no local effect
0	DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and ENTC dobutamine ENTCEND induced ENTD ischaemia ENTDEND
0	Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both ENTC dobutamine ENTCEND  and exercise induced ENTD myocardial ischaemia ENTDEND
1	CONCLUSIONS: In patients with coronary artery disease, ENTC dobutamine ENTCEND induced ischaemia results in prolonged reversible ENTD left ventricular dysfunction ENTDEND , presumed to be myocardial stunning, similar to that seen after exercise
1	CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be ENTD myocardial stunning ENTDEND  similar to that seen after exercise. ENTC Dobutamine ENTCEND induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease
0	53) or ST ENTD depression ENTDEND (p = 0.63) with either form of stress. After exercise, ejection fraction was reduced at 15 and 30 minutes compared with baseline (mean (SEM), -5.6 (1.5)%, p < 0.05; and -6.1 (2.2)%, p < 0. 01), and at 30 and 45 minutes after ENTC dobutamine ENTCEND (-10
0	CONCLUSIONS: In patients with ENTD coronary artery disease ENTDEND ENTC dobutamine ENTCEND induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise
0	DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and ENTC dobutamine ENTCEND  induced ischaemia. SUBJECTS: 10 patients with ENTD stable angina ENTDEND , angiographically proven coronary artery disease, and normal left ventricular function
0	The ENTC dopamine ENTCEND agonist significantly ENTD impaired novel word learning ENTDEND compared to placebo
1	Subjects received the tonically stimulating dopamine-receptor agonist ENTC pergolide ENTCEND (0.1 mg) vs placebo 120 min before training on each training day. The dopamine agonist significantly ENTD impaired novel word learning ENTDEND compared to placebo
0	Tonic dopaminergic stimulation ENTD impairs associative learning ENTDEND  in healthy subjects.Endogenous dopamine plays a central role in salience coding during associative learning. Administration of the dopamine precursor ENTC levodopa ENTCEND enhances learning in healthy subjects and stroke patients
0	Thus, phasic signaling seems to be the critical mechanism by which ENTC dopamine ENTCEND enhances associative learning in healthy subjects and ENTD stroke ENTDEND patients
0	The extent of 'flattened' affect with ENTC pergolide ENTCEND was related to the degree of learning inhibition. These findings suggest that tonic occupation of dopamine receptors impairs learning by competition with phasic dopamine signals. Thus, phasic signaling seems to be the critical mechanism by which dopamine enhances associative learning in healthy subjects and ENTD stroke ENTDEND patients
0	Administration of the dopamine precursor levodopa enhances learning in healthy subjects and ENTD stroke ENTDEND patients. Because ENTC levodopa ENTCEND increases both phasic and tonic dopaminergic neurotransmission, the critical mechanism mediating the enhancement of learning is unresolved
0	1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or ENTD schizoaffective disorder ENTDEND (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or ENTC risperidone ENTCEND (1-6 mg/day)
0	1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or ENTD schizoaffective disorder ENTDEND  (8%) were randomly assigned to treatment with ENTC olanzapine ENTCEND (2
1	Significantly more ENTD weight gain ENTDEND occurred with olanzapine than with ENTC risperidone ENTCEND : the increase in weight at 4 months relative to baseline weight was 17
1	Significantly more ENTD weight gain ENTDEND  occurred with ENTC olanzapine ENTCEND than with risperidone: the increase in weight at 4 months relative to baseline weight was 17
1	ENTD Extrapyramidal symptom ENTDEND severity scores were 1.4 (95% CI=1.2-1.6) with ENTC risperidone ENTCEND and 1
1	ENTD Extrapyramidal symptom ENTDEND  severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with ENTC olanzapine ENTCEND
0	OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus ENTC risperidone ENTCEND in patients with first-episode ENTD schizophrenia ENTDEND spectrum disorders
0	OBJECTIVE: The authors compared 4-month treatment outcomes for ENTC olanzapine ENTCEND versus risperidone in patients with first-episode ENTD schizophrenia ENTDEND spectrum disorders
0	Negative symptom outcomes and measures of parkinsonism and ENTD akathisia ENTDEND did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with ENTC risperidone ENTCEND and 1
0	Negative symptom outcomes and measures of parkinsonism and ENTD akathisia ENTDEND  did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with ENTC olanzapine ENTCEND
0	Negative symptom outcomes and measures of ENTD parkinsonism ENTDEND and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with ENTC risperidone ENTCEND and 1
0	Negative symptom outcomes and measures of ENTD parkinsonism ENTDEND  and akathisia did not differ between medications. Extrapyramidal symptom severity scores were 1.4 (95% CI=1.2-1.6) with risperidone and 1.2 (95% CI=1.0-1.4) with ENTC olanzapine ENTCEND
0	Of 6 patients with irreversible visual impairment, 4 patients had diabetes mellitus, ENTD glaucoma ENTDEND and a history of heavy smoking. CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ENTC ethambutol ENTCEND therapy
0	METHOD: Thirteen patients who developed optic neuropathy after being treated with ENTC ethambutol ENTCEND for ENTD tuberculosis of the lung or lymph node ENTDEND at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed
0	CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ENTC ethambutol ENTCEND  therapy. A low dose and prompt discontinuation of the drug is recommended particularly in individuals with ENTD diabetes mellitus ENTDEND , glaucoma or who are heavy smokers
0	Of 6 patients with irreversible ENTD visual impairment ENTDEND  4 patients had diabetes mellitus, glaucoma and a history of heavy smoking. CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ENTC ethambutol ENTCEND therapy
1	ENTC Ethambutol ENTCEND  and ENTD optic neuropathy ENTDEND
0	METHOD: Thirteen patients who developed optic neuropathy after being treated with ENTC ethambutol ENTCEND  for ENTD tuberculosis of the lung or lymph node ENTDEND at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed
0	0 mg/dL), patients in the ENTD hypercalcemic ENTDEND group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of ENTC vitamin D ENTCEND metabolites were similar in both groups
0	Fourteen of 39 dialysis patients (36%) became ENTD hypercalcemic ENTDEND after switching to calcium carbonate as their principal ENTC phosphate ENTCEND binder
0	0 mg/dL), patients in the ENTD hypercalcemic ENTDEND  group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of vitamin D metabolites were similar in both groups. Physical activity index and predialysis serum ENTC bicarbonate ENTCEND levels also were similar in both groups
1	Fourteen of 39 dialysis patients (36%) became ENTD hypercalcemic ENTDEND  after switching to ENTC calcium carbonate ENTCEND as their principal phosphate binder
0	In addition to experiencing ENTD hypercalcemic ENTDEND episodes with peak ENTC calcium ENTCEND values of 2
0	In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENTD renal disease ENTDEND  In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of ENTC vitamin D ENTCEND metabolites were similar in both groups
0	Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to calcium carbonate as their principal ENTC phosphate ENTCEND  binder. In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENTD renal disease ENTDEND
0	In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENTD renal disease ENTDEND . In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/- 0.03 to 2.5 +/- 0.03 mmol/L [9.7 +/- 0.2 to 10.2 +/- 0.1 mg/dL], P = 0.006). In contrast, eucalcemic patients exhibited no change in mean calcium values over the same time period (2.3 +/- 0.05 to 2.3 +/- 0.05 mmol/L [9.2 +/- 0.2 to 9.2 +/- 0.2 mg/dL]). CaCO3 dosage, calculated dietary calcium intake, and circulating levels of vitamin D metabolites were similar in both groups. Physical activity index and predialysis serum ENTC bicarbonate ENTCEND levels also were similar in both groups
0	Fourteen of 39 dialysis patients (36%) became hypercalcemic after switching to ENTC calcium carbonate ENTCEND  as their principal phosphate binder. In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENTD renal disease ENTDEND
0	In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of ENTD renal disease ENTDEND . In addition to experiencing hypercalcemic episodes with peak ENTC calcium ENTCEND values of 2
0	Thalidomide neuropathy in patients treated for metastatic ENTD prostate cancer ENTDEND .We prospectively evaluated ENTC thalidomide ENTCEND -induced neuropathy using electrodiagnostic studies
0	Sixty-seven men with metastatic ENTC androgen ENTCEND independent ENTD prostate cancer ENTDEND in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment
1	Neuropathy may thus be a common complication of ENTC thalidomide ENTCEND in older patients. The SNAP index can be used to monitor ENTD peripheral neuropathy ENTDEND , but not for early detection
0	ENTC Thalidomide ENTCEND ENTD neuropathy ENTDEND in patients treated for metastatic prostate cancer
0	We prospectively evaluated thalidomide-induced ENTD neuropathy ENTDEND using electrodiagnostic studies. Sixty-seven men with metastatic ENTC androgen ENTCEND -independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment
0	However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of ENTC tetracycline ENTCEND on ENTD depression ENTDEND of output of triglyceride under these experimental conditions
0	With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and ENTD depression ENTDEND of output of ENTC triglyceride ENTCEND by livers from male and female rats
0	With provision of adequate ENTC oleic acid ENTCEND as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and ENTD depression ENTDEND of output of triglyceride by livers from male and female rats
1	ENTD Fatty liver ENTDEND  induced by ENTC tetracycline ENTCEND in the rat
0	Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the ENTC triglyceride ENTCEND rich ENTD fatty liver ENTDEND in response to tetracycline
0	These differences between the sexes could not be related to altered disposition of tetracycline or altered uptake of ENTC oleic acid ENTCEND  Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich ENTD fatty liver ENTDEND in response to tetracycline
1	The main side-effects were ENTD headache ENTDEND  dizziness, palpitation and flushing and these were not more frequent than reported in other studies with ENTC isradipine ENTCEND or with placebo
0	The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with ENTC isradipine ENTCEND  or with placebo. Supine blood pressure was reduced (P less than 0.01) from 170 +/- 20/102 +/- 6 mmHg to 153 +/- 19/92 +/- 8, 147 +/- 18/88 +/- 7 and 144 +/- 14/87 +/- 6 mmHg at 2, 4 and 6 weeks respectively in evaluable patients. Similar reductions occurred in standing blood pressure and there was no evidence of ENTD postural hypotension ENTDEND
0	ENTC Isradipine ENTCEND  treatment for ENTD hypertension ENTDEND in general practice in Hong Kong
1	The main side-effects were headache, dizziness, palpitation and ENTD flushing ENTDEND and these were not more frequent than reported in other studies with ENTC isradipine ENTCEND or with placebo
1	The main side-effects were headache, ENTD dizziness ENTDEND  palpitation and flushing and these were not more frequent than reported in other studies with ENTC isradipine ENTCEND or with placebo
0	Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) ENTD acute lymphoblastic leukemia ENTDEND  protocols (ACCL0131): a ENTC methotrexate ENTCEND consequence? A report from the Children's Oncology Group
1	Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic ENTC MTX ENTCEND administration in children with acute lymphoblastic leukemia. In this study, neurocognitive outcomes and neuroradiologic evidence of ENTD leukoencephalopathy ENTDEND were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201)
0	Concerns about long-term methotrexate ( ENTC MTX ENTCEND  ENTD neurotoxicity ENTDEND in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia
1	Children on both studies had significant ENTD attention problems ENTDEND  but P9605 children scored below average on more neurocognitive measures than those treated on P9201 (82%, 14/17 measures vs. 24%, 4/17 measures). This supports ongoing concerns about intensive ENTC MTX ENTCEND exposure as a major contributor to CNS late effects
0	Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic ENTC MTX ENTCEND  administration in children with acute lymphoblastic leukemia. In this study, neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201). A total of 66 children from 16 Pediatric Oncology Group institutions with "standard-risk" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS ENTD leukemia ENTDEND at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605
1	A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in ENTC GM ENTCEND mediated ENTD nephropathy ENTDEND
0	Administration of GM at 40 mg/kg sc for 13 days to rats induced a significant reduction in renal blood flow (RBF) and inulin clearance (CIn) as well as marked ENTD tubular damage ENTDEND  A significant reduction in urinary ENTC guanosine 3',5'-cyclic monophosphate ENTCEND (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy
0	A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated ENTD nephropathy ENTDEND . ENTC Superoxide ENTCEND dismutase (SOD) or dimethylthiourea (DMTU) significantly lessened the GM-induced decrement in CIn
0	SOD did not attenuate the ENTD tubular damage ENTDEND  In contrast, ENTC DMTU ENTCEND significantly reduced the tubular damage and lipid peroxidation, but it did not affect renal hemodynamics and vasoactive substances
0	The total doses of ACC-9653 or ENTC phenytoin sodium ENTCEND necessary to convert the ENTD arrhythmia ENTDEND to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively
0	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ENTC ouabain ENTCEND induced ventricular tachycardia in anesthetized dogs. The total doses of ACC-9653 or phenytoin sodium necessary to convert the ENTD arrhythmia ENTDEND to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively
1	Only phenytoin sodium displayed in vitro antiarrhythmic activity against ENTC strophanthidin ENTCEND induced ENTD arrhythmias ENTDEND in guinea pig right atria
0	ACC-9653, the disodium phosphate ester of ENTC 3-hydroxymethyl-5,5-diphenylhydantoin ENTCEND  is a prodrug of phenytoin with advantageous physicochemical properties. ACC-9653 is rapidly converted enzymatically to phenytoin in vivo. ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against ENTD seizures ENTDEND induced by maximal electroshock (MES) in mice following i
0	ACC-9653 and ENTC phenytoin sodium ENTCEND have equivalent anticonvulsant activity against ENTD seizures ENTDEND induced by maximal electroshock (MES) in mice following i
0	ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against ENTD seizures ENTDEND  induced by maximal electroshock (MES) in mice following i.p., oral, or i.v. administration. The ED50 doses were 16 mg/kg for i.v. ACC-9653 and 8 mg/kg for i.v. phenytoin sodium. ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ENTC ouabain ENTCEND -induced ventricular tachycardia in anesthetized dogs
0	ACC-9653 is rapidly converted enzymatically to ENTC phenytoin ENTCEND in vivo. ACC-9653 and phenytoin sodium have equivalent anticonvulsant activity against ENTD seizures ENTDEND induced by maximal electroshock (MES) in mice following i
0	Acute ENTD toxicity ENTDEND studies of ENTC ACC-9653 ENTCEND and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i
0	Only phenytoin sodium displayed in vitro antiarrhythmic activity against ENTC strophanthidin ENTCEND -induced arrhythmias in guinea pig right atria. In anesthetized dogs, a high dose of ACC-9653 (31 mg/kg) was infused over 15, 20, and 30 min and the responses were compared to an equimolar dose of phenytoin sodium (21 mg/kg). The ACC-9653 and phenytoin sodium treatments produced similar marked reductions in diastolic blood pressure and contractile force (LVdP/dt). The maximum effects of each treatment occurred at the time of maximum phenytoin sodium levels. Acute ENTD toxicity ENTDEND studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i
0	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ENTD ventricular tachycardia ENTDEND in anesthetized dogs. The total doses of ENTC ACC-9653 ENTCEND or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively
1	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ENTC ouabain ENTCEND -induced ENTD ventricular tachycardia ENTDEND in anesthetized dogs
0	ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ENTD ventricular tachycardia ENTDEND  in anesthetized dogs. The total doses of ACC-9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/- 6 and 14 +/- 3 mg/kg, respectively. Only phenytoin sodium displayed in vitro antiarrhythmic activity against ENTC strophanthidin ENTCEND -induced arrhythmias in guinea pig right atria
0	Furthermore, Rg1 showed a tendency to aggravate ENTD OIH ENTDEND in the ENTC acetic acid ENTCEND -induced writhing test
0	Effects of ENTC ginsenosides ENTCEND  on opioid-induced ENTD hyperalgesia ENTDEND in mice
1	ENTD OIH ENTDEND was achieved in mice after subcutaneous administration of ENTC morphine ENTCEND for 7 consecutive days three times per day
0	However, the ENTC Rg1 and Rb1 ginsenosides ENTCEND failed to prevent ENTD OIH ENTDEND in either test
0	ENTC Re ENTCEND (300 mg/kg) inhibited ENTD OIH ENTDEND in both the thermal sensitivity test and the acetic acid-induced writhing test
0	However, the ENTC Rg1 and Rb1 ginsenosides ENTCEND failed to prevent ENTD OIH ENTDEND in either test
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENTD opioid addiction ENTDEND  In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH. OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day. During withdrawal (days 8 and 9), these mice were administered Re, Rg1, or Rb1 intragastrically two times per day. On the test day (day 10), mice were subjected to the thermal sensitivity test and the ENTC acetic acid ENTCEND -induced writhing test
0	Effects of ENTC ginsenosides ENTCEND  on opioid-induced hyperalgesia in mice.Opioid-induced hyperalgesia (OIH) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use. OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENTD opioid addiction ENTDEND
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENTD opioid addiction ENTDEND . In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH. OIH was achieved in mice after subcutaneous administration of ENTC morphine ENTCEND for 7 consecutive days three times per day
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENTD opioid addiction ENTDEND . In this study, we investigated the effects of ENTC Re, Rg1, and Rb1 ginsenosides ENTCEND , the bioactive components of ginseng, on OIH
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENTD opioid addiction ENTDEND . In this study, we investigated the effects of ENTC Re, Rg1, and Rb1 ginsenosides ENTCEND , the bioactive components of ginseng, on OIH
0	OIH can limit the clinical use of opioid analgesics and complicate withdrawal from ENTD opioid addiction ENTDEND . In this study, we investigated the effects of ENTC Re, Rg1, and Rb1 ginsenosides ENTCEND , the bioactive components of ginseng, on OIH
0	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle ENTD necroses ENTDEND  The initial response to the primary attack by the ENTC cyclophosphamide ENTCEND metabolites seems to be fragmentation of the luminal membrane
0	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle ENTD necroses ENTDEND . The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENTC luminal ENTCEND membrane
0	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by ENTC mesna ENTCEND .Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle ENTD necroses ENTDEND
0	Fully developed ENTC cyclophosphamide ENTCEND induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal ENTD edema ENTDEND owing to damage to the microvascular bed and focal muscle necroses
0	Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal ENTD edema ENTDEND  owing to damage to the microvascular bed and focal muscle necroses. The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENTC luminal ENTCEND membrane
0	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by ENTC mesna ENTCEND .Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal ENTD edema ENTDEND owing to damage to the microvascular bed and focal muscle necroses
0	Fully developed ENTC cyclophosphamide ENTCEND -induced ENTD cystitis ENTDEND is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses
0	Fully developed cyclophosphamide-induced ENTD cystitis ENTDEND  is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses. The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENTC luminal ENTCEND membrane
0	Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by ENTC mesna ENTCEND .Fully developed cyclophosphamide-induced ENTD cystitis ENTDEND is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses
1	Electron microscopic investigations of the ENTC cyclophosphamide ENTCEND -induced ENTD lesions of the urinary bladder ENTDEND of the rat and their prevention by mesna
0	Electron microscopic investigations of the cyclophosphamide-induced ENTD lesions of the urinary bladder ENTDEND  of the rat and their prevention by mesna.Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses. The initial response to the primary attack by the cyclophosphamide metabolites seems to be fragmentation of the ENTC luminal ENTCEND membrane
0	Electron microscopic investigations of the cyclophosphamide-induced ENTD lesions of the urinary bladder ENTDEND  of the rat and their prevention by ENTC mesna ENTCEND
0	RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of ENTC triglyceride ENTCEND levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by ENTD coronary heart disease ENTDEND
0	5 years on ENTC CPA ENTCEND treatment, four patients out of twenty-four were found to be affected by ENTD coronary heart disease ENTDEND
0	5 years on CPA treatment, four patients out of twenty-four were found to be affected by ENTD coronary heart disease ENTDEND . CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL ENTC cholesterol ENTCEND , Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen
0	5 years on CPA treatment, four patients out of twenty-four were found to be affected by ENTD coronary heart disease ENTDEND . CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by ENTC estrogen ENTCEND
0	AIM: To study the change of lipid metabolism by antiandrogen therapy in patients with ENTD prostate cancer ENTDEND  MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), ENTC triglycerides ENTCEND (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy
0	5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk ENTD prostate cancer ENTDEND (stage: T1cN0M0, Gleason score: 2-5) during treatment with ENTC cyproterone acetate ENTCEND (CPA) without surgical management or radiation therapy
0	AIM: To study the change of lipid metabolism by antiandrogen therapy in patients with ENTD prostate cancer ENTDEND . MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma ENTC cholesterols ENTCEND (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy
0	5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk ENTD prostate cancer ENTDEND  (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy. RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by ENTC estrogen ENTCEND
0	RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of ENTC triglyceride ENTCEND  levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known ENTD hyperglyceridemic effect ENTDEND caused by estrogen
1	6% as caused by prolonged ENTC CPA ENTCEND therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known ENTD hyperglyceridemic effect ENTDEND caused by estrogen
0	6% as caused by prolonged CPA therapy is mediated through changes in HDL ENTC cholesterol ENTCEND , Apo A-I and Apo A-II pro fi les, other than the well-known ENTD hyperglyceridemic effect ENTDEND caused by estrogen
0	6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known ENTD hyperglyceridemic effect ENTDEND  caused by ENTC estrogen ENTCEND
0	RESULTS: Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of ENTC triglyceride ENTCEND  levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease. CONCLUSIONS: Ischaemic ENTD coronary arteriosclerosis ENTDEND with an incidence rate of 16
1	CONCLUSIONS: Ischaemic ENTD coronary arteriosclerosis ENTDEND  with an incidence rate of 16.6% as caused by prolonged ENTC CPA ENTCEND therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen
0	CONCLUSIONS: Ischaemic ENTD coronary arteriosclerosis ENTDEND  with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL ENTC cholesterol ENTCEND , Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen
0	CONCLUSIONS: Ischaemic ENTD coronary arteriosclerosis ENTDEND  with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by ENTC estrogen ENTCEND
1	The effect of ENTD pupil dilation ENTDEND  with ENTC tropicamide ENTCEND on vision and driving simulator performance
0	ENTC Metformin ENTCEND  protects against seizures, ENTD learning and memory impairments ENTDEND and oxidative damage induced by pentylenetetrazole-induced kindling in mice
1	Metformin protects against seizures, ENTD learning and memory impairments ENTDEND  and oxidative damage induced by ENTC pentylenetetrazole ENTCEND -induced kindling in mice
0	This study was designed to evaluate the ameliorative effects of ENTC metformin ENTCEND on ENTD seizures ENTDEND , cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals
1	Metformin protects against ENTD seizures ENTDEND , learning and memory impairments and oxidative damage induced by ENTC pentylenetetrazole ENTCEND -induced kindling in mice
0	ENTC Metformin ENTCEND  protects against seizures, ENTD learning and memory impairments ENTDEND and oxidative damage induced by pentylenetetrazole-induced kindling in mice
1	Metformin protects against seizures, ENTD learning and memory impairments ENTDEND  and oxidative damage induced by ENTC pentylenetetrazole ENTCEND -induced kindling in mice
0	This study was designed to evaluate the ameliorative effects of ENTC metformin ENTCEND  on seizures, ENTD cognitive impairment ENTDEND and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals
1	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by ENTC pentylenetetrazole ENTCEND -induced kindling in mice. ENTD Cognitive impairment ENTDEND , the most common and severe comorbidity of epilepsy, greatly diminishes the quality of life
0	Thus the present study concluded that ENTC metformin ENTCEND may be a potential agent for the treatment of ENTD epilepsy ENTDEND as well as a protective medicine against cognitive impairment induced by seizures
0	Metformin protects against seizures, learning and memory impairments and oxidative damage induced by ENTC pentylenetetrazole ENTCEND -induced kindling in mice.Cognitive impairment, the most common and severe comorbidity of ENTD epilepsy ENTDEND , greatly diminishes the quality of life
1	A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion ( ENTC DEP ENTCEND  became ENTD manic ENTDEND during his second week on the study drug
0	Pupillary changes associated with the development of stimulant-induced ENTD mania ENTDEND : a case report.A 30-year-old ENTC cocaine ENTCEND -dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug
0	Pupillometric changes while on ENTC DEP ENTCEND  especially changes in the total power of ENTD pupillary oscillation ENTDEND , were dramatically different than those observed in the eight other study subjects who did not become manic
0	A 30-year-old ENTC cocaine ENTCEND -dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug. Pupillometric changes while on DEP, especially changes in the total power of ENTD pupillary oscillation ENTDEND , were dramatically different than those observed in the eight other study subjects who did not become manic
1	A Case of ENTD Sudden Cardiac Death ENTDEND  due to ENTC Pilsicainide ENTCEND -Induced Torsades de Pointes
0	A Case of ENTD Sudden Cardiac Death ENTDEND  due to Pilsicainide-Induced Torsades de Pointes.An 84-year-old male received oral pilsicainide, a pure ENTC sodium ENTCEND channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later
0	Although the oral administration of class IC drugs, including ENTC pilsicainide ENTCEND  is effective to terminate ENTD atrial fibrillation ENTDEND , careful consideration must be taken before giving these drugs to octogenarians
0	An 84-year-old male received oral pilsicainide, a pure ENTC sodium ENTCEND  channel blocker with slow recovery kinetics, to convert his paroxysmal ENTD atrial fibrillation ENTDEND to a sinus rhythm; the patient developed sudden cardiac death two days later
1	A Case of Sudden Cardiac Death due to ENTC Pilsicainide ENTCEND -Induced ENTD Torsades de Pointes ENTDEND
0	A Case of Sudden Cardiac Death due to Pilsicainide-Induced ENTD Torsades de Pointes ENTDEND .An 84-year-old male received oral pilsicainide, a pure ENTC sodium ENTCEND channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later
1	The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on ENTC isoproterenol ENTCEND induced ENTD myocardial infarction ENTDEND in rats with respect to lipid metabolism in serum and heart tissue has been investigated
0	The cardioprotective effect of the ENTC ethanol ENTCEND extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced ENTD myocardial infarction ENTDEND in rats with respect to lipid metabolism in serum and heart tissue has been investigated
1	Severe ENTD polyneuropathy ENTDEND  and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented. Both cases developed axonal neuropathy with motor predominance in the lower extremities 1 and 6 months after IT chemotherapy was administered. Neurologic toxicities have been described with IT- ENTC methotrexate ENTCEND , IT-cytosine arabinoside and IT-TSPA
1	Severe ENTD polyneuropathy ENTDEND  and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented. Both cases developed axonal neuropathy with motor predominance in the lower extremities 1 and 6 months after IT chemotherapy was administered. Neurologic toxicities have been described with IT-methotrexate, IT- ENTC cytosine arabinoside ENTCEND and IT-TSPA
1	Severe ENTD polyneuropathy ENTDEND  and motor loss after intrathecal ENTC thiotepa ENTCEND combination chemotherapy: description of two cases
1	ENTD Neurologic toxicities ENTDEND have been described with IT ENTC methotrexate ENTCEND , IT-cytosine arabinoside and IT-TSPA
1	In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ENTC ara-C ENTCEND and radiotherapy could cause severe ENTD neurotoxicity ENTDEND
1	ENTD Neurologic toxicities ENTDEND  have been described with IT-methotrexate, IT-cytosine arabinoside and IT- ENTC TSPA ENTCEND
0	Neurologic toxicities have been described with IT- ENTC methotrexate ENTCEND , IT-cytosine arabinoside and IT-TSPA. To our knowledge, however, ENTD axonal neuropathy ENTDEND following administration of these three agents has not been previously described
0	Neurologic toxicities have been described with IT-methotrexate, IT- ENTC cytosine arabinoside ENTCEND  and IT-TSPA. To our knowledge, however, ENTD axonal neuropathy ENTDEND following administration of these three agents has not been previously described
0	Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT- ENTC TSPA ENTCEND . To our knowledge, however, ENTD axonal neuropathy ENTDEND following administration of these three agents has not been previously described
1	Worsening of ENTD Parkinsonism ENTDEND  after the use of ENTC veralipride ENTCEND for treatment of menopause: case report
0	Segmental necrotising glomerulonephritis has been reported as complication of ENTC rifampicin ENTCEND therapy in patients receiving treatment for ENTD tuberculosis ENTDEND
0	Changing epidemiology of ENTD infections ENTDEND such as infective endocarditis (IE) has led to an increase in the use of ENTC rifampicin ENTCEND for Staphylococcal infections
0	Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of ENTC rifampicin ENTCEND  for ENTD Staphylococcal infections ENTDEND
0	Changing epidemiology of infections such as infective endocarditis ( ENTD IE ENTDEND  has led to an increase in the use of ENTC rifampicin ENTCEND for Staphylococcal infections
1	We describe a case of a patient with Staphylococcal IE who developed ENTD acute renal failure ENTDEND secondary to a segmental necrotising glomerulonephritis while being treated with ENTC rifampicin ENTCEND , and review the literature regarding this complication of rifampicin therapy
1	We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising ENTD glomerulonephritis ENTDEND while being treated with ENTC rifampicin ENTCEND , and review the literature regarding this complication of rifampicin therapy
0	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/ ENTC K ENTCEND +)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human ENTD bipolar mania ENTDEND
0	Clinical studies have shown that ENTD bipolar disorder ENTDEND may be related to mitochondrial dysfunction. Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, ENTC thiobarbituric acid ENTCEND reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala
1	In conclusion, ENTC ouabain ENTCEND induced ENTD mania ENTDEND -like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder
0	In addition, we observed that the persistent increase in the rat spontaneous locomotion is associated with increased TBARS levels and ENTC superoxide ENTCEND generation in submitochondrial particles in the prefrontal cortex, striatum and amygdala. In conclusion, ouabain-induced ENTD mania ENTDEND -like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder
0	The intracerebroventricular (ICV) administration of ouabain (a ENTC Na ENTCEND +)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human ENTD bipolar mania ENTDEND
0	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/ ENTC K ENTCEND (+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to ENTD mitochondrial dysfunction ENTDEND
0	Clinical studies have shown that bipolar disorder may be related to ENTD mitochondrial dysfunction ENTDEND . Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, ENTC thiobarbituric acid ENTCEND reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala
0	Clinical studies have shown that bipolar disorder may be related to ENTD mitochondrial dysfunction ENTDEND . Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ENTC ouabain ENTCEND in rats
0	Clinical studies have shown that bipolar disorder may be related to ENTD mitochondrial dysfunction ENTDEND . Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, thiobarbituric acid reactive substances (TBARSs) and ENTC superoxide ENTCEND production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala
0	The intracerebroventricular (ICV) administration of ouabain (a ENTC Na ENTCEND (+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to ENTD mitochondrial dysfunction ENTDEND
0	The intracerebroventricular (ICV) administration of ouabain (a Na(+)/ ENTC K ENTCEND (+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to mitochondrial dysfunction. Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, thiobarbituric acid reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENTD hyperlocomotion ENTDEND in rats, and this response remained up to 7 days following a single ICV injection
0	Additionally, ENTC thiobarbituric acid ENTCEND  reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENTD hyperlocomotion ENTDEND in rats, and this response remained up to 7 days following a single ICV injection
0	Our findings demonstrated that ENTC ouabain ENTCEND at 10(-2) and 10(-3)M induced ENTD hyperlocomotion ENTDEND in rats, and this response remained up to 7 days following a single ICV injection
0	Additionally, thiobarbituric acid reactive substances (TBARSs) and ENTC superoxide ENTCEND  production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENTD hyperlocomotion ENTDEND in rats, and this response remained up to 7 days following a single ICV injection
0	The intracerebroventricular (ICV) administration of ouabain (a ENTC Na ENTCEND (+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania. Clinical studies have shown that bipolar disorder may be related to mitochondrial dysfunction. Herein, we investigated the behavioral and biochemical effects induced by the ICV administration of ouabain in rats. To achieve this aim, the effects of ouabain injection immediately after and 7 days following a single ICV administration (at concentrations of 10(-2) and 10(-3)M) on locomotion was measured using the open-field test. Additionally, thiobarbituric acid reactive substances (TBARSs) and superoxide production were measured in submitochondrial particles of the prefrontal cortex, hippocampus, striatum and amygdala. Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced ENTD hyperlocomotion ENTDEND in rats, and this response remained up to 7 days following a single ICV injection
1	ENTD Pain ENTDEND on injection (80 vs. 20%, p < 0.01) and thrombophlebitis (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with ENTC Disoprivan ENTCEND
1	01) and ENTD thrombophlebitis ENTDEND (93.3 vs. 6.6%, p < 0.001) occurred more frequently with AM149 than with ENTC Disoprivan ENTCEND
0	The patient's observations were within normal limits, he was administered ENTC oxygen ENTCEND via a face mask and glyceryl trinitrate (GTN). Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge. There was no further deterioration in the patient's condition during transport to hospital. There are very few documented case like this in the prehospital scientific literature. The cause appears to be the Bezold-Jarish reflex, stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre. Prehospital care providers who are managing any patient with a ENTD syncopal episode ENTDEND that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly
0	Several minutes after the ENTC GTN ENTCEND the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by atropine sulphate and a fluid challenge. There was no further deterioration in the patient's condition during transport to hospital. There are very few documented case like this in the prehospital scientific literature. The cause appears to be the Bezold-Jarish reflex, stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre. Prehospital care providers who are managing any patient with a ENTD syncopal episode ENTDEND that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly
0	Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by ENTC atropine sulphate ENTCEND and a fluid challenge. There was no further deterioration in the patient's condition during transport to hospital. There are very few documented case like this in the prehospital scientific literature. The cause appears to be the Bezold-Jarish reflex, stimulation of the ventricular walls which in turn decreases sympathetic outflow from the vasomotor centre. Prehospital care providers who are managing any patient with a ENTD syncopal episode ENTDEND that fails to recover within a reasonable time frame should consider the Bezold-Jarisch reflex as the cause and manage the patient accordingly
0	A male in his sixties with no history of cardiac chest pain awoke with ENTD chest pain ENTDEND following an afternoon sleep. The patient did not self medicate. The patient's observations were within normal limits, he was administered ENTC oxygen ENTCEND via a face mask and glyceryl trinitrate (GTN)
0	A dramatic drop in blood pressure following prehospital ENTC GTN ENTCEND  administration.A male in his sixties with no history of cardiac ENTD chest pain ENTDEND awoke with chest pain following an afternoon sleep
0	A male in his sixties with no history of cardiac chest pain awoke with ENTD chest pain ENTDEND  following an afternoon sleep. The patient did not self medicate. The patient's observations were within normal limits, he was administered oxygen via a face mask and glyceryl trinitrate (GTN). Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate, this was rectified by ENTC atropine sulphate ENTCEND and a fluid challenge
1	The patient's observations were within normal limits, he was administered ENTC oxygen ENTCEND  via a face mask and glyceryl trinitrate (GTN). Several minutes after the GTN the patient experienced a sudden ENTD drop in blood pressure ENTDEND and heart rate, this was rectified by atropine sulphate and a fluid challenge
1	A dramatic ENTD drop in blood pressure ENTDEND  following prehospital ENTC GTN ENTCEND administration
0	Several minutes after the GTN the patient experienced a sudden ENTD drop in blood pressure ENTDEND  and heart rate, this was rectified by ENTC atropine sulphate ENTCEND and a fluid challenge
1	These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to ENTC isoproterenol ENTCEND induced ENTD cardiac hypertrophy ENTDEND
0	Assessment of cardiomyocyte DNA synthesis during ENTD hypertrophy ENTDEND  in adult mice.The ability of cardiomyocytes to synthesize DNA in response to experimentally induced cardiac hypertrophy was assessed in adult mice. ENTC Isoproterenol ENTCEND delivered by osmotic minipump implantation in adult C3Heb/FeJ mice resulted in a 46% increase in heart weight and a 19
0	ENTD Convulsion ENTDEND  following intravenous ENTC fluorescein ENTCEND angiography
1	Convulsion following intravenous ENTC fluorescein ENTCEND  angiography. ENTD Tonic-clonic seizures ENTDEND followed intravenous fluorescein injection for fundus angiography in a 47-year-old male
1	METHODS: Newborn piglets received ENTC levobupivacaine ENTCEND until ENTD cardiovascular collapse ENTDEND occurred
0	BACKGROUND: The optimal dosing regimens of lipid emulsion, ENTC epinephrine ENTCEND  or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity (LAST). METHODS: Newborn piglets received levobupivacaine until ENTD cardiovascular collapse ENTDEND occurred
0	Resuscitation with lipid, epinephrine, or both in ENTC levobupivacaine ENTCEND -induced ENTD cardiac toxicity ENTDEND in newborn piglets
0	Resuscitation with lipid, ENTC epinephrine ENTCEND , or both in levobupivacaine-induced ENTD cardiac toxicity ENTDEND in newborn piglets
0	BACKGROUND: The optimal dosing regimens of lipid emulsion, epinephrine, or both are not yet determined in neonates in cases of local anaesthetic systemic ENTD toxicity ENTDEND (LAST). METHODS: Newborn piglets received ENTC levobupivacaine ENTCEND until cardiovascular collapse occurred
0	BACKGROUND: The optimal dosing regimens of lipid emulsion, ENTC epinephrine ENTCEND , or both are not yet determined in neonates in cases of local anaesthetic systemic ENTD toxicity ENTDEND (LAST)
0	METHODS: Newborn piglets received ENTC levobupivacaine ENTCEND  until cardiovascular collapse occurred. Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ventricular tachycardia, ENTD fibrillation ENTDEND , or QRS prolongation
0	Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ventricular tachycardia, ENTD fibrillation ENTDEND , or QRS prolongation. Piglets were then randomly allocated to four groups: control (saline), Intralipid( ) alone, ENTC epinephrine ENTCEND alone, or a combination of Intralipd plus epinephrine
0	METHODS: Newborn piglets received ENTC levobupivacaine ENTCEND  until cardiovascular collapse occurred. Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ENTD ventricular tachycardia ENTDEND , fibrillation, or QRS prolongation
0	Standard cardiopulmonary resuscitation was started and electrocardiogram (ECG) was monitored for ENTD ventricular tachycardia ENTDEND , fibrillation, or QRS prolongation. Piglets were then randomly allocated to four groups: control (saline), Intralipid( ) alone, ENTC epinephrine ENTCEND alone, or a combination of Intralipd plus epinephrine
0	On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, ENTD confusion ENTDEND and falls. The electrocardiogram revealed a 37 beats/min sinus bradycardia. A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENTC bisoprolol ENTCEND and the heart rate remained normal
0	On the 49th day of ENTC terbinafine ENTCEND therapy, he was brought to the emergency room for a decrease of his global health status, ENTD confusion ENTDEND and falls
0	A 63 year-old Caucasian man on ENTC metoprolol ENTCEND 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis. On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, ENTD confusion ENTDEND and falls
0	A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's ENTD sinus bradycardia ENTDEND and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENTC bisoprolol ENTCEND and the heart rate remained normal
0	To report a ENTD sinus bradycardia ENTDEND induced by metoprolol and ENTC terbinafine ENTCEND drug-drug interaction and its management
0	To report a ENTD sinus bradycardia ENTDEND  induced by ENTC metoprolol ENTCEND and terbinafine drug-drug interaction and its management
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for ENTD onychomycosis ENTDEND  On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls. The electrocardiogram revealed a 37 beats/min sinus bradycardia. A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENTC bisoprolol ENTCEND and the heart rate remained normal
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral ENTC terbinafine ENTCEND 250 mg/day for ENTD onychomycosis ENTDEND
0	A 63 year-old Caucasian man on ENTC metoprolol ENTCEND  200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for ENTD onychomycosis ENTDEND
0	A score of 7 on the Naranjo ENTD adverse drug reaction ENTDEND probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENTC bisoprolol ENTCEND and the heart rate remained normal
0	A score of 7 on the Naranjo ENTD adverse drug reaction ENTDEND  probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and ENTC terbinafine ENTCEND
0	A score of 7 on the Naranjo ENTD adverse drug reaction ENTDEND  probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between ENTC metoprolol ENTCEND and terbinafine
1	A metoprolol- ENTC terbinafine ENTCEND  combination induced ENTD bradycardia ENTDEND
1	A ENTC metoprolol ENTCEND -terbinafine combination induced ENTD bradycardia ENTDEND
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable ENTD coronary artery disease ENTDEND was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis. On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls. The electrocardiogram revealed a 37 beats/min sinus bradycardia. A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine. The heart rate ameliorated first with a decrease in the dose of metoprolol. It was subsequently changed to ENTC bisoprolol ENTCEND and the heart rate remained normal
0	A 63 year-old Caucasian man on metoprolol 200 mg/day for stable ENTD coronary artery disease ENTDEND  was prescribed a 90-day course of oral ENTC terbinafine ENTCEND 250 mg/day for onychomycosis
0	A 63 year-old Caucasian man on ENTC metoprolol ENTCEND  200 mg/day for stable ENTD coronary artery disease ENTDEND was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis
1	PRACTICAL IMPLICATIONS: As much as 15% of ENTC lithium ENTCEND treated patients become ENTD hypercalcemic ENTDEND
0	PRACTICAL IMPLICATIONS: As much as 15% of lithium-treated patients become ENTD hypercalcemic ENTDEND . By routinely monitoring serum ENTC calcium ENTCEND levels, healthcare providers can improve the quality of life of this patient group
0	CONCLUSION: ENTD Primary hyperparathyroidism ENTDEND is a rare but potentially life-threatening side effect of long-term ENTC lithium ENTCEND therapy
0	PURPOSE: This paper reviews the effect of chronic lithium therapy on serum ENTC calcium ENTCEND level and parathyroid glands, its pathogenesis, and treatment options. We examined the case of a lithium-treated patient who had recurrent hypercalcemia to better understand the disease process. CONCLUSION: ENTD Primary hyperparathyroidism ENTDEND is a rare but potentially life-threatening side effect of long-term lithium therapy
1	Long-term ENTC lithium ENTCEND  therapy leading to ENTD hyperparathyroidism ENTDEND : a case report
0	Long-term lithium therapy leading to ENTD hyperparathyroidism ENTDEND : a case report.PURPOSE: This paper reviews the effect of chronic lithium therapy on serum ENTC calcium ENTCEND level and parathyroid glands, its pathogenesis, and treatment options
0	CONCLUSION: In patients with FHF and cerebral edema from ENTC acetaminophen ENTCEND overdose, prolonged therapeutic ENTD hypothermia ENTDEND could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery
0	Initial evaluation confirmed FHF from ENTC acetaminophen ENTCEND and cerebral edema. The patient was treated with hyperosmolar therapy, ENTD hyperventilation ENTDEND , sedation, and chemical paralysis
1	At re-warming, patient had resolution of her cerebral edema and ENTD intracranial hypertension ENTDEND  At discharge, she had complete recovery of neurological and hepatic functions. CONCLUSION: In patients with FHF and cerebral edema from ENTC acetaminophen ENTCEND overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery
0	RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed ENTD toxicity ENTDEND from ENTC acetaminophen ENTCEND which was ingested over a 2-day period
1	Initial evaluation confirmed FHF from ENTC acetaminophen ENTCEND  and ENTD cerebral edema ENTDEND
0	CONCLUSION: In patients with FHF and cerebral edema from ENTC acetaminophen ENTCEND  ENTD overdose ENTDEND , prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery
1	METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with ENTD FHF ENTDEND from ENTC acetaminophen ENTCEND and resultant cerebral edema
0	Initial evaluation confirmed FHF from ENTC acetaminophen ENTCEND  and cerebral edema. The patient was treated with hyperosmolar therapy, hyperventilation, sedation, and chemical ENTD paralysis ENTDEND
0	Three patients had acute viral myocarditis, one had a ENTC carbamazepine ENTCEND induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock. All patients were continuously monitored with central venous and arterial catheters in addition to routine noninvasive monitoring. An introducer sheath, a pacemaker, and sterile pacing wires were made readily available for the patients, should the need arise to terminate resistant cardiac ENTD dysrhythmias ENTDEND
0	Three patients had acute viral myocarditis, one had a ENTC carbamazepine ENTCEND -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock. All patients were continuously monitored with central venous and arterial catheters in addition to routine noninvasive monitoring. An introducer sheath, a pacemaker, and sterile pacing wires were made readily available for the patients, should the need arise to terminate resistant cardiac dysrhythmias. All patients developed cardiocirculatory arrest associated with extreme ENTD hypotension ENTDEND and dysrhythmias within the first 48 hours of their admission to the pediatric intensive care unit (PICU)
0	We describe the cardiopulmonary resuscitation efforts on five patients who presented in acute circulatory failure from ENTD myocardial dysfunction ENTDEND  Three patients had acute viral myocarditis, one had a ENTC carbamazepine ENTCEND -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock
0	Three patients had acute viral myocarditis, one had a ENTC carbamazepine ENTCEND -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute ENTD cardiogenic shock ENTDEND
1	Three patients had acute viral myocarditis, one had a ENTC carbamazepine ENTCEND -induced acute ENTD eosinophilic myocarditis ENTDEND , and one had cardiac hemosiderosis resulting in acute cardiogenic shock
1	Three patients had acute viral ENTD myocarditis ENTDEND  one had a ENTC carbamazepine ENTCEND -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock
0	We describe the cardiopulmonary resuscitation efforts on five patients who presented in acute ENTD circulatory failure ENTDEND from myocardial dysfunction. Three patients had acute viral myocarditis, one had a ENTC carbamazepine ENTCEND -induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock
0	Significant clinical manifestations have included confusion, papilledema, ENTD somnolence ENTDEND  exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND therapy
0	This developed a median of 9 days after initiation of high-dose ENTC etoposide ENTCEND therapy. Significant clinical manifestations have included confusion, papilledema, ENTD somnolence ENTDEND , exacerbation of motor deficits, and sharp increase in seizure activity
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans. This complication appears to represent a significant new toxicity of high-dose etoposide therapy for ENTD malignant glioma ENTDEND
0	Acute neurologic dysfunction after high-dose etoposide therapy for ENTD malignant glioma ENTDEND . ENTC Etoposide ENTCEND (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans. This complication appears to represent a significant new ENTD toxicity ENTDEND of high-dose etoposide therapy for malignant glioma
0	This complication appears to represent a significant new ENTD toxicity ENTDEND  of high-dose ENTC etoposide ENTCEND therapy for malignant glioma
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in ENTD tumor ENTDEND size and peritumor edema when compared with pretransplant scans
0	Etoposide ( ENTC VP-16-213 ENTCEND  has been used in the treatment of many solid ENTD tumors ENTDEND and hematologic malignancies
0	Significant clinical manifestations have included ENTD confusion ENTDEND  papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND therapy
1	This developed a median of 9 days after initiation of high-dose ENTC etoposide ENTCEND  therapy. Significant clinical manifestations have included ENTD confusion ENTDEND , papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity
0	In six of eight patients (75%) who we treated for recurrent or resistant glioma, sudden severe ENTD neurologic deterioration ENTDEND occurred. This developed a median of 9 days after initiation of high-dose etoposide therapy. Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND therapy
0	ENTD Acute neurologic dysfunction ENTDEND  after high-dose ENTC etoposide ENTCEND therapy for malignant glioma
0	Significant clinical manifestations have included confusion, ENTD papilledema ENTDEND  somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND therapy
1	This developed a median of 9 days after initiation of high-dose ENTC etoposide ENTCEND  therapy. Significant clinical manifestations have included confusion, ENTD papilledema ENTDEND , somnolence, exacerbation of motor deficits, and sharp increase in seizure activity
0	Etoposide (VP-16-213) has been used in the treatment of many solid tumors and ENTD hematologic malignancies ENTDEND  When used in high doses and in conjunction with autologous bone marrow transplantation, this agent has activity against several treatment-resistant cancers including malignant glioma. In six of eight patients (75%) who we treated for recurrent or resistant glioma, sudden severe neurologic deterioration occurred. This developed a median of 9 days after initiation of high-dose etoposide therapy. Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in seizure activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND therapy
0	Etoposide ( ENTC VP-16-213 ENTCEND ) has been used in the treatment of many solid tumors and ENTD hematologic malignancies ENTDEND
0	Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in ENTD seizure ENTDEND activity. These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND therapy
1	This developed a median of 9 days after initiation of high-dose ENTC etoposide ENTCEND  therapy. Significant clinical manifestations have included confusion, papilledema, somnolence, exacerbation of motor deficits, and sharp increase in ENTD seizure ENTDEND activity
0	These abnormalities resolved rapidly after initiation of high-dose intravenous ENTC dexamethasone ENTCEND  therapy. In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor ENTD edema ENTDEND when compared with pretransplant scans
0	In all patients, computerized tomographic (CT) brain scans demonstrated stability in tumor size and peritumor ENTD edema ENTDEND  when compared with pretransplant scans. This complication appears to represent a significant new toxicity of high-dose ENTC etoposide ENTCEND therapy for malignant glioma
1	Thereafter, seizures were induced by ENTC pilocarpine ENTCEND injections in trained and non-trained control groups. During the acute period of ENTD status epilepticus ENTDEND , we measured: (1) the latency of the first motor sign, (2) the intensity of seizures, (3) the time when it occurred within the 6-h observation period, and (4) the time when the acute period ended
1	Physical training decreases susceptibility to subsequent ENTC pilocarpine ENTCEND -induced ENTD seizures ENTDEND in the rat
0	Physical training decreases susceptibility to subsequent ENTC pilocarpine ENTCEND -induced seizures in the rat.Regular motor activity has many benefits for mental and physical condition but its implications for ENTD epilepsy ENTDEND are still controversial
0	An integrated characterization of serological, pathological, and functional events in ENTC doxorubicin ENTCEND -induced ENTD cardiotoxicity ENTDEND
0	25 mg/kg ENTC DOX ENTCEND weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, ENTD hypertrophy ENTDEND /cytomegaly, and extensive vacuolation after two doses
0	Histopathological analysis revealed progressive cardiomyocyte degeneration, ENTD hypertrophy ENTDEND /cytomegaly, and extensive vacuolation after two doses. Extensive replacement fibrosis (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" LV dysfunction by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak ENTC gadolinium ENTCEND contrast enhancement, histopathological grading, and diastolic dysfunction
1	25 mg/kg ENTC DOX ENTCEND  weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, hypertrophy/cytomegaly, and extensive vacuolation after two doses. Extensive replacement ENTD fibrosis ENTDEND (quantified by Sirius red staining) developed during the off-dosing period
0	Extensive replacement ENTD fibrosis ENTDEND  (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" LV dysfunction by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak ENTC gadolinium ENTCEND contrast enhancement, histopathological grading, and diastolic dysfunction
0	25 mg/kg ENTC DOX ENTCEND  weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed ENTD subcellular degeneration ENTDEND and marked mitochondrial changes after a single dose
0	Troponin I levels positively correlated with delayed and peak ENTC gadolinium ENTCEND  contrast enhancement, histopathological grading, and diastolic dysfunction. In summary, subcellular ENTD cardiomyocyte degeneration ENTDEND was the earliest marker, followed by progressive functional decline and histopathological manifestations
0	An integrated characterization of serological, pathological, and functional events in ENTC doxorubicin ENTCEND -induced cardiotoxicity.Many efficacious ENTD cancer ENTDEND treatments cause significant cardiac morbidity, yet biomarkers or functional indices of early damage, which would allow monitoring and intervention, are lacking
0	In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this ENTD toxicity ENTDEND  Hannover Wistar rats were dosed with 1.25 mg/kg ENTC DOX ENTCEND weekly for 8 weeks followed by a 4 week off-dosing "recovery" period
1	In this study, we have utilized a rat model of progressive doxorubicin ( ENTC DOX ENTCEND -induced ENTD cardiomyopathy ENTDEND , applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity
1	25 mg/kg ENTC DOX ENTCEND  weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, hypertrophy/cytomegaly, and extensive vacuolation after two doses. Extensive replacement fibrosis (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" ENTD LV dysfunction ENTDEND by 12 weeks
0	Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" ENTD LV dysfunction ENTDEND  by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to <50%. Troponin I levels positively correlated with delayed and peak ENTC gadolinium ENTCEND contrast enhancement, histopathological grading, and diastolic dysfunction
0	Troponin I levels positively correlated with delayed and peak ENTC gadolinium ENTCEND  contrast enhancement, histopathological grading, and ENTD diastolic dysfunction ENTDEND
0	We report on a 14-year-old boy who developed ENTD acute renal failure ENTDEND 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a ENTC blood urea nitrogen ENTCEND (BUN) concentration of of 147 mg/dl, creatinine of 15
0	We report on a 14-year-old boy who developed ENTD acute renal failure ENTDEND  2 weeks after aortic valve surgery. He was put on ENTC aspirin ENTCEND following surgery and took ibuprofen for fever for nearly a week prior to presentation
0	We report on a 14-year-old boy who developed ENTD acute renal failure ENTDEND  2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENTC creatinine ENTCEND of 15
0	We report on a 14-year-old boy who developed ENTD acute renal failure ENTDEND  2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum ENTC potassium ENTCEND of 8
1	We report on a 14-year-old boy who developed ENTD acute renal failure ENTDEND  2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ENTC ibuprofen ENTCEND for fever for nearly a week prior to presentation
0	He was put on aspirin following surgery and took ibuprofen for ENTD fever ENTDEND for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with ENTC steroids ENTCEND for 6 months
0	He was put on aspirin following surgery and took ibuprofen for ENTD fever ENTDEND  for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a ENTC blood urea nitrogen ENTCEND (BUN) concentration of of 147 mg/dl, creatinine of 15
0	He was put on ENTC aspirin ENTCEND  following surgery and took ibuprofen for ENTD fever ENTDEND for nearly a week prior to presentation
0	He was put on aspirin following surgery and took ibuprofen for ENTD fever ENTDEND  for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENTC creatinine ENTCEND of 15
0	He was put on aspirin following surgery and took ibuprofen for ENTD fever ENTDEND  for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum ENTC potassium ENTCEND of 8
0	He was put on aspirin following surgery and took ENTC ibuprofen ENTCEND  for ENTD fever ENTDEND for nearly a week prior to presentation
0	He needed dialysis for 2 weeks and was treated successfully with ENTC steroids ENTCEND  for 6 months. His renal recovery and disappearance of ENTD proteinuria ENTDEND took a year
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen ( ENTC BUN ENTCEND  concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with steroids for 6 months. His renal recovery and disappearance of ENTD proteinuria ENTDEND took a year
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENTC creatinine ENTCEND  of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with steroids for 6 months. His renal recovery and disappearance of ENTD proteinuria ENTDEND took a year
0	3 mg/dl and serum ENTC potassium ENTCEND  of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ATIN. However, in the tubular basement membrane (TBM), very intense granular deposits of polyclonal IgG and C3 were noted. He needed dialysis for 2 weeks and was treated successfully with steroids for 6 months. His renal recovery and disappearance of ENTD proteinuria ENTDEND took a year
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENTD tubulo-interstitial injury ENTDEND  but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a ENTC blood urea nitrogen ENTCEND (BUN) concentration of of 147 mg/dl, creatinine of 15
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENTD tubulo-interstitial injury ENTDEND , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on ENTC aspirin ENTCEND following surgery and took ibuprofen for fever for nearly a week prior to presentation
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENTD tubulo-interstitial injury ENTDEND , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENTC creatinine ENTCEND of 15
0	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENTD tubulo-interstitial injury ENTDEND , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation. He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum ENTC potassium ENTCEND of 8
1	Acute tubulo-interstitial nephritis (ATIN) is an important cause of acute renal failure resulting from a variety of insults, including immune complex-mediated ENTD tubulo-interstitial injury ENTDEND , but drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) are a far more frequent cause. Overall, as an entity, ATIN remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ENTC ibuprofen ENTCEND for fever for nearly a week prior to presentation
0	He needed dialysis for 2 weeks and was treated successfully with ENTC steroids ENTCEND  for 6 months. His renal recovery and disappearance of proteinuria took a year. In conclusion, this is a first report of NSAIDs-associated ENTD ATIN ENTDEND , showing deposits of granular immune complex present only in the TBM and not in the glomeruli
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen ( ENTC BUN ENTCEND ) concentration of of 147 mg/dl, creatinine of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ENTD ATIN ENTDEND
0	Overall, as an entity, ENTD ATIN ENTDEND remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on ENTC aspirin ENTCEND following surgery and took ibuprofen for fever for nearly a week prior to presentation
0	He then presented to the emergency department feeling quite ill and was found to have a blood urea nitrogen (BUN) concentration of of 147 mg/dl, ENTC creatinine ENTCEND  of 15.3 mg/dl and serum potassium of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ENTD ATIN ENTDEND
0	3 mg/dl and serum ENTC potassium ENTCEND  of 8.7 mEq/l. Dialysis was immediately initiated. A kidney biopsy showed inflammatory infiltrate consistent with ENTD ATIN ENTDEND
0	Overall, as an entity, ENTD ATIN ENTDEND  remains under-diagnosed, as symptoms resolve spontaneously if the medication is stopped. We report on a 14-year-old boy who developed acute renal failure 2 weeks after aortic valve surgery. He was put on aspirin following surgery and took ENTC ibuprofen ENTCEND for fever for nearly a week prior to presentation
1	ENTD Encephalopathy ENTDEND  during ENTC amitriptyline ENTCEND therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression
0	The major determinant of the symptoms may have been ENTC dopamine ENTCEND serotonin imbalance in the central nervous system. The NMS-like ENTD encephalopathy ENTDEND that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	The major determinant of the symptoms may have been dopamine/ ENTC serotonin ENTCEND imbalance in the central nervous system. The NMS-like ENTD encephalopathy ENTDEND that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	Encephalopathy during ENTC amitriptyline ENTCEND  therapy: are ENTD neuroleptic malignant syndrome ENTDEND and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression
0	The major determinant of the symptoms may have been ENTC dopamine ENTCEND /serotonin imbalance in the central nervous system. The ENTD NMS ENTDEND -like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	The major determinant of the symptoms may have been dopamine/ ENTC serotonin ENTCEND  imbalance in the central nervous system. The ENTD NMS ENTDEND -like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects
0	Encephalopathy during ENTC amitriptyline ENTCEND  therapy: are neuroleptic malignant syndrome and ENTD serotonin syndrome ENTDEND spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression
0	This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome ( ENTD SS ENTDEND . The major determinant of the symptoms may have been ENTC dopamine ENTCEND /serotonin imbalance in the central nervous system
0	This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome ( ENTD SS ENTDEND ). The major determinant of the symptoms may have been dopamine ENTC serotonin ENTCEND imbalance in the central nervous system
0	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of ENTC amitriptyline ENTCEND therapy, during a remission of ENTD unipolar depression ENTDEND
0	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of ENTD unipolar depression ENTDEND . This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS). The major determinant of the symptoms may have been ENTC dopamine ENTCEND /serotonin imbalance in the central nervous system
0	Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of ENTD unipolar depression ENTDEND . This patient could have been diagnosed as having either neuroleptic malignant syndrome (NMS) or serotonin syndrome (SS). The major determinant of the symptoms may have been dopamine ENTC serotonin ENTCEND imbalance in the central nervous system
0	contrast material to enable diagnosis of ureteric stones or obstruction in patients with ENTD HIV infection ENTDEND who receive ENTC indinavir ENTCEND therapy
1	OBJECTIVE: We describe the unique CT features of ENTD ureteric calculi ENTDEND in six HIV-infected patients receiving ENTC indinavir ENTCEND , the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis
0	OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of ENTD urolithiasis ENTDEND  CONCLUSION: Ureteric obstruction caused by precipitated ENTC indinavir ENTCEND crystals may be difficult to diagnose with unenhanced CT
0	CONCLUSION: ENTD Ureteric obstruction ENTDEND caused by precipitated ENTC indinavir ENTCEND crystals may be difficult to diagnose with unenhanced CT
1	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after ENTC pilocarpine ENTCEND induced ENTD SE ENTDEND
0	CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after ENTC pilocarpine ENTCEND -induced SE. ENTD Seizures ENTDEND also result in changes to CCR2 receptor expression in neurons and astrocytes
0	In addition, rats that experienced SE exhibited CCR2-labeling in populations of ENTD hypertrophied ENTDEND astrocytes, especially in CA1 and dentate gyrus. These CCR2+ astroctytes were not observed in control rats. Examination of CCL2 expression showed that it was elevated in the hippocampus following SE. CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after ENTC pilocarpine ENTCEND -induced SE
0	Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following ENTC pilocarpine ENTCEND -induced status epilepticus.BACKGROUND: ENTD Neuroinflammation ENTDEND occurs after seizures and is implicated in epileptogenesis
0	The ENTD ischemia ENTDEND probably induced by coronary artery spasm was reversed by ENTC nitroglycerin ENTCEND and calcium blocking agents
0	We report a case of myocardial ischemia induced by ENTC cocaine ENTCEND  The ENTD ischemia ENTDEND probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents
0	The ENTD ischemia ENTDEND  probably induced by coronary artery spasm was reversed by nitroglycerin and ENTC calcium ENTCEND blocking agents
0	The ischemia probably induced by ENTD coronary artery spasm ENTDEND was reversed by ENTC nitroglycerin ENTCEND and calcium blocking agents
1	We report a case of myocardial ischemia induced by ENTC cocaine ENTCEND . The ischemia probably induced by ENTD coronary artery spasm ENTDEND was reversed by nitroglycerin and calcium blocking agents
0	The ischemia probably induced by ENTD coronary artery spasm ENTDEND  was reversed by nitroglycerin and ENTC calcium ENTCEND blocking agents
0	We report a case of ENTD myocardial ischemia ENTDEND induced by cocaine. The ischemia probably induced by coronary artery spasm was reversed by ENTC nitroglycerin ENTCEND and calcium blocking agents
1	ENTC Cocaine ENTCEND  induced ENTD myocardial ischemia ENTDEND
0	We report a case of ENTD myocardial ischemia ENTDEND  induced by cocaine. The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and ENTC calcium ENTCEND blocking agents
1	Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through ENTC valproic acid ENTCEND induced ENTD hyperammonemia ENTDEND
1	Reversible ENTC valproic acid ENTCEND -induced ENTD dementia ENTDEND : a case report
0	Reversible ENTC valproic acid ENTCEND induced dementia was documented in a 21-year-old man with ENTD epilepsy ENTDEND who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies
0	Active ENTD vasculitis ENTDEND was noted in 36.3% patients at baseline and 0% at 3 years of follow-up. More than 20% (47.61-67.2%) reduction in central retinal thickness was noted in all patients with cystoid macular edema at 6 months, 1 year, 2 years, and 3 years postimplant. At baseline, 54.5% patients were on immunomodulatory agents. This percentage decreased to 45.45, 44.4, and 14.28% at 1 year, 2 years, and 3 years postimplant, respectively. Adverse events included increased intraocular pressure (54.5%) and cataract formation (100%). CONCLUSION: The data suggest that ENTC fluocinolone acetonide ENTCEND implant (0
0	CONCLUSION: The data suggest that ENTC fluocinolone acetonide ENTCEND  implant (0.59 mg) helps to control ENTD inflammation ENTDEND in otherwise treatment-refractory cases of birdshot retinochoroidopathy
0	2%) reduction in central retinal thickness was noted in all patients with ENTD cystoid macular edema ENTDEND at 6 months, 1 year, 2 years, and 3 years postimplant. At baseline, 54.5% patients were on immunomodulatory agents. This percentage decreased to 45.45, 44.4, and 14.28% at 1 year, 2 years, and 3 years postimplant, respectively. Adverse events included increased intraocular pressure (54.5%) and cataract formation (100%). CONCLUSION: The data suggest that ENTC fluocinolone acetonide ENTCEND implant (0
0	Treatment outcomes of interest were noted at baseline, before ENTC fluocinolone acetonide ENTCEND implant, and then at 6 months, 1 year, 2 years, 3 years, and beyond 3 years. Disease activity markers, including signs of ocular inflammation, evidence of ENTD retinal vasculitis ENTDEND , Swedish interactive threshold algorithm-short wavelength automated perimetry Humphrey visual field analysis, electroretinographic parameters, and optical coherence tomography were recorded
1	5%) and ENTD cataract ENTDEND formation (100%). CONCLUSION: The data suggest that ENTC fluocinolone acetonide ENTCEND implant (0
1	Adverse events included ENTD increased intraocular pressure ENTDEND (54.5%) and cataract formation (100%). CONCLUSION: The data suggest that ENTC fluocinolone acetonide ENTCEND implant (0
0	Safety and efficacy of ENTC fluocinolone acetonide ENTCEND  intravitreal implant (0.59 mg) in ENTD birdshot retinochoroidopathy ENTDEND
0	ENTC Glibenclamide ENTCEND -sensitive ENTD hypotension ENTDEND produced by helodermin assessed in the rat
1	Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine ( ENTC ACh ENTCEND -produced ENTD hypotension ENTDEND
0	EDRF (endothelium-derived relaxing factor)/ ENTC nitric oxide ENTCEND does not seem to play an important role in the peptide-produced ENTD hypotension ENTDEND
0	These findings suggest that helodermin-produced ENTD hypotension ENTDEND is partly attributable to the activation of glibenclamide-sensitive K+ channels (K( ENTC ATP ENTCEND ) channels), which presumably exist on arterial smooth muscle cells
1	ENTD Hypotension ENTDEND induced by both peptides was significantly attenuated by glibenclamide, which abolished a ENTC levcromakalim ENTCEND -produced decrease in arterial blood pressure
1	Oxyhemoglobin did not affect ENTC helodermin ENTCEND induced ENTD hypotension ENTDEND , whereas it shortened the duration of acetylcholine (ACh)-produced hypotension
0	These findings suggest that helodermin-produced ENTD hypotension ENTDEND  is partly attributable to the activation of glibenclamide-sensitive ENTC K ENTCEND + channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells
0	Glibenclamide-sensitive ENTD hypotension ENTDEND  produced by helodermin assessed in the rat.The effects of helodermin, a basic 35- ENTC amino acid ENTCEND peptide isolated from the venom of a lizard salivary gland, on arterial blood pressure and heart rate were examined in the rat, focusing on the possibility that activation of ATP sensitive K+ (K(ATP)) channels is involved in the responses
1	The incidence of abductor paralysis after ENTC Botox ENTCEND injection for ENTD ADSD ENTDEND was 0
0	METHODS: Patients that received ENTC Botox ENTCEND injections for ENTD spasmodic dysphonia ENTDEND between January 2000 and October 2009 were evaluated
0	Reported adverse effects include a period of breathiness, ENTD throat pain ENTDEND  and difficulty with swallowing liquids. Here we report multiple cases of bilateral abductor paralysis following ENTC Botox ENTCEND injections for ADSD, a complication previously unreported
0	Abductor ENTD paralysis ENTDEND  after ENTC botox ENTCEND injection for adductor spasmodic dysphonia
0	Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of ENTD tumor ENTDEND cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced ENTC silver ENTCEND grains over nuclei than cytoplasm of these cells
0	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary ENTC diethylstilbesterol ENTCEND induced renal carcinomas in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of ENTD tumor ENTDEND cells; stereologic analysis revealed a 4
0	Radiolabelling, following the in vivo injection of 3H-17 beta ENTC estradiol ENTCEND  was increased only over the nuclei of ENTD tumor ENTDEND cells; stereologic analysis revealed a 4
0	ENTC Estrogen ENTCEND binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of ENTD tumor ENTDEND cells; stereologic analysis revealed a 4
0	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced ENTD renal carcinomas ENTDEND in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced ENTC silver ENTCEND grains over nuclei than cytoplasm of these cells
1	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary ENTC diethylstilbesterol ENTCEND  induced ENTD renal carcinomas ENTDEND in three hamsters
0	Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced ENTD renal carcinomas ENTDEND  in three hamsters. Radiolabelling, following the in vivo injection of 3H-17 beta ENTC estradiol ENTCEND , was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4
0	Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster ENTD renal carcinomas ENTDEND ENTC Estrogen ENTCEND binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters
0	ENTC Rifampicin ENTCEND was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like ENTD nausea ENTDEND , vomiting and fever with chills and rigors
1	ENTD Acute renal failure ENTDEND  due to ENTC rifampicin ENTCEND
0	ENTC Rifampicin ENTCEND  was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and ENTD fever ENTDEND with chills and rigors
0	Acute renal failure due to ENTC rifampicin ENTCEND .A 23-year-old male patient with bacteriologically proven ENTD pulmonary tuberculosis ENTDEND was treated with the various regimens of antituberculosis drugs for nearly 15 months
0	ENTC Rifampicin ENTCEND  was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, ENTD vomiting ENTDEND and fever with chills and rigors
0	The results suggest that increased brain serotoninergic transmission with ENTC fluoxetine ENTCEND may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating ENTD parkinsonian ENTDEND motor disability
0	05) of ENTC apomorphine ENTCEND induced dyskinesias without modification of ENTD parkinsonian ENTDEND motor disability
0	We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with ENTD Parkinson's disease ENTDEND after an acute challenge with the mixed ENTC dopamine ENTCEND agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
0	We evaluated the severity of motor disability and dyskinesias in seven ENTC levodopa ENTCEND responsive patients with ENTD Parkinson's disease ENTDEND after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
1	Levodopa-induced ENTD dyskinesias ENTDEND  are improved by ENTC fluoxetine ENTCEND
1	05) of ENTC apomorphine ENTCEND -induced ENTD dyskinesias ENTDEND without modification of parkinsonian motor disability
0	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENTC dopamine ENTCEND agonist-induced ENTD dyskinesias ENTDEND without aggravating parkinsonian motor disability
0	ENTC Levodopa ENTCEND -induced ENTD dyskinesias ENTDEND are improved by fluoxetine
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENTD choreic mid-dose dyskinesias ENTDEND  The results suggest that increased brain serotoninergic transmission with ENTC fluoxetine ENTCEND may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	05) of ENTC apomorphine ENTCEND -induced dyskinesias without modification of parkinsonian motor disability. The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENTD choreic mid-dose dyskinesias ENTDEND
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENTD choreic mid-dose dyskinesias ENTDEND . The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENTC dopamine ENTCEND agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during ENTD choreic mid-dose dyskinesias ENTDEND . The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce ENTC levodopa ENTCEND - or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENTD dystonic dyskinesias ENTDEND (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with ENTC fluoxetine ENTCEND may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	05) of ENTC apomorphine ENTCEND -induced dyskinesias without modification of parkinsonian motor disability. The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENTD dystonic dyskinesias ENTDEND (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENTD dystonic dyskinesias ENTDEND  (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENTC dopamine ENTCEND agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of ENTD dystonic dyskinesias ENTDEND  (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce ENTC levodopa ENTCEND - or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability
0	Levodopa-induced dyskinesias are improved by ENTC fluoxetine ENTCEND .We evaluated the severity of ENTD motor disability ENTDEND and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
0	05) of ENTC apomorphine ENTCEND -induced dyskinesias without modification of parkinsonian ENTD motor disability ENTDEND
0	The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or ENTC dopamine ENTCEND  agonist-induced dyskinesias without aggravating parkinsonian ENTD motor disability ENTDEND
0	We evaluated the severity of ENTD motor disability ENTDEND  and dyskinesias in seven ENTC levodopa ENTCEND -responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days
0	In 5 consecutive patients with ENTD rheumatoid arthritis ENTDEND who received intravenous high-dose ENTC methylprednisolone ENTCEND (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4
0	Electrocardiographic registrations showed ENTD sinus bradycardia ENTDEND in all cases. No significant changes in plasma concentrations of electrolytes were found. Careful observation of patients receiving high-dose ENTC MP ENTCEND is recommended
0	High-dose ENTC MP ENTCEND may be contraindicated in patients with known ENTD heart disease ENTDEND
1	ENTD Bradycardia ENTDEND  after high-dose intravenous ENTC methylprednisolone ENTCEND therapy
1	A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with ENTC fluvastatin ENTCEND  Patient presented with complaints of increasing ENTD nausea ENTDEND , anorexia, and upper abdominal pain
0	Although ENTC statins ENTCEND are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported. A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing ENTD nausea ENTDEND , anorexia, and upper abdominal pain
0	Patient presented with complaints of increasing ENTD nausea ENTDEND , anorexia, and upper abdominal pain. His laboratory values showed elevated ENTC creatine ENTCEND kinase and transaminases
1	A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with ENTC fluvastatin ENTCEND . Patient presented with complaints of increasing nausea, ENTD anorexia ENTDEND , and upper abdominal pain
0	Although ENTC statins ENTCEND  are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported. A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing nausea, ENTD anorexia ENTDEND , and upper abdominal pain
0	Patient presented with complaints of increasing nausea, ENTD anorexia ENTDEND , and upper abdominal pain. His laboratory values showed elevated ENTC creatine ENTCEND kinase and transaminases
1	ENTD Drug-Induced Acute Liver Injury ENTDEND  Within 12 Hours After ENTC Fluvastatin ENTCEND Therapy
0	Although ENTC statins ENTCEND  are generally well-tolerated drugs, recent cases of ENTD drug-induced liver injury ENTDEND associated with their use have been reported
0	A 52-year-old Chinese man reported with ENTD liver damage ENTDEND  which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing nausea, anorexia, and upper abdominal pain. His laboratory values showed elevated ENTC creatine ENTCEND kinase and transaminases
1	A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with ENTC fluvastatin ENTCEND . Patient presented with complaints of increasing nausea, anorexia, and upper ENTD abdominal pain ENTDEND
0	Although ENTC statins ENTCEND  are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported. A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin. Patient presented with complaints of increasing nausea, anorexia, and upper ENTD abdominal pain ENTDEND
0	Patient presented with complaints of increasing nausea, anorexia, and upper ENTD abdominal pain ENTDEND . His laboratory values showed elevated ENTC creatine ENTCEND kinase and transaminases
0	This report of torsade de pointes ventricular tachycardia during intermittent ENTC dobutamine ENTCEND supports the hypothesis that unpredictable fatal ENTD arrhythmias ENTDEND may occur even with low doses and in patients with no history of significant rhythm disturbances
0	Torsade de pointes ventricular tachycardia during low dose intermittent ENTC dobutamine ENTCEND  treatment in a patient with ENTD dilated cardiomyopathy ENTDEND and congestive heart failure
0	This report of torsade de pointes ENTD ventricular tachycardia ENTDEND during intermittent ENTC dobutamine ENTCEND supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances
0	The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed ENTD QT prolongation ENTDEND and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) ENTC dobutamine ENTCEND
0	Torsade de pointes ventricular tachycardia during low dose intermittent ENTC dobutamine ENTCEND  treatment in a patient with dilated cardiomyopathy and ENTD congestive heart failure ENTDEND
1	5 mcg/kg per min) ENTC dobutamine ENTCEND . This report of ENTD torsade de pointes ENTDEND ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances
0	There was no change in hepatic tissue total ENTC glutathione ENTCEND following intestinal ENTD ischemia ENTDEND -reperfusion injury
0	There was no change in hepatic tissue total glutathione following intestinal ENTD ischemia ENTDEND -reperfusion injury. ENTC Oxidized glutathione ENTCEND (GSSG) increased significantly following 30 and 60 min of reperfusion
0	This study was undertaken to determine whether oxidants are associated with the ENTD hepatic injury ENTDEND and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENTC oxidized and reduced glutathione ENTCEND
0	This study was undertaken to determine whether oxidants are associated with the ENTD hepatic injury ENTDEND  and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENTC oxidized and reduced glutathione ENTCEND
0	There was no change in hepatic tissue total ENTC glutathione ENTCEND  following intestinal ischemia- ENTD reperfusion injury ENTDEND
1	There was no change in hepatic tissue total glutathione following intestinal ischemia- ENTD reperfusion injury ENTDEND . ENTC Oxidized glutathione ENTCEND (GSSG) increased significantly following 30 and 60 min of reperfusion
0	Reperfusion of ischemic intestine results in acute ENTD liver dysfunction ENTDEND characterized by hepatocellular enzyme release into plasma, reduction in bile flow rate, and neutrophil sequestration within the liver. The pathophysiology underlying this acute hepatic injury is unknown. This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENTC oxidized and reduced glutathione ENTCEND
0	Reperfusion of ischemic intestine results in acute ENTD liver dysfunction ENTDEND  characterized by hepatocellular enzyme release into plasma, reduction in bile flow rate, and neutrophil sequestration within the liver. The pathophysiology underlying this acute hepatic injury is unknown. This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo. Rats were subjected to a standardized intestinal ischemia-reperfusion injury. Hepatic tissue was assayed for lipid peroxidation products and ENTC oxidized and reduced glutathione ENTCEND
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENTC aristolochic acids ENTCEND  We report a 23-year-old woman who developed ENTD acute renal failure ENTDEND following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb)
0	Although a causal relationship between the use of an ENTC anthraquinone ENTCEND containing herbal agent and ENTD renal injury ENTDEND remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure
1	The ENTD renal injury ENTDEND was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENTC diclofenac ENTCEND
1	We report a 23-year-old woman who developed ENTD acute renal failure ENTDEND  following prolonged use of a proprietary ENTC Chinese herbal ENTCEND slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb)
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENTC aristolochic acids ENTCEND . We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENTD renal failure ENTDEND
0	Although a causal relationship between the use of an ENTC anthraquinone ENTCEND -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENTD renal failure ENTDEND
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENTC diclofenac ENTCEND . Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENTD renal failure ENTDEND
0	We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary ENTC Chinese herbal ENTCEND  slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained ENTD renal failure ENTDEND
0	ENTD Nephropathy ENTDEND caused by Chinese herbs has previously been reported, usually involving the use of ENTC aristolochic acids ENTCEND
0	Although a causal relationship between the use of an ENTC anthraquinone ENTCEND -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial ENTD nephropathy ENTDEND should be considered in patients who present with unexplained renal failure
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENTC diclofenac ENTCEND . Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial ENTD nephropathy ENTDEND should be considered in patients who present with unexplained renal failure
0	ENTD Nephropathy ENTDEND  caused by ENTC Chinese herbs ENTCEND has previously been reported, usually involving the use of aristolochic acids
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENTC aristolochic acids ENTCEND . We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENTD atrophy ENTDEND was still evident histologically 4 months later
0	Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENTD atrophy ENTDEND  was still evident histologically 4 months later. Although a causal relationship between the use of an ENTC anthraquinone ENTCEND -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENTC diclofenac ENTCEND . Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENTD atrophy ENTDEND was still evident histologically 4 months later
0	We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary ENTC Chinese herbal ENTCEND  slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial fibrosis. Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial fibrosis and tubular ENTD atrophy ENTDEND was still evident histologically 4 months later
0	Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of ENTC aristolochic acids ENTCEND . We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial ENTD fibrosis ENTDEND
0	Spontaneous renal recovery occurred upon cessation of the slimming pills, but mild interstitial ENTD fibrosis ENTDEND and tubular atrophy was still evident histologically 4 months later. Although a causal relationship between the use of an ENTC anthraquinone ENTCEND -containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure
0	The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, ENTC diclofenac ENTCEND . Renal pathology was that of hypocellular interstitial ENTD fibrosis ENTDEND
0	We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary ENTC Chinese herbal ENTCEND  slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb). The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac. Renal pathology was that of hypocellular interstitial ENTD fibrosis ENTDEND
1	Reduced ENTD cardiotoxicity ENTDEND  of ENTC doxorubicin ENTCEND given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat
0	A rat model was used to evaluate the general acute toxicity and the late ENTD cardiotoxicity ENTDEND of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases (Gly-Phe-Leu-Gly). In addition, one biodegradable conjugate containing ENTC galactosamine ENTCEND was used; this residue was targeted to the liver
0	A rat model was used to evaluate the general acute toxicity and the late ENTD cardiotoxicity ENTDEND  of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases ( ENTC Gly-Phe-Leu-Gly ENTCEND )
0	Reduced ENTD cardiotoxicity ENTDEND  of doxorubicin given in the form of ENTC N-(2-hydroxypropyl)methacrylamide ENTCEND conjugates: and experimental study in the rat
0	A rat model was used to evaluate the general acute ENTD toxicity ENTDEND and the late cardiotoxicity of 4 mg/kg ENTC doxorubicin ENTCEND (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates
0	A rat model was used to evaluate the general acute ENTD toxicity ENTDEND  and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases (Gly-Phe-Leu-Gly). In addition, one biodegradable conjugate containing ENTC galactosamine ENTCEND was used; this residue was targeted to the liver
0	A rat model was used to evaluate the general acute ENTD toxicity ENTDEND  and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates. In these HPMA copolymers, DOX was covalently bound via peptide linkages that were either non-biodegradable (Gly-Gly) or degradable by lysosomal proteinases ENTC Gly-Phe-Leu-Gly ENTCEND )
0	Reduced cardiotoxicity of doxorubicin given in the form of ENTC N-(2-hydroxypropyl)methacrylamide ENTCEND  conjugates: and experimental study in the rat.A rat model was used to evaluate the general acute ENTD toxicity ENTDEND and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates
0	Both CSSEPs as central and NMPs as peripheral correlates of ENTD pain ENTDEND were obtained in response to the ENTC CO2 ENTCEND stimuli
1	METHODS: According to a double-blind, randomised, controlled, threefold cross-over design, 18 healthy subjects (11 males, 7 females; mean age 26 years) received either placebo, 400 mg ibuprofen, or 800 mg ENTC ibuprofen ENTCEND  Phasic ENTD pain ENTDEND was applied by means of short pulses of CO2 to the nasal mucosa (stimulus duration 500 ms, interval approximately 60 s), and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature, humidity and flow rate (22 degrees C, 0% relative humidity, 145 ml
0	A muscarinic receptor blocker, atropine, disrupted haloperidol-induced ENTD catalepsy ENTDEND  Intracranial injection of an ENTC acetylcholine ENTCEND -synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol
0	Intracranial injection of an acetylcholine-synthesis inhibitor, ENTC hemicholinium ENTCEND  prevented the ENTD catalepsy ENTDEND that is usually induced by haloperidol
0	Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of ENTC neuroleptic ENTCEND induced ENTD catalepsy ENTDEND
0	A muscarinic receptor blocker, ENTC atropine ENTCEND  disrupted haloperidol-induced ENTD catalepsy ENTDEND
1	Large doses of the cholinomimetic, ENTC pilocarpine ENTCEND  could induce ENTD catalepsy ENTDEND when peripheral cholinergic receptors were blocked
1	Evidence for a cholinergic role in ENTC haloperidol ENTCEND -induced ENTD catalepsy ENTDEND
1	A case of ENTD isotretinoin embryopathy ENTDEND  with bilateral anotia and Taussig-Bing malformation.We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to ENTC isotretinoin ENTCEND within the first trimester
0	A case of ENTD isotretinoin embryopathy ENTDEND  with bilateral anotia and Taussig-Bing malformation.We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester. In this paper we aim to draw to the fact that caution is needed when prescribing ENTC vitamin A ENTCEND -containing drugs to women of childbearing years
1	We report a newborn infant with multiple congenital anomalies ( ENTD anotia ENTDEND and Taussig-Bing malformation) due to exposure to ENTC isotretinoin ENTCEND within the first trimester
0	We report a newborn infant with multiple congenital anomalies ( ENTD anotia ENTDEND  and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester. In this paper we aim to draw to the fact that caution is needed when prescribing ENTC vitamin A ENTCEND -containing drugs to women of childbearing years
1	We report a newborn infant with multiple congenital anomalies (anotia and ENTD Taussig-Bing malformation ENTDEND  due to exposure to ENTC isotretinoin ENTCEND within the first trimester
0	We report a newborn infant with multiple congenital anomalies (anotia and ENTD Taussig-Bing malformation ENTDEND ) due to exposure to isotretinoin within the first trimester. In this paper we aim to draw to the fact that caution is needed when prescribing ENTC vitamin A ENTCEND -containing drugs to women of childbearing years
1	Their cardiac tissues were processed for light microscopy, after which ENTD cardiomyocyte damage ENTDEND was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978). Microscopic evaluation revealed that treatment with ENTC DOX ENTCEND alone induced significant cardiac damage in comparison to the saline control group (P<0
0	The semisynthetic ENTC flavonoid ENTCEND monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which ENTD cardiomyocyte damage ENTDEND was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978)
0	) preceded by ENTC monoHER ENTCEND (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which ENTD cardiomyocyte damage ENTDEND was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978)
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and ENTC iron ENTCEND chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which ENTD cardiomyocyte damage ENTDEND was evaluated according to Billingham (in Cancer Treat Rep 62(6):865-872, 1978)
0	Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENTD Cancer ENTDEND Treat Rep 62(6):865-872, 1978). Microscopic evaluation revealed that treatment with ENTC DOX ENTCEND alone induced significant cardiac damage in comparison to the saline control group (P<0
0	The semisynthetic ENTC flavonoid ENTCEND  monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENTD Cancer ENTDEND Treat Rep 62(6):865-872, 1978)
0	) preceded by ENTC monoHER ENTCEND  (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENTD Cancer ENTDEND Treat Rep 62(6):865-872, 1978)
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and ENTC iron ENTCEND  chelating properties. Because of the relatively short final half-life of monoHER (about 30 min), it is expected that the time interval between monoHER and DOX might be of influence on the cardioprotective effect of monoHER. Therefore, the aim of the present study was to investigate this possible effect. METHODS: Six groups of 6 BALB/c mice were treated with saline, DOX alone or DOX (4 mg/kg i.v.) preceded by monoHER (500 mg/kg i.p.) with an interval of 10, 30, 60 or 120 min. After a 6-week treatment period and additional observation for 2 weeks, the mice were sacrificed. Their cardiac tissues were processed for light microscopy, after which cardiomyocyte damage was evaluated according to Billingham (in ENTD Cancer ENTDEND Treat Rep 62(6):865-872, 1978)
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against ENTC DOX ENTCEND induced ENTD cardiotoxicity ENTDEND through its radical scavenging and iron chelating properties
0	The semisynthetic ENTC flavonoid ENTCEND  monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced ENTD cardiotoxicity ENTDEND through its radical scavenging and iron chelating properties
0	PURPOSE: Despite its well-known ENTD cardiotoxicity ENTDEND  the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent. DOX-induced cardiac damage presumably results from the formation of free radicals by DOX. Reactive ENTC oxygen ENTCEND species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system
0	The semisynthetic flavonoid monohydroxyethylrutoside ( ENTC monoHER ENTCEND  showed cardioprotection against DOX-induced ENTD cardiotoxicity ENTDEND through its radical scavenging and iron chelating properties
0	The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced ENTD cardiotoxicity ENTDEND  through its radical scavenging and ENTC iron ENTCEND chelating properties
0	ENTC DOX ENTCEND induced ENTD cardiac damage ENTDEND presumably results from the formation of free radicals by DOX
0	DOX-induced ENTD cardiac damage ENTDEND  presumably results from the formation of free radicals by DOX. Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system. The semisynthetic ENTC flavonoid ENTCEND monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties
0	DOX-induced ENTD cardiac damage ENTDEND  presumably results from the formation of free radicals by DOX. Reactive ENTC oxygen ENTCEND species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system
0	DOX-induced ENTD cardiac damage ENTDEND  presumably results from the formation of free radicals by DOX. Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system. The semisynthetic flavonoid ENTC monohydroxyethylrutoside ENTCEND (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties
0	DOX-induced ENTD cardiac damage ENTDEND  presumably results from the formation of free radicals by DOX. Reactive oxygen species particularly affect the cardiac myocytes because these cells seem to have a relatively poor antioxidant defense system. The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and ENTC iron ENTCEND chelating properties
1	Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in ENTC doxorubicin ENTCEND ENTD cardiotoxicity ENTDEND
0	Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with ENTC I-131 HA ENTCEND are not the initiating factor in doxorubicin ENTD cardiotoxicity ENTDEND
0	Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the ENTD hypercapnic ENTDEND  ventilatory response in humans.Human corticotropin-releasing hormone (hCRH) and thyrotropin-releasing hormone (TRH) are known to stimulate ventilation after i.v. administration in humans. In a placebo-controlled, single-blind study we aimed to clarify if both peptides act by altering central chemosensitivity. Two subsequent CO2-rebreathing tests were performed in healthy young volunteers. During the first test 0.9% ENTC NaCl ENTCEND was given i
1	The ENTC CO2 ENTCEND response curves in the control group were nearly identical. The results indicate an additive effect of both releasing hormones on the ENTD hypercapnic ENTDEND ventilatory response in humans, presumably independent of central chemosensitivity
0	Human corticotropin-releasing hormone and ENTC thyrotropin ENTCEND -releasing hormone modulate the ENTD hypercapnic ENTDEND ventilatory response in humans
0	Human corticotropin-releasing hormone and thyrotropin-releasing hormone modulate the ENTD hypercapnic ENTDEND  ventilatory response in humans.Human ENTC corticotropin ENTCEND -releasing hormone (hCRH) and thyrotropin-releasing hormone (TRH) are known to stimulate ventilation after i
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal ENTC methimazole ENTCEND associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described. The literature related to antithyroid drug side effects and the mechanisms for their occurrence are reviewed and the efficacy and complications of thyroidectomy and radioiodine compared to those of antithyroid drugs. It is concluded that in most circumstances 131I is the therapy of choice for ENTD hyperthyroidism ENTDEND
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of ENTC propylthiouracil ENTCEND associated lupus-like syndrome are described. The literature related to antithyroid drug side effects and the mechanisms for their occurrence are reviewed and the efficacy and complications of thyroidectomy and radioiodine compared to those of antithyroid drugs. It is concluded that in most circumstances 131I is the therapy of choice for ENTD hyperthyroidism ENTDEND
0	Two cases of propylthiouracil-associated acute ENTD hepatitis ENTDEND  one case of fatal ENTC methimazole ENTCEND -associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described
1	Two cases of ENTC propylthiouracil ENTCEND associated acute ENTD hepatitis ENTDEND , one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal ENTC methimazole ENTCEND -associated hepatocellular necrosis and one case of propylthiouracil-associated ENTD lupus-like syndrome ENTDEND are described
1	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of ENTC propylthiouracil ENTCEND -associated ENTD lupus-like syndrome ENTDEND are described
1	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal ENTC methimazole ENTCEND -associated ENTD hepatocellular necrosis ENTDEND and one case of propylthiouracil-associated lupus-like syndrome are described
0	Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated ENTD hepatocellular necrosis ENTDEND  and one case of ENTC propylthiouracil ENTCEND -associated lupus-like syndrome are described
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, ENTD anemia ENTDEND in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, ENTD anemia ENTDEND  in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included ENTD nausea ENTDEND in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included ENTD nausea ENTDEND  in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENTD neutropenic fever ENTDEND in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients
0	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENTD neutropenic fever ENTDEND  in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic ENTD toxicity ENTDEND included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
0	METHODS: The combination of ENTC carboplatin ENTCEND (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and ENTD toxicity ENTDEND profile
1	Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, ENTD emesis ENTDEND in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, ENTD emesis ENTDEND  in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, ENTD weight loss ENTDEND in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENTC doxorubicin ENTCEND has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, ENTD weight loss ENTDEND  in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, ENTD thrombocytopenia ENTDEND in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, ENTD thrombocytopenia ENTDEND  in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Phase II study of carboplatin and liposomal ENTC doxorubicin ENTCEND  in patients with recurrent ENTD squamous cell carcinoma of the cervix ENTDEND
0	BACKGROUND: The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent ENTD cervical carcinoma ENTDEND  METHODS: The combination of ENTC carboplatin ENTCEND (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile
0	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, ENTD hand-foot syndrome ENTDEND in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENTC doxorubicin ENTCEND has modest activity in patients with recurrent cervical carcinoma
0	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, ENTD hand-foot syndrome ENTDEND  in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Phase II study of carboplatin and liposomal ENTC doxorubicin ENTCEND  in patients with recurrent ENTD squamous cell carcinoma of the cervix ENTDEND
0	Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent ENTD squamous cell carcinoma of the cervix ENTDEND .BACKGROUND: The activity of the combination of ENTC carboplatin ENTCEND and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, ENTD constipation ENTDEND in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENTC doxorubicin ENTCEND has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, ENTD constipation ENTDEND  in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or ENTD stomatitis ENTDEND in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
0	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or ENTD stomatitis ENTDEND  in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and ENTD skin reactions ENTDEND in 3 patients. CONCLUSIONS: The combination of carboplatin and liposomal ENTC doxorubicin ENTCEND has modest activity in patients with recurrent cervical carcinoma
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and ENTD skin reactions ENTDEND  in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, ENTD mucositis ENTDEND and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, ENTD mucositis ENTDEND  and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
0	The main toxic effect was ENTD myelosuppression ENTDEND  with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients
0	METHODS: The combination of ENTC carboplatin ENTCEND  (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile. RESULTS: Twenty-nine patients were assessable for response, and 35 patients were assessable for toxicity. The overall response rate was 38%, the median time to response was 10 weeks, the median duration of response was 26 weeks, and the median survival was 37 weeks. The main toxic effect was ENTD myelosuppression ENTDEND , with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and neutropenic fever in 3 patients
1	Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, ENTD fatigue ENTDEND in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients
1	Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, ENTD fatigue ENTDEND  in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENTD neutropenic fever ENTDEND in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal ENTC doxorubicin ENTCEND , leading to treatment discontinuation in three patients
1	The main toxic effect was myelosuppression, with Grade 3 and 4 neutropenia in 16 patients, anemia in 12 patients, thrombocytopenia in 11 patients, and ENTD neutropenic fever ENTDEND  in 3 patients. Four patients had five infusion-related reactions during the infusion of liposomal doxorubicin, leading to treatment discontinuation in three patients. Grade > or = 2 nonhematologic toxicity included nausea in 17 patients, emesis in 14 patients, fatigue in 9 patients, mucositis and/or stomatitis in 8 patients, constipation in 6 patients, weight loss in 5 patients, hand-foot syndrome in 2 patients, and skin reactions in 3 patients. CONCLUSIONS: The combination of ENTC carboplatin ENTCEND and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma
1	The ENTC Dimer-X ENTCEND group had a higher incidence of ENTD nausea ENTDEND and dizziness
0	Comparative study: Endografine ( ENTC diatrizoate ENTCEND ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of ENTD nausea ENTDEND and dizziness
0	The Dimer-X group had a higher incidence of ENTD nausea ENTDEND  and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and ENTC Vasurix polyvidone ENTCEND are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of ENTD nausea ENTDEND  and dizziness. The ENTC Endografine ENTCEND group had a higher incidence of abdominal pain
0	The Dimer-X group had a higher incidence of ENTD nausea ENTDEND  and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best ENTC contrast media ENTCEND for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of ENTD nausea ENTDEND  and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. ENTC Hexabrix ENTCEND and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The ENTC Dimer-X ENTCEND  group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENTD toxicity ENTDEND Hexabrix should be preferred
0	Comparative study: Endografine ( ENTC diatrizoate ENTCEND ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENTD toxicity ENTDEND Hexabrix should be preferred
0	Hexabrix and ENTC Vasurix polyvidone ENTCEND  are considered the best contrast media for hysterosalpingography and perhaps because of its low ENTD toxicity ENTDEND Hexabrix should be preferred
0	The ENTC Endografine ENTCEND  group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENTD toxicity ENTDEND Hexabrix should be preferred
0	Hexabrix and Vasurix polyvidone are considered the best ENTC contrast media ENTCEND  for hysterosalpingography and perhaps because of its low ENTD toxicity ENTDEND Hexabrix should be preferred
0	Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low ENTD toxicity ENTDEND  ENTC Hexabrix ENTCEND should be preferred
0	The ENTC Dimer-X ENTCEND  group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of ENTD abdominal pain ENTDEND
0	Comparative study: Endografine ( ENTC diatrizoate ENTCEND ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of nausea and dizziness. The Endografine group had a higher incidence of ENTD abdominal pain ENTDEND
0	The Endografine group had a higher incidence of ENTD abdominal pain ENTDEND . These differences occur especially in the age groups under 30 years. Hexabrix and ENTC Vasurix polyvidone ENTCEND are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
1	The ENTC Endografine ENTCEND  group had a higher incidence of ENTD abdominal pain ENTDEND
0	The Endografine group had a higher incidence of ENTD abdominal pain ENTDEND . These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best ENTC contrast media ENTCEND for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Endografine group had a higher incidence of ENTD abdominal pain ENTDEND . These differences occur especially in the age groups under 30 years. ENTC Hexabrix ENTCEND and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
1	The ENTC Dimer-X ENTCEND  group had a higher incidence of nausea and ENTD dizziness ENTDEND
0	Comparative study: Endografine ( ENTC diatrizoate ENTCEND ), Vasurix polyvidone (acetrizoate), Dimer-X (iocarmate) and Hexabrix (ioxaglate) in hysterosalpingography.Side effects of hysterosalpingography with Dimer-X, Hexabrix, Vasurix polyvidone and Endografine in 142 consecutive patients, receiving one of the four tested media were evaluated from replies to postal questionnaires. The Dimer-X group had a higher incidence of nausea and ENTD dizziness ENTDEND
0	The Dimer-X group had a higher incidence of nausea and ENTD dizziness ENTDEND . The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and ENTC Vasurix polyvidone ENTCEND are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of nausea and ENTD dizziness ENTDEND . The ENTC Endografine ENTCEND group had a higher incidence of abdominal pain
0	The Dimer-X group had a higher incidence of nausea and ENTD dizziness ENTDEND . The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. Hexabrix and Vasurix polyvidone are considered the best ENTC contrast media ENTCEND for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	The Dimer-X group had a higher incidence of nausea and ENTD dizziness ENTDEND . The Endografine group had a higher incidence of abdominal pain. These differences occur especially in the age groups under 30 years. ENTC Hexabrix ENTCEND and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred
0	ENTC 5-Fluorouracil ENTCEND ENTD cardiotoxicity ENTDEND induced by alpha-fluoro-beta-alanine
0	As the precordial pain in this patient was considered to have been due to 5-FU-induced ENTD cardiotoxicity ENTDEND  the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENTC dihydropyrimidine ENTCEND dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	5-Fluorouracil cardiotoxicity induced by ENTC alpha-fluoro-beta-alanine ENTCEND . ENTD Cardiotoxicity ENTDEND is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies
0	Cardiotoxicity is a rare complication occurring during 5-fluorouracil ( ENTC 5-FU ENTCEND  treatment for ENTD malignancies ENTDEND
0	5-Fluorouracil cardiotoxicity induced by ENTC alpha-fluoro-beta-alanine ENTCEND .Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for ENTD malignancies ENTDEND
0	We herein report the case of a 70-year-old man with ENTC 5-FU ENTCEND induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed. The patient, who had unresectable ENTD colon cancer ENTDEND metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history
0	The patient, who had unresectable ENTD colon cancer ENTDEND  metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history. After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml. Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU. As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENTC dihydropyrimidine ENTCEND dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine ( ENTC FBAL ENTCEND  was observed. The patient, who had unresectable ENTD colon cancer ENTDEND metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history
0	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of ENTC 5-FU ENTCEND into FBAL. The serum FBAL concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration. Thereafter, no ENTD cardiac symptoms ENTDEND were observed
0	Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENTC dihydropyrimidine ENTCEND  dehydrogenase, which catalyzes the degradative of 5-FU into FBAL. The serum FBAL concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration. Thereafter, no ENTD cardiac symptoms ENTDEND were observed
0	The serum ENTC FBAL ENTCEND concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration. Thereafter, no ENTD cardiac symptoms ENTDEND were observed
1	Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of ENTC 5-FU ENTCEND  As the ENTD precordial pain ENTDEND in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned
0	As the ENTD precordial pain ENTDEND  in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENTC dihydropyrimidine ENTCEND dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum ENTC FBAL ENTCEND concentration of 1955 ng/ml. Both the ENTD precordial pain ENTDEND and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU
1	After admission, the patient received a continuous intravenous infusion of ENTC 5-FU ENTCEND (1000 mg/day), during which precordial pain with ENTD right bundle branch block ENTDEND occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml
0	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with ENTD right bundle branch block ENTDEND  occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml. Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU. As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on ENTC dihydropyrimidine ENTCEND dehydrogenase, which catalyzes the degradative of 5-FU into FBAL
0	After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with ENTD right bundle branch block ENTDEND  occurred concomitantly with a high serum ENTC FBAL ENTCEND concentration of 1955 ng/ml
0	Indomethacin induced ENTD hypotension ENTDEND  in sodium and volume depleted rats.After a single oral dose of 4 mg/kg indomethacin (IDM) to sodium and volume depleted rats plasma renin activity (PRA) and systolic blood pressure fell significantly within four hours. In sodium repleted animals indomethacin did not change systolic blood pressure (BP) although plasma renin activity was decreased. Thus, indomethacin by inhibition of ENTC prostaglandin ENTCEND synthesis may diminish the blood pressure maintaining effect of the stimulated renin-angiotensin system in sodium and volume depletion
0	Indomethacin induced ENTD hypotension ENTDEND  in sodium and volume depleted rats.After a single oral dose of 4 mg/kg indomethacin (IDM) to sodium and volume depleted rats plasma renin activity (PRA) and systolic blood pressure fell significantly within four hours. In sodium repleted animals indomethacin did not change systolic blood pressure (BP) although plasma renin activity was decreased. Thus, indomethacin by inhibition of prostaglandin synthesis may diminish the blood pressure maintaining effect of the stimulated renin- ENTC angiotensin ENTCEND system in sodium and volume depletion
1	ENTC Indomethacin ENTCEND  induced ENTD hypotension ENTDEND in sodium and volume depleted rats
0	Indomethacin induced ENTD hypotension ENTDEND  in ENTC sodium ENTCEND and volume depleted rats
0	Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide ( ENTC CCK-8 ENTCEND NS) enhanced the latency of ENTD seizures ENTDEND induced by picrotoxin in mice
0	Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced ENTD seizures ENTDEND  by ENTC cholecystokinin ENTCEND , fragments and analogues of cholecystokinin in mice
1	Structure-activity and dose-effect relationships of the antagonism of ENTC picrotoxin ENTCEND -induced ENTD seizures ENTDEND by cholecystokinin, fragments and analogues of cholecystokinin in mice
0	Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of ENTD seizures ENTDEND  induced by picrotoxin in mice. Experiments with N- and C-terminal fragments revealed that the C-terminal tetrapeptide (CCK-5-8) was the active centre of the CCK octapeptide molecule. The analogues CCK-8-SE and CCK-8-NS (dose range 0.2-6.4 mumol/kg) and ENTC caerulein ENTCEND dose range 0
0	2 mumol/kg and larger doses of the reference drug, ENTC diazepam ENTCEND  totally prevented picrotoxin-induced ENTD seizures ENTDEND and mortality
0	Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion: Control, normotensive reperfusion; 90/hypertension (90/HTN), blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only; 15/hypertension (15/HTN), normotensive reperfusion for 30 min followed by 15 min of ENTD hypertension ENTDEND and 75 min of normotension. Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENTC 2,3,5-triphenyltetrazolium chloride ENTCEND and edema was evaluated by microgravimetry
1	Focal cerebral ischemia in rats: effect of ENTC phenylephrine ENTCEND -induced ENTD hypertension ENTDEND during reperfusion
0	ENTC Evans Blue ENTCEND (mug g-1 of brain tissue) was greater in the 90/ ENTD HTN ENTDEND group (24
0	After 180 min of temporary ENTD middle cerebral artery occlusion ENTDEND in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined. Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion: Control, normotensive reperfusion; 90/hypertension (90/HTN), blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only; 15/hypertension (15/HTN), normotensive reperfusion for 30 min followed by 15 min of hypertension and 75 min of normotension. Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENTC 2,3,5-triphenyltetrazolium chloride ENTCEND and edema was evaluated by microgravimetry
0	After 180 min of temporary ENTD middle cerebral artery occlusion ENTDEND  in spontaneously hypertensive rats, the effect of ENTC phenylephrine ENTCEND -induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined
0	Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENTC 2,3,5-triphenyltetrazolium chloride ENTCEND  and ENTD edema ENTDEND was evaluated by microgravimetry
0	After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of ENTC phenylephrine ENTCEND -induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined. Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion: Control, normotensive reperfusion; 90/hypertension (90/HTN), blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only; 15/hypertension (15/HTN), normotensive reperfusion for 30 min followed by 15 min of hypertension and 75 min of normotension. Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and ENTD edema ENTDEND was evaluated by microgravimetry
0	ENTC Evans Blue ENTCEND  (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases brain injury and ENTD edema ENTDEND ; and that sustained hypertension increases the risk of vasogenic edema
0	Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENTC 2,3,5-triphenyltetrazolium chloride ENTCEND  and edema was evaluated by microgravimetry. Part B, for eight different rats in each group blood-brain barrier permeability was evaluated by measuring the amount and extent of extravasation of Evans Blue dye. Brain injury (percentage of the ischemic hemisphere) was less in the 15/HTN group (16 +/- 6, mean +/- SD) versus the 90/HTN group (30 +/- 6), which was in turn less than the control group (42 +/- 5). Specific gravity was greater in the 15/HTN group (1.043 +/- 0.002) versus the 90/HTN (1.036 +/- 0.003) and control (1.037 +/- 0.003) groups. Evans Blue (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases brain injury and edema; and that sustained hypertension increases the risk of ENTD vasogenic edema ENTDEND
0	ENTC Evans Blue ENTCEND  (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases brain injury and edema; and that sustained hypertension increases the risk of ENTD vasogenic edema ENTDEND
0	Part A, for eight rats in each group brain injury was evaluated by staining tissue using ENTC 2,3,5-triphenyltetrazolium chloride ENTCEND  and edema was evaluated by microgravimetry. Part B, for eight different rats in each group blood-brain barrier permeability was evaluated by measuring the amount and extent of extravasation of Evans Blue dye. Brain injury (percentage of the ENTD ischemic hemisphere ENTDEND ) was less in the 15/HTN group (16 +/- 6, mean +/- SD) versus the 90/HTN group (30 +/- 6), which was in turn less than the control group (42 +/- 5)
0	Focal ENTD cerebral ischemia ENTDEND  in rats: effect of ENTC phenylephrine ENTCEND -induced hypertension during reperfusion
0	Brain injury (percentage of the ENTD ischemic hemisphere ENTDEND ) was less in the 15/HTN group (16 +/- 6, mean +/- SD) versus the 90/HTN group (30 +/- 6), which was in turn less than the control group (42 +/- 5). Specific gravity was greater in the 15/HTN group (1.043 +/- 0.002) versus the 90/HTN (1.036 +/- 0.003) and control (1.037 +/- 0.003) groups. ENTC Evans Blue ENTCEND (mug g-1 of brain tissue) was greater in the 90/HTN group (24
0	Part A, for eight rats in each group ENTD brain injury ENTDEND was evaluated by staining tissue using ENTC 2,3,5-triphenyltetrazolium chloride ENTCEND and edema was evaluated by microgravimetry
0	After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of ENTC phenylephrine ENTCEND -induced hypertension on ENTD ischemic brain injury ENTDEND and blood-brain barrier permeability was determined
0	ENTC Evans Blue ENTCEND  (mug g-1 of brain tissue) was greater in the 90/HTN group (24.4 +/- 6.0) versus the control group (12.3 +/- 4.1), which was in turn greater than the 15/HTN group (7.3 +/- 3.2). This study supports a hypothesis that during reperfusion, a short interval of hypertension decreases ENTD brain injury ENTDEND and edema; and that sustained hypertension increases the risk of vasogenic edema
0	Lithium inhibits IMPase and ENTC valproate ENTCEND inhibits MIP synthase. This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced ENTD seizures ENTDEND model
0	This study shows that ENTC MIP ENTCEND synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced ENTD seizures ENTDEND model
0	This study shows that MIP synthase inhibition does not replicate or augment the effects of ENTC lithium ENTCEND in the inositol sensitive pilocarpine-induced ENTD seizures ENTDEND model
1	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive ENTC pilocarpine ENTCEND induced ENTD seizures ENTDEND model
0	This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the ENTC inositol ENTCEND sensitive pilocarpine-induced ENTD seizures ENTDEND model
1	In this study, we evaluate the role DRD2 plays in ENTC chlorpromazine ENTCEND induced ENTD EPS ENTDEND in schizophrenic patients
0	In this study, we evaluate the role DRD2 plays in ENTC chlorpromazine ENTCEND -induced EPS in ENTD schizophrenic ENTDEND patients
0	Clinicians need to be aware of prescribing concomitant medications that increase the risk of ENTD myopathy ENTDEND or inhibit the CYP3A4 enzyme. Our case suggests that troponin elevation could be associated with ENTC statin ENTCEND induced rhabdomyolysis, which may warrant further studies
0	This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of ENTC clarithromycin ENTCEND  The patient developed raised cardiac biomarkers without any obvious cardiac issues, a phenomenon that has been linked to rhabdomyolysis previously. To date, there has been no reported effect of rhabdomyolysis on the structure and function of cardiac muscle. Clinicians need to be aware of prescribing concomitant medications that increase the risk of ENTD myopathy ENTDEND or inhibit the CYP3A4 enzyme
1	Our case suggests that troponin elevation could be associated with ENTC statin ENTCEND  induced ENTD rhabdomyolysis ENTDEND , which may warrant further studies
1	This particular case is of interest as ENTD rhabdomyolysis ENTDEND only occurred after an increase in the dose of ENTC clarithromycin ENTCEND
1	The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a ENTD hypersensitivity ENTDEND mechanism. This first case of ENTC meloxicam ENTCEND related liver toxicity demonstrates the potential of this drug to induce hepatic damage
1	We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic ENTD hepatitis ENTDEND due to ENTC meloxicam ENTCEND
0	We report the case of a female patient with ENTD rheumatoid arthritis ENTDEND who developed acute cytolytic hepatitis due to ENTC meloxicam ENTCEND
1	ENTC Methoxamine ENTCEND evoked non-significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage. Systemic side effects including piloerection, ENTD headache ENTDEND , and cold extremities were experienced in all subjects
1	ENTC Methoxamine ENTCEND  evoked non-significant increases in MUP and diastolic blood pressure but caused ENTD a significant rise in systolic blood pressure ENTDEND and significant fall in heart rate at maximum dosage
0	Effect of ENTC methoxamine ENTCEND  on maximum urethral pressure in women with genuine ENTD stress incontinence ENTDEND : a placebo-controlled, double-blind crossover study
1	Participation of a bulbospinal serotonergic pathway in the rat brain in ENTC clonidine ENTCEND -induced ENTD hypotension ENTDEND and bradycardia
0	The effects of microinjection of clonidine (1-10 micrograms in 1 microliter) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in ENTC urethane ENTCEND anesthetized rats. Intramedullary administration of clonidine, but not saline vehicle, caused a dose-dependent decrease in both the mean arterial pressure and the heart rate. The clonidine-induced ENTD hypotension ENTDEND was antagonized by prior spinal transection, but not bilateral vagotomy
0	The clonidine-induced ENTD hypotension ENTDEND  was antagonized by prior spinal transection, but not bilateral vagotomy. On the other hand, the clonidine-induced bradycardia was antagonized by prior bilateral vagotomy, but not spinal transection. Furthermore, selective destruction of the spinal ENTC 5-HT ENTCEND nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats
0	Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of ENTC 5,7-dihydroxytryptamine ENTCEND  reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats. The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced ENTD hypotension ENTDEND and bradycardia
1	On the other hand, the ENTC clonidine ENTCEND induced ENTD bradycardia ENTDEND was antagonized by prior bilateral vagotomy, but not spinal transection
0	Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and ENTD bradycardia ENTDEND .The effects of microinjection of clonidine (1-10 micrograms in 1 microliter) into a region adjacent to the ventrolateral surface of the medulla oblongata on cardiovascular function were assessed in ENTC urethane ENTCEND -anesthetized rats
0	On the other hand, the clonidine-induced ENTD bradycardia ENTDEND  was antagonized by prior bilateral vagotomy, but not spinal transection. Furthermore, selective destruction of the spinal ENTC 5-HT ENTCEND nerves, produced by bilateral spinal injection of 5,7-dihydroxytryptamine, reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats
0	Furthermore, selective destruction of the spinal 5-HT nerves, produced by bilateral spinal injection of ENTC 5,7-dihydroxytryptamine ENTCEND , reduced the magnitude of the vasodepressor or the ENTD bradycardiac ENTDEND responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, ENTC paroxetine ENTCEND 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENTC levothyroxine ENTCEND 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND
0	Flecainide had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND . Laboratory test findings on admission were notable only for a flecainide plasma concentration of 1360 microg/L (reference range 200-1000). A metabolic drug interaction between flecainide and paroxetine, which the patient had been taking for more than 5 years, was considered. Paroxetine was discontinued and the dose of flecainide was reduced to 50 mg twice daily. Her delirium resolved 3 days later. DISCUSSION: Flecainide and pharmacologically similar agents that interact with ENTC sodium ENTCEND channels may cause delirium in susceptible patients
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENTC pantoprazole ENTCEND 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND
0	On admission the patient was taking carvedilol 12 mg twice daily, ENTC warfarin ENTCEND 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND
0	On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENTC folic acid ENTCEND 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND
0	On admission the patient was taking ENTC carvedilol ENTCEND 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily. Flecainide had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND
0	ENTC Flecainide ENTCEND had been started 2 weeks prior for ENTD atrial fibrillation ENTDEND
0	Because ENTD toxicity ENTDEND may occur when flecainide is prescribed with ENTC paroxetine ENTCEND and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors
0	DISCUSSION: Flecainide and pharmacologically similar agents that interact with ENTC sodium ENTCEND  channels may cause delirium in susceptible patients. A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium. According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium. Because ENTD toxicity ENTDEND may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors
0	Because ENTD toxicity ENTDEND  may occur when ENTC flecainide ENTCEND is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors
0	OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with ENTC paroxetine ENTCEND  CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENTD confusion ENTDEND and paranoia over the past several days
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENTD confusion ENTDEND  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENTC levothyroxine ENTCEND 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENTD confusion ENTDEND  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENTC pantoprazole ENTCEND 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENTD confusion ENTDEND  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, ENTC warfarin ENTCEND 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENTD confusion ENTDEND  and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENTC folic acid ENTCEND 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENTD confusion ENTDEND  and paranoia over the past several days. On admission the patient was taking ENTC carvedilol ENTCEND 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of ENTC flecainide ENTCEND induced delirium associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of ENTD confusion ENTDEND and paranoia over the past several days
1	Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with ENTC paroxetine ENTCEND .OBJECTIVE: To describe a case of flecainide-induced ENTD delirium ENTDEND associated with a pharmacokinetic drug interaction with paroxetine
0	OBJECTIVE: To describe a case of flecainide-induced ENTD delirium ENTDEND  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENTC levothyroxine ENTCEND 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	DISCUSSION: Flecainide and pharmacologically similar agents that interact with ENTC sodium ENTCEND  channels may cause ENTD delirium ENTDEND in susceptible patients
0	OBJECTIVE: To describe a case of flecainide-induced ENTD delirium ENTDEND  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENTC pantoprazole ENTCEND 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of flecainide-induced ENTD delirium ENTDEND  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, ENTC warfarin ENTCEND 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of flecainide-induced ENTD delirium ENTDEND  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENTC folic acid ENTCEND 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of flecainide-induced ENTD delirium ENTDEND  associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and paranoia over the past several days. On admission the patient was taking ENTC carvedilol ENTCEND 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
1	OBJECTIVE: To describe a case of ENTC flecainide ENTCEND -induced ENTD delirium ENTDEND associated with a pharmacokinetic drug interaction with paroxetine
0	OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with ENTC paroxetine ENTCEND . CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENTD paranoia ENTDEND over the past several days
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENTD paranoia ENTDEND  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, ENTC levothyroxine ENTCEND 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENTD paranoia ENTDEND  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, ENTC pantoprazole ENTCEND 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENTD paranoia ENTDEND  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, ENTC warfarin ENTCEND 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENTD paranoia ENTDEND  over the past several days. On admission the patient was taking carvedilol 12 mg twice daily, warfarin 2 mg/day, ENTC folic acid ENTCEND 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENTD paranoia ENTDEND  over the past several days. On admission the patient was taking ENTC carvedilol ENTCEND 12 mg twice daily, warfarin 2 mg/day, folic acid 1 mg/day, levothyroxine 100 microg/day, pantoprazole 40 mg/day, paroxetine 40 mg/day, and flecainide 100 mg twice daily
0	OBJECTIVE: To describe a case of ENTC flecainide ENTCEND -induced delirium associated with a pharmacokinetic drug interaction with paroxetine. CASE SUMMARY: A 69-year-old white female presented to the emergency department with a history of confusion and ENTD paranoia ENTDEND over the past several days
1	Two cats had transient ENTD lethargy ENTDEND and inappetence. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that ENTC levetiracetam ENTCEND is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy
0	Two cats had transient ENTD lethargy ENTDEND  and inappetence. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to ENTC phenobarbital ENTCEND treatment in cats with idiopathic epilepsy
0	Median seizure frequency prior to treatment with ENTC levetiracetam ENTCEND (2.1 ENTD seizures ENTDEND /mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0
0	42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in ENTD seizure ENTDEND frequency of >or=50%). Two cats had transient lethargy and inappetence. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to ENTC phenobarbital ENTCEND treatment in cats with idiopathic epilepsy
0	ENTC Levetiracetam ENTCEND  as an adjunct to phenobarbital treatment in cats with suspected ENTD idiopathic epilepsy ENTDEND
0	CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to ENTC phenobarbital ENTCEND  treatment in cats with ENTD idiopathic epilepsy ENTDEND
1	Baboon syndrome induced by ENTC ketoconazole ENTCEND .A 27-year-old male patient presented with a ENTD maculopapular eruption ENTDEND on the flexural areas and buttocks after using oral ketoconazole
0	Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of ENTC lorazepam ENTCEND  The potential ENTD neurotoxic ENTDEND effects of the drug (and its vehicle) in this population are discussed
1	ENTD Myoclonus ENTDEND  associated with ENTC lorazepam ENTCEND therapy in very-low-birth-weight infants
0	A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became ENTD hypotensive ENTDEND during ENTC halothane ENTCEND anaesthesia
1	Intraoperative bradycardia and ENTD hypotension ENTDEND  associated with ENTC timolol ENTCEND and pilocarpine eye drops
1	It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and ENTD hypotension ENTDEND  ENTC Pilocarpine ENTCEND may have had a contributory effect
0	It is postulated that this action may have been enhanced during ENTC halothane ENTCEND anaesthesia with resultant ENTD bradycardia ENTDEND and hypotension
1	A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and ENTC timolol maleate ENTCEND eye drops, developed a ENTD bradycardia ENTDEND and became hypotensive during halothane anaesthesia
1	It is postulated that this action may have been enhanced during halothane anaesthesia with resultant ENTD bradycardia ENTDEND  and hypotension. ENTC Pilocarpine ENTCEND may have had a contributory effect
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with ENTD cancer ENTDEND  METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine ( ENTC Cr ENTCEND ) of 0
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced nephropathy (CIN) in hospitalised patients with ENTD cancer ENTDEND . METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum ENTC creatinine ENTCEND (Cr) of 0
0	5-times more frequently in patients with ENTD cancer ENTDEND who had undergone recent chemotherapy. Hypertension and the combination of bevacizumab/ ENTC irinotecan ENTCEND may be additional risk factors for CIN development
0	Incidence of ENTC contrast ENTCEND -induced nephropathy in hospitalised patients with ENTD cancer ENTDEND
0	Patients with risk factors for ENTD acute renal failure ENTDEND were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine ENTC Cr ENTCEND ) of 0
0	Patients with risk factors for ENTD acute renal failure ENTDEND  were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum ENTC creatinine ENTCEND (Cr) of 0
0	Patients with risk factors for ENTD acute renal failure ENTDEND  were excluded. Blood samples were examined the day before ENTC contrast ENTCEND -enhanced computed tomography (CT) and serially for 3 days thereafter
0	5 mg/dl or more, or elevation of ENTC Cr ENTCEND to 25 % over baseline. Relationships between CIN and possible risk factors were investigated. RESULTS: CIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P = 0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P = 0.005); it was also an independent risk factor (P = 0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with ENTD hypertension ENTDEND (P = 0
0	CIN was defined as an increase in serum ENTC creatinine ENTCEND  (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline. Relationships between CIN and possible risk factors were investigated. RESULTS: CIN was detected in 18/90 (20 %) patients. CIN developed in 25.5 % patients who underwent chemotherapy and in 11 % patients who did not (P = 0.1). CIN more frequently developed in patients who had undergone CT within 45 days after the last chemotherapy (P = 0.005); it was also an independent risk factor (P = 0.017). CIN was significantly more after treatment with bevacizumab/irinotecan (P = 0.021) and in patients with ENTD hypertension ENTDEND (P = 0
0	CIN was significantly more after treatment with bevacizumab/ ENTC irinotecan ENTCEND (P = 0.021) and in patients with ENTD hypertension ENTDEND (P = 0
0	ENTD Hypertension ENTDEND and the combination of bevacizumab/irinotecan may be additional risk factors for CIN development. KEY POINTS: . ENTC Contrast ENTCEND -induced nephropathy (CIN) is a concern for oncological patients undergoing CT
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced ENTD nephropathy ENTDEND (CIN) in hospitalised patients with cancer. METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum creatinine ENTC Cr ENTCEND ) of 0
0	OBJECTIVES: To determine the frequency of and possible factors related to contrast-induced ENTD nephropathy ENTDEND  (CIN) in hospitalised patients with cancer. METHODS: Ninety adult patients were enrolled. Patients with risk factors for acute renal failure were excluded. Blood samples were examined the day before contrast-enhanced computed tomography (CT) and serially for 3 days thereafter. CIN was defined as an increase in serum ENTC creatinine ENTCEND (Cr) of 0
1	Hypertension and the combination of bevacizumab/ ENTC irinotecan ENTCEND  may be additional risk factors for CIN development. KEY POINTS: . Contrast-induced ENTD nephropathy ENTDEND (CIN) is a concern for oncological patients undergoing CT
1	Incidence of ENTC contrast ENTCEND -induced ENTD nephropathy ENTDEND in hospitalised patients with cancer
0	This case further supports the concern about ENTD thromboembolic ENTDEND complications associated with ATRA therapy in APL patients. The patients, a 43-year-old man, presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA. After 10 days of treatment, he developed acute renal failure that was completely reversible after complete remission of APL was achieved and therapy discontinued. We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected. Thrombotic events, however, could be avoided by using low-dose ENTC heparin ENTCEND
0	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and ENTC tranexamic acid ENTCEND has been described recently. We report a case of acute renal failure in an APL patient treated with ATRA alone. This case further supports the concern about ENTD thromboembolic ENTDEND complications associated with ATRA therapy in APL patients
0	This case further supports the concern about ENTD thromboembolic ENTDEND  complications associated with ENTC ATRA ENTCEND therapy in APL patients
0	After 10 days of treatment, he developed ENTD acute renal failure ENTDEND that was completely reversible after complete remission of APL was achieved and therapy discontinued. We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected. Thrombotic events, however, could be avoided by using low-dose ENTC heparin ENTCEND
0	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and ENTC tranexamic acid ENTCEND  has been described recently. We report a case of ENTD acute renal failure ENTDEND in an APL patient treated with ATRA alone
1	Thrombotic complications in acute promyelocytic leukemia during ENTC all-trans-retinoic acid ENTCEND  therapy.A case of ENTD acute renal failure ENTDEND , due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently
0	We conclude that ATRA is a valid therapeutic choice for patients with ENTD APL ENTDEND  although the procoagulant tendency is not completely corrected. Thrombotic events, however, could be avoided by using low-dose ENTC heparin ENTCEND
0	A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia ( ENTD APL ENTDEND  treated with all-trans-retinoic acid (ATRA) and ENTC tranexamic acid ENTCEND has been described recently
0	This case further supports the concern about thromboembolic complications associated with ENTC ATRA ENTCEND  therapy in ENTD APL ENTDEND patients
0	ENTD Thrombotic ENTDEND events, however, could be avoided by using low-dose ENTC heparin ENTCEND
0	ENTD Thrombotic ENTDEND  complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and ENTC tranexamic acid ENTCEND has been described recently
1	ENTD Thrombotic ENTDEND  complications in acute promyelocytic leukemia during ENTC all-trans-retinoic acid ENTCEND therapy
0	Takotsubo syndrome (or apical ballooning syndrome) secondary to ENTC Zolmitriptan ENTCEND .Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an ENTD acute coronary syndrome ENTDEND (ie, ST-segment elevation, T wave inversions, and pathologic Q waves)
0	Takotsubo syndrome (or apical ballooning syndrome) secondary to ENTC Zolmitriptan ENTCEND .Takotsubo syndrome (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves). We report a case of 54-year-old woman with medical history of ENTD mitral valve prolapse ENTDEND and migraines, who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I
0	Detailed history obtained retrospectively revealed that the patient took ENTC zolmitriptan ENTCEND sparingly only when she had ENTD migraines ENTDEND
1	Takotsubo syndrome (or apical ballooning syndrome) secondary to ENTC Zolmitriptan ENTCEND . ENTD Takotsubo syndrome ENTDEND (TS), also known as broken heart syndrome, is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome (ie, ST-segment elevation, T wave inversions, and pathologic Q waves)
0	We report a case of 54-year-old woman with medical history of mitral valve prolapse and migraines, who was admitted to the hospital for substernal ENTD chest pain ENTDEND and electrocardiogram demonstrated 1/2 mm ST-segment elevation in leads II, III, aVF, V5, and V6 and positive troponin I. Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS. Detailed history obtained retrospectively revealed that the patient took ENTC zolmitriptan ENTCEND sparingly only when she had migraines
1	Extensive literature search revealed multiple cases of ENTD coronary artery vasospasm ENTDEND secondary to ENTC zolmitriptan ENTCEND , but none of the cases were associated with TS
1	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and ENTD peliosis ENTDEND can develop in patients with androgen- and ENTC corticosteroid ENTCEND -treated Fanconi's anemia
1	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and ENTD peliosis ENTDEND  can develop in patients with ENTC androgen ENTCEND - and corticosteroid-treated Fanconi's anemia
1	ENTD Hepatocellular carcinoma ENTDEND  in Fanconi's anemia treated with androgen and ENTC corticosteroid ENTCEND
1	ENTD Hepatocellular carcinoma ENTDEND  in Fanconi's anemia treated with ENTC androgen ENTCEND and corticosteroid
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, ENTC corticosteroids ENTCEND and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with ENTD septicemia ENTDEND and marked abnormalities in liver function and died of hemorrhagic bronchopneumonia
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with ENTC androgens ENTCEND  corticosteroids and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with ENTD septicemia ENTDEND and marked abnormalities in liver function and died of hemorrhagic bronchopneumonia
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, ENTC corticosteroids ENTCEND  and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with septicemia and marked abnormalities in liver function and died of ENTD hemorrhagic bronchopneumonia ENTDEND
0	The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with ENTC androgens ENTCEND , corticosteroids and transfusions. Two weeks before his death he was readmitted because of aplastic crisis with septicemia and marked abnormalities in liver function and died of ENTD hemorrhagic bronchopneumonia ENTDEND
0	This case contributes to the previous observations that non-metastasizing ENTD hepatic neoplasms ENTDEND and peliosis can develop in patients with androgen- and ENTC corticosteroid ENTCEND -treated Fanconi's anemia
0	This case contributes to the previous observations that non-metastasizing ENTD hepatic neoplasms ENTDEND  and peliosis can develop in patients with ENTC androgen ENTCEND - and corticosteroid-treated Fanconi's anemia
0	This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and ENTC corticosteroid ENTCEND -treated ENTD Fanconi's anemia ENTDEND
0	Hepatocellular carcinoma in ENTD Fanconi's anemia ENTDEND  treated with ENTC androgen ENTCEND and corticosteroid
0	Given the lifelong nature of hypertension, there is a need to evaluate the long-term efficacy and tolerability of higher doses of combination anti- ENTD hypertensive ENTDEND therapies. OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or ENTC hydrochlorothiazide ENTCEND (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension
0	Given the lifelong nature of hypertension, there is a need to evaluate the long-term efficacy and tolerability of higher doses of combination anti- ENTD hypertensive ENTDEND  therapies. OBJECTIVE: This study investigated the efficacy and tolerability of ENTC valsartan ENTCEND (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension
1	CONCLUSIONS: In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less ENTD hypokalemia ENTDEND than ENTC HCTZ ENTCEND alone
0	The incidence of ENTD hypokalemia ENTDEND was lower with ENTC VAL ENTCEND /HCTZ combinations (1
0	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide ( ENTC HCTZ ENTCEND -monotherapy and higher-dose combinations in patients with ENTD essential hypertension ENTDEND
0	OBJECTIVE: This study investigated the efficacy and tolerability of valsartan ( ENTC VAL ENTCEND  or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with ENTD essential hypertension ENTDEND
0	Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning ENTD arrhythmias ENTDEND between 15 and 45 minutes after the administration of ENTC lidocaine ENTCEND (p less than 0
1	During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the ENTC lidocaine ENTCEND group, ENTD hypotension ENTDEND occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine
0	The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute ENTD infarction ENTDEND  The mean plasma ENTC lidocaine ENTCEND level of patients on beta-blocking agents was no different from that in patients not on beta blocking agents
0	During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ENTD ventricular tachycardia ENTDEND among the 204 patients with acute myocardial infarction was low, 1.5%. ENTC Lidocaine ENTCEND , given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0
0	Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of ENTC lidocaine ENTCEND vs placebo. During the 1 hour after administration of the drug the incidence of ENTD ventricular fibrillation ENTDEND or sustained ventricular tachycardia among the 204 patients with acute myocardial infarction was low, 1
0	During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ventricular tachycardia among the 204 patients with acute ENTD myocardial infarction ENTDEND was low, 1.5%. ENTC Lidocaine ENTCEND , given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0
0	During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from ENTD asystole ENTDEND  three of whom had had ENTC lidocaine ENTCEND
0	ENTC Bort ENTCEND dex was an effective salvage treatment for ENTD MM ENTDEND patients, particularly for those in first relapse
0	Bort- ENTC dex ENTCEND was an effective salvage treatment for ENTD MM ENTDEND patients, particularly for those in first relapse
1	The most relevant adverse event was ENTD peripheral neuropathy ENTDEND  which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %. With a median follow up of 22 months, median time to progression, progression-free survival (PFS) and overall survival (OS) were 8.9, 8.7, and 22 months, respectively. Prolonged PFS and OS were observed in patients achieving CR and receiving ENTC bort ENTCEND -dex a single line of prior therapy
1	The median number of bort- ENTC dex ENTCEND cycles was 6, up to a maximum of 12 cycles. On an intention-to-treat basis, 55 % of the patients achieved at least partial response, including 19 % CR and 35 % achieved at least very good partial response. Median durations of response, time to next therapy and treatment-free interval were 8, 11.2, and 5.1 months, respectively. The most relevant adverse event was ENTD peripheral neuropathy ENTDEND , which occurred in 78 % of the patients (grade II, 38 %; grade III, 21 %) and led to treatment discontinuation in 6 %
0	Intracerebroventricular injection of ethacrynic acid (50% ENTD convulsive ENTDEND dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and ENTC acetylcholine ENTCEND in mouse brain
0	These effects were completely antagonized by pretreatment with a glutamate/ ENTC N-methyl-D-aspartate ENTCEND antagonist, aminophosphonovaleric acid. In ethacrynic acid-induced ENTD convulsions ENTDEND , these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain
0	Intracerebroventricular injection of ethacrynic acid (50% ENTD convulsive ENTDEND  dose; 50 micrograms/mouse) accelerated the synthesis/turnover of ENTC 5-hydroxytryptamine ENTCEND (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain
0	Intracerebroventricular injection of ethacrynic acid (50% ENTD convulsive ENTDEND  dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of ENTC gamma-aminobutyric acid ENTCEND and acetylcholine in mouse brain
1	Intracerebroventricular injection of ENTC ethacrynic acid ENTCEND (50% ENTD convulsive ENTDEND dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain
0	These effects were completely antagonized by pretreatment with a ENTC glutamate ENTCEND N-methyl-D-aspartate antagonist, aminophosphonovaleric acid. In ethacrynic acid-induced ENTD convulsions ENTDEND , these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain
0	In the media of the saphenous artery and its distal branch, vasoconstriction induced by ENTC L-norepinephrine ENTCEND produced many cell-to-cell ENTD hernias ENTDEND within 15 minutes
1	Medial changes in arterial ENTD spasm ENTDEND  induced by ENTC L-norepinephrine ENTCEND
0	Exclusion criteria were any preexisting predisposing factor for delirium or other potentially confounding ENTD neurological dysfunctions ENTDEND  Patients were assessed daily using the confusion assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to ENTC propofol ENTCEND (57
0	Exclusion criteria were any preexisting predisposing factor for delirium or other potentially confounding ENTD neurological dysfunctions ENTDEND . Patients were assessed daily using the confusion assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of ENTC thiopentone ENTCEND was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57
0	Patients were assessed daily using the ENTD confusion ENTDEND assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to ENTC propofol ENTCEND (57
0	Patients were assessed daily using the ENTD confusion ENTDEND  assessment method for the ICU scale for 3 days after the surgical procedure. Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models. RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early postoperative delirium. The use of ENTC thiopentone ENTCEND was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57
0	The use of thiopentone was significantly associated with an eight-fold-higher risk for ENTD delirium ENTDEND compared to ENTC propofol ENTCEND (57
1	The use of ENTC thiopentone ENTCEND  was significantly associated with an eight-fold-higher risk for ENTD delirium ENTDEND compared to propofol (57
0	The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to ENTC propofol ENTCEND  (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early ENTD postoperative delirium ENTDEND was found to be a very common complication after major surgery, even in a population without known risk factors
1	RESULTS: According to the confusion assessment method for the ICU scale, 28 % of patients were diagnosed with early ENTD postoperative delirium ENTDEND  The use of ENTC thiopentone ENTCEND was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57
0	We report a case about a female with essential ENTD hypertension ENTDEND on drug treatment with ENTC amlodipine ENTCEND developed loss of taste sensation
1	Is Dysguesia Going to be a Rare or a Common Side-effect of Amlodipine?A very rare side-effect of ENTC amlodipine ENTCEND is ENTD dysguesia ENTDEND
0	We report a case about a female with essential hypertension on drug treatment with ENTC amlodipine ENTCEND  developed ENTD loss of taste sensation ENTDEND
0	METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson ENTD Cancer ENTDEND Center between years 2009 and 2012, who developed ENTC ifosfamide ENTCEND related acute encephalopathy
0	BACKGROUND: ENTC Ifosfamide ENTCEND is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, ENTD lymphoma ENTDEND , gynecologic and testicular cancers
1	RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving ENTC ifosfamide ENTCEND  Two patients developed generalized convulsions while one patient developed continuous ENTD non-convulsive status epilepticus ENTDEND (NCSE) that required ICU admission and intubation
1	RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving ENTC ifosfamide ENTCEND . Two patients developed generalized ENTD convulsions ENTDEND while one patient developed continuous non-convulsive status epilepticus (NCSE) that required ICU admission and intubation
0	ENTC Ifosfamide ENTCEND  related ENTD encephalopathy ENTDEND : the need for a timely EEG evaluation
0	BACKGROUND: ENTC Ifosfamide ENTCEND  is an alkylating agent useful in the treatment of a wide range of cancers including ENTD sarcomas ENTDEND , lymphoma, gynecologic and testicular cancers
0	The best clinical effect was found with ENTC terbutaline ENTCEND  Both anti-asthmatic and ENTD tremorgenic ENTDEND effects of procaterol were dose-related
1	Both anti-asthmatic and ENTD tremorgenic ENTDEND  effects of ENTC procaterol ENTCEND were dose-related
0	Procaterol and ENTC terbutaline ENTCEND  in ENTD bronchial asthma ENTDEND
0	Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with ENTD bronchial asthma ENTDEND  Oral ENTC procaterol ENTCEND 50 micrograms b
0	OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined ENTC diazinon ENTCEND associated ENTD cancer ENTDEND risk
0	Incidence of solid ENTD tumours ENTDEND  among pesticide applicators exposed to the ENTC organophosphate ENTCEND insecticide diazinon in the Agricultural Health Study: an updated analysis
0	02) and IW days of ENTC diazinon ENTCEND use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08). ENTD Kidney cancer ENTDEND (N=94) risks were non-significantly elevated (RRLT days=1
0	OBJECTIVE: Diazinon, a common ENTC organophosphate ENTCEND insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk. We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS. METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment (1993-1997) and follow-up (1998-2005); cancer incidence was assessed through 2010(North Carolina)/2011(Iowa). Among applicators with usage information sufficient to evaluate exposure-response patterns, we used Poisson regression to estimate adjusted rate ratios (RRs) and 95% CI for cancer sites with >10 exposed cases for both lifetime (LT) exposure days and intensity-weighted (IW) lifetime exposure days (accounting for factors impacting exposure). RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08). ENTD Kidney cancer ENTDEND (N=94) risks were non-significantly elevated (RRLT days=1
1	CONCLUSIONS: Our updated evaluation of ENTC diazinon ENTCEND provides additional evidence of an association with ENTD lung cancer ENTDEND risk
0	OBJECTIVE: Diazinon, a common ENTC organophosphate ENTCEND  insecticide with genotoxic properties, was previously associated with ENTD lung cancer ENTDEND in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk
0	50), as were risks for aggressive ENTD prostate cancer ENTDEND (N=656). CONCLUSIONS: Our updated evaluation of ENTC diazinon ENTCEND provides additional evidence of an association with lung cancer risk
0	OBJECTIVE: Diazinon, a common ENTC organophosphate ENTCEND  insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk. We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS. METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment (1993-1997) and follow-up (1998-2005); cancer incidence was assessed through 2010(North Carolina)/2011(Iowa). Among applicators with usage information sufficient to evaluate exposure-response patterns, we used Poisson regression to estimate adjusted rate ratios (RRs) and 95% CI for cancer sites with >10 exposed cases for both lifetime (LT) exposure days and intensity-weighted (IW) lifetime exposure days (accounting for factors impacting exposure). RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08). Kidney cancer (N=94) risks were non-significantly elevated (RRLT days=1.77; 95% CI 0.90 to 3.51; Ptrend=0.09; RRIW days 1.37; 95% CI 0.64 to 2.92; Ptrend=0.50), as were risks for aggressive ENTD prostate cancer ENTDEND (N=656)
0	The results revealed that the adult offspring kidneys in the PCE group exhibited ENTD glomerulosclerosis ENTDEND as well as interstitial fibrosis, accompanied by elevated levels of serum ENTC creatinine ENTCEND and urine protein
0	The results revealed that the adult offspring kidneys in the PCE group exhibited ENTD glomerulosclerosis ENTDEND  as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein. Renal ENTC angiotensin II ENTCEND receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased
0	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/ ENTC tyrosine ENTCEND kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as ENTD glomerulosclerosis ENTDEND of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
0	Low functional programming of renal AT2R mediates the developmental origin of ENTD glomerulosclerosis ENTDEND  in adult offspring induced by prenatal ENTC caffeine ENTCEND exposure
0	A rat model of ENTD IUGR ENTDEND was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum ENTC creatinine ENTCEND and urine protein
0	A rat model of ENTD IUGR ENTDEND  was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein. Renal ENTC angiotensin II ENTCEND receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased
0	A rat model of ENTD IUGR ENTDEND  was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein. Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF) ENTC tyrosine ENTCEND kinase receptor (c-Ret) signaling pathway
1	UNASSIGNED: Our previous study has indicated that prenatal ENTC caffeine ENTCEND exposure (PCE) could induce ENTD intrauterine growth retardation ENTDEND (IUGR) of offspring
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENTD interstitial fibrosis ENTDEND  accompanied by elevated levels of serum ENTC creatinine ENTCEND and urine protein
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENTD interstitial fibrosis ENTDEND , accompanied by elevated levels of serum creatinine and urine protein. Renal ENTC angiotensin II ENTCEND receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENTD interstitial fibrosis ENTDEND , accompanied by elevated levels of serum creatinine and urine protein. Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF) ENTC tyrosine ENTCEND kinase receptor (c-Ret) signaling pathway
1	UNASSIGNED: Our previous study has indicated that prenatal ENTC caffeine ENTCEND  exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring. Recent research suggested that IUGR is a risk factor for glomerulosclerosis. However, whether PCE could induce glomerulosclerosis and its underlying mechanisms remain unknown. This study aimed to demonstrate the induction to glomerulosclerosis in adult offspring by PCE and its intrauterine programming mechanisms. A rat model of IUGR was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized. The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as ENTD interstitial fibrosis ENTDEND , accompanied by elevated levels of serum creatinine and urine protein
0	The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum ENTC creatinine ENTCEND  and urine protein. Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce ENTD dysplasia of fetal kidneys ENTDEND as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
0	Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal ENTC angiotensin II ENTCEND receptor type 1a (AT1aR)/AT2R expression ratio was increased. The fetal kidneys in the PCE group displayed an enlarged Bowman's space and a shrunken glomerular tuft, accompanied by a reduced cortex width and an increase in the nephrogenic zone/cortical zone ratio. Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR. Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce ENTD dysplasia of fetal kidneys ENTDEND as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
0	Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/ ENTC tyrosine ENTCEND  kinase receptor (c-Ret) signaling pathway. These results demonstrated that PCE could induce ENTD dysplasia of fetal kidneys ENTDEND as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis
1	51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and ENTC L-DOPA ENTCEND induced ENTD dyskinesias ENTDEND
0	51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, ENTD rigidity ENTDEND  and ENTC L-DOPA ENTCEND -induced dyskinesias
0	51 patients with medically refractory ENTD Parkinson's disease ENTDEND underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and ENTC L-DOPA ENTCEND -induced dyskinesias
0	51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of ENTD bradykinesia ENTDEND  rigidity, and ENTC L-DOPA ENTCEND -induced dyskinesias
0	Univariate analysis showed that the risk factors associated with ENTD seizures ENTDEND after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total ENTC bilirubin ENTCEND after surgery, and trough TAC level
1	High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for ENTC TAC ENTCEND related ENTD seizures ENTDEND
0	Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total ENTC bilirubin ENTCEND  after surgery, and trough TAC level. Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures. All children who experienced seizures survived with good graft function and remained seizure-free without anti- ENTD epileptic ENTDEND drugs over a mean follow-up period of 33
0	All children who experienced seizures survived with good graft function and remained seizure-free without anti- ENTD epileptic ENTDEND  drugs over a mean follow-up period of 33.7 + 14.6 months. High trough ENTC TAC ENTCEND level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT
0	All exhibited generalized ENTD tonic-clonic seizures ENTDEND within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total ENTC bilirubin ENTCEND after surgery, and trough TAC level
0	All exhibited generalized ENTD tonic-clonic seizures ENTDEND  within the first two wk after LT. Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough ENTC TAC ENTCEND level
0	Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric ENTD end-stage liver disease ENTDEND score before surgery, Child-Pugh score before surgery, serum total ENTC bilirubin ENTCEND after surgery, and trough TAC level
0	Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric ENTD end-stage liver disease ENTDEND  score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough ENTC TAC ENTCEND level
0	We describe three patients in whom severe, life-threatening ENTD hyperkalemia ENTDEND and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of ENTC prostaglandin ENTCEND synthesis and consequent hyporeninemic hypoaidosteronism
0	We describe three patients in whom severe, life-threatening ENTD hyperkalemia ENTDEND  and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and ENTC potassium ENTCEND balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
1	ENTC Indomethacin ENTCEND -induced ENTD hyperkalemia ENTDEND in three patients with gouty arthritis
0	This complication may result from an inhibition of ENTC prostaglandin ENTCEND  synthesis and consequent ENTD hyporeninemic hypoaidosteronism ENTDEND
0	This complication may result from an inhibition of prostaglandin synthesis and consequent ENTD hyporeninemic hypoaidosteronism ENTDEND . Careful attention to renal function and ENTC potassium ENTCEND balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
0	This complication may result from an inhibition of prostaglandin synthesis and consequent ENTD hyporeninemic hypoaidosteronism ENTDEND . Careful attention to renal function and potassium balance in patients receiving ENTC indomethacin ENTCEND or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
0	This complication may result from an inhibition of ENTC prostaglandin ENTCEND  synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with ENTD diabetes mellitus ENTDEND or preexisting renal disease, will help prevent this potentially serious complication
0	Careful attention to renal function and ENTC potassium ENTCEND  balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with ENTD diabetes mellitus ENTDEND or preexisting renal disease, will help prevent this potentially serious complication
0	Careful attention to renal function and potassium balance in patients receiving ENTC indomethacin ENTCEND  or other nonsteroidal anti-inflammatory agents, particularly in those patients with ENTD diabetes mellitus ENTDEND or preexisting renal disease, will help prevent this potentially serious complication
0	We describe three patients in whom severe, life-threatening hyperkalemia and ENTD renal insufficiency ENTDEND developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of ENTC prostaglandin ENTCEND synthesis and consequent hyporeninemic hypoaidosteronism
0	We describe three patients in whom severe, life-threatening hyperkalemia and ENTD renal insufficiency ENTDEND  developed after treatment of acute gouty arthritis with indomethacin. This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and ENTC potassium ENTCEND balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
1	We describe three patients in whom severe, life-threatening hyperkalemia and ENTD renal insufficiency ENTDEND  developed after treatment of acute gouty arthritis with ENTC indomethacin ENTCEND
0	This complication may result from an inhibition of ENTC prostaglandin ENTCEND  synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting ENTD renal disease ENTDEND , will help prevent this potentially serious complication
0	Careful attention to renal function and ENTC potassium ENTCEND  balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting ENTD renal disease ENTDEND , will help prevent this potentially serious complication
0	Careful attention to renal function and potassium balance in patients receiving ENTC indomethacin ENTCEND  or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting ENTD renal disease ENTDEND , will help prevent this potentially serious complication
0	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute ENTD gouty arthritis ENTDEND with indomethacin. This complication may result from an inhibition of ENTC prostaglandin ENTCEND synthesis and consequent hyporeninemic hypoaidosteronism
0	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute ENTD gouty arthritis ENTDEND  with indomethacin. This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism. Careful attention to renal function and ENTC potassium ENTCEND balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication
0	We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute ENTD gouty arthritis ENTDEND  with ENTC indomethacin ENTCEND
0	After transfer to an internal ward, we noted ENTD aphasia ENTDEND and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENTC heroin ENTCEND simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	After transfer to an internal ward, we noted ENTD aphasia ENTDEND  and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using ENTC methadone ENTCEND and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke
1	Hypotheses of ENTC heroin ENTCEND related ENTD rhabdomyolysis ENTDEND and stroke in heroin abusers are discussed
1	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of ENTD rhabdomyolysis ENTDEND and ischemic stroke. Patients under ENTC methadone ENTCEND maintenance therapy should be warned regarding these serious adverse events
0	After transfer to an internal ward, we noted aphasia and ENTD weakness ENTDEND of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENTC heroin ENTCEND simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	After transfer to an internal ward, we noted aphasia and ENTD weakness ENTDEND  of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using ENTC methadone ENTCEND and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	In the ICU, we found rhabdomyolysis, acute renal failure and acute ENTD respiratory failure ENTDEND  After transfer to an internal ward, we noted aphasia and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENTC heroin ENTCEND simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	In the ICU, we found rhabdomyolysis, acute renal failure and acute ENTD respiratory failure ENTDEND . After transfer to an internal ward, we noted aphasia and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using ENTC methadone ENTCEND and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke
1	Hypotheses of heroin-related rhabdomyolysis and ENTD stroke ENTDEND in ENTC heroin ENTCEND abusers are discussed
1	Patients under ENTC methadone ENTCEND  maintenance therapy should be warned regarding these serious adverse events. Hypotheses of heroin-related rhabdomyolysis and ENTD stroke ENTDEND in heroin abusers are discussed
0	Rhabdomyolysis and brain ENTD ischemic stroke ENTDEND  in a ENTC heroin ENTCEND -dependent male under methadone maintenance therapy
0	CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ENTD ischemic stroke ENTDEND  Patients under ENTC methadone ENTCEND maintenance therapy should be warned regarding these serious adverse events
0	In the ICU, we found rhabdomyolysis, ENTD acute renal failure ENTDEND and acute respiratory failure. After transfer to an internal ward, we noted aphasia and weakness of his left limbs. After MRI, we found cerebral ischemic infarction. CONCLUSION: Those using methadone and ENTC heroin ENTCEND simultaneously may increase risk of rhabdomyolysis and ischemic stroke
0	He had used heroin since age 20, and had used 150 mg ENTC methadone ENTCEND daily for 6 months. He was found unconsciousness at home and was sent to our hospital. In the ER, his opiate level was 4497 ng/ml. In the ICU, we found rhabdomyolysis, ENTD acute renal failure ENTDEND and acute respiratory failure
0	He had used ENTC heroin ENTCEND since age 20, and had used 150 mg methadone daily for 6 months. He was found ENTD unconsciousness ENTDEND at home and was sent to our hospital
0	He had used heroin since age 20, and had used 150 mg ENTC methadone ENTCEND  daily for 6 months. He was found ENTD unconsciousness ENTDEND at home and was sent to our hospital
0	Rhabdomyolysis and brain ischemic stroke in a ENTC heroin ENTCEND -dependent male under methadone maintenance therapy.OBJECTIVE: There are several complications associated with ENTD heroin abuse ENTDEND , some of which are life-threatening
0	OBJECTIVE: There are several complications associated with ENTD heroin abuse ENTDEND , some of which are life-threatening. ENTC Methadone ENTCEND may aggravate this problem
0	For patients in sinus rhythm and ENTD heart failure ENTDEND the situation is less clear. ENTC Digoxin ENTCEND has a narrow therapeutic:toxic ratio and concentrations are affected by a number of drugs
1	Also, ENTC digoxin ENTCEND has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing ENTD arrhythmias ENTDEND
0	In patients with ENTD atrial fibrillation ENTDEND ENTC digoxin ENTCEND is beneficial for ventricular rate control
0	Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction ( ENTD MI ENTDEND . ENTC Angiotensin ENTCEND -converting enzyme (ACE) inhibitors should be used first as they are safer, do not require blood level monitoring, modify progression of disease, relieve symptoms, improve exercise tolerance and reduce mortality
0	Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that ENTC digoxin ENTCEND may increase mortality after ENTD myocardial infarction ENTDEND (MI)
1	After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction (dyspnea, loss of consciousness) and delayed macro-papular rash appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent ENTD pain ENTDEND at the site of injection immediately and a generalised macro-papular reaction after 24 hours. The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some ENTC PRC ENTCEND with common chains in their structures
1	The authors report two observations on patients with delayed reactions in whom intradermoreactions (IDR) and patch tests to a series of ionic and non ionic ENTC PRC ENTCEND were studied. After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction (dyspnea, loss of consciousness) and delayed ENTD macro-papular rash ENTDEND appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent pain at the site of injection immediately and a generalised macro-papular reaction after 24 hours
1	The authors report two observations on patients with delayed reactions in whom intradermoreactions (IDR) and patch tests to a series of ionic and non ionic ENTC PRC ENTCEND  were studied. After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction (dyspnea, ENTD loss of consciousness ENTDEND ) and delayed macro-papular rash appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent pain at the site of injection immediately and a generalised macro-papular reaction after 24 hours
0	The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some ENTC PRC ENTCEND  with common chains in their structures. The positive skin tests are in favour of immunological reactions and may help in diagnosis of ENTD allergy ENTDEND in the patients
1	The authors report two observations on patients with delayed reactions in whom intradermoreactions (IDR) and patch tests to a series of ionic and non ionic ENTC PRC ENTCEND  were studied. After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( ENTD dyspnea ENTDEND , loss of consciousness) and delayed macro-papular rash appeared, whilst patient n degree 2 developed a generalised sensation of heat, persistent pain at the site of injection immediately and a generalised macro-papular reaction after 24 hours
0	Oxidative stress is involved in several processes including cancer, aging and ENTD cardiovascular disease ENTDEND  and has been shown to potentiate the therapeutic effect of drugs such as ENTC doxorubicin ENTCEND
0	ENTC Hydroxytyrosol ENTCEND  ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.Oxidative stress is involved in several processes including cancer, aging and ENTD cardiovascular disease ENTDEND , and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin
0	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in ENTC doxorubicin ENTCEND -induced ENTD cardiotoxicity ENTDEND in rats with breast cancer
0	Herein, we investigate whether doxorubicin-associated chronic ENTD cardiac toxicity ENTDEND can be ameliorated with the antioxidant ENTC hydroxytyrosol ENTCEND in rats with breast cancer
0	Hydroxytyrosol ameliorates oxidative stress and ENTD mitochondrial dysfunction ENTDEND  in ENTC doxorubicin ENTCEND -induced cardiotoxicity in rats with breast cancer
0	ENTC Hydroxytyrosol ENTCEND  ameliorates oxidative stress and ENTD mitochondrial dysfunction ENTDEND in doxorubicin-induced cardiotoxicity in rats with breast cancer
0	Oxidative stress is involved in several processes including ENTD cancer ENTDEND  aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as ENTC doxorubicin ENTCEND
0	ENTC Hydroxytyrosol ENTCEND  ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.Oxidative stress is involved in several processes including ENTD cancer ENTDEND , aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin
0	Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in ENTC doxorubicin ENTCEND -induced cardiotoxicity in rats with ENTD breast cancer ENTDEND
0	Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant ENTC hydroxytyrosol ENTCEND  in rats with ENTD breast cancer ENTDEND
1	This study demonstrates that hydroxytyrosol protect rat ENTD heart damage ENTDEND provoked by ENTC doxorubicin ENTCEND decreasing oxidative damage and mitochondrial alterations
0	5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus ENTC hydroxytyrosol ENTCEND  ENTD Cardiac disturbances ENTDEND at the cellular and mitochondrial level, mitochondrial electron transport chain complexes I-IV and apoptosis-inducing factor, and oxidative stress markers have been analyzed
1	CONCLUSIONS: Evidence is mounting that relates early-life ENTC iAs ENTCEND exposure and ENTD cancer ENTDEND development later in life
0	Mechanisms Underlying Latent Disease Risk Associated with Early-Life ENTC Arsenic ENTCEND  Exposure: Current Research Trends and Scientific Gaps.BACKGROUND: Millions of individuals worldwide, particularly those living in rural and developing areas, are exposed to harmful levels of inorganic arsenic (iAs) in their drinking water. Inorganic As exposure during key developmental periods is associated with a variety of adverse health effects including those that are evident in adulthood. There is considerable interest in identifying the molecular mechanisms that relate early-life iAs exposure to the development of these latent diseases, particularly in relationship to ENTD cancer ENTDEND
1	These findings demonstrate for the first time that a single high dose of ENTC METH ENTCEND induces long-lasting ENTD depressive ENTDEND -like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and ENTC serotonin ENTCEND  observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENTD depression ENTDEND --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and ENTC HVA ENTCEND  tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENTD depression ENTDEND --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, ENTC DOPAC ENTCEND and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENTD depression ENTDEND --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of ENTC dopamine ENTCEND  DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENTD depression ENTDEND --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, ENTC tyrosine ENTCEND hydroxylase and serotonin, observed at both 3 and 49 days post-administration. In parallel, another neurochemical feature of ENTD depression ENTDEND --astroglial dysfunction--was unaffected in the cortex and the striatal levels of the astrocytic protein marker, glial fibrillary acidic protein, were only transiently increased at 3 days
0	A single ENTD neurotoxic ENTDEND  dose of ENTC methamphetamine ENTCEND induces a long-lasting depressive-like behaviour in mice
0	A single ENTD neurotoxic ENTDEND  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and ENTC serotonin ENTCEND , observed at both 3 and 49 days post-administration
0	A single ENTD neurotoxic ENTDEND  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and ENTC HVA ENTCEND , tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	A single ENTD neurotoxic ENTDEND  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, ENTC DOPAC ENTCEND and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	A single ENTD neurotoxic ENTDEND  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of ENTC dopamine ENTCEND , DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	A single ENTD neurotoxic ENTDEND  dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal. However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits. Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.). METH did not alter the motor function and procedural memory of mice as assessed by swimming speed and escape latency to find the platform in a cued version of the water maze task. However, METH significantly increased the immobility time in the tail suspension test at 3 and 49 days post-administration. This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, ENTC tyrosine ENTCEND hydroxylase and serotonin, observed at both 3 and 49 days post-administration
0	Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates ENTC isoproterenol ENTCEND -induced acute ENTD myocardial injury ENTDEND in rats
0	The protective role of ENTC betaine ENTCEND on ENTD myocardial damage ENTDEND was further confirmed by histopathological examination
1	Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ENTD ventricular remodeling ENTDEND  Western blot analysis showed that ENTC isoproterenol ENTCEND -induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium
0	Oral administration of ENTC betaine ENTCEND (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ENTD ventricular remodeling ENTDEND
1	In summary, our results showed that betaine pretreatment attenuated ENTC isoproterenol ENTCEND induced acute ENTD myocardial ischemia ENTDEND via the regulation of STAT3 and apoptotic pathways
0	The present study was designed to investigate the cardioprotective effects of ENTC betaine ENTCEND on acute ENTD myocardial ischemia ENTDEND induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect
0	Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the ENTC MK-801 ENTCEND treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that ENTD status epilepticus ENTDEND induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
0	ENTC Pentobarbital ENTCEND  scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that ENTD status epilepticus ENTDEND induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
0	These results indicate that ENTD status epilepticus ENTDEND  induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory ENTC NMDA ENTCEND receptor-mediated mechanism
1	These results indicate that ENTD status epilepticus ENTDEND  induced by ENTC pilocarpine ENTCEND is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
0	Pentobarbital, ENTC scopolamine ENTCEND and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that ENTD status epilepticus ENTDEND induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism
1	Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic ENTD seizure ENTDEND  ENTC MK-801 ENTCEND treatment augmented the electrographic seizure induced by pilocarpine
0	Intraperitoneal injection of pilocarpine (400 mg/kg) induced ENTD tonic and clonic seizure ENTDEND  Scopolamine (10 mg/kg) and ENTC pentobarbital ENTCEND (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0
1	The authors examined the anticonvulsant effects of MK-801 on the ENTC pilocarpine ENTCEND induced ENTD seizure ENTDEND model
0	Intraperitoneal injection of pilocarpine (400 mg/kg) induced ENTD tonic and clonic seizure ENTDEND . ENTC Scopolamine ENTCEND (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0
0	Pentobarbital, scopolamine and ENTC MK-801 ENTCEND protected the ENTD brain damage ENTDEND by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	ENTC Pentobarbital ENTCEND , scopolamine and MK-801 protected the ENTD brain damage ENTDEND by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause ENTD brain damage ENTDEND through an excitatory ENTC NMDA ENTCEND receptor-mediated mechanism
0	Pentobarbital, scopolamine and MK-801 protected the ENTD brain damage ENTDEND  by ENTC pilocarpine ENTCEND , though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pentobarbital, ENTC scopolamine ENTCEND  and MK-801 protected the ENTD brain damage ENTDEND by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pilocarpine produced ENTD neuronal death ENTDEND in the hippocampus, which showed pyknotic changes. Pentobarbital, scopolamine and ENTC MK-801 ENTCEND protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pilocarpine produced ENTD neuronal death ENTDEND  in the hippocampus, which showed pyknotic changes. ENTC Pentobarbital ENTCEND , scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
0	Pilocarpine produced ENTD neuronal death ENTDEND  in the hippocampus, which showed pyknotic changes. Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal. In all treatments, granule cells of the dentate gyrus were not affected. 4. These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory ENTC NMDA ENTCEND receptor-mediated mechanism
1	ENTC Pilocarpine ENTCEND produced ENTD neuronal death ENTDEND in the hippocampus, which showed pyknotic changes
0	Pilocarpine produced ENTD neuronal death ENTDEND  in the hippocampus, which showed pyknotic changes. Pentobarbital, ENTC scopolamine ENTCEND and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal
1	A case of fatal ENTD aplastic anemia ENTDEND due to ENTC carbamazepine ENTCEND treatment in an epileptic woman is reported
0	Despite concerns of fatal ENTD bone marrow toxicity ENTDEND due to ENTC carbamazepine ENTCEND , this is only the fourth documented and published report
0	A case of fatal aplastic anemia due to ENTC carbamazepine ENTCEND  treatment in an ENTD epileptic ENTDEND woman is reported
0	The case discussed herein initially appeared to be neurogenic diabetes insipidus ( ENTD DI ENTDEND  secondary to a traumatic brain injury. The nursing staff, by reviewing the patient's health history with his family, discovered a history of polydipsia and long-standing ENTC lithium ENTCEND use
0	The nursing staff, by reviewing the patient's health history with his family, discovered a history of ENTD polydipsia ENTDEND and long-standing ENTC lithium ENTCEND use
0	By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his ENTC lithium ENTCEND induced nephrogenic DI and developed neurogenic DI secondary to ENTD brain trauma ENTDEND
1	By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his ENTC lithium ENTCEND -induced ENTD nephrogenic DI ENTDEND and developed neurogenic DI secondary to brain trauma
0	3-3% of diet weight) of certain amino derivatives of ENTC caproate ENTCEND resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENTD glucosuria ENTDEND
0	3-3% of diet weight) of certain ENTC amino ENTCEND derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENTD glucosuria ENTDEND
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENTD glucosuria ENTDEND . Effective compounds included norleucine, norvaline, glutamate, epsilon-aminocaproate, ENTC methionine ENTCEND , and leucine
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated ENTC glucose ENTCEND tolerance curve and, occasionally, ENTD glucosuria ENTDEND
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, ENTD glucosuria ENTDEND . Effective compounds included norleucine, norvaline, ENTC glutamate ENTCEND , epsilon-aminocaproate, methionine, and leucine
0	3-3% of diet weight) of certain amino derivatives of ENTC caproate ENTCEND  resulted in ENTD hyperglycemia ENTDEND , an elevated glucose tolerance curve and, occasionally, glucosuria
1	ENTD Hyperglycemic ENTDEND  effect of ENTC amino ENTCEND compounds structurally related to caproate in rats
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in ENTD hyperglycemia ENTDEND , an elevated glucose tolerance curve and, occasionally, glucosuria. Effective compounds included norleucine, norvaline, glutamate, epsilon-aminocaproate, ENTC methionine ENTCEND , and leucine
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in ENTD hyperglycemia ENTDEND , an elevated ENTC glucose ENTCEND tolerance curve and, occasionally, glucosuria
0	3-3% of diet weight) of certain amino derivatives of caproate resulted in ENTD hyperglycemia ENTDEND , an elevated glucose tolerance curve and, occasionally, glucosuria. Effective compounds included norleucine, norvaline, ENTC glutamate ENTCEND , epsilon-aminocaproate, methionine, and leucine
1	Inhibition of nuclear factor-kappaB activation attenuates ENTD tubulointerstitial nephritis ENTDEND  induced by ENTC gentamicin ENTCEND
0	Treatment with ENTC PDTC ENTCEND reduced the functional and structural changes induced by gentamicin. CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates ENTD tubulointerstitial nephritis ENTDEND induced by gentamicin
0	RESULTS: Gentamicin-treated rats presented a transitory increase in plasma ENTC creatinine ENTCEND levels. Increased ED-1, MAP kinases and NF-kappaB staining were also observed in the renal cortex from all gentamicin-treated rats compared to control (p < 0.05). The animals killed on day 30 also presented fibrosis in the renal cortex despite the recovery of renal function. Treatment with PDTC reduced the functional and structural changes induced by gentamicin. CONCLUSIONS: These data show that inhibition of NF-kappaB activation attenuates ENTD tubulointerstitial nephritis ENTDEND induced by gentamicin
0	Inhibition of nuclear factor-kappaB activation attenuates ENTD tubulointerstitial nephritis ENTDEND  induced by gentamicin.BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex. This study investigated the expression of nuclear factor-kappaB (NF-kappaB), mitogen-activated protein (MAP) kinases and macrophages in the renal cortex and structural and functional renal changes of rats treated with gentamicin or gentamicin + pyrrolidine dithiocarbamate (PDTC), an NF-kappaB inhibitor. METHODS: 38 female Wistar rats were injected with gentamicin, 40 mg/kg, twice a day for 9 days, 38 with gentamicin + PDTC, and 28 with 0.15 M ENTC NaCl ENTCEND solution
0	BACKGROUND: Animals treated with ENTC gentamicin ENTCEND can show residual areas of interstitial ENTD fibrosis ENTDEND in the renal cortex
0	The animals killed on day 30 also presented ENTD fibrosis ENTDEND in the renal cortex despite the recovery of renal function. Treatment with ENTC PDTC ENTCEND reduced the functional and structural changes induced by gentamicin
0	RESULTS: Gentamicin-treated rats presented a transitory increase in plasma ENTC creatinine ENTCEND  levels. Increased ED-1, MAP kinases and NF-kappaB staining were also observed in the renal cortex from all gentamicin-treated rats compared to control (p < 0.05). The animals killed on day 30 also presented ENTD fibrosis ENTDEND in the renal cortex despite the recovery of renal function
0	BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial ENTD fibrosis ENTDEND  in the renal cortex. This study investigated the expression of nuclear factor-kappaB (NF-kappaB), mitogen-activated protein (MAP) kinases and macrophages in the renal cortex and structural and functional renal changes of rats treated with gentamicin or gentamicin + pyrrolidine dithiocarbamate (PDTC), an NF-kappaB inhibitor. METHODS: 38 female Wistar rats were injected with gentamicin, 40 mg/kg, twice a day for 9 days, 38 with gentamicin + PDTC, and 28 with 0.15 M ENTC NaCl ENTCEND solution
1	Five patients complained of ENTD paresthesias ENTDEND and leg cramps. After ENTC thalidomide ENTCEND treatment, sural SAP amplitude recovered in 3 patients
1	ENTC Thalidomide ENTCEND  and ENTD sensory neurotoxicity ENTDEND : a neurophysiological study
1	Five patients complained of paresthesias and leg ENTD cramps ENTDEND  After ENTC thalidomide ENTCEND treatment, sural SAP amplitude recovered in 3 patients
0	The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the ENTD neurotoxic ENTDEND potential of ENTC thalidomide ENTCEND and the recovery capacity of sensory fibres after discontinuation of treatment
0	The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus ( ENTD CLE ENTDEND  treated with ENTC thalidomide ENTCEND and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment
0	Persistent sterile leukocyturia is associated with impaired renal function in ENTD human immunodeficiency virus type 1-infected ENTDEND  children treated with ENTC indinavir ENTCEND
0	DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 ENTD human immunodeficiency virus type 1-infected ENTDEND children treated with indinavir. METHODS: Urinary pH, albumin, ENTC creatinine ENTCEND , the presence of erythrocytes, leukocytes, bacteria and crystals, and culture were analyzed every 3 months for 96 weeks
0	The impairment of the renal function in these children occurred in the absence of clinical symptoms of ENTD nephrolithiasis ENTDEND  ENTC Indinavir ENTCEND -associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5
0	Children with persistent sterile leukocyturia more frequently had an increase in serum ENTC creatinine ENTCEND levels of >50% above normal. Younger children have an additional risk for renal complications. The impairment of the renal function in these children occurred in the absence of clinical symptoms of ENTD nephrolithiasis ENTDEND
1	DESIGN: A prospective study to monitor ENTC indinavir ENTCEND related ENTD nephrotoxicity ENTDEND in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir
0	In 4 children, indinavir was discontinued because of ENTD nephrotoxicity ENTDEND  Subsequently, the serum ENTC creatinine ENTCEND levels decreased, the urine albumin/creatinine ratios returned to zero, and the leukocyturia disappeared within 3 months
1	Steady-state pharmacokinetics of indinavir were done at week 4 after the initiation of ENTC indinavir ENTCEND  RESULTS: The cumulative incidence of persistent sterile leukocyturia (> or =75 cells/ micro L in at least 2 consecutive visits) after 96 weeks was 53%. Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic ENTD hematuria ENTDEND
0	Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/ ENTC creatinine ENTCEND ratio and by microscopic ENTD hematuria ENTDEND
0	075mg/kg dose of ENTC Fazadinium ENTCEND  did not influence the occurrence of scoline ENTD pain ENTDEND
0	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or ENTC bromide ENTCEND , affected the incidence of scoline ENTD pain ENTDEND
0	075mg/kg dose of Fazadinium) did not influence the occurrence of scoline ENTD pain ENTDEND . Neither the type of induction agent ( ENTC Althesin ENTCEND or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
0	075mg/kg dose of Fazadinium) did not influence the occurrence of scoline ENTD pain ENTDEND . Neither the type of induction agent (Althesin or ENTC Thiopentone ENTCEND ) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
1	Contrary to an earlier report by Coxon, ENTC scoline ENTCEND ENTD pain ENTDEND occurs in African negroes
0	Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used ( ENTC chloride ENTCEND or bromide), affected the incidence of scoline ENTD pain ENTDEND
0	The abolition of muscle ENTD fasciculations ENTDEND (by 0.075mg/kg dose of ENTC Fazadinium ENTCEND ) did not influence the occurrence of scoline pain
0	The abolition of muscle ENTD fasciculations ENTDEND  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or ENTC bromide ENTCEND ), affected the incidence of scoline pain
0	The abolition of muscle ENTD fasciculations ENTDEND  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent ENTC Althesin ENTCEND or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
0	The abolition of muscle ENTD fasciculations ENTDEND  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent (Althesin or ENTC Thiopentone ENTCEND ) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain
1	The abolition of muscle ENTD fasciculations ENTDEND  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of ENTC scoline ENTCEND pain
0	The abolition of muscle ENTD fasciculations ENTDEND  (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain. Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used ENTC chloride ENTCEND or bromide), affected the incidence of scoline pain
1	Previous studies indicate that ENTC ecstasy ENTCEND users have marked and persistent neurocognitive and ENTD sleep-related impairments ENTDEND
1	We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation ENTD memory impairments ENTDEND in regular ENTC ecstasy ENTCEND users
0	If confirmed in controlled trials, the long-term results of this open, non-randomized study might indicate that the analgesic effect of ENTC capsaicin ENTCEND in ENTD PHN ENTDEND is mediated by both interference with neuropeptide metabolism and morphological changes (perhaps degeneration) of nociceptive afferents
1	025% ENTC capsaicin ENTCEND cream for 8 weeks. During therapy the patients rated their ENTD pain ENTDEND on a visual analogue scale (VAS) and a verbal outcome scale
1	8%) discontinued therapy due to side-effects such as intolerable ENTC capsaicin ENTCEND induced burning sensations (4) or ENTD mastitis ENTDEND (1); 15 (38
0	In a series of five experiments, the modulating role of naloxone on a scopolamine-induced ENTD retention deficit ENTDEND in a passive avoidance paradigm was investigated in mice. Scopolamine, but not ENTC methyl scopolamine ENTCEND (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters
0	In a series of five experiments, the modulating role of ENTC naloxone ENTCEND on a scopolamine-induced ENTD retention deficit ENTDEND in a passive avoidance paradigm was investigated in mice
0	3, 1, 3, and 10 mg/kg) injected prior to training attenuated the ENTD retention deficit ENTDEND with a peak of activity at 3 mg/kg. The effect of naloxone could be antagonized with ENTC morphine ENTCEND (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect
0	In a series of five experiments, the modulating role of naloxone on a ENTC scopolamine ENTCEND induced ENTD retention deficit ENTDEND in a passive avoidance paradigm was investigated in mice
0	Scopolamine, but not ENTC methyl scopolamine ENTCEND  (1 and 3 mg/kg), induced an ENTD amnesia ENTDEND as measured by latency and duration parameters
0	Reversal of scopolamine-induced ENTD amnesia ENTDEND  of passive avoidance by pre- and post-training ENTC naloxone ENTCEND
0	The effect of naloxone could be antagonized with ENTC morphine ENTCEND  (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect. Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced ENTD amnesia ENTDEND
1	Reversal of ENTC scopolamine ENTCEND -induced ENTD amnesia ENTDEND of passive avoidance by pre- and post-training naloxone
0	Scopolamine, but not ENTC methyl scopolamine ENTCEND  (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters. Naloxone (0.3, 1, 3, and 10 mg/kg) injected prior to training attenuated the retention deficit with a peak of activity at 3 mg/kg. The effect of naloxone could be antagonized with morphine (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect. Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia. Control experiments indicated that neither an increase in ENTD pain ENTDEND sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	Control experiments indicated that neither an increase in ENTD pain ENTDEND  sensitivity (pre-training ENTC naloxone ENTCEND ) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	The effect of naloxone could be antagonized with ENTC morphine ENTCEND  (1, 3, and 10 mg/kg), demonstrating the opioid specificity of the naloxone effect. Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia. Control experiments indicated that neither an increase in ENTD pain ENTDEND sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the ENTC scopolamine ENTCEND induced amnesia. Control experiments indicated that neither an increase in ENTD pain ENTDEND sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit
0	A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of ENTC hydrochlorothiazide ENTCEND  administered twice daily for one month to ENTD hypertensive ENTDEND patients
0	A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of ENTC timolol maleate ENTCEND and 25 mg of hydrochlorothiazide, administered twice daily for one month to ENTD hypertensive ENTDEND patients
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol- ENTC hydrochlorothiazide ENTCEND therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, dizziness, and ENTD weakness ENTDEND
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of ENTC timolol ENTCEND hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, dizziness, and ENTD weakness ENTDEND
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol- ENTC hydrochlorothiazide ENTCEND  therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being ENTD fatigue ENTDEND , dizziness, and weakness
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of ENTC timolol ENTCEND -hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being ENTD fatigue ENTDEND , dizziness, and weakness
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of timolol- ENTC hydrochlorothiazide ENTCEND  therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, ENTD dizziness ENTDEND , and weakness
1	Mean systolic blood pressure decreased 25 mmHg and mean diastolic blood pressure declined 15 mmHg after one month of ENTC timolol ENTCEND -hydrochlorothiazide therapy (P less than 0.01, both comparisons). Age, race, and sex appeared to have no influence on the decrease in blood pressure. The antihypertensive effect of the drug was greater in patients with more severe hypertension. Overall, 1,453 patients experienced a total of 2,658 adverse events, the most common being fatigue, ENTD dizziness ENTDEND , and weakness
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENTC oxytocin ENTCEND , when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENTD hyper- or hypotension ENTDEND (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENTC carbetocin ENTCEND were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENTD hyper- or hypotension ENTDEND (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENTC oxytocin ENTCEND ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENTD hyper- or hypotension ENTDEND (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENTC carbetocin ENTCEND  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: ENTD hyper- or hypotension ENTDEND (three), severe abdominal pain (0), vomiting (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENTC oxytocin ENTCEND ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), ENTD vomiting ENTDEND (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENTC carbetocin ENTCEND  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), ENTD vomiting ENTDEND (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENTC oxytocin ENTCEND ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe ENTD abdominal pain ENTDEND (0), vomiting (0) and retained placenta (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENTC carbetocin ENTCEND  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe ENTD abdominal pain ENTDEND (0), vomiting (0) and retained placenta (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENTC oxytocin ENTCEND ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), vomiting (0) and ENTD retained placenta ENTDEND (four)
1	Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg ENTC carbetocin ENTCEND  were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), vomiting (0) and ENTD retained placenta ENTDEND (four)
0	OBJECTIVE: To determine the maximum tolerated dose (MTD) of carbetocin (a long-acting synthetic analogue of ENTC oxytocin ENTCEND ), when administered immediately after vaginal delivery at term. MATERIALS AND METHODS: Carbetocin was given as an intramuscular injection immediately after the birth of the infant in 45 healthy women with normal singleton pregnancies who delivered vaginally at term. Dosage groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 microg carbetocin were assigned to blocks of three women according to the continual reassessment method (CRM). RESULTS: All dosage groups consisted of three women, except those with 100 microg (n=6) and 200 microg (n=18). Recorded were dose-limiting adverse events: hyper- or hypotension (three), severe abdominal pain (0), vomiting (0) and retained placenta (four). Serious adverse events occurred in seven women: six cases with ENTD blood loss ENTDEND > or = 1000 ml, four cases of manual placenta removal, five cases of additional oxytocics administration and five cases of blood transfusion
1	Four out of six cases with ENTD blood loss ENTDEND > or = 1000 ml occurred in the 200 microg group. The majority of additional administration of oxytocics (4/5) and blood transfusion (3/5) occurred in the dose groups of 200 microg. All retained placentae were found in the group of 200 microg. CONCLUSION: The MTD was calculated to be at 200 microg ENTC carbetocin ENTCEND
0	Serum levels of ENTD tumor ENTDEND necrosis factor-alpha and interferon-gamma were also determined by ELISA. RESULTS: Serum sFas was significantly increased in patients with acute liver failure (median, 26.8 U/mL; range, 6.9-52.7 U/mL) compared to the normal controls (median, 8.6 U/mL; range, 6.5-12.0 U/mL, P < 0.0001). Levels were significantly greater in patients with acute liver failure due to ENTC paracetamol ENTCEND overdose (median, 28
0	A significant correlation was observed between serum sFas levels and ENTC aspartate ENTCEND aminotransferase (r = 0.613, P < 0.01). CONCLUSIONS: The increased concentration of sFas in serum of patients with acute liver failure may reflect activation of Fas-mediated apoptosis in the liver and this together with increased ENTD tumor ENTDEND necrosis factor-alpha may be an important factor in liver cell loss
0	Levels were significantly greater in patients with acute liver failure due to ENTC paracetamol ENTCEND  overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E ENTD hepatitis ENTDEND (median, 12
0	7 U/mL, n = 17) than those due to non-A to E ENTD hepatitis ENTDEND  (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01). There was no relationship of sFas to eventual outcome in the patients. A significant correlation was observed between serum sFas levels and ENTC aspartate ENTCEND aminotransferase (r = 0
0	Increased serum soluble Fas in patients with acute liver failure due to ENTC paracetamol ENTCEND ENTD overdose ENTDEND
0	Levels were significantly greater in patients with acute liver failure due to paracetamol ENTD overdose ENTDEND (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01). There was no relationship of sFas to eventual outcome in the patients. A significant correlation was observed between serum sFas levels and ENTC aspartate ENTCEND aminotransferase (r = 0
0	Serum levels of tumor ENTD necrosis ENTDEND factor-alpha and interferon-gamma were also determined by ELISA. RESULTS: Serum sFas was significantly increased in patients with acute liver failure (median, 26.8 U/mL; range, 6.9-52.7 U/mL) compared to the normal controls (median, 8.6 U/mL; range, 6.5-12.0 U/mL, P < 0.0001). Levels were significantly greater in patients with acute liver failure due to ENTC paracetamol ENTCEND overdose (median, 28
0	A significant correlation was observed between serum sFas levels and ENTC aspartate ENTCEND  aminotransferase (r = 0.613, P < 0.01). CONCLUSIONS: The increased concentration of sFas in serum of patients with acute liver failure may reflect activation of Fas-mediated apoptosis in the liver and this together with increased tumor ENTD necrosis ENTDEND factor-alpha may be an important factor in liver cell loss
1	Increased serum soluble Fas in patients with ENTD acute liver failure ENTDEND  due to ENTC paracetamol ENTCEND overdose
0	A significant correlation was observed between serum sFas levels and ENTC aspartate ENTCEND  aminotransferase (r = 0.613, P < 0.01). CONCLUSIONS: The increased concentration of sFas in serum of patients with ENTD acute liver failure ENTDEND may reflect activation of Fas-mediated apoptosis in the liver and this together with increased tumor necrosis factor-alpha may be an important factor in liver cell loss
1	ENTD Toxic hepatitis ENTDEND  induced by ENTC disulfiram ENTCEND in a non-alcoholic
0	The mechanism whereby the ENTD hepatitis ENTDEND was induced is not known. However, the patient tolerated well an alternative reverse transcriptase inhibitor, ENTC 2'3' dideoxyinosine ENTCEND
1	ENTC Zidovudine ENTCEND -induced ENTD hepatitis ENTDEND
0	However, the patient tolerated well an alternative reverse transcriptase inhibitor, ENTC 2'3' dideoxyinosine ENTCEND . Physicians caring for patients with ENTD AIDS ENTDEND should be aware of this hitherto rarely reported complication
0	A case of acute hepatitis induced by ENTC zidovudine ENTCEND in a 38-year-old patient with ENTD AIDS ENTDEND is presented
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of ENTC lidocaine ENTCEND in patients with cocaine-associated MI was not associated with significant ENTD cardiovascular or central nervous system toxicity ENTDEND
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with ENTC cocaine ENTCEND associated MI was not associated with significant ENTD cardiovascular or central nervous system toxicity ENTDEND
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine ENTD toxicity ENTDEND  the use of ENTC lidocaine ENTCEND in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance ENTC cocaine ENTCEND ENTD toxicity ENTDEND , the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of ENTC lidocaine ENTCEND  in patients with cocaine-associated MI was not associated with significant ENTD cardiovascular or central nervous system toxicity ENTDEND
0	CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with ENTC cocaine ENTCEND -associated MI was not associated with significant ENTD cardiovascular or central nervous system toxicity ENTDEND
0	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ENTD ventricular tachycardia ENTDEND  or ventricular fibrillation; or experienced seizures after administration of ENTC lidocaine ENTCEND (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENTC cocaine ENTCEND associated MI, no patient died; exhibited bradydysrhythmias, ENTD ventricular tachycardia ENTDEND , or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received ENTC lidocaine ENTCEND in the setting of cocaine-associated MI, no patient died; exhibited ENTD bradydysrhythmias ENTDEND , ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENTC cocaine ENTCEND -associated MI, no patient died; exhibited ENTD bradydysrhythmias ENTDEND , ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ENTD ventricular fibrillation ENTDEND  or experienced seizures after administration of ENTC lidocaine ENTCEND (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENTC cocaine ENTCEND -associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ENTD ventricular fibrillation ENTDEND ; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%)
0	PARTICIPANTS: Patients with cocaine-associated ENTD MI ENTDEND who received ENTC lidocaine ENTCEND in the emergency department
1	PARTICIPANTS: Patients with ENTC cocaine ENTCEND associated ENTD MI ENTDEND who received lidocaine in the emergency department
0	RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced ENTD seizures ENTDEND after administration of ENTC lidocaine ENTCEND (95% confidence interval, 0% to 11%)
0	RESULTS: Of 29 patients who received lidocaine in the setting of ENTC cocaine ENTCEND -associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced ENTD seizures ENTDEND after administration of lidocaine (95% confidence interval, 0% to 11%)
0	In a 38-year-old male patient suffering from a severe ENTD postzosteric ENTDEND trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENTC muscarine ENTCEND receptors
0	In a 38-year-old male patient suffering from a severe ENTD postzosteric ENTDEND  trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of ENTC orciprenaline ENTCEND under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe ENTD postzosteric ENTDEND  trigeminal neuralgia, intravenous application of 10 mg ENTC biperiden lactate ENTCEND led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	Bradycardia due to ENTC biperiden ENTCEND .In a 38-year-old male patient suffering from a severe ENTD postzosteric ENTDEND trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	In a 38-year-old male patient suffering from a severe ENTD postzosteric ENTDEND  trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENTC atropine ENTCEND -like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric ENTD trigeminal neuralgia ENTDEND  intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENTC muscarine ENTCEND receptors
0	In a 38-year-old male patient suffering from a severe postzosteric ENTD trigeminal neuralgia ENTDEND , intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of ENTC orciprenaline ENTCEND under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe postzosteric ENTD trigeminal neuralgia ENTDEND , intravenous application of 10 mg ENTC biperiden lactate ENTCEND led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	Bradycardia due to ENTC biperiden ENTCEND .In a 38-year-old male patient suffering from a severe postzosteric ENTD trigeminal neuralgia ENTDEND , intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia
0	In a 38-year-old male patient suffering from a severe postzosteric ENTD trigeminal neuralgia ENTDEND , intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENTC atropine ENTCEND -like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENTD dysphagia ENTDEND  The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENTC muscarine ENTCEND receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENTD dysphagia ENTDEND . The heart rate was back to normal within 12 hours upon administration of ENTC orciprenaline ENTCEND under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg ENTC biperiden lactate ENTCEND  led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENTD dysphagia ENTDEND
1	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENTD dysphagia ENTDEND . The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by ENTC biperiden ENTCEND is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and ENTD dysphagia ENTDEND . The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENTC atropine ENTCEND -like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENTD dysarthria ENTDEND  and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENTC muscarine ENTCEND receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENTD dysarthria ENTDEND , and dysphagia. The heart rate was back to normal within 12 hours upon administration of ENTC orciprenaline ENTCEND under cardiac monitoring in an intensive care unit
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg ENTC biperiden lactate ENTCEND  led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENTD dysarthria ENTDEND , and dysphagia
1	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENTD dysarthria ENTDEND , and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by ENTC biperiden ENTCEND is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, ENTD dysarthria ENTDEND , and dysphagia. The heart rate was back to normal within 12 hours upon administration of orciprenaline under cardiac monitoring in an intensive care unit. Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENTC atropine ENTCEND -like drugs on muscarine receptors
0	ENTD Bradycardia ENTDEND induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on ENTC muscarine ENTCEND receptors
0	The heart rate was back to normal within 12 hours upon administration of ENTC orciprenaline ENTCEND  under cardiac monitoring in an intensive care unit. ENTD Bradycardia ENTDEND induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors
0	In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg ENTC biperiden lactate ENTCEND  led to a long-lasting paradoxical reaction characterized by considerable ENTD bradycardia ENTDEND , dysarthria, and dysphagia
1	ENTD Bradycardia ENTDEND  due to ENTC biperiden ENTCEND
0	ENTD Bradycardia ENTDEND  induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of ENTC atropine ENTCEND -like drugs on muscarine receptors
0	A 69-year-old man operated for acute cholecystitis under ENTC methoxyflurane ENTCEND anesthesia developed postoperatively a ENTD hepatic insufficiency syndrome ENTDEND and renal tubular acidosis
1	ENTD Hepatitis ENTDEND  and renal tubular acidosis after anesthesia with ENTC methoxyflurane ENTCEND
0	A 69-year-old man operated for acute cholecystitis under ENTC methoxyflurane ENTCEND  anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis. Massive ENTD bleeding ENTDEND appeared during surgery which lasted for six hours
0	A 69-year-old man operated for ENTD acute cholecystitis ENTDEND under ENTC methoxyflurane ENTCEND anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis
1	Hepatitis and ENTD renal tubular acidosis ENTDEND  after anesthesia with ENTC methoxyflurane ENTCEND
0	Although the patient recovered, he experienced permanent vision and hearing loss, as well as ENTD end-stage renal disease ENTDEND  CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with ENTC argatroban ENTCEND and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as ENTD end-stage renal disease ENTDEND
1	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and ENTD pulmonary embolism ENTDEND secondary to ENTC heparin ENTCEND -induced thrombocytopenia
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and ENTD pulmonary embolism ENTDEND  secondary to heparin-induced thrombocytopenia. A continuous i.v. infusion of ENTC argatroban ENTCEND was initiated, and the patient was managed on the general medical floor
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to ENTC heparin ENTCEND -induced thrombocytopenia. A continuous i.v. infusion of argatroban was initiated, and the patient was managed on the general medical floor. After one week of therapy, he was transferred to the intensive care unit with cardiopulmonary compromise related to ENTD superior vena cava (SVC) syndrome ENTDEND
0	CONCLUSION: A 63-year-old man with renal amyloidosis and ENTD SVC syndrome ENTDEND secondary to HITT was successfully treated with ENTC argatroban ENTCEND and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal amyloidosis and ENTD SVC syndrome ENTDEND secondary to HITT was successfully treated with argatroban and CDT with alteplase
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral ENTD upper-extremity deep venous thrombosis ENTDEND (DVT) and pulmonary embolism secondary to ENTC heparin ENTCEND -induced thrombocytopenia
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral ENTD upper-extremity deep venous thrombosis ENTDEND  (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia. A continuous i.v. infusion of ENTC argatroban ENTCEND was initiated, and the patient was managed on the general medical floor
1	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with ENTC heparin ENTCEND -induced ENTD thrombocytopenia ENTDEND with thrombosis
0	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis ( ENTD HITT ENTDEND  and was treated with ENTC argatroban ENTCEND plus catheter-directed thrombolysis (CDT) with alteplase is presented
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to ENTD HITT ENTDEND was successfully treated with argatroban and CDT with alteplase
0	PURPOSE: The case of an oncology patient who developed ENTC heparin ENTCEND induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented. SUMMARY: A 63-year-old Caucasian man with renal ENTD amyloidosis ENTDEND undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia
0	CONCLUSION: A 63-year-old man with renal ENTD amyloidosis ENTDEND and SVC syndrome secondary to HITT was successfully treated with ENTC argatroban ENTCEND and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal ENTD amyloidosis ENTDEND and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on ENTC argatroban ENTCEND  ultimately, he was transitioned to warfarin for long-term anticoagulation. Although the patient recovered, he experienced permanent ENTD vision and hearing loss ENTDEND , as well as end-stage renal disease
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND  for long-term anticoagulation. Although the patient recovered, he experienced permanent ENTD vision and hearing loss ENTDEND , as well as end-stage renal disease
0	Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with ENTC heparin ENTCEND -induced thrombocytopenia with ENTD thrombosis ENTDEND
0	PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis ( ENTD HITT ENTDEND  and was treated with ENTC argatroban ENTCEND plus catheter-directed thrombolysis (CDT) with alteplase is presented
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND  for long-term anticoagulation. Although the patient recovered, he experienced permanent vision and hearing loss, as well as end-stage renal disease. CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to ENTD HITT ENTDEND was successfully treated with argatroban and CDT with alteplase
0	Alteplase was discontinued, and the patient was reinitiated on ENTC argatroban ENTCEND ; ultimately, he was transitioned to warfarin for long-term anticoagulation. Although the patient recovered, he experienced permanent ENTD vision and hearing loss ENTDEND , as well as end-stage renal disease
0	Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND  for long-term anticoagulation. Although the patient recovered, he experienced permanent ENTD vision and hearing loss ENTDEND , as well as end-stage renal disease
1	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis ( ENTD DVT ENTDEND  and pulmonary embolism secondary to ENTC heparin ENTCEND -induced thrombocytopenia
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis ( ENTD DVT ENTDEND ) and pulmonary embolism secondary to heparin-induced thrombocytopenia. A continuous i.v. infusion of ENTC argatroban ENTCEND was initiated, and the patient was managed on the general medical floor
0	Use of argatroban and catheter-directed ENTD thrombolysis ENTDEND  with alteplase in an oncology patient with ENTC heparin ENTCEND -induced thrombocytopenia with thrombosis
0	Use of ENTC argatroban ENTCEND  and catheter-directed ENTD thrombolysis ENTDEND with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis
0	SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to ENTC heparin ENTCEND -induced thrombocytopenia. A continuous i.v. infusion of argatroban was initiated, and the patient was managed on the general medical floor. After one week of therapy, he was transferred to the intensive care unit with cardiopulmonary compromise related to superior vena cava (SVC) syndrome. A percutaneous mechanical thrombectomy and CDT with alteplase were attempted, but the procedure was aborted due to ENTD epistaxis ENTDEND
0	The ENTD epistaxis ENTDEND resolved the next day, and the patient was restarted on ENTC argatroban ENTCEND
0	The ENTD epistaxis ENTDEND  resolved the next day, and the patient was restarted on argatroban. A second percutaneous mechanical thrombectomy was performed six days later and resulted in partial revascularization of the SVC and central veins. Postthrombectomy continuous CDT with alteplase was commenced while argatroban was withheld, and complete patency of the SVC and central veins was achieved after three days of therapy. Alteplase was discontinued, and the patient was reinitiated on argatroban; ultimately, he was transitioned to ENTC warfarin ENTCEND for long-term anticoagulation
1	A case of bilateral ENTD optic neuropathy ENTDEND  in a patient on ENTC tacrolimus ENTCEND (FK506) therapy after liver transplantation
0	ENTD Deterioration of vision ENTDEND occurred despite discontinuation of the ENTC tacrolimus ENTCEND
0	RESULTS: The patient had episodic deterioration of vision in both eyes, with clinical features resembling ENTD ischemic optic neuropathies ENTDEND  Deterioration of vision occurred despite discontinuation of the ENTC tacrolimus ENTCEND
0	4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from ENTD malignancy ENTDEND  Cyclical low-dose oestrogen therapy with 7--13 days of ENTC progestagen ENTCEND does not seem to increase the risk of endometrial hyperplasia or carcinoma
0	Two courses of 21 days of 5 mg ENTC norethisterone ENTCEND daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from ENTD malignancy ENTDEND
0	4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from ENTD malignancy ENTDEND . Cyclical low-dose ENTC oestrogen ENTCEND therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma
0	The treatment regimens are described in 74 patients with ENTD endometrial disease ENTDEND among 850 climacteric women receiving oestrogen therapy. Cystic hyperplasia was associated with unopposed oestrogen therapy without ENTC progestagen ENTCEND
0	The treatment regimens are described in 74 patients with ENTD endometrial disease ENTDEND  among 850 climacteric women receiving oestrogen therapy. Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen. Two courses of 21 days of 5 mg ENTC norethisterone ENTCEND daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia
0	Prevention and treatment of ENTD endometrial disease ENTDEND  in climacteric women receiving ENTC oestrogen ENTCEND therapy
0	Cystic ENTD hyperplasia ENTDEND was associated with unopposed oestrogen therapy without ENTC progestagen ENTCEND
0	Two courses of 21 days of 5 mg ENTC norethisterone ENTCEND  daily caused reversion to normal in all 57 cases of cystic ENTD hyperplasia ENTDEND and 6 of the 8 cases of atypical hyperplasia
1	The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving ENTC oestrogen ENTCEND therapy. Cystic ENTD hyperplasia ENTDEND was associated with unopposed oestrogen therapy without progestagen
0	Cyclical low-dose oestrogen therapy with 7--13 days of ENTC progestagen ENTCEND  does not seem to increase the risk of endometrial hyperplasia or ENTD carcinoma ENTDEND
0	Two courses of 21 days of 5 mg ENTC norethisterone ENTCEND  daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy. Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or ENTD carcinoma ENTDEND
0	Cyclical low-dose ENTC oestrogen ENTCEND  therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or ENTD carcinoma ENTDEND
0	Cyclical low-dose oestrogen therapy with 7--13 days of ENTC progestagen ENTCEND  does not seem to increase the risk of ENTD endometrial hyperplasia ENTDEND or carcinoma
0	Two courses of 21 days of 5 mg ENTC norethisterone ENTCEND  daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy. Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of ENTD endometrial hyperplasia ENTDEND or carcinoma
0	Cyclical low-dose ENTC oestrogen ENTCEND  therapy with 7--13 days of progestagen does not seem to increase the risk of ENTD endometrial hyperplasia ENTDEND or carcinoma
0	Cystic hyperplasia was associated with unopposed oestrogen therapy without ENTC progestagen ENTCEND . Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of ENTD endometrial carcinoma ENTDEND referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy
0	Two courses of 21 days of 5 mg ENTC norethisterone ENTCEND  daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of ENTD endometrial carcinoma ENTDEND referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy
0	4 cases of ENTD endometrial carcinoma ENTDEND  referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed ENTC oestrogen ENTCEND therapy and the difficulty in distinguishing severe hyperplasia from malignancy
1	Only a handful of cases of ENTC ATRA ENTCEND induced ENTD myositis ENTDEND in children have been reported, and none in the radiology literature
0	All-trans retinoic acid-induced inflammatory myositis in a patient with ENTD acute promyelocytic leukemia ENTDEND . ENTC All-trans retinoic acid ENTCEND (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENTD aphasia ENTDEND  incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENTC polyethylene glycol-asparaginase ENTCEND were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENTD aphasia ENTDEND , incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENTC dexamethasone ENTCEND , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENTD aphasia ENTDEND , incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENTC Vincristine ENTCEND , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, ENTD aphasia ENTDEND , incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENTC cytarabine ENTCEND
0	ENTD Acute encephalopathy ENTDEND  and cerebral vasospasm after multiagent chemotherapy including ENTC PEG-asparaginase ENTCEND and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia
0	The patient developed ENTD acute encephalopathy ENTDEND evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENTC dexamethasone ENTCEND , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	The patient developed ENTD acute encephalopathy ENTDEND  evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENTC Vincristine ENTCEND , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	ENTD Acute encephalopathy ENTDEND  and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal ENTC cytarabine ENTCEND for the treatment of acute lymphoblastic leukemia
0	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including ENTC PEG-asparaginase ENTCEND  and intrathecal cytarabine for the treatment of ENTD acute lymphoblastic leukemia ENTDEND
0	A 7-year-old girl with an unusual reaction to induction chemotherapy for precursor B-cell acute lymphoblastic leukemia ( ENTD ALL ENTDEND  is described. The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENTC dexamethasone ENTCEND , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	A 7-year-old girl with an unusual reaction to induction chemotherapy for precursor B-cell acute lymphoblastic leukemia ( ENTD ALL ENTDEND ) is described. The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENTC Vincristine ENTCEND , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
0	Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal ENTC cytarabine ENTCEND  for the treatment of ENTD acute lymphoblastic leukemia ENTDEND
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENTD weakness ENTDEND with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENTC polyethylene glycol-asparaginase ENTCEND were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENTD weakness ENTDEND  with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENTC dexamethasone ENTCEND , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENTD weakness ENTDEND  with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENTC Vincristine ENTCEND , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided ENTD weakness ENTDEND  with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENTC cytarabine ENTCEND
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENTD incontinence ENTDEND  visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENTC polyethylene glycol-asparaginase ENTCEND were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENTD incontinence ENTDEND , visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENTC dexamethasone ENTCEND , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENTD incontinence ENTDEND , visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENTC Vincristine ENTCEND , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, ENTD incontinence ENTDEND , visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENTC cytarabine ENTCEND
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENTD visual hallucinations ENTDEND  and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, dexamethasone, and ENTC polyethylene glycol-asparaginase ENTCEND were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENTD visual hallucinations ENTDEND , and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENTC dexamethasone ENTCEND , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENTD visual hallucinations ENTDEND , and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine. ENTC Vincristine ENTCEND , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, ENTD visual hallucinations ENTDEND , and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal ENTC cytarabine ENTCEND
1	Acute encephalopathy and ENTD cerebral vasospasm ENTDEND  after multiagent chemotherapy including ENTC PEG-asparaginase ENTCEND and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse ENTD cerebral vasospasm ENTDEND on magnetic resonance angiography after the administration of intrathecal cytarabine. Vincristine, ENTC dexamethasone ENTCEND , and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse ENTD cerebral vasospasm ENTDEND  on magnetic resonance angiography after the administration of intrathecal cytarabine. ENTC Vincristine ENTCEND , dexamethasone, and polyethylene glycol-asparaginase were also administered before the episode as part of induction therapy
1	Acute encephalopathy and ENTD cerebral vasospasm ENTDEND  after multiagent chemotherapy including PEG-asparaginase and intrathecal ENTC cytarabine ENTCEND for the treatment of acute lymphoblastic leukemia
0	Gemfibrozil-lovastatin therapy for primary ENTD hyperlipoproteinemias ENTDEND .The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 ENTC creatine ENTCEND phosphokinase levels measured
0	Gemfibrozil-lovastatin therapy for primary ENTD hyperlipoproteinemias ENTDEND .The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENTC triglyceride ENTCEND levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7
0	Gemfibrozil-lovastatin therapy for primary ENTD hyperlipoproteinemias ENTDEND .The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) ENTC cholesterol ENTCEND less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4
0	Gemfibrozil- ENTC lovastatin ENTCEND  therapy for primary ENTD hyperlipoproteinemias ENTDEND
0	ENTC Gemfibrozil ENTCEND -lovastatin therapy for primary ENTD hyperlipoproteinemias ENTDEND
0	ENTD Myositis ENTDEND  attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high ENTC creatine ENTCEND phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENTC triglyceride ENTCEND  levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENTD Myositis ENTDEND , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL ENTC cholesterol ENTCEND ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENTD Myositis ENTDEND , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
1	2 g/day)- ENTC lovastatin ENTCEND (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENTD Myositis ENTDEND , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
1	5 mg/dl) with diet plus a single drug, ENTC gemfibrozil ENTCEND (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. ENTD Myositis ENTDEND , attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria
0	Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high ENTC creatine ENTCEND  phosphokinase (769 U/liter); no patients had ENTD rhabdomyolysis ENTDEND or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENTC triglyceride ENTCEND  levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENTD rhabdomyolysis ENTDEND or myoglobinuria
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL ENTC cholesterol ENTCEND  ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENTD rhabdomyolysis ENTDEND or myoglobinuria
0	2 g/day)- ENTC lovastatin ENTCEND  (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENTD rhabdomyolysis ENTDEND or myoglobinuria
0	5 mg/dl) with diet plus a single drug, ENTC gemfibrozil ENTCEND  (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had ENTD rhabdomyolysis ENTDEND or myoglobinuria
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed ENTD hyperlipidemia ENTDEND (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 ENTC creatine ENTCEND phosphokinase levels measured
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed ENTD hyperlipidemia ENTDEND  (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENTC triglyceride ENTCEND levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed ENTD hyperlipidemia ENTDEND  (68% of whom had atherosclerotic vascular disease). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) ENTC cholesterol ENTCEND less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil- ENTC lovastatin ENTCEND treatment in 80 patients with primary mixed ENTD hyperlipidemia ENTDEND (68% of whom had atherosclerotic vascular disease)
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, ENTC gemfibrozil ENTCEND lovastatin treatment in 80 patients with primary mixed ENTD hyperlipidemia ENTDEND (68% of whom had atherosclerotic vascular disease)
0	Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high ENTC creatine ENTCEND  phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENTD myoglobinuria ENTDEND
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENTC triglyceride ENTCEND  levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENTD myoglobinuria ENTDEND
0	With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL ENTC cholesterol ENTCEND  ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENTD myoglobinuria ENTDEND
0	2 g/day)- ENTC lovastatin ENTCEND  (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENTD myoglobinuria ENTDEND
0	5 mg/dl) with diet plus a single drug, ENTC gemfibrozil ENTCEND  (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, triglyceride levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7.1 to 5.4, all p less than or equal to 0.0001. Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or ENTD myoglobinuria ENTDEND
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENTD atherosclerotic vascular disease ENTDEND . Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 ENTC creatine ENTCEND phosphokinase levels measured
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENTD atherosclerotic vascular disease ENTDEND ). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) cholesterol less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4.5 mg/dl) with diet plus a single drug, gemfibrozil (1.2 g/day)-lovastatin (primarily 20 or 40 mg) treatment was given. Follow-up visits were scheduled with 2-drug therapy every 6 to 8 weeks, an average of 10.3 visits per patient, with 741 batteries of 6 liver function tests and 714 creatine phosphokinase levels measured. Only 1 of the 4,446 liver function tests (0.02%), a gamma glutamyl transferase, was greater than or equal to 3 times the upper normal limit. Of the 714 creatine phosphokinase levels, 9% were high; only 1 (0.1%) was greater than or equal to 3 times the upper normal limit. With 2-drug therapy, mean total cholesterol decreased 22% from 255 to 200 mg/dl, ENTC triglyceride ENTCEND levels decreased 35% from 236 to 154 mg/dl, LDL cholesterol decreased 26% from 176 to 131 mg/dl, and the total cholesterol/HDL cholesterol ratio decreased 24% from 7
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENTD atherosclerotic vascular disease ENTDEND ). Because ideal lipid targets were not reached (low-density lipoprotein (LDL) ENTC cholesterol ENTCEND less than 130 mg/dl, high-density lipoprotein (HDL) cholesterol greater than 35 mg/dl, or total cholesterol/HDL cholesterol less than 4
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil- ENTC lovastatin ENTCEND  treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENTD atherosclerotic vascular disease ENTDEND )
0	The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, ENTC gemfibrozil ENTCEND -lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had ENTD atherosclerotic vascular disease ENTDEND )
1	7e exhibits a high reversal of ENTD catalepsy ENTDEND induced by ENTC haloperidol ENTCEND indicating its atypical antipsychotic nature
0	63) for ENTC paracetamol ENTCEND  and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular ENTD nephropathy ENTDEND as underlying disease [2
0	76) for ENTC pyrazolones ENTCEND  0.80 (0.39-1.63) for paracetamol, and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular ENTD nephropathy ENTDEND as underlying disease [2
0	The risk of ESRD associated with ENTC aspirin ENTCEND was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular ENTD nephropathy ENTDEND as underlying disease [2
0	63) for ENTC paracetamol ENTCEND , and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ENTD ESRD ENTDEND associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2
0	76) for ENTC pyrazolones ENTCEND , 0.80 (0.39-1.63) for paracetamol, and 0.94 (0.57-1.56) for nonaspirin NSAIDs. The risk of ENTD ESRD ENTDEND associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2
1	The risk of ENTD ESRD ENTDEND  associated with ENTC aspirin ENTCEND was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2
1	BACKGROUND: In dogs, a large amount of intravenous ENTC cocaine ENTCEND causes a profound ENTD deterioration of left ventricular (LV) systolic function ENTDEND and an increase in LV end-diastolic pressure
0	This study was done to assess the influence of a high intracoronary ENTC cocaine ENTCEND concentration on LV systolic and diastolic function in humans. METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of ENTD chest pain ENTDEND , we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10)
1	Two cases of ENTC propylthiouracil ENTCEND induced ENTD liver damage ENTDEND have been observed
1	Two cases of ENTC propylthiouracil ENTCEND -induced liver damage have been observed. The first case is of an acute type of damage, proven by rechallenge; the second presents a clinical and histologic picture resembling ENTD chronic active hepatitis ENTDEND , with spontaneous remission
1	OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon ENTC carboplatin ENTCEND chemotherapy. METHODS: We noted ENTD abnormal ocular motility ENTDEND in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin
1	CONCLUSIONS: Subtenon ENTC carboplatin ENTCEND chemotherapy is associated with significant ENTD fibrosis ENTDEND of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult
0	The enucleations were technically difficult and hazardous for globe ENTD rupture ENTDEND because of extensive orbital soft tissue adhesions. CONCLUSIONS: Subtenon ENTC carboplatin ENTCEND chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult
0	METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon ENTC carboplatin ENTCEND  During ocular manipulation under general anesthesia, we assessed their eyes by forced duction testing, comparing ocular motility after ENTD tumor ENTDEND control with ocular motility at diagnosis
0	Subtenon ENTC carboplatin ENTCEND is not free of ENTD toxicity ENTDEND , and its use is best restricted to specific indications
0	Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye, indicative of phagocytosis of previously existing fat cells and suggesting prior fat ENTD necrosis ENTDEND  The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions. CONCLUSIONS: Subtenon ENTC carboplatin ENTCEND chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult
0	Ocular motility changes after subtenon ENTC carboplatin ENTCEND  chemotherapy for ENTD retinoblastoma ENTDEND
1	No subject reported side effects of oxitropium, as compared to three subjects reporting ENTD nausea ENTDEND  vomiting and tremors after ENTC theophylline ENTCEND
0	No subject reported side effects of ENTC oxitropium ENTCEND  as compared to three subjects reporting ENTD nausea ENTDEND , vomiting and tremors after theophylline
1	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and ENTD tremors ENTDEND after ENTC theophylline ENTCEND
0	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and ENTD tremors ENTDEND  after theophylline. ENTC Oxitropium ENTCEND proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage
1	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, ENTD vomiting ENTDEND and tremors after ENTC theophylline ENTCEND
0	No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, ENTD vomiting ENTDEND  and tremors after theophylline. ENTC Oxitropium ENTCEND proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage
0	Comparison of the effect of oxitropium bromide and of slow-release ENTC theophylline ENTCEND  on nocturnal ENTD asthma ENTDEND
0	Comparison of the effect of ENTC oxitropium bromide ENTCEND  and of slow-release theophylline on nocturnal ENTD asthma ENTDEND
1	Twenty-one reports of antimicrobial-induced ENTD mania ENTDEND were found in the literature. There were 6 cases implicating clarithromycin, 13 implicating ENTC isoniazid ENTCEND , and 1 case each implicating erythromycin and amoxicillin
1	Twenty-one reports of antimicrobial-induced ENTD mania ENTDEND  were found in the literature. There were 6 cases implicating clarithromycin, 13 implicating isoniazid, and 1 case each implicating erythromycin and ENTC amoxicillin ENTCEND
1	ENTC Cotrimoxazole ENTCEND  metronidazole, and erythromycin were involved in 15 reported ENTD manic ENTDEND episodes
1	Cases reported by the FDA showed clarithromycin and ENTC ciprofloxacin ENTCEND to be the most frequently associated with the development of ENTD mania ENTDEND
1	Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported ENTD manic ENTDEND  episodes. Cases reported by the FDA showed ENTC clarithromycin ENTCEND and ciprofloxacin to be the most frequently associated with the development of mania
1	4%) cases, and ENTC ofloxacin ENTCEND in 10 (12%) cases. Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported ENTD manic ENTDEND episodes
1	Cotrimoxazole, metronidazole, and ENTC erythromycin ENTCEND were involved in 15 reported ENTD manic ENTDEND episodes
1	Cotrimoxazole, ENTC metronidazole ENTCEND  and erythromycin were involved in 15 reported ENTD manic ENTDEND episodes
0	Rats treated with 500 ppm ENTC quinacrine hydrochloride ENTCEND in the diet all developed a high incidence of left atrial thrombosis. The lesion was associated with cardiac hypertrophy and dilatation and focal ENTD myocardial degeneration ENTDEND
0	The lesion was associated with cardiac hypertrophy and dilatation and focal ENTD myocardial degeneration ENTDEND . Rats died from cardiac hypertrophy with severe acute and chronic congestion of the lungs, liver, and other organs. Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm ENTC sodium nitrite ENTCEND simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
1	Rats treated with 500 ppm ENTC quinacrine hydrochloride ENTCEND  in the diet all developed a high incidence of left atrial thrombosis. The lesion was associated with ENTD cardiac hypertrophy ENTDEND and dilatation and focal myocardial degeneration
0	Rats died from ENTD cardiac hypertrophy ENTDEND with severe acute and chronic congestion of the lungs, liver, and other organs. Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm ENTC sodium nitrite ENTCEND simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
0	Seventy percent of rats given 250 ppm ENTC quinacrine hydrochloride ENTCEND and 1,000 ppm sodium nitrite simultaneously in the diet had ENTD thrombosis ENTDEND of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
0	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm ENTC sodium nitrite ENTCEND  simultaneously in the diet had ENTD thrombosis ENTDEND of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis
1	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have ENTD atrial thrombosis ENTDEND  Sodium nitrite in combination with ENTC quinacrine hydrochloride ENTCEND appeared to have no additional effect
0	Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have ENTD atrial thrombosis ENTDEND . ENTC Sodium nitrite ENTCEND in combination with quinacrine hydrochloride appeared to have no additional effect
0	All of the patients' plasma blood urea nitrogen ( ENTC BUN ENTCEND  and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material. RESULTS: The basal creatinine levels were similar for all three groups (p > 0.05). Among a total of 60 patients included in the study, 16 patients developed ENTD acute renal failure ENTDEND (ARF) on the second day after contrast material was injected (26
0	The number of patients who developed ENTD ARF ENTDEND on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05). CONCLUSION: There was no significant difference between isotonic ENTC sodium chloride ENTCEND , sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN
0	RESULTS: The basal ENTC creatinine ENTCEND levels were similar for all three groups (p > 0.05). Among a total of 60 patients included in the study, 16 patients developed ENTD acute renal failure ENTDEND (ARF) on the second day after contrast material was injected (26
0	The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% ENTC dextrose ENTCEND and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection. The third group received an additional injection of diltiazem the day before and first 2 days after the contrast injection. All of the patients' plasma blood urea nitrogen (BUN) and creatinine levels were measured on the second and seventh day after the administration of intravenous contrast material. RESULTS: The basal creatinine levels were similar for all three groups (p > 0.05). Among a total of 60 patients included in the study, 16 patients developed ENTD acute renal failure ENTDEND (ARF) on the second day after contrast material was injected (26
0	The number of patients who developed ENTD ARF ENTDEND  on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05). CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with ENTC diltiazem ENTCEND application in prevention of CIN
1	Among a total of 60 patients included in the study, 16 patients developed acute renal failure ( ENTD ARF ENTDEND  on the second day after ENTC contrast ENTCEND material was injected (26
0	The number of patients who developed ENTD ARF ENTDEND  on the second day after the injection in the first group was five (25%), in the second group was six (30%) and the third group was five (25%) (p > 0.05). CONCLUSION: There was no significant difference between isotonic sodium chloride, ENTC sodium bicarbonate ENTCEND and isotonic sodium chloride with diltiazem application in prevention of CIN
0	Comparison of effects of isotonic ENTC sodium chloride ENTCEND  with diltiazem in prevention of contrast-induced ENTD nephropathy ENTDEND
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENTD nephropathy ENTDEND (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a ENTC calcium ENTCEND channel blocker, in preventing CIN
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENTD nephropathy ENTDEND  (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN. MATERIALS AND METHODS: Our study included patients who were administered 30-60 mL of iodinated contrast agent for percutaneous coronary angiography (PCAG), all with ENTC creatinine ENTCEND values between 1
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENTD nephropathy ENTDEND  (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN. MATERIALS AND METHODS: Our study included patients who were administered 30-60 mL of iodinated contrast agent for percutaneous coronary angiography (PCAG), all with creatinine values between 1.1 and 3.1 mg/dL. Patients were divided into three groups and each group had 20 patients. The first group of patients was administered isotonic sodium chloride; the second group was administered a solution that of 5% ENTC dextrose ENTCEND and sodium bicarbonate, while the third group was administered isotonic sodium chloride before and after the contrast injection
0	Comparison of effects of isotonic sodium chloride with ENTC diltiazem ENTCEND  in prevention of contrast-induced ENTD nephropathy ENTDEND
0	Comparison of effects of isotonic sodium chloride with diltiazem in prevention of ENTC contrast ENTCEND -induced ENTD nephropathy ENTDEND
0	INTRODUCTION AND OBJECTIVE: Contrast-induced ENTD nephropathy ENTDEND  (CIN) significantly increases the morbidity and mortality of patients. The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with ENTC sodium bicarbonate ENTCEND infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN
0	The present experiments were performed to study the effect of the ENTC flavonoid ENTCEND apigenin (20 mg/kg intraperitoneally (i.p.), 1 h before acquisition), on 24 h retention performance and forgetting of a step-through passive avoidance task, in young male Wistar rats. There were no differences between saline- and apigenin-treated groups in the 24 h retention trial. Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p., 30 min before the acquisition). The saline- and apigenin-treated rats that did not step through into the dark compartment during the cut-off time (540 s) were retested weekly for up to eight weeks. In the saline treated group, the first significant decline in passive avoidance response was observed at four weeks, and complete ENTD memory loss ENTDEND was found five weeks after the acquisition of the passive avoidance task
0	In the saline treated group, the first significant decline in passive avoidance response was observed at four weeks, and complete ENTD memory loss ENTDEND  was found five weeks after the acquisition of the passive avoidance task. At the end of the experimental period, 60% of the animals treated with ENTC apigenin ENTCEND still did not step through
0	Furthermore, apigenin did not prevent the amnesia induced by ENTC scopolamine ENTCEND (1mg/kg, i.p., 30 min before the acquisition). The saline- and apigenin-treated rats that did not step through into the dark compartment during the cut-off time (540 s) were retested weekly for up to eight weeks. In the saline treated group, the first significant decline in passive avoidance response was observed at four weeks, and complete ENTD memory loss ENTDEND was found five weeks after the acquisition of the passive avoidance task
0	The present experiments were performed to study the effect of the ENTC flavonoid ENTCEND  apigenin (20 mg/kg intraperitoneally (i.p.), 1 h before acquisition), on 24 h retention performance and forgetting of a step-through passive avoidance task, in young male Wistar rats. There were no differences between saline- and apigenin-treated groups in the 24 h retention trial. Furthermore, apigenin did not prevent the ENTD amnesia ENTDEND induced by scopolamine (1mg/kg, i
0	Furthermore, ENTC apigenin ENTCEND did not prevent the ENTD amnesia ENTDEND induced by scopolamine (1mg/kg, i
1	Furthermore, apigenin did not prevent the ENTD amnesia ENTDEND  induced by ENTC scopolamine ENTCEND (1mg/kg, i
0	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENTD nausea ENTDEND  palpitations, restlessness, and tremors in the patients compared with healthy subjects. In the patients, but not the healthy subjects, these symptoms were significantly correlated with plasma caffeine levels. Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks. Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an ENTC adenosine ENTCEND receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENTC MHPG ENTCEND  and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENTD nausea ENTDEND , palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENTC cortisol ENTCEND were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENTD nausea ENTDEND , palpitations, restlessness, and tremors in the patients compared with healthy subjects
1	ENTC Caffeine ENTCEND produced significantly greater increases in subject-rated anxiety, nervousness, fear, ENTD nausea ENTDEND , palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENTD restlessness ENTDEND  and tremors in the patients compared with healthy subjects. In the patients, but not the healthy subjects, these symptoms were significantly correlated with plasma caffeine levels. Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks. Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an ENTC adenosine ENTCEND receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENTC MHPG ENTCEND ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENTD restlessness ENTDEND , and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENTC cortisol ENTCEND  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENTD restlessness ENTDEND , and tremors in the patients compared with healthy subjects
0	ENTC Caffeine ENTCEND  produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, ENTD restlessness ENTDEND , and tremors in the patients compared with healthy subjects
0	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENTD abnormalities in neuronal systems ENTDEND involving ENTC adenosine ENTCEND
0	Caffeine did not alter plasma ENTC MHPG ENTCEND levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENTD abnormalities in neuronal systems ENTDEND involving adenosine
0	Caffeine increased plasma ENTC cortisol ENTCEND levels equally in the patient and healthy groups. Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENTD abnormalities in neuronal systems ENTDEND involving adenosine
0	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have ENTD abnormalities in neuronal systems ENTDEND  involving adenosine. Patients with anxiety disorders may benefit by avoiding ENTC caffeine ENTCEND -containing foods and beverages
0	Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving ENTC adenosine ENTCEND . Patients with ENTD anxiety disorders ENTDEND may benefit by avoiding caffeine-containing foods and beverages
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENTC MHPG ENTCEND ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated ENTD anxiety ENTDEND , nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENTC cortisol ENTCEND  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated ENTD anxiety ENTDEND , nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
1	Patients with ENTD anxiety disorders ENTDEND  may benefit by avoiding ENTC caffeine ENTCEND -containing foods and beverages
0	Because caffeine is an ENTC adenosine ENTCEND  receptor antagonist, these results suggest that some ENTD panic disorder ENTDEND patients may have abnormalities in neuronal systems involving adenosine
0	Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during ENTD panic attacks ENTDEND  Caffeine did not alter plasma ENTC MHPG ENTCEND levels in either the healthy subjects or patients
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENTC cortisol ENTCEND  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with ENTD panic attacks ENTDEND or panic disorder
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or ENTD panic disorder ENTDEND ENTC Caffeine ENTCEND produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENTC MHPG ENTCEND ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for ENTD agoraphobia ENTDEND with panic attacks or panic disorder
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENTC cortisol ENTCEND  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for ENTD agoraphobia ENTDEND with panic attacks or panic disorder
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for ENTD agoraphobia ENTDEND  with panic attacks or panic disorder. ENTC Caffeine ENTCEND produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects
0	Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENTD tremors ENTDEND in the patients compared with healthy subjects. In the patients, but not the healthy subjects, these symptoms were significantly correlated with plasma caffeine levels. Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks. Caffeine did not alter plasma MHPG levels in either the healthy subjects or patients. Caffeine increased plasma cortisol levels equally in the patient and healthy groups. Because caffeine is an ENTC adenosine ENTCEND receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol ( ENTC MHPG ENTCEND ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENTD tremors ENTDEND in the patients compared with healthy subjects
0	The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and ENTC cortisol ENTCEND  were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder. Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENTD tremors ENTDEND in the patients compared with healthy subjects
1	ENTC Caffeine ENTCEND  produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and ENTD tremors ENTDEND in the patients compared with healthy subjects
0	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined ENTC beta adrenergic and muscarinic receptors blockade ENTCEND but drug-induced ENTD tachycardia ENTDEND was abolished
0	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined ENTC beta adrenergic and muscarinic receptors blockade ENTCEND but drug-induced ENTD tachycardia ENTDEND was abolished
1	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced ENTD tachycardia ENTDEND  was abolished. When circumflex artery blood flow was maintained constant, the increases in CxAD induced by ENTC cromakalim ENTCEND (10 micrograms/kg), pinacidil (30 micrograms/kg) and nitroglycerin (10 micrograms/kg) were reduced by 68 +/- 7, 54 +/- 9 and 1 +/- 1%, respectively
0	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced ENTD tachycardia ENTDEND  was abolished. When circumflex artery blood flow was maintained constant, the increases in CxAD induced by cromakalim (10 micrograms/kg), pinacidil (30 micrograms/kg) and ENTC nitroglycerin ENTCEND (10 micrograms/kg) were reduced by 68 +/- 7, 54 +/- 9 and 1 +/- 1%, respectively
1	Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and ENTC pinacidil ENTCEND were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced ENTD tachycardia ENTDEND was abolished
0	Vasodilation of large and small coronary vessels and ENTD hypotension ENTDEND induced by cromakalim and pinacidil were not affected by prior combined ENTC beta adrenergic and muscarinic receptors blockade ENTCEND but drug-induced tachycardia was abolished
0	Vasodilation of large and small coronary vessels and ENTD hypotension ENTDEND  induced by cromakalim and pinacidil were not affected by prior combined ENTC beta adrenergic and muscarinic receptors blockade ENTCEND but drug-induced tachycardia was abolished
1	Vasodilation of large and small coronary vessels and ENTD hypotension ENTDEND  induced by ENTC cromakalim ENTCEND and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished
0	Vasodilation of large and small coronary vessels and ENTD hypotension ENTDEND  induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished. When circumflex artery blood flow was maintained constant, the increases in CxAD induced by cromakalim (10 micrograms/kg), pinacidil (30 micrograms/kg) and ENTC nitroglycerin ENTCEND (10 micrograms/kg) were reduced by 68 +/- 7, 54 +/- 9 and 1 +/- 1%, respectively
1	Vasodilation of large and small coronary vessels and ENTD hypotension ENTDEND  induced by cromakalim and ENTC pinacidil ENTCEND were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished
0	ENTD Flushing ENTDEND was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%. Incidence of increased ENTC aspartate ENTCEND aminotransferase and/or alanine aminotransferase >3 times the upper limit of normal was <0
0	ENTD Flushing ENTDEND  was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%. Incidence of increased aspartate aminotransferase and/or ENTC alanine ENTCEND aminotransferase >3 times the upper limit of normal was <0
0	ENTD Flushing ENTDEND  was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%. Incidence of increased aspartate aminotransferase and/or alanine aminotransferase >3 times the upper limit of normal was <0.3%. An increase of ENTC creatine ENTCEND phosphokinase to >5 times the upper limit of normal occurred in 0
1	Compliance to ENTC niacin extended-release/lovastatin ENTCEND was 77%, with 3,245 patients completing the study. Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates. ENTD Flushing ENTDEND was the most common adverse event, reported by 18% of patients and leading to discontinuation by 6%
0	Incidence of increased ENTC aspartate ENTCEND  aminotransferase and/or alanine aminotransferase >3 times the upper limit of normal was <0.3%. An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced ENTD myopathy ENTDEND were observed
0	Patients were treated with 1 tablet (500 mg of niacin extended-release/20 mg of ENTC lovastatin ENTCEND  once nightly for 4 weeks and then 2 tablets for 8 weeks. Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin. Primary end points were study compliance, increases in liver transaminases to >3 times the upper limit of normal, and clinical ENTD myopathy ENTDEND
0	Incidence of increased aspartate aminotransferase and/or ENTC alanine ENTCEND  aminotransferase >3 times the upper limit of normal was <0.3%. An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced ENTD myopathy ENTDEND were observed
0	Patients were treated with 1 tablet (500 mg of ENTC niacin ENTCEND extended-release/20 mg of lovastatin) once nightly for 4 weeks and then 2 tablets for 8 weeks. Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin. Primary end points were study compliance, increases in liver transaminases to >3 times the upper limit of normal, and clinical ENTD myopathy ENTDEND
0	An increase of ENTC creatine ENTCEND  phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced ENTD myopathy ENTDEND were observed
0	24% of patients, and no cases of drug-induced ENTD myopathy ENTDEND  were observed. ENTC Niacin extended-release/lovastatin ENTCEND 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes
0	Niacin extended-release/lovastatin is a new combination product approved for treatment of primary ENTD hypercholesterolemia ENTDEND and mixed dyslipidemia. This open-labeled, multicenter study evaluated the safety of bedtime niacin extended-release/lovastatin when dosed as initial therapy and patient compliance to treatment in various clinical practice settings. A total of 4,499 patients with dyslipidemia requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of niacin extended-release/20 mg of ENTC lovastatin ENTCEND ) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	Niacin extended-release/lovastatin is a new combination product approved for treatment of primary ENTD hypercholesterolemia ENTDEND  and mixed dyslipidemia. This open-labeled, multicenter study evaluated the safety of bedtime niacin extended-release/lovastatin when dosed as initial therapy and patient compliance to treatment in various clinical practice settings. A total of 4,499 patients with dyslipidemia requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of ENTC niacin ENTCEND extended-release/20 mg of lovastatin) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	ENTC Niacin extended-release/lovastatin ENTCEND is a new combination product approved for treatment of primary ENTD hypercholesterolemia ENTDEND and mixed dyslipidemia
0	A total of 4,499 patients with ENTD dyslipidemia ENTDEND requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of niacin extended-release/20 mg of ENTC lovastatin ENTCEND ) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	A total of 4,499 patients with ENTD dyslipidemia ENTDEND  requiring drug intervention was enrolled at 1,081 sites. Patients were treated with 1 tablet (500 mg of ENTC niacin ENTCEND extended-release/20 mg of lovastatin) once nightly for 4 weeks and then 2 tablets for 8 weeks
0	Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about ENTD dyslipidemia ENTDEND and ENTC niacin extended-release/lovastatin ENTCEND
0	We studied 212 ENTD RRMM ENTDEND patients who received RD in RW. Objective response (>PR (partial response)) rate was 77.4 % (complete response (CR), 20.2 %). Median time to first and best response was 2 and 5 months, respectively. Median time to CR when RD was given as 2nd or >2(nd)-line treatment at 4 and 11 months, respectively. Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENTC bortezomib ENTCEND
0	We studied 212 ENTD RRMM ENTDEND  patients who received ENTC RD ENTCEND in RW
0	We studied 212 ENTD RRMM ENTDEND  patients who received RD in RW. Objective response (>PR (partial response)) rate was 77.4 % (complete response (CR), 20.2 %). Median time to first and best response was 2 and 5 months, respectively. Median time to CR when RD was given as 2nd or >2(nd)-line treatment at 4 and 11 months, respectively. Quality of response was independent of previous lines of therapies or previous exposure to ENTC thalidomide ENTCEND or bortezomib
0	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek ENTD Myeloma ENTDEND  Study Group. ENTC Lenalidomide ENTCEND and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition
0	Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENTC bortezomib ENTCEND . Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. Peripheral neuropathy was observed only in 2.5 % of patients and ENTD deep vein thrombosis ENTDEND in 5
1	5 % of patients and ENTD deep vein thrombosis ENTDEND  in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial lenalidomide dose predicted for treatment discontinuation. Extra-medullary relapses occurred in 3.8 % of patients. Our study confirms that ENTC RD ENTCEND is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease
0	Quality of response was independent of previous lines of therapies or previous exposure to ENTC thalidomide ENTCEND  or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. Peripheral neuropathy was observed only in 2.5 % of patients and ENTD deep vein thrombosis ENTDEND in 5
1	5 % of patients and ENTD deep vein thrombosis ENTDEND  in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial ENTC lenalidomide ENTCEND dose predicted for treatment discontinuation
0	Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENTC bortezomib ENTCEND . Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ( ENTD myelosuppression ENTDEND in 49
1	4 months, and it was higher in patients who received ENTC RD ENTCEND until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ENTD myelosuppression ENTDEND in 49
0	Quality of response was independent of previous lines of therapies or previous exposure to ENTC thalidomide ENTCEND  or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ENTD myelosuppression ENTDEND in 49
1	4 months, and it was higher in patients who received ENTC RD ENTCEND until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients ENTD myelosuppression ENTDEND in 49
0	Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or ENTC bortezomib ENTCEND . Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. ENTD Peripheral neuropathy ENTDEND was observed only in 2
1	4 months, and it was higher in patients who received ENTC RD ENTCEND  until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. ENTD Peripheral neuropathy ENTDEND was observed only in 2
0	Quality of response was independent of previous lines of therapies or previous exposure to ENTC thalidomide ENTCEND  or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. ENTD Peripheral neuropathy ENTDEND was observed only in 2
1	ENTD Peripheral neuropathy ENTDEND  was observed only in 2.5 % of patients and deep vein thrombosis in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial ENTC lenalidomide ENTCEND dose predicted for treatment discontinuation
0	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with ENTC streptozotocin ENTCEND .Basic and clinical research has demonstrated that ENTD dementia ENTDEND of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Long-term oral ENTC galactose ENTCEND  treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.Basic and clinical research has demonstrated that ENTD dementia ENTDEND of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Basic and clinical research has demonstrated that ENTD dementia ENTDEND  of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased ENTC glucose ENTCEND transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the ENTC STZ ENTCEND icv-induced cognitive deficits. Beneficial effect of oral galactose was independent of the rat age and of the galactose dose ranging from 100 to 300 mg/kg/day. Additionally, oral galactose administration led to the appearance of galactose in the blood. The increase of galactose concentration in the cerebrospinal fluid was several times lower after oral than after parenteral administration of the same galactose dose. Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with ENTD glucose hypometabolism ENTDEND in AD
0	Oral ENTC galactose ENTCEND exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with ENTD glucose hypometabolism ENTDEND in AD
1	We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on ENTD cognitive deficits ENTDEND in ENTC streptozotocin ENTCEND -induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively
1	Long-term oral ENTC galactose ENTCEND  treatment prevents ENTD cognitive deficits ENTDEND in male Wistar rats treated intracerebroventricularly with streptozotocin
0	Long-term oral galactose treatment prevents ENTD cognitive deficits ENTDEND  in male Wistar rats treated intracerebroventricularly with streptozotocin.Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased ENTC glucose ENTCEND transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
1	Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with ENTC streptozotocin ENTCEND .Basic and clinical research has demonstrated that dementia of sporadic ENTD Alzheimer's disease ENTDEND (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Oral ENTC galactose ENTCEND  exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in ENTD AD ENTDEND
1	Basic and clinical research has demonstrated that dementia of sporadic ENTD Alzheimer's disease ENTDEND  (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased ENTC glucose ENTCEND transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells
0	Exclusively parenteral daily injections of galactose induce ENTD memory deterioration ENTDEND in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested. We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in ENTC streptozotocin ENTCEND -induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively
0	Exclusively parenteral daily injections of ENTC galactose ENTCEND induce ENTD memory deterioration ENTDEND in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested
0	An alternative source of energy is d-galactose (the C-4-epimer of d-glucose) which is transported into the brain by insulin-independent GLUT3 transporter where it might be metabolized to ENTC glucose ENTCEND via the Leloir pathway. Exclusively parenteral daily injections of galactose induce ENTD memory deterioration ENTDEND in rodents and are used to generate animal aging model, but the effects of oral galactose treatment on cognitive functions have never been tested
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENTD necrosis ENTDEND in ENTC VCM ENTCEND -treated rats more than those of the control and the erdosteine groups
0	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased ENTC superoxide ENTCEND dismutase (SOD) and catalase (CAT) activities. Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENTD necrosis ENTDEND in VCM-treated rats more than those of the control and the erdosteine groups
0	Erdosteine administration with VCM injections caused significantly decreased renal ENTC MDA ENTCEND and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENTD necrosis ENTDEND in VCM-treated rats more than those of the control and the erdosteine groups
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and ENTD necrosis ENTDEND  in VCM-treated rats more than those of the control and the ENTC erdosteine ENTCEND groups
0	In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced ENTD nephrotoxicity ENTDEND : protection by erdosteine.The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive ENTC oxygen ENTCEND species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats
1	It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the ENTC VCM ENTCEND induced ENTD kidney damage ENTDEND both at the biochemical and histological levels
0	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of ENTD renal tubular injury ENTDEND  excretion but decreased ENTC superoxide ENTCEND dismutase (SOD) and catalase (CAT) activities
0	VCM administration to control rats significantly increased renal malondialdehyde ( ENTC MDA ENTCEND  and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of ENTD renal tubular injury ENTDEND ) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities
0	In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced ENTD nephrotoxicity ENTDEND : protection by ENTC erdosteine ENTCEND
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENTD atrophy ENTDEND  desquamation, and necrosis in ENTC VCM ENTCEND -treated rats more than those of the control and the erdosteine groups
0	VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased ENTC superoxide ENTCEND  dismutase (SOD) and catalase (CAT) activities. Erdosteine administration with VCM injections caused significantly decreased renal MDA and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENTD atrophy ENTDEND , desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups
0	Erdosteine administration with VCM injections caused significantly decreased renal ENTC MDA ENTCEND  and urinary NAG excretion, and increased SOD activity, but not CAT activity in renal tissue when compared with VCM alone. Erdosteine showed histopathological protection against VCM-induced nephrotoxicity. There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENTD atrophy ENTDEND , desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups
0	There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, ENTD atrophy ENTDEND , desquamation, and necrosis in VCM-treated rats more than those of the control and the ENTC erdosteine ENTCEND groups
0	Treatment of ENTD ovarian cancer ENTDEND  with a combination of cis-platinum, ENTC adriamycin ENTCEND , cyclophosphamide and hexamethylmelamine
0	Treatment of ENTD ovarian cancer ENTDEND  with a combination of cis-platinum, adriamycin, ENTC cyclophosphamide ENTCEND and hexamethylmelamine
0	During the last 2 1/2 years, 38 patients with ENTD ovarian cancer ENTDEND were treated with a combination of cisplatinum ( ENTC CPDD ENTCEND ), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days
0	Treatment of ENTD ovarian cancer ENTDEND  with a combination of ENTC cis-platinum ENTCEND , adriamycin, cyclophosphamide and hexamethylmelamine
0	Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and ENTC hexamethylmelamine ENTCEND .During the last 2 1/2 years, 38 patients with ENTD ovarian cancer ENTDEND were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days
1	Hematologic toxicity was moderate and with reversible ENTD anemia ENTDEND developing in 71% of patients. Gastrointestinal side effects from ENTC CPDD ENTCEND were universal
0	Hematologic toxicity was moderate and with reversible ENTD anemia ENTDEND  developing in 71% of patients. Gastrointestinal side effects from CPDD were universal. ENTC HMM ENTCEND gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients
1	Gastrointestinal side effects from ENTC CPDD ENTCEND  were universal. HMM gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients. Severe ENTD nephrotoxicity ENTDEND was observed in 2 patients but was reversible
0	ENTC HMM ENTCEND  gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients. Severe ENTD nephrotoxicity ENTDEND was observed in 2 patients but was reversible
1	Gastrointestinal side effects from ENTC CPDD ENTCEND  were universal. HMM ENTD gastrointestinal toxicity ENTDEND necessitated discontinuation of the drug in 5 patients
0	ENTC HMM ENTCEND ENTD gastrointestinal toxicity ENTDEND necessitated discontinuation of the drug in 5 patients
0	ENTD Hematologic toxicity ENTDEND was moderate and with reversible anemia developing in 71% of patients. Gastrointestinal side effects from ENTC CPDD ENTCEND were universal
0	ENTD Hematologic toxicity ENTDEND  was moderate and with reversible anemia developing in 71% of patients. Gastrointestinal side effects from CPDD were universal. ENTC HMM ENTCEND gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients
0	These rats are also highly susceptible to develop ENTD papillary necrosis ENTDEND with analgesic administration. We used homozygous (jj) and phenotypically normal heterozygous (jJ) animals. Four groups of rats (n = 7) were studied: jj and jJ rats treated either with ENTC aspirin ENTCEND 300 mg/kg every other day or sham-treated
0	We examined the potential role of ENTC prostaglandins ENTCEND in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla. These rats are also highly susceptible to develop ENTD papillary necrosis ENTDEND with analgesic administration
0	ENTC Salicylate ENTCEND  nephropathy in the Gunn rat: potential role of prostaglandins.We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla. These rats are also highly susceptible to develop ENTD papillary necrosis ENTDEND with analgesic administration
0	The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked ENTC bilirubin ENTCEND deposition in renal medulla and papilla. These rats are also highly susceptible to develop ENTD papillary necrosis ENTDEND with analgesic administration
0	Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary ENTC PGE2 ENTCEND remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0.05). PGF2 alpha was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENTD pathological renal medullary lesions ENTDEND and deterioration of renal function
0	ENTC PGF2 alpha ENTCEND was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENTD pathological renal medullary lesions ENTDEND and deterioration of renal function
0	005 compared to either sham-treated jj or ENTC aspirin ENTCEND treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENTD pathological renal medullary lesions ENTDEND and deterioration of renal function
0	These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of ENTC prostaglandin ENTCEND synthesis may lead to ENTD pathological renal medullary lesions ENTDEND and deterioration of renal function
0	01); increased serum ENTC creatinine ENTCEND (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ). These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity, and that inhibition of prostaglandin synthesis may lead to ENTD pathological renal medullary lesions ENTDEND and deterioration of renal function
0	Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary ENTC PGE2 ENTCEND  remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0.05). PGF2 alpha was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of ENTD renal damage ENTDEND in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0
0	ENTC PGF2 alpha ENTCEND  was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of ENTD renal damage ENTDEND in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0
1	The changes in renal prostaglandin synthesis were accompanied by evidence of ENTD renal damage ENTDEND  in ENTC aspirin ENTCEND -treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0
0	We examined the potential role of ENTC prostaglandins ENTCEND  in the development of analgesic ENTD nephropathy ENTDEND in the Gunn strain of rat
0	ENTC Salicylate ENTCEND ENTD nephropathy ENTDEND in the Gunn rat: potential role of prostaglandins
0	We examined the potential role of prostaglandins in the development of analgesic ENTD nephropathy ENTDEND  in the Gunn strain of rat. The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked ENTC bilirubin ENTCEND deposition in renal medulla and papilla
0	The changes in renal prostaglandin synthesis were accompanied by evidence of ENTD renal damage ENTDEND  in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum ENTC creatinine ENTCEND (p less than 0
0	Aspirin treatment reduced PGE2 synthesis in all regions, but outer medullary ENTC PGE2 ENTCEND  remained higher in jj (18 +/- 3) than jJ rats (9 +/- 2) (p less than 0.05). PGF2 alpha was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENTD hematuria ENTDEND (p less than 0
0	ENTC PGF2 alpha ENTCEND  was also significantly higher in the outer medulla of jj rats with and without aspirin administration (p less than 0.05). The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENTD hematuria ENTDEND (p less than 0
0	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in ENTC aspirin ENTCEND -treated jj but not jJ rats as evidenced by: increased incidence and severity of ENTD hematuria ENTDEND (p less than 0
0	The changes in renal ENTC prostaglandin ENTCEND synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENTD hematuria ENTDEND (p less than 0
0	The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of ENTD hematuria ENTDEND  (p less than 0.01); increased serum ENTC creatinine ENTCEND (p less than 0
0	The homozygous Gunn rats have unconjugated ENTD hyperbilirubinemia ENTDEND due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla. These rats are also highly susceptible to develop papillary necrosis with analgesic administration. We used homozygous (jj) and phenotypically normal heterozygous (jJ) animals. Four groups of rats (n = 7) were studied: jj and jJ rats treated either with ENTC aspirin ENTCEND 300 mg/kg every other day or sham-treated
0	We examined the potential role of ENTC prostaglandins ENTCEND  in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated ENTD hyperbilirubinemia ENTDEND due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla
0	ENTC Salicylate ENTCEND  nephropathy in the Gunn rat: potential role of prostaglandins.We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat. The homozygous Gunn rats have unconjugated ENTD hyperbilirubinemia ENTDEND due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla
0	The homozygous Gunn rats have unconjugated ENTD hyperbilirubinemia ENTDEND  due to the absence of glucuronyl transferase, leading to marked ENTC bilirubin ENTCEND deposition in renal medulla and papilla
1	OBJECTIVE: This study describes associations of ozone and fine ENTC particulate matter ENTCEND with ENTD Parkinson's disease ENTDEND observed among farmers in North Carolina and Iowa
1	RESULTS: We observed positive associations of ENTD Parkinson's disease ENTDEND with ENTC ozone ENTCEND (odds ratio = 1
1	CONCLUSIONS: ENTC Indomethacin ENTCEND resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal ENTD mastocytosis ENTDEND
0	0001) and penetration of ENTC lanthanum nitrate ENTCEND through intercellular areas of the epithelium. Furthermore, the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant (P <0.0001). CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal ENTD mastocytosis ENTDEND
0	OBJECTIVES: To evaluate the morphologic changes in rat urothelium induced by ENTC indomethacin ENTCEND  Nonsteroidal anti-inflammatory drug-induced ENTD cystitis ENTDEND is a poorly recognized and under-reported condition
0	Nonsteroidal anti-inflammatory drug-induced ENTD cystitis ENTDEND  is a poorly recognized and under-reported condition. In addition to ENTC tiaprofenic acid ENTCEND , indomethacin has been reported to be associated with this condition
0	0001) and penetration of ENTC lanthanum nitrate ENTCEND  through intercellular areas of the epithelium. Furthermore, the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant (P <0.0001). CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis. The true incidence of nonsteroidal anti-inflammatory drug-induced ENTD cystitis ENTDEND in humans must be clarified by prospective clinical trials
1	CONCLUSIONS: ENTC Indomethacin ENTCEND  resulted in histopathologic findings typical of ENTD interstitial cystitis ENTDEND , such as leaky bladder epithelium and mucosal mastocytosis
0	0001) and penetration of ENTC lanthanum nitrate ENTCEND  through intercellular areas of the epithelium. Furthermore, the difference in mast cell counts between the high and therapeutic dose groups was also statistically significant (P <0.0001). CONCLUSIONS: Indomethacin resulted in histopathologic findings typical of ENTD interstitial cystitis ENTDEND , such as leaky bladder epithelium and mucosal mastocytosis
0	55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, dizziness and general ENTD fatigue ENTDEND in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENTC potassium ENTCEND concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, dizziness and general ENTD fatigue ENTDEND  in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum potassium concentration and the ECG should always be done during ENTC Bpd ENTCEND administration, particularly in elderly patients
0	The major triggering factors of Tdp were ENTD hypokalemia ENTDEND and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENTC potassium ENTCEND concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
0	The major triggering factors of Tdp were ENTD hypokalemia ENTDEND  and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum potassium concentration and the ECG should always be done during ENTC Bpd ENTCEND administration, particularly in elderly patients
0	In 4 of 13 patients with ENTD QT prolongation ENTDEND  Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENTC potassium ENTCEND concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	ENTC Bpd ENTCEND was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases. Mean left ventricular ejection fraction and atrial dimension (LAD) were 66+/-11% and 40+/-6 mm, respectively. Adverse effects were observed in 19 patients (4%) during an average follow-up of 20 months. There was marked ENTD QT prolongation ENTDEND greater than 0
1	There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with ENTD Tdp ENTDEND  CONCLUSION: Careful observation of serum ENTC potassium ENTCEND concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	However, serious adverse effects, including torsade de pointes ( ENTD Tdp ENTDEND , have been reported. METHODS AND RESULTS: Adverse effects of ENTC Bpd ENTCEND requiring discontinuation of treatment were evaluated
0	Clinical evaluation of adverse effects during ENTC bepridil ENTCEND  administration for ENTD atrial fibrillation and flutter ENTDEND
0	Clinical evaluation of adverse effects during ENTC bepridil ENTCEND  administration for ENTD atrial fibrillation and flutter ENTDEND
0	55 s in 13 patients, ENTD bradycardia ENTDEND less than 40 beats/min in 6 patients, dizziness and general fatigue in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENTC potassium ENTCEND concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	ENTC Bpd ENTCEND  was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases. Mean left ventricular ejection fraction and atrial dimension (LAD) were 66+/-11% and 40+/-6 mm, respectively. Adverse effects were observed in 19 patients (4%) during an average follow-up of 20 months. There was marked QT prolongation greater than 0.55 s in 13 patients, ENTD bradycardia ENTDEND less than 40 beats/min in 6 patients, dizziness and general fatigue in 1 patient each
0	55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, ENTD dizziness ENTDEND and general fatigue in 1 patient each. In 4 of 13 patients with QT prolongation, Tdp occurred. The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate. There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age, which were larger and older in the patients with Tdp. CONCLUSION: Careful observation of serum ENTC potassium ENTCEND concentration and the ECG should always be done during Bpd administration, particularly in elderly patients
1	ENTC Bpd ENTCEND  was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases. Mean left ventricular ejection fraction and atrial dimension (LAD) were 66+/-11% and 40+/-6 mm, respectively. Adverse effects were observed in 19 patients (4%) during an average follow-up of 20 months. There was marked QT prolongation greater than 0.55 s in 13 patients, bradycardia less than 40 beats/min in 6 patients, ENTD dizziness ENTDEND and general fatigue in 1 patient each
1	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or ENTC propofol ENTCEND  Providers should similarly consider the likelihood of ENTD hypotension ENTDEND or bradycardia before starting either sedative
1	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive ENTC dexmedetomidine ENTCEND or propofol. Providers should similarly consider the likelihood of ENTD hypotension ENTDEND or bradycardia before starting either sedative
1	CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or ENTC propofol ENTCEND . Providers should similarly consider the likelihood of hypotension or ENTD bradycardia ENTDEND before starting either sedative
1	CONCLUSIONS: Severe hypotension and ENTD bradycardia ENTDEND occur at similar prevalence in neurocritical care patients who receive ENTC dexmedetomidine ENTCEND or propofol
1	Intravascular hemolysis leading to ENTD acute renal failure ENTDEND following ENTC rifampin ENTCEND therapy is extremely rare
0	Intravascular hemolysis leading to acute renal failure following ENTC rifampin ENTCEND  therapy is extremely rare. Two patients with ENTD leprosy ENTDEND who developed hemolysis and acute renal failure following rifampin are reported
1	Renal failure is a rare complication associated with the use of ENTC rifampin ENTCEND  Intravascular ENTD hemolysis ENTDEND leading to acute renal failure following rifampin therapy is extremely rare
0	Intravascular hemolysis and acute renal failure following intermittent ENTC rifampin ENTCEND  therapy. ENTD Renal failure ENTDEND is a rare complication associated with the use of rifampin
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, ENTD colorectal cancer ENTDEND  ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, ENTD colorectal cancer ENTDEND , ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ( ENTC oestrogens ENTCEND with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	It has also been used for the management and prevention of ENTD cardiovascular disease ENTDEND  osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	Among women with ENTD cardiovascular disease ENTDEND  long-term use of combined continuous HT significantly increased the risk of venous thromboembolism. No trials focussed specifically on younger women. However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENTC oestrogen ENTCEND -only HT, versus similar-sized placebo groups
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, ENTD gallbladder disease ENTDEND  cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	In relatively healthy women, combined continuous HT significantly increased the risk of venous thromboembolism or coronary event (after one year's use), stroke (after 3 years), breast cancer (after 5 years) and ENTD gallbladder disease ENTDEND  Long-term ENTC oestrogen ENTCEND -only HT also significantly increased the risk of stroke and gallbladder disease
0	Long-term ENTC oestrogen ENTCEND -only HT also significantly increased the risk of stroke and gallbladder disease. Overall, the only statistically significant benefits of HT were a decreased incidence of fractures and ENTD colon cancer ENTDEND with long-term use
0	It has also been used for the management and prevention of cardiovascular disease, ENTD osteoporosis ENTDEND and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	It has also been used for the management and prevention of cardiovascular disease, ENTD osteoporosis ENTDEND  and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENTC oestrogens ENTCEND with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, ENTD breast cancer ENTDEND  colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	In relatively healthy women, combined continuous HT significantly increased the risk of venous thromboembolism or coronary event (after one year's use), stroke (after 3 years), ENTD breast cancer ENTDEND (after 5 years) and gallbladder disease. Long-term ENTC oestrogen ENTCEND -only HT also significantly increased the risk of stroke and gallbladder disease
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, ENTD endometrial cancer ENTDEND  gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, ENTD endometrial cancer ENTDEND , gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENTC oestrogens ENTCEND with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENTC oestrogen ENTCEND -only HT, versus similar-sized placebo groups. The only significantly increased risk reported was for venous thromboembolism in women taking combined continuous HT; their absolute risk remained very low. AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of ENTD chronic disease ENTDEND
0	BACKGROUND: Hormone therapy (HT) is widely used for controlling ENTD menopausal symptoms ENTDEND  It has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	BACKGROUND: Hormone therapy (HT) is widely used for controlling ENTD menopausal symptoms ENTDEND . It has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational. OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENTC oestrogens ENTCEND with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, ENTD stroke ENTDEND  transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	Long-term ENTC oestrogen ENTCEND -only HT also significantly increased the risk of ENTD stroke ENTDEND and gallbladder disease
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ENTD ovarian cancer ENTDEND  endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ENTD ovarian cancer ENTDEND , endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENTC oestrogens ENTCEND with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, ENTD dementia ENTDEND  fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	Among relatively healthy women over 65 years taking continuous combined HT, there was a statistically significant increase in the incidence of ENTD dementia ENTDEND  Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thromboembolism. No trials focussed specifically on younger women. However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENTC oestrogen ENTCEND -only HT, versus similar-sized placebo groups
0	OBJECTIVES: To assess the effect of long-term HT on mortality, ENTD heart disease ENTDEND  venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, ENTD heart disease ENTDEND , venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENTC oestrogens ENTCEND with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, transient ischaemic attacks, breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, ENTD fractures ENTDEND and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	Long-term ENTC oestrogen ENTCEND -only HT also significantly increased the risk of stroke and gallbladder disease. Overall, the only statistically significant benefits of HT were a decreased incidence of ENTD fractures ENTDEND and colon cancer with long-term use
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, ENTD transient ischaemic attacks ENTDEND  breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT (oestrogens with or without ENTC progestogens ENTCEND ) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
0	OBJECTIVES: To assess the effect of long-term HT on mortality, heart disease, venous thromboembolism, stroke, ENTD transient ischaemic attacks ENTDEND , breast cancer, colorectal cancer, ovarian cancer, endometrial cancer, gallbladder disease, cognitive function, dementia, fractures and quality of life. SEARCH STRATEGY: We searched the following databases up to November 2004: the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Biological Abstracts. Relevant non-indexed journals and conference abstracts were also searched. SELECTION CRITERIA: Randomised double-blind trials of HT ENTC oestrogens ENTCEND with or without progestogens) versus placebo, taken for at least one year by perimenopausal or postmenopausal women
1	However, one trial analysed subgroups of 2839 relatively healthy 50 to 59 year-old women taking combined continuous HT and 1637 taking ENTC oestrogen ENTCEND -only HT, versus similar-sized placebo groups. The only significantly increased risk reported was for ENTD venous thromboembolism ENTDEND in women taking combined continuous HT; their absolute risk remained very low
0	These data suggest a protective role for the central ENTC dopamine ENTCEND blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of ENTD seizures ENTDEND
1	Haloperidol decreased the incidence of ENTC cocaine ENTCEND induced ENTD seizures ENTDEND at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose
0	These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of ENTD seizures ENTDEND . In contrast, ENTC haloperidol ENTCEND demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality
1	Haloperidol failed to prevent ENTC amphetamine ENTCEND induced ENTD seizures ENTDEND , but did lower the mortality rate at most doses tested
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ENTC ADP ENTCEND -stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, ENTC sodium ENTCEND  neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND and apoptosis of tubular cells on 24 h
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive ENTC oxygen ENTCEND species (ROS) production in LLC-PK1 cells in culture
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, ENTC glucose ENTCEND  sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND and apoptosis of tubular cells on 24 h
0	The potential protective effect of the dietary antioxidant ENTC curcumin ENTCEND (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated. Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND and apoptosis of tubular cells on 24 h
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using ENTC malate ENTCEND /glutamate as substrate
1	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. ENTC Maleate ENTCEND induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture
0	Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of ENTD necrosis ENTDEND  and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/ ENTC glutamate ENTCEND as substrate
0	In addition, maleate treatment reduced oxygen consumption in ENTC ADP ENTCEND -stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate. The activities of both complex I and aconitase were also diminished. All the above-described alterations were prevented by curcumin. It is concluded that curcumin is able to attenuate in vivo maleate-induced ENTD nephropathy ENTDEND and in vitro cell damage
0	Maleate-induced ENTD renal injury ENTDEND included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, ENTC sodium ENTCEND , neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	Curcumin prevents maleate-induced ENTD nephrotoxicity ENTDEND : relation to hemodynamic alterations, oxidative stress, mitochondrial ENTC oxygen ENTCEND consumption and activity of respiratory complex I
0	Maleate-induced ENTD renal injury ENTDEND  included increase in renal vascular resistance and in the urinary excretion of total protein, ENTC glucose ENTCEND , sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	ENTC Curcumin ENTCEND  prevents maleate-induced ENTD nephrotoxicity ENTDEND : relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I
0	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using ENTC malate ENTCEND /glutamate as substrate. The activities of both complex I and aconitase were also diminished. All the above-described alterations were prevented by curcumin. It is concluded that curcumin is able to attenuate in vivo maleate-induced ENTD nephropathy ENTDEND and in vitro cell damage
1	It is concluded that curcumin is able to attenuate in vivo ENTC maleate ENTCEND induced ENTD nephropathy ENTDEND and in vitro cell damage
0	In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate/ ENTC glutamate ENTCEND  as substrate. The activities of both complex I and aconitase were also diminished. All the above-described alterations were prevented by curcumin. It is concluded that curcumin is able to attenuate in vivo maleate-induced ENTD nephropathy ENTDEND and in vitro cell damage
0	Tubular ENTD proteinuria ENTDEND and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ENTC ADP ENTCEND -stimulated mitochondria and diminished respiratory control index when using malate/glutamate as substrate
0	Tubular ENTD proteinuria ENTDEND  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, ENTC sodium ENTCEND , neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial ENTC oxygen ENTCEND  consumption and activity of respiratory complex I.The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated. Tubular ENTD proteinuria ENTDEND and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats
0	Tubular ENTD proteinuria ENTDEND  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, ENTC glucose ENTCEND , sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h
0	The potential protective effect of the dietary antioxidant ENTC curcumin ENTCEND  (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated. Tubular ENTD proteinuria ENTDEND and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats
0	Tubular ENTD proteinuria ENTDEND  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using ENTC malate ENTCEND /glutamate as substrate
1	The potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by ENTC maleate ENTCEND was evaluated. Tubular ENTD proteinuria ENTDEND and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats
0	Tubular ENTD proteinuria ENTDEND  and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats. Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels. Studies were also conducted in renal epithelial LLC-PK1 cells and in mitochondria isolated from kidneys of all the experimental groups. Maleate induced cell damage and reactive oxygen species (ROS) production in LLC-PK1 cells in culture. In addition, maleate treatment reduced oxygen consumption in ADP-stimulated mitochondria and diminished respiratory control index when using malate ENTC glutamate ENTCEND as substrate
0	Myopathy due to lack of ENTC vitamin E ENTCEND and ENTD myopathy ENTDEND induced by certain viruses have much in common anatomically and pathologically with the human form
0	The authors conclude by affirming the undoubted efficacy of the anabolizing ENTC steroids ENTCEND in experimental ENTD myopathic disease ENTDEND , but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the "regeneration" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown
0	The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent ( ENTC Dianabol ENTCEND  CIBA) at high doses in rats rendered ENTD myopathic ENTDEND by a diet deficient in vitamin E
1	The authors induced ENTD myodystrophy ENTDEND in the rat by giving it a diet lacking in ENTC vitamin E ENTCEND
0	The authors induced ENTD myodystrophy ENTDEND  in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated. It is thus confirmed that the histological characteristics of myopathic rat muscle induced experimentally are extraordinarily similar to those of human myopathy as confirmed during biopsies performed at the Orthopaedic Traumatological Centre, Florence. The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing ENTC steroids ENTCEND have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E
1	The authors induced ENTD myodystrophy ENTDEND  in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated. It is thus confirmed that the histological characteristics of myopathic rat muscle induced experimentally are extraordinarily similar to those of human myopathy as confirmed during biopsies performed at the Orthopaedic Traumatological Centre, Florence. The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent ENTC Dianabol ENTCEND , CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E
0	After ENTC dipyridamole ENTCEND  ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the ENTD INF-MI ENTDEND group and 61% of the total population
0	After ENTC dipyridamole ENTCEND , ENTD ischemic ENTDEND ST-segment depression (0
0	After ENTC dipyridamole ENTCEND , ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ENTD ANT-MI ENTDEND group, 63% of the INF-MI group and 61% of the total population
1	The data suggest that the ENTC dipyridamole ENTCEND induced ENTD myocardial ischemia ENTDEND is caused by the inhomogenous distribution of myocardial blood flow
0	After ENTC dipyridamole ENTCEND , ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non- ENTD MI ENTDEND group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population
0	After ENTC dipyridamole ENTCEND , ischemic ST-segment ENTD depression ENTDEND (0
0	Non-invasive detection of ENTD coronary artery disease ENTDEND  by body surface electrocardiographic mapping after ENTC dipyridamole ENTCEND infusion
0	Aconitine-induced Ca2+ overload causes ENTD arrhythmia ENTDEND  and triggers apoptosis through p38 MAPK signaling pathway in rats.Aconitine is a major bioactive diterpenoid alkaloid with high content derived from herbal aconitum plants. Emerging evidence indicates that voltage-dependent ENTC Na ENTCEND (+) channels have pivotal roles in the cardiotoxicity of aconitine
0	We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused ENTD arrhythmia ENTDEND in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats. The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP- ENTC biotin ENTCEND nick end labeling assay
0	We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused ENTD arrhythmia ENTDEND  in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENTC lactate ENTCEND dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	ENTC Aconitine ENTCEND -induced Ca2+ overload causes ENTD arrhythmia ENTDEND and triggers apoptosis through p38 MAPK signaling pathway in rats
0	Aconitine-induced ENTC Ca ENTCEND 2+ overload causes ENTD arrhythmia ENTDEND and triggers apoptosis through p38 MAPK signaling pathway in rats
0	Emerging evidence indicates that voltage-dependent ENTC Na ENTCEND (+) channels have pivotal roles in the cardiotoxicity of aconitine. However, no reports are available on the role of Ca(2+) in aconitine ENTD poisoning ENTDEND
0	In this study, we explored the importance of pathological Ca(2+) signaling in aconitine ENTD poisoning ENTDEND in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats. The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP ENTC biotin ENTCEND nick end labeling assay
0	In this study, we explored the importance of pathological Ca(2+) signaling in aconitine ENTD poisoning ENTDEND  in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENTC lactate ENTCEND dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	However, no reports are available on the role of Ca(2+) in ENTC aconitine ENTCEND ENTD poisoning ENTDEND
0	However, no reports are available on the role of ENTC Ca ENTCEND 2+) in aconitine ENTD poisoning ENTDEND
0	Emerging evidence indicates that voltage-dependent ENTC Na ENTCEND (+) channels have pivotal roles in the ENTD cardiotoxicity ENTDEND of aconitine
0	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the ENTD cardiotoxicity ENTDEND  of aconitine. However, no reports are available on the role of Ca(2+) in aconitine poisoning. In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENTC lactate ENTCEND dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the ENTD cardiotoxicity ENTDEND  of ENTC aconitine ENTCEND
0	Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the ENTD cardiotoxicity ENTDEND  of aconitine. However, no reports are available on the role of ENTC Ca ENTCEND (2+) in aconitine poisoning
0	Emerging evidence indicates that voltage-dependent ENTC Na ENTCEND (+) channels have pivotal roles in the cardiotoxicity of aconitine. However, no reports are available on the role of Ca(2+) in aconitine poisoning. In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed ENTD cytotoxicity ENTDEND assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	To investigate effects of aconitine on myocardial injury, we performed ENTD cytotoxicity ENTDEND  assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats. The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP ENTC biotin ENTCEND nick end labeling assay
0	To investigate effects of aconitine on myocardial injury, we performed ENTD cytotoxicity ENTDEND  assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENTC lactate ENTCEND dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	To investigate effects of ENTC aconitine ENTCEND on myocardial injury, we performed ENTD cytotoxicity ENTDEND assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	We found that ENTC Ca ENTCEND 2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on myocardial injury, we performed ENTD cytotoxicity ENTDEND assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	Emerging evidence indicates that voltage-dependent ENTC Na ENTCEND (+) channels have pivotal roles in the cardiotoxicity of aconitine. However, no reports are available on the role of Ca(2+) in aconitine poisoning. In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo. We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on ENTD myocardial injury ENTDEND , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	The results showed that aconitine resulted in ENTD myocardial injury ENTDEND and reduced NRVMs viability dose-dependently. To confirm the pro-apoptotic effects, we performed flow cytometric detection, cardiac histology, transmission electron microscopy and terminal deoxynucleotidyl transferase-mediated dUTP ENTC biotin ENTCEND nick end labeling assay
0	To investigate effects of aconitine on ENTD myocardial injury ENTDEND , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured ENTC lactate ENTCEND dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	To investigate effects of ENTC aconitine ENTCEND  on ENTD myocardial injury ENTDEND , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
0	We found that ENTC Ca ENTCEND (2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats. To investigate effects of aconitine on ENTD myocardial injury ENTDEND , we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats
1	Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in ENTC Gentamicin ENTCEND -induced ENTD Nephropathy ENTDEND
0	The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin-induced ENTD nephropathy ENTDEND  Sprague-Dawley male rats (200~250 g) were subcutaneously injected with gentamicin (100 mg/kg per day) for 7 days, and the expression of tubular transporters was determined by immunoblotting and immunohistochemistry. The mRNA and protein expression of OAT was also determined. Gentamicin-treated rats exhibited significantly decreased ENTC creatinine ENTCEND clearance along with increased plasma creatinine levels
0	Decreased Expression of Na/ ENTC K ENTCEND -ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced ENTD Nephropathy ENTDEND
0	Decreased Expression of ENTC Na ENTCEND /K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced ENTD Nephropathy ENTDEND
1	Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and ENTD hepatomegaly ENTDEND  after ENTC phenobarbital ENTCEND administration
0	RESULTS: While the ENTC CAN ENTCEND and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENTD impaired memory ENTDEND and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	CONCLUSIONS: Given this record of ENTD impaired memory ENTDEND  and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ENTC ecstasy ENTCEND users is a major cause for concern
0	RESULTS: While the ENTC CAN ENTCEND and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENTD impaired memory ENTDEND and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	RESULTS: While the ENTC CAN ENTCEND and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENTD impaired memory ENTDEND and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENTC alcohol ENTCEND nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of ENTD impaired memory ENTDEND and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine ( ENTC CAN ENTCEND , non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENTD Depression ENTDEND Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
1	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX- ENTC MDMA ENTCEND . Participants completed a drug history questionnaire, Beck ENTD Depression ENTDEND Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine ( ENTC CAN ENTCEND , non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENTD Depression ENTDEND Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine ( ENTC CAN ENTCEND , non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENTD Depression ENTDEND Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENTC alcohol ENTCEND /nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck ENTD Depression ENTDEND Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENTD Impulsiveness ENTDEND Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the ENTC CAN ENTCEND and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures
1	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, ENTD impulsiveness ENTDEND  and sleep disturbance, the prognosis for the current generation of ENTC ecstasy ENTCEND users is a major cause for concern
0	Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENTD Impulsiveness ENTDEND  Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the ENTC CAN ENTCEND and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures
0	Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENTD Impulsiveness ENTDEND  Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the ENTC CAN ENTCEND and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENTC alcohol ENTCEND /nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt ENTD Impulsiveness ENTDEND Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures
0	RESULTS: While the ENTC CAN ENTCEND  and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENTD sleep disturbance ENTDEND , the prognosis for the current generation of ecstasy users is a major cause for concern
1	CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENTD sleep disturbance ENTDEND , the prognosis for the current generation of ENTC ecstasy ENTCEND users is a major cause for concern
0	RESULTS: While the ENTC CAN ENTCEND  and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENTD sleep disturbance ENTDEND , the prognosis for the current generation of ecstasy users is a major cause for concern
0	RESULTS: While the ENTC CAN ENTCEND  and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENTD sleep disturbance ENTDEND , the prognosis for the current generation of ecstasy users is a major cause for concern
0	METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/ ENTC alcohol ENTCEND /nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA). Participants completed a drug history questionnaire, Beck Depression Inventory, Barratt Impulsiveness Scale, Pittsburgh Sleep Quality Index, and Wechsler Memory Scale-Revised which, in total, provided 13 psychometric measures. RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures. Strikingly, despite prolonged abstinence (mean, 4.98; range, 4-9 years), past ecstasy users showed few signs of recovery. Compared with present ecstasy users, the past users showed no change for ten measures, increased impairment for two measures, and improvement on just one measure. CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and ENTD sleep disturbance ENTDEND , the prognosis for the current generation of ecstasy users is a major cause for concern
0	Anaesthesia with a ENTC propofol ENTCEND infusion and avoidance of serotonin antagonists provided a ENTD nausea ENTDEND -free postoperative course without exacerbation of the depression disorder
0	Anaesthesia with a propofol infusion and avoidance of ENTC serotonin ENTCEND antagonists provided a ENTD nausea ENTDEND -free postoperative course without exacerbation of the depression disorder
0	A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ENTC ondansetron ENTCEND prophylaxis had been used. She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist. Nine years before she had experienced a self-limited puerperal depressive episode. Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a ENTD nausea ENTDEND -free postoperative course without exacerbation of the depression disorder
0	She had developed a severe acute ENTD major depression disorder ENTDEND almost immediately thereafter, possibly related to the use of a serotonin antagonist. Nine years before she had experienced a self-limited puerperal depressive episode. Anaesthesia with a ENTC propofol ENTCEND infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	She had developed a severe acute ENTD major depression disorder ENTDEND  almost immediately thereafter, possibly related to the use of a ENTC serotonin ENTCEND antagonist
1	A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ENTC ondansetron ENTCEND  prophylaxis had been used. She had developed a severe acute ENTD major depression disorder ENTDEND almost immediately thereafter, possibly related to the use of a serotonin antagonist
0	Nine years before she had experienced a self-limited puerperal ENTD depressive episode ENTDEND  Anaesthesia with a ENTC propofol ENTCEND infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	Nine years before she had experienced a self-limited puerperal ENTD depressive episode ENTDEND . Anaesthesia with a propofol infusion and avoidance of ENTC serotonin ENTCEND antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	Acute severe ENTD depression ENTDEND  following peri-operative ENTC ondansetron ENTCEND
0	A 41-year-old woman with a strong history of ENTD postoperative nausea and vomiting ENTDEND presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used. She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist. Nine years before she had experienced a self-limited puerperal depressive episode. Anaesthesia with a ENTC propofol ENTCEND infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder
0	A 41-year-old woman with a strong history of ENTD postoperative nausea and vomiting ENTDEND  presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used. She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a ENTC serotonin ENTCEND antagonist
0	Acute severe depression following peri-operative ENTC ondansetron ENTCEND .A 41-year-old woman with a strong history of ENTD postoperative nausea and vomiting ENTDEND presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used
1	5 patients with acute renal failure (3 with ENTD thrombopenia ENTDEND and hemolysis) induced by the reintroduction of ENTC rifampicin ENTCEND are described
0	5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of ENTC rifampicin ENTCEND  are described. No correlation was found between the severity of clinical manifestations and the total dose taken by the patients. In all but 1 patient, antirifampicin antibodies were detected. Antibodies suggested to be of the IgM class were detected in all 3 patients with ENTD hematological disorders ENTDEND
1	5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of ENTC rifampicin ENTCEND  are described. No correlation was found between the severity of clinical manifestations and the total dose taken by the patients. In all but 1 patient, antirifampicin antibodies were detected. Antibodies suggested to be of the IgM class were detected in all 3 patients with hematological disorders. The pattern of non-specific ENTD acute tubular necrosis ENTDEND found in the 2 biopsied patients, indistinguishable from that of ischemic origin, raised the possibility of a vascular-mediated damage
0	Antirifampicin antibodies in acute ENTC rifampicin ENTCEND -associated renal failure.5 patients with ENTD acute renal failure ENTDEND (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described
0	Antirifampicin antibodies in acute ENTC rifampicin ENTCEND -associated ENTD renal failure ENTDEND
1	5 patients with acute renal failure (3 with thrombopenia and ENTD hemolysis ENTDEND  induced by the reintroduction of ENTC rifampicin ENTCEND are described
0	001) but none in ENTC warfarin ENTCEND users with ENTD IS ENTDEND /TIA (OR, 1
0	METHODS: We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ENTD ischemic ENTDEND events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB. RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in ENTC warfarin ENTCEND users (P difference=0
0	001) but none in ENTC warfarin ENTCEND  users with IS/ ENTD TIA ENTDEND (OR, 1
0	METHODS: We performed a systematic review of published and unpublished data from cohorts with ENTD stroke ENTDEND or TIA to compare the presence of MB in: (1) antithrombotic users vs nonantithrombotic users with ICH; (2) antithrombotic users vs nonusers with IS/TIA; and (3) ICH vs ischemic events stratified by antithrombotic use. We also analyzed published and unpublished follow-up data to determine the risk of ICH in antithrombotic users with MB. RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in ENTC warfarin ENTCEND users (P difference=0
1	CONCLUSIONS: The excess of MB in ENTC warfarin ENTCEND users with ENTD ICH ENTDEND compared to other groups suggests that MB increase the risk of warfarin-associated ICH
0	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of ENTD Mental Disorders ENTDEND  Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral ENTC caffeine ENTCEND challenge test
0	The patients with PD and ENTD MDP ENTDEND were more sensitive to ENTC caffeine ENTCEND than were patients with MD and healthy volunteers
0	ENTC Caffeine ENTCEND  challenge test in panic disorder and ENTD depression ENTDEND with panic attacks
1	Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of ENTD panic attacks ENTDEND by an oral ENTC caffeine ENTCEND challenge test
0	In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a ENTC caffeine ENTCEND free (placebo) solution were administered in a coffee form and ENTD anxiety ENTDEND scales were applied before and after each test
0	Neither dosage nor serum levels of ENTC CBZ ENTCEND were in a higher range. We consider asterixis to be an easily overlooked sign of ENTD neurotoxicity ENTDEND , which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ
0	We consider asterixis to be an easily overlooked sign of ENTD neurotoxicity ENTDEND , which may occur even at low or moderate dosage levels, if certain drugs as ENTC lithium ENTCEND or clozapine are used in combination with CBZ
0	We consider asterixis to be an easily overlooked sign of ENTD neurotoxicity ENTDEND , which may occur even at low or moderate dosage levels, if certain drugs as lithium or ENTC clozapine ENTCEND are used in combination with CBZ
0	ENTD Asterixis ENTDEND  induced by ENTC carbamazepine ENTCEND therapy
1	We consider ENTD asterixis ENTDEND to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as ENTC lithium ENTCEND or clozapine are used in combination with CBZ
1	We consider ENTD asterixis ENTDEND  to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or ENTC clozapine ENTCEND are used in combination with CBZ
0	In the first case a caesarean section was done one week after replacement of warfarin with ENTC heparin ENTCEND  The baby died of cerebral and pulmonary hemorrhage. The second mother had a male infant by caesarean section. The baby showed warfarin-induced ENTD embryopathy ENTDEND with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata)
0	The baby showed ENTC warfarin ENTCEND induced ENTD embryopathy ENTDEND with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata)
0	In the first case a caesarean section was done one week after replacement of warfarin with ENTC heparin ENTCEND . The baby died of cerebral and pulmonary hemorrhage. The second mother had a male infant by caesarean section. The baby showed warfarin-induced embryopathy with nasal hypoplasia and ENTD stippled epiphyses ENTDEND (chondrodysplasia punctata)
1	The baby showed ENTC warfarin ENTCEND -induced embryopathy with nasal hypoplasia and ENTD stippled epiphyses ENTDEND (chondrodysplasia punctata)
0	In the first case a caesarean section was done one week after replacement of warfarin with ENTC heparin ENTCEND . The baby died of ENTD cerebral and pulmonary hemorrhage ENTDEND
1	In the first case a caesarean section was done one week after replacement of ENTC warfarin ENTCEND with heparin. The baby died of ENTD cerebral and pulmonary hemorrhage ENTDEND
0	In the first case a caesarean section was done one week after replacement of warfarin with ENTC heparin ENTCEND . The baby died of ENTD cerebral and pulmonary hemorrhage ENTDEND
1	In the first case a caesarean section was done one week after replacement of ENTC warfarin ENTCEND  with heparin. The baby died of ENTD cerebral and pulmonary hemorrhage ENTDEND
0	In the first case a caesarean section was done one week after replacement of warfarin with ENTC heparin ENTCEND . The baby died of ENTD cerebral and pulmonary hemorrhage ENTDEND
1	In the first case a caesarean section was done one week after replacement of ENTC warfarin ENTCEND  with heparin. The baby died of ENTD cerebral and pulmonary hemorrhage ENTDEND
0	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed ENTD MM ENTDEND  VTD consisted of ENTC bortezomib ENTCEND at a dose of 1
0	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed ENTD MM ENTDEND . VTD consisted of bortezomib at a dose of 1.3 mg/m(2) and ENTC dexamethasone ENTCEND at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day
0	In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, ENTC thalidomide ENTCEND  and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed ENTD MM ENTDEND
1	VTD consisted of ENTC bortezomib ENTCEND  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and ENTD thrombocytopenia ENTDEND were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and ENTC dexamethasone ENTCEND  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and ENTD thrombocytopenia ENTDEND were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENTC thalidomide ENTCEND at a dose of 100 mg/day. Grade 3-4 neutropenia and ENTD thrombocytopenia ENTDEND were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	VTD consisted of ENTC bortezomib ENTCEND  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. ENTD Peripheral neuropathy ENTDEND was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed
1	3 mg/m(2) and ENTC dexamethasone ENTCEND  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. ENTD Peripheral neuropathy ENTDEND was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed
1	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENTC thalidomide ENTCEND  at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case. ENTD Peripheral neuropathy ENTDEND was common (63 %), but severe grade 3-4 peripheral neuropathy was not observed
1	VTD consisted of ENTC bortezomib ENTCEND  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 ENTD neutropenia ENTDEND and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and ENTC dexamethasone ENTCEND  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 ENTD neutropenia ENTDEND and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
1	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENTC thalidomide ENTCEND  at a dose of 100 mg/day. Grade 3-4 ENTD neutropenia ENTDEND and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to cytopenia was not required in any case
0	VTD consisted of ENTC bortezomib ENTCEND  at a dose of 1.3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to ENTD cytopenia ENTDEND was not required in any case
0	3 mg/m(2) and ENTC dexamethasone ENTCEND  at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral thalidomide at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to ENTD cytopenia ENTDEND was not required in any case
0	3 mg/m(2) and dexamethasone at a dose of 40 mg/day on days 1, 8, 15, and 22 of a 35-day cycle, with daily oral ENTC thalidomide ENTCEND  at a dose of 100 mg/day. Grade 3-4 neutropenia and thrombocytopenia were documented in four and three patients (17 and 13 %), respectively, but drug dose reduction due to ENTD cytopenia ENTDEND was not required in any case
1	ENTC Famotidine ENTCEND -associated ENTD delirium ENTDEND
0	ENTC Famotidine ENTCEND is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ENTD ulcers ENTDEND and is showing increasing popularity because of its low cost
1	As heparin remains one of the most frequently used medications today with potential for ENTD HIT ENTDEND with every ENTC heparin ENTCEND exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated
0	ENTC Direct thrombin inhibitors ENTCEND are appropriate, evidence-based alternatives to heparin in patients with a history of ENTD HIT ENTDEND , who need to undergo percutaneous coronary intervention
1	HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever ENTD thrombosis ENTDEND occurs after ENTC heparin ENTCEND exposure
0	HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever ENTD thrombosis ENTDEND  occurs after heparin exposure. Early recognition that incorporates the clinical and serologic clues is paramount to timely institution of treatment, as its delay may result in catastrophic outcomes. The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a ENTC direct thrombin inhibitor ENTCEND
0	The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental ENTD glomerulosclerosis ENTDEND  tubulointerstitial injury, or renal cortical malondialdehyde content. In rats with ENTC PAN ENTCEND nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA
0	The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental ENTD glomerulosclerosis ENTDEND , tubulointerstitial injury, or renal cortical ENTC malondialdehyde ENTCEND content
0	In rats with ENTC PAN ENTCEND  nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA. In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, ENTD proteinuria ENTDEND , GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4)
0	In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, ENTD proteinuria ENTDEND , GFR, glomerular planar area, renal cortical ENTC malondialdehyde ENTCEND content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4)
1	Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic ENTC PAN ENTCEND ENTD nephropathy ENTDEND
0	The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical ENTC malondialdehyde ENTCEND  content. In rats with PAN ENTD nephropathy ENTDEND , administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA
0	Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of ENTD growth failure ENTDEND in rats with chronic ENTC PAN ENTCEND nephropathy
1	A 27-yr-old man developed jaundice 2 wk after exposure to ENTC thiabendazole ENTCEND  Cholestasis persisted for 3 yr, at which time a liver transplant was performed. Two liver biopsy specimens and the hepatectomy specimen were remarkable for almost complete disappearance of interlobular bile ducts. Prominent fibrosis and hepatocellular regeneration were also present; however, the lobular architecture was preserved. This case represents an example of "idiosyncratic" ENTD drug-induced liver damage ENTDEND in which the primary target of injury is the bile duct
0	Progressive ENTD bile duct injury ENTDEND  after ENTC thiabendazole ENTCEND administration
0	A 27-yr-old man developed ENTD jaundice ENTDEND 2 wk after exposure to ENTC thiabendazole ENTCEND
0	A 27-yr-old man developed jaundice 2 wk after exposure to ENTC thiabendazole ENTCEND . Cholestasis persisted for 3 yr, at which time a liver transplant was performed. Two liver biopsy specimens and the hepatectomy specimen were remarkable for almost complete disappearance of interlobular bile ducts. Prominent ENTD fibrosis ENTDEND and hepatocellular regeneration were also present; however, the lobular architecture was preserved
1	A 27-yr-old man developed jaundice 2 wk after exposure to ENTC thiabendazole ENTCEND . ENTD Cholestasis ENTDEND persisted for 3 yr, at which time a liver transplant was performed
1	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, ENTD anemia ENTDEND  and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENTC RAD001 ENTCEND 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	RAD001, an oral inhibitor of the mammalian target of ENTC rapamycin ENTCEND (mTOR), has shown phase I efficacy in NSCLC. METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENTD tumor ENTDEND from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one ENTC platinum ENTCEND based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENTD tumor ENTDEND from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor ENTC tyrosine ENTCEND kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENTD tumor ENTDEND from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received ENTC RAD001 ENTCEND 10 mg/day until progression or unacceptable toxicity. Primary objective was overall response rate (ORR). Analyses of markers associated with the mTOR pathway were carried out on archival ENTD tumor ENTDEND from a subgroup using immunohistochemistry (IHC) and direct mutation sequencing
1	Common > or =grade 3 events were fatigue, dyspnea, ENTD stomatitis ENTDEND  anemia, and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENTC RAD001 ENTCEND 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	RAD001, an oral inhibitor of the mammalian target of ENTC rapamycin ENTCEND  (mTOR), has shown phase I efficacy in NSCLC. METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable ENTD toxicity ENTDEND
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one ENTC platinum ENTCEND  based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable ENTD toxicity ENTDEND
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor ENTC tyrosine ENTCEND  kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable ENTD toxicity ENTDEND
0	METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received ENTC RAD001 ENTCEND  10 mg/day until progression or unacceptable ENTD toxicity ENTDEND
0	ENTD Pneumonitis ENTDEND  probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENTC RAD001 ENTCEND 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
1	Common > or =grade 3 events were fatigue, dyspnea, stomatitis, anemia, and ENTD thrombocytopenia ENTDEND  Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENTC RAD001 ENTCEND 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
1	Common > or =grade 3 events were ENTD fatigue ENTDEND  dyspnea, stomatitis, anemia, and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENTC RAD001 ENTCEND 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	RAD001, an oral inhibitor of the mammalian target of ENTC rapamycin ENTCEND  (mTOR), has shown phase I efficacy in ENTD NSCLC ENTDEND
0	METHODS: Stage IIIb or IV ENTD NSCLC ENTDEND patients, with two or fewer prior chemotherapy regimens, one ENTC platinum ENTCEND based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity
0	METHODS: Stage IIIb or IV ENTD NSCLC ENTDEND  patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor ENTC tyrosine ENTCEND kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity
0	BACKGROUND: Treatment options are scarce in pretreated advanced non-small-cell lung cancer ( ENTD NSCLC ENTDEND  patients. ENTC RAD001 ENTCEND , an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC
1	Common > or =grade 3 events were fatigue, ENTD dyspnea ENTDEND  stomatitis, anemia, and thrombocytopenia. Pneumonitis, probably or possibly related, mainly grade 1/2, occurred in 25%. Cox regression analysis of IHC scores found that only phospho AKT (pAKT) was a significant independent predictor of worse PFS. CONCLUSIONS: ENTC RAD001 ENTCEND 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC
0	Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in ENTC heparin ENTCEND -induced ENTD thrombocytopenia ENTDEND
0	Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced ENTD thrombocytopenia ENTDEND . ENTC Argatroban ENTCEND is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)
0	Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to- ENTC warfarin ENTCEND transition should be followed. Major bleeding with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally. Argatroban has no specific antidote, and if excessive anticoagulation occurs, argatroban infusion should be stopped or reduced. Improved familiarity of healthcare professionals with argatroban therapy in ENTD HIT ENTDEND , including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of ENTD thrombosis ENTDEND in ENTC heparin ENTCEND -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)
0	ENTC Argatroban ENTCEND  is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of ENTD thrombosis ENTDEND in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENTC heparin ENTCEND -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds). Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion, e.g. heart failure, yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or ENTD obesity ENTDEND
0	heart failure, yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or ENTD obesity ENTDEND . ENTC Argatroban ENTCEND 0
0	For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or ENTD obesity ENTDEND  and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition. Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to ENTC warfarin ENTCEND transition should be followed
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENTC heparin ENTCEND -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds). Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion, e.g. heart failure, yet are unnecessary for ENTD renal dysfunction ENTDEND , adult age, sex, race/ethnicity or obesity
0	heart failure, yet are unnecessary for ENTD renal dysfunction ENTDEND , adult age, sex, race/ethnicity or obesity. ENTC Argatroban ENTCEND 0
0	heart failure, yet are unnecessary for ENTD renal dysfunction ENTDEND , adult age, sex, race/ethnicity or obesity. Argatroban 0.5-1.2 microg/kg/min typically supports therapeutic aPTTs. The FDA-recommended dose during PCI is 25 microg/kg/min (350 microg/kg initial bolus), adjusted to achieve activated clotting times (ACTs) of 300-450 sec. For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition. Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to ENTC warfarin ENTCEND transition should be followed
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENTC heparin ENTCEND -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds). Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion, e.g. ENTD heart failure ENTDEND , yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or obesity
0	ENTD heart failure ENTDEND , yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or obesity. ENTC Argatroban ENTCEND 0
0	ENTD heart failure ENTDEND , yet are unnecessary for renal dysfunction, adult age, sex, race/ethnicity or obesity. Argatroban 0.5-1.2 microg/kg/min typically supports therapeutic aPTTs. The FDA-recommended dose during PCI is 25 microg/kg/min (350 microg/kg initial bolus), adjusted to achieve activated clotting times (ACTs) of 300-450 sec. For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition. Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to ENTC warfarin ENTCEND transition should be followed
1	Major ENTD bleeding ENTDEND with ENTC argatroban ENTCEND is 0-10% in the non-interventional setting and 0-5
0	Argatroban prolongs the International Normalized Ratio, and published approaches for monitoring the argatroban-to- ENTC warfarin ENTCEND  transition should be followed. Major ENTD bleeding ENTDEND with argatroban is 0-10% in the non-interventional setting and 0-5
0	Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in ENTC heparin ENTCEND -induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI). The objective of this review is to summarize practical considerations of argatroban therapy in HIT. The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with ENTD hepatic impairment ENTDEND and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1
0	The US FDA-recommended ENTC argatroban ENTCEND dose in HIT is 2 microg/kg/min (reduced in patients with ENTD hepatic impairment ENTDEND and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1
0	After pretreatment with 3 mg of cyproheptadine, 2 mg ENTC mianserin ENTCEND  or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENTD encephalopathy ENTDEND in mice
1	Treatment of lethal ENTC pertussis vaccine ENTCEND  reaction with histamine H1 antagonists.We studied mortality after pertussis immunization in the mouse. Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of pertussis immunization. After pretreatment with 3 mg of cyproheptadine, 2 mg mianserin, or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENTD encephalopathy ENTDEND in mice
0	Blockade of ENTC histamine ENTCEND H1 receptors may reduce mortality in pertussis immunization-induced ENTD encephalopathy ENTDEND in mice
0	After pretreatment with 3 mg of ENTC cyproheptadine ENTCEND  2 mg mianserin, or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENTD encephalopathy ENTDEND in mice
0	After pretreatment with 3 mg of cyproheptadine, 2 mg mianserin, or 2 mg ENTC chlorpheniramine ENTCEND  only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0.001). Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced ENTD encephalopathy ENTDEND in mice
0	Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of ENTD pertussis ENTDEND immunization. After pretreatment with 3 mg of cyproheptadine, 2 mg ENTC mianserin ENTCEND , or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0
0	Treatment of lethal ENTC pertussis vaccine ENTCEND  reaction with histamine H1 antagonists.We studied mortality after ENTD pertussis ENTDEND immunization in the mouse
0	Blockade of ENTC histamine ENTCEND  H1 receptors may reduce mortality in ENTD pertussis ENTDEND immunization-induced encephalopathy in mice
0	Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of ENTD pertussis ENTDEND  immunization. After pretreatment with 3 mg of ENTC cyproheptadine ENTCEND , 2 mg mianserin, or 2 mg chlorpheniramine, only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0
0	Without treatment, 73 of 92 animals (80%) died after injection of bovine serum albumin (BSA) on day +7 of ENTD pertussis ENTDEND  immunization. After pretreatment with 3 mg of cyproheptadine, 2 mg mianserin, or 2 mg ENTC chlorpheniramine ENTCEND , only 5 of 105 animals (5%) died after receiving BSA on day +7 (p less than 0
1	Recurrent myocardial infarction in a postpartum patient receiving ENTC bromocriptine ENTCEND . ENTD Myocardial infarction ENTDEND in puerperium is infrequently reported
0	Recurrent myocardial infarction in a postpartum patient receiving ENTC bromocriptine ENTCEND .Myocardial infarction in puerperium is infrequently reported. ENTD Spasm ENTDEND , coronary dissection, or atheromatous etiology has been described
0	The results warrant clinical trials of ENTC denopamine ENTCEND in the treatment of ENTD cardiac failure ENTDEND
1	Improvement by denopamine (TA-064) of ENTC pentobarbital ENTCEND -induced ENTD cardiac failure ENTDEND in the dog heart-lung preparation
0	No ENTD arrhythmias ENTDEND were induced by these doses of ENTC denopamine ENTCEND
0	Cardiac functions depressed by ENTC pentobarbital ENTCEND (118 +/- 28 mg; mean value +/- SD) such that cardiac output and maximum rate of rise of left ventricular pressure (LV dP/dt max) had been reduced by about 35% and 26% of the respective controls were improved by denopamine (10-300 micrograms) in a dose-dependent manner. With 100 micrograms denopamine, almost complete restoration of cardiac performance was attained, associated with a slight increase in heart rate. No ENTD arrhythmias ENTDEND were induced by these doses of denopamine
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENTD diabetes insipidus ENTDEND after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of ENTC angiotensin ENTCEND II forming and receptor binding capacity for sodium balance in the brain
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENTD diabetes insipidus ENTDEND  after ENTC DOCA ENTCEND -salt treatment
1	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with ENTC lithium ENTCEND treated ENTD diabetes insipidus ENTDEND after DOCA-salt treatment
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENTD diabetes insipidus ENTDEND  after DOCA-salt treatment. Administration of DDAVP which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP. Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension. Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension. An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for ENTC sodium ENTCEND balance in the brain
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENTD diabetes insipidus ENTDEND  after DOCA-salt treatment. Administration of ENTC DDAVP ENTCEND which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP
0	ENTC Vasopressin ENTCEND plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated ENTD diabetes insipidus ENTDEND after DOCA-salt treatment
0	Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in ENTD hypertension ENTDEND  An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of ENTC angiotensin ENTCEND II forming and receptor binding capacity for sodium balance in the brain
1	Vasopressin plays a major role in the pathogenesis of ENTC DOCA ENTCEND salt ENTD hypertension ENTDEND , since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt ENTD hypertension ENTDEND , since the elevation of blood pressure was not substantial in the rats with ENTC lithium ENTCEND -treated diabetes insipidus after DOCA-salt treatment
0	An unproportional release of vasopressin compared to plasma osmolality may be induced by the absence of an adjusting control of angiotensin II forming and receptor binding capacity for ENTC sodium ENTCEND  balance in the brain. However, the role of vasopressin remains to be determined in human essential ENTD hypertension ENTDEND
0	Vasopressin plays a major role in the pathogenesis of DOCA-salt ENTD hypertension ENTDEND , since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment. Administration of ENTC DDAVP ENTCEND which has antidiuretic action but minimal vasopressor effect failed to increase blood pressure to the levels observed after administration of AVP
0	Vasopressin as a possible contributor to ENTD hypertension ENTDEND .The role of ENTC vasopressin ENTCEND as a pressor agent to the hypertensive process was examined
0	All 36 patients receiving ENTC lamivudine ENTCEND had a decrease in ENTD hepatitis B ENTDEND virus (HBV) DNA values of >90% (P <
1	Lamivudine is effective in suppressing ENTD hepatitis B ENTDEND  virus DNA in Chinese ENTC hepatitis B surface antigen ENTCEND carriers: a placebo-controlled trial
0	In some cases, a high serum concentration of ENTC citalopram ENTCEND (> 600 nmol/L) in elderly patients has been associated with increased ENTD somnolence ENTDEND and movement difficulties
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased ENTD somnolence ENTDEND  and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus ENTC desmethylfluoxetine ENTCEND ) concentration
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased ENTD somnolence ENTDEND  and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total ENTC fluoxetine ENTCEND (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENTC serotonin ENTCEND reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased ENTD somnolence ENTDEND and movement difficulties
0	In some cases, a high serum concentration of ENTC citalopram ENTCEND  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute ENTD hyperkinetic ENTDEND delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration
0	In this report, we describe a patient with acute ENTD hyperkinetic ENTDEND  delirium connected with a high serum total fluoxetine (fluoxetine plus ENTC desmethylfluoxetine ENTCEND ) concentration
1	In this report, we describe a patient with acute ENTD hyperkinetic ENTDEND  delirium connected with a high serum total ENTC fluoxetine ENTCEND (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENTC serotonin ENTCEND  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute ENTD hyperkinetic ENTDEND delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration
0	In some cases, a high serum concentration of ENTC citalopram ENTCEND  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as ENTD delirium ENTDEND , have not been previously linked with high blood levels of SSRIs
0	In this report, we describe a patient with acute hyperkinetic ENTD delirium ENTDEND connected with a high serum total fluoxetine (fluoxetine plus ENTC desmethylfluoxetine ENTCEND ) concentration
1	ENTD Delirium ENTDEND  during ENTC fluoxetine ENTCEND treatment
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENTC serotonin ENTCEND  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread cognitive disorders, such as ENTD delirium ENTDEND , have not been previously linked with high blood levels of SSRIs
0	In some cases, a high serum concentration of ENTC citalopram ENTCEND  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread ENTD cognitive disorders ENTDEND , such as delirium, have not been previously linked with high blood levels of SSRIs
0	Widespread ENTD cognitive disorders ENTDEND , such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus ENTC desmethylfluoxetine ENTCEND ) concentration
0	Widespread ENTD cognitive disorders ENTDEND , such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total ENTC fluoxetine ENTCEND (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENTC serotonin ENTCEND  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties. Widespread ENTD cognitive disorders ENTDEND , such as delirium, have not been previously linked with high blood levels of SSRIs
0	In some cases, a high serum concentration of ENTC citalopram ENTCEND  (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENTD movement difficulties ENTDEND
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENTD movement difficulties ENTDEND . Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus ENTC desmethylfluoxetine ENTCEND ) concentration
0	In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENTD movement difficulties ENTDEND . Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs. In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total ENTC fluoxetine ENTCEND (fluoxetine plus desmethylfluoxetine) concentration
0	Only a few reports exist, however, on the relationship between the serum concentrations of selective ENTC serotonin ENTCEND  reuptake inhibitors (SSRIs) and their toxic effects. In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and ENTD movement difficulties ENTDEND
0	Suxamethonium-induced ENTD jaw stiffness ENTDEND  and myalgia associated with atypical cholinesterase: case report.An 11-year-old boy was given ENTC halothane ENTCEND , nitrous oxide and oxygen, pancuronium 0
0	An 11-year-old boy was given halothane, nitrous oxide and oxygen, ENTC pancuronium ENTCEND 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked ENTD jaw stiffness ENTDEND occurred which lasted for two minutes and the anaesthesia were terminated
0	He was found to have atypical plasma cholinesterase with a ENTC dibucaine ENTCEND number of 12, indicating homozygocity. This was verified by study of the family. The case shows that ENTD prolonged jaw rigidity ENTDEND and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium
0	An 11-year-old boy was given halothane, nitrous oxide and ENTC oxygen ENTCEND  pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked ENTD jaw stiffness ENTDEND occurred which lasted for two minutes and the anaesthesia were terminated
1	ENTC Suxamethonium ENTCEND -induced ENTD jaw stiffness ENTDEND and myalgia associated with atypical cholinesterase: case report
0	Suxamethonium-induced ENTD jaw stiffness ENTDEND  and myalgia associated with atypical cholinesterase: case report.An 11-year-old boy was given halothane, ENTC nitrous oxide ENTCEND and oxygen, pancuronium 0
0	An 11-year-old boy was given ENTC halothane ENTCEND , nitrous oxide and oxygen, pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENTD apnoea ENTDEND ensued and he suffered generalized severe myalgia lasting for one week
0	An 11-year-old boy was given halothane, nitrous oxide and oxygen, ENTC pancuronium ENTCEND  0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENTD apnoea ENTDEND ensued and he suffered generalized severe myalgia lasting for one week
0	Four hours of ENTD apnoea ENTDEND  ensued and he suffered generalized severe myalgia lasting for one week. He was found to have atypical plasma cholinesterase with a ENTC dibucaine ENTCEND number of 12, indicating homozygocity
0	An 11-year-old boy was given halothane, nitrous oxide and ENTC oxygen ENTCEND , pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENTD apnoea ENTDEND ensued and he suffered generalized severe myalgia lasting for one week
1	4 mg and ENTC suxamethonium ENTCEND 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENTD apnoea ENTDEND ensued and he suffered generalized severe myalgia lasting for one week
0	An 11-year-old boy was given halothane, ENTC nitrous oxide ENTCEND  and oxygen, pancuronium 0.4 mg and suxamethonium 100 mg for induction of anaesthesia. In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated. Four hours of ENTD apnoea ENTDEND ensued and he suffered generalized severe myalgia lasting for one week
0	Suxamethonium-induced jaw stiffness and ENTD myalgia ENTDEND  associated with atypical cholinesterase: case report.An 11-year-old boy was given ENTC halothane ENTCEND , nitrous oxide and oxygen, pancuronium 0
0	The case shows that prolonged jaw rigidity and ENTD myalgia ENTDEND may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with ENTC pancuronium ENTCEND
0	Four hours of apnoea ensued and he suffered generalized severe ENTD myalgia ENTDEND lasting for one week. He was found to have atypical plasma cholinesterase with a ENTC dibucaine ENTCEND number of 12, indicating homozygocity
0	Suxamethonium-induced jaw stiffness and ENTD myalgia ENTDEND  associated with atypical cholinesterase: case report.An 11-year-old boy was given halothane, nitrous oxide and ENTC oxygen ENTCEND , pancuronium 0
1	The case shows that prolonged jaw rigidity and ENTD myalgia ENTDEND  may occur after ENTC suxamethonium ENTCEND in patients with atypical cholinesterase despite pretreatment with pancuronium
0	Suxamethonium-induced jaw stiffness and ENTD myalgia ENTDEND  associated with atypical cholinesterase: case report.An 11-year-old boy was given halothane, ENTC nitrous oxide ENTCEND and oxygen, pancuronium 0
0	Furthermore, there have been reports of thrombotic microangiopathy precipitated by ENTC cyclosporine ENTCEND in patients with SSc. In this article, we report a patient with ENTD SRC ENTDEND induced by tacrolimus and corticosteroids
0	In this article, we report a patient with ENTD SRC ENTDEND  induced by ENTC tacrolimus ENTCEND and corticosteroids
0	In this article, we report a patient with ENTD SRC ENTDEND  induced by tacrolimus and ENTC corticosteroids ENTCEND
0	Late-onset scleroderma renal crisis induced by tacrolimus and ENTC prednisolone ENTCEND : a case report. ENTD Scleroderma renal crisis ENTDEND (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy
1	Furthermore, there have been reports of ENTD thrombotic microangiopathy ENTDEND precipitated by ENTC cyclosporine ENTCEND in patients with SSc
0	Furthermore, there have been reports of ENTD thrombotic microangiopathy ENTDEND  precipitated by cyclosporine in patients with SSc. In this article, we report a patient with SRC induced by ENTC tacrolimus ENTCEND and corticosteroids
0	Moderate to high dose ENTC corticosteroid ENTCEND use is recognized as a major risk factor for SRC. Furthermore, there have been reports of ENTD thrombotic microangiopathy ENTDEND precipitated by cyclosporine in patients with SSc
0	Late-onset scleroderma renal crisis induced by tacrolimus and ENTC prednisolone ENTCEND : a case report.Scleroderma renal crisis (SRC) is a rare complication of systemic sclerosis (SSc) but can be severe enough to require temporary or permanent renal replacement therapy. Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC. Furthermore, there have been reports of ENTD thrombotic microangiopathy ENTDEND precipitated by cyclosporine in patients with SSc
0	Furthermore, there have been reports of thrombotic microangiopathy precipitated by ENTC cyclosporine ENTCEND  in patients with ENTD SSc ENTDEND
1	The aim of this work is to call attention to the risk of ENTC tacrolimus ENTCEND use in patients with ENTD SSc ENTDEND
1	Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with ENTD SSc ENTDEND . In this article, we report a patient with SRC induced by tacrolimus and ENTC corticosteroids ENTCEND
0	Late-onset scleroderma renal crisis induced by tacrolimus and ENTC prednisolone ENTCEND : a case report.Scleroderma renal crisis (SRC) is a rare complication of ENTD systemic sclerosis ENTDEND (SSc) but can be severe enough to require temporary or permanent renal replacement therapy
1	ENTC CYP ENTCEND induced ENTD cystitis ENTDEND increased (P < or = 0
0	Previous studies have examined the expression and regulation of ENTC tyrosine ENTCEND kinase receptors (Trks) in micturition reflexes with ENTD urinary bladder inflammation ENTDEND
0	OBJECTIVES: The present study investigates the effects of ENTC nicotine ENTCEND on ENTD anxiety ENTDEND induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice
1	25 mg/kg) pretreatment blocked the caffeine- but not ENTC pentylenetetrazole ENTCEND induced ENTD anxiety ENTDEND
1	CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on ENTC caffeine ENTCEND induced ENTD anxiety ENTDEND is specific to caffeine, instead of a non-specific anxiolytic effect
1	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and ENTC levomepromazine ENTCEND  In addition to the typical symptoms of ENTD NMS ENTDEND , massive intestinal bleeding was observed during the episode
1	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome ( ENTD NMS ENTDEND  after administration of ENTC risperidone ENTCEND and levomepromazine
0	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and ENTC levomepromazine ENTCEND . In addition to the typical symptoms of NMS, massive intestinal ENTD bleeding ENTDEND was observed during the episode
0	A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of ENTC risperidone ENTCEND  and levomepromazine. In addition to the typical symptoms of NMS, massive intestinal ENTD bleeding ENTDEND was observed during the episode
0	A patient with chronic renal failure ( ENTD CRF ENTDEND  developed neuroleptic malignant syndrome (NMS) after administration of risperidone and ENTC levomepromazine ENTCEND
0	A patient with chronic renal failure ( ENTD CRF ENTDEND ) developed neuroleptic malignant syndrome (NMS) after administration of ENTC risperidone ENTCEND and levomepromazine
1	These results support the conclusion that NO plays a role of endogenous convulsant in rat model of ENTC lindane ENTCEND ENTD seizures ENTDEND
0	It evokes ENTD convulsions ENTDEND mainly trough the blockage of ENTC GABA ENTCEND (A) receptors
0	On the contrary, pretreatment with ENTC L-NAME ENTCEND (500, 700 and 900 mg/kg, i.p.) decreased ENTD convulsion ENTDEND incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i
0	The role of ENTC nitric oxide ENTCEND  in ENTD convulsions ENTDEND induced by lindane in rats
0	The administration of ENTC L-arginine ENTCEND (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased ENTD convulsion ENTDEND incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i
0	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of ENTC lindane ENTCEND induced ENTD epilepsy ENTDEND in male Wistar albino rats
0	It evokes convulsions mainly trough the blockage of ENTC GABA ENTCEND (A) receptors. Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different ENTD epilepsy ENTDEND models
0	Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and ENTC L-NAME ENTCEND (NOS inhibitor) observed in different ENTD epilepsy ENTDEND models
0	The aim of the current study was to determine the effects of ENTC NO ENTCEND on the behavioral and EEG characteristics of lindane-induced ENTD epilepsy ENTDEND in male Wistar albino rats
0	The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced ENTD epilepsy ENTDEND  in male Wistar albino rats. The administration of ENTC L-arginine ENTCEND (600, 800 and 1000 mg/kg, i
1	Support for ENTC adrenaline ENTCEND ENTD hypertension ENTDEND hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion
0	Over the total postinfusion period systolic and diastolic arterial pressure were 6 (SEM 2)% and 7 (2)%, respectively, higher than after ENTC dextrose ENTCEND infusion (ANOVA, p less than 0.001). Thus, "stress" levels of adrenaline (230 pg/ml) for 6 h cause a delayed and protracted pressor effect. These findings are strong support for the adrenaline- ENTD hypertension ENTDEND hypothesis in man
0	Support for adrenaline- ENTD hypertension ENTDEND  hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion.In a double blind, crossover study 6 h infusions of adrenaline (15 ng/kg/min; 1 ng = 5.458 pmol), ENTC noradrenaline ENTCEND (30 ng/kg/min; 1 ng = 5
1	05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the ENTD convulsions ENTDEND induced by ENTC isoniazid ENTCEND (200 mg/kg s
0	injection to rats, abecarnil and ENTC diazepam ENTCEND decreased in a time-dependent and dose-related (0.25-20 mg/kg i.p.) manner [35S]TBPS binding measured ex vivo in the cerebral cortex. Moreover, both drugs at the dose of 0.5 mg/kg antagonized completely the convulsant activity and the increase of [35S]TBPS binding induced by isoniazide (350 mg/kg s.c.) as well as the increase of [35S]TBPS binding induced by foot-shock stress. To better correlate the biochemical and the pharmacological effects, we studied the action of abecarnil on [35S]TBPS binding, exploratory motility and on isoniazid-induced biochemical and pharmacological effects in mice. In these animals, abecarnil produced a paralleled dose-dependent (0.05-1 mg/kg i.p.) reduction of both motor behavior and cortical [35S]TBPS binding. Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the ENTD convulsions ENTDEND induced by isoniazid (200 mg/kg s
0	In these animals, ENTC abecarnil ENTCEND produced a paralleled dose-dependent (0.05-1 mg/kg i.p.) reduction of both motor behavior and cortical [35S]TBPS binding. Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the ENTD convulsions ENTDEND induced by isoniazid (200 mg/kg s
0	05 mg/kg of this ENTC beta-carboline ENTCEND reduced markedly the increase of [35S]TBPS binding and the ENTD convulsions ENTDEND induced by isoniazid (200 mg/kg s
0	05 mg/kg of this beta-carboline reduced markedly the increase of ENTC [35S]TBPS ENTCEND binding and the ENTD convulsions ENTDEND induced by isoniazid (200 mg/kg s
0	We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent ENTD prostate cancer ENTDEND  The mean time of study was 109 days (median 107, range 4-184 days). Patients underwent regular measurement of prostate-specific antigen (PSA), ENTC urea ENTCEND and electrolytes, serum bFGF and VEGF
0	An open-label phase II study of low-dose ENTC thalidomide ENTCEND  in androgen-independent ENTD prostate cancer ENTDEND
0	An open-label phase II study of low-dose thalidomide in ENTC androgen ENTCEND -independent ENTD prostate cancer ENTDEND
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENTC urea ENTCEND  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning drowsiness, dizziness and ENTD rash ENTDEND , and resulted in withdrawal from the study by three men
1	Adverse effects included constipation, morning drowsiness, dizziness and ENTD rash ENTDEND , and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENTC thalidomide ENTCEND , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENTC urea ENTCEND  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning ENTD drowsiness ENTDEND , dizziness and rash, and resulted in withdrawal from the study by three men
1	Adverse effects included constipation, morning ENTD drowsiness ENTDEND , dizziness and rash, and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENTC thalidomide ENTCEND , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENTC urea ENTCEND  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning drowsiness, dizziness and rash, and resulted in withdrawal from the study by three men. Evidence of ENTD peripheral sensory neuropathy ENTDEND was found in nine of 13 men before treatment
1	In the seven men who completed six months on ENTC thalidomide ENTCEND , subclinical evidence of ENTD peripheral neuropathy ENTDEND was found in four before treatment, but in all seven at repeat testing
0	The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and ENTD haematological malignancies ENTDEND  Thalidomide blocks the activity of angiogenic agents including bFGF, VEGF and IL-6. We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent prostate cancer. The mean time of study was 109 days (median 107, range 4-184 days). Patients underwent regular measurement of prostate-specific antigen (PSA), ENTC urea ENTCEND and electrolytes, serum bFGF and VEGF
0	The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and ENTD haematological malignancies ENTDEND . ENTC Thalidomide ENTCEND blocks the activity of angiogenic agents including bFGF, VEGF and IL-6
0	An open-label phase II study of low-dose thalidomide in ENTC androgen ENTCEND -independent prostate cancer.The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and ENTD haematological malignancies ENTDEND
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENTC urea ENTCEND  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included ENTD constipation ENTDEND , morning drowsiness, dizziness and rash, and resulted in withdrawal from the study by three men
1	Adverse effects included ENTD constipation ENTDEND , morning drowsiness, dizziness and rash, and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENTC thalidomide ENTCEND , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
0	Patients underwent regular measurement of prostate-specific antigen (PSA), ENTC urea ENTCEND  and electrolytes, serum bFGF and VEGF. Three men (15%) showed a decline in serum PSA of at least 50%, sustained throughout treatment. Of 16 men treated for at least 2 months, six (37.5%) showed a fall in absolute PSA by a median of 48%. Increasing levels of serum bFGF and VEGF were associated with progressive disease; five of six men who demonstrated a fall in PSA also showed a decline in bFGF and VEGF levels, and three of four men with a rising PSA showed an increase in both growth factors. Adverse effects included constipation, morning drowsiness, ENTD dizziness ENTDEND and rash, and resulted in withdrawal from the study by three men
1	Adverse effects included constipation, morning drowsiness, ENTD dizziness ENTDEND  and rash, and resulted in withdrawal from the study by three men. Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment. In the seven men who completed six months on ENTC thalidomide ENTCEND , subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing
1	Toxicity included embryolethality, teratogenicity, and ENTD growth retardation ENTDEND  Dermal administration of ENTC S-23121 ENTCEND at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121
1	BACKGROUND: ENTC S-53482 ENTCEND and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and ENTD growth retardation ENTDEND in rats in conventional oral developmental toxicity studies
1	Dermal administration of ENTC S-23121 ENTCEND  at 800 mg/kg resulted in an increased incidence of embryonic death and ENTD ventricular septal defect ENTDEND , but retarded fetal growth was not observed as it was following oral exposure to S-23121
1	BACKGROUND: ENTC S-53482 ENTCEND  and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ENTD ventricular septal defects ENTDEND and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
1	BACKGROUND: S-53482 and ENTC S-23121 ENTCEND are N-phenylimide herbicides and produced ENTD embryolethality ENTDEND , teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
1	BACKGROUND: ENTC S-53482 ENTCEND  and S-23121 are N-phenylimide herbicides and produced ENTD embryolethality ENTDEND , teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
0	Dermal developmental ENTD toxicity ENTDEND  of N-phenylimide herbicides in rats.BACKGROUND: S-53482 and ENTC S-23121 ENTCEND are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
0	Dermal developmental ENTD toxicity ENTDEND  of N-phenylimide herbicides in rats.BACKGROUND: ENTC S-53482 ENTCEND and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies
1	CONCLUSIONS: Based on the results, S-53482 and ENTC S-23121 ENTCEND were ENTD teratogenic ENTDEND when administered dermally to pregnant rats as were the compounds administered orally
1	CONCLUSIONS: Based on the results, ENTC S-53482 ENTCEND and S-23121 were ENTD teratogenic ENTDEND when administered dermally to pregnant rats as were the compounds administered orally
0	However, it would seem prudent not to use ENTC mefenamic acid ENTCEND in ENTD hypothyroid ENTDEND patients until the hypothyroidism has been corrected
1	ENTC Mefenamic acid ENTCEND -induced ENTD neutropenia ENTDEND and renal failure in elderly females with hypothyroidism
1	We report ENTC mefenamic acid ENTCEND induced non-oliguric ENTD renal failure ENTDEND and severe neutropenia occurring simultaneously in two elderly females
0	ENTC Fluoxetine ENTCEND  improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. ENTD Cancer ENTDEND patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition
0	Fluoxetine improves the memory deficits caused by the chemotherapy agent ENTC 5-fluorouracil ENTCEND ENTD Cancer ENTDEND patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition
0	ENTD Cancer ENTDEND  patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition. A widely used chemotherapeutic agent, 5-fluorouracil (5-FU), readily crosses the blood-brain barrier and so could have a direct effect on brain function. In particular this anti mitotic drug could reduce cell proliferation in the neurogenic regions of the adult brain. In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the ENTC SSRI ENTCEND antidepressant Fluoxetine
0	ENTC Fluoxetine ENTCEND  improves the ENTD memory deficits ENTDEND caused by the chemotherapy agent 5-fluorouracil
1	Fluoxetine improves the ENTD memory deficits ENTDEND  caused by the chemotherapy agent ENTC 5-fluorouracil ENTCEND
0	Fluoxetine improves the ENTD memory deficits ENTDEND  caused by the chemotherapy agent 5-fluorouracil.Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition. A widely used chemotherapeutic agent, 5-fluorouracil (5-FU), readily crosses the blood-brain barrier and so could have a direct effect on brain function. In particular this anti mitotic drug could reduce cell proliferation in the neurogenic regions of the adult brain. In contrast reports indicate that hippocampal dependent neurogenesis and cognition are enhanced by the ENTC SSRI ENTCEND antidepressant Fluoxetine
0	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENTC suxamethonium ENTCEND  The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a ENTD myotonic condition ENTDEND
0	Anaesthetic complications associated with myotonia congenita: case study and comparison with other ENTD myotonic disorders ENTDEND .Myotonia congenita (MC) is caused by a defect in the skeletal muscle ENTC chloride ENTCEND channel function, which may cause sustained membrane depolarisation
0	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENTC suxamethonium ENTCEND . The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a myotonic condition. ENTD Myotonia ENTDEND was found on clinical examination and EMG
0	Myotonia congenita (MC) is caused by a defect in the skeletal muscle ENTC chloride ENTCEND  channel function, which may cause sustained membrane depolarisation. We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium. The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a myotonic condition. ENTD Myotonia ENTDEND was found on clinical examination and EMG
0	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENTC suxamethonium ENTCEND . The muscle spasms disappeared spontaneously and the surgery proceeded without further problems. When subsequently questioned, she reported minor symptoms suggesting a myotonic condition. Myotonia was found on clinical examination and EMG. The diagnosis ENTD MC ENTDEND was confirmed genetically
0	Myotonia congenita ( ENTD MC ENTDEND  is caused by a defect in the skeletal muscle ENTC chloride ENTCEND channel function, which may cause sustained membrane depolarisation
1	We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of ENTC suxamethonium ENTCEND . The ENTD muscle spasms ENTDEND disappeared spontaneously and the surgery proceeded without further problems
0	Myotonia congenita (MC) is caused by a defect in the skeletal muscle ENTC chloride ENTCEND  channel function, which may cause sustained membrane depolarisation. We describe a previously healthy 32-year-old woman who developed a life-threatening ENTD muscle spasm ENTDEND and secondary ventilation difficulties following a preoperative injection of suxamethonium
0	Premedication of ENTC diazepam ENTCEND 10 mg and atropine 0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly ENTD pain ENTDEND and myoclonia, which caused the technique to be abandoned in two cases
1	The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly ENTD pain ENTDEND  and myoclonia, which caused the technique to be abandoned in two cases. It is considered unlikely that ENTC etomidate ENTCEND will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration
0	Premedication of diazepam 10 mg and ENTC atropine ENTCEND 0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly ENTD pain ENTDEND and myoclonia, which caused the technique to be abandoned in two cases
0	Premedication of ENTC diazepam ENTCEND  10 mg and atropine 0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly pain and ENTD myoclonia ENTDEND , which caused the technique to be abandoned in two cases
1	The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly pain and ENTD myoclonia ENTDEND , which caused the technique to be abandoned in two cases. It is considered unlikely that ENTC etomidate ENTCEND will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration
0	Premedication of diazepam 10 mg and ENTC atropine ENTCEND  0.5 mg was given, and sleep was induced and maintained by intermittent intravenous injections of etomidate 0.1/mg/kg, given whenever the patient would open his eyes on request. A mean overall dose of etomidate 17.4 microgram/kg/min. was required to maintain sleep, but great individual variation occurred, with older patients requiring less drug. The investigation was discontinued after 18 patients because of the frequency and intensity of side-effects, particularly pain and ENTD myoclonia ENTDEND , which caused the technique to be abandoned in two cases
0	DESIGN: Dose response curves for nonsedating doses of morphine and ENTC CNSB002 ENTCEND given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENTD pain ENTDEND models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENTD pain ENTDEND  models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: ENTC morphine ENTCEND , 3
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENTD pain ENTDEND  models: ENTC carrageenan ENTCEND -induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENTD pain ENTDEND  models: carrageenan-induced paw inflammation and ENTC streptozotocin ENTCEND (STZ)-induced diabetic neuropathy
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENTC sodium ENTCEND channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat ENTD pain ENTDEND models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced ENTD diabetic neuropathy ENTDEND  RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; ENTC CNSB002 ENTCEND 10
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced ENTD diabetic neuropathy ENTDEND . RESULTS: The maximum nonsedating doses were: ENTC morphine ENTCEND , 3
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: ENTC carrageenan ENTCEND -induced paw inflammation and streptozotocin (STZ)-induced ENTD diabetic neuropathy ENTDEND
1	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin ( ENTC STZ ENTCEND -induced ENTD diabetic neuropathy ENTDEND
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENTC sodium ENTCEND  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced ENTD diabetic neuropathy ENTDEND
0	Studies of synergy between morphine and a novel sodium channel blocker, ENTC CNSB002 ENTCEND , in rat models of inflammatory and ENTD neuropathic pain ENTDEND
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with ENTC morphine ENTCEND in rat models of inflammatory and ENTD neuropathic pain ENTDEND
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and ENTD neuropathic pain ENTDEND . DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: ENTC carrageenan ENTCEND -induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and ENTD neuropathic pain ENTDEND . DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and ENTC streptozotocin ENTCEND (STZ)-induced diabetic neuropathy
0	Studies of synergy between morphine and a novel ENTC sodium ENTCEND  channel blocker, CNSB002, in rat models of inflammatory and ENTD neuropathic pain ENTDEND
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENTD inflammation ENTDEND and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; ENTC CNSB002 ENTCEND 10
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENTD inflammation ENTDEND  and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: ENTC morphine ENTCEND , 3
1	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: ENTC carrageenan ENTCEND -induced paw ENTD inflammation ENTDEND and streptozotocin (STZ)-induced diabetic neuropathy
0	DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENTD inflammation ENTDEND  and ENTC streptozotocin ENTCEND (STZ)-induced diabetic neuropathy
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENTC sodium ENTCEND  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw ENTD inflammation ENTDEND and streptozotocin (STZ)-induced diabetic neuropathy
0	24) in the STZ-induced ENTD neuropathy ENTDEND model for ENTC CNSB002 ENTCEND and morphine, respectively (mg/kg; mean, SEM)
0	24) in the STZ-induced ENTD neuropathy ENTDEND  model for CNSB002 and ENTC morphine ENTCEND , respectively (mg/kg; mean, SEM)
0	55) in the ENTC carrageenan ENTCEND model and 1.37 (1.23) in the ENTD neuropathy ENTDEND model (mg/kg; mean, SEM)
0	24) in the ENTC STZ ENTCEND induced ENTD neuropathy ENTDEND model for CNSB002 and morphine, respectively (mg/kg; mean, SEM)
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENTC sodium ENTCEND  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination. The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced ENTD neuropathy ENTDEND model for CNSB002 and morphine, respectively (mg/kg; mean, SEM)
0	2 mg/kg) was increased by co-administration with ENTC CNSB002 ENTCEND from 28.0 and 31.7% to 114.6 and 56.9% reversal of ENTD hyperalgesia ENTDEND in the inflammatory and neuropathic models, respectively (P < 0
0	0 mg/kg CNSB002 with ENTC morphine ENTCEND 3.2 mg/kg in combination. The doses calculated to cause 50% reversal of ENTD hyperalgesia ENTDEND (ED50) were 7
1	The doses calculated to cause 50% reversal of ENTD hyperalgesia ENTDEND  (ED50) were 7.54 (1.81) and 4.83 (1.54) in the ENTC carrageenan ENTCEND model and 44
1	The doses calculated to cause 50% reversal of ENTD hyperalgesia ENTDEND  (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the ENTC STZ ENTCEND -induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM)
0	OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a ENTC sodium ENTCEND  channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain. DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy. RESULTS: The maximum nonsedating doses were: morphine, 3.2 mg/kg; CNSB002 10.0 mg/kg; 5.0 mg/kg CNSB002 with morphine 3.2 mg/kg in combination. The doses calculated to cause 50% reversal of ENTD hyperalgesia ENTDEND (ED50) were 7
0	Adverse effects included a mildly ENTD dry mouth ENTDEND and a sore throat in 2 patients (2% ENTC glycopyrrolate ENTCEND ), a light headache in 1 patient (1
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENTC aluminum chloride ENTCEND  and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis. After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%). All had reported incidents of being very embarrassed whilst eating hot spicy foods. Adverse effects included a mildly ENTD dry mouth ENTDEND and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1
0	All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal ENTD hyperhidrosis ENTDEND  After applying topical ENTC glycopyrrolate ENTCEND , the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%)
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENTC aluminum chloride ENTCEND , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal ENTD hyperhidrosis ENTDEND
1	Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% ENTC glycopyrrolate ENTCEND ), a light ENTD headache ENTDEND in 1 patient (1
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENTC aluminum chloride ENTCEND , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis. After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%). All had reported incidents of being very embarrassed whilst eating hot spicy foods. Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light ENTD headache ENTDEND in 1 patient (1
0	Treatment of compensatory gustatory hyperhidrosis with topical ENTC glycopyrrolate ENTCEND . ENTD Gustatory hyperhidrosis ENTDEND is facial sweating usually associated with the eating of hot spicy food or even smelling this food
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENTC aluminum chloride ENTCEND , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had ENTD gustatory hyperhidrosis ENTDEND , which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis
1	Adverse effects included a mildly dry mouth and a ENTD sore throat ENTDEND in 2 patients (2% ENTC glycopyrrolate ENTCEND ), a light headache in 1 patient (1
0	Current options of treatment include oral anticholinergic drugs, the topical application of anticholinergics or ENTC aluminum chloride ENTCEND , and the injection of botulinum toxin. Thirteen patients have been treated to date with 1.5% or 2% topical glycopyrrolate. All patients had gustatory hyperhidrosis, which interfered with their social activities, after transthroacic endoscopic sympathectomy, and which was associated with compensatory focal hyperhidrosis. After applying topical glycopyrrolate, the subjective effect was excellent (no sweating after eating hot spicy food) in 10 patients (77%), and fair (clearly reduced sweating) in 3 patients (23%). All had reported incidents of being very embarrassed whilst eating hot spicy foods. Adverse effects included a mildly dry mouth and a ENTD sore throat ENTDEND in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1
0	METHODS: Outcomes were examined in patients admitted for possible MI after ENTC cocaine ENTCEND use. All patients underwent a rapid rule-in protocol that included serial sampling of creatine kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, ENTD cardiac death ENTDEND , and significant coronary disease (>or=50%)
0	All patients underwent a rapid rule-in protocol that included serial sampling of ENTC creatine ENTCEND kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, ENTD cardiac death ENTDEND , and significant coronary disease (>or=50%)
0	Baseline electrocardiogram abnormalities and market elevations not associated with ENTD myocardial necrosis ENTDEND make accurate diagnosis of myocardial infarction (MI) difficult in patients with ENTC cocaine ENTCEND -associated chest pain
0	Baseline electrocardiogram abnormalities and market elevations not associated with ENTD myocardial necrosis ENTDEND  make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain. Troponin sampling may offer greater diagnostic utility in these patients. OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI. METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use. All patients underwent a rapid rule-in protocol that included serial sampling of ENTC creatine ENTCEND kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours
1	METHODS: Outcomes were examined in patients admitted for possible ENTD MI ENTDEND after ENTC cocaine ENTCEND use
0	All patients underwent a rapid rule-in protocol that included serial sampling of ENTC creatine ENTCEND  kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB ENTD MI ENTDEND (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, cardiac death, and significant coronary disease (>or=50%)
0	Troponin appears to have an equivalent diagnostic accuracy compared with CK-MB for diagnosing ENTD necrosis ENTDEND in patients with ENTC cocaine ENTCEND -associated chest pain and suspected MI
0	OBJECTIVE: To assess outcomes based on troponin positivity in patients with ENTC cocaine ENTCEND ENTD chest pain ENTDEND admitted for exclusion of MI
0	OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine ENTD chest pain ENTDEND  admitted for exclusion of MI. METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use. All patients underwent a rapid rule-in protocol that included serial sampling of ENTC creatine ENTCEND kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours
0	METHODS: Outcomes were examined in patients admitted for possible MI after ENTC cocaine ENTCEND  use. All patients underwent a rapid rule-in protocol that included serial sampling of creatine kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, cardiac death, and significant ENTD coronary disease ENTDEND (>or=50%)
0	All patients underwent a rapid rule-in protocol that included serial sampling of ENTC creatine ENTCEND  kinase (CK), CK-MB, and cardiac troponin I (cTnI) over eight hours. Outcomes included CK-MB MI (CK-MB >or= 8 ng/mL with a relative index [(CK-MB x 100)/total CK] >or= 4, cardiac death, and significant ENTD coronary disease ENTDEND (>or=50%)
0	We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENTD left ventricular dysfunction ENTDEND  Seven days of cocaine administration to rats led to an increased ENTC oxygen ENTCEND consumption detected in cardiac fibers, specifically through complex I and complex III
0	We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENTD left ventricular dysfunction ENTDEND . Seven days of ENTC cocaine ENTCEND administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III
0	We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENTD left ventricular dysfunction ENTDEND . Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ENTC ATP ENTCEND synthesis, whereas no difference was observed in subsarcolemmal mitochondria
0	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant ENTC MitoQ ENTCEND .The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction. We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause ENTD left ventricular dysfunction ENTDEND
0	The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced ENTD cardiac dysfunction ENTDEND  We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased ENTC oxygen ENTCEND consumption detected in cardiac fibers, specifically through complex I and complex III
1	Mitochondrial impairment contributes to ENTC cocaine ENTCEND -induced ENTD cardiac dysfunction ENTDEND : Prevention by the targeted antioxidant MitoQ
0	The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced ENTD cardiac dysfunction ENTDEND . We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ENTC ATP ENTCEND synthesis, whereas no difference was observed in subsarcolemmal mitochondria
0	Mitochondrial impairment contributes to cocaine-induced ENTD cardiac dysfunction ENTDEND : Prevention by the targeted antioxidant ENTC MitoQ ENTCEND
0	Seven days of cocaine administration to rats led to an increased ENTC oxygen ENTCEND  consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ATP synthesis, whereas no difference was observed in subsarcolemmal mitochondria. This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to cocaine, suggesting that these ENTD mitochondrial abnormalities ENTDEND were a late rather than a primary event in the pathological response to cocaine
0	ENTD Mitochondrial impairment ENTDEND  contributes to ENTC cocaine ENTCEND -induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ
0	In parallel there was a decrease in ENTC ATP ENTCEND  synthesis, whereas no difference was observed in subsarcolemmal mitochondria. This uncoupling effect on oxidative phosphorylation was not detectable after short-term exposure to cocaine, suggesting that these ENTD mitochondrial abnormalities ENTDEND were a late rather than a primary event in the pathological response to cocaine
0	ENTC MitoQ ENTCEND  a mitochondrial-targeted antioxidant, was shown to completely prevent these ENTD mitochondrial abnormalities ENTDEND as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure-volume data
0	We hypothesized that ENTD cocaine abuse ENTDEND may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased ENTC oxygen ENTCEND consumption detected in cardiac fibers, specifically through complex I and complex III
0	The goal of this study was to assess mitochondrial function and ROS production in an experimental model of ENTC cocaine ENTCEND induced cardiac dysfunction. We hypothesized that ENTD cocaine abuse ENTDEND may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction
0	We hypothesized that ENTD cocaine abuse ENTDEND  may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction. Seven days of cocaine administration to rats led to an increased oxygen consumption detected in cardiac fibers, specifically through complex I and complex III. ROS levels were increased, specifically in interfibrillar mitochondria. In parallel there was a decrease in ENTC ATP ENTCEND synthesis, whereas no difference was observed in subsarcolemmal mitochondria
0	Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant ENTC MitoQ ENTCEND .The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction. We hypothesized that ENTD cocaine abuse ENTDEND may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction
0	Bilateral basal ganglia infarcts after the use of cocaine, without concurrent ENTC heroin ENTCEND use, have never been reported. In our patient, transient ENTD cardiac arrhythmia ENTDEND or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient ENTD cardiac arrhythmia ENTDEND  or respiratory dysfunction related to ENTC cocaine ENTCEND and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient ENTD cardiac arrhythmia ENTDEND  or respiratory dysfunction related to cocaine and/or ENTC ethanol ENTCEND use were the most likely causes of cerebral hypoperfusion
0	Bilateral basal ganglia infarcts after the use of cocaine, without concurrent ENTC heroin ENTCEND  use, have never been reported. In our patient, transient cardiac arrhythmia or ENTD respiratory dysfunction ENTDEND related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient cardiac arrhythmia or ENTD respiratory dysfunction ENTDEND  related to ENTC cocaine ENTCEND and/or ethanol use were the most likely causes of cerebral hypoperfusion
0	In our patient, transient cardiac arrhythmia or ENTD respiratory dysfunction ENTDEND  related to cocaine and/or ENTC ethanol ENTCEND use were the most likely causes of cerebral hypoperfusion
1	Drug-related globus pallidus infarctions are most often associated with ENTC heroin ENTCEND  Bilateral ENTD basal ganglia infarcts ENTDEND after the use of cocaine, without concurrent heroin use, have never been reported
0	Bilateral ENTD basal ganglia infarcts ENTDEND  after the use of ENTC cocaine ENTCEND , without concurrent heroin use, have never been reported
0	Bilateral ENTD haemorrhagic infarction of the globus pallidus ENTDEND  after cocaine and ENTC alcohol ENTCEND intoxication
0	Cocaine is a risk factor for both ENTD ischemic and haemorrhagic stroke ENTDEND  We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENTC heroin ENTCEND
0	ENTC Cocaine ENTCEND is a risk factor for both ENTD ischemic and haemorrhagic stroke ENTDEND
1	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and ENTC alcohol ENTCEND  intoxication.Cocaine is a risk factor for both ENTD ischemic and haemorrhagic stroke ENTDEND
0	Cocaine is a risk factor for both ENTD ischemic and haemorrhagic stroke ENTDEND  We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENTC heroin ENTCEND
0	ENTC Cocaine ENTCEND  is a risk factor for both ENTD ischemic and haemorrhagic stroke ENTDEND
1	Bilateral haemorrhagic infarction of the globus pallidus after cocaine and ENTC alcohol ENTCEND  intoxication.Cocaine is a risk factor for both ENTD ischemic and haemorrhagic stroke ENTDEND
0	We present the case of a 31-year-old man with bilateral ENTD ischemia of the globus pallidus ENTDEND after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENTC heroin ENTCEND
1	We present the case of a 31-year-old man with bilateral ENTD ischemia of the globus pallidus ENTDEND  after excessive alcohol and intranasal ENTC cocaine ENTCEND use
0	We present the case of a 31-year-old man with bilateral ENTD ischemia of the globus pallidus ENTDEND  after excessive ENTC alcohol ENTCEND and intranasal cocaine use
0	Bilateral ENTD haemorrhagic infarction of the globus pallidus ENTDEND  after cocaine and alcohol intoxication.Cocaine is a risk factor for both ischemic and haemorrhagic stroke. We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use. Drug-related globus pallidus infarctions are most often associated with ENTC heroin ENTCEND
0	Bilateral ENTD haemorrhagic infarction of the globus pallidus ENTDEND  after ENTC cocaine ENTCEND and alcohol intoxication
0	Bilateral ENTD haemorrhagic infarction of the globus pallidus ENTDEND  after cocaine and ENTC alcohol ENTCEND intoxication
0	A 37-year-old Caucasian woman with a history of ENTD T-cell lymphoblastic lymphoma ENTDEND was admitted for relapsed disease. She was originally treated with induction chemotherapy followed by an autologous transplant. She developed relapsed disease 10 months later with leukemic involvement. She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENTC cytarabine ENTCEND 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	Severe ENTC nelarabine ENTCEND neurotoxicity in a patient who received concurrent intrathecal (IT) chemotherapy is reported. A 37-year-old Caucasian woman with a history of ENTD T-cell lymphoblastic lymphoma ENTDEND was admitted for relapsed disease
0	Severe nelarabine ENTD neurotoxicity ENTDEND in a patient who received concurrent intrathecal (IT) chemotherapy is reported. A 37-year-old Caucasian woman with a history of T-cell lymphoblastic lymphoma was admitted for relapsed disease. She was originally treated with induction chemotherapy followed by an autologous transplant. She developed relapsed disease 10 months later with leukemic involvement. She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENTC cytarabine ENTCEND 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	ENTC Nelarabine ENTCEND ENTD neurotoxicity ENTDEND with concurrent intrathecal chemotherapy: Case report and review of literature
0	She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENTC cytarabine ENTCEND  100 mg on day 2 as central nervous system (CNS) prophylaxis. At the time of treatment, she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome (TLS). She tolerated therapy well, entered a complete remission, and recovered her renal function. She received a second cycle of nelarabine without additional IT prophylaxis one month later. A week after this second cycle, she noted numbness in her lower extremities. Predominantly sensory, though also motor and autonomic, ENTD peripheral neuropathy ENTDEND started in her feet, ascended proximally to the mid-thoracic region, and eventually included her distal upper extremities
1	She received a second cycle of ENTC nelarabine ENTCEND without additional IT prophylaxis one month later. A week after this second cycle, she noted numbness in her lower extremities. Predominantly sensory, though also motor and autonomic, ENTD peripheral neuropathy ENTDEND started in her feet, ascended proximally to the mid-thoracic region, and eventually included her distal upper extremities
0	ENTC Nelarabine ENTCEND was felt to be the cause of her symptoms. Her ENTD neuropathy ENTDEND stabilized and showed slight improvement and ultimately received an unrelated, reduced-intensity allogeneic transplant while in complete remission, but relapsed disease 10 weeks later
0	She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENTC cytarabine ENTCEND  100 mg on day 2 as central nervous system (CNS) prophylaxis. At the time of treatment, she was on continuous renal replacement therapy due to sequelae of ENTD tumor lysis syndrome ENTDEND (TLS)
0	At the time of treatment, she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome ( ENTD TLS ENTDEND . She tolerated therapy well, entered a complete remission, and recovered her renal function. She received a second cycle of ENTC nelarabine ENTCEND without additional IT prophylaxis one month later
0	She developed relapsed disease 10 months later with ENTD leukemic ENTDEND involvement. She was re-induced with nelarabine 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT ENTC cytarabine ENTCEND 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	She developed relapsed disease 10 months later with ENTD leukemic ENTDEND  involvement. She was re-induced with ENTC nelarabine ENTCEND 1500 mg/m(2) on days 1, 3, and 5 with 1 dose of IT cytarabine 100 mg on day 2 as central nervous system (CNS) prophylaxis
0	Signs of ENTC FZP ENTCEND ENTD toxocity ENTDEND in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions
0	Signs of FZP ENTD toxocity ENTDEND  in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENTC pentylenetetrazol ENTCEND (PTZ) was shown by pretreating mice with FZP before PTZ challenge
1	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and ENTD convulsions ENTDEND  An interaction between ENTC FZP ENTCEND and pentylenetetrazol (PTZ) was shown by pretreating mice with FZP before PTZ challenge
1	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and ENTD convulsions ENTDEND . An interaction between FZP and ENTC pentylenetetrazol ENTCEND (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Signs of ENTC FZP ENTCEND  toxocity in cats included excessive ENTD salivation ENTDEND , extreme apprehensive behavior, retching, muscle tremors and convulsions
0	Signs of FZP toxocity in cats included excessive ENTD salivation ENTDEND , extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENTC pentylenetetrazol ENTCEND (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	These results may be relevant to the use of ENTC FZP ENTCEND in clinical situations in which there is increased neural excitability, such as ENTD epilepsy ENTDEND or sedative-hypnotic drug withdrawal
0	An interaction between FZP and pentylenetetrazol (PTZ) was shown by pretreating mice with FZP before ENTC PTZ ENTCEND challenge. As a function of dose, FZP first protected against convulsions and death. At higher doses, however, convulsions again emerged. These doses of FZP were lower than those that would alone cause convulsions. These results may be relevant to the use of FZP in clinical situations in which there is increased neural excitability, such as ENTD epilepsy ENTDEND or sedative-hypnotic drug withdrawal
0	Toxic actions of flurazepam ( ENTC FZP ENTCEND  were studied in cats, mice and rats. High doses caused an apparent central excitation, most clearly seen as clonic convulsions, superimposed on general ENTD depression ENTDEND
0	Comparing the relative sensitivity to central ENTD depression ENTDEND and excitation revealed that rats were least likely to have convulsions at doses that did not first cause loss of consciousness, while cats most clearly showed marked central excitatory actions. Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENTC pentylenetetrazol ENTCEND (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Comparing the relative sensitivity to central depression and excitation revealed that rats were least likely to have convulsions at doses that did not first cause ENTD loss of consciousness ENTDEND  while cats most clearly showed marked central excitatory actions. Signs of ENTC FZP ENTCEND toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions
0	Comparing the relative sensitivity to central depression and excitation revealed that rats were least likely to have convulsions at doses that did not first cause ENTD loss of consciousness ENTDEND , while cats most clearly showed marked central excitatory actions. Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions. An interaction between FZP and ENTC pentylenetetrazol ENTCEND (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, ENTD muscle tremors ENTDEND and convulsions. An interaction between ENTC FZP ENTCEND and pentylenetetrazol (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, ENTD muscle tremors ENTDEND  and convulsions. An interaction between FZP and ENTC pentylenetetrazol ENTCEND (PTZ) was shown by pretreating mice with FZP before PTZ challenge
0	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked ENTD hypersensitivity ENTDEND to the pressor effects of infused ENTC norepinephrine ENTCEND
0	They all exhibited markedly reduced plasma ENTC catecholamines ENTCEND and plasma renin activity in both recumbent and upright positions and had marked ENTD hypersensitivity ENTDEND to the pressor effects of infused norepinephrine
0	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked ENTD hypersensitivity ENTDEND  to the pressor effects of infused norepinephrine. Treatment with ENTC propanolol ENTCEND administered intravenously (1-5 mg) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11/6 to 22/11 mmHg
0	They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused ENTC norepinephrine ENTCEND . Treatment with propanolol administered intravenously (1-5 mg) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11/6 to 22/11 mmHg. Chronic oral administration of propranolol (40-160 mg/day) also elevated the blood pressures of these individuals with increases in the order of 20-35/15-25 mmg being observed. In 1 patient, marked ENTD hypertension ENTDEND was induced by propranolol and the drug had to be withdrawn
0	They all exhibited markedly reduced plasma ENTC catecholamines ENTCEND  and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine. Treatment with propanolol administered intravenously (1-5 mg) produced increases in supine and upright blood pressure in 4 of the 5 individuals with rises ranging from 11/6 to 22/11 mmHg. Chronic oral administration of propranolol (40-160 mg/day) also elevated the blood pressures of these individuals with increases in the order of 20-35/15-25 mmg being observed. In 1 patient, marked ENTD hypertension ENTDEND was induced by propranolol and the drug had to be withdrawn
1	In 1 patient, marked ENTD hypertension ENTDEND  was induced by ENTC propranolol ENTCEND and the drug had to be withdrawn
0	Five patients with ENTD idiopathic orthostatic hypotension ENTDEND who had physiologic and biochemical evidence of severe autonomic dysfunction were included in the study. They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused ENTC norepinephrine ENTCEND
0	Five patients with ENTD idiopathic orthostatic hypotension ENTDEND  who had physiologic and biochemical evidence of severe autonomic dysfunction were included in the study. They all exhibited markedly reduced plasma ENTC catecholamines ENTCEND and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine
0	Use of ENTC propranolol ENTCEND  in the treatment of ENTD idiopathic orthostatic hypotension ENTDEND
1	Eight patients stopped using ENTC GTN ENTCEND because ENTD headache ENTDEND --attributed to its use--became intolerable
0	Headache was significantly increased by GTN but not by ENTC DCF ENTCEND  Eight patients stopped using GTN because ENTD headache ENTDEND --attributed to its use--became intolerable
0	The difference in ENTD pain ENTDEND intensity score (DPI) was the main outcome variable. Both treatments significantly reduced DPI by the 30th minute ( ENTC GTN ENTCEND , -12
0	The difference in ENTD pain ENTDEND  intensity score (DPI) was the main outcome variable. Both treatments significantly reduced DPI by the 30th minute (GTN, -12.8 +/- 17.9; ENTC DCF ENTCEND , -18
0	Primary ENTD dysmenorrhea ENTDEND is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial ENTC prostaglandins ENTCEND ; non-steroidal anti-inflammatory drugs are the first choice for its treatment
0	The aim of the present study was to determine the efficacy of glyceryl trinitrate ( ENTC GTN ENTCEND , an NO donor, in the resolution of primary ENTD dysmenorrhea ENTDEND in comparison with diclofenac (DCF)
0	The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an ENTC NO ENTCEND donor, in the resolution of primary ENTD dysmenorrhea ENTDEND in comparison with diclofenac (DCF)
0	The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary ENTD dysmenorrhea ENTDEND  in comparison with ENTC diclofenac ENTCEND (DCF)
0	6 and after two hours: ENTC GTN ENTCEND  -23.7 +/- 20.5; DFC, -59.7 +/- 17.9, p = 0.0001). ENTD Low back pain ENTDEND was also relieved by both drugs
0	ENTD Low back pain ENTDEND  was also relieved by both drugs. Headache was significantly increased by GTN but not by ENTC DCF ENTCEND
0	However, DCF continued to be effective in reducing ENTD pelvic pain ENTDEND for two hours, whereas ENTC GTN ENTCEND scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12
0	However, ENTC DCF ENTCEND continued to be effective in reducing ENTD pelvic pain ENTDEND for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12
0	Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to ENTC VGB ENTCEND . Groups were matched with respect to age, gender, and ENTD seizure ENTDEND frequency
1	Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify ENTD retinal toxicity ENTDEND associated with ENTC VGB ENTCEND
0	This study investigated the visual defects associated with the antiepileptic drug vigabatrin ( ENTC VGB ENTCEND . Two hundred four people with ENTD epilepsy ENTDEND were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to VGB)
1	Assessment of retinal function revealed abnormal responses in 48% of current VGB users and 22% of prior VGB users, but in none of the patients without previous exposure to ENTC VGB ENTCEND  ENTD Bilateral visual field abnormalities ENTDEND are common in the treated epilepsy population, irrespective of drug history
0	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, ENTD congestive heart failure ENTDEND  deep hypothermic circulatory arrest, duration of aortic cross-clamp and ENTC tranexamic acid ENTCEND
0	Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep ENTD hypothermic ENTDEND circulatory arrest, duration of aortic cross-clamp and ENTC tranexamic acid ENTCEND
1	The association between ENTC tranexamic acid ENTCEND  and ENTD convulsive ENTDEND seizures after cardiac surgery: a multivariate analysis in 11 529 patients
0	The association between ENTC tranexamic acid ENTCEND  and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.Because of a lack of contemporary data regarding seizures after cardiac surgery, we undertook a retrospective analysis of prospectively collected data from 11 529 patients in whom cardiopulmonary bypass was used from January 2004 to December 2010. A convulsive seizure was defined as a transient episode of disturbed brain function characterised by ENTD abnormal involuntary motor movements ENTDEND
0	Convulsive seizures are a serious ENTD postoperative complication ENTDEND after cardiac surgery. As ENTC tranexamic acid ENTCEND is the only modifiable factor, its administration, particularly in doses exceeding 80 mg
0	Tobramycin was given to a total daily dose of 300 mg/m2 and ENTC carbenicillin ENTCEND was given at a dose of 5 gm every four hours. There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy. The overall cure rate was 70%. Pneumonia was the most common infection and 61% of 59 episodes were cured. Gram-negative bacilli were the most common causative organisms and 69% of these infections were cured. The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all ENTD gram-negative bacillary infections ENTDEND
0	The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all ENTD gram-negative bacillary infections ENTDEND . Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENTC creatinine ENTCEND greater than 2
0	The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all ENTD gram-negative bacillary infections ENTDEND . Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum creatinine greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%. Azotemia was not related to duration of therapy or serum ENTC tobramycin ENTCEND concentration
0	To overcome the adverse effects of ENTD neutropenia ENTDEND  tobramycin was given by continuous infusion and combined with intermittent ENTC carbenicillin ENTCEND
0	Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe ENTD neutropenia ENTDEND  However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENTC creatinine ENTCEND greater than 2
0	To overcome the adverse effects of ENTD neutropenia ENTDEND , ENTC tobramycin ENTCEND was given by continuous infusion and combined with intermittent carbenicillin
0	Continuous infusion tobramycin combined with ENTC carbenicillin ENTCEND  for infections in ENTD cancer ENTDEND patients
0	Continuous infusion ENTC tobramycin ENTCEND  combined with carbenicillin for infections in ENTD cancer ENTDEND patients
0	Continuous infusion tobramycin combined with ENTC carbenicillin ENTCEND  for ENTD infections ENTDEND in cancer patients
0	Gram-negative bacilli were the most common causative organisms and 69% of these ENTD infections ENTDEND were cured. The most common pathogen was Klebsiella pneumoniae and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all gram-negative bacillary infections. Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENTC creatinine ENTCEND greater than 2
0	Continuous infusion ENTC tobramycin ENTCEND  combined with carbenicillin for ENTD infections ENTDEND in cancer patients
0	Major ENTD azotemia ENTDEND (serum ENTC creatinine ENTCEND greater than 2
1	ENTD Azotemia ENTDEND was not related to duration of therapy or serum ENTC tobramycin ENTCEND concentration
0	Tobramycin was given to a total daily dose of 300 mg/m2 and ENTC carbenicillin ENTCEND  was given at a dose of 5 gm every four hours. There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy. The overall cure rate was 70%. ENTD Pneumonia ENTDEND was the most common infection and 61% of 59 episodes were cured
0	The most common pathogen was Klebsiella ENTD pneumoniae ENTDEND and this, together with Escherichia coli and Pseudomonas aeruginosa, accounted for 74% of all gram-negative bacillary infections. Response was not influenced by the initial neutrophil count, with a 62% cure rate for 39 episodes associated with severe neutropenia. However, failure of the neutrophil count to increase during therapy adversely affected response. Azotemia was the major side effect recognized, and it occurred in 11% of episodes. Major azotemia (serum ENTC creatinine ENTCEND greater than 2
0	ENTC Tobramycin ENTCEND was given to a total daily dose of 300 mg/m2 and carbenicillin was given at a dose of 5 gm every four hours. There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy. The overall cure rate was 70%. ENTD Pneumonia ENTDEND was the most common infection and 61% of 59 episodes were cured
0	Major azotemia (serum ENTC creatinine ENTCEND  greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%. Azotemia was not related to duration of therapy or serum tobramycin concentration. This antibiotic regimen showed both therapeutic efficacy and acceptable ENTD renal toxicity ENTDEND for these patients
0	Azotemia was not related to duration of therapy or serum ENTC tobramycin ENTCEND  concentration. This antibiotic regimen showed both therapeutic efficacy and acceptable ENTD renal toxicity ENTDEND for these patients
1	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with ENTD QT prolongation ENTDEND induced by dl- ENTC sotalol ENTCEND and azimilide
0	dl-Sotalol preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to ENTD QT prolongation ENTDEND and an increase in TDR. ENTC Azimilide ENTCEND , however, significantly prolonged APD and QT interval at concentrations from 0
1	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes ( ENTD TdP ENTDEND  with QT prolongation induced by dl ENTC sotalol ENTCEND and azimilide
0	BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes ( ENTD TdP ENTDEND ) with QT prolongation induced by dl-sotalol and ENTC azimilide ENTCEND
0	Phase 2 early afterdepolarization as a trigger of polymorphic ENTD ventricular tachycardia ENTDEND  in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl ENTC sotalol ENTCEND and azimilide
0	Phase 2 early afterdepolarization as a trigger of polymorphic ENTD ventricular tachycardia ENTDEND  in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and ENTC azimilide ENTCEND
1	708), ENTD bipolar disorder ENTDEND (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy ENTC methamphetamine ENTCEND uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors
0	It was associated with co-morbid ENTD affective disorder ENTDEND  antisocial personality, and heavy ENTC methamphetamine ENTCEND use
0	) for ENTC methamphetamine ENTCEND induced psychosis and other Axis I ENTD psychiatric disorders ENTDEND
1	It was associated with co-morbid affective disorder, ENTD antisocial personality ENTDEND  and heavy ENTC methamphetamine ENTCEND use
1	The risk and associated factors of ENTC methamphetamine ENTCEND ENTD psychosis ENTDEND in methamphetamine-dependent patients in Malaysia
0	759) and heavy methamphetamine uses were significantly associated with lifetime ENTC methamphetamine ENTCEND induced psychosis after adjusted for other factors. ENTD Major depressive disorder ENTDEND (OR=2
0	Co-morbid major ENTD depressive disorder ENTDEND (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy ENTC methamphetamine ENTCEND uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors
0	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine ( ENTC CBZ ENTCEND  and oxcarbazepine (OXC). We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial ENTD seizures ENTDEND can be elicited repeatedly on different days without changes in threshold or seizure patterns
1	In the animals treated with threshold doses of ENTC picrotoxin ENTCEND  the average number of ENTD seizures ENTDEND was 2
0	Eslicarbazepine acetate (BIA 2-093, S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine-5-carboxamide) is a novel antiepileptic drug, now in Phase III clinical trials, designed with the aim of improving efficacy and safety in comparison with the structurally related drugs carbamazepine (CBZ) and oxcarbazepine ( ENTC OXC ENTCEND . We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial ENTD seizures ENTDEND can be elicited repeatedly on different days without changes in threshold or seizure patterns
0	Anticonvulsant effect of eslicarbazepine acetate ( ENTC BIA 2-093 ENTCEND ) on ENTD seizures ENTDEND induced by microperfusion of picrotoxin in the hippocampus of freely moving rats
0	In patients with impaired renal and liver function, and those who need long-term ENTD pain ENTDEND control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term ENTD pain ENTDEND  control, ENTC pethidine ENTCEND may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its ENTD neurotoxic ENTDEND metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, ENTC pethidine ENTCEND  may cause excitatory central nervous system (CNS) effects through its ENTD neurotoxic ENTDEND metabolite, norpethidine, resulting in irritability and seizure attack
0	Common side effects include nausea, ENTD vomiting ENTDEND and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
1	Common side effects include nausea, ENTD vomiting ENTDEND  and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, ENTC pethidine ENTCEND may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	Common side effects include nausea, vomiting and ENTD hypotension ENTDEND  In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
1	Common side effects include nausea, vomiting and ENTD hypotension ENTDEND . In patients with impaired renal and liver function, and those who need long-term pain control, ENTC pethidine ENTCEND may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	In patients with ENTD impaired renal and liver function ENTDEND  and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
0	In patients with ENTD impaired renal and liver function ENTDEND , and those who need long-term pain control, ENTC pethidine ENTCEND may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in ENTD irritability ENTDEND and seizure attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in ENTD irritability ENTDEND  and seizure attack. On the contrary, though not clinically apparent, ENTC pethidine ENTCEND potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term
0	ENTD Cerebellar and oculomotor dysfunction ENTDEND  induced by rapid infusion of pethidine.Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors. However, rapid pain relief sometimes brings about unfavourable side effects that largely limit its clinical utility. Common side effects include nausea, vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
0	ENTD Cerebellar and oculomotor dysfunction ENTDEND  induced by rapid infusion of ENTC pethidine ENTCEND
0	ENTD Cerebellar and oculomotor dysfunction ENTDEND  induced by rapid infusion of pethidine.Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors. However, rapid pain relief sometimes brings about unfavourable side effects that largely limit its clinical utility. Common side effects include nausea, vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
0	ENTD Cerebellar and oculomotor dysfunction ENTDEND  induced by rapid infusion of ENTC pethidine ENTCEND
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack. On the contrary, though not clinically apparent, pethidine potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes ENTD dysmetria ENTDEND , dysarthria, reduced smooth pursuit gain and decreased saccadic velocity
1	On the contrary, though not clinically apparent, ENTC pethidine ENTCEND  potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes ENTD dysmetria ENTDEND , dysarthria, reduced smooth pursuit gain and decreased saccadic velocity
0	In patients with ENTD impaired renal and liver function ENTDEND  and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
0	In patients with ENTD impaired renal and liver function ENTDEND , and those who need long-term pain control, ENTC pethidine ENTCEND may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
0	Common side effects include ENTD nausea ENTDEND  vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack
1	Common side effects include ENTD nausea ENTDEND , vomiting and hypotension. In patients with impaired renal and liver function, and those who need long-term pain control, ENTC pethidine ENTCEND may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack
1	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and ENTD seizure ENTDEND attack
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and ENTD seizure ENTDEND  attack. On the contrary, though not clinically apparent, ENTC pethidine ENTCEND potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term
0	In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, ENTC norpethidine ENTCEND , resulting in irritability and seizure attack. On the contrary, though not clinically apparent, pethidine potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes dysmetria, ENTD dysarthria ENTDEND , reduced smooth pursuit gain and decreased saccadic velocity
1	On the contrary, though not clinically apparent, ENTC pethidine ENTCEND  potentially causes inhibitory impacts on the CNS and impairs normal cerebellar and oculomotor function in the short term. In this case report, we highlight opioid's inhibitory side effects on the cerebellar structure that causes dysmetria, ENTD dysarthria ENTDEND , reduced smooth pursuit gain and decreased saccadic velocity
1	The mechanism of doxorubicin ( ENTC DOX ENTCEND -induced ENTD cardiotoxicity ENTDEND remains controversial
0	Increased resistance to the oxidative stress is plausible for the multiple dose of ENTC DOX ENTCEND  Thus, different mechanisms may be involved in acute ENTD toxicity ENTDEND versus chronic toxicity
1	Single dose of ENTC DOX ENTCEND was associated with increased cardiac disarrangement, ENTD necrosis ENTDEND , and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP
0	Single dose of ENTC DOX ENTCEND  was associated with increased ENTD cardiac disarrangement ENTDEND , necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP
0	levodopa were examined in ENTD parkinsonian ENTDEND patients with stable and fluctuating responses to levodopa. The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders. Stable responders demonstrated a small hypotensive response. Baseline blood pressures were higher in fluctuating patients; a higher baseline blood pressure correlated with greater hypotensive effects. Antiparkinsonian effects of levodopa temporally correlated with blood pressure changes. ENTC Phenylalanine ENTCEND , a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa
0	levodopa were examined in ENTD parkinsonian ENTDEND  patients with stable and fluctuating responses to levodopa. The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders. Stable responders demonstrated a small hypotensive response. Baseline blood pressures were higher in fluctuating patients; a higher baseline blood pressure correlated with greater hypotensive effects. Antiparkinsonian effects of levodopa temporally correlated with blood pressure changes. Phenylalanine, a large neutral ENTC amino acid ENTCEND (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa
0	Pharmacodynamics of the hypotensive effect of ENTC levodopa ENTCEND  in ENTD parkinsonian ENTDEND patients
0	Baseline blood pressures were higher in fluctuating patients; a higher baseline blood pressure correlated with greater ENTD hypotensive ENTDEND effects. Antiparkinsonian effects of levodopa temporally correlated with blood pressure changes. ENTC Phenylalanine ENTCEND , a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa
0	Phenylalanine, a large neutral ENTC amino acid ENTCEND  (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the ENTD hypotensive ENTDEND and antiparkinsonian effects of levodopa
1	Pharmacodynamics of the ENTD hypotensive ENTDEND  effect of ENTC levodopa ENTCEND in parkinsonian patients
0	ENTD Hypoxaemia ENTDEND resolved quickly on inhaled ENTC nitric oxide ENTCEND therapy
1	We report three cases of severe ENTD hypoxaemia ENTDEND after ENTC ibuprofen ENTCEND administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation
0	We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of ENTD patent ductus arteriosus ENTDEND with ibuprofen in premature infants born at less than 28 weeks of gestation. Echocardiography showed severely decreased pulmonary blood flow. Hypoxaemia resolved quickly on inhaled ENTC nitric oxide ENTCEND therapy
0	We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of ENTD patent ductus arteriosus ENTDEND  with ENTC ibuprofen ENTCEND in premature infants born at less than 28 weeks of gestation
0	ENTD Pulmonary hypertension ENTDEND  after ibuprofen prophylaxis in very preterm infants.We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation. Echocardiography showed severely decreased pulmonary blood flow. Hypoxaemia resolved quickly on inhaled ENTC nitric oxide ENTCEND therapy
1	ENTD Pulmonary hypertension ENTDEND  after ENTC ibuprofen ENTCEND prophylaxis in very preterm infants
0	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from ENTD acute lymphoblastic leukemia ENTDEND treated with high-dose ENTC methotrexate ENTCEND
1	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing ENTD leukoencephalopathy ENTDEND  which developed from acute lymphoblastic leukemia treated with high-dose ENTC methotrexate ENTCEND
1	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose ENTC methotrexate ENTCEND . In both patients, the enhancement was more pronounced near the base of the brain than at the vertex. Necropsy of the first case revealed loss of myelination and ENTD necrosis ENTDEND of the white matter
1	This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose ENTC methotrexate ENTCEND . In both patients, the enhancement was more pronounced near the base of the brain than at the vertex. Necropsy of the first case revealed ENTD loss of myelination ENTDEND and necrosis of the white matter
1	ENTD Pulmonary edema ENTDEND  and shock after high-dose ENTC aracytine-C ENTCEND for lymphoma; possible role of TNF-alpha and PAF
1	It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, acute renal failure, metabolic acidosis, ENTD weight gain ENTDEND and leukocytosis. Thorough bacteriological screening failed to provide evidence of infection. Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENTC Ara-C ENTCEND infusion to ten patients, including the four who developed the syndrome
1	Four out of 23 consecutive patients treated with high-dose ENTC Ara-C ENTCEND for lymphomas in our institution developed a strikingly similar syndrome during the perfusion. It was characterized by the onset of ENTD fever ENTDEND , diarrhea, shock, pulmonary edema, acute renal failure, metabolic acidosis, weight gain and leukocytosis
1	Pulmonary edema and ENTD shock ENTDEND  after high-dose ENTC aracytine-C ENTCEND for lymphoma; possible role of TNF-alpha and PAF
1	It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, acute renal failure, ENTD metabolic acidosis ENTDEND  weight gain and leukocytosis. Thorough bacteriological screening failed to provide evidence of infection. Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENTC Ara-C ENTCEND infusion to ten patients, including the four who developed the syndrome
0	Thorough bacteriological screening failed to provide evidence of ENTD infection ENTDEND  Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENTC Ara-C ENTCEND infusion to ten patients, including the four who developed the syndrome
1	It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, acute renal failure, metabolic acidosis, weight gain and ENTD leukocytosis ENTDEND  Thorough bacteriological screening failed to provide evidence of infection. Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during ENTC Ara-C ENTCEND infusion to ten patients, including the four who developed the syndrome
1	Four out of 23 consecutive patients treated with high-dose ENTC Ara-C ENTCEND  for lymphomas in our institution developed a strikingly similar syndrome during the perfusion. It was characterized by the onset of fever, diarrhea, shock, pulmonary edema, ENTD acute renal failure ENTDEND , metabolic acidosis, weight gain and leukocytosis
0	Four out of 23 consecutive patients treated with high-dose ENTC Ara-C ENTCEND  for ENTD lymphomas ENTDEND in our institution developed a strikingly similar syndrome during the perfusion
1	Four out of 23 consecutive patients treated with high-dose ENTC Ara-C ENTCEND  for lymphomas in our institution developed a strikingly similar syndrome during the perfusion. It was characterized by the onset of fever, ENTD diarrhea ENTDEND , shock, pulmonary edema, acute renal failure, metabolic acidosis, weight gain and leukocytosis
0	As TNF and PAF are thought to be involved in the development of septic shock and ENTD adult respiratory distress syndrome ENTDEND  we hypothesize that high-dose ENTC Ara-C ENTCEND may be associated with cytokine release
0	Antitumor effect, ENTD cardiotoxicity ENTDEND , and nephrotoxicity of ENTC doxorubicin ENTCEND in the IgM solid immunocytoma-bearing LOU/M/WSL rat
0	Complete disappearance of the ENTD tumor ENTDEND was induced with 1.0 mg ENTC doxorubicin ENTCEND /kg
1	0 mg ENTC doxorubicin ENTCEND kg, the serum albumin level decreased from 33.6 +/- 4.1 to 1.5 +/- 0.5 g/liter. ENTD Ascites ENTDEND and hydrothorax were observed simultaneously
1	5 mg ENTC doxorubicin ENTCEND kg, which resulted in ENTD albuminuria ENTDEND and very low serum albumin levels
1	0 mg ENTC doxorubicin ENTCEND /kg, the serum albumin level decreased from 33.6 +/- 4.1 to 1.5 +/- 0.5 g/liter. Ascites and ENTD hydrothorax ENTDEND were observed simultaneously
0	0 mg ENTC doxorubicin ENTCEND /kg, the serum albumin level decreased from 33.6 +/- 4.1 to 1.5 +/- 0.5 g/liter. Ascites and hydrothorax were observed simultaneously. The same experiments were performed with non-tumor-bearing rats, in which no major differences were observed. In conclusion, antitumor activity, cardiotoxicity, and nephrotoxicity were studied simultaneously in the same LOU/M/WSL rat. Albuminuria due to renal damage led to extremely low serum albumin levels, so ascites and hydrothorax were not necessarily a consequence of the observed ENTD cardiomyopathy ENTDEND
0	Antitumor effect, cardiotoxicity, and ENTD nephrotoxicity ENTDEND  of ENTC doxorubicin ENTCEND in the IgM solid immunocytoma-bearing LOU/M/WSL rat
0	Her medications included desvenlafaxine, and symptoms included ENTD nausea ENTDEND  anxiety and confusion. The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH. Desvenlafaxine was ceased and fluid restriction implemented. After 4 days the sodium increased to 128 mmol/L and fluid restriction was relaxed. During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENTC mirtazapine ENTCEND
1	Her medications included ENTC desvenlafaxine ENTCEND  and symptoms included ENTD nausea ENTDEND , anxiety and confusion
0	Her medications included desvenlafaxine, and symptoms included ENTD nausea ENTDEND , anxiety and confusion. The serum ENTC sodium ENTCEND at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENTC mirtazapine ENTCEND . DISCUSSION: SIADH has been widely reported with a range of antidepressants. This case report suggests that desvenlafaxine might cause clinically significant ENTD hyponatremia ENTDEND
1	CASE SUMMARY: A 57-year old female with ENTD hyponatraemia ENTDEND  Her medications included ENTC desvenlafaxine ENTCEND , and symptoms included nausea, anxiety and confusion
0	CASE SUMMARY: A 57-year old female with ENTD hyponatraemia ENTDEND . Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion. The serum ENTC sodium ENTCEND at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	Her medications included desvenlafaxine, and symptoms included nausea, anxiety and ENTD confusion ENTDEND  The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH. Desvenlafaxine was ceased and fluid restriction implemented. After 4 days the sodium increased to 128 mmol/L and fluid restriction was relaxed. During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENTC mirtazapine ENTCEND
1	Her medications included ENTC desvenlafaxine ENTCEND , and symptoms included nausea, anxiety and ENTD confusion ENTDEND
0	Her medications included desvenlafaxine, and symptoms included nausea, anxiety and ENTD confusion ENTDEND . The serum ENTC sodium ENTCEND at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENTC mirtazapine ENTCEND . DISCUSSION: ENTD SIADH ENTDEND has been widely reported with a range of antidepressants
1	The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of ENTD SIADH ENTDEND  ENTC Desvenlafaxine ENTCEND was ceased and fluid restriction implemented
0	The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine ENTC sodium ENTCEND 63 mmol/L, consistent with a diagnosis of ENTD SIADH ENTDEND
0	Her medications included desvenlafaxine, and symptoms included nausea, ENTD anxiety ENTDEND and confusion. The serum sodium at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH. Desvenlafaxine was ceased and fluid restriction implemented. After 4 days the sodium increased to 128 mmol/L and fluid restriction was relaxed. During her further 3 weeks inpatient admission the serum sodium ranged from 134 to 137 mmol/L during treatment with ENTC mirtazapine ENTCEND
1	Her medications included ENTC desvenlafaxine ENTCEND , and symptoms included nausea, ENTD anxiety ENTDEND and confusion
0	Her medications included desvenlafaxine, and symptoms included nausea, ENTD anxiety ENTDEND  and confusion. The serum ENTC sodium ENTCEND at this time was 120 mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH
0	For example, the symptoms of ENTD RLS ENTDEND can be dramatically improved by levodopa and ENTC dopamine ENTCEND agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms
0	For example, the symptoms of ENTD RLS ENTDEND  can be dramatically improved by ENTC levodopa ENTCEND and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms
0	Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of ENTC domperione ENTCEND on mirtazapine-associated ENTD RLS ENTDEND
1	To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of ENTD RLS ENTDEND  ENTC Mirtazapine ENTCEND , the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications
0	To our knowledge, there is no previous report regarding whether domperidone, a peripheral ENTC dopamine ENTCEND D2 receptor antagonist, can also induce or aggravate symptoms of RLS. Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications. The authors report here a depressed patient comorbid with ENTD postprandial dyspepsia ENTDEND who developed RLS after mirtazapine had been added to his domperidone therapy
0	For example, the symptoms of RLS can be dramatically improved by ENTC levodopa ENTCEND  and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms. To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS. Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications. The authors report here a depressed patient comorbid with ENTD postprandial dyspepsia ENTDEND who developed RLS after mirtazapine had been added to his domperidone therapy
0	The authors report here a depressed patient comorbid with ENTD postprandial dyspepsia ENTDEND  who developed RLS after mirtazapine had been added to his ENTC domperidone ENTCEND therapy
0	The authors report here a depressed patient comorbid with ENTD postprandial dyspepsia ENTDEND  who developed RLS after ENTC mirtazapine ENTCEND had been added to his domperidone therapy
1	Five cases of encephalitis during treatment of loiasis with ENTC diethylcarbamazine ENTCEND .Five cases of ENTD encephalitis ENTDEND following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis
0	Five cases of encephalitis during treatment of ENTD loiasis ENTDEND  with ENTC diethylcarbamazine ENTCEND
0	Five cases of encephalitis following treatment with diethylcarbamazine ( ENTC DEC ENTCEND  were observed in Congolese patients with Loa loa ENTD filariasis ENTDEND
1	Pituitary response to luteinizing hormone-releasing hormone during ENTC haloperidol ENTCEND -induced ENTD hyperprolactinemia ENTDEND
0	9% ENTC NaCl ENTCEND solution. During the course of haloperidol infusions, significant ENTD hyperprolactinemia ENTDEND was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects
1	In six dogs with ENTC doxorubicin ENTCEND induced ENTD heart failure ENTDEND , VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0
0	In six dogs with doxorubicin-induced ENTD heart failure ENTDEND , VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENTC catecholamines ENTCEND were also determined in 14 subjects; a weak correlation (r = 0
0	Myocardial levels of VIP were assayed before and after the development of ENTD heart failure ENTDEND in two canine models. In the first, ENTC cobalt ENTCEND cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0
0	In six dogs with doxorubicin-induced ENTD heart failure ENTDEND , VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENTC norepinephrine ENTCEND was noted
0	In the first, cobalt ENTD cardiomyopathy ENTDEND was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with ENTC doxorubicin ENTCEND -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0
1	In the first, ENTC cobalt ENTCEND ENTD cardiomyopathy ENTDEND was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0
0	In six dogs with ENTC doxorubicin ENTCEND -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENTD rheumatic disease ENTDEND , nine with myxomatous degeneration) receiving mitral valve prostheses
0	In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENTD rheumatic disease ENTDEND , nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENTC catecholamines ENTCEND were also determined in 14 subjects; a weak correlation (r = 0
0	In the first, ENTC cobalt ENTCEND  cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENTD rheumatic disease ENTDEND , nine with myxomatous degeneration) receiving mitral valve prostheses
0	In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with ENTD rheumatic disease ENTDEND , nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without coronary artery disease (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENTC norepinephrine ENTCEND was noted
0	In six dogs with ENTC doxorubicin ENTCEND -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with ENTD coronary disease ENTDEND (one patient receiving a transplant and three receiving mitral prostheses) (6
0	9 pg/mg protein, and this was greater than in hearts of the patients with ENTD coronary disease ENTDEND and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENTC catecholamines ENTCEND were also determined in 14 subjects; a weak correlation (r = 0
0	In the first, ENTC cobalt ENTCEND  cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with ENTD coronary disease ENTDEND (one patient receiving a transplant and three receiving mitral prostheses) (6
0	9 pg/mg protein, and this was greater than in hearts of the patients with ENTD coronary disease ENTDEND  and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENTC norepinephrine ENTCEND was noted
0	In six dogs with ENTC doxorubicin ENTCEND -induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without ENTD coronary artery disease ENTDEND (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14
0	The hearts without ENTD coronary artery disease ENTDEND  (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial ENTC catecholamines ENTCEND were also determined in 14 subjects; a weak correlation (r = 0
0	In the first, ENTC cobalt ENTCEND  cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/- 11 pg/mg protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P less than 0.05). In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than 0.05). In addition, VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients (five with rheumatic disease, nine with myxomatous degeneration) receiving mitral valve prostheses. The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease (one patient receiving a transplant and three receiving mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The other patients undergoing transplantation had an average ejection fraction of 17% +/- 6% and a VIP level of 8.8 +/- 3.9 pg/mg protein. The hearts without ENTD coronary artery disease ENTDEND (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14
0	The hearts without ENTD coronary artery disease ENTDEND  (average ejection fraction of this group 62% +/- 10%) had a VIP concentration of 14.1 +/- 7.9 pg/mg protein, and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant (P less than 0.05). Myocardial catecholamines were also determined in 14 subjects; a weak correlation (r = 0.57, P less than 0.05) between the tissue concentrations of VIP and ENTC norepinephrine ENTCEND was noted
0	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of ENTD Pb poisoning ENTDEND  RESULTS: ENTC Pb ENTCEND exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children
0	OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with ENTC succimer ENTCEND  a widely used chelating agent for the treatment of ENTD Pb poisoning ENTDEND
1	RESULTS: ENTC Pb ENTCEND  exposure produced lasting ENTD impairments in learning, attention, inhibitory control, and arousal regulation ENTDEND , paralleling the areas of dysfunction seen in Pb-exposed children
0	RESULTS: Pb exposure produced lasting ENTD impairments in learning, attention, inhibitory control, and arousal regulation ENTDEND , paralleling the areas of dysfunction seen in Pb-exposed children. ENTC Succimer ENTCEND treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit
1	RESULTS: ENTC Pb ENTCEND  exposure produced lasting ENTD impairments in learning, attention, inhibitory control, and arousal regulation ENTDEND , paralleling the areas of dysfunction seen in Pb-exposed children
0	RESULTS: Pb exposure produced lasting ENTD impairments in learning, attention, inhibitory control, and arousal regulation ENTDEND , paralleling the areas of dysfunction seen in Pb-exposed children. ENTC Succimer ENTCEND treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit
0	CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate ENTD cognitive deficits ENTDEND due to ENTC Pb ENTCEND exposure
1	CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate ENTD cognitive deficits ENTDEND  due to Pb exposure. These findings suggest that it may be possible to identify a ENTC succimer ENTCEND treatment protocol that improves cognitive outcomes in Pb-exposed children
0	In contrast, succimer treatment of rats not previously exposed to ENTC Pb ENTCEND produced lasting and pervasive ENTD cognitive and affective dysfunction ENTDEND comparable in magnitude to that produced by the higher Pb exposure regimen
0	In contrast, ENTC succimer ENTCEND treatment of rats not previously exposed to Pb produced lasting and pervasive ENTD cognitive and affective dysfunction ENTDEND comparable in magnitude to that produced by the higher Pb exposure regimen
0	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of ENTC 5-fluorouracil ENTCEND  with the complication of dehydration and ENTD infection ENTDEND
0	Among the 32 episodes, 26 (81%) had various degrees of azotemia, 18 (56%) occurred during bacterial infections and 14 (44%) without ENTD infection ENTDEND occurred during periods of dehydration. Higher plasma ENTC ammonium ENTCEND levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0
0	In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of ENTC 5-FU ENTCEND  Azotemia, body fluid insufficiency and ENTD bacterial infections ENTDEND were frequently found in these patients
0	Higher plasma ENTC ammonium ENTCEND  levels and more rapid onset of hyperammonemia were seen in 18 patients with ENTD bacterial infections ENTDEND (p=0
0	Risk of transient hyperammonemic encephalopathy in ENTD cancer ENTDEND  patients who received continuous infusion of ENTC 5-fluorouracil ENTCEND with the complication of dehydration and infection
0	From 1986 to 1998, 29 ENTD cancer ENTDEND patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified. None of the patients had decompensated liver disease. Onset of hyperammonemic encephalopathy varied from 0.5 to 5 days (mean: 2.6 +/- 1.3 days) after the initiation of chemotherapy. Plasma ENTC ammonium ENTCEND level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%)
1	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient ENTD hyperammonemic encephalopathy ENTDEND related to continuous infusion of ENTC 5-fluorouracil ENTCEND (5-FU) were identified
0	Higher plasma ENTC ammonium ENTCEND  levels and more rapid onset of ENTD hyperammonemia ENTDEND were seen in 18 patients with bacterial infections (p=0
0	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil ( ENTC 5-FU ENTCEND  were identified. None of the patients had decompensated ENTD liver disease ENTDEND
0	None of the patients had decompensated ENTD liver disease ENTDEND . Onset of hyperammonemic encephalopathy varied from 0.5 to 5 days (mean: 2.6 +/- 1.3 days) after the initiation of chemotherapy. Plasma ENTC ammonium ENTCEND level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%)
1	From 1986 to 1998, 29 cancer patients who had 32 episodes of transient ENTD hyperammonemic encephalopathy ENTDEND related to continuous infusion of ENTC 5-fluorouracil ENTCEND (5-FU) were identified
0	Onset of ENTD hyperammonemic encephalopathy ENTDEND varied from 0.5 to 5 days (mean: 2.6 +/- 1.3 days) after the initiation of chemotherapy. Plasma ENTC ammonium ENTCEND level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%)
0	Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of ENTC 5-fluorouracil ENTCEND  with the complication of ENTD dehydration ENTDEND and infection
0	Among the 32 episodes, 26 (81%) had various degrees of azotemia, 18 (56%) occurred during bacterial infections and 14 (44%) without infection occurred during periods of ENTD dehydration ENTDEND  Higher plasma ENTC ammonium ENTCEND levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0
0	In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of ENTC 5-FU ENTCEND . ENTD Azotemia ENTDEND , body fluid insufficiency and bacterial infections were frequently found in these patients
0	Plasma ENTC ammonium ENTCEND  level ranged from 248 to 2387 microg% (mean: 626 +/- 431 microg%). Among the 32 episodes, 26 (81%) had various degrees of ENTD azotemia ENTDEND , 18 (56%) occurred during bacterial infections and 14 (44%) without infection occurred during periods of dehydration
0	Neither patient developed signs of ENTD cardiovascular toxicity ENTDEND  Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of ENTC levobupivacaine ENTCEND with epinephrine
0	5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous ENTC epinephrine ENTCEND administration. The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient. Neither patient developed signs of ENTD cardiovascular toxicity ENTDEND
0	The seizures were successfully treated with ENTC sodium thiopental ENTCEND in addition to succinylcholine in 1 patient. Neither patient developed signs of ENTD cardiovascular toxicity ENTDEND
0	The seizures were successfully treated with sodium thiopental in addition to ENTC succinylcholine ENTCEND in 1 patient. Neither patient developed signs of ENTD cardiovascular toxicity ENTDEND
0	Neither patient developed signs of ENTD cardiovascular toxicity ENTDEND . Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic ENTC bupivacaine ENTCEND , if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	CONCLUSIONS: Although ENTC levobupivacaine ENTCEND may have a safer ENTD cardiac toxicity ENTDEND profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with ENTC epinephrine ENTCEND  CONCLUSIONS: Although levobupivacaine may have a safer ENTD cardiac toxicity ENTDEND profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	The seizures were successfully treated with ENTC sodium thiopental ENTCEND  in addition to succinylcholine in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer ENTD cardiac toxicity ENTDEND profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	The seizures were successfully treated with sodium thiopental in addition to ENTC succinylcholine ENTCEND  in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer ENTD cardiac toxicity ENTDEND profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	CONCLUSIONS: Although levobupivacaine may have a safer ENTD cardiac toxicity ENTDEND  profile than racemic ENTC bupivacaine ENTCEND , if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions
0	ENTD Central nervous system toxicity ENTDEND  following the administration of ENTC levobupivacaine ENTCEND for lumbar plexus block: A report of two cases
0	Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with ENTC epinephrine ENTCEND . CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENTD central nervous system toxicity ENTDEND did not produce manifestations of cardiac toxicity in these 2 patients
0	The seizures were successfully treated with ENTC sodium thiopental ENTCEND  in addition to succinylcholine in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENTD central nervous system toxicity ENTDEND did not produce manifestations of cardiac toxicity in these 2 patients
0	The seizures were successfully treated with sodium thiopental in addition to ENTC succinylcholine ENTCEND  in 1 patient. Neither patient developed signs of cardiovascular toxicity. Both patients were treated preoperatively with beta-adrenergic antagonist medications, which may have masked the cardiovascular signs of the unintentional intravascular administration of levobupivacaine with epinephrine. CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENTD central nervous system toxicity ENTDEND did not produce manifestations of cardiac toxicity in these 2 patients
0	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic ENTC bupivacaine ENTCEND , if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions. Plasma concentrations sufficient to result in ENTD central nervous system toxicity ENTDEND did not produce manifestations of cardiac toxicity in these 2 patients
0	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of ENTC levobupivacaine ENTCEND reach the circulation, it will result in ENTD convulsions ENTDEND
0	5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous ENTC epinephrine ENTCEND  administration. The ENTD seizures ENTDEND were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient
0	The ENTD seizures ENTDEND  were successfully treated with ENTC sodium thiopental ENTCEND in addition to succinylcholine in 1 patient
0	The ENTD seizures ENTDEND  were successfully treated with sodium thiopental in addition to ENTC succinylcholine ENTCEND in 1 patient
0	CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic ENTC bupivacaine ENTCEND , if adequate amounts of levobupivacaine reach the circulation, it will result in ENTD convulsions ENTDEND
1	We describe 2 cases of ENTD grand mal seizures ENTDEND following accidental intravascular injection of ENTC levobupivacaine ENTCEND
0	5% with ENTC epinephrine ENTCEND 2.5 microgram/mL, the patients developed ENTD grand mal seizures ENTDEND , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration
0	5 microgram/mL, the patients developed ENTD grand mal seizures ENTDEND , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration. The seizures were successfully treated with ENTC sodium thiopental ENTCEND in addition to succinylcholine in 1 patient
0	5 microgram/mL, the patients developed ENTD grand mal seizures ENTDEND , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration. The seizures were successfully treated with sodium thiopental in addition to ENTC succinylcholine ENTCEND in 1 patient
0	Levobupivacaine, the pure S(-) enantiomer of bupivacaine, was developed to improve the cardiac safety profile of ENTC bupivacaine ENTCEND  We describe 2 cases of ENTD grand mal seizures ENTDEND following accidental intravascular injection of levobupivacaine
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin ( ENTC ADR ENTCEND -induced ENTD cardiotoxicity ENTDEND actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/ ENTC nitrogen ENTCEND species (RNS) reported to be present in adriamycin (ADR)-induced ENTD cardiotoxicity ENTDEND actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	The purpose of the present study was to determine if elevated reactive ENTC oxygen ENTCEND (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced ENTD cardiotoxicity ENTDEND actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced ENTD cardiotoxicity ENTDEND  actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach. B6C3 mice were treated with a single dose of 20 mg/kg ADR. Ultrastructural damage and levels of ENTC 4-hydroxy-2-nonenal ENTCEND (4HNE)-protein adducts and 3-nitrotyrosine (3NT) were analyzed
0	The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced ENTD cardiotoxicity ENTDEND  actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach. B6C3 mice were treated with a single dose of 20 mg/kg ADR. Ultrastructural damage and levels of 4-hydroxy-2-nonenal (4HNE)-protein adducts and ENTC 3-nitrotyrosine ENTCEND (3NT) were analyzed
1	Oxidative damage precedes nitrative damage in ENTC adriamycin ENTCEND -induced cardiac ENTD mitochondrial injury ENTDEND
0	Oxidative damage precedes nitrative damage in adriamycin-induced cardiac ENTD mitochondrial injury ENTDEND .The purpose of the present study was to determine if elevated reactive oxygen (ROS) ENTC nitrogen ENTCEND species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	Oxidative damage precedes nitrative damage in adriamycin-induced cardiac ENTD mitochondrial injury ENTDEND .The purpose of the present study was to determine if elevated reactive ENTC oxygen ENTCEND (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach
0	Our data showed ADR induced ENTC 4HNE ENTCEND protein adducts in mitochondria at the same time point as when ENTD mitochondrial injury ENTDEND initially appeared
0	ENTC 3NT ENTCEND levels were significantly increased in all subcellular compartments at 6 hours and subsequently declined at 24 hours. Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when ENTD mitochondrial injury ENTDEND initially appeared
0	This dual effect of ENTC temsirolimus ENTCEND on ENTD tumor ENTDEND tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy
1	Moreover, numerous patchy, well-limited fibrotic areas, compatible with post- ENTD necrotic ENTDEND tissue repair, were found after 6-month ENTC temsirolimus ENTCEND therapy
0	However, a 38% remission rate has been recently reported in refractory ENTD MCL ENTDEND treated with ENTC temsirolimus ENTCEND , a mTOR inhibitor
0	Cytostatic and anti-angiogenic effects of ENTC temsirolimus ENTCEND  in refractory mantle cell lymphoma.Mantle cell lymphoma (MCL) is a rare and aggressive type of ENTD B-cell non-Hodgkin's lymphoma ENTDEND
0	Alternatively, ENTD anemia ENTDEND could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of ENTC phosphatidylserine ENTCEND (PS) at the erythrocyte surface and by cell shrinkage
0	The effect of azathioprine on both annexin V binding and forward scatter was significantly blunted in the nominal absence of extracellular ENTC Ca ENTCEND +. CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced ENTD anemia ENTDEND
0	Alternatively, ENTD anemia ENTDEND  could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage. METHODS: The present experiments explored whether azathioprine influences eryptosis. According to annexin V binding, erythrocytes from patients indeed showed a significant increase of PS exposure within 1 week of treatment with azathioprine. In a second series, cytosolic Ca2+ activity ( ENTC Fluo3 ENTCEND fluorescence), cell volume (forward scatter), and PS-exposure (annexin V binding) were determined by FACS analysis in erythrocytes from healthy volunteers
1	The side effects of ENTC azathioprine ENTCEND include ENTD anemia ENTDEND , which has been attributed to bone marrow suppression
1	This occlusion occurred after ENTC EACA ENTCEND therapy in a patient with SAH and histopathological documentation of recurrent SAH. The corresponding clinical event was characterized by marked ENTD hypertension ENTDEND and abrupt neurological deterioration
0	Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, ENTC EACA ENTCEND should not be implicated in the pathogenesis of fibrin thrombi in patients with ENTD disseminated intravascular coagulation ENTDEND or other "consumption coagulopathies
0	Recurrent subarachnoid hemorrhage associated with ENTC aminocaproic acid ENTCEND  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena. Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with ENTD disseminated intravascular coagulation ENTDEND or other "consumption coagulopathies
0	" This report describes subtotal ENTD infarction ENTDEND of the kidney due to thrombosis of a normal renal artery. This occlusion occurred after ENTC EACA ENTCEND therapy in a patient with SAH and histopathological documentation of recurrent SAH
0	Recurrent subarachnoid hemorrhage associated with ENTC aminocaproic acid ENTCEND  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena. Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other "consumption coagulopathies." This report describes subtotal ENTD infarction ENTDEND of the kidney due to thrombosis of a normal renal artery
0	These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with ENTC EACA ENTCEND  or other ENTD thromboembolic phenomena ENTDEND
0	Recurrent subarachnoid hemorrhage associated with ENTC aminocaproic acid ENTCEND  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other ENTD thromboembolic phenomena ENTDEND
1	Although this agent does decrease the frequency of rebleeding, several reports have described ENTD thrombotic ENTDEND complications of ENTC EACA ENTCEND therapy
0	Recurrent subarachnoid hemorrhage associated with ENTC aminocaproic acid ENTCEND  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described ENTD thrombotic ENTDEND complications of EACA therapy
1	This occlusion occurred after ENTC EACA ENTCEND  therapy in a patient with ENTD SAH ENTDEND and histopathological documentation of recurrent SAH
0	Recurrent ENTD subarachnoid hemorrhage ENTDEND  associated with ENTC aminocaproic acid ENTCEND therapy and acute renal artery thrombosis
1	Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and ENTD acute renal artery thrombosis ENTDEND . Case report. ENTC Epsilon aminocaproic acid ENTCEND (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH)
0	Recurrent subarachnoid hemorrhage associated with ENTC aminocaproic acid ENTCEND  therapy and ENTD acute renal artery thrombosis ENTDEND
1	Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of ENTC EACA ENTCEND  therapy. These complications have included clinical deterioration and ENTD intracranial vascular thrombosis ENTDEND in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena
0	Recurrent subarachnoid hemorrhage associated with ENTC aminocaproic acid ENTCEND  therapy and acute renal artery thrombosis. Case report.Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH). Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy. These complications have included clinical deterioration and ENTD intracranial vascular thrombosis ENTDEND in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena
0	Cholestatic presentation of yellow ENTC phosphorus ENTCEND ENTD poisoning ENTDEND
1	Poisoning with yellow ENTC phosphorus ENTCEND classically manifests with ENTD acute hepatitis ENTDEND leading to acute liver failure which may need liver transplantation
0	We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow ENTC phosphorus ENTCEND ENTD hepatotoxicity ENTDEND
1	Poisoning with yellow ENTC phosphorus ENTCEND  classically manifests with acute hepatitis leading to ENTD acute liver failure ENTDEND which may need liver transplantation
1	ENTD Cholestatic ENTDEND  presentation of yellow ENTC phosphorus ENTCEND poisoning
0	Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ENTD ischemia ENTDEND  Because of the theoretical concern regarding administration of dobutamine in the setting of ENTC cocaine ENTCEND use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain
0	Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ENTD ischemia ENTDEND . Because of the theoretical concern regarding administration of ENTC dobutamine ENTCEND in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain
0	Patients exhibiting signs of continuing ENTC cocaine ENTCEND ENTD toxicity ENTDEND were excluded from the study
0	Because of the theoretical concern regarding administration of ENTC dobutamine ENTCEND  in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital. Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level. Patients exhibiting signs of continuing cocaine ENTD toxicity ENTDEND were excluded from the study
0	None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding ENTD sinus tachycardia ENTDEND . Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental atropine to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with ENTC cocaine ENTCEND -related chest pain
0	None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding ENTD sinus tachycardia ENTDEND ). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental atropine to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when ENTC dobutamine ENTCEND was administered to patients with cocaine-related chest pain
0	None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding ENTD sinus tachycardia ENTDEND ). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental ENTC atropine ENTCEND to reach their target heart rates
1	CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with ENTC cocaine ENTCEND -related ENTD chest pain ENTDEND
0	CONCLUSION: No exaggerated adrenergic response was detected when ENTC dobutamine ENTCEND  was administered to patients with cocaine-related ENTD chest pain ENTDEND
0	Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental ENTC atropine ENTCEND  to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related ENTD chest pain ENTDEND
0	Patients exhibiting signs of continuing ENTC cocaine ENTCEND  toxicity were excluded from the study. All patients were admitted to the hospital for serial testing after the DSE testing in the intensive diagnostic and treatment unit. RESULTS: Twenty-four patients were enrolled. Two patients had inadequate resting images, one DSE was terminated because of inferior ENTD hypokinesis ENTDEND , another DSE was terminated because of a rate-related atrial conduction deficit, and 1 patient did not reach the target heart rate
0	Two patients had inadequate resting images, one DSE was terminated because of inferior ENTD hypokinesis ENTDEND , another DSE was terminated because of a rate-related atrial conduction deficit, and 1 patient did not reach the target heart rate. Thus, 19 patients completed a DSE and reached their target heart rates. None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding sinus tachycardia). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental atropine to reach their target heart rates. CONCLUSION: No exaggerated adrenergic response was detected when ENTC dobutamine ENTCEND was administered to patients with cocaine-related chest pain
0	Two patients had inadequate resting images, one DSE was terminated because of inferior ENTD hypokinesis ENTDEND , another DSE was terminated because of a rate-related atrial conduction deficit, and 1 patient did not reach the target heart rate. Thus, 19 patients completed a DSE and reached their target heart rates. None of the patients experienced signs of exaggerated adrenergic response, which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias (excluding sinus tachycardia). Further suggesting lack of exaggerated adrenergic response, 13 (65%) of 20 patients required supplemental ENTC atropine ENTCEND to reach their target heart rates
1	Pubertal exposure to ENTC Bisphenol A ENTCEND  increases ENTD anxiety ENTDEND -like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice
0	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of ENTC CCK-8 ENTCEND on morphine-induced ENTD memory impairment ENTDEND
0	The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on ENTC morphine ENTCEND induced ENTD memory impairment ENTDEND
0	We have previously reported that ENTC CCK-8 ENTCEND significantly alleviated morphine-induced ENTD amnesia ENTDEND and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals
1	We have previously reported that CCK-8 significantly alleviated ENTC morphine ENTCEND induced ENTD amnesia ENTDEND and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals
1	Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to ENTC fluoxetine ENTCEND induced ENTD mania ENTDEND in adolescents
0	ENTD Mania ENTDEND  associated with fluoxetine treatment in adolescents.Fluoxetine, a selective ENTC serotonin ENTCEND reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression
0	Apparent risk factors for the development of mania or hypomania during ENTC fluoxetine ENTCEND pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with ENTD psychotic ENTDEND features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective ENTC serotonin ENTCEND  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression. Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania. The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here. Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with ENTD psychotic ENTDEND features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent ENTD depression ENTDEND  Generally safe and well tolerated by adults, ENTC fluoxetine ENTCEND has been reported to induce mania
0	Fluoxetine, a selective ENTC serotonin ENTCEND  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent ENTD depression ENTDEND
0	Apparent risk factors for the development of mania or hypomania during ENTC fluoxetine ENTCEND  pharmacotherapy in this population were the combination of ENTD attention-deficit hyperactivity disorder ENTDEND and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective ENTC serotonin ENTCEND  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression. Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania. The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here. Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of ENTD attention-deficit hyperactivity disorder ENTDEND and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder
0	Apparent risk factors for the development of mania or hypomania during ENTC fluoxetine ENTCEND  pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of ENTD affective disorder ENTDEND , especially bipolar disorder; and a diagnosis of bipolar disorder
0	Fluoxetine, a selective ENTC serotonin ENTCEND  reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression. Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania. The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here. Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of ENTD affective disorder ENTDEND , especially bipolar disorder; and a diagnosis of bipolar disorder
0	The ENTC trimethaphan ENTCEND induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion. Therefore, rostral ventrolateral medulla neurons appear to play a significant role in maintaining ENTD hypertension ENTDEND in conscious spontaneously hypertensive rats
0	We studied the effects of chronic selective neuronal lesion of rostral ventrolateral medulla on mean arterial pressure, heart rate, and neurogenic tone in conscious, unrestrained spontaneously ENTD hypertensive ENTDEND rats. The lesions were placed via bilateral microinjections of 30 nmol/200 nl ENTC N-methyl-D-aspartic acid ENTCEND
1	The ENTC trimethaphan ENTCEND -induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a ENTD tachycardia ENTDEND in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The restimulation of this area with ENTC N-methyl-D-aspartic acid ENTCEND 15 days postlesion failed to produce a pressor response. One day postlesion, the resting mean arterial pressure was significantly decreased in lesioned rats when compared with sham rats (100 +/- 7 versus 173 +/- 4 mm Hg, p less than 0.05). Fifteen days later, the lesioned group still showed values significantly lower than the sham group (150 +/- 6 versus 167 +/- 5 mm Hg, p less than 0.05). No significant heart rate differences were observed between the sham and lesioned groups. The ganglionic blocker trimethaphan (5 mg/kg i.v.) caused similar reductions in mean arterial pressure in both lesioned and sham groups. The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a ENTD tachycardia ENTDEND in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
1	The ENTC trimethaphan ENTCEND -induced ENTD hypotension ENTDEND was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The restimulation of this area with ENTC N-methyl-D-aspartic acid ENTCEND  15 days postlesion failed to produce a pressor response. One day postlesion, the resting mean arterial pressure was significantly decreased in lesioned rats when compared with sham rats (100 +/- 7 versus 173 +/- 4 mm Hg, p less than 0.05). Fifteen days later, the lesioned group still showed values significantly lower than the sham group (150 +/- 6 versus 167 +/- 5 mm Hg, p less than 0.05). No significant heart rate differences were observed between the sham and lesioned groups. The ganglionic blocker trimethaphan (5 mg/kg i.v.) caused similar reductions in mean arterial pressure in both lesioned and sham groups. The trimethaphan-induced ENTD hypotension ENTDEND was accompanied by a significant bradycardia in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The ENTC trimethaphan ENTCEND -induced hypotension was accompanied by a significant ENTD bradycardia ENTDEND in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
0	The restimulation of this area with ENTC N-methyl-D-aspartic acid ENTCEND  15 days postlesion failed to produce a pressor response. One day postlesion, the resting mean arterial pressure was significantly decreased in lesioned rats when compared with sham rats (100 +/- 7 versus 173 +/- 4 mm Hg, p less than 0.05). Fifteen days later, the lesioned group still showed values significantly lower than the sham group (150 +/- 6 versus 167 +/- 5 mm Hg, p less than 0.05). No significant heart rate differences were observed between the sham and lesioned groups. The ganglionic blocker trimethaphan (5 mg/kg i.v.) caused similar reductions in mean arterial pressure in both lesioned and sham groups. The trimethaphan-induced hypotension was accompanied by a significant ENTD bradycardia ENTDEND in lesioned rats (-32 +/- 13 beats per minute) but a tachycardia in sham rats (+33 +/- 12 beats per minute) 1 day postlesion
1	The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in ENTC gentamicin ENTCEND induced ENTD ARF ENTDEND
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing ENTD acute renal failure ENTDEND after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C] ENTC p-aminohippuric acid ENTCEND clearances) and morphological (degree of necrosis) indices
0	However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENTC NaOH ENTCEND . The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ENTD ARF ENTDEND
0	Effect of alkylxanthines on gentamicin-induced ENTD acute renal failure ENTDEND  in the rat. ENTC Adenosine ENTCEND antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF)
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing ENTD acute renal failure ENTDEND  after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma ENTC urea ENTCEND and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENTC theophylline ENTCEND and enprofylline, were examined in rats developing ENTD acute renal failure ENTDEND after 4 daily injections of gentamicin (200 mg kg-1)
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENTC 8-phenyltheophylline ENTCEND  theophylline and enprofylline, were examined in rats developing ENTD acute renal failure ENTDEND after 4 daily injections of gentamicin (200 mg kg-1)
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing ENTD acute renal failure ENTDEND  after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and ENTC creatinine ENTCEND ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENTC enprofylline ENTCEND  were examined in rats developing ENTD acute renal failure ENTDEND after 4 daily injections of gentamicin (200 mg kg-1)
0	However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ( ENTC polyethylene glycol ENTCEND and NaOH). The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ENTD ARF ENTDEND
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of ENTC gentamicin ENTCEND (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C] ENTC p-aminohippuric acid ENTCEND  clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENTC NaOH ENTCEND )
0	In the present study, the effects of three alkylxanthines with different potencies as ENTC adenosine ENTCEND antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	Renal function was assessed by biochemical (plasma ENTC urea ENTCEND  and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENTC theophylline ENTCEND  and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENTC 8-phenyltheophylline ENTCEND , theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	Renal function was assessed by biochemical (plasma urea and ENTC creatinine ENTCEND ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENTC enprofylline ENTCEND , were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices
0	Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of ENTD necrosis ENTDEND ) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ENTC polyethylene glycol ENTCEND and NaOH)
0	Effect of alkylxanthines on ENTC gentamicin ENTCEND -induced acute renal failure in the rat.Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C ENTC p-aminohippuric acid ENTCEND clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENTC NaOH ENTCEND )
0	ENTC Adenosine ENTCEND  antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma ENTC urea ENTCEND and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENTC theophylline ENTCEND and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENTC 8-phenyltheophylline ENTCEND , theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and ENTC creatinine ENTCEND ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENTC enprofylline ENTCEND , were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ischaemic and ENTD nephrotoxic ENTDEND  models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ENTC polyethylene glycol ENTCEND and NaOH)
0	Effect of alkylxanthines on ENTC gentamicin ENTCEND -induced acute renal failure in the rat.Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND and nephrotoxic models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C ENTC p-aminohippuric acid ENTCEND clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle (polyethylene glycol and ENTC NaOH ENTCEND )
0	ENTC Adenosine ENTCEND  antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND and nephrotoxic models of acute renal failure (ARF)
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma ENTC urea ENTCEND and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, ENTC theophylline ENTCEND and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists ENTC 8-phenyltheophylline ENTCEND , theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and ENTC creatinine ENTCEND ), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and ENTC enprofylline ENTCEND , were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1)
0	Adenosine antagonists have been previously shown to be of benefit in some ENTD ischaemic ENTDEND  and nephrotoxic models of acute renal failure (ARF). In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1). Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices. The various drug treatments produced improvements in some, but not all, measurements of renal function. However, any improvement produced by drug treatment was largely a result of a beneficial effect exerted by its vehicle ENTC polyethylene glycol ENTCEND and NaOH)
1	ENTC Valproate ENTCEND -induced ENTD hyperammonemic ENTDEND encephalopathy in a renal transplanted patient
0	ENTC Valproate ENTCEND -induced hyperammonemic ENTD encephalopathy ENTDEND in a renal transplanted patient
0	ENTC Valproate ENTCEND -induced hyperammonemic encephalopathy in a renal transplanted patient. ENTD Neurological complications ENTDEND after renal transplantation constitute an important cause of morbidity and mortality
1	Here, we describe the case of a 15-year-old girl who was on a long-term therapy with ENTC valproate ENTCEND due to epilepsy and revealed ENTD impaired consciousness ENTDEND with hyperammonemia 12 days after renal transplantation
0	Here, we describe the case of a 15-year-old girl who was on a long-term therapy with ENTC valproate ENTCEND  due to ENTD epilepsy ENTDEND and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation
0	STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known ENTD CVD ENTDEND  Does ENTC aspirin ENTCEND increase gastrointestinal bleeding or hemorrhagic strokes? DATA EXTRACTION: All studies were reviewed, abstracted, and rated for quality by using predefined USPSTF criteria
0	BACKGROUND: Coronary heart disease and ENTD cerebrovascular disease ENTDEND are leading causes of death in the United States. In 2002, the U.S. Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss ENTC aspirin ENTCEND with adults who are at increased risk for coronary heart disease
0	CONCLUSION: ENTC Aspirin ENTCEND reduces the risk for ENTD myocardial infarction ENTDEND in men and strokes in women
1	Men in these studies experienced fewer myocardial infarctions and women experienced fewer ischemic ENTD strokes ENTDEND  ENTC Aspirin ENTCEND does not seem to affect CVD mortality or all-cause mortality in either men or women
0	Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss ENTC aspirin ENTCEND  with adults who are at increased risk for ENTD coronary heart disease ENTDEND
1	Men have an increased risk for ENTD hemorrhagic strokes ENTDEND with ENTC aspirin ENTCEND use
0	ENTC Aspirin ENTCEND use increases the risk for serious ENTD bleeding ENTDEND events
1	STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD? Does ENTC aspirin ENTCEND  increase ENTD gastrointestinal bleeding ENTDEND or hemorrhagic strokes? DATA EXTRACTION: All studies were reviewed, abstracted, and rated for quality by using predefined USPSTF criteria
1	Crocin reduced inhibition of ERK activation and ENTC diazinon ENTCEND induced ENTD hyperlipemia ENTDEND and increased levels of LDLr transcript
0	Crocin reduced inhibition of ERK activation and diazinon-induced ENTD hyperlipemia ENTDEND  and increased levels of LDLr transcript. CONCLUSIONS: ENTC Crocin ENTCEND may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression
0	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, ENTC triglyceride ENTCEND and LDL. Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript. Crocin reduced inhibition of ERK activation and diazinon-induced ENTD hyperlipemia ENTDEND and increased levels of LDLr transcript
0	RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of ENTC cholesterol ENTCEND  triglyceride and LDL. Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript. Crocin reduced inhibition of ERK activation and diazinon-induced ENTD hyperlipemia ENTDEND and increased levels of LDLr transcript
0	Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENTC creatinine ENTCEND  > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with diabetes) generally tolerated the high-dose strategy. CONCLUSIONS: These findings demonstrate that ACE inhibitor therapy in most patients with ENTD CHF ENTDEND can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted
0	CONCLUSIONS: These findings demonstrate that ENTC ACE inhibitor ENTCEND therapy in most patients with ENTD CHF ENTDEND can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted
0	The present study examines the safety and tolerability of high- compared with low-dose ENTC lisinopril ENTCEND in ENTD CHF ENTDEND
0	0%) or because of renal dysfunction or ENTD hyperkalemia ENTDEND (2.3%). Doses in more than 90% of randomized patients in the high- and low-dose groups were titrated to their assigned target, and the mean doses of blinded medication in both groups remained similar throughout the study. Withdrawals occurred in 27.1% of the high- and 30.7% of the low-dose groups. Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENTC creatinine ENTCEND , > or =132
0	RESULTS: Of 405 patients not previously receiving an ENTC ACE inhibitor ENTCEND  doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or ENTD hyperkalemia ENTDEND (2
1	METHODS: The Assessment of Lisinopril and Survival study was a multicenter, randomized, double-blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium-dose ENTC lisinopril ENTCEND (12.5 or 15.0 mg once daily [OD]) for 2 to 4 weeks and then randomized to high- (35.0 or 32.5 mg OD) or low-dose (5.0 or 2.5 mg OD) groups. Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0.30 (n = 3164) were randomized and followed up for a median of 46 months. We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on hypotension and renal dysfunction. RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or ENTD hyperkalemia ENTDEND (2
0	0%) or because of ENTD renal dysfunction ENTDEND or hyperkalemia (2.3%). Doses in more than 90% of randomized patients in the high- and low-dose groups were titrated to their assigned target, and the mean doses of blinded medication in both groups remained similar throughout the study. Withdrawals occurred in 27.1% of the high- and 30.7% of the low-dose groups. Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENTC creatinine ENTCEND , > or =132
0	We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on hypotension and ENTD renal dysfunction ENTDEND  RESULTS: Of 405 patients not previously receiving an ENTC ACE inhibitor ENTCEND , doses in only 4
1	METHODS: The Assessment of Lisinopril and Survival study was a multicenter, randomized, double-blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium-dose ENTC lisinopril ENTCEND  (12.5 or 15.0 mg once daily [OD]) for 2 to 4 weeks and then randomized to high- (35.0 or 32.5 mg OD) or low-dose (5.0 or 2.5 mg OD) groups. Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0.30 (n = 3164) were randomized and followed up for a median of 46 months. We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on hypotension and ENTD renal dysfunction ENTDEND
0	2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to ENTD hypotension ENTDEND (2.0%) or because of renal dysfunction or hyperkalemia (2.3%). Doses in more than 90% of randomized patients in the high- and low-dose groups were titrated to their assigned target, and the mean doses of blinded medication in both groups remained similar throughout the study. Withdrawals occurred in 27.1% of the high- and 30.7% of the low-dose groups. Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENTC creatinine ENTCEND , > or =132
0	We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on ENTD hypotension ENTDEND and renal dysfunction. RESULTS: Of 405 patients not previously receiving an ENTC ACE inhibitor ENTCEND , doses in only 4
1	METHODS: The Assessment of Lisinopril and Survival study was a multicenter, randomized, double-blind trial in which patients with or without previous ACE inhibitor treatment were stabilized receiving medium-dose ENTC lisinopril ENTCEND  (12.5 or 15.0 mg once daily [OD]) for 2 to 4 weeks and then randomized to high- (35.0 or 32.5 mg OD) or low-dose (5.0 or 2.5 mg OD) groups. Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0.30 (n = 3164) were randomized and followed up for a median of 46 months. We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment, with a focus on ENTD hypotension ENTDEND and renal dysfunction
0	Subgroups presumed to be at higher risk for ACE inhibitor intolerance (blood pressure, <120 mm Hg; ENTC creatinine ENTCEND , > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with ENTD diabetes ENTDEND ) generally tolerated the high-dose strategy
0	5 mg/dL]; age, > or =70 years; and patients with ENTD diabetes ENTDEND ) generally tolerated the high-dose strategy. CONCLUSIONS: These findings demonstrate that ENTC ACE inhibitor ENTCEND therapy in most patients with CHF can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted
0	On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENTC CTX ENTCEND (divided over 5 days) q 4 wk is tolerable in ENTD tumor ENTDEND -bearing dogs
0	On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENTC CCNU ENTCEND combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in ENTD tumor ENTDEND -bearing dogs
0	This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide ( ENTC CTX ENTCEND  in dogs with ENTD lymphoma ENTDEND
0	This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with ENTD lymphoma ENTDEND . ENTC CCNU ENTCEND was administered per os (PO) at a targeted dosage of 60 mg/m(2) body surface area on day 0, CTX was administered PO at a targeted dosage of 250 mg/m(2) divided over days 0 through 4, and all dogs received prophylactic antibiotics
0	This retrospective study describes ENTD toxicity ENTDEND associated with a protocol of lomustine (CCNU) and ENTC cyclophosphamide ENTCEND (CTX) in dogs with lymphoma
0	This retrospective study describes ENTD toxicity ENTDEND  associated with a protocol of ENTC lomustine ENTCEND (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma
0	No dogs had evidence of either ENTD renal toxicity ENTDEND or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENTC CTX ENTCEND (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either ENTD renal toxicity ENTDEND  or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENTC CCNU ENTCEND combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENTD hemorrhagic cystitis ENTDEND  Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENTC CTX ENTCEND (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENTD hemorrhagic cystitis ENTDEND . Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENTC CCNU ENTCEND combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	One dog (3%) developed hematologic changes suggestive of ENTD hepatotoxicity ENTDEND  No dogs had evidence of either renal toxicity or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENTC CTX ENTCEND (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	One dog (3%) developed hematologic changes suggestive of ENTD hepatotoxicity ENTDEND . No dogs had evidence of either renal toxicity or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENTC CCNU ENTCEND combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENTD hemorrhagic cystitis ENTDEND  Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of ENTC CTX ENTCEND (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
0	No dogs had evidence of either renal toxicity or ENTD hemorrhagic cystitis ENTDEND . Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m(2) of ENTC CCNU ENTCEND combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs
1	Neutropenia was the principal toxic effect, and the overall frequency of grade 4 ENTD neutropenia ENTDEND after the first treatment of CCNU/ ENTC CTX ENTCEND was 30% (95% confidence interval, 19-43%)
1	Neutropenia was the principal toxic effect, and the overall frequency of grade 4 ENTD neutropenia ENTDEND  after the first treatment of ENTC CCNU ENTCEND /CTX was 30% (95% confidence interval, 19-43%)
1	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with ENTC clonazepam ENTCEND  Disappearance of seizures and normalization of abnormal EEG with disappearance of seizures were recognized in 77% and 50%, respectively. Seizures disappeared in 71% of the patients with generalized seizures and 89% of partial seizures. Improvement of abnormal EEG was noticed in 76% of diffuse paroxysms and in 67% of focal paroxysms. In excellent cases, mean effective dosages were 0.086 +/- 0.021 mg/kg/day in infants and 0.057 +/- 0.022 mg/kg/day in schoolchildren, this difference was statistically significant (p less than 0.005). The incidence of side effects such as drowsiness and ENTD ataxia ENTDEND was only 5%
1	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with ENTC clonazepam ENTCEND . Disappearance of seizures and normalization of abnormal EEG with disappearance of seizures were recognized in 77% and 50%, respectively. Seizures disappeared in 71% of the patients with generalized seizures and 89% of partial seizures. Improvement of abnormal EEG was noticed in 76% of diffuse paroxysms and in 67% of focal paroxysms. In excellent cases, mean effective dosages were 0.086 +/- 0.021 mg/kg/day in infants and 0.057 +/- 0.022 mg/kg/day in schoolchildren, this difference was statistically significant (p less than 0.005). The incidence of side effects such as ENTD drowsiness ENTDEND and ataxia was only 5%
0	Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with ENTC clonazepam ENTCEND . Disappearance of ENTD seizures ENTDEND and normalization of abnormal EEG with disappearance of seizures were recognized in 77% and 50%, respectively
0	Sixty patients (age-range one month to 14 years) with other types of epilepsy than ENTD infantile spasms ENTDEND were treated with ENTC clonazepam ENTCEND
0	ENTC Clonazepam ENTCEND  monotherapy for ENTD epilepsy ENTDEND in childhood
0	Smoking of ENTC crack cocaine ENTCEND  as a risk factor for ENTD HIV infection ENTDEND among people who use injection drugs
1	To determine whether the risk of ENTD HIV seroconversion ENTDEND among daily smokers of ENTC crack cocaine ENTCEND changed over time, we used Cox proportional hazards regression and divided the study into 3 periods: May 1, 1996-Nov
0	It was hypothesized that ENTC progestins ENTCEND could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy. The treatment schedule consisted of conjugated estrogens (Premarin) 1.25 mg/day for 21 days and Medroxyprogesterone acetate 10 mg/day for 10 days in each month. The mean treatment period was 18 months. During the follow-up period, attention was paid to breast modifications as evidenced by symptomatology, physical examination, and plate thermography. ENTD Mastodynia ENTDEND was reported by 21 patients, and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women
1	25 mg/day for 21 days and ENTC Medroxyprogesterone acetate ENTCEND 10 mg/day for 10 days in each month. The mean treatment period was 18 months. During the follow-up period, attention was paid to breast modifications as evidenced by symptomatology, physical examination, and plate thermography. ENTD Mastodynia ENTDEND was reported by 21 patients, and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women
1	The treatment schedule consisted of conjugated estrogens ( ENTC Premarin ENTCEND  1.25 mg/day for 21 days and Medroxyprogesterone acetate 10 mg/day for 10 days in each month. The mean treatment period was 18 months. During the follow-up period, attention was paid to breast modifications as evidenced by symptomatology, physical examination, and plate thermography. ENTD Mastodynia ENTDEND was reported by 21 patients, and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women
0	Themography confirmed the existence of an excessive breast stimulation in 1 women who complained of moderate mastodynia and in 5 of the 7 women who complained of severe ENTD mastodynia ENTDEND  Normalization was obtained by halving the ENTC estrogen ENTCEND dose
0	Hormones and risk of ENTD breast cancer ENTDEND .This paper reports the results of a study of 50 menopausal women receiving hormonal replacement therapy. The majority (29) had surgical menopause; their mean age was 45.7 years. It was hypothesized that ENTC progestins ENTCEND could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy
0	Hormones and risk of ENTD breast cancer ENTDEND .This paper reports the results of a study of 50 menopausal women receiving hormonal replacement therapy. The majority (29) had surgical menopause; their mean age was 45.7 years. It was hypothesized that progestins could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy. The treatment schedule consisted of conjugated estrogens (Premarin) 1.25 mg/day for 21 days and ENTC Medroxyprogesterone acetate ENTCEND 10 mg/day for 10 days in each month
0	Hormones and risk of ENTD breast cancer ENTDEND .This paper reports the results of a study of 50 menopausal women receiving hormonal replacement therapy. The majority (29) had surgical menopause; their mean age was 45.7 years. It was hypothesized that progestins could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy. The treatment schedule consisted of ENTC conjugated estrogens ENTCEND (Premarin) 1
0	We investigated the effects of clentiazem, a ENTC 1,5-benzothiazepine ENTCEND calcium antagonist, on epinephrine-induced ENTD cardiomyopathy ENTDEND in rats
1	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on ENTC epinephrine ENTCEND induced ENTD cardiomyopathy ENTDEND in rats
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced ENTD cardiomyopathy ENTDEND  in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed. In epinephrine-treated rats, left atrial and left ventricular papillary muscle contractile responses to ENTC isoproterenol ENTCEND were reduced, but responses to calcium were normal or enhanced compared to controls
0	We investigated the effects of ENTC clentiazem ENTCEND  a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced ENTD cardiomyopathy ENTDEND in rats
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine ENTC calcium ENTCEND antagonist, on epinephrine-induced ENTD cardiomyopathy ENTDEND in rats
0	We investigated the effects of clentiazem, a ENTC 1,5-benzothiazepine ENTCEND  calcium antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ENTD ischemic lesions ENTDEND and fibrosis of the left ventricles were observed
0	With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ENTD ischemic lesions ENTDEND  and fibrosis of the left ventricles were observed. In ENTC epinephrine ENTCEND -treated rats, left atrial and left ventricular papillary muscle contractile responses to isoproterenol were reduced, but responses to calcium were normal or enhanced compared to controls
0	05), and attenuated the ventricular ENTD ischemic lesions ENTDEND and fibrosis, in a dose-dependent manner. Left atrial and left ventricular papillary muscle contractile responses to ENTC isoproterenol ENTCEND were reduced compared to controls in groups treated with clentiazem alone, but combined with epinephrine, clentiazem restored left atrial responses and enhanced left ventricular papillary responses to isoproterenol
0	Treatment with ENTC clentiazem ENTCEND prevented epinephrine-induced death (P < .05), and attenuated the ventricular ENTD ischemic lesions ENTDEND and fibrosis, in a dose-dependent manner
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine ENTC calcium ENTCEND  antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ENTD ischemic lesions ENTDEND and fibrosis of the left ventricles were observed
0	Protective effect of clentiazem against epinephrine-induced ENTD cardiac injury ENTDEND  in rats.We investigated the effects of clentiazem, a ENTC 1,5-benzothiazepine ENTCEND calcium antagonist, on epinephrine-induced cardiomyopathy in rats
0	Protective effect of clentiazem against ENTC epinephrine ENTCEND -induced ENTD cardiac injury ENTDEND in rats
0	Protective effect of clentiazem against epinephrine-induced ENTD cardiac injury ENTDEND  in rats.We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed. In epinephrine-treated rats, left atrial and left ventricular papillary muscle contractile responses to ENTC isoproterenol ENTCEND were reduced, but responses to calcium were normal or enhanced compared to controls
0	Protective effect of ENTC clentiazem ENTCEND  against epinephrine-induced ENTD cardiac injury ENTDEND in rats
0	Protective effect of clentiazem against epinephrine-induced ENTD cardiac injury ENTDEND  in rats.We investigated the effects of clentiazem, a 1,5-benzothiazepine ENTC calcium ENTCEND antagonist, on epinephrine-induced cardiomyopathy in rats
0	We investigated the effects of clentiazem, a ENTC 1,5-benzothiazepine ENTCEND  calcium antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and ENTD fibrosis ENTDEND of the left ventricles were observed
0	With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and ENTD fibrosis ENTDEND  of the left ventricles were observed. In ENTC epinephrine ENTCEND -treated rats, left atrial and left ventricular papillary muscle contractile responses to isoproterenol were reduced, but responses to calcium were normal or enhanced compared to controls
0	05), and attenuated the ventricular ischemic lesions and ENTD fibrosis ENTDEND  in a dose-dependent manner. Left atrial and left ventricular papillary muscle contractile responses to ENTC isoproterenol ENTCEND were reduced compared to controls in groups treated with clentiazem alone, but combined with epinephrine, clentiazem restored left atrial responses and enhanced left ventricular papillary responses to isoproterenol
0	Treatment with ENTC clentiazem ENTCEND  prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and ENTD fibrosis ENTDEND , in a dose-dependent manner
0	We investigated the effects of clentiazem, a 1,5-benzothiazepine ENTC calcium ENTCEND  antagonist, on epinephrine-induced cardiomyopathy in rats. With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and ENTD fibrosis ENTDEND of the left ventricles were observed
0	Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of ENTD status epilepticus ENTDEND  in rats. ENTC MK-801 ENTCEND , a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone
0	These results suggest that activation of ENTC NMDA ENTCEND receptors plays an important role in ENTD status epilepticus ENTDEND and brain damage in the lithium-pilocarpine model
1	Anticonvulsant actions of MK-801 on the ENTC lithium ENTCEND -pilocarpine model of ENTD status epilepticus ENTDEND in rats
1	Anticonvulsant actions of MK-801 on the lithium- ENTC pilocarpine ENTCEND  model of ENTD status epilepticus ENTDEND in rats
0	Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the ENTD seizures ENTDEND  Administration of ENTC MK-801 ENTCEND 30 or 60 min after pilocarpine, i
0	This observation is suggested to be an in vivo demonstration of the conclusion derived from in vitro experiments that MK-801 binding requires agonist-induced opening of the channel sites of the ENTC NMDA ENTCEND receptor. Third, although it is relatively easy to block ENTD seizures ENTDEND induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures
0	Third, although it is relatively easy to block ENTD seizures ENTDEND  induced by ENTC lithium ENTCEND and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures
0	Third, although it is relatively easy to block ENTD seizures ENTDEND  induced by lithium and ENTC pilocarpine ENTCEND by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures
0	Administration of ENTC MK-801 ENTCEND  30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate. These results suggest that activation of NMDA receptors plays an important role in status epilepticus and ENTD brain damage ENTDEND in the lithium-pilocarpine model
0	These results suggest that activation of ENTC NMDA ENTCEND  receptors plays an important role in status epilepticus and ENTD brain damage ENTDEND in the lithium-pilocarpine model
0	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and ENTD brain damage ENTDEND  in the ENTC lithium ENTCEND -pilocarpine model
0	These results suggest that activation of NMDA receptors plays an important role in status epilepticus and ENTD brain damage ENTDEND  in the lithium- ENTC pilocarpine ENTCEND model
1	ENTD Hyperosmolar nonketotic coma ENTDEND  precipitated by ENTC lithium ENTCEND -induced nephrogenic diabetes insipidus
0	A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with ENTD hyperosmolar, nonketotic coma ENTDEND  He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for ENTC glucose ENTCEND
0	A 45-year-old man, with a 10-year history of ENTD manic depression ENTDEND treated with ENTC lithium ENTCEND , was admitted with hyperosmolar, nonketotic coma
0	A 45-year-old man, with a 10-year history of ENTD manic depression ENTDEND  treated with lithium, was admitted with hyperosmolar, nonketotic coma. He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for ENTC glucose ENTCEND
1	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be ENTC lithium ENTCEND induced. We hypothesize that when this man developed type 2 diabetes, chronic ENTD polyuria ENTDEND due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration
0	After recovery from hyperglycaemia, he remained ENTD polyuric ENTDEND despite normal blood ENTC glucose ENTCEND concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced
1	Hyperosmolar nonketotic coma precipitated by ENTC lithium ENTCEND -induced ENTD nephrogenic diabetes insipidus ENTDEND
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood ENTC glucose ENTCEND  concentrations; water deprivation testing indicated ENTD nephrogenic diabetes insipidus ENTDEND , likely to be lithium-induced
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be ENTC lithium ENTCEND -induced. We hypothesize that when this man developed ENTD type 2 diabetes ENTDEND , chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood ENTC glucose ENTCEND  concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced. We hypothesize that when this man developed ENTD type 2 diabetes ENTDEND , chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration
0	A 45-year-old man, with a 10-year history of manic depression treated with ENTC lithium ENTCEND , was admitted with hyperosmolar, nonketotic coma. He gave a five-year history of polyuria and ENTD polydipsia ENTDEND , during which time urinalysis had been negative for glucose
0	He gave a five-year history of polyuria and ENTD polydipsia ENTDEND , during which time urinalysis had been negative for ENTC glucose ENTCEND
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be ENTC lithium ENTCEND -induced. We hypothesize that when this man developed type 2 diabetes, chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar ENTD dehydration ENTDEND
0	After recovery from hyperglycaemia, he remained polyuric despite normal blood ENTC glucose ENTCEND  concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced. We hypothesize that when this man developed type 2 diabetes, chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar ENTD dehydration ENTDEND
1	Ionizing radiation is capable of inducing the requisite CML-associated t(9:22) translocation ( ENTD Philadelphia chromosome ENTDEND  in appropriate cells in vitro but, thus far, chemicals have not shown this capacity. We have proposed that ENTC 1,3-butadiene ENTCEND metabolites be so tested as a reality check on the epidemiological reports
0	ENTC 1,3-Butadiene ENTCEND , ENTD CML ENTDEND and the t(9:22) translocation: A reality check
1	Branch ENTD retinal vein occlusion ENTDEND  and ENTC fluoxetine ENTCEND
0	A case of branch ENTD retinal vein occlusion ENTDEND associated with fluoxetine-induced secondary hypertension is described. Although an infrequent complication of selective ENTC serotonin ENTCEND reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed
1	A case of branch retinal vein occlusion associated with ENTC fluoxetine ENTCEND induced secondary ENTD hypertension ENTDEND is described
0	A case of branch retinal vein occlusion associated with fluoxetine-induced secondary ENTD hypertension ENTDEND  is described. Although an infrequent complication of selective ENTC serotonin ENTCEND reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed
0	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, ENTD rigidity ENTDEND  and ENTC levodopa ENTCEND -induced dyskinesias underwent bilateral implantation of electrodes in the STN
0	METHOD: Twenty-three patients suffering from severe ENTD Parkinson's disease ENTDEND (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and ENTC levodopa ENTCEND -induced dyskinesias underwent bilateral implantation of electrodes in the STN
1	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and ENTC levodopa ENTCEND -induced ENTD dyskinesias ENTDEND underwent bilateral implantation of electrodes in the STN
0	METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly ENTD bradykinesia ENTDEND  rigidity, and ENTC levodopa ENTCEND -induced dyskinesias underwent bilateral implantation of electrodes in the STN
0	The subscores for the akinesia, rigidity, ENTD tremor ENTDEND and gait also improved. (p<0.0005). The average ENTC levodopa ENTCEND dose decreased from 813 mg to 359 mg
0	The ENTC DHEA ENTCEND was administered intraperitoneally (ip) for 5 days. Amphetamine (3 mg/kg ip) induced ENTD hyper ENTDEND locomotion, apomorphine (1
0	Amphetamine (3 mg/kg ip) induced ENTD hyper ENTDEND  locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and ENTC haloperidol ENTCEND (1
0	ENTC Amphetamine ENTCEND (3 mg/kg ip) induced ENTD hyper ENTDEND locomotion, apomorphine (1
0	Amphetamine (3 mg/kg ip) induced ENTD hyper ENTDEND  locomotion, ENTC apomorphine ENTCEND (1
0	CONCLUSION: We observed that ENTC DHEA ENTCEND reduced locomotor activity and increased ENTD catalepsy ENTDEND at both doses, while it had no effect on climbing behavior
1	There was a significant difference between groups in the ENTC haloperidol ENTCEND induced ENTD catalepsy ENTDEND test (p<0
0	Statistical analysis was carried out using Kruskal-Wallis test for hyper locomotion, and one-way ANOVA for climbing and ENTD catalepsy ENTDEND tests. RESULTS: In the ENTC amphetamine ENTCEND -induced locomotion test, there were significant increases in all movements compared with the amphetamine-free group
0	Amphetamine (3 mg/kg ip) induced hyper locomotion, ENTC apomorphine ENTCEND  (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced ENTD catalepsy ENTDEND tests were used as animal models of schizophrenia
0	OBJECTIVE: To examine the effects of dehydroepiandrosterone ( ENTC DHEA ENTCEND  on animal models of ENTD schizophrenia ENTDEND
1	5 mg/kg subcutaneously [sc]) induced climbing, and ENTC haloperidol ENTCEND  (1.5 mg/kg sc) induced catalepsy tests were used as animal models of ENTD schizophrenia ENTDEND
1	Effects of dehydroepiandrosterone in ENTC amphetamine ENTCEND -induced ENTD schizophrenia ENTDEND models in mice
1	Amphetamine (3 mg/kg ip) induced hyper locomotion, ENTC apomorphine ENTCEND  (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of ENTD schizophrenia ENTDEND
0	Levodopa is the most effective symptomatic therapy for ENTD Parkinson's disease ENTDEND  but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations. HOMER1 is a protein with pivotal function in ENTC glutamate ENTCEND transmission, which has been related to the pathogenesis of these complications
0	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in ENTD Parkinson's disease ENTDEND  patients. ENTC Levodopa ENTCEND is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations
0	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, ENTD dyskinesia ENTDEND and visual hallucinations. HOMER1 is a protein with pivotal function in ENTC glutamate ENTCEND transmission, which has been related to the pathogenesis of these complications
1	ENTC Levodopa ENTCEND  is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, ENTD dyskinesia ENTDEND and visual hallucinations
0	Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and ENTD visual hallucinations ENTDEND  HOMER1 is a protein with pivotal function in ENTC glutamate ENTCEND transmission, which has been related to the pathogenesis of these complications
1	009) and ENTD visual hallucinations ENTDEND (PR=0.515, 95% CI 0.295-0.899, P=0.020). Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of ENTC levodopa ENTCEND adverse effects
0	Efficacy and safety of ENTC granisetron ENTCEND , a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of ENTD nausea ENTDEND and vomiting induced by high-dose cisplatin
1	PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of ENTC cisplatin ENTCEND induced ENTD nausea ENTDEND and vomiting
0	Efficacy and safety of granisetron, a selective ENTC 5-hydroxytryptamine ENTCEND -3 receptor antagonist, in the prevention of ENTD nausea ENTDEND and vomiting induced by high-dose cisplatin
1	As ENTC granisetron ENTCEND dose increased, appetite return increased (P = .040). ENTD Headache ENTDEND was the most frequently reported adverse event (20%)
0	ENTD Headache ENTDEND  was the most frequently reported adverse event (20%). CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received ENTC cisplatin ENTCEND at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients
0	CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of ENTC granisetron ENTCEND was effective in controlling ENTD vomiting ENTDEND in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients
1	PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of ENTC cisplatin ENTCEND -induced nausea and ENTD vomiting ENTDEND
0	Efficacy and safety of granisetron, a selective ENTC 5-hydroxytryptamine ENTCEND -3 receptor antagonist, in the prevention of nausea and ENTD vomiting ENTDEND induced by high-dose cisplatin
0	The cause of ENTD hyperkalemia ENTDEND was considered to be several doses of spiranolactone, an ENTC aldosterone ENTCEND antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
1	The cause of ENTD hyperkalemia ENTDEND  was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENTC ramipril ENTCEND , an ACE inhibitor
0	Syncope caused by ENTD hyperkalemia ENTDEND  during use of a combined therapy with the ENTC angiotensin ENTCEND -converting enzyme inhibitor and spironolactone
0	The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum ENTC potassium ENTCEND level. The cause of ENTD hyperkalemia ENTDEND was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
1	The cause of ENTD hyperkalemia ENTDEND  was considered to be several doses of ENTC spiranolactone ENTCEND , an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	ENTD Syncope ENTDEND  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENTC aldosterone ENTCEND antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	ENTD Syncope ENTDEND  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENTC ramipril ENTCEND , an ACE inhibitor
0	ENTD Syncope ENTDEND  caused by hyperkalemia during use of a combined therapy with the ENTC angiotensin ENTCEND -converting enzyme inhibitor and spironolactone
0	ENTD Syncope ENTDEND  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum ENTC potassium ENTCEND was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	ENTD Syncope ENTDEND  caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENTC spironolactone ENTCEND
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENTD bradycardia ENTDEND caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENTC aldosterone ENTCEND antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENTD bradycardia ENTDEND  caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENTC ramipril ENTCEND , an ACE inhibitor
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENTC angiotensin ENTCEND -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENTD bradycardia ENTDEND caused by hyperkalemia
1	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENTD bradycardia ENTDEND  caused by hyperkalemia. The concentration of serum ENTC potassium ENTCEND was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENTC spironolactone ENTCEND .A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked ENTD bradycardia ENTDEND caused by hyperkalemia
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior ENTD myocardial infarction ENTDEND was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENTC aldosterone ENTCEND antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior ENTD myocardial infarction ENTDEND  was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENTC ramipril ENTCEND , an ACE inhibitor
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENTC angiotensin ENTCEND -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior ENTD myocardial infarction ENTDEND was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior ENTD myocardial infarction ENTDEND  was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum ENTC potassium ENTCEND was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENTC spironolactone ENTCEND .A 76 year-old woman with a history of coronary artery bypass grafting and prior ENTD myocardial infarction ENTDEND was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia
0	The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENTC aldosterone ENTCEND  antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENTD renal disturbance ENTDEND
0	The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENTC ramipril ENTCEND , an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENTD renal disturbance ENTDEND
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENTC angiotensin ENTCEND -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENTD renal disturbance ENTDEND
0	Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with ENTC potassium ENTCEND sparing agents and who have mild ENTD renal disturbance ENTDEND
0	The cause of hyperkalemia was considered to be several doses of ENTC spiranolactone ENTCEND , an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor. This case is a good example of electrolyte imbalance causing acute life-threatening cardiac events. Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild ENTD renal disturbance ENTDEND
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENTD loss of consciousness ENTDEND due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an ENTC aldosterone ENTCEND antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENTD loss of consciousness ENTDEND  due to marked bradycardia caused by hyperkalemia. The concentration of serum potassium was high, and normal sinus rhythm was restored after correction of the serum potassium level. The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ENTC ramipril ENTCEND , an ACE inhibitor
0	Syncope caused by hyperkalemia during use of a combined therapy with the ENTC angiotensin ENTCEND -converting enzyme inhibitor and spironolactone.A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENTD loss of consciousness ENTDEND due to marked bradycardia caused by hyperkalemia
0	A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENTD loss of consciousness ENTDEND  due to marked bradycardia caused by hyperkalemia. The concentration of serum ENTC potassium ENTCEND was high, and normal sinus rhythm was restored after correction of the serum potassium level
0	Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and ENTC spironolactone ENTCEND .A 76 year-old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with ENTD loss of consciousness ENTDEND due to marked bradycardia caused by hyperkalemia
1	1/0, ENTD hand-foot syndrome ENTDEND 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENTC 5-FU ENTCEND /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1/0, ENTD hand-foot syndrome ENTDEND  12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
1	1/0, ENTD hand-foot syndrome ENTDEND  12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/ ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1/0, ENTD hand-foot syndrome ENTDEND  12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/ ENTC MMC ENTCEND is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENTD vomitus ENTDEND 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENTC 5-FU ENTCEND /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1, ENTD vomitus ENTDEND  24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
1	1, ENTD vomitus ENTDEND  24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENTD vomitus ENTDEND  24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENTC MMC ENTCEND is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENTD thrombocytopenia ENTDEND 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENTC 5-FU ENTCEND /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1, ENTD thrombocytopenia ENTDEND  33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
1	1, ENTD thrombocytopenia ENTDEND  33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1, ENTD thrombocytopenia ENTDEND  33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENTC MMC ENTCEND is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	Two patients developed hemolytic-uremic syndrome ( ENTD HUS ENTDEND . CONCLUSIONS: High-dose ENTC 5-FU ENTCEND /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly ENTD HUS ENTDEND may occur
1	Two patients developed hemolytic-uremic syndrome ( ENTD HUS ENTDEND ). CONCLUSIONS: High-dose 5-FU ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	Two patients developed hemolytic-uremic syndrome ( ENTD HUS ENTDEND ). CONCLUSIONS: High-dose 5-FU/FA ENTC MMC ENTCEND is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	In a previous phase II study with 3-weekly bolus ENTC 5-FU ENTCEND  FA and mitomycin C (MMC) we found a low ENTD toxicity ENTDEND rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival
0	The worst ENTD toxicities ENTDEND (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
0	In a previous phase II study with 3-weekly bolus 5-FU, ENTC FA ENTCEND and mitomycin C (MMC) we found a low ENTD toxicity ENTDEND rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival
0	In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C ( ENTC MMC ENTCEND  we found a low ENTD toxicity ENTDEND rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival
1	0, ENTD stomatitis ENTDEND 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENTC 5-FU ENTCEND /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	0, ENTD stomatitis ENTDEND  18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
1	0, ENTD stomatitis ENTDEND  18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	0, ENTD stomatitis ENTDEND  18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENTC MMC ENTCEND is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENTD leukopenia ENTDEND 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENTC 5-FU ENTCEND /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENTD leukopenia ENTDEND  45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
1	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENTD leukopenia ENTDEND  45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	The worst toxicities (%) observed were (CTC-NCI 1/2/3): ENTD leukopenia ENTDEND  45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENTC MMC ENTCEND is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	PATIENTS AND METHODS: From February, 1998 to September, 2000 we recruited 33 patients with ENTD AGC ENTDEND to receive weekly 24-hour ENTC 5-FU ENTCEND 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period
0	CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for ENTD AGC ENTDEND (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
0	CONCLUSIONS: High-dose 5-FU/ ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for ENTD AGC ENTDEND (objective response rate 54
0	High-dose 5-fluorouracil / folinic acid in combination with three-weekly ENTC mitomycin C ENTCEND  in the treatment of advanced ENTD gastric cancer ENTDEND
1	1/0, ENTD diarrhea ENTDEND 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose ENTC 5-FU ENTCEND /FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
0	1/0, ENTD diarrhea ENTDEND  36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%). It may serve as an alternative to ENTC cisplatin ENTCEND -containing regimens; however, it has to be considered that possibly HUS may occur
1	1/0, ENTD diarrhea ENTDEND  36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU ENTC FA ENTCEND /MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	1/0, ENTD diarrhea ENTDEND  36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0. Two patients developed hemolytic-uremic syndrome (HUS). CONCLUSIONS: High-dose 5-FU/FA ENTC MMC ENTCEND is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54
1	We report a case of acute interstitial nephritis (AIN) due to nicergoline ( ENTC Sermion ENTCEND . A 50-year-old patient admitted to our hospital for ENTD fever ENTDEND and acute renal failure
0	A 50-year-old patient admitted to our hospital for ENTD fever ENTDEND  and acute renal failure. Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND due to retinal vein occlusion at ophthalmologic department
0	arthralgia and ENTD fever ENTDEND  and laboratory findings (i.e. eosinophilia and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENTC methylprednisolone ENTCEND , and his renal function was completely recovered
0	Before admission, he had been taking ENTC nicergoline ENTCEND and bendazac lysine due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and ENTD skin rash ENTDEND
0	Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and ENTD skin rash ENTDEND
0	Thereafter, he experienced intermittent fever and ENTD skin rash ENTDEND . On admission, clinical symptoms (i.e. arthralgia and fever) and laboratory findings (i.e. eosinophilia and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENTC methylprednisolone ENTCEND , and his renal function was completely recovered
1	We report a case of acute interstitial nephritis ( ENTD AIN ENTDEND  due to ENTC nicergoline ENTCEND (Sermion)
0	We report a case of acute interstitial nephritis ( ENTD AIN ENTDEND ) due to nicergoline (Sermion). A 50-year-old patient admitted to our hospital for fever and acute renal failure. Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND due to retinal vein occlusion at ophthalmologic department
0	Treatment was consisted of withdrawal of nicergoline and intravenous ENTC methylprednisolone ENTCEND , and his renal function was completely recovered. To our knowledge, this is the first report of nicergoline-associated ENTD AIN ENTDEND
1	eosinophilia and ENTD renal failure ENTDEND  suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against ENTC nicergoline ENTCEND
0	Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. arthralgia and fever) and laboratory findings (i.e. eosinophilia and ENTD renal failure ENTDEND ) suggested AIN, and which was confirmed by pathologic findings on renal biopsy
0	eosinophilia and ENTD renal failure ENTDEND ) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENTC methylprednisolone ENTCEND , and his renal function was completely recovered
1	Before admission, he had been taking ENTC nicergoline ENTCEND  and bendazac lysine due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. ENTD arthralgia ENTDEND and fever) and laboratory findings (i
0	Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. ENTD arthralgia ENTDEND and fever) and laboratory findings (i
0	ENTD arthralgia ENTDEND  and fever) and laboratory findings (i.e. eosinophilia and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENTC methylprednisolone ENTCEND , and his renal function was completely recovered
0	Before admission, he had been taking ENTC nicergoline ENTCEND  and bendazac lysine due to ENTD retinal vein occlusion ENTDEND at ophthalmologic department
0	Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND  due to ENTD retinal vein occlusion ENTDEND at ophthalmologic department
0	A 50-year-old patient admitted to our hospital for fever and ENTD acute renal failure ENTDEND  Before admission, he had been taking ENTC nicergoline ENTCEND and bendazac lysine due to retinal vein occlusion at ophthalmologic department
0	A 50-year-old patient admitted to our hospital for fever and ENTD acute renal failure ENTDEND . Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND due to retinal vein occlusion at ophthalmologic department
1	ENTD eosinophilia ENTDEND and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against ENTC nicergoline ENTCEND
0	Before admission, he had been taking nicergoline and ENTC bendazac lysine ENTCEND  due to retinal vein occlusion at ophthalmologic department. Thereafter, he experienced intermittent fever and skin rash. On admission, clinical symptoms (i.e. arthralgia and fever) and laboratory findings (i.e. ENTD eosinophilia ENTDEND and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy
0	ENTD eosinophilia ENTDEND  and renal failure) suggested AIN, and which was confirmed by pathologic findings on renal biopsy. A lymphocyte transformation test demonstrated a positive result against nicergoline. Treatment was consisted of withdrawal of nicergoline and intravenous ENTC methylprednisolone ENTCEND , and his renal function was completely recovered
0	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to ENTC sodium pentobarbital ENTCEND suggest the existence of a heretofore undescribed ENTD cardiomyopathic disorder ENTDEND induced by chronic barium exposure
0	Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed ENTD cardiomyopathic disorder ENTDEND  induced by chronic ENTC barium ENTCEND exposure
0	The lack of a similar response to ketamine and ENTC xylazine ENTCEND anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed ENTD cardiomyopathic disorder ENTDEND induced by chronic barium exposure
0	The lack of a similar response to ENTC ketamine ENTCEND and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed ENTD cardiomyopathic disorder ENTDEND induced by chronic barium exposure
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced ENTD disturbances within the cardiovascular system ENTDEND  The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under ENTC barbiturate ENTCEND anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats
0	ENTD Cardiovascular dysfunction ENTDEND  and hypersensitivity to ENTC sodium pentobarbital ENTCEND induced by chronic barium chloride ingestion
0	ENTD Cardiovascular dysfunction ENTDEND  and hypersensitivity to sodium pentobarbital induced by chronic ENTC barium chloride ENTCEND ingestion
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant ENTC barium ENTCEND induced ENTD disturbances within the cardiovascular system ENTDEND
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced ENTD disturbances within the cardiovascular system ENTDEND . The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ketamine and ENTC xylazine ENTCEND anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced ENTD disturbances within the cardiovascular system ENTDEND . The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ENTC ketamine ENTCEND and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	The most distinctive aspect of the barium effect was a demonstrated ENTD hypersensitivity ENTDEND of the cardiovascular system to sodium pentobarbital. Under ENTC barbiturate ENTCEND anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats
0	Cardiovascular dysfunction and ENTD hypersensitivity ENTDEND  to ENTC sodium pentobarbital ENTCEND induced by chronic barium chloride ingestion
0	Cardiovascular dysfunction and ENTD hypersensitivity ENTDEND  to sodium pentobarbital induced by chronic ENTC barium chloride ENTCEND ingestion
0	The most distinctive aspect of the ENTC barium ENTCEND effect was a demonstrated ENTD hypersensitivity ENTDEND of the cardiovascular system to sodium pentobarbital
0	The most distinctive aspect of the barium effect was a demonstrated ENTD hypersensitivity ENTDEND  of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ketamine and ENTC xylazine ENTCEND anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	The most distinctive aspect of the barium effect was a demonstrated ENTD hypersensitivity ENTDEND  of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ENTC ketamine ENTCEND and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENTD hypertension ENTDEND that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment. Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system. The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under ENTC barbiturate ENTCEND anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats
0	Cardiovascular dysfunction and hypersensitivity to ENTC sodium pentobarbital ENTCEND  induced by chronic barium chloride ingestion.Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENTD hypertension ENTDEND that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment
1	Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic ENTC barium chloride ENTCEND  ingestion.Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENTD hypertension ENTDEND that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENTD hypertension ENTDEND  that was evident after 1 month of ENTC barium ENTCEND (100 micrograms/ml mineral fortified water) treatment
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENTD hypertension ENTDEND  that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment. Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system. The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ketamine and ENTC xylazine ENTCEND anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Barium-supplemented Long-Evans hooded rats were characterized by a persistent ENTD hypertension ENTDEND  that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment. Analysis of in vivo myocardial excitability, contractility, and metabolic characteristics at 16 months revealed other significant barium-induced disturbances within the cardiovascular system. The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital. Under barbiturate anesthesia, virtually all of the myocardial contractile indices were depressed significantly in barium-exposed rats relative to the corresponding control-fed rats. The lack of a similar response to ENTC ketamine ENTCEND and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response
0	Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENTD metabolic disturbances ENTDEND  and the hypersensitivity of the cardiovascular system to ENTC sodium pentobarbital ENTCEND suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from ENTC barium ENTCEND exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENTD metabolic disturbances ENTDEND , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	The lack of a similar response to ketamine and ENTC xylazine ENTCEND  anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENTD metabolic disturbances ENTDEND , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	The lack of a similar response to ENTC ketamine ENTCEND  and xylazine anesthesia revealed that the cardiovascular actions of sodium pentobarbital in barium-treated rats were linked specifically to this anesthetic, and were not representative of a generalized anesthetic response. Other myocardial pathophysiologic and metabolic changes induced by barium were manifest, irrespective of the anesthetic employed. The contractile element shortening velocity of the cardiac muscle fibers was significantly slower in both groups of barium-treated rats relative to the control groups, irrespective of the anesthetic regimen. Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity. In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats. Overall, the altered cardiac contractility and excitability characteristics, the myocardial ENTD metabolic disturbances ENTDEND , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure
0	A 77-year-old woman with refractory ENTD multiple myeloma ENTDEND was treated with a 4-day continuous intravenous infusion of vincristine and ENTC doxorubicin ENTCEND and 4 days of oral dexamethasone
0	Syndrome of inappropriate secretion of antidiuretic hormone after infusional ENTC vincristine ENTCEND .A 77-year-old woman with refractory ENTD multiple myeloma ENTDEND was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone
0	A 77-year-old woman with refractory ENTD multiple myeloma ENTDEND  was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENTC dexamethasone ENTCEND
0	A 77-year-old woman with refractory ENTD multiple myeloma ENTDEND  was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and weakness associated with hyponatremia. Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENTC sodium ENTCEND levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and ENTC doxorubicin ENTCEND  and 4 days of oral dexamethasone. Nine days after her second cycle she presented with ENTD lethargy ENTDEND and weakness associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of ENTC vincristine ENTCEND and doxorubicin and 4 days of oral dexamethasone. Nine days after her second cycle she presented with ENTD lethargy ENTDEND and weakness associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENTC dexamethasone ENTCEND . Nine days after her second cycle she presented with ENTD lethargy ENTDEND and weakness associated with hyponatremia
0	Nine days after her second cycle she presented with ENTD lethargy ENTDEND  and weakness associated with hyponatremia. Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENTC sodium ENTCEND levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and ENTC doxorubicin ENTCEND  and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and ENTD weakness ENTDEND associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of ENTC vincristine ENTCEND  and doxorubicin and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and ENTD weakness ENTDEND associated with hyponatremia
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENTC dexamethasone ENTCEND . Nine days after her second cycle she presented with lethargy and ENTD weakness ENTDEND associated with hyponatremia
0	Nine days after her second cycle she presented with lethargy and ENTD weakness ENTDEND  associated with hyponatremia. Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENTC sodium ENTCEND levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	Evaluation revealed the ENTD syndrome of inappropriate secretion of antidiuretic hormone ENTDEND  which was attributed to the vincristine infusion. After normal serum sodium levels returned, further ENTC doxorubicin ENTCEND and dexamethasone chemotherapy without vincristine did not produce this complication
1	ENTD Syndrome of inappropriate secretion of antidiuretic hormone ENTDEND  after infusional ENTC vincristine ENTCEND
0	Evaluation revealed the ENTD syndrome of inappropriate secretion of antidiuretic hormone ENTDEND , which was attributed to the vincristine infusion. After normal serum sodium levels returned, further doxorubicin and ENTC dexamethasone ENTCEND chemotherapy without vincristine did not produce this complication
0	Evaluation revealed the ENTD syndrome of inappropriate secretion of antidiuretic hormone ENTDEND , which was attributed to the vincristine infusion. After normal serum ENTC sodium ENTCEND levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and ENTC doxorubicin ENTCEND  and 4 days of oral dexamethasone. Nine days after her second cycle she presented with lethargy and weakness associated with ENTD hyponatremia ENTDEND
0	Nine days after her second cycle she presented with lethargy and weakness associated with ENTD hyponatremia ENTDEND . Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the ENTC vincristine ENTCEND infusion
0	A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral ENTC dexamethasone ENTCEND . Nine days after her second cycle she presented with lethargy and weakness associated with ENTD hyponatremia ENTDEND
0	Nine days after her second cycle she presented with lethargy and weakness associated with ENTD hyponatremia ENTDEND . Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone, which was attributed to the vincristine infusion. After normal serum ENTC sodium ENTCEND levels returned, further doxorubicin and dexamethasone chemotherapy without vincristine did not produce this complication
1	ENTC Penicillamine ENTCEND -related ENTD lichenoid dermatitis ENTDEND and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities
0	Penicillamine-related ENTD lichenoid dermatitis ENTDEND  and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic ENTC copper ENTCEND metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	During the follow-up of our patient, penicillamine was interrupted after the appearance of a ENTD lichenoid dermatitis ENTDEND  and ENTC zinc acetate ENTCEND permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND  We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENTC penicillamine ENTCEND was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENTC copper ENTCEND accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND
0	Penicillamine-related lichenoid dermatitis and utility of ENTC zinc acetate ENTCEND  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND
0	ENTC Penicillamine ENTCEND -related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and ENTD toxicity ENTDEND in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENTC copper ENTCEND  accumulation and ENTD toxicity ENTDEND in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Penicillamine-related lichenoid dermatitis and utility of ENTC zinc acetate ENTCEND  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and ENTD toxicity ENTDEND in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND  We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENTC penicillamine ENTCEND was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENTC copper ENTCEND  accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND
0	Penicillamine-related lichenoid dermatitis and utility of ENTC zinc acetate ENTCEND  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND
0	ENTC Penicillamine ENTCEND -related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, ENTD anxiety ENTDEND and SPECT abnormalities
0	Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, ENTD anxiety ENTDEND  and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic ENTC copper ENTCEND metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Penicillamine-related lichenoid dermatitis and utility of ENTC zinc acetate ENTCEND  in a Wilson disease patient with hepatic presentation, ENTD anxiety ENTDEND and SPECT abnormalities
0	We report a case of Wilson's disease with ENTD chronic liver disease ENTDEND  moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENTC penicillamine ENTCEND was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENTC copper ENTCEND  accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders. We report a case of Wilson's disease with ENTD chronic liver disease ENTDEND ; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe
0	We report a case of Wilson's disease with ENTD chronic liver disease ENTDEND ; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and ENTC zinc acetate ENTCEND permitted to continue the successful treatment of the patient without side-effects
0	Since most of Wilson's disease ENTC penicillamine ENTCEND treated patients do not seem to develop this ENTD skin lesion ENTDEND , it could be conceivable that a specific genetic factor is involved in drug response
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENTC copper ENTCEND  accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders. We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects. In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared. The safety of the zinc acetate allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson's disease. Since most of Wilson's disease penicillamine-treated patients do not seem to develop this ENTD skin lesion ENTDEND , it could be conceivable that a specific genetic factor is involved in drug response
0	The safety of the ENTC zinc acetate ENTCEND allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson's disease. Since most of Wilson's disease penicillamine-treated patients do not seem to develop this ENTD skin lesion ENTDEND , it could be conceivable that a specific genetic factor is involved in drug response
0	Since most of ENTD Wilson's disease ENTDEND ENTC penicillamine ENTCEND -treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response
0	ENTD Wilson's disease ENTDEND is an autosomal recessive disorder of hepatic ENTC copper ENTCEND metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders
0	Penicillamine-related lichenoid dermatitis and utility of ENTC zinc acetate ENTCEND  in a ENTD Wilson disease ENTDEND patient with hepatic presentation, anxiety and SPECT abnormalities
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND  We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENTC penicillamine ENTCEND was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENTC copper ENTCEND  accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND
0	Penicillamine-related lichenoid dermatitis and utility of ENTC zinc acetate ENTCEND  in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent ENTD hepatic, neurologic and psychiatric disorders ENTDEND
0	We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without ENTD depression ENTDEND  99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, ENTC penicillamine ENTCEND was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects
0	Wilson's disease is an autosomal recessive disorder of hepatic copper metabolism with consequent ENTC copper ENTCEND  accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric disorders. We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without ENTD depression ENTDEND , 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe
0	We report a case of Wilson's disease with chronic liver disease; moreover, in our patient, presenting also with high levels of state anxiety without ENTD depression ENTDEND , 99mTc-ECD-SPECT showed cortical hypoperfusion in frontal lobes, more marked on the left frontal lobe. During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and ENTC zinc acetate ENTCEND permitted to continue the successful treatment of the patient without side-effects
1	BACKGROUND: ENTC Acetaminophen ENTCEND induced ENTD hepatotoxicity ENTDEND is the most common cause of acute liver failure (ALF) in the UK
1	AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for ENTC acetaminophen ENTCEND induced ENTD ALF ENTDEND (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34)
0	AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease ( ENTD CLD ENTDEND  n=34). RESULTS: ENTC Acetaminophen ENTCEND -induced ALF patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups
0	We report the case of a 35-year-old patient suffering from ENTD schizo-affective disorder ENTDEND since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and ENTC lithium ENTCEND (1200 mg/day) (serum lithium=0
0	We report the case of a 35-year-old patient suffering from ENTD schizo-affective disorder ENTDEND  since the age of 19 years, treated by a combination of first-generation antipsychotics, ENTC zuclopenthixol ENTCEND (100 mg/day) and lithium (1200 mg/day) (serum lithium=0
0	Paradoxical severe agitation induced by add-on high-doses ENTC quetiapine ENTCEND  in ENTD schizo-affective disorder ENTDEND
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENTC lithium ENTCEND 0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of ENTD manic ENTDEND shift and akathisia were dismissed
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENTC zuclopenthixol ENTCEND  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of ENTD manic ENTDEND shift and akathisia were dismissed
0	The diagnoses of ENTD manic ENTDEND  shift and akathisia were dismissed. The withdrawal and the gradual reintroduction of ENTC quetiapine ENTCEND 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENTC lithium ENTCEND =0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no ENTD substance abuse disorder ENTDEND
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENTC zuclopenthixol ENTCEND  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no ENTD substance abuse disorder ENTDEND
0	This patient had no associated personality disorder (particularly no antisocial disorder) and no ENTD substance abuse disorder ENTDEND . Within the 48 h following the gradual introduction of ENTC quetiapine ENTCEND (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENTC lithium ENTCEND =0.85 mEq/l). This patient had no associated personality disorder (particularly no ENTD antisocial disorder ENTDEND ) and no substance abuse disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENTC zuclopenthixol ENTCEND  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no ENTD antisocial disorder ENTDEND ) and no substance abuse disorder
0	This patient had no associated personality disorder (particularly no ENTD antisocial disorder ENTDEND ) and no substance abuse disorder. Within the 48 h following the gradual introduction of ENTC quetiapine ENTCEND (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENTC lithium ENTCEND =0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe ENTD agitation ENTDEND without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder
0	Paradoxical severe ENTD agitation ENTDEND  induced by add-on high-doses quetiapine in schizo-affective disorder.We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENTC zuclopenthixol ENTCEND (100 mg/day) and lithium (1200 mg/day) (serum lithium=0
1	The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the ENTD agitation ENTDEND specifically to ENTC quetiapine ENTCEND
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENTC lithium ENTCEND =0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of manic shift and ENTD akathisia ENTDEND were dismissed
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENTC zuclopenthixol ENTCEND  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated personality disorder (particularly no antisocial disorder) and no substance abuse disorder. Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder. The diagnoses of manic shift and ENTD akathisia ENTDEND were dismissed
0	The diagnoses of manic shift and ENTD akathisia ENTDEND  were dismissed. The withdrawal and the gradual reintroduction of ENTC quetiapine ENTCEND 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, zuclopenthixol (100 mg/day) and lithium (1200 mg/day) (serum ENTC lithium ENTCEND =0.85 mEq/l). This patient had no associated ENTD personality disorder ENTDEND (particularly no antisocial disorder) and no substance abuse disorder
0	We report the case of a 35-year-old patient suffering from schizo-affective disorder since the age of 19 years, treated by a combination of first-generation antipsychotics, ENTC zuclopenthixol ENTCEND  (100 mg/day) and lithium (1200 mg/day) (serum lithium=0.85 mEq/l). This patient had no associated ENTD personality disorder ENTDEND (particularly no antisocial disorder) and no substance abuse disorder
0	Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or ENTD personality disorder ENTDEND  The diagnoses of manic shift and akathisia were dismissed. The withdrawal and the gradual reintroduction of ENTC quetiapine ENTCEND 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine
0	Increase in intragastric pressure during suxamethonium-induced ENTD muscle fasciculations ENTDEND  in children: inhibition by ENTC alfentanil ENTCEND
0	Anaesthesia was induced with ENTC thiopentone ENTCEND 5 mg kg-1. The incidence and intensity of ENTD muscle fasciculations ENTDEND caused by suxamethonium were significantly greater in the control than in the alfentanil group
1	Increase in intragastric pressure during ENTC suxamethonium ENTCEND -induced ENTD muscle fasciculations ENTDEND in children: inhibition by alfentanil
0	The intragastric pressure during ENTD muscle fasciculations ENTDEND was significantly higher in the control group (16 +/- 0.7 (SEM) cm ENTC H2O ENTCEND ) than in the alfentanil group (7
1	Both isomers of propranolol were capable of preventing adrenaline-induced ENTD cardiac arrhythmias ENTDEND in cats anaesthetized with ENTC halothane ENTCEND , but the mean dose of (-)-propranolol was 0
0	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both ENTC lactate ENTCEND and glucose.4. Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5. The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine. The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENTD cardiac arrhythmias ENTDEND in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	Blockade of ENTD arrhythmias ENTDEND with both isomers was surmountable by increasing the dose of adrenaline.7. Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ENTC ouabain ENTCEND in anaesthetized cats and dogs
0	(+)-Propranolol had no effect on fatty acid mobilization but significantly reduced the increments in both lactate and ENTC glucose ENTCEND 4. Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5. The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine. The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENTD cardiac arrhythmias ENTDEND in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
1	Both isomers of propranolol were capable of preventing ENTC adrenaline ENTCEND induced ENTD cardiac arrhythmias ENTDEND in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of ENTC procaine ENTCEND  The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENTD cardiac arrhythmias ENTDEND in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	The biological properties of the optical isomers of propranolol and their effects on ENTD cardiac arrhythmias ENTDEND .1. The optical isomers of propranolol have been compared for their beta-blocking and antiarrhythmic activities.2. In blocking the positive inotropic and chronotropic responses to ENTC isoprenaline ENTCEND , (+)-propranolol had less than one hundredth the potency of (-)-propranolol
0	(+)-Propranolol had no effect on ENTC fatty acid ENTCEND mobilization but significantly reduced the increments in both lactate and glucose.4. Both isomers of propranolol possessed similar depressant potency on isolated atrial muscle taken from guinea-pigs.5. The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of procaine. The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced ENTD cardiac arrhythmias ENTDEND in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0
0	The biological properties of the optical isomers of ENTC propranolol ENTCEND  and their effects on ENTD cardiac arrhythmias ENTDEND
0	Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with ENTC halothane ENTCEND , but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg. At the effective dose level of (+)-propranolol there was a significant prolongation of the PR interval of the electrocardiogram. Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7. Both isomers of propranolol were also capable of reversing ENTD ventricular tachycardia ENTDEND caused by ouabain in anaesthetized cats and dogs
1	Both isomers of propranolol were also capable of reversing ENTD ventricular tachycardia ENTDEND  caused by ENTC ouabain ENTCEND in anaesthetized cats and dogs
0	Blockade of arrhythmias with both isomers was surmountable by increasing the dose of ENTC adrenaline ENTCEND 7. Both isomers of propranolol were also capable of reversing ENTD ventricular tachycardia ENTDEND caused by ouabain in anaesthetized cats and dogs
0	The isomers of propranolol exhibited similar local anaesthetic potencies on an isolated frog nerve preparation at a level approximately three times that of ENTC procaine ENTCEND . The racemic compound was significantly less potent than either isomer.6. Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg. At the effective dose level of (+)-propranolol there was a significant prolongation of the PR interval of the electrocardiogram. Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7. Both isomers of propranolol were also capable of reversing ENTD ventricular tachycardia ENTDEND caused by ouabain in anaesthetized cats and dogs
0	Both isomers of ENTC propranolol ENTCEND were also capable of reversing ENTD ventricular tachycardia ENTDEND caused by ouabain in anaesthetized cats and dogs
1	ENTD Thoracic hematomyelia ENTDEND  secondary to ENTC coumadin ENTCEND anticoagulant therapy: a case report
1	In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin ( ENTC STZ ENTCEND  induced ENTD memory impaired ENTDEND rats was explored
0	In experiment set up 1: ENTD Memory deficit ENTDEND was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration. STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation. STZ also significantly increased the level of ROS, nitrite, ENTC Ca ENTCEND (2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	In experiment set up 1: ENTD Memory deficit ENTDEND  was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration. STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation. STZ also significantly increased the level of ROS, ENTC nitrite ENTCEND , Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	In the present study the role of glial activation and post synaptic ENTD toxicity ENTDEND in ICV ENTC Streptozotocin ENTCEND (STZ) induced memory impaired rats was explored
0	STZ also significantly increased the level of ROS, nitrite, ENTC Ca ENTCEND (2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENTD excitotoxicity ENTDEND
0	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENTD excitotoxicity ENTDEND . Increased expression and activity of Caspase-3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex. STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity. Oral treatment with ENTC Memantine ENTCEND (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	STZ also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENTD excitotoxicity ENTDEND . Increased expression and activity of Caspase-3 was also observed in STZ treated rat which specify apoptotic cell death in hippocampus and cortex. STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity. Oral treatment with Memantine (10mg/kg) and ENTC Ibuprofen ENTCEND (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	STZ also significantly increased the level of ROS, ENTC nitrite ENTCEND , Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and ENTD excitotoxicity ENTDEND
0	Present study clearly suggests that glial activation and post synaptic ENTD neurotoxicity ENTDEND are the key factors in ENTC STZ ENTCEND induced memory impairment and neuronal cell death
0	On the other hand, apoptotic marker, synaptic markers, mitochondrial activity and ENTC Ca ENTCEND 2+) levels remained unaffected. Collective data indicates that neuroinflammatory process and oxidative stress occurs earlier to apoptosis and does not affect memory function. Present study clearly suggests that glial activation and post synaptic ENTD neurotoxicity ENTDEND are the key factors in STZ induced memory impairment and neuronal cell death
0	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic ENTD neurotoxicity ENTDEND  Oral treatment with ENTC Memantine ENTCEND (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic ENTD neurotoxicity ENTDEND . Oral treatment with Memantine (10mg/kg) and ENTC Ibuprofen ENTCEND (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain
0	Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic ENTD neurotoxicity ENTDEND in rat brain. Further, in experiment set up 2: where memory function was not affected i.e. 7-9 days after STZ treatment. The level of GFAP, CD11b, TNF-a, ROS and ENTC nitrite ENTCEND levels were increased
1	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and ENTD neuroinflammation ENTDEND  ENTC STZ ENTCEND also significantly increased the level of ROS, nitrite, Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and ENTD neuroinflammation ENTDEND . STZ also significantly increased the level of ROS, nitrite, ENTC Ca ENTCEND (2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	Oral treatment with ENTC Memantine ENTCEND  (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain. Further, in experiment set up 2: where memory function was not affected i.e. 7-9 days after STZ treatment. The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased. On the other hand, apoptotic marker, synaptic markers, mitochondrial activity and Ca(2+) levels remained unaffected. Collective data indicates that ENTD neuroinflammatory ENTDEND process and oxidative stress occurs earlier to apoptosis and does not affect memory function
0	Oral treatment with Memantine (10mg/kg) and ENTC Ibuprofen ENTCEND  (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain. Further, in experiment set up 2: where memory function was not affected i.e. 7-9 days after STZ treatment. The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased. On the other hand, apoptotic marker, synaptic markers, mitochondrial activity and Ca(2+) levels remained unaffected. Collective data indicates that ENTD neuroinflammatory ENTDEND process and oxidative stress occurs earlier to apoptosis and does not affect memory function
0	STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and ENTD neuroinflammation ENTDEND . STZ also significantly increased the level of ROS, ENTC nitrite ENTCEND , Ca(2+) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity
0	The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ENTC ecstasy ENTCEND  because recent and less recent users of these drugs within this group were similarly impaired. Possible parallels between RC users and ENTD psychopaths ENTDEND with respect to impaired fear recognition, amygdala dysfunction, and etiology are discussed
0	The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of ENTC cocaine ENTCEND  or ecstasy, because recent and less recent users of these drugs within this group were similarly impaired. Possible parallels between RC users and ENTD psychopaths ENTDEND with respect to impaired fear recognition, amygdala dysfunction, and etiology are discussed
0	The selective ENTD deficit in fear recognition ENTDEND accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine, or ENTC ecstasy ENTCEND , because recent and less recent users of these drugs within this group were similarly impaired
1	ENTD Impaired fear recognition ENTDEND  in regular recreational ENTC cocaine ENTCEND users
1	Administration of flutamide, letrozole or ENTC tamoxifen ENTCEND significantly ENTD impaired the memory ENTDEND in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment
0	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced ENTD memory impairment ENTDEND in male rats. METHODS: Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 ug) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ. Castration surgery was performed in another group of rats, and the passive avoidance task was assessed 4 weeks after the operation. Testosterone (1 mg.kg(-1).d(-1), sc), the ENTC androgen ENTCEND receptor antagonist flutamide (10 mg
0	Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced ENTD memory impairment ENTDEND  CONCLUSION: ENTC Testosterone ENTCEND administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats
1	AIM: To study the effects of testosterone on streptozotocin ( ENTC STZ ENTCEND -induced ENTD memory impairment ENTDEND in male rats
1	Administration of flutamide, ENTC letrozole ENTCEND or tamoxifen significantly ENTD impaired the memory ENTDEND in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment
1	Administration of ENTC flutamide ENTCEND  letrozole or tamoxifen significantly ENTD impaired the memory ENTDEND in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment
0	AIM: To study the effects of testosterone on streptozotocin (STZ)-induced ENTD memory impairment ENTDEND  in male rats. METHODS: Adult male Wistar rats were intracerebroventricularly (icv) infused with STZ (750 ug) on d 1 and d 3, and a passive avoidance task was assessed 2 weeks after the first injection of STZ. Castration surgery was performed in another group of rats, and the passive avoidance task was assessed 4 weeks after the operation. Testosterone (1 mg.kg(-1).d(-1), sc), the androgen receptor antagonist flutamide (10 mg.kg(-1).d(-1), ip), the ENTC estrogen ENTCEND receptor antagonist tamoxifen (1 mg
0	A 54-year-old man with severe left ventricular dysfunction due to ENTD dilated cardiomyopathy ENTDEND was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of nifekalant hydrochloride, sustained VT was terminated. An alternate class III agent, sotalol, was also effective for the prevention of VT. However, one month after switching over nifekalant to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting ENTC diltiazem ENTCEND
0	ENTC Sotalol ENTCEND -induced coronary spasm in a patient with ENTD dilated cardiomyopathy ENTDEND associated with sustained ventricular tachycardia
0	A 54-year-old man with severe left ventricular dysfunction due to ENTD dilated cardiomyopathy ENTDEND  was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of ENTC nifekalant hydrochloride ENTCEND , sustained VT was terminated
0	A 54-year-old man with severe left ENTD ventricular dysfunction ENTDEND due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of nifekalant hydrochloride, sustained VT was terminated. An alternate class III agent, sotalol, was also effective for the prevention of VT. However, one month after switching over nifekalant to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting ENTC diltiazem ENTCEND
0	ENTC Sotalol ENTCEND -induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.A 54-year-old man with severe left ENTD ventricular dysfunction ENTDEND due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT)
0	A 54-year-old man with severe left ENTD ventricular dysfunction ENTDEND  due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia (VT). After the administration of ENTC nifekalant hydrochloride ENTCEND , sustained VT was terminated
0	An alternate class III agent, sotalol, was also effective for the prevention of ENTD VT ENTDEND  However, one month after switching over nifekalant to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting ENTC diltiazem ENTCEND
0	An alternate class III agent, ENTC sotalol ENTCEND  was also effective for the prevention of ENTD VT ENTDEND
0	After the administration of ENTC nifekalant hydrochloride ENTCEND , sustained ENTD VT ENTDEND was terminated
0	ST elevation with chest discomfort disappeared since he began taking long-acting ENTC diltiazem ENTCEND . ENTD Coronary vasospasm ENTDEND may be induced by the non-selective beta-blocking properties of sotalol
1	ENTC Sotalol ENTCEND -induced ENTD coronary spasm ENTDEND in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia
0	However, one month after switching over ENTC nifekalant ENTCEND to sotalol, a short duration of ST elevation was documented in ECG monitoring at almost the same time for three consecutive days. ST elevation with chest discomfort disappeared since he began taking long-acting diltiazem. ENTD Coronary vasospasm ENTDEND may be induced by the non-selective beta-blocking properties of sotalol
1	The current study identified the optimal dose of rocuronium to prevent ENTC succinylcholine ENTCEND induced ENTD fasciculation ENTDEND and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine
0	Optimal precurarizing dose of ENTC rocuronium ENTCEND  to decrease ENTD fasciculation ENTDEND and myalgia following succinylcholine administration
1	Optimal precurarizing dose of rocuronium to decrease fasciculation and ENTD myalgia ENTDEND  following ENTC succinylcholine ENTCEND administration
0	RESULTS: The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of ENTC rocuronium ENTCEND (P < 0.001). Those of ENTD myalgia ENTDEND tend to decrease according to increasing the amount of precurarizing dose of rocuronium, but there was no significance (P = 0
0	Butyrylcholinesterase deficiency is characterized by prolonged ENTD apnea ENTDEND after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with ENTC butyrylthiocholine ENTCEND (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
0	Butyrylcholinesterase deficiency is characterized by prolonged ENTD apnea ENTDEND  after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and ENTC benzoylcholine ENTCEND , and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
1	Butyrylcholinesterase deficiency is characterized by prolonged ENTD apnea ENTDEND  after the use of muscle relaxants (suxamethonium or ENTC mivacurium ENTCEND ) in patients who have mutations in the BCHE gene
0	Butyrylcholinesterase deficiency is characterized by prolonged ENTD apnea ENTDEND  after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of ENTC dibucaine ENTCEND and fluoride numbers fit with heterozygous atypical silent genotype
1	Val204Asp) causes loss of activity and prolonged ENTD apnea ENTDEND  with ENTC suxamethonium ENTCEND
0	Butyrylcholinesterase deficiency is characterized by prolonged ENTD apnea ENTDEND  after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and ENTC fluoride ENTCEND numbers fit with heterozygous atypical silent genotype
0	ENTD Butyrylcholinesterase deficiency ENTDEND is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with ENTC butyrylthiocholine ENTCEND (BTC) and benzoylcholine, and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
0	ENTD Butyrylcholinesterase deficiency ENTDEND  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and ENTC benzoylcholine ENTCEND , and values of dibucaine and fluoride numbers fit with heterozygous atypical silent genotype
1	ENTD Butyrylcholinesterase deficiency ENTDEND  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or ENTC mivacurium ENTCEND ) in patients who have mutations in the BCHE gene
0	ENTD Butyrylcholinesterase deficiency ENTDEND  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of ENTC dibucaine ENTCEND and fluoride numbers fit with heterozygous atypical silent genotype
1	Val204Asp) causes loss of activity and prolonged apnea with ENTC suxamethonium ENTCEND ENTD Butyrylcholinesterase deficiency ENTDEND is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene
0	ENTD Butyrylcholinesterase deficiency ENTDEND  is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.Val204Asp). Inhibition studies, kinetic analysis and molecular dynamics were undertaken to understand how this mutation disrupts the catalytic triad and determines a "silent" phenotype. Low activity of patient plasma butyrylcholinesterase with butyrylthiocholine (BTC) and benzoylcholine, and values of dibucaine and ENTC fluoride ENTCEND numbers fit with heterozygous atypical silent genotype
1	A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent ENTC albuterol ENTCEND (INA) treatments is reported. Forty matched pairs of patients with asthma are compared. CNA was administered for a mean of 11 +/- 10 hr. The incidence of ENTD cardiac dysrhythmias ENTDEND was similar between groups
0	A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent ENTC albuterol ENTCEND  (INA) treatments is reported. Forty matched pairs of patients with asthma are compared. CNA was administered for a mean of 11 +/- 10 hr. The incidence of cardiac dysrhythmias was similar between groups. Symptomatic ENTD hypokalemia ENTDEND did not occur
0	Continuously nebulized ENTC albuterol ENTCEND  in severe exacerbations of ENTD asthma ENTDEND in adults: a case-controlled study
0	The severity of ENTD pain ENTDEND due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated. RESULTS: Study results showed that myoclonus incidence was 85%, 40%, 70%, and 25% in Group NP, Group F, Group M, and Group FM, respectively, and were significantly lower in Group F and Group FM. CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and ENTC midazolam ENTCEND was effective in preventing etomidate-induced myoclonus
0	The severity of ENTD pain ENTDEND  due to ENTC etomidate ENTCEND injection, mean arterial pressure, heart rate, and adverse effects were also evaluated
0	The severity of ENTD pain ENTDEND  due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated. RESULTS: Study results showed that myoclonus incidence was 85%, 40%, 70%, and 25% in Group NP, Group F, Group M, and Group FM, respectively, and were significantly lower in Group F and Group FM. CONCLUSIONS: We conclude that pretreatment with ENTC fentanyl ENTCEND or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus
0	BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and ENTC midazolam ENTCEND to prevent etomidate-induced ENTD myoclonus ENTDEND
1	Prevention of ENTC etomidate ENTCEND -induced ENTD myoclonus ENTDEND : which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study
0	Prevention of etomidate-induced ENTD myoclonus ENTDEND : which is superior: ENTC Fentanyl ENTCEND , midazolam, or a combination? A Retrospective comparative study
0	kg-1 (Group M), and ENTC midazolam ENTCEND 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM). Patients who received the same anesthetic procedure were selected: 2 minutes after intravenous injections of the pretreatment drugs, anesthesia is induced with 0.3 mg.kg-1 etomidate injected intravenously over a period of 20-30 seconds. ENTD Myoclonic movements ENTDEND are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection
0	kg-1 ENTC etomidate ENTCEND injected intravenously over a period of 20-30 seconds. ENTD Myoclonic movements ENTDEND are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection
0	kg-1 + ENTC fentanyl ENTCEND 0.5 ug.kg-1 (Group FM). Patients who received the same anesthetic procedure were selected: 2 minutes after intravenous injections of the pretreatment drugs, anesthesia is induced with 0.3 mg.kg-1 etomidate injected intravenously over a period of 20-30 seconds. ENTD Myoclonic movements ENTDEND are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection
0	Rhabdomyolysis in a ENTD hepatitis C virus infected ENTDEND  patient treated with ENTC telaprevir ENTCEND and simvastatin
0	Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and ENTC simvastatin ENTCEND .A 46-year old man with a chronic ENTD hepatitis C virus infection ENTDEND received triple therapy with ribavirin, pegylated interferon and telaprevir
0	A 46-year old man with a chronic ENTD hepatitis C virus infection ENTDEND  received triple therapy with ribavirin, ENTC pegylated interferon ENTCEND and telaprevir
0	A 46-year old man with a chronic ENTD hepatitis C virus infection ENTDEND  received triple therapy with ENTC ribavirin ENTCEND , pegylated interferon and telaprevir
0	A 46-year old man with a chronic ENTD hepatitis C virus infection ENTDEND  received triple therapy with ribavirin, pegylated interferon and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected. The ENTC creatine ENTCEND kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline
0	Simvastatin plasma concentration increased 30 times in this patient and statin induced ENTD muscle toxicity ENTDEND is related to the concentration of the statin in blood. In conclusion, with this case we illustrate that ENTC telaprevir ENTCEND as well as statins are susceptible to clinical relevant drug-drug interactions
1	Simvastatin plasma concentration increased 30 times in this patient and ENTC statin ENTCEND induced ENTD muscle toxicity ENTDEND is related to the concentration of the statin in blood
0	Fourteen days after hospitalization, ENTC creatine ENTCEND kinase level had returned to 230 IU/L and the patient was discharged. Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale. The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance. Simvastatin plasma concentration increased 30 times in this patient and statin induced ENTD muscle toxicity ENTDEND is related to the concentration of the statin in blood
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and ENTC telaprevir ENTCEND  The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because ENTD toxicity ENTDEND due to a drug-drug interaction was suspected
0	At admission ENTC simvastatin ENTCEND and all antiviral drugs were discontinued because ENTD toxicity ENTDEND due to a drug-drug interaction was suspected
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, ENTC pegylated interferon ENTCEND  and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because ENTD toxicity ENTDEND due to a drug-drug interaction was suspected
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ENTC ribavirin ENTCEND , pegylated interferon and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because ENTD toxicity ENTDEND due to a drug-drug interaction was suspected
0	At admission simvastatin and all antiviral drugs were discontinued because ENTD toxicity ENTDEND  due to a drug-drug interaction was suspected. The ENTC creatine ENTCEND kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline
1	ENTD Rhabdomyolysis ENTDEND  in a hepatitis C virus infected patient treated with ENTC telaprevir ENTCEND and simvastatin
1	One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed ENTD rhabdomyolysis ENTDEND  At admission ENTC simvastatin ENTCEND and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected
0	A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, ENTC pegylated interferon ENTCEND  and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed ENTD rhabdomyolysis ENTDEND
0	ENTD Rhabdomyolysis ENTDEND  in a hepatitis C virus infected patient treated with telaprevir and simvastatin.A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ENTC ribavirin ENTCEND , pegylated interferon and telaprevir
0	One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed ENTD rhabdomyolysis ENTDEND . At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected. The ENTC creatine ENTCEND kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline
0	One day after experimental myocardial infarction, six additional ENTC halothane ENTCEND anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared. After 45 min, 1 mg/kg bupivacaine was injected over 5 min, again followed by 4 micrograms.kg-1.min-1 epinephrine. In these dogs, the prodysrhythmic response to epinephrine was also mitigated by preceding bupivacaine. Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct ENTD dysrhythmias ENTDEND
0	Since bupivacaine and ENTC epinephrine ENTCEND may both precipitate ENTD dysrhythmias ENTDEND , circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine
0	Since bupivacaine and epinephrine may both precipitate ENTD dysrhythmias ENTDEND , circulating ENTC bupivacaine ENTCEND during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine
0	One day after experimental ENTD myocardial infarction ENTDEND  six additional ENTC halothane ENTCEND -anesthetized dogs received 4 micrograms
0	We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of ENTC epinephrine ENTCEND in conscious, healthy dogs and in anesthetized dogs with ENTD myocardial infarction ENTDEND
0	Epinephrine shortened QT less after ENTC bupivacaine ENTCEND than in control animals. One day after experimental ENTD myocardial infarction ENTDEND , six additional halothane-anesthetized dogs received 4 micrograms
0	One day after experimental myocardial infarction, six additional ENTC halothane ENTCEND -anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until ENTD VT ENTDEND appeared
1	min-1 ENTC epinephrine ENTCEND until ENTD VT ENTDEND appeared
0	In the bupivacaine groups, epinephrine caused fewer prodysrhythmic effects than without ENTC bupivacaine ENTCEND  ENTD VT ENTDEND appeared in fewer dogs and at a later time, and there were more sinoatrial beats and less ectopies
0	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or ENTC diltiazem ENTCEND  In the presence of ENTD coronary artery stenosis ENTDEND , 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram
0	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial ENTD coronary stenosis ENTDEND .Effects of CD-832 on ENTC isoproterenol ENTCEND (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem
0	Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial ENTD coronary stenosis ENTDEND .Effects of ENTC CD-832 ENTCEND on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem
0	Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for ENTC nifedipine ENTCEND or diltiazem. In the presence of ENTD coronary artery stenosis ENTDEND , 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram
0	Effects of a new ENTC calcium ENTCEND  antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial ENTD coronary stenosis ENTDEND
0	01) at 3 min after ISO infusion with ENTD stenosis ENTDEND  ENTC Diltiazem ENTCEND (30 micrograms/kg/min) also prevented the decrease in percentage segmental shortening from 34 +/- 14% to 63 +/- 18% of the control value (P <
0	After the control ENTC ISO ENTCEND infusion with ENTD stenosis ENTDEND was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion
0	01) at 3 min after ISO infusion with ENTD stenosis ENTDEND  These data show that ENTC CD-832 ENTCEND improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832
0	After the control ISO infusion with ENTD stenosis ENTDEND  was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), ENTC nifedipine ENTCEND (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion
0	Effects of a new ENTC calcium ENTCEND  antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem. In the presence of coronary artery stenosis, 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram. After the control ISO infusion with ENTD stenosis ENTDEND was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion
0	Effects of CD-832 on isoproterenol (ISO)-induced ENTD myocardial ischemia ENTDEND were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or ENTC diltiazem ENTCEND
1	These data show that CD-832 improves ENTD myocardial ischemia ENTDEND during ENTC ISO ENTCEND infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832
0	These data show that ENTC CD-832 ENTCEND  improves ENTD myocardial ischemia ENTDEND during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832
0	Effects of CD-832 on isoproterenol (ISO)-induced ENTD myocardial ischemia ENTDEND  were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for ENTC nifedipine ENTCEND or diltiazem
0	Effects of a new ENTC calcium ENTCEND  antagonist, CD-832, on isoproterenol-induced ENTD myocardial ischemia ENTDEND in dogs with partial coronary stenosis
1	ENTC Amiodarone ENTCEND -induced ENTD myxoedema coma ENTDEND
0	The 24 hour excretion of ENTC iodine ENTCEND was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENTD myxoedema coma ENTDEND in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	The patient was maintained on ENTC levothyroxine ENTCEND 175 (g POorally daily. A thyroid ultrasound showed diffuse heterogeneity. The 24 hour excretion of iodine was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENTD myxoedema coma ENTDEND in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	Amiodarone-induced ENTD myxoedema coma ENTDEND .A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENTC steroids ENTCEND ; he was intubated and admitted to the intensive care unit
1	A 62-year-old man was found to have bradycardia, ENTD hypothermia ENTDEND and respiratory failure 3 weeks after initiation of ENTC amiodarone ENTCEND therapy for atrial fibrillation
0	A 62-year-old man was found to have bradycardia, ENTD hypothermia ENTDEND  and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENTC thyroxine ENTCEND (FT4) was <0
0	A 62-year-old man was found to have bradycardia, ENTD hypothermia ENTDEND  and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENTC steroids ENTCEND ; he was intubated and admitted to the intensive care unit
0	This case represents the most thoroughly investigated case of ENTC amiodarone ENTCEND induced myxoedema coma with a history significant for subclinical ENTD thyroid disease ENTDEND
0	The 24 hour excretion of ENTC iodine ENTCEND  was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement. This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical ENTD thyroid disease ENTDEND
0	The patient was maintained on ENTC levothyroxine ENTCEND  175 (g POorally daily. A thyroid ultrasound showed diffuse heterogeneity. The 24 hour excretion of iodine was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement. This case represents the most thoroughly investigated case of amiodarone-induced myxoedema coma with a history significant for subclinical ENTD thyroid disease ENTDEND
1	ENTC Amiodarone ENTCEND -induced myxoedema coma.A 62-year-old man was found to have ENTD bradycardia ENTDEND , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation
0	A 62-year-old man was found to have ENTD bradycardia ENTDEND , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENTC thyroxine ENTCEND (FT4) was <0
0	A 62-year-old man was found to have ENTD bradycardia ENTDEND , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENTC steroids ENTCEND ; he was intubated and admitted to the intensive care unit
0	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of ENTC amiodarone ENTCEND  therapy for ENTD atrial fibrillation ENTDEND
0	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for ENTD atrial fibrillation ENTDEND . Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENTC thyroxine ENTCEND (FT4) was <0
0	A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for ENTD atrial fibrillation ENTDEND . Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENTC steroids ENTCEND ; he was intubated and admitted to the intensive care unit
1	A 62-year-old man was found to have bradycardia, hypothermia and ENTD respiratory failure ENTDEND 3 weeks after initiation of ENTC amiodarone ENTCEND therapy for atrial fibrillation
0	A 62-year-old man was found to have bradycardia, hypothermia and ENTD respiratory failure ENTDEND  3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free ENTC thyroxine ENTCEND (FT4) was <0
0	A 62-year-old man was found to have bradycardia, hypothermia and ENTD respiratory failure ENTDEND  3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENTC steroids ENTCEND ; he was intubated and admitted to the intensive care unit
1	ENTC Amiodarone ENTCEND -induced ENTD myxoedema coma ENTDEND
0	The 24 hour excretion of ENTC iodine ENTCEND  was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENTD myxoedema coma ENTDEND in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	The patient was maintained on ENTC levothyroxine ENTCEND  175 (g POorally daily. A thyroid ultrasound showed diffuse heterogeneity. The 24 hour excretion of iodine was 3657 (mcg (25-756 ( mcg). The only two cases of amiodarone-induced ENTD myxoedema coma ENTDEND in the literature report patient death despite supportive therapy and thyroid hormone replacement
0	Amiodarone-induced ENTD myxoedema coma ENTDEND .A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation. Thyroid-stimulating hormone was found to be 168 uIU/mL (nl. 0.3-5 uIU/mL) and free thyroxine (FT4) was <0.2 ng/dL (nl. 0.8-1.8 ng/dL). He received intravenous fluids, vasopressor therapy and stress dose ENTC steroids ENTCEND ; he was intubated and admitted to the intensive care unit
0	A large population-based follow-up study of trimethoprim-sulfamethoxazole, ENTC trimethoprim ENTCEND , and cephalexin for uncommon serious ENTD drug toxicity ENTDEND
0	A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and ENTC cephalexin ENTCEND  for uncommon serious ENTD drug toxicity ENTDEND
0	A large population-based follow-up study of ENTC trimethoprim-sulfamethoxazole ENTCEND , trimethoprim, and cephalexin for uncommon serious ENTD drug toxicity ENTDEND
0	2/100,000) and those prescribed ENTC trimethoprim ENTCEND alone (3.8/100,000). The risk for those prescribed cephalexin was somewhat lower (2.0/100,000). Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with ENTD erythema multiforme ENTDEND and Stevens-Johnson syndrome, four were exposed to TMP-SMZ
0	The risk for those prescribed ENTC cephalexin ENTCEND was somewhat lower (2.0/100,000). Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with ENTD erythema multiforme ENTDEND and Stevens-Johnson syndrome, four were exposed to TMP-SMZ
0	Only five patients experienced blood disorders, one of whom was exposed to ENTC TMP-SMZ ENTCEND  of seven with ENTD erythema multiforme ENTDEND and Stevens-Johnson syndrome, four were exposed to TMP-SMZ
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed ENTC trimethoprim ENTCEND alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENTC cephalexin ENTCEND  to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole ( ENTC TMP-SMZ ENTCEND , 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed ENTC trimethoprim ENTCEND  alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENTC cephalexin ENTCEND , to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole ( ENTC TMP-SMZ ENTCEND ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed ENTC trimethoprim ENTCEND  alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENTC cephalexin ENTCEND , to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole ( ENTC TMP-SMZ ENTCEND ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
0	2/100,000) and those prescribed ENTC trimethoprim ENTCEND  alone (3.8/100,000). The risk for those prescribed cephalexin was somewhat lower (2.0/100,000). Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and ENTD Stevens-Johnson syndrome ENTDEND , four were exposed to TMP-SMZ
1	The one case of ENTD toxic epidermal necrolysis ENTDEND occurred in a patient who took ENTC cephalexin ENTCEND
1	Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to ENTC TMP-SMZ ENTCEND  The one case of ENTD toxic epidermal necrolysis ENTDEND occurred in a patient who took cephalexin
1	The risk of clinically important idiopathic ENTD liver disease ENTDEND was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed ENTC trimethoprim ENTCEND alone (3
1	We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed ENTC cephalexin ENTCEND , to estimate the risk of serious ENTD liver, blood, skin, and renal disorders ENTDEND resulting in referral or hospitalization associated with these drugs
1	The risk of clinically important idiopathic ENTD liver disease ENTDEND  was similar for persons prescribed ENTC TMP-SMZ ENTCEND (5
0	Longitudinal association of ENTC alcohol ENTCEND  use with ENTD HIV disease ENTDEND progression and psychological health of women with HIV
1	The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies- ENTD Depression ENTDEND Scale), and ENTC alcohol ENTCEND use assessment at enrollment, and semiannually until March 2000
0	This study shows that ENTC busulfan ENTCEND ENTD neurotoxicity ENTDEND is dose-dependent in children and efficiently prevented by clonazepam
0	This study shows that busulfan ENTD neurotoxicity ENTDEND  is dose-dependent in children and efficiently prevented by ENTC clonazepam ENTCEND
0	5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid ENTD tumors ENTDEND  brain tumors excluded. ENTC Busulfan ENTCEND was given p
0	Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without ENTD central nervous system disease ENTDEND under 600 mg/m2 ENTC busulfan ENTCEND with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1
0	Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without ENTD central nervous system disease ENTDEND  under 600 mg/m2 busulfan with ENTC clonazepam ENTCEND :busulfan cerebrospinal fluid:plasma ratio was 1
1	5%) developed ENTD seizures ENTDEND during the 4 days of the ENTC busulfan ENTCEND course or within 24 h after the last dosing
0	5%) developed ENTD seizures ENTDEND  during the 4 days of the busulfan course or within 24 h after the last dosing. When the total busulfan dose was taken into account, there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg/kg (1 of 57, 1.7%) and patients under 600 mg/m2 (6 of 39, 15.4%) (P less than 0.02). Twenty-seven patients were given a 600-mg/m2 busulfan total dose with continuous i.v. infusion of ENTC clonazepam ENTCEND ; none had any neurological symptoms
0	infusion of clonazepam; none had any ENTD neurological symptoms ENTDEND  ENTC Busulfan ENTCEND levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1
0	infusion of ENTC clonazepam ENTCEND ; none had any ENTD neurological symptoms ENTDEND
0	5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, ENTD brain tumors ENTDEND excluded. ENTC Busulfan ENTCEND was given p
0	In the absence of ENTC amiodarone ENTCEND therapy, a second bladder irrigation did not induce TdP despite hypokalemia and ENTD hypomagnesemia ENTDEND
0	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and ENTC digoxin ENTCEND excess. Transient prolongation of the QT during bladder irrigation prompted the episode of TdP. It is well known that bradycardia exacerbates acquired TdP. The authors speculate that the increased vagal tone during bladder irrigation, a vagal maneuver, in the context of amiodarone therapy resulted in amiodarone-induced proarrhythmia. In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and ENTD hypomagnesemia ENTDEND
1	ENTC Amiodarone ENTCEND -induced ENTD torsade de pointes ENTDEND during bladder irrigation: an unusual presentation--a case report
0	Consistent with other reports this case of ENTD TdP ENTDEND occurred in the context of multiple exacerbating factors including hypokalemia and ENTC digoxin ENTCEND excess
0	In the absence of ENTC amiodarone ENTCEND  therapy, a second bladder irrigation did not induce TdP despite ENTD hypokalemia ENTDEND and hypomagnesemia
0	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including ENTD hypokalemia ENTDEND and ENTC digoxin ENTCEND excess
0	It is well known that ENTD bradycardia ENTDEND exacerbates acquired TdP. The authors speculate that the increased vagal tone during bladder irrigation, a vagal maneuver, in the context of ENTC amiodarone ENTCEND therapy resulted in amiodarone-induced proarrhythmia
0	Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and ENTC digoxin ENTCEND  excess. Transient prolongation of the QT during bladder irrigation prompted the episode of TdP. It is well known that ENTD bradycardia ENTDEND exacerbates acquired TdP
1	ENTC Linezolid ENTCEND -induced ENTD optic neuropathy ENTDEND
0	ENTC Ethambutol ENTCEND induced ENTD toxic optic neuropathy ENTDEND was suspected and tablet ethambutol was withdrawn
0	ENTD Deterioration of vision ENTDEND occurred despite withdrawal of ethambutol. Discontinuation of ENTC linezolid ENTCEND resulted in marked improvement of vision
0	Ethambutol-induced toxic optic neuropathy was suspected and tablet ENTC ethambutol ENTCEND was withdrawn. ENTD Deterioration of vision ENTDEND occurred despite withdrawal of ethambutol
0	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including ENTC linezolid ENTCEND and ethambutol for ENTD extensively drug-resistant tuberculosis ENTDEND (XDR-TB) presented to us with painless progressive loss of vision in both eyes
0	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ENTC ethambutol ENTCEND for ENTD extensively drug-resistant tuberculosis ENTDEND (XDR-TB) presented to us with painless progressive loss of vision in both eyes
1	Color vision was defective and fundus examination revealed ENTD optic disc edema ENTDEND in both eyes. Ethambutol-induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn. Deterioration of vision occurred despite withdrawal of ethambutol. Discontinuation of ENTC linezolid ENTCEND resulted in marked improvement of vision
0	Color vision was defective and fundus examination revealed ENTD optic disc edema ENTDEND  in both eyes. ENTC Ethambutol ENTCEND -induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn
0	We describe a case of progressive ENTD loss of vision ENTDEND associated with ENTC linezolid ENTCEND therapy
0	A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ENTC ethambutol ENTCEND  for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive ENTD loss of vision ENTDEND in both eyes
1	The effects on ENTC isoproterenol ENTCEND ENTD tachycardia ENTDEND were determined before and after atropine (0
0	The effects on isoproterenol ENTD tachycardia ENTDEND  were determined before and after ENTC atropine ENTCEND (0
0	We compared the effects of single doses of 50 mg ENTC atenolol ENTCEND (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced ENTD tachycardia ENTDEND in two experiments involving nine normal subjects
0	We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg ENTC propranolol ENTCEND (nonselective), and placebo on both exercise- and isoproterenol-induced ENTD tachycardia ENTDEND in two experiments involving nine normal subjects
0	25 per cent to 2 per cent, their vehicle, and 1 per cent silver sulphadiazine (AgSD) cream, an antimicrobial agent frequently used for topical treatment of ENTD burn ENTDEND wounds. The other site was always treated with ENTC AgSD ENTCEND cream
0	Effective topical antimicrobial agents decrease infection and mortality in ENTD burn ENTDEND patients. ENTC Chlorhexidine phosphanilate ENTCEND (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application
0	Effective topical antimicrobial agents decrease ENTD infection ENTDEND and mortality in burn patients. Chlorhexidine phosphanilate (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application. This study compared various concentrations of CHP to determine if a tolerable concentration could be identified with retention of antimicrobial efficacy. Twenty-nine burn patients, each with two similar burns which could be separately treated, were given pairs of treatments at successive 12-h intervals over a 3-day period. One burn site was treated with each of four different CHP concentrations, from 0.25 per cent to 2 per cent, their vehicle, and 1 per cent ENTC silver sulphadiazine ENTCEND (AgSD) cream, an antimicrobial agent frequently used for topical treatment of burn wounds
0	Effective topical antimicrobial agents decrease ENTD infection ENTDEND  and mortality in burn patients. ENTC Chlorhexidine phosphanilate ENTCEND (CHP), a new broad-spectrum antimicrobial agent, has been evaluated as a topical burn wound dressing in cream form, but preliminary clinical trials reported that it was painful upon application
0	25 per cent CHP cream was closest to ENTC AgSD ENTCEND in ENTD pain ENTDEND tolerance; however, none of the treatments differed statistically from AgSD or from each other
1	25 per cent ENTC CHP ENTCEND cream was closest to AgSD in ENTD pain ENTDEND tolerance; however, none of the treatments differed statistically from AgSD or from each other
1	Loss of endothelial cell-derived nitric oxide ( ENTC NO ENTCEND  in ENTD hypertension ENTDEND is a hallmark of arterial dysfunction
0	Maximum contraction of vena cava to ENTC norepinephrine ENTCEND (37% control) also was reduced but no change in response to ET-1 was observed. Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA ENTD hypertension ENTDEND at 1 or 2 weeks after LNNA
0	Similarly, ganglionic blockade with ENTC hexamethonium ENTCEND caused a significantly greater fall in LNNA ENTD hypertensive ENTDEND rats (76 +/- 9 mm Hg) compared with control rats (35 +/- 10 mm Hg)
0	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in ENTC LNNA ENTCEND ENTD hypertension ENTDEND at 1 or 2 weeks after LNNA
0	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA ENTD hypertension ENTDEND  at 1 or 2 weeks after LNNA. The superoxide scavenger ENTC tempol ENTCEND (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg)
0	Mean circulatory filling pressure, an in vivo measure of venomotor tone, was not elevated in LNNA ENTD hypertension ENTDEND  at 1 or 2 weeks after LNNA. The ENTC superoxide ENTCEND scavenger tempol (30, 100, and 300 micromol kg(-1), IV) did not change arterial pressure in control rats but caused a dose-dependent decrease in LNNA rats (-18 +/- 8, -26 +/- 15, and -54 +/- 11 mm Hg)
0	Loss of endothelial cell-derived nitric oxide ( ENTC NO ENTCEND ) in hypertension is a hallmark of ENTD arterial dysfunction ENTDEND
0	Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of ENTD arterial dysfunction ENTDEND . Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity. These include augmented endothelin-1 (ET-1) release, increased sympathetic nervous system activity, and elevated tissue oxidative stress. We hypothesized that increased venous smooth muscle (venomotor) tone plays a role in ENTC Nomega-nitro-L-arginine ENTCEND (LNNA) hypertension through these mechanisms
0	Hypercalcemia, ENTD arrhythmia ENTDEND , and mood stabilizers.Recent findings in a bipolar patient receiving maintenance ENTC lithium ENTCEND therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia
1	Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with ENTC lithium ENTCEND associated ENTD hypercalcemia ENTDEND
0	Thus, two control groups were generated: group C1, which included age- and sex-comparable ENTC lithium ENTCEND treated ENTD bipolar ENTDEND normocalcemic patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers
0	After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non- ENTC lithium ENTCEND treated patients with hypercalcemias related to ENTD malignancies ENTDEND and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B)
0	Recent findings in a bipolar patient receiving maintenance ENTC lithium ENTCEND  therapy who developed hypercalcemia and severe ENTD bradyarrhythmia ENTDEND prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as ENTD venous thrombosis ENTDEND not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ENTC ethinyloestradiol ENTCEND than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of ENTC progestagen ENTCEND only OCs. Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as ENTD deep-vein thrombosis ENTDEND , 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified
0	BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens ENTC gestodene ENTCEND or desogestrel than in users of OCs containing second-generation progestagens. However, confounding and bias in the design of these studies may have affected the findings. The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies. METHODS: We used computer records of patients from 143 general practices in the UK. The study was based on the medical records of about 540,000 women born between 1941 and 1981. All women who had a recorded diagnosis of ENTD deep-vein thrombosis ENTDEND , venous thrombosis not otherwise specified, or pulmonary embolus during the study period, and who had been treated with an anticoagulant were identified as potential cases of VTE
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as ENTD venous thrombosis ENTDEND  not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation ENTC progestagens ENTCEND , the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as ENTD venous thrombosis ENTDEND  not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of ENTC desogestrel ENTCEND with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined ENTC OCs ENTCEND  43 were recorded as ENTD deep-vein thrombosis ENTDEND , 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified
0	Among users of third-generation progestagens, the risk of ENTD VTE ENTDEND was higher in users of desogestrel with 20 g ENTC ethinyloestradiol ENTCEND than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	FINDINGS: 85 women met the inclusion criteria for ENTD VTE ENTDEND  two of whom were users of ENTC progestagen ENTCEND -only OCs
0	Among users of third-generation progestagens, the risk of ENTD VTE ENTDEND  was higher in users of desogestrel with 20 g ethinyloestradiol than in users of ENTC gestodene ENTCEND or desogestrel with 30 g ethinyloestradiol
0	Among users of third-generation ENTC progestagens ENTCEND , the risk of ENTD VTE ENTDEND was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Among users of third-generation progestagens, the risk of ENTD VTE ENTDEND  was higher in users of ENTC desogestrel ENTCEND with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
1	The aim of our study was to re-examine the association between risk of ENTD VTE ENTDEND and ENTC OC ENTCEND use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENTD thrombosis ENTDEND  and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ENTC ethinyloestradiol ENTCEND than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of ENTC progestagen ENTCEND -only OCs. Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENTD thrombosis ENTDEND , and five as venous thrombosis not otherwise specified
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENTD thrombosis ENTDEND , and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of ENTC gestodene ENTCEND or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENTD thrombosis ENTDEND , and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation ENTC progestagens ENTCEND , the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENTD thrombosis ENTDEND , and five as venous thrombosis not otherwise specified. The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations. After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75). Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs. Among users of third-generation progestagens, the risk of VTE was higher in users of ENTC desogestrel ENTCEND with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol
0	Of the 83 cases of VTE associated with use of combined ENTC OCs ENTCEND , 43 were recorded as deep-vein thrombosis, 35 as pulmonary ENTD thrombosis ENTDEND , and five as venous thrombosis not otherwise specified
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENTD cardiotoxic ENTDEND effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The ENTC norepinephrine ENTCEND content was significantly increased while epinephrine remained unchanged
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENTD cardiotoxic ENTDEND  effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of ENTC catecholamines ENTCEND was estimated in these 8 day diabetic rats
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENTD cardiotoxic ENTDEND  effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood ENTC glucose ENTCEND after insulin treatment appeared
0	The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the ENTD cardiotoxic ENTDEND  effect of high doses of isoproterenol (ISO) was investigated in rats. Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The norepinephrine content was significantly increased while ENTC epinephrine ENTCEND remained unchanged
0	Acute insulin treatment normalizes the resistance to the ENTD cardiotoxic ENTDEND  effect of ENTC isoproterenol ENTCEND in streptozotocin diabetic rats
0	The acute effect of insulin treatment on the earlier reported protective effect of ENTC streptozotocin ENTCEND diabetes against the ENTD cardiotoxic ENTDEND effect of high doses of isoproterenol (ISO) was investigated in rats
0	The myocardial content of catecholamines was estimated in these 8 day ENTD diabetic ENTDEND rats. The ENTC norepinephrine ENTCEND content was significantly increased while epinephrine remained unchanged
0	The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial ENTC catecholamine ENTCEND sensitivity in ENTD diabetic ENTDEND rats
0	006) to the slope of the fall in blood ENTC glucose ENTCEND  after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day ENTD diabetic ENTDEND rats
0	The myocardial content of catecholamines was estimated in these 8 day ENTD diabetic ENTDEND  rats. The norepinephrine content was significantly increased while ENTC epinephrine ENTCEND remained unchanged
0	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of ENTC isoproterenol ENTCEND  in streptozotocin ENTD diabetic ENTDEND rats
1	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in ENTC streptozotocin ENTCEND ENTD diabetic ENTDEND rats
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENTD fibrosis ENTDEND in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The ENTC norepinephrine ENTCEND content was significantly increased while epinephrine remained unchanged
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENTD fibrosis ENTDEND  in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of ENTC catecholamines ENTCEND was estimated in these 8 day diabetic rats
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENTD fibrosis ENTDEND  in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood ENTC glucose ENTCEND after insulin treatment appeared
0	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced ENTD fibrosis ENTDEND  in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared. The myocardial content of catecholamines was estimated in these 8 day diabetic rats. The norepinephrine content was significantly increased while ENTC epinephrine ENTCEND remained unchanged
1	Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ENTC ISO ENTCEND induced ENTD fibrosis ENTDEND in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0
0	Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in ENTC streptozotocin ENTCEND  diabetic rats. A morphometric study of isoproterenol induced myocardial ENTD fibrosis ENTDEND
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced ENTD hyperactivity ENTDEND seems to be connected to both quinine- and ENTC 4-aminopyridine ENTCEND -sensitive K(+)-channels
0	Quinine is known to block voltage-, calcium- and ENTC ATP ENTCEND sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary ENTD hyperactivity ENTDEND
1	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas ENTC morphine ENTCEND induced ENTD hyperactivity ENTDEND seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels
0	Quinine is known to block voltage-, ENTC calcium ENTCEND  and ATP-sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary ENTD hyperactivity ENTDEND
0	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both ENTC K ENTCEND +)-channel blockers prevented morphine-induced secondary ENTD hyperactivity ENTDEND
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced ENTD hyperactivity ENTDEND  seems to be connected to both ENTC quinine ENTCEND - and 4-aminopyridine-sensitive K(+)-channels
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced ENTD hypoactivity ENTDEND whereas morphine-induced hyperactivity seems to be connected to both quinine- and ENTC 4-aminopyridine ENTCEND -sensitive K(+)-channels
0	Quinine is known to block voltage-, calcium- and ENTC ATP ENTCEND -sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced ENTD hypoactivity ENTDEND , but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity
0	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected ENTC morphine ENTCEND induced ENTD hypoactivity ENTDEND , but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity
0	Quinine is known to block voltage-, ENTC calcium ENTCEND - and ATP-sensitive K(+)-channels while 4-aminopyridine is known to block voltage-sensitive K(+)-channels. 2. In the counterbalanced method, quinine attenuated morphine-induced place preference, whereas 4-aminopyridine was ineffective. In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced ENTD hypoactivity ENTDEND , but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity
0	In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced ENTD hypoactivity ENTDEND , but both ENTC K ENTCEND (+)-channel blockers prevented morphine-induced secondary hyperactivity
0	It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced ENTD hypoactivity ENTDEND  whereas morphine-induced hyperactivity seems to be connected to both ENTC quinine ENTCEND - and 4-aminopyridine-sensitive K(+)-channels
0	It is widely used in folk medicine to treat ENTD skin diseases ENTDEND in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENTC aspartate ENTCEND and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Garcinielliptone FC ( ENTC GFC ENTCEND  isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat ENTD skin diseases ENTDEND in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases
0	It is widely used in folk medicine to treat ENTD skin diseases ENTDEND  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ( ENTC r-aminobutyric acid ENTCEND (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat ENTD skin diseases ENTDEND  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENTC amino acid ENTCEND (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat ENTD skin diseases ENTDEND  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENTC glutathione ENTCEND ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENTC pilocarpine ENTCEND -induced seizures.Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat ENTD skin diseases ENTDEND in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases
0	It is widely used in folk medicine to treat ENTD skin diseases ENTDEND  in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENTC glutamine ENTCEND , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENTD inflammatory diseases ENTDEND  However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENTC aspartate ENTCEND and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENTD inflammatory diseases ENTDEND . However, there is no research on ENTC GFC ENTCEND effects in the central nervous system of rodents
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENTD inflammatory diseases ENTDEND . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ENTC r-aminobutyric acid ENTCEND (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENTD inflammatory diseases ENTDEND . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENTC amino acid ENTCEND (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENTD inflammatory diseases ENTDEND . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENTC glutathione ENTCEND ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENTC pilocarpine ENTCEND -induced seizures.Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENTD inflammatory diseases ENTDEND
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and ENTD inflammatory diseases ENTDEND . However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENTC glutamine ENTCEND , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENTC aspartate ENTCEND  and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after ENTD seizures ENTDEND
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after ENTD seizures ENTDEND . ENTC GFC ENTCEND produced an increased latency to first seizure, at doses 25mg/kg (20
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on ENTD seizure ENTDEND parameters to determine their anticonvulsant activity and its effects on amino acid ENTC r-aminobutyric acid ENTCEND (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on ENTD seizure ENTDEND  parameters to determine their anticonvulsant activity and its effects on ENTC amino acid ENTCEND (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENTC glutathione ENTCEND ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after ENTD seizures ENTDEND
1	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENTC pilocarpine ENTCEND -induced ENTD seizures ENTDEND
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on ENTD seizure ENTDEND  parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENTC glutamine ENTCEND , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENTD diarrheas ENTDEND and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, ENTC aspartate ENTCEND and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENTD diarrheas ENTDEND  and inflammatory diseases. However, there is no research on ENTC GFC ENTCEND effects in the central nervous system of rodents
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENTD diarrheas ENTDEND  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ENTC r-aminobutyric acid ENTCEND (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENTD diarrheas ENTDEND  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENTC amino acid ENTCEND (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENTD diarrheas ENTDEND  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENTC glutathione ENTCEND ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in ENTC pilocarpine ENTCEND -induced seizures.Garcinielliptone FC (GFC) isolated from hexanic fraction seed extract of species Platonia insignis Mart. It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENTD diarrheas ENTDEND and inflammatory diseases
0	It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat ENTD diarrheas ENTDEND  and inflammatory diseases. However, there is no research on GFC effects in the central nervous system of rodents. The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), ENTC glutamine ENTCEND , aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures
0	In ENTC aspartate ENTCEND  glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice. Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice. The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENTD status epilepticus ENTDEND , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The results indicate that ENTC GFC ENTCEND can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENTD status epilepticus ENTDEND , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENTD status epilepticus ENTDEND , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals. In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the ENTC GABA ENTCEND and glutamate contents and of AChE activity in seized mice hippocampus
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on ENTC amino acid ENTCEND  (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures. GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice. In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice. In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice. Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice. The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENTD status epilepticus ENTDEND , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and ENTC glutathione ENTCEND ) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures. GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice. In addition, GABA content of mice hippocampus treated with GFC75 plus P400 showed an increase of 46.90% when compared with seized mice. In aspartate, glutamine and glutamate levels detected a decrease of 5.21%, 13.55% and 21.80%, respectively in mice hippocampus treated with GFC75 plus P400 when compared with seized mice. Hippocampus mice treated with GFC75 plus P400 showed an increase in AChE activity (63.30%) when compared with seized mice. The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENTD status epilepticus ENTDEND , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
1	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of ENTC pilocarpine ENTCEND induced ENTD status epilepticus ENTDEND , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals
0	The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced ENTD status epilepticus ENTDEND , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals. In conclusion, our data suggest that GFC may influence in epileptogenesis and promote anticonvulsant actions in pilocarpine model by modulating the GABA and ENTC glutamate ENTCEND contents and of AChE activity in seized mice hippocampus
1	We conclude that ENTD coronary artery or myocardial disease ENTDEND is common (38%) in young asymptomatic chronic ENTC cocaine ENTCEND users
0	Finally, resting and peak exercise ENTD abnormal left ventricular filling ENTDEND was detected in 38 and 35% of patients as compared to 19 and 9% of controls, respectively (p = 0.11 and 0.02, respectively). We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic ENTC cocaine ENTCEND users
0	Prevalence of ENTD heart disease ENTDEND  in asymptomatic chronic ENTC cocaine ENTCEND users
1	We conclude that ENTD coronary artery or myocardial disease ENTDEND is common (38%) in young asymptomatic chronic ENTC cocaine ENTCEND users
1	Anaesthesia was maintained with intermittent ENTC etomidate ENTCEND in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous ENTD pain ENTDEND occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia
0	Unpremedicated patients were given ENTC fentanyl ENTCEND 1 microgram/kg followed by etomidate 0.3 mg/kg. Anaesthesia was maintained with intermittent etomidate in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous ENTD pain ENTDEND occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia
1	Anaesthesia was maintained with intermittent ENTC etomidate ENTCEND  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced ENTD respiratory upset ENTDEND , one sufficiently severe to necessitate abandoning the technique
0	Unpremedicated patients were given ENTC fentanyl ENTCEND  1 microgram/kg followed by etomidate 0.3 mg/kg. Anaesthesia was maintained with intermittent etomidate in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced ENTD respiratory upset ENTDEND , one sufficiently severe to necessitate abandoning the technique
1	Anaesthesia was maintained with intermittent ENTC etomidate ENTCEND  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced respiratory upset, one sufficiently severe to necessitate abandoning the technique. Nausea and ENTD vomiting ENTDEND occurred in 40% and 25% had disturbing emergence psychoses
1	Anaesthesia was maintained with intermittent ENTC etomidate ENTCEND  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced respiratory upset, one sufficiently severe to necessitate abandoning the technique. Nausea and vomiting occurred in 40% and 25% had disturbing emergence ENTD psychoses ENTDEND
1	Anaesthesia was maintained with intermittent ENTC etomidate ENTCEND  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or swelling related to the injection site, in some cases lasting up to three weeks after anaesthesia. Skeletal movements occurred in 50% of patients; 30% experienced respiratory upset, one sufficiently severe to necessitate abandoning the technique. ENTD Nausea ENTDEND and vomiting occurred in 40% and 25% had disturbing emergence psychoses
0	Anaesthesia was maintained with intermittent ENTC etomidate ENTCEND  in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or ENTD swelling ENTDEND related to the injection site, in some cases lasting up to three weeks after anaesthesia
0	Unpremedicated patients were given ENTC fentanyl ENTCEND  1 microgram/kg followed by etomidate 0.3 mg/kg. Anaesthesia was maintained with intermittent etomidate in 2-4 mg doses. Patients were interviewed personally later the same day, and by questionnaire three to four weeks later. The trial was discontinued after 20 cases because of an unacceptable incidence of side effects. Venous pain occurred in 68% of patients and 50% had redness, pain or ENTD swelling ENTDEND related to the injection site, in some cases lasting up to three weeks after anaesthesia
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENTD status epilepticus ENTDEND  Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions. Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg. Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg. Application of an irreversible inhibitor of GABA transaminase, ENTC gamma-vinyl-GABA ENTCEND (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg
0	In animals pretreated with microinjections of ENTC isoniazid ENTCEND  150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENTD status epilepticus ENTDEND
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the ENTC GABA ENTCEND synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENTD status epilepticus ENTDEND
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of ENTC pilocarpine ENTCEND  100 and 200 mg/kg, resulted in severe motor limbic seizures and ENTD status epilepticus ENTDEND
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENTC L-glutamic acid ENTCEND decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and ENTD status epilepticus ENTDEND
0	Susceptibility to ENTD seizures ENTDEND  produced by pilocarpine in rats after microinjection of isoniazid or ENTC gamma-vinyl-GABA ENTCEND into the substantia nigra
0	Bilateral intrastriatal injections of ENTC isoniazid ENTCEND did not augment ENTD seizures ENTDEND produced by pilocarpine, 200 mg/kg
0	The results demonstrate that the threshold for pilocarpine-induced ENTD seizures ENTDEND in rats is subjected to the regulation of the ENTC GABA ENTCEND -mediated synaptic inhibition within the substantia nigra
1	The results demonstrate that the threshold for ENTC pilocarpine ENTCEND induced ENTD seizures ENTDEND in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENTC L-glutamic acid ENTCEND  decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic ENTD seizures ENTDEND and status epilepticus
0	This treatment was also sufficient to protect animals from the occurrence of ENTD brain damage ENTDEND  Microinjections of ENTC gamma-vinyl-GABA ENTCEND , 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg
0	Bilateral intrastriatal injections of ENTC isoniazid ENTCEND  did not augment seizures produced by pilocarpine, 200 mg/kg. Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENTD brain damage ENTDEND
0	Application of an irreversible inhibitor of ENTC GABA ENTCEND transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENTD brain damage ENTDEND
0	Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by ENTC pilocarpine ENTCEND  380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENTD brain damage ENTDEND
0	In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENTC L-glutamic acid ENTCEND  decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus. Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions. Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg. Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg. Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg. This treatment was also sufficient to protect animals from the occurrence of ENTD brain damage ENTDEND
0	Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or ENTC gamma-vinyl-GABA ENTCEND  into the substantia nigra.Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENTD temporal lobe epilepsy ENTDEND and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain
0	Susceptibility to seizures produced by pilocarpine in rats after microinjection of ENTC isoniazid ENTCEND  or gamma-vinyl-GABA into the substantia nigra.Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENTD temporal lobe epilepsy ENTDEND and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain
0	Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENTD temporal lobe epilepsy ENTDEND  and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain. In the present study, the effects of manipulating the activity of the ENTC gamma-aminobutyric acid ENTCEND (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated
0	ENTC Pilocarpine ENTCEND  given intraperitoneally to rats, reproduces the neuropathological sequelae of ENTD temporal lobe epilepsy ENTDEND and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain
0	Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of ENTD temporal lobe epilepsy ENTDEND  and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain. In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated. In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, ENTC L-glutamic acid ENTCEND decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus
0	Among the patients with 1 year of follow-up, ENTC NVP ENTCEND therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). ENTD Anemia ENTDEND and hepatitis often occur within 12 weeks of initiating generic HAART
0	Clinically significant ENTD anemia ENTDEND (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENTC alanine ENTCEND aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENTC 3TC ENTCEND + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant ENTD anemia ENTDEND (hemoglobin <7 g/dL) was observed in 5
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENTC d4T ENTCEND therapy with developing peripheral neuropathy (p < 0.05). ENTD Anemia ENTDEND and hepatitis often occur within 12 weeks of initiating generic HAART
0	1%), and AZT + 3TC + ENTC EFV ENTCEND (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant ENTD anemia ENTDEND (hemoglobin <7 g/dL) was observed in 5
0	1%), and ENTC AZT ENTCEND + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant ENTD anemia ENTDEND (hemoglobin <7 g/dL) was observed in 5
1	Among the patients with 1 year of follow-up, ENTC NVP ENTCEND  therapy was significantly associated with developing ENTD rash ENTDEND and d4T therapy with developing peripheral neuropathy (p < 0
0	The most common adverse events and median CD4 at time of event were ENTD rash ENTDEND (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENTC alanine ENTCEND aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENTC 3TC ENTCEND  + EFV (5.4%). The most common adverse events and median CD4 at time of event were ENTD rash ENTDEND (15
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing ENTD rash ENTDEND  and ENTC d4T ENTCEND therapy with developing peripheral neuropathy (p < 0
0	1%), and AZT + 3TC + ENTC EFV ENTCEND  (5.4%). The most common adverse events and median CD4 at time of event were ENTD rash ENTDEND (15
0	1%), and ENTC AZT ENTCEND  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were ENTD rash ENTDEND (15
0	Women were significantly more likely to experience ENTD lactic acidosis ENTDEND  while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, ENTC NVP ENTCEND therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENTC alanine ENTCEND  aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENTD lactic acidosis ENTDEND , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	1%), and AZT + ENTC 3TC ENTCEND  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENTD lactic acidosis ENTDEND , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	Women were significantly more likely to experience ENTD lactic acidosis ENTDEND , while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENTC d4T ENTCEND therapy with developing peripheral neuropathy (p < 0
0	1%), and AZT + 3TC + ENTC EFV ENTCEND  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENTD lactic acidosis ENTDEND , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	1%), and ENTC AZT ENTCEND  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience ENTD lactic acidosis ENTDEND , while men were significantly more likely to experience immune reconstitution syndrome (p < 0
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENTD HIV-infected ENTDEND individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + ENTC nevirapine ENTCEND (NVP) (54
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENTD HIV-infected ENTDEND  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENTC alanine ENTCEND aminotransferase > 5 times upper limits of normal) in 3
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENTD HIV-infected ENTDEND  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were ENTC 3TC ENTCEND + d4T + nevirapine (NVP) (54
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENTD HIV-infected ENTDEND  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + ENTC d4T ENTCEND + nevirapine (NVP) (54
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENTD HIV-infected ENTDEND  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), zidovudine (AZT) + 3TC + NVP (14.5%), 3TC + d4T + ENTC efavirenz ENTCEND (EFV) (20
0	To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 ENTD HIV-infected ENTDEND  individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India. The most common regimens were 3TC + d4T + nevirapine (NVP) (54.8%), ENTC zidovudine ENTCEND (AZT) + 3TC + NVP (14
0	Among the patients with 1 year of follow-up, ENTC NVP ENTCEND  therapy was significantly associated with developing rash and d4T therapy with developing ENTD peripheral neuropathy ENTDEND (p < 0
0	2%; CD4, 285 cells/microL) and ENTD peripheral neuropathy ENTDEND (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENTC alanine ENTCEND aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENTC 3TC ENTCEND  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and ENTD peripheral neuropathy ENTDEND (9
1	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENTC d4T ENTCEND  therapy with developing ENTD peripheral neuropathy ENTDEND (p < 0
0	1%), and AZT + 3TC + ENTC EFV ENTCEND  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and ENTD peripheral neuropathy ENTDEND (9
0	1%), and ENTC AZT ENTCEND  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and ENTD peripheral neuropathy ENTDEND (9
0	Among the patients with 1 year of follow-up, ENTC NVP ENTCEND  therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these ENTD toxicities ENTDEND is warranted in developing countries where generic HAART is increasingly available
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENTC alanine ENTCEND  aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these ENTD toxicities ENTDEND is warranted in developing countries where generic HAART is increasingly available
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENTC d4T ENTCEND  therapy with developing peripheral neuropathy (p < 0.05). Anemia and hepatitis often occur within 12 weeks of initiating generic HAART. Frequent and early monitoring for these ENTD toxicities ENTDEND is warranted in developing countries where generic HAART is increasingly available
0	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENTD immune reconstitution syndrome ENTDEND (p < 0.05). Among the patients with 1 year of follow-up, ENTC NVP ENTCEND therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with ENTC alanine ENTCEND  aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENTD immune reconstitution syndrome ENTDEND (p < 0
0	1%), and AZT + ENTC 3TC ENTCEND  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENTD immune reconstitution syndrome ENTDEND (p < 0
0	Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENTD immune reconstitution syndrome ENTDEND  (p < 0.05). Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENTC d4T ENTCEND therapy with developing peripheral neuropathy (p < 0
0	1%), and AZT + 3TC + ENTC EFV ENTCEND  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENTD immune reconstitution syndrome ENTDEND (p < 0
0	1%), and ENTC AZT ENTCEND  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience ENTD immune reconstitution syndrome ENTDEND (p < 0
0	Among the patients with 1 year of follow-up, ENTC NVP ENTCEND  therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05). Anemia and ENTD hepatitis ENTDEND often occur within 12 weeks of initiating generic HAART
0	4% of patients (CD4, 165 cells/microL) and ENTD hepatitis ENTDEND (clinical jaundice with ENTC alanine ENTCEND aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENTC 3TC ENTCEND  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and ENTD hepatitis ENTDEND (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3
0	Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and ENTC d4T ENTCEND  therapy with developing peripheral neuropathy (p < 0.05). Anemia and ENTD hepatitis ENTDEND often occur within 12 weeks of initiating generic HAART
0	1%), and AZT + 3TC + ENTC EFV ENTCEND  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and ENTD hepatitis ENTDEND (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3
0	1%), and ENTC AZT ENTCEND  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and ENTD hepatitis ENTDEND (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENTD jaundice ENTDEND with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL). Women were significantly more likely to experience lactic acidosis, while men were significantly more likely to experience immune reconstitution syndrome (p < 0.05). Among the patients with 1 year of follow-up, ENTC NVP ENTCEND therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0
0	4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENTD jaundice ENTDEND  with ENTC alanine ENTCEND aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + ENTC 3TC ENTCEND  + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENTD jaundice ENTDEND with alanine aminotransferase > 5 times upper limits of normal) in 3
0	5%), 3TC + ENTC d4T ENTCEND + efavirenz (EFV) (20.1%), and AZT + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENTD jaundice ENTDEND with alanine aminotransferase > 5 times upper limits of normal) in 3
0	1%), and AZT + 3TC + ENTC EFV ENTCEND  (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENTD jaundice ENTDEND with alanine aminotransferase > 5 times upper limits of normal) in 3
0	1%), and ENTC AZT ENTCEND  + 3TC + EFV (5.4%). The most common adverse events and median CD4 at time of event were rash (15.2%; CD4, 285 cells/microL) and peripheral neuropathy (9.0% and 348 cells/microL). Clinically significant anemia (hemoglobin <7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical ENTD jaundice ENTDEND with alanine aminotransferase > 5 times upper limits of normal) in 3
0	Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for ENTD angina ENTDEND with 80 mg ENTC propranolol ENTCEND daily
1	Alternating sinus rhythm and intermittent sinoatrial block induced by ENTC propranolol ENTCEND . ENTD Alternating sinus rhythm ENTDEND and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily
0	ENTC Atropine ENTCEND 1 mg given intravenously resulted in shortening of all P-P intervals without changing the rhythm. The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 ENTD S-A block ENTDEND was seen
1	Alternating sinus rhythm and intermittent ENTD sinoatrial block ENTDEND  induced by ENTC propranolol ENTCEND
0	ENTC Atropine ENTCEND  1 mg given intravenously resulted in shortening of all P-P intervals without changing the rhythm. The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2/1 S-A block was seen. This was accepted as evidence for propranolol being the cause of this ENTD conduction disorder ENTDEND
0	This was accepted as evidence for ENTC propranolol ENTCEND being the cause of this ENTD conduction disorder ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENTD pupillary abnormalities ENTDEND , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND  or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENTD pupillary abnormalities ENTDEND , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND  epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENTD pupillary abnormalities ENTDEND , and conjunctival hemorrhages with edema
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENTC corticosteroid ENTCEND  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENTD pupillary abnormalities ENTDEND , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, ENTD pupillary abnormalities ENTDEND , and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENTD chorioretinal atrophy ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENTD chorioretinal atrophy ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENTD chorioretinal atrophy ENTDEND
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENTC corticosteroid ENTCEND  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENTD chorioretinal atrophy ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked visual loss, constricted visual fields, optic nerve pallor, vascular attenuation, and ENTD chorioretinal atrophy ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENTD visual loss ENTDEND , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENTD visual loss ENTDEND , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENTD visual loss ENTDEND , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENTC corticosteroid ENTCEND  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENTD visual loss ENTDEND , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with edema. Follow-up changes showed marked ENTD visual loss ENTDEND , constricted visual fields, optic nerve pallor, vascular attenuation, and chorioretinal atrophy
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENTD blindness ENTDEND following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENTD blindness ENTDEND  following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND , or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENTD blindness ENTDEND  following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND , epinephrine, or penicillin are reported
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENTC corticosteroid ENTCEND  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENTD blindness ENTDEND following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with ENTD blindness ENTDEND  following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND in combination with lidocaine, epinephrine, or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENTD edema ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENTD edema ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENTD edema ENTDEND
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENTC corticosteroid ENTCEND  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENTD edema ENTDEND
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival hemorrhages with ENTD edema ENTDEND
0	Two well-documented cases of bilateral ENTD retinal artery and choriocapillaris occlusions ENTDEND with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND are reported
0	Two well-documented cases of bilateral ENTD retinal artery and choriocapillaris occlusions ENTDEND  with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND , or penicillin are reported
0	Two well-documented cases of bilateral ENTD retinal artery and choriocapillaris occlusions ENTDEND  with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND , epinephrine, or penicillin are reported
0	Bilateral ENTD retinal artery and choriocapillaris occlusion ENTDEND  following the injection of long-acting ENTC corticosteroid ENTCEND suspensions in combination with other drugs: I
1	Two well-documented cases of bilateral ENTD retinal artery and choriocapillaris occlusions ENTDEND  with blindness following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND in combination with lidocaine, epinephrine, or penicillin are reported
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENTD hemorrhages ENTDEND with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENTD hemorrhages ENTDEND with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENTD hemorrhages ENTDEND with edema
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENTC corticosteroid ENTCEND  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENTD hemorrhages ENTDEND with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze palsy, pupillary abnormalities, and conjunctival ENTD hemorrhages ENTDEND with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or ENTC penicillin ENTCEND  are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENTD palsy ENTDEND , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, ENTC epinephrine ENTCEND , or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENTD palsy ENTDEND , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with ENTC lidocaine ENTCEND , epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENTD palsy ENTDEND , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Bilateral retinal artery and choriocapillaris occlusion following the injection of long-acting ENTC corticosteroid ENTCEND  suspensions in combination with other drugs: I. Clinical studies.Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENTD palsy ENTDEND , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with ENTC methylprednisolone acetate ENTCEND  in combination with lidocaine, epinephrine, or penicillin are reported. One case had only a unilateral injection. The acute observations included hazy sensorium, superior gaze ENTD palsy ENTDEND , pupillary abnormalities, and conjunctival hemorrhages with edema
0	Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during ENTC epirubicine ENTCEND -based chemotherapy.AIMS: To investigate whether alterations of ENTD myocardial strain ENTDEND and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure
1	METHODS: Seventy-five patients with non-Hodgkin lymphoma treated with ENTC epirubicin ENTCEND were studied. Blood collection and echocardiography were performed at baseline, 1 day after the third cycle, and 1 day after completion of chemotherapy. Patients were studied using echocardiography during follow-up. Global longitudinal (GLS), circumferential (GCS), and radial strain (GRS) were calculated using speckle tracking echocardiography. Left ventricular ejection fraction was analysed by real-time 3D echocardiography. Cardiotoxicity was defined as a reduction of the LVEF of >5% to <55% with symptoms of ENTD heart failure ENTDEND or an asymptomatic reduction of the LVEF of >10% to <55%
0	The decrease in GLS remained the only independent predictor of ENTD cardiotoxicity ENTDEND (P = 0.000). CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving ENTC anthracycline ENTCEND -based chemotherapy
1	Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of ENTD cardiotoxicity ENTDEND  during ENTC epirubicine ENTCEND -based chemotherapy
0	CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict ENTD cardiac dysfunction ENTDEND in patients receiving ENTC anthracycline ENTCEND -based chemotherapy
0	AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future ENTD cardiac dysfunction ENTDEND in patients after ENTC epirubicin ENTCEND exposure
0	METHODS: Seventy-five patients with ENTD non-Hodgkin lymphoma ENTDEND treated with ENTC epirubicin ENTCEND were studied
1	All animals suffered tonic ENTD convulsions ENTDEND at 18.3 +/- 1.4 min after ENTC lindane ENTCEND administration
0	We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of ENTC GABA ENTCEND  dopamine and its metabolites in 7 brain areas at the onset of ENTD seizures ENTDEND
0	All animals suffered tonic ENTD convulsions ENTDEND  at 18.3 +/- 1.4 min after lindane administration. The concentration of GABA was only slightly but significantly decreased in the colliculi without modifications in the other areas. The concentration of dopamine was increased in the mesencephalon and that of its metabolite ENTC DOPAC ENTCEND was also increased in the mesencephalon and the striatum
0	We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, ENTC dopamine ENTCEND and its metabolites in 7 brain areas at the onset of ENTD seizures ENTDEND
0	Lindane ( ENTC gamma-hexachlorocyclohexane ENTCEND  is an organochlorine insecticide with known ENTD neurotoxic ENTDEND effects
0	Convulsant effect of lindane and regional brain concentration of ENTC GABA ENTCEND  and dopamine.Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known ENTD neurotoxic ENTDEND effects
0	Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known ENTD neurotoxic ENTDEND  effects. Its mechanism of action is not well understood although it has been proposed that lindane acts as a non-competitive antagonist at the gamma-aminobutyric acid (GABA)-A receptor. We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures. All animals suffered tonic convulsions at 18.3 +/- 1.4 min after lindane administration. The concentration of GABA was only slightly but significantly decreased in the colliculi without modifications in the other areas. The concentration of dopamine was increased in the mesencephalon and that of its metabolite ENTC DOPAC ENTCEND was also increased in the mesencephalon and the striatum
0	Convulsant effect of lindane and regional brain concentration of GABA and ENTC dopamine ENTCEND .Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known ENTD neurotoxic ENTDEND effects
0	Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENTD weight loss ENTDEND  The inability of ENTC amiodarone ENTCEND to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect
0	Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENTC fatty acid ENTCEND oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENTD weight loss ENTDEND
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENTC triglycerides ENTCEND and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENTD weight loss ENTDEND
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENTC glucose ENTCEND  Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body ENTD weight loss ENTDEND
1	These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against ENTC amiodarone ENTCEND induced ENTD hepatotoxicity ENTDEND
0	Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause ENTD hepatotoxicity ENTDEND in some patients. To gain insight into the mechanism of this unwanted effect, mice were administered various doses of amiodarone and examined for changes in hepatic histology and gene regulation. Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENTC fatty acid ENTCEND oxidation, lipoprotein assembly, and lipid transport
0	Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause ENTD hepatotoxicity ENTDEND  in some patients. To gain insight into the mechanism of this unwanted effect, mice were administered various doses of amiodarone and examined for changes in hepatic histology and gene regulation. Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENTC triglycerides ENTCEND and glucose
0	Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause ENTD hepatotoxicity ENTDEND  in some patients. To gain insight into the mechanism of this unwanted effect, mice were administered various doses of amiodarone and examined for changes in hepatic histology and gene regulation. Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENTC glucose ENTCEND
0	The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENTD hepatoma ENTDEND cells indicates that the effects of ENTC amiodarone ENTCEND on the function of this receptor were indirect
0	Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENTC fatty acid ENTCEND  oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss. The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENTD hepatoma ENTDEND cells indicates that the effects of amiodarone on the function of this receptor were indirect
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENTC triglycerides ENTCEND  and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss. The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENTD hepatoma ENTDEND cells indicates that the effects of amiodarone on the function of this receptor were indirect
0	Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENTC glucose ENTCEND . Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for fatty acid oxidation, lipoprotein assembly, and lipid transport. Many of these genes are regulated by the peroxisome proliferator-activated receptor-alpha (PPARalpha), a ligand-activated nuclear hormone receptor transcription factor. The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene. Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss. The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 ENTD hepatoma ENTDEND cells indicates that the effects of amiodarone on the function of this receptor were indirect
1	ENTC Amiodarone ENTCEND induced ENTD hepatomegaly ENTDEND , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose
0	Amiodarone induced ENTD hepatomegaly ENTDEND , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose. Northern blot analysis of hepatic RNA revealed a dose-dependent increase in the expression of a number of genes critical for ENTC fatty acid ENTCEND oxidation, lipoprotein assembly, and lipid transport
0	Amiodarone induced ENTD hepatomegaly ENTDEND , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum ENTC triglycerides ENTCEND and glucose
0	Amiodarone induced ENTD hepatomegaly ENTDEND , hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and ENTC glucose ENTCEND
0	After the withdrawal of ENTC VPA ENTCEND therapy, our patient showed a significant ENTD weight loss ENTDEND , a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization
1	We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during ENTC VPA ENTCEND treatment. Laboratory data revealed ENTD hyperinsulinemia ENTDEND with insulin resistance
1	Laboratory data revealed hyperinsulinemia with ENTD insulin resistance ENTDEND  After the withdrawal of ENTC VPA ENTCEND therapy, our patient showed a significant weight loss, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization
1	ENTD Nonalcoholic fatty liver disease ENTDEND  during ENTC valproate ENTCEND therapy
0	Valproic acid ( ENTC VPA ENTCEND  is effective for the treatment of many types of ENTD epilepsy ENTDEND , but its use can be associated with an increase in body weight
1	We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed ENTD obesity ENTDEND during ENTC VPA ENTCEND treatment
0	All adenosine receptor agonists significantly ENTD decreased the locomotor activity ENTDEND in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and ENTC 5'-N-ethylcarboxamidoadenosine ENTCEND (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	All ENTC adenosine ENTCEND receptor agonists significantly ENTD decreased the locomotor activity ENTDEND in mice, and the effects were dose-dependent
1	The influence of adenosine receptor agonists and antagonists on cocaine-and ENTC amphetamine ENTCEND induced hyperactivity was examined in mice. All adenosine receptor agonists significantly ENTD decreased the locomotor activity ENTDEND in mice, and the effects were dose-dependent
1	The influence of adenosine receptor agonists and antagonists on ENTC cocaine ENTCEND and amphetamine-induced hyperactivity was examined in mice. All adenosine receptor agonists significantly ENTD decreased the locomotor activity ENTDEND in mice, and the effects were dose-dependent
1	All adenosine receptor agonists significantly ENTD decreased the locomotor activity ENTDEND  in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity. CPA reduced cocaine action at the doses which, given alone, did not influence motility, while CGS 21680 and NECA decreased the action of cocaine at the doses which, given alone, decreased locomotor activity in animals. These results suggest the involvement of both adenosine receptors in the action of cocaine although agonists of A1 receptors seem to have stronger influence on it. The selective blockade of A2 adenosine receptor by ENTC DMPX ENTCEND (3,7-dimethyl-1-propargylxanthine) significantly enhanced cocaine-induced locomotor activity of animals
0	All adenosine receptor agonists significantly ENTD decreased the locomotor activity ENTDEND  in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, ENTC N6-cyclopentyladenosine ENTCEND (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	All adenosine receptor agonists significantly ENTD decreased the locomotor activity ENTDEND  in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: ENTC 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine ENTCEND (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced ENTD hyperactivity ENTDEND was examined in mice. All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and ENTC 5'-N-ethylcarboxamidoadenosine ENTCEND (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced ENTD hyperactivity ENTDEND .The influence of ENTC adenosine ENTCEND receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice
0	Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than ENTC amphetamine ENTCEND -induced ENTD hyperactivity ENTDEND
0	Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced ENTD hyperactivity ENTDEND  The selective blockade of A2 adenosine receptors (DMPX) and non-selective blockade of adenosine receptors ( ENTC caffeine ENTCEND ) significantly increased the action of amphetamine in the locomotor activity test
0	ENTC Cocaine ENTCEND -induced ENTD hyperactivity ENTDEND is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity
0	CPT ( ENTC 8-cyclopentyltheophylline ENTCEND --A1 receptor antagonist, did not show any influence in this test. Similarly, all adenosine receptor agonists decreased amphetamine-induced ENTD hyperactivity ENTDEND , but at the higher doses than those which were active in cocaine-induced hyperactivity
0	Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced ENTD hyperactivity ENTDEND . The selective blockade of A2 adenosine receptors ( ENTC DMPX ENTCEND ) and non-selective blockade of adenosine receptors (caffeine) significantly increased the action of amphetamine in the locomotor activity test
0	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced ENTD hyperactivity ENTDEND  was examined in mice. All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), A2A receptor agonist, ENTC N6-cyclopentyladenosine ENTCEND (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
0	The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced ENTD hyperactivity ENTDEND  was examined in mice. All adenosine receptor agonists significantly decreased the locomotor activity in mice, and the effects were dose-dependent. It seems that adenosine A1 and A2 receptors might be involved in this reaction. Moreover, all adenosine receptor agonists: ENTC 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine ENTCEND (CGS 21680), A2A receptor agonist, N6-cyclopentyladenosine (CPA), A1 receptor agonist, and 5'-N-ethylcarboxamidoadenosine (NECA), A2/A1 receptor agonist significantly and dose-dependently decreased cocaine-induced locomotor activity
1	ENTC Adrenaline ENTCEND induced ENTD hypertension ENTDEND was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s
0	Adrenaline-induced ENTD hypertension ENTDEND  was used to destroy the BBB, which was evaluated using ENTC triphenyltetrazolium ENTCEND (TTC) staining of the brain slices just after giving adrenaline for 30 s
0	After ENTC adrenaline ENTCEND infusion for 30 s, there were large unstained areas in the left brain in right-pawed animals, and vice versa in left-pawed animals. Similar results were obtained in ENTD seizure ENTDEND -induced breakdown of BBB
0	In normal rats, the whole brain sections exhibited complete staining with ENTC TTC ENTCEND  After adrenaline infusion for 30 s, there were large unstained areas in the left brain in right-pawed animals, and vice versa in left-pawed animals. Similar results were obtained in ENTD seizure ENTDEND -induced breakdown of BBB
0	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the ENTD emergency department ENTDEND with near-syncope. The boy had been treated with intravenous ENTC methyldopa ENTCEND during a trauma admission seven weeks prior to presentation
0	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the ENTD emergency department ENTDEND  with near-syncope. The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENTC corticosteroid ENTCEND therapy resulted in a complete recovery of the patient
1	ENTC Methyldopa ENTCEND -induced ENTD hemolytic anemia ENTDEND in a 15 year old presenting as near-syncope
0	Transfusion and ENTC corticosteroid ENTCEND  therapy resulted in a complete recovery of the patient. Emergency physicians treating children must be aware of this syndrome in order to diagnose and treat it correctly. A brief review of autoimmune and drug-induced ENTD hemolytic anemias ENTDEND is provided
0	ENTC Methyldopa ENTCEND causes an ENTD autoimmune hemolytic anemia ENTDEND in a small percentage of patients who take the drug
0	Methyldopa causes an ENTD autoimmune hemolytic anemia ENTDEND  in a small percentage of patients who take the drug. We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope. The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENTC corticosteroid ENTCEND therapy resulted in a complete recovery of the patient
0	The boy had been treated with intravenous ENTC methyldopa ENTCEND  during a ENTD trauma ENTDEND admission seven weeks prior to presentation
0	The boy had been treated with intravenous methyldopa during a ENTD trauma ENTDEND  admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENTC corticosteroid ENTCEND therapy resulted in a complete recovery of the patient
0	Methyldopa-induced hemolytic anemia in a 15 year old presenting as near- ENTD syncope ENTDEND . ENTC Methyldopa ENTCEND is an antihypertensive medication which is available generically and under the trade name Aldomet that is widely prescribed in the adult population and infrequently used in children
0	We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near- ENTD syncope ENTDEND  The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation. Evaluation revealed a hemoglobin of three grams, 3+ Coombs' test with polyspecific anti-human globulin and monospecific IgG reagents, and a warm reacting autoantibody. Transfusion and ENTC corticosteroid ENTCEND therapy resulted in a complete recovery of the patient
0	The mean ENTC H ENTCEND concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	In addition, the patients received fentanyl and ENTC d-tubocurarine ENTCEND  The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENTC isoflurane ENTCEND group. After hypotension there was no rebound phenomenon in either blood pressure or heart rate. These results indicate that labetalol induces easily adjustable hypotension without compensatory ENTD tachycardia ENTDEND and rebound hypertension
0	In addition, the patients received ENTC fentanyl ENTCEND and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND . The operating conditions regarding bleeding were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum ENTC creatinine ENTCEND concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
0	These results indicate that ENTC labetalol ENTCEND induces easily adjustable hypotension without compensatory ENTD tachycardia ENTDEND and rebound hypertension
0	1 vol%, the mean ENTC E ENTCEND concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	The mean ENTC H ENTCEND  concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENTD bleeding ENTDEND were estimated in a double-blind manner, and did not differ significantly between the groups
0	In addition, the patients received fentanyl and ENTC d-tubocurarine ENTCEND . The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENTD bleeding ENTDEND were estimated in a double-blind manner, and did not differ significantly between the groups
0	The operating conditions regarding ENTD bleeding ENTDEND  were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENTC isoflurane ENTCEND group
0	In addition, the patients received ENTC fentanyl ENTCEND  and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENTD bleeding ENTDEND were estimated in a double-blind manner, and did not differ significantly between the groups
0	The operating conditions regarding ENTD bleeding ENTDEND  were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum ENTC creatinine ENTCEND concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
0	The initial dose of ENTC labetalol ENTCEND for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENTD bleeding ENTDEND were estimated in a double-blind manner, and did not differ significantly between the groups
0	1 vol%, the mean ENTC E ENTCEND  concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without tachy- or bradycardia. The operating conditions regarding ENTD bleeding ENTDEND were estimated in a double-blind manner, and did not differ significantly between the groups
0	During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENTC isoflurane ENTCEND  group. After hypotension there was no rebound phenomenon in either blood pressure or heart rate. These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound ENTD hypertension ENTDEND
0	During hypotension, the serum ENTC creatinine ENTCEND  concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group. After hypotension there was no rebound phenomenon in either blood pressure or heart rate. These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound ENTD hypertension ENTDEND
0	These results indicate that ENTC labetalol ENTCEND  induces easily adjustable hypotension without compensatory tachycardia and rebound ENTD hypertension ENTDEND
1	The mean ENTC H ENTCEND  concentration during ENTD hypotension ENTDEND in the inspiratory gas was 0
0	In addition, the patients received fentanyl and ENTC d-tubocurarine ENTCEND . The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During ENTD hypotension ENTDEND , the heart rate was stable without tachy- or bradycardia
1	During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the ENTC isoflurane ENTCEND  group. After ENTD hypotension ENTDEND there was no rebound phenomenon in either blood pressure or heart rate
0	In addition, the patients received ENTC fentanyl ENTCEND  and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During ENTD hypotension ENTDEND , the heart rate was stable without tachy- or bradycardia
0	During ENTD hypotension ENTDEND  the serum ENTC creatinine ENTCEND concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
1	Deliberate ENTD hypotension ENTDEND  induced by ENTC labetalol ENTCEND with halothane, enflurane or isoflurane for middle-ear surgery
1	Deliberate ENTD hypotension ENTDEND  induced by labetalol with halothane, ENTC enflurane ENTCEND or isoflurane for middle-ear surgery
0	The mean ENTC H ENTCEND  concentration during hypotension in the inspiratory gas was 0.7 +/- 0.1 vol%, the mean E concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	In addition, the patients received fentanyl and ENTC d-tubocurarine ENTCEND . The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	2 vol%, and the mean ENTC I ENTCEND concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	In addition, the patients received ENTC fentanyl ENTCEND  and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND . The operating conditions regarding bleeding were estimated in a double-blind manner, and did not differ significantly between the groups. During hypotension, the serum ENTC creatinine ENTCEND concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group
0	The initial dose of ENTC labetalol ENTCEND  for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	1 vol%, the mean ENTC E ENTCEND  concentration 1.6 +/- 0.2 vol%, and the mean I concentration 1.0 +/- 0.1 vol%. In addition, the patients received fentanyl and d-tubocurarine. The initial dose of labetalol for lowering blood pressure was similar, 0.52-0.59 mg/kg, in all the groups. During hypotension, the heart rate was stable without ENTD tachy- or bradycardia ENTDEND
0	Skin tests and in vitro lymphocyte stimulation revealed that the patient was sensitized to cephalothin and also to ENTC ampicillin ENTCEND  Careful investigation of drug-induced ENTD hemolytic anemias ENTDEND reveals the complexity of the immune mechanisms involved
1	ENTC Cephalothin ENTCEND -induced immune ENTD hemolytic anemia ENTDEND
0	A patient with ENTD renal disease ENTDEND developed Coombs-positive hemolytic anemia while receiving cephalothin therapy. An anti-cephalothin IgG antibody was detected in the patient's serum and in the eluates from her erythrocytes. In addition, nonimmunologic binding of normal and patient's serum proteins to her own and cephalothin-coated normal red cells was demonstrated. Skin tests and in vitro lymphocyte stimulation revealed that the patient was sensitized to cephalothin and also to ENTC ampicillin ENTCEND
0	ENTC Cephalothin ENTCEND -induced immune hemolytic anemia.A patient with ENTD renal disease ENTDEND developed Coombs-positive hemolytic anemia while receiving cephalothin therapy
1	It is characterized by its intense urotoxic action, leading to ENTD hemorrhagic cystitis ENTDEND  This side effect of ENTC IFO ENTCEND raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect
0	Ifosfamide (IFO) is an alkylating ENTC nitrogen ENTCEND mustard, administrated as an antineoplasmic agent. It is characterized by its intense urotoxic action, leading to ENTD hemorrhagic cystitis ENTDEND
0	It is characterized by its intense urotoxic action, leading to ENTD hemorrhagic cystitis ENTDEND . This side effect of IFO raises the requirement for the co-administration with ENTC sodium 2-sulfanylethanesulfonate ENTCEND (Mesna) aiming to avoid or minimize this effect
0	Mesna significantly reduces ENTC IFO ENTCEND s ENTD genotoxicity ENTDEND , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug
0	ENTC Mesna ENTCEND significantly reduces IFO's ENTD genotoxicity ENTDEND , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug
1	It is characterized by its intense urotoxic action, leading to ENTD hemorrhagic cystitis ENTDEND  This side effect of ENTC IFO ENTCEND raises the requirement for the co-administration with sodium 2-sulfanylethanesulfonate (Mesna) aiming to avoid or minimize this effect
0	Ifosfamide (IFO) is an alkylating ENTC nitrogen ENTCEND  mustard, administrated as an antineoplasmic agent. It is characterized by its intense urotoxic action, leading to ENTD hemorrhagic cystitis ENTDEND
0	It is characterized by its intense urotoxic action, leading to ENTD hemorrhagic cystitis ENTDEND . This side effect of IFO raises the requirement for the co-administration with ENTC sodium 2-sulfanylethanesulfonate ENTCEND (Mesna) aiming to avoid or minimize this effect
0	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti- ENTD tumor ENTDEND therapy with ENTC IFO ENTCEND
0	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti- ENTD tumor ENTDEND  therapy with IFO. Depletion of sulfhydryl (SH) groups has been reported from cell culture, animal and clinical studies. In this work the effect of CAA on human proximal tubule cells in primary culture (hRPTEC) was investigated. Toxicity of CAA was determined by protein content, cell number, LDH release, ENTC trypan blue ENTCEND exclusion assay and caspase-3 activity
0	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical ENTC thiol ENTCEND  groups in ifosfamide nephropathy.Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti ENTD tumor ENTDEND therapy with IFO
0	Chloroacetaldehyde ( ENTC CAA ENTCEND  is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti ENTD tumor ENTDEND therapy with IFO
0	Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its ENTD toxicity ENTDEND on hRPTEC. This effect can be reduced by acidification. Therefore, urinary acidification could be an option to prevent ENTC IFO ENTCEND nephropathy in patients
0	ENTD Toxicity ENTDEND of CAA was determined by protein content, cell number, LDH release, ENTC trypan blue ENTCEND exclusion assay and caspase-3 activity
0	ENTD Toxicity ENTDEND  of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity. Free thiols were measured by the method of Ellman. CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers. CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by ENTC cisplatin ENTCEND was inhibited by CAA
0	Thus, CAA directly reacts with cellular protein and non-protein ENTC thiols ENTCEND  mediating its ENTD toxicity ENTDEND on hRPTEC
0	ENTD Toxicity ENTDEND  of ENTC CAA ENTCEND was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and ENTC cysteine ENTCEND protease inhibition in living cells. Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its ENTD toxicity ENTDEND on hRPTEC
0	ENTD Toxicity ENTDEND  of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity. Free thiols were measured by the method of Ellman. CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers. CAA but not ENTC acrolein ENTCEND inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on ENTD necrosis ENTDEND markers, thiol depletion and cysteine protease inhibition in living cells. Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC. This effect can be reduced by acidification. Therefore, urinary acidification could be an option to prevent ENTC IFO ENTCEND nephropathy in patients
0	Toxicity of CAA was determined by protein content, cell number, LDH release, ENTC trypan blue ENTCEND  exclusion assay and caspase-3 activity. Free thiols were measured by the method of Ellman. CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in ENTD necrosis ENTDEND markers
0	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in ENTD necrosis ENTDEND  markers. CAA but not acrolein inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B. Caspase activation by ENTC cisplatin ENTCEND was inhibited by CAA
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on ENTD necrosis ENTDEND  markers, ENTC thiol ENTCEND depletion and cysteine protease inhibition in living cells
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of ENTC CAA ENTCEND on ENTD necrosis ENTDEND markers, thiol depletion and cysteine protease inhibition in living cells
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on ENTD necrosis ENTDEND  markers, thiol depletion and ENTC cysteine ENTCEND protease inhibition in living cells
0	CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in ENTD necrosis ENTDEND  markers. CAA but not ENTC acrolein ENTCEND inhibited the cysteine proteases caspase-3, caspase-8 and cathepsin B
1	Therefore, urinary acidification could be an option to prevent ENTC IFO ENTCEND  ENTD nephropathy ENTDEND in patients
0	Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for ENTD renal damage ENTDEND following anti-tumor therapy with IFO. Depletion of sulfhydryl (SH) groups has been reported from cell culture, animal and clinical studies. In this work the effect of CAA on human proximal tubule cells in primary culture (hRPTEC) was investigated. Toxicity of CAA was determined by protein content, cell number, LDH release, ENTC trypan blue ENTCEND exclusion assay and caspase-3 activity
0	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical ENTC thiol ENTCEND  groups in ifosfamide ENTD nephropathy ENTDEND
0	Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide ENTD nephropathy ENTDEND . ENTC Chloroacetaldehyde ENTCEND (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO
0	Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and ENTC cysteine ENTCEND  protease inhibition in living cells. Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC. This effect can be reduced by acidification. Therefore, urinary acidification could be an option to prevent IFO ENTD nephropathy ENTDEND in patients
1	In conclusion, we believe that physicians should carefully consider the risk of drug-induced ENTD hepatic injury ENTDEND when ENTC clopidogrel ENTCEND is prescribed
1	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of ENTD gingival hyperplasia ENTDEND in 2 of the 13 patients. Our findings indicate that sustained-release ENTC nifedipine ENTCEND is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
1	Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with ENTC cyclosporin A ENTCEND  but that these patients should be monitored for ENTD gingival hyperplasia ENTDEND
0	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in ENTC blood urea nitrogen ENTCEND levels in 9 of the 13 patients and development of ENTD gingival hyperplasia ENTDEND in 2 of the 13 patients
0	Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a ENTC calcium ENTCEND channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs. Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy. Both systolic and diastolic blood pressures of these 13 patients were decreased significantly after 4 weeks of nifedipine therapy, and blood pressure was maintained within the normal range thereafter for 25 months. The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of ENTD gingival hyperplasia ENTDEND in 2 of the 13 patients
0	Our findings indicate that sustained-release ENTC nifedipine ENTCEND  is useful for ENTD hypertensive ENTDEND psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
1	Long-term efficacy and adverse event of nifedipine sustained-release tablets for ENTC cyclosporin A ENTCEND -induced ENTD hypertension ENTDEND in patients with psoriasis
0	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in ENTC blood urea nitrogen ENTCEND  levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for ENTD hypertensive ENTDEND psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
0	Thirteen psoriatic patients with ENTD hypertension ENTDEND during the course of cyclosporin A therapy were treated for 25 months with a ENTC calcium ENTCEND channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs
0	Our findings indicate that sustained-release ENTC nifedipine ENTCEND  is useful for hypertensive ENTD psoriatic ENTDEND patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
0	Long-term efficacy and adverse event of nifedipine sustained-release tablets for ENTC cyclosporin A ENTCEND -induced hypertension in patients with ENTD psoriasis ENTDEND
0	The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in ENTC blood urea nitrogen ENTCEND  levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients. Our findings indicate that sustained-release nifedipine is useful for hypertensive ENTD psoriatic ENTDEND patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia
0	Thirteen ENTD psoriatic ENTDEND patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a ENTC calcium ENTCEND channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs
1	To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to ENTD status epilepticus ENTDEND induced by ENTC pilocarpine ENTCEND (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS
0	To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to ENTD status epilepticus ENTDEND  induced by pilocarpine (Pilo), previously injected or not with ENTC cycloheximide ENTCEND (CHX), which has been shown to inhibit MFS
0	PURPOSE: GAP43 has been thought to be linked with mossy fiber sprouting (MFS) in various experimental models of ENTD epilepsy ENTDEND  To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by ENTC pilocarpine ENTCEND (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS
0	Growth-associated protein 43 expression in hippocampal molecular layer of chronic ENTD epileptic ENTDEND  rats treated with ENTC cycloheximide ENTCEND
1	The influence of d-ribose on ENTC adriamycin ENTCEND induced ENTD myocardiopathy ENTDEND in rats was studied
0	The influence of ENTC d-ribose ENTCEND on adriamycin-induced ENTD myocardiopathy ENTDEND in rats was studied
0	D-ribose in the multiple doses of 200 mg/kg did not influence ENTC ADR ENTCEND ENTD cardiotoxicity ENTDEND
0	Adriamycin in the cumulative dose of 25 mg/kg evoked fully developed ENTD cardiac toxicity ENTDEND  ENTC D-ribose ENTCEND in the multiple doses of 200 mg/kg did not influence ADR cardiotoxicity
0	PATIENTS: We investigated 102 untreated patients with ENTD hyperthyroidism ENTDEND due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting ENTC PTU ENTCEND therapy
1	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher ENTD fever ENTDEND  oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping ENTC PTU ENTCEND therapy, and the MPO-ANCA titre decreased to 20
0	Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and ENTD vasculitis ENTDEND during ENTC PTU ENTCEND therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients
0	Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in ENTD Graves' disease ENTDEND  patients treated with ENTC propylthiouracil ENTCEND and the relationship between MPO-ANCA and clinical manifestations
0	0 U/ml, respectively, despite continued ENTC PTU ENTCEND therapy, but no ENTD vasculitic disorders ENTDEND developed
1	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, ENTD oral ulcers ENTDEND and polyarthralgia, but the symptoms resolved 2 weeks after stopping ENTC PTU ENTCEND therapy, and the MPO-ANCA titre decreased to 20
1	In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and ENTD polyarthralgia ENTDEND  but the symptoms resolved 2 weeks after stopping ENTC PTU ENTCEND therapy, and the MPO-ANCA titre decreased to 20
0	5 mg/kg/min propofol in intralipid (Group P), ENTC propofol ENTCEND in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first ENTD dysrhythmia ENTDEND occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption
0	Thereafter, 2 mg/kg/min ENTC bupivacaine ENTCEND 0.5% was infused. We recorded time to first ENTD dysrhythmia ENTDEND occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption
0	METHODS: Rats were anaesthetised with ENTC ketamine ENTCEND and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first ENTD dysrhythmia ENTDEND occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption
0	Pre-treatment of bupivacaine-induced ENTD cardiovascular depression ENTDEND  using different lipid formulations of ENTC propofol ENTCEND
0	Pre-treatment of ENTC bupivacaine ENTCEND -induced ENTD cardiovascular depression ENTDEND using different lipid formulations of propofol
0	Pre-treatment of bupivacaine-induced ENTD cardiovascular depression ENTDEND  using different lipid formulations of propofol.BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity. The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity. METHODS: Rats were anaesthetised with ENTC ketamine ENTCEND and were given 0
0	BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of ENTC propofol ENTCEND may alleviate bupivacaine-induced ENTD cardiotoxicity ENTDEND
1	CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of ENTC bupivacaine ENTCEND induced ENTD cardiotoxic ENTDEND effects as well as reduced plasma bupivacaine levels
0	The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced ENTD cardiotoxicity ENTDEND  METHODS: Rats were anaesthetised with ENTC ketamine ENTCEND and were given 0
0	5 mg/kg/min propofol in intralipid (Group P), ENTC propofol ENTCEND  in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to ENTD asystole ENTDEND and total amount of bupivacaine consumption
1	We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to ENTD asystole ENTDEND  and total amount of ENTC bupivacaine ENTCEND consumption
0	METHODS: Rats were anaesthetised with ENTC ketamine ENTCEND  and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to ENTD asystole ENTDEND and total amount of bupivacaine consumption
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENTC heparin ENTCEND associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and ENTD alopecia ENTDEND will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced ENTD thrombocytopenia ENTDEND ENTC heparin ENTCEND -associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Heparin-induced thrombocytopenia, paradoxical ENTD thromboembolism ENTDEND , and other side effects of ENTC heparin ENTCEND therapy
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated ENTD osteoporosis ENTDEND , eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated osteoporosis, ENTD eosinophilia ENTDEND , skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated osteoporosis, eosinophilia, ENTD skin reactions ENTDEND , allergic reactions other than thrombocytopenia and alopecia will be discussed in this article
1	Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, ENTC heparin ENTCEND -associated osteoporosis, eosinophilia, skin reactions, ENTD allergic reactions ENTDEND other than thrombocytopenia and alopecia will be discussed in this article
1	This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral ENTC verapamil ENTCEND  ENTD Accelerated junctional rhythms ENTDEND and AV dissociation were frequent in patients with supraventricular tachyarrhythmias, particularly AV nodal reentry
0	Accelerated junctional rhythms and AV dissociation were frequent in patients with ENTD supraventricular tachyarrhythmias ENTDEND  particularly AV nodal reentry. ENTC Verapamil ENTCEND administration to these patients led to an asymptomatic increase in activity of these junctional pacemakers
0	In patients with various ENTD chest pain ENTDEND syndromes, ENTC verapamil ENTCEND neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENTC angiotensin ENTCEND converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced ENTD nephrotic ENTDEND rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside ( ENTC PAN ENTCEND  - induced ENTD nephrotic ENTDEND rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced ENTD nephrotic ENTDEND  rats. Nephrosis was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats. Four groups were used, i) the PAN group (14), ii) PAN/ ENTC temocapril ENTCEND (13), iii) temocapril (14) and iv) untreated controls (15)
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENTC angiotensin ENTCEND  converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular ENTD hypertrophy ENTDEND and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular ENTD hypertrophy ENTDEND  and prevented glomerulosclerosis in chronic ENTC puromycin aminonucleoside ENTCEND (PAN) - induced nephrotic rats
0	The purpose of the present study was to determine whether chronic administration of ENTC temocapril ENTCEND  a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular ENTD hypertrophy ENTDEND and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
0	Temocapril, a long-acting non-SH group ENTC angiotensin ENTCEND  converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside ENTD nephrosis ENTDEND
1	It appears that temocapril was effective in retarding renal progression and protected renal function in ENTC PAN ENTCEND ENTD neprotic ENTDEND rats
0	It appears that ENTC temocapril ENTCEND was effective in retarding renal progression and protected renal function in PAN ENTD neprotic ENTDEND rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENTC angiotensin ENTCEND  converting enzyme (ACE) inhibitor, reduced ENTD proteinuria ENTDEND , inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
1	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced ENTD proteinuria ENTDEND , inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic ENTC puromycin aminonucleoside ENTCEND (PAN) - induced nephrotic rats
0	ENTC Temocapril ENTCEND did not attenuate ENTD proteinuria ENTDEND at 8 days, but it did markedly lower it from weeks 4 to 20
0	Temocapril, a long-acting non-SH group ENTC angiotensin ENTCEND  converting enzyme inhibitor, modulates ENTD glomerular injury ENTDEND in chronic puromycin aminonucleoside nephrosis
0	Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates ENTD glomerular injury ENTDEND  in chronic ENTC puromycin aminonucleoside ENTCEND nephrosis
0	ENTC Temocapril ENTCEND , a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates ENTD glomerular injury ENTDEND in chronic puromycin aminonucleoside nephrosis
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group ENTC angiotensin ENTCEND  converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented ENTD glomerulosclerosis ENTDEND in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats
0	The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented ENTD glomerulosclerosis ENTDEND  in chronic ENTC puromycin aminonucleoside ENTCEND (PAN) - induced nephrotic rats
0	ENTC Temocapril ENTCEND  did not attenuate proteinuria at 8 days, but it did markedly lower it from weeks 4 to 20. The ENTD glomerulosclerosis ENTDEND index (GSI) was 6
0	ENTC Angiotensin-converting enzyme (ACE) inhibitors ENTCEND  used to treat hypertension and ENTD congestive heart failure ENTDEND , were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively
0	Adverse reactions to drugs are well recognized as a cause of acute or chronic ENTD urticaria ENTDEND  and angio-oedema. ENTC Angiotensin-converting enzyme (ACE) inhibitors ENTCEND , used to treat hypertension and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively
0	ENTC Angiotensin-converting enzyme (ACE) inhibitors ENTCEND , used to treat ENTD hypertension ENTDEND and congestive heart failure, were introduced in Europe in the middle of the eighties, and the use of these drugs has increased progressively
1	Soon after the introduction of ENTC ACE inhibitors ENTCEND  acute bouts of ENTD angio-oedema ENTDEND were reported in association with the use of these drugs
0	We conclude that the CYA cardiotoxicity correlates with ENTC CYA ENTCEND dosage as calculated by body surface area, and that patients with ENTD aplastic anemia ENTDEND and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1
0	Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of ENTC CYA ENTCEND ENTD cardiotoxicity ENTDEND correlated with the dose per body surface area
0	We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and ENTD immunodeficiencies ENTDEND can be effectively prepared for bone marrow grafting at a ENTC CYA ENTCEND dose of 1
0	Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, ENTD Wiskott-Aldrich syndrome ENTDEND  or severe combined immunodeficiency syndrome. Fourteen of 84 (17%) patients had symptoms and signs consistent with ENTC CYA ENTCEND cardiotoxicity within ten days of receiving 1 to 4 doses of CYA
0	55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose ENTC CYA ENTCEND dosage is calculated based on weight. This study reaffirms the principle that drug ENTD toxicity ENTDEND correlates with dose per body surface area
0	Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or ENTD severe combined immunodeficiency syndrome ENTDEND  Fourteen of 84 (17%) patients had symptoms and signs consistent with ENTC CYA ENTCEND cardiotoxicity within ten days of receiving 1 to 4 doses of CYA
1	Six of the 14 patients died with ENTD congestive heart failure ENTDEND  The dose of ENTC CYA ENTCEND per body surface area was calculated for all patients and the patients were divided into two groups based on daily CYA dose: Group 1, CYA less than or equal to 1
1	Twelve asthmatic patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled ENTC salbutamol ENTCEND (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENTD tremor ENTDEND , and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENTD tremor ENTDEND , and metabolic ( ENTC K ENTCEND , Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENTD tremor ENTDEND , and metabolic (K, ENTC Glu ENTCEND ) responses were measured at each step (from 100 to 4,000 micrograms)
0	During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ENTC ipratropium bromide ENTCEND was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), ENTD tremor ENTDEND , and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled ENTC salbutamol ENTCEND  in ENTD asthmatics ENTDEND
0	Twelve ENTD asthmatic ENTDEND patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic ENTC K ENTCEND , Glu) responses were measured at each step (from 100 to 4,000 micrograms)
0	Twelve ENTD asthmatic ENTDEND  patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ipratropium bromide was substituted for rescue purposes. At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, ENTC Glu ENTCEND ) responses were measured at each step (from 100 to 4,000 micrograms)
0	Twelve ENTD asthmatic ENTDEND  patients (FEV1, 81 +/- 4% predicted), requiring only occasional inhaled beta-agonists as their sole therapy, were given a 14-day treatment with high dose inhaled salbutamol (HDS), 4,000 micrograms daily, low dose inhaled salbutamol (LDS), 800 micrograms daily, or placebo (PI) by metered-dose inhaler in a double-blind, randomized crossover design. During the 14-day run-in and during washout periods, inhaled beta-agonists were withheld and ENTC ipratropium bromide ENTCEND was substituted for rescue purposes
1	Diffuse skeletal ENTD pain ENTDEND  after administration of ENTC alendronate ENTCEND
0	CONCLUSION: We conclude that patients with osteoporosis can report ENTD pain ENTDEND  and ENTC bisphosphonate ENTCEND -related pain should also be considered before ascribing this complaint to osteoporosis
0	ENTC Alendronate ENTCEND  a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. ENTD Musculoskeletal pain ENTDEND may be an important side effect in these patients
0	BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and ENTC bisphosphonates ENTCEND  are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few and prominently gastrointestinal. ENTD Musculoskeletal pain ENTDEND may be an important side effect in these patients
0	Diffuse skeletal pain after administration of ENTC alendronate ENTCEND .BACKGROUND: ENTD Osteoporosis ENTDEND is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption
0	CONCLUSION: We conclude that patients with ENTD osteoporosis ENTDEND can report pain, and ENTC bisphosphonate ENTCEND -related pain should also be considered before ascribing this complaint to osteoporosis
0	There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid ( ENTC 5-HIAA ENTCEND  in the AN after 6-months of ENTD hyperprolactinemia ENTDEND and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia
0	After 6 months of ENTD hyperprolactinemia ENTDEND  ENTC dopamine ENTCEND (DA) concentrations in the median eminence (ME) increased by 84% over the control group
1	However, DA response was lost if a 9-month long ENTC haloperidol ENTCEND induced ENTD hyperprolactinemia ENTDEND was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule
0	However, DA response was lost if a 9-month long haloperidol-induced ENTD hyperprolactinemia ENTDEND  was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule. There was no change in the levels of DA, norepinephrine (NE), ENTC serotonin ENTCEND (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia
0	However, DA response was lost if a 9-month long haloperidol-induced ENTD hyperprolactinemia ENTDEND  was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule. There was no change in the levels of DA, ENTC norepinephrine ENTCEND (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia
0	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given ENTC Imipramine ENTCEND to control a behavior disorder. It was determined later that this patient's ENTD tumor ENTDEND was recurring at the time of her hypertensive episode
0	It was determined later that this patient's ENTD tumor ENTDEND  was recurring at the time of her hypertensive episode. Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension. The mechanism for this reaction is believed to be increased levels of vasoactive ENTC catecholamines ENTCEND due to interference of their physiologic inactivation by Imipramine
1	Hypertension in neuroblastoma induced by ENTC imipramine ENTCEND . ENTD Hypertension ENTDEND is a well-known finding in some patients with neuroblastoma
0	Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her ENTD hypertension ENTDEND  The mechanism for this reaction is believed to be increased levels of vasoactive ENTC catecholamines ENTCEND due to interference of their physiologic inactivation by Imipramine
0	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given ENTC Imipramine ENTCEND  to control a ENTD behavior disorder ENTDEND
0	We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a ENTD behavior disorder ENTDEND . It was determined later that this patient's tumor was recurring at the time of her hypertensive episode. Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension. The mechanism for this reaction is believed to be increased levels of vasoactive ENTC catecholamines ENTCEND due to interference of their physiologic inactivation by Imipramine
0	Hypertension in ENTD neuroblastoma ENTDEND  induced by ENTC imipramine ENTCEND
0	The mechanism for this reaction is believed to be increased levels of vasoactive ENTC catecholamines ENTCEND  due to interference of their physiologic inactivation by Imipramine. From this experience, we urge extreme caution in the use of tricyclic antidepressants in children with active ENTD neuroblastoma ENTDEND
1	We report a case of hypersensitivity myocarditis secondary to administration of ENTC carbamazepine ENTCEND  Acute ENTD hypersensitivity ENTDEND myocarditis was not suspected clinically, and the diagnosis was made post-mortem
1	Fatal ENTC carbamazepine ENTCEND  induced ENTD fulminant eosinophilic ENTDEND (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis
1	Clinically, death was due to ENTD cardiogenic shock ENTDEND  To best of our knowledge this is the second case of fatal ENTC carbamazepine ENTCEND induced myocarditis reported in English literature
1	To best of our knowledge this is the second case of fatal ENTC carbamazepine ENTCEND  induced ENTD myocarditis ENTDEND reported in English literature
1	Transmural ENTD myocardial infarction ENTDEND  with ENTC sumatriptan ENTCEND
0	We describe a 47-year-old woman with an acute myocardial infarction after administration of ENTC sumatriptan ENTCEND 6 mg subcutaneously for cluster headache. The patient had no history of underlying ENTD ischaemic heart disease ENTDEND or Prinzmetal's angina
0	We describe a 47-year-old woman with an acute myocardial infarction after administration of ENTC sumatriptan ENTCEND  6 mg subcutaneously for cluster headache. The patient had no history of underlying ischaemic heart disease or ENTD Prinzmetal's angina ENTDEND
0	We describe a 47-year-old woman with an acute myocardial infarction after administration of ENTC sumatriptan ENTCEND  6 mg subcutaneously for ENTD cluster headache ENTDEND
0	), no effects were observed in ENTD convulsions ENTDEND induced by ENTC N-methyl-D-aspartate ENTCEND , picrotoxin, or electroshock in Slc:ddY mice
0	, respectively, while that of ENTC flunarizine ENTCEND was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic ENTD convulsions ENTDEND induced by pentylenetetrazole (85 mg/kg, s
1	) or ENTC bemegride ENTCEND (40 mg/kg, s.c.), no effects were observed in ENTD convulsions ENTDEND induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice
1	Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic ENTD convulsions ENTDEND  induced by ENTC pentylenetetrazole ENTCEND (85 mg/kg, s
0	S-312, S-312-d, but not S-312-l, L-type ENTC calcium ENTCEND channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic ENTD convulsions ENTDEND induced by pentylenetetrazole (85 mg/kg, s
0	Although moderate anticonvulsant effects of ENTC S-312-d ENTCEND in higher doses were observed against the clonic ENTD convulsions ENTDEND induced by pentylenetetrazole (85 mg/kg, s
1	), no effects were observed in ENTD convulsions ENTDEND  induced by N-methyl-D-aspartate, ENTC picrotoxin ENTCEND , or electroshock in Slc:ddY mice
0	), no effects were observed in convulsions induced by ENTC N-methyl-D-aspartate ENTCEND , picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENTD epilepsy ENTDEND
0	, respectively, while that of ENTC flunarizine ENTCEND  was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENTD epilepsy ENTDEND
0	) or ENTC bemegride ENTCEND  (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENTD epilepsy ENTDEND
0	Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by ENTC pentylenetetrazole ENTCEND  (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENTD epilepsy ENTDEND
0	S-312, S-312-d, but not S-312-l, L-type ENTC calcium ENTCEND  channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENTD epilepsy ENTDEND
0	ENTC S-312-d ENTCEND may be useful in the therapy of certain types of human ENTD epilepsy ENTDEND
0	), no effects were observed in convulsions induced by N-methyl-D-aspartate, ENTC picrotoxin ENTCEND , or electroshock in Slc:ddY mice. S-312-d may be useful in the therapy of certain types of human ENTD epilepsy ENTDEND
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENTD audiogenic tonic convulsions ENTDEND in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by ENTC N-methyl-D-aspartate ENTCEND , picrotoxin, or electroshock in Slc:ddY mice
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENTD audiogenic tonic convulsions ENTDEND  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of ENTC flunarizine ENTCEND was 34
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENTD audiogenic tonic convulsions ENTDEND  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or ENTC bemegride ENTCEND (40 mg/kg, s
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENTD audiogenic tonic convulsions ENTDEND  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by ENTC pentylenetetrazole ENTCEND (85 mg/kg, s
0	S-312, S-312-d, but not S-312-l, L-type ENTC calcium ENTCEND  channel antagonists, showed anticonvulsant effects on the ENTD audiogenic tonic convulsions ENTDEND in DBA/2 mice; and their ED50 values were 18
0	S-312, ENTC S-312-d ENTCEND  but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENTD audiogenic tonic convulsions ENTDEND in DBA/2 mice; and their ED50 values were 18
0	S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the ENTD audiogenic tonic convulsions ENTDEND  in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8) mg/kg, p.o. Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, ENTC picrotoxin ENTCEND , or electroshock in Slc:ddY mice
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENTC isotretinoin ENTCEND  a commonly used drug in the treatment of severe cystic acne. Blepharoconjunctivitis, subjective complaints of dry eyes, blurred vision, contact lens intolerance, and ENTD photodermatitis ENTDEND are reversible side effects
0	ENTC Isotretinoin ENTCEND is contraindicated in pregnancy because of the many reported ENTD congenital abnormalities ENTDEND after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENTC isotretinoin ENTCEND , a commonly used drug in the treatment of severe cystic acne. ENTD Blepharoconjunctivitis ENTDEND , subjective complaints of dry eyes, blurred vision, contact lens intolerance, and photodermatitis are reversible side effects
1	More serious ocular adverse reactions include ENTD papilledema ENTDEND  pseudotumor cerebri, and white or gray subepithelial corneal opacities; all of these are reversible if the drug is discontinued. Reported cases of decreased dark adaptation are under investigation. ENTC Isotretinoin ENTCEND is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
1	More serious ocular adverse reactions include papilledema, pseudotumor cerebri, and white or gray subepithelial ENTD corneal opacities ENTDEND  all of these are reversible if the drug is discontinued. Reported cases of decreased dark adaptation are under investigation. ENTC Isotretinoin ENTCEND is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENTC isotretinoin ENTCEND , a commonly used drug in the treatment of severe cystic acne. Blepharoconjunctivitis, subjective complaints of dry eyes, ENTD blurred vision ENTDEND , contact lens intolerance, and photodermatitis are reversible side effects
1	A total of 261 adverse ocular reactions occurred in 237 patients who received ENTC isotretinoin ENTCEND , a commonly used drug in the treatment of severe cystic acne. Blepharoconjunctivitis, subjective complaints of ENTD dry eyes ENTDEND , blurred vision, contact lens intolerance, and photodermatitis are reversible side effects
0	ENTC Isotretinoin ENTCEND  is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital ENTD hypertelorism ENTDEND , and optic nerve hypoplasia)
1	More serious ocular adverse reactions include papilledema, ENTD pseudotumor cerebri ENTDEND  and white or gray subepithelial corneal opacities; all of these are reversible if the drug is discontinued. Reported cases of decreased dark adaptation are under investigation. ENTC Isotretinoin ENTCEND is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia)
0	A total of 261 adverse ocular reactions occurred in 237 patients who received ENTC isotretinoin ENTCEND , a commonly used drug in the treatment of severe cystic ENTD acne ENTDEND
0	ENTC Isotretinoin ENTCEND  is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including ENTD microphthalmos ENTDEND , orbital hypertelorism, and optic nerve hypoplasia)
0	ENTC Isotretinoin ENTCEND  is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and ENTD optic nerve hypoplasia ENTDEND )
0	BACKGROUND: Reports of severe bradyarrhythmia during ENTC amiodarone ENTCEND therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENTD ventricular arrhythmias ENTDEND
0	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENTD ventricular arrhythmias ENTDEND . METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENTC sotalol ENTCEND , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENTD ventricular arrhythmias ENTDEND . METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and ENTC digoxin ENTCEND
0	BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ENTD ventricular arrhythmias ENTDEND . METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENTC calcium ENTCEND channel blockers, and digoxin
0	CONCLUSIONS: This study suggests that the use of ENTC amiodarone ENTCEND in elderly patients with AF and a previous ENTD MI ENTDEND increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction ( ENTD MI ENTDEND  between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENTC sotalol ENTCEND , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	ENTC Digoxin ENTCEND was the only other medication associated with an increased risk of pacemaker insertion (OR: 1.78, 95% CI: 1.37 to 2.31). CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous ENTD MI ENTDEND increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction ( ENTD MI ENTDEND ) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENTC calcium ENTCEND channel blockers, and digoxin
0	OBJECTIVES: The aim of this study was to determine whether the use of ENTC amiodarone ENTCEND in patients with ENTD atrial fibrillation ENTDEND (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of ENTD AF ENTDEND was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENTC sotalol ENTCEND , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	ENTC Digoxin ENTCEND  was the only other medication associated with an increased risk of pacemaker insertion (OR: 1.78, 95% CI: 1.37 to 2.31). CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with ENTD AF ENTDEND and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker
0	METHODS: A study cohort of 8,770 patients age > or =65 years with a new diagnosis of ENTD AF ENTDEND  was identified from a provincewide database of Quebec residents with a myocardial infarction (MI) between 1991 and 1999. Using a nested case-control design, 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENTC calcium ENTCEND channel blockers, and digoxin
1	BACKGROUND: Reports of severe ENTD bradyarrhythmia ENTDEND during ENTC amiodarone ENTCEND therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias
0	Using a nested case-control design, 477 cases of ENTD bradyarrhythmia ENTDEND requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to ENTC sotalol ENTCEND , Class I antiarrhythmic agents, beta-blockers, calcium channel blockers, and digoxin
0	ENTC Digoxin ENTCEND  was the only other medication associated with an increased risk of pacemaker insertion (OR: 1.78, 95% CI: 1.37 to 2.31). CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of ENTD bradyarrhythmia ENTDEND requiring a permanent pacemaker
0	Using a nested case-control design, 477 cases of ENTD bradyarrhythmia ENTDEND  requiring a permanent pacemaker were matched (1:4) to 1,908 controls. Multivariable logistic regression was used to estimate the odds ratio (OR) of pacemaker insertion associated with amiodarone use, controlling for baseline risk factors and exposure to sotalol, Class I antiarrhythmic agents, beta-blockers, ENTC calcium ENTCEND channel blockers, and digoxin
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and ENTD perioral dermatitis ENTDEND  We report on rosaceiform dermatitis as a complication of treatment with ENTC tacrolimus ENTCEND ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENTC steroid ENTCEND aggravated rosacea and ENTD perioral dermatitis ENTDEND
1	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated ENTD rosacea ENTDEND and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with ENTC tacrolimus ENTCEND ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENTC steroid ENTCEND -aggravated ENTD rosacea ENTDEND and perioral dermatitis
0	Induction of rosaceiform dermatitis during treatment of ENTD facial inflammatory dermatoses ENTDEND  with ENTC tacrolimus ENTCEND ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENTC steroid ENTCEND -aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment. OBSERVATIONS: Six adult patients with ENTD inflammatory facial dermatoses ENTDEND were treated with tacrolimus ointment because of the ineffectiveness of standard treatments
0	In 1 patient with eyelid ENTD eczema ENTDEND  rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment. In 1 patient with atopic dermatitis, telangiectatic and papular rosacea insidiously appeared after 5 months of treatment. CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with ENTC tacrolimus ENTCEND ointment is heterogeneous
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENTC steroid ENTCEND -aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment. OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions. Biopsy revealed an abundance of Demodex mites in 2 of these patients. In 1 patient with eyelid ENTD eczema ENTDEND , rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment
0	In 1 patient with ENTD atopic dermatitis ENTDEND  telangiectatic and papular rosacea insidiously appeared after 5 months of treatment. CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with ENTC tacrolimus ENTCEND ointment is heterogeneous
0	OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with ENTC tacrolimus ENTCEND ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of ENTD acne ENTDEND experienced sudden worsening with pustular rosaceiform lesions
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENTC steroid ENTCEND -aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment. OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of ENTD acne ENTDEND experienced sudden worsening with pustular rosaceiform lesions
0	We report on rosaceiform ENTD dermatitis ENTDEND as a complication of treatment with ENTC tacrolimus ENTCEND ointment
0	BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in ENTC steroid ENTCEND -aggravated rosacea and perioral dermatitis. We report on rosaceiform ENTD dermatitis ENTDEND as a complication of treatment with tacrolimus ointment
1	A case of nontraumatic ENTD dissecting aneurysm ENTDEND of the basilar artery in association with hypertension, smoke, and ENTC oral contraceptives ENTCEND is reported in a young female patient with a locked-in syndrome
0	A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and ENTC oral contraceptives ENTCEND  is reported in a young female patient with a ENTD locked-in syndrome ENTDEND
0	A case of nontraumatic dissecting aneurysm of the basilar artery in association with ENTD hypertension ENTDEND  smoke, and ENTC oral contraceptives ENTCEND is reported in a young female patient with a locked-in syndrome
0	PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good ENTD seizure ENTDEND control. METHODS: All patients taking ENTC Vigabatrin ENTCEND alone or in combination with other antiepileptic drugs for at least 5 years (range 5-12 years) were entered into a visual surveillance programme
0	These data give support to the hypothesis that the pathogenesis of ENTC Vigabatrin ENTCEND associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent ENTD toxicity ENTDEND
1	The natural history of ENTC Vigabatrin ENTCEND  associated ENTD visual field defects ENTDEND in patients electing to continue their medication
0	The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal ENTC methotrexate ENTCEND ENTD toxicity ENTDEND is unclear
1	ENTD Paraplegia ENTDEND  following intrathecal ENTC methotrexate ENTCEND : report of a case and review of the literature
0	The role of ENTC methotrexate ENTCEND contaminants, local ENTD folate deficiency ENTDEND , and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear
0	The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal ENTC methotrexate ENTCEND  toxicity is unclear. The incidence of ENTD neurotoxicity ENTDEND may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage
0	The incidence of neurotoxicity may be reduced by employing lower doses of ENTC methotrexate ENTCEND in the presence of ENTD central nervous system leukemia ENTDEND , in older children and adults, and in the presence of epidural leakage
1	ENTC Ethambutol ENTCEND is known to cause optic neuropathy and, more rarely, axonal ENTD polyneuropathy ENTDEND
1	We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and ENTD paresthesias ENTDEND after 11 weeks of exposure to a supratherapeutic dose of ENTC ethambutol ENTCEND
0	Optochiasmatic and ENTD peripheral neuropathy ENTDEND  due to ENTC ethambutol ENTCEND overtreatment
0	This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to ENTC ethambutol ENTCEND ENTD toxicity ENTDEND
1	We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed ENTD visual loss ENTDEND and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ENTC ethambutol ENTCEND
1	ENTC Ethambutol ENTCEND  is known to cause ENTD optic neuropathy ENTDEND and, more rarely, axonal polyneuropathy
1	ENTC Metronidazole ENTCEND -induced ENTD encephalopathy ENTDEND : an uncommon scenario
0	The diagnosis of ENTC metronidazole ENTCEND ENTD toxicity ENTDEND was made by the MRI findings and supported clinically
1	Typical S-T/T changes occurred in the insulin-group but in none of the ENTC propranolol ENTCEND insulin group. ENTD Hypertension ENTDEND in diabetics prone to hypoglycaemia attacks should not be treated with beta-blockers because these drugs may cause a sharp rise in blood-pressure in such patients
0	Modification by ENTC propranolol ENTCEND  of cardiovascular effects of induced ENTD hypoglycaemia ENTDEND
0	Typical S-T/T changes occurred in the insulin-group but in none of the ENTC propranolol ENTCEND -insulin group. Hypertension in ENTD diabetics ENTDEND prone to hypoglycaemia attacks should not be treated with beta-blockers because these drugs may cause a sharp rise in blood-pressure in such patients
0	Postoperatively, she was given a patient-controlled analgesia device delivering boluses of ENTC diamorphine ENTCEND 0.5 mg and droperidol 0.025 mg. Whilst using the device she gradually became anxious, the feeling worsening after each bolus. The diagnosis of droperidol-induced ENTD psychological disturbance ENTDEND was not made straight away although on subsequent close questioning the patient gave a very clear history
1	A case of postoperative ENTD anxiety ENTDEND  due to low dose ENTC droperidol ENTCEND used with patient-controlled analgesia
0	CONCLUSION: In this open trial, ENTC galantamine ENTCEND was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly ENTD aggression ENTDEND , behavioral dyscontrol, and inattention
1	Overall, galantamine was well-tolerated, with no significant adverse effects apart from ENTD headaches ENTDEND in one patient. CONCLUSION: In this open trial, ENTC galantamine ENTCEND was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention
0	CONCLUSION: In this open trial, ENTC galantamine ENTCEND  was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and ENTD inattention ENTDEND
0	A prospective, open-label trial of ENTC galantamine ENTCEND  in ENTD autistic disorder ENTDEND
0	CONCLUSION: In this open trial, ENTC galantamine ENTCEND  was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, ENTD behavioral dyscontrol ENTDEND , and inattention
0	ENTC Viracept ENTCEND  and ENTD irregular heartbeat ENTDEND warning
1	A group of doctors in Boston warn that the protease inhibitor ENTC Viracept ENTCEND may cause an irregular heart beat, known as ENTD bradycardia ENTDEND , in people with HIV
1	Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating ENTC lithium ENTCEND induced ENTD polyuria ENTDEND
0	Urinary ENTC sodium ENTCEND  potassium and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe ENTD polyuria ENTDEND associated with lithium therapy
0	The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing ENTC urea ENTCEND transporter (UT-A1) and water channel (AQP2) expression in the inner medulla. Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced ENTD polyuria ENTDEND
0	Urinary sodium, potassium and ENTC calcium ENTCEND were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe ENTD polyuria ENTDEND associated with lithium therapy
0	Urinary sodium, ENTC potassium ENTCEND and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe ENTD polyuria ENTDEND associated with lithium therapy
0	The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the ENTC cAMP ENTCEND pathway and chronically reducing urea transporter (UT-A1) and water channel (AQP2) expression in the inner medulla. Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced ENTD polyuria ENTDEND
1	Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in ENTC lithium ENTCEND induced ENTD NDI ENTDEND , and prevents the development of the severe polyuria associated with lithium therapy
0	Urinary ENTC sodium ENTCEND , potassium and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced ENTD NDI ENTDEND , and prevents the development of the severe polyuria associated with lithium therapy
0	Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus ( ENTD NDI ENTDEND  in  40% of patients. The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the cAMP pathway and chronically reducing ENTC urea ENTCEND transporter (UT-A1) and water channel (AQP2) expression in the inner medulla
0	Urinary sodium, potassium and ENTC calcium ENTCEND  were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced ENTD NDI ENTDEND , and prevents the development of the severe polyuria associated with lithium therapy
0	Urinary sodium, ENTC potassium ENTCEND  and calcium were elevated in lithium-fed WT but not in lithium-fed PKCa KO mice. Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced ENTD NDI ENTDEND , and prevents the development of the severe polyuria associated with lithium therapy
0	Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus ( ENTD NDI ENTDEND ) in  40% of patients. The decreased capacity to concentrate urine is likely due to lithium acutely disrupting the ENTC cAMP ENTCEND pathway and chronically reducing urea transporter (UT-A1) and water channel (AQP2) expression in the inner medulla
1	RESULTS: A total of 76 cases of ENTD hyponatremia ENTDEND and/or SIADH associated with ENTC vincristine ENTCEND use were identified
0	Approximately 75% of the patients were receiving treatment for leukemia or ENTD lymphoma ENTDEND  Among the 39 reports that included information on race, the racial distribution was: 1 Black, 3 Caucasian, and 35 Asian. CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with ENTC vincristine ENTCEND use
1	Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone ( ENTD SIADH ENTDEND  among ENTC vincristine ENTCEND -treated patients and to explore the possibility of at-risk population subgroups
0	RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with ENTC vincristine ENTCEND  use were identified. The overall reporting rate was estimated to be 1.3/100,000 treated patients. The average age of patients was 35.6 +/- 28.3 years, and 62% were males. Approximately 75% of the patients were receiving treatment for ENTD leukemia ENTDEND or lymphoma
0	8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given ENTC vincristine sulfate ENTCEND 4 days previously resulted in fatal ENTD infection ENTDEND in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died
0	ENTD Leukocytosis ENTDEND was observed in all monkeys. Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of ENTC vincristine sulfate ENTCEND was followed by leukopenia in 4 to 5 days
1	5 mg of ENTC vincristine sulfate ENTCEND  was followed by ENTD leukopenia ENTDEND in 4 to 5 days
1	Effect of ENTC vincristine sulfate ENTCEND  on ENTD Pseudomonas infections ENTDEND in monkeys
1	8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given ENTC vincristine sulfate ENTCEND  4 days previously resulted in fatal infection in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died. These studies suggest that an antimetabolite-induced leukopenia predisposes to severe Pseudomonas ENTD sepsis ENTDEND and that such monkeys may serve as a biological model for study of comparative efficacy of antimicrobial agents
0	Cardiac symptoms, including hypotension, developed in three patients with advanced ENTD colorectal carcinoma ENTDEND while being treated with cisplatin (CDDP) and ENTC 5-fluorouracil ENTCEND (5-FU)
0	Cardiac symptoms, including hypotension, developed in three patients with advanced ENTD colorectal carcinoma ENTDEND  while being treated with ENTC cisplatin ENTCEND (CDDP) and 5-fluorouracil (5-FU)
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil ( ENTC 5-FU ENTCEND . In two patients, hypotension was associated with severe ENTD left ventricular dysfunction ENTDEND
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin ( ENTC CDDP ENTCEND  and 5-fluorouracil (5-FU). In two patients, hypotension was associated with severe ENTD left ventricular dysfunction ENTDEND
0	The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of ENTC 5-FU ENTCEND ENTD cardiotoxicity ENTDEND that may be influenced by CDDP
0	The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU ENTD cardiotoxicity ENTDEND  that may be influenced by ENTC CDDP ENTCEND
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil ( ENTC 5-FU ENTCEND ). In two patients, ENTD hypotension ENTDEND was associated with severe left ventricular dysfunction
1	Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin ( ENTC CDDP ENTCEND ) and 5-fluorouracil (5-FU). In two patients, ENTD hypotension ENTDEND was associated with severe left ventricular dysfunction
0	ENTC Creatine ENTCEND kinase levels were normal prior to daptomycin therapy and were not reassessed. DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute ENTD interstitial nephritis ENTDEND and relapsing bacteremia
0	DISCUSSION: ENTC Daptomycin ENTCEND was initiated in our patient secondary to possible nafcillin-induced acute ENTD interstitial nephritis ENTDEND and relapsing bacteremia
1	DISCUSSION: Daptomycin was initiated in our patient secondary to possible ENTC nafcillin ENTCEND induced acute ENTD interstitial nephritis ENTDEND and relapsing bacteremia
0	OBJECTIVE: To report a case of ENTC methicillin ENTCEND sensitive Staphylococcus aureus (MSSA) ENTD bacteremia ENTDEND with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENTD bacteremia ENTDEND  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/ ENTC tazobactam ENTCEND
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENTD bacteremia ENTDEND  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENTC levofloxacin ENTCEND , and piperacillin/tazobactam
0	ENTC Creatine ENTCEND  kinase levels were normal prior to daptomycin therapy and were not reassessed. DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing ENTD bacteremia ENTDEND
0	aureus susceptible to ENTC oxacillin ENTCEND  Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA ENTD bacteremia ENTDEND on day 9, increasing the suspicion for a central nervous system (CNS) infection
0	CONCLUSIONS: High-dose ENTC daptomycin ENTCEND may be an alternative option for MSSA ENTD bacteremia ENTDEND with or without a CNS source in patients who have failed or cannot tolerate standard therapy
0	On day 8, the patient developed acute renal failure (serum ENTC creatinine ENTCEND 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA ENTD bacteremia ENTDEND on day 9, increasing the suspicion for a central nervous system (CNS) infection
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENTD bacteremia ENTDEND  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with ENTC vancomycin ENTCEND , levofloxacin, and piperacillin/tazobactam
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) ENTD bacteremia ENTDEND  with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENTC piperacillin ENTCEND /tazobactam
0	DISCUSSION: Daptomycin was initiated in our patient secondary to possible ENTC nafcillin ENTCEND -induced acute interstitial nephritis and relapsing ENTD bacteremia ENTDEND
0	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENTD infection ENTDEND  Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16. Daptomycin serum and CSF trough concentrations were 11.21 ug/mL and 0.52 ug/mL, respectively, prior to the third dose. Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA. ENTC Creatine ENTCEND kinase levels were normal prior to daptomycin therapy and were not reassessed
0	aureus susceptible to ENTC oxacillin ENTCEND . Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENTD infection ENTDEND
0	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENTD infection ENTDEND . Nafcillin was discontinued and ENTC daptomycin ENTCEND 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	On day 8, the patient developed acute renal failure (serum ENTC creatinine ENTCEND  1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENTD infection ENTDEND
0	The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) ENTD infection ENTDEND . ENTC Nafcillin ENTCEND was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	OBJECTIVE: To report a case of ENTC methicillin ENTCEND -sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND and presumed health-care-associated pneumonia shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin ENTC tazobactam ENTCEND
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENTC levofloxacin ENTCEND , and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to ENTC oxacillin ENTCEND
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose ENTC daptomycin ENTCEND assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND and presumed health-care-associated pneumonia shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum ENTC creatinine ENTCEND 1
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with ENTC vancomycin ENTCEND , levofloxacin, and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENTC piperacillin ENTCEND /tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized ENTD weakness ENTDEND  and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to ENTC nafcillin ENTCEND on day 4
0	Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/ ENTC tazobactam ENTCEND . Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENTD acute renal failure ENTDEND (serum creatinine 1
0	Treatment was empirically initiated with vancomycin, ENTC levofloxacin ENTCEND , and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENTD acute renal failure ENTDEND (serum creatinine 1
0	aureus susceptible to ENTC oxacillin ENTCEND . Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENTD acute renal failure ENTDEND (serum creatinine 1
0	On day 8, the patient developed ENTD acute renal failure ENTDEND  (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and ENTC daptomycin ENTCEND 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	On day 8, the patient developed ENTD acute renal failure ENTDEND  (serum ENTC creatinine ENTCEND 1
0	Treatment was empirically initiated with ENTC vancomycin ENTCEND , levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENTD acute renal failure ENTDEND (serum creatinine 1
0	Treatment was empirically initiated with vancomycin, levofloxacin, and ENTC piperacillin ENTCEND /tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed ENTD acute renal failure ENTDEND (serum creatinine 1
0	Empiric antibiotic treatment was narrowed to ENTC nafcillin ENTCEND  on day 4. On day 8, the patient developed ENTD acute renal failure ENTDEND (serum creatinine 1
0	Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/ ENTC tazobactam ENTCEND . Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND on day 10
0	Treatment was empirically initiated with vancomycin, ENTC levofloxacin ENTCEND , and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND on day 10
0	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND  on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16. Daptomycin serum and CSF trough concentrations were 11.21 ug/mL and 0.52 ug/mL, respectively, prior to the third dose. Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA. ENTC Creatine ENTCEND kinase levels were normal prior to daptomycin therapy and were not reassessed
0	aureus susceptible to ENTC oxacillin ENTCEND . Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND on day 10
0	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND  on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and ENTC daptomycin ENTCEND 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	On day 8, the patient developed acute renal failure (serum ENTC creatinine ENTCEND  1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND on day 10
0	Treatment was empirically initiated with ENTC vancomycin ENTCEND , levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND on day 10
0	Treatment was empirically initiated with vancomycin, levofloxacin, and ENTC piperacillin ENTCEND /tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND on day 10
0	The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of ENTD cardiac arrest ENTDEND  on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. ENTC Nafcillin ENTCEND was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16
0	OBJECTIVE: To report a case of ENTC methicillin ENTCEND -sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin ENTC tazobactam ENTCEND
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND  shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENTC levofloxacin ENTCEND , and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to ENTC oxacillin ENTCEND
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose ENTC daptomycin ENTCEND  assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND shown on chest radiograph
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to nafcillin on day 4. On day 8, the patient developed acute renal failure (serum ENTC creatinine ENTCEND 1
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND  shown on chest radiograph. Treatment was empirically initiated with ENTC vancomycin ENTCEND , levofloxacin, and piperacillin/tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENTC piperacillin ENTCEND /tazobactam
0	CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated ENTD pneumonia ENTDEND  shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to oxacillin. Empiric antibiotic treatment was narrowed to ENTC nafcillin ENTCEND on day 4
0	Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus ENTD meningitis ENTDEND .OBJECTIVE: To report a case of ENTC methicillin ENTCEND -sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENTD meningitis ENTDEND treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin ENTC tazobactam ENTCEND
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENTD meningitis ENTDEND  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, ENTC levofloxacin ENTCEND , and piperacillin/tazobactam
0	Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected ENTD meningitis ENTDEND and was continued until the patient's death on day 16. Daptomycin serum and CSF trough concentrations were 11.21 ug/mL and 0.52 ug/mL, respectively, prior to the third dose. Lumbar puncture results were inconclusive and no further blood cultures were positive for MSSA. ENTC Creatine ENTCEND kinase levels were normal prior to daptomycin therapy and were not reassessed
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENTD meningitis ENTDEND  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and piperacillin/tazobactam. Blood cultures revealed S. aureus susceptible to ENTC oxacillin ENTCEND
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENTD meningitis ENTDEND  treated with high-dose ENTC daptomycin ENTCEND assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations
0	On day 8, the patient developed acute renal failure (serum ENTC creatinine ENTCEND  1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission). The patient's Glasgow Coma Score was 3, with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10. The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection. Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected ENTD meningitis ENTDEND and was continued until the patient's death on day 16
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENTD meningitis ENTDEND  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with ENTC vancomycin ENTCEND , levofloxacin, and piperacillin/tazobactam
0	OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA ENTD meningitis ENTDEND  treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations. CASE SUMMARY: A 54-year-old male presented to the emergency department with generalized weakness and presumed health-care-associated pneumonia shown on chest radiograph. Treatment was empirically initiated with vancomycin, levofloxacin, and ENTC piperacillin ENTCEND /tazobactam
0	ENTC Nafcillin ENTCEND  was discontinued and daptomycin 9 mg/kg daily was initiated for suspected ENTD meningitis ENTDEND and was continued until the patient's death on day 16
0	005), and systemic ENTD fungal infections ENTDEND occurred only in the liver transplant group. Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of ENTC cyclosporine ENTCEND patients and 76% of Aza patients
0	ENTC Aza ENTCEND patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic ENTD fungal infections ENTDEND occurred only in the liver transplant group
0	Serological evidence for ENTD Epstein Barr Virus infection ENTDEND was found in 20% of 65 ENTC cyclosporine ENTCEND patients studied
0	Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of ENTC Aza ENTCEND patients. Of the cyclosporine patients, 15% had symptoms related to CMV infection. Serological evidence for ENTD Epstein Barr Virus infection ENTDEND was found in 20% of 65 cyclosporine patients studied
0	Renal patients on ENTC cyclosporine ENTCEND had the fewest ENTD bacteremias ENTDEND
0	All others received cyclosporine and ENTC prednisone ENTCEND  The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients. Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients. There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest ENTD bacteremias ENTDEND
0	There were no infectious deaths in renal transplant patients on cyclosporine or ENTC Aza ENTCEND  but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest ENTD bacteremias ENTDEND
1	Heart and liver patients had more ENTD infections ENTDEND than ENTC cyclosporine ENTCEND renal patients but fewer infections than the Aza renal patients
0	All others received cyclosporine and ENTC prednisone ENTCEND . The randomized Aza patients had more overall ENTD infections ENTDEND (P less than 0
1	There were no infectious deaths in renal transplant patients on cyclosporine or ENTC Aza ENTCEND , but ENTD infection ENTDEND played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths
0	Of the ENTC cyclosporine ENTCEND patients, 15% had symptoms related to ENTD CMV infection ENTDEND
0	Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of ENTC Aza ENTCEND  patients. Of the cyclosporine patients, 15% had symptoms related to ENTD CMV infection ENTDEND
0	Pulmonary infections were less common in ENTC cyclosporine ENTCEND treated renal patients than in Aza-treated patients (P less than 0.05). Aza patients had significantly more ENTD staphylococcal infections ENTDEND than all other transplant groups (P less than 0
0	ENTC Aza ENTCEND  patients had significantly more ENTD staphylococcal infections ENTDEND than all other transplant groups (P less than 0
0	Renal patients on ENTC cyclosporine ENTCEND  had the fewest bacteremias. Analysis of site of infection showed a preponderance of ENTD abdominal infections ENTDEND in liver patients, intrathoracic infections in heart patients, and urinary tract infections in renal patients
0	All others received cyclosporine and ENTC prednisone ENTCEND . The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients. Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients. There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest bacteremias. Analysis of site of infection showed a preponderance of ENTD abdominal infections ENTDEND in liver patients, intrathoracic infections in heart patients, and urinary tract infections in renal patients
0	Analysis of site of infection showed a preponderance of ENTD abdominal infections ENTDEND  in liver patients, intrathoracic infections in heart patients, and urinary tract infections in renal patients. Pulmonary infections were less common in cyclosporine-treated renal patients than in ENTC Aza ENTCEND -treated patients (P less than 0
0	Serological evidence for Epstein Barr Virus infection was found in 20% of 65 ENTC cyclosporine ENTCEND  patients studied. Three had associated symptoms, and one developed a ENTD lymphoma ENTDEND
0	Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of ENTC Aza ENTCEND  patients. Of the cyclosporine patients, 15% had symptoms related to CMV infection. Serological evidence for Epstein Barr Virus infection was found in 20% of 65 cyclosporine patients studied. Three had associated symptoms, and one developed a ENTD lymphoma ENTDEND
0	Analysis of site of infection showed a preponderance of abdominal infections in liver patients, intrathoracic infections in heart patients, and ENTD urinary tract infections ENTDEND in renal patients. Pulmonary infections were less common in ENTC cyclosporine ENTCEND -treated renal patients than in Aza-treated patients (P less than 0
0	All others received cyclosporine and ENTC prednisone ENTCEND . The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients. Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients. There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths. Renal patients on cyclosporine had the fewest bacteremias. Analysis of site of infection showed a preponderance of abdominal infections in liver patients, intrathoracic infections in heart patients, and ENTD urinary tract infections ENTDEND in renal patients
0	Analysis of site of infection showed a preponderance of abdominal infections in liver patients, intrathoracic infections in heart patients, and ENTD urinary tract infections ENTDEND  in renal patients. Pulmonary infections were less common in cyclosporine-treated renal patients than in ENTC Aza ENTCEND -treated patients (P less than 0
0	Patients were managed with ENTC cyclosporine ENTCEND and azathioprine. No prophylaxis with antilymphocyte globulin was used. Steroids were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%). Five patients (14%) received maintenance steroids. Four patients died in the perioperative period and one died 4 months later. There have been no deaths related to rejection or ENTD infection ENTDEND
0	Freedom from serious ENTD infections ENTDEND was 83% at 1 month and 65% at 1 year. Cytomegalovirus infections were treated successfully with ENTC ganciclovir ENTCEND in 11 patients
0	Five patients (14%) received maintenance ENTC steroids ENTCEND  Four patients died in the perioperative period and one died 4 months later. There have been no deaths related to rejection or ENTD infection ENTDEND
0	Patients were managed with cyclosporine and ENTC azathioprine ENTCEND  No prophylaxis with antilymphocyte globulin was used. Steroids were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%). Five patients (14%) received maintenance steroids. Four patients died in the perioperative period and one died 4 months later. There have been no deaths related to rejection or ENTD infection ENTDEND
0	Cytomegalovirus infections were treated successfully with ENTC ganciclovir ENTCEND  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed. Seizures occurred in five patients (14%) and ENTD hypertension ENTDEND was treated in 10 patients (28%)
0	Indications for transplantation were ENTD idiopathic cardiomyopathy ENTDEND (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and ENTC doxorubicin ENTCEND cardiomyopathy (5%)
0	Indications for transplantation were ENTD idiopathic cardiomyopathy ENTDEND  (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENTC cyclosporine ENTCEND and azathioprine
0	Pediatric heart transplantation without chronic maintenance ENTC steroids ENTCEND .From 1986 to February 1993, 40 children aged 2 months to 18 years (average age 10.4 +/- 5.8 years) underwent heart transplantation. Indications for transplantation were ENTD idiopathic cardiomyopathy ENTDEND (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%)
0	Indications for transplantation were ENTD idiopathic cardiomyopathy ENTDEND  (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENTC azathioprine ENTCEND
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENTD hypertrophic cardiomyopathy ENTDEND (5%), valvular heart disease (3%), and ENTC doxorubicin ENTCEND cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENTD hypertrophic cardiomyopathy ENTDEND  (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENTC cyclosporine ENTCEND and azathioprine
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENTD hypertrophic cardiomyopathy ENTDEND  (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and azathioprine. No prophylaxis with antilymphocyte globulin was used. ENTC Steroids ENTCEND were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), ENTD hypertrophic cardiomyopathy ENTDEND  (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENTC azathioprine ENTCEND
1	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and ENTC doxorubicin ENTCEND  ENTD cardiomyopathy ENTDEND (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin ENTD cardiomyopathy ENTDEND  (5%). Patients were managed with ENTC cyclosporine ENTCEND and azathioprine
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin ENTD cardiomyopathy ENTDEND  (5%). Patients were managed with cyclosporine and azathioprine. No prophylaxis with antilymphocyte globulin was used. ENTC Steroids ENTCEND were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin ENTD cardiomyopathy ENTDEND  (5%). Patients were managed with cyclosporine and ENTC azathioprine ENTCEND
0	ENTD Cytomegalovirus infections ENTDEND were treated successfully with ENTC ganciclovir ENTCEND in 11 patients
0	Cytomegalovirus infections were treated successfully with ENTC ganciclovir ENTCEND  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed. ENTD Seizures ENTDEND occurred in five patients (14%) and hypertension was treated in 10 patients (28%)
0	Cytomegalovirus infections were treated successfully with ENTC ganciclovir ENTCEND  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft ENTD atherosclerosis ENTDEND has been observed
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENTD valvular heart disease ENTDEND (3%), and ENTC doxorubicin ENTCEND cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENTD valvular heart disease ENTDEND  (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENTC cyclosporine ENTCEND and azathioprine
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENTD valvular heart disease ENTDEND  (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and azathioprine. No prophylaxis with antilymphocyte globulin was used. ENTC Steroids ENTCEND were given to 39% of patients for refractory rejection, but weaning was always attempted and generally successful (64%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), ENTD valvular heart disease ENTDEND  (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENTC azathioprine ENTCEND
0	Indications for transplantation were idiopathic cardiomyopathy (52%), ENTD congenital heart disease ENTDEND (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and ENTC doxorubicin ENTCEND cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), ENTD congenital heart disease ENTDEND  (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with ENTC cyclosporine ENTCEND and azathioprine
0	Pediatric heart transplantation without chronic maintenance ENTC steroids ENTCEND .From 1986 to February 1993, 40 children aged 2 months to 18 years (average age 10.4 +/- 5.8 years) underwent heart transplantation. Indications for transplantation were idiopathic cardiomyopathy (52%), ENTD congenital heart disease ENTDEND (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%)
0	Indications for transplantation were idiopathic cardiomyopathy (52%), ENTD congenital heart disease ENTDEND  (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%). Patients were managed with cyclosporine and ENTC azathioprine ENTCEND
0	Cytomegalovirus infections were treated successfully with ENTC ganciclovir ENTCEND  in 11 patients. No impairment of growth was observed in children who underwent transplantation compared with a control population. Twenty-one patients (60%) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed. Seizures occurred in five patients (14%) and hypertension was treated in 10 patients (28%). No patient was disabled and no ENTD lymphoproliferative disorder ENTDEND was observed
0	METHODS: The effect of pretreatment with trazodone on ENTC dexamphetamine ENTCEND  and apomorphine-induced ENTD oral stereotypies ENTDEND , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENTD oral stereotypies ENTDEND , on catalepsy induced by ENTC haloperidol ENTCEND and apomorphine (0
0	The antidepressant trazodone is a ENTC 5-HT ENTCEND 2A/2C receptor antagonist. OBJECTIVES: To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system. METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENTD oral stereotypies ENTDEND , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENTD oral stereotypies ENTDEND , on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and ENTC fluoxetine ENTCEND -induced penile erections was studied in rats
0	METHODS: The effect of pretreatment with ENTC trazodone ENTCEND on dexamphetamine- and apomorphine-induced ENTD oral stereotypies ENTDEND , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENTD oral stereotypies ENTDEND , on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ENTC ergometrine ENTCEND -induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats
0	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on ENTC dopamine ENTCEND -dependent behaviors in rats.RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission. The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist. OBJECTIVES: To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system. METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced ENTD oral stereotypies ENTDEND , on catalepsy induced by haloperidol and apomorphine (0
0	METHODS: The effect of pretreatment with trazodone on dexamphetamine- and ENTC apomorphine ENTCEND induced ENTD oral stereotypies ENTDEND , on catalepsy induced by haloperidol and apomorphine (0
0	induced ENTD catalepsy ENTDEND and antagonized apomorphine and ENTC dexamphetamine ENTCEND stereotypies
1	trazodone enhanced dexamphetamine stereotypy, and antagonized ENTC haloperidol ENTCEND ENTD catalepsy ENTDEND , ergometrine-induced WDS behavior and fluoxetine-induced penile erections
0	We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by ENTC 5-HT ENTCEND  and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol ENTD catalepsy ENTDEND
0	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol ENTD catalepsy ENTDEND , ergometrine-induced WDS behavior and ENTC fluoxetine ENTCEND -induced penile erections
0	We also investigated whether ENTC trazodone ENTCEND induces ENTD catalepsy ENTDEND in rats
0	trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol ENTD catalepsy ENTDEND , ENTC ergometrine ENTCEND -induced WDS behavior and fluoxetine-induced penile erections
0	Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on ENTC dopamine ENTCEND -dependent behaviors in rats.RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission. The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist. OBJECTIVES: To evaluate the effect of trazodone treatment on behaviors dependent on the functional status of the nigrostriatal DAergic system. METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on ENTD catalepsy ENTDEND induced by haloperidol and apomorphine (0
1	induced ENTD catalepsy ENTDEND  and antagonized ENTC apomorphine ENTCEND and dexamphetamine stereotypies
0	Recurrence rates of ventricular tachyarrhythmias are high despite complete suppression of the ENTD arrhythmia ENTDEND during programmed stimulation. Therefore programmed electrical stimulation in the case of ENTC d,l-sotalol ENTCEND seems to be of limited prognostic value
0	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with ENTD dilated cardiomyopathy ENTDEND  with inducible sustained ventricular tachycardia or ventricular fibrillation received oral ENTC d,l-sotalol ENTCEND to prevent induction of the ventricular tachyarrhythmia
0	Efficacy and proarrhythmia with the use of ENTC d,l-sotalol ENTCEND  for sustained ENTD ventricular tachyarrhythmias ENTDEND
0	Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ENTD ventricular fibrillation ENTDEND received oral ENTC d,l-sotalol ENTCEND to prevent induction of the ventricular tachyarrhythmia
0	One female patient with stable ENTD cardiac disease ENTDEND had recurrent torsades de pointes after 2 years of successful treatment with ENTC d,l-sotalol ENTCEND
0	This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with ENTC d,l-sotalol ENTCEND for sustained ventricular tachyarrhythmias. Eighty-one consecutive patients (54 with ENTD coronary artery disease ENTDEND , and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia
1	One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with ENTC d,l-sotalol ENTCEND . ENTD Torsades de pointes ENTDEND occurred early during treatment even with low doses of oral d,l-sotalol
0	Patients were asked about dysphagia and evaluated with the Unified ENTD Parkinson's Disease ENTDEND Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENTC barium ENTCEND swallow with videofluoroscopy
0	The aim of this study was to characterize the oropharyngeal dynamics in ENTD PD ENTDEND patients with and without ENTC levodopa ENTCEND -induced dyskinesia
0	Deglutition was assessed using modified ENTC barium ENTCEND  swallow with videofluoroscopy. Nondyskinetic patients, but not the ENTD dyskinetic ENTDEND ones, showed less oropharyngeal swallowing efficiency (OPSE) for liquid food than controls (Dunnett, P = 0
1	The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without ENTC levodopa ENTCEND -induced ENTD dyskinesia ENTDEND
0	Patients were asked about ENTD dysphagia ENTDEND and evaluated with the Unified Parkinson's Disease Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENTC barium ENTCEND swallow with videofluoroscopy
0	Our results suggest a role for ENTC levodopa ENTCEND in the oral phase of deglutition and confirm that ENTD dysphagia ENTDEND is not a good predictor of deglutition alterations in PD
0	ENTD Gastrointestinal abnormalities ENTDEND in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia. Fifteen dyskinetic, 12 nondyskinetic patients, and a control group were included. Patients were asked about dysphagia and evaluated with the Unified Parkinson's Disease Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENTC barium ENTCEND swallow with videofluoroscopy
0	ENTD Gastrointestinal abnormalities ENTDEND  in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without ENTC levodopa ENTCEND -induced dyskinesia
0	ENTD Swallowing abnormalities ENTDEND  and dyskinesia in Parkinson's disease.Gastrointestinal abnormalities in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia. Fifteen dyskinetic, 12 nondyskinetic patients, and a control group were included. Patients were asked about dysphagia and evaluated with the Unified Parkinson's Disease Rating Scale Parts II and III and the Hoehn and Yahr scale. Deglutition was assessed using modified ENTC barium ENTCEND swallow with videofluoroscopy
0	ENTD Swallowing abnormalities ENTDEND  and dyskinesia in Parkinson's disease.Gastrointestinal abnormalities in Parkinson's disease (PD) have been known for almost two centuries, but many aspects concerning their pathophysiology have not been completely clarified. The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without ENTC levodopa ENTCEND -induced dyskinesia
0	Nefiracetam is a novel ENTC pyrrolidone ENTCEND derivative which attenuates scopolamine-induced ENTD learning and post-training consolidation deficits ENTDEND
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENTD learning and post-training consolidation deficits ENTDEND . Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism. A step-down passive avoidance paradigm was employed and nefiracetam (3 mg/kg) and apomorphine (0.5 mg/kg) were given alone or in combination during training and at the 10-12h post-training period of consolidation. Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect. However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H] ENTC spiperone ENTCEND binding from D1 or D2 dopamine receptor subtypes, respectively
1	Nefiracetam is a novel pyrrolidone derivative which attenuates ENTC scopolamine ENTCEND induced ENTD learning and post-training consolidation deficits ENTDEND
0	ENTC Nefiracetam ENTCEND is a novel pyrrolidone derivative which attenuates scopolamine-induced ENTD learning and post-training consolidation deficits ENTDEND
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENTD learning and post-training consolidation deficits ENTDEND . Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism. A step-down passive avoidance paradigm was employed and nefiracetam (3 mg/kg) and apomorphine (0.5 mg/kg) were given alone or in combination during training and at the 10-12h post-training period of consolidation. Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect. However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H] ENTC SCH 23390 ENTCEND or [3H]spiperone binding from D1 or D2 dopamine receptor subtypes, respectively
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENTD learning and post-training consolidation deficits ENTDEND . Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism. A step-down passive avoidance paradigm was employed and nefiracetam (3 mg/kg) and apomorphine (0.5 mg/kg) were given alone or in combination during training and at the 10-12h post-training period of consolidation. Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect. However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H]spiperone binding from D1 or D2 ENTC dopamine ENTCEND receptor subtypes, respectively
0	Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine-induced ENTD learning and post-training consolidation deficits ENTDEND . Given that ENTC apomorphine ENTCEND inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism
0	Nefiracetam (DM-9384) reverses apomorphine-induced ENTD amnesia ENTDEND  of a passive avoidance response: delayed emergence of the memory retention effects.Nefiracetam is a novel ENTC pyrrolidone ENTCEND derivative which attenuates scopolamine-induced learning and post-training consolidation deficits
0	However, administration of nefiracetam during training completely reversed the ENTD amnesia ENTDEND induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H ENTC spiperone ENTCEND binding from D1 or D2 dopamine receptor subtypes, respectively
0	Nefiracetam (DM-9384) reverses apomorphine-induced ENTD amnesia ENTDEND  of a passive avoidance response: delayed emergence of the memory retention effects.Nefiracetam is a novel pyrrolidone derivative which attenuates ENTC scopolamine ENTCEND -induced learning and post-training consolidation deficits
0	Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of ENTC nefiracetam ENTCEND to attenuate ENTD amnesia ENTDEND induced by dopaminergic agonism
0	However, administration of nefiracetam during training completely reversed the ENTD amnesia ENTDEND  induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H ENTC SCH 23390 ENTCEND or [3H]spiperone binding from D1 or D2 dopamine receptor subtypes, respectively
0	However, administration of nefiracetam during training completely reversed the ENTD amnesia ENTDEND  induced by apomorphine at the 10h post-training time and the converse was also true. These effects were not mediated by a dopaminergic mechanism as nefiracetam, at millimolar concentrations, failed to displace either [3H]SCH 23390 or [3H]spiperone binding from D1 or D2 ENTC dopamine ENTCEND receptor subtypes, respectively
1	Nefiracetam (DM-9384) reverses ENTC apomorphine ENTCEND -induced ENTD amnesia ENTDEND of a passive avoidance response: delayed emergence of the memory retention effects
0	Differential effects of ENTC 1,4-dihydropyridine ENTCEND  calcium channel blockers: therapeutic implications.Increasing recognition of the importance of calcium in the pathogenesis of ENTD cardiovascular disease ENTDEND has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of ENTD cardiovascular diseases ENTDEND  The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND controls angina and hypertension with minimal depression of cardiac function
0	Increasing recognition of the importance of ENTC calcium ENTCEND in the pathogenesis of ENTD cardiovascular disease ENTDEND has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of ENTD cardiovascular diseases ENTDEND . The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to ENTC verapamil ENTCEND and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of ENTD cardiovascular diseases ENTDEND . The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and ENTC diltiazem ENTCEND , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue
0	Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of ENTC calcium channel blocking agents ENTCEND for treatment of a variety of ENTD cardiovascular diseases ENTDEND
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of ENTD hypertension ENTDEND
0	As the first ENTC dihydropyridine ENTCEND available for use in the United States, nifedipine controls angina and ENTD hypertension ENTDEND with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and ENTD hypertension ENTDEND with minimal depression of cardiac function
0	Increasing recognition of the importance of ENTC calcium ENTCEND  in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases. The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENTD hypertension ENTDEND with minimal depression of cardiac function
0	In contrast to ENTC verapamil ENTCEND  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENTD hypertension ENTDEND with minimal depression of cardiac function
0	Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of ENTD hypertension ENTDEND . The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke
0	Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of ENTD hypertension ENTDEND . The coronary vasodilating properties of ENTC nisoldipine ENTCEND have led to the investigation of this agent for use in angina
0	In contrast to verapamil and ENTC diltiazem ENTCEND , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENTD hypertension ENTDEND with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, nifedipine controls angina and ENTD hypertension ENTDEND  with minimal depression of cardiac function. Additional members of this group of ENTC calcium channel blockers ENTCEND have been studied for a variety of indications for which they may offer advantages over current therapy
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in ENTD angina ENTDEND
0	As the first ENTC dihydropyridine ENTCEND  available for use in the United States, nifedipine controls ENTD angina ENTDEND and hypertension with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls ENTD angina ENTDEND and hypertension with minimal depression of cardiac function
0	Increasing recognition of the importance of ENTC calcium ENTCEND  in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases. The favorable efficacy and tolerability profiles of these agents make them attractive therapeutic modalities. Clinical applications of calcium channel blockers parallel their tissue selectivity. In contrast to verapamil and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls ENTD angina ENTDEND and hypertension with minimal depression of cardiac function
0	In contrast to ENTC verapamil ENTCEND  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls ENTD angina ENTDEND and hypertension with minimal depression of cardiac function
0	The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in ENTD angina ENTDEND . Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in ENTD angina ENTDEND
0	In contrast to verapamil and ENTC diltiazem ENTCEND , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls ENTD angina ENTDEND and hypertension with minimal depression of cardiac function
0	As the first dihydropyridine available for use in the United States, nifedipine controls ENTD angina ENTDEND  and hypertension with minimal depression of cardiac function. Additional members of this group of ENTC calcium channel blockers ENTCEND have been studied for a variety of indications for which they may offer advantages over current therapy
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENTD nausea ENTDEND , anorexia, and dizziness being the more common adverse effects
0	In general, the ENTC dihydropyridine ENTCEND calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENTD nausea ENTDEND , anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENTD nausea ENTDEND , anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENTD nausea ENTDEND , anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, ENTD nausea ENTDEND , anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENTC calcium channel blockers ENTCEND are usually well tolerated, with headache, facial flushing, palpitations, edema, ENTD nausea ENTDEND , anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENTD anorexia ENTDEND , and dizziness being the more common adverse effects
0	In general, the ENTC dihydropyridine ENTCEND  calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENTD anorexia ENTDEND , and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENTD anorexia ENTDEND , and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENTD anorexia ENTDEND , and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENTD anorexia ENTDEND , and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENTC calcium channel blockers ENTCEND  are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, ENTD anorexia ENTDEND , and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke. In general, the ENTC dihydropyridine ENTCEND calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke
0	In contrast to ENTC verapamil ENTCEND  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke
0	In contrast to verapamil and ENTC diltiazem ENTCEND , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, ENTD migraine headache ENTDEND , dementia, and stroke. In general, the dihydropyridine ENTC calcium channel blockers ENTCEND are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENTD headache ENTDEND , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	In general, the ENTC dihydropyridine ENTCEND  calcium channel blockers are usually well tolerated, with ENTD headache ENTDEND , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENTD headache ENTDEND , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENTD headache ENTDEND , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with ENTD headache ENTDEND , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENTC calcium channel blockers ENTCEND  are usually well tolerated, with ENTD headache ENTDEND , facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke. In general, the ENTC dihydropyridine ENTCEND calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke
0	In contrast to ENTC verapamil ENTCEND  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke
0	In contrast to verapamil and ENTC diltiazem ENTCEND , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of ENTD subarachnoid hemorrhage ENTDEND , migraine headache, dementia, and stroke. In general, the dihydropyridine ENTC calcium channel blockers ENTCEND are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENTD edema ENTDEND , nausea, anorexia, and dizziness being the more common adverse effects
0	In general, the ENTC dihydropyridine ENTCEND  calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENTD edema ENTDEND , nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENTD edema ENTDEND , nausea, anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENTD edema ENTDEND , nausea, anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, ENTD edema ENTDEND , nausea, anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENTC calcium channel blockers ENTCEND  are usually well tolerated, with headache, facial flushing, palpitations, ENTD edema ENTDEND , nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND . In general, the ENTC dihydropyridine ENTCEND calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND
0	In contrast to ENTC verapamil ENTCEND  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND
0	In contrast to verapamil and ENTC diltiazem ENTCEND , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and ENTD stroke ENTDEND . In general, the dihydropyridine ENTC calcium channel blockers ENTCEND are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke. In general, the ENTC dihydropyridine ENTCEND calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke
0	In contrast to ENTC verapamil ENTCEND  and diltiazem, which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke
0	In contrast to verapamil and ENTC diltiazem ENTCEND , which are roughly equipotent in their actions on the heart and vascular smooth muscle, the dihydropyridine calcium channel blockers are a group of potent peripheral vasodilator agents that exert minimal electrophysiologic effects on cardiac nodal or conduction tissue. As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke
0	Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, ENTD dementia ENTDEND , and stroke. In general, the dihydropyridine ENTC calcium channel blockers ENTCEND are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENTD flushing ENTDEND , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	In general, the ENTC dihydropyridine ENTCEND  calcium channel blockers are usually well tolerated, with headache, facial ENTD flushing ENTDEND , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENTD flushing ENTDEND , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENTD flushing ENTDEND , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial ENTD flushing ENTDEND , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
1	In general, the dihydropyridine ENTC calcium channel blockers ENTCEND  are usually well tolerated, with headache, facial ENTD flushing ENTDEND , palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects
0	Once or twice daily dosage possible with ENTC nitrendipine ENTCEND  and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENTD dizziness ENTDEND being the more common adverse effects
0	In general, the ENTC dihydropyridine ENTCEND  calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENTD dizziness ENTDEND being the more common adverse effects
0	As the first dihydropyridine available for use in the United States, ENTC nifedipine ENTCEND  controls angina and hypertension with minimal depression of cardiac function. Additional members of this group of calcium channel blockers have been studied for a variety of indications for which they may offer advantages over current therapy. Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension. The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENTD dizziness ENTDEND being the more common adverse effects
0	Selectivity for the cerebrovascular bed makes ENTC nimodipine ENTCEND  potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENTD dizziness ENTDEND being the more common adverse effects
0	The coronary vasodilating properties of ENTC nisoldipine ENTCEND  have led to the investigation of this agent for use in angina. Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke. In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENTD dizziness ENTDEND being the more common adverse effects
1	In general, the dihydropyridine ENTC calcium channel blockers ENTCEND  are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and ENTD dizziness ENTDEND being the more common adverse effects
0	Damage of substantia nigra pars reticulata during ENTC pilocarpine ENTCEND -induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.The substantia nigra has a gating function controlling the spread of ENTD epileptic seizure ENTDEND activity
0	The substantia nigra has a gating function controlling the spread of ENTD epileptic seizure ENTDEND  activity. Additionally, in models of prolonged status epilepticus the pars reticulata of substantia nigra (SNR) suffers from a massive lesion which may arise from a massive metabolic derangement and hyperexcitation developing in the activated SNR. In this study, status epilepticus was induced by systemic injection of pilocarpine in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific ENTC calcium ENTCEND -binding protein, parvalbumin, served to detect neuronal damage in SNR
0	In this study, status epilepticus was induced by systemic injection of ENTC pilocarpine ENTCEND in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect ENTD neuronal damage ENTDEND in SNR
0	Nissl-staining and antibodies against the neuron-specific ENTC calcium ENTCEND -binding protein, parvalbumin, served to detect ENTD neuronal damage ENTDEND in SNR
1	Damage of substantia nigra pars reticulata during ENTC pilocarpine ENTCEND -induced ENTD status epilepticus ENTDEND in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation
0	Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of ENTD status epilepticus ENTDEND were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific ENTC calcium ENTCEND -binding protein, parvalbumin, served to detect neuronal damage in SNR
0	Antibodies against the astroglia-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP), and against the glial ENTC calcium ENTCEND binding protein, S-100 protein, were used to assess the status of astrocytes. Immunohistochemical staining for serum-albumin and immunoglobulins in brain tissue was taken as indicator of blood-brain barrier disturbances and vasogenic edema formation. Immunohistochemical staining indicated loss of GFAP-staining already at 30 min after induction of ENTD seizures ENTDEND in an oval focus situated in the center of SNR while sparing medial and lateral aspects
0	In this study, status epilepticus was induced by systemic injection of ENTC pilocarpine ENTCEND  in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect neuronal damage in SNR. Antibodies against the astroglia-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP), and against the glial calcium-binding protein, S-100 protein, were used to assess the status of astrocytes. Immunohistochemical staining for serum-albumin and immunoglobulins in brain tissue was taken as indicator of blood-brain barrier disturbances and ENTD vasogenic edema ENTDEND formation
0	Antibodies against the astroglia-specific cytoskeletal protein, glial fibrillary acidic protein (GFAP), and against the glial ENTC calcium ENTCEND -binding protein, S-100 protein, were used to assess the status of astrocytes. Immunohistochemical staining for serum-albumin and immunoglobulins in brain tissue was taken as indicator of blood-brain barrier disturbances and ENTD vasogenic edema ENTDEND formation
1	ENTD Damage of substantia nigra pars reticulata ENTDEND  during ENTC pilocarpine ENTCEND -induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation
0	Additionally, in models of prolonged status epilepticus the pars reticulata of substantia nigra (SNR) suffers from a massive lesion which may arise from a massive ENTD metabolic derangement ENTDEND and hyperexcitation developing in the activated SNR. In this study, status epilepticus was induced by systemic injection of ENTC pilocarpine ENTCEND in rats
0	Additionally, in models of prolonged status epilepticus the pars reticulata of substantia nigra (SNR) suffers from a massive lesion which may arise from a massive ENTD metabolic derangement ENTDEND  and hyperexcitation developing in the activated SNR. In this study, status epilepticus was induced by systemic injection of pilocarpine in rats. The neuropathology of SNR was investigated using immunohistochemical techniques with the major emphasis on the time-course of changes in neurons and astrocytes. Animals surviving 20, 30, 40, 60 min, 2, 3, 6 hours, 1, 2, and 3 days after induction of status epilepticus were perfusion-fixed, and brains processed for immunohistochemical staining of SNR. Nissl-staining and antibodies against the neuron-specific ENTC calcium ENTCEND -binding protein, parvalbumin, served to detect neuronal damage in SNR
1	CONCLUSIONS: ENTD QT interval prolongation ENTDEND in ENTC methadone ENTCEND maintenance patients hospitalized in a tertiary care center is a frequent finding
0	Methadone dose, presence of cytochrome P-450 3A4 inhibitors, ENTC potassium ENTCEND level, and liver function contribute to ENTD QT prolongation ENTDEND
0	6%) in the ENTC methadone ENTCEND group presented ENTD torsades de pointes ENTDEND
0	6%) in the methadone group presented ENTD torsades de pointes ENTDEND . QTc length was weakly but significantly associated with methadone daily dose (Spearman rank correlation coefficient, 0.20; P<.01). Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function. CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, ENTC potassium ENTCEND level, and liver function contribute to QT prolongation
0	8% of QTc variability to ENTC methadone ENTCEND dose, cytochrome P-450 3A4 drug-drug interactions, ENTD hypokalemia ENTDEND , and altered liver function
0	8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, ENTD hypokalemia ENTDEND , and altered liver function. CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding. Methadone dose, presence of cytochrome P-450 3A4 inhibitors, ENTC potassium ENTCEND level, and liver function contribute to QT prolongation
0	Nociceptin/orphanin FQ and ENTC nocistatin ENTCEND  on ENTD learning and memory impairment ENTDEND induced by scopolamine in mice
0	Nociceptin/ ENTC orphanin FQ ENTCEND  and nocistatin on ENTD learning and memory impairment ENTDEND induced by scopolamine in mice
1	Nociceptin/orphanin FQ and nocistatin on ENTD learning and memory impairment ENTDEND  induced by ENTC scopolamine ENTCEND in mice
0	Nociceptin/orphanin FQ and ENTC nocistatin ENTCEND  on ENTD learning and memory impairment ENTDEND induced by scopolamine in mice
0	Nociceptin/ ENTC orphanin FQ ENTCEND  and nocistatin on ENTD learning and memory impairment ENTDEND induced by scopolamine in mice
1	Nociceptin/orphanin FQ and nocistatin on ENTD learning and memory impairment ENTDEND  induced by ENTC scopolamine ENTCEND in mice
0	On the other hand, ENTC nocistatin ENTCEND is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced ENTD allodynia ENTDEND and hyperalgesia
0	On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks ENTC nociceptin ENTCEND induced ENTD allodynia ENTDEND and hyperalgesia
0	Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by ENTC scopolamine ENTCEND  in mice.1. Nociceptin, also known as orphanin FQ, is an endogenous ligand for the orphan opioid receptor-like receptor 1 (ORL1) and involves in various functions in the central nervous system (CNS). On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced ENTD allodynia ENTDEND and hyperalgesia
0	Thirty-six nonobese subjects with schizophrenia or ENTD schizoaffective disorder ENTDEND  matched by body mass index and treated with either clozapine, olanzapine, or ENTC risperidone ENTCEND , were included in the analysis
0	Thirty-six nonobese subjects with schizophrenia or ENTD schizoaffective disorder ENTDEND , matched by body mass index and treated with either ENTC clozapine ENTCEND , olanzapine, or risperidone, were included in the analysis
0	Thirty-six nonobese subjects with schizophrenia or ENTD schizoaffective disorder ENTDEND , matched by body mass index and treated with either clozapine, ENTC olanzapine ENTCEND , or risperidone, were included in the analysis
0	Patients Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous ENTC glucose ENTCEND tolerance test. Thirty-six nonobese subjects with schizophrenia or ENTD schizoaffective disorder ENTDEND , matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis
0	001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant ENTD insulin resistance ENTDEND compared with subjects who were treated with ENTC risperidone ENTCEND (clozapine vs risperidone, t(33) = -4
1	Patients taking ENTC clozapine ENTCEND and olanzapine must be examined for ENTD insulin resistance ENTDEND and its consequences
1	Patients taking clozapine and ENTC olanzapine ENTCEND must be examined for ENTD insulin resistance ENTDEND and its consequences
0	MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of ENTD insulin resistance ENTDEND  and ENTC glucose ENTCEND effectiveness
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for ENTD diabetes ENTDEND  OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and olanzapine) and ENTC risperidone ENTCEND using a frequently sampled intravenous glucose tolerance test
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for ENTD diabetes ENTDEND . OBJECTIVE: To study the 2 drugs most clearly implicated ( ENTC clozapine ENTCEND and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for ENTD diabetes ENTDEND . OBJECTIVE: To study the 2 drugs most clearly implicated (clozapine and ENTC olanzapine ENTCEND ) and risperidone using a frequently sampled intravenous glucose tolerance test
0	BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting ENTC glucose ENTCEND metabolism or simply increasing known risk factors for ENTD diabetes ENTDEND
0	Thirty-six nonobese subjects with ENTD schizophrenia ENTDEND or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or ENTC risperidone ENTCEND , were included in the analysis
0	Thirty-six nonobese subjects with ENTD schizophrenia ENTDEND  or schizoaffective disorder, matched by body mass index and treated with either ENTC clozapine ENTCEND , olanzapine, or risperidone, were included in the analysis
0	Thirty-six nonobese subjects with ENTD schizophrenia ENTDEND  or schizoaffective disorder, matched by body mass index and treated with either clozapine, ENTC olanzapine ENTCEND , or risperidone, were included in the analysis
0	ENTC Glucose ENTCEND  metabolism in patients with ENTD schizophrenia ENTDEND treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis
0	ENTC Amiodarone ENTCEND is an anti- ENTD arrhythmic ENTDEND drug for life-threatening tachycardia, but various adverse effects have been reported
0	76 g/day) after treatment with ENTC amiodarone ENTCEND for a long time. The lung mass was highly suspected to be ENTD lung cancer ENTDEND on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion
1	ENTC Amiodarone ENTCEND -related pulmonary mass and unique ENTD membranous glomerulonephritis ENTDEND in a patient with valvular heart disease: Diagnostic pitfall and new findings
0	Autoimmune diseases, ENTD viral hepatitis ENTDEND  malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found. The present case highlights the possibility that differential diagnosis between an ENTC amiodarone ENTCEND -related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment
0	5 cm in diameter) and ENTD proteinuria ENTDEND (2.76 g/day) after treatment with ENTC amiodarone ENTCEND for a long time
0	The present case highlights the possibility that differential diagnosis between an ENTC amiodarone ENTCEND -related pulmonary lesion and a ENTD neoplasm ENTDEND can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment
0	ENTD Autoimmune diseases ENTDEND  viral hepatitis, malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found. The present case highlights the possibility that differential diagnosis between an ENTC amiodarone ENTCEND -related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment
0	ENTC Amiodarone ENTCEND  is an anti-arrhythmic drug for life-threatening ENTD tachycardia ENTDEND , but various adverse effects have been reported
1	The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an ENTC amiodarone ENTCEND related lesion. In addition, the lung tissue had unevenly distributed ENTD hemosiderin ENTDEND deposition, and abnormally tortuous capillaries were seen in the mass and in heavily hemosiderotic lung portions outside the mass
0	Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with ENTD valvular heart disease ENTDEND : Diagnostic pitfall and new findings ENTC Amiodarone ENTCEND is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported
1	ENTC Amiodarone ENTCEND -related ENTD pulmonary mass ENTDEND and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings
0	17 required ENTC epinephrine ENTCEND infusion to treat ENTD hypotension ENTDEND
0	Blood pressure, heart rate, respiratory rate and ENTC oxygen ENTCEND saturation were monitored over 1 hour. RESULTS: Three patients (8.1%) in the unilateral group and 5 (13.5%) in the conventional group developed ENTD hypotension ENTDEND , P= 0
1	5% hyperbaric ENTC bupivacaine ENTCEND through a 25-gauge spinal needle. Patients in the unilateral group were maintained in the lateral position for 15 minutes following spinal injection while those in the conventional group were turned supine immediately after injection. Blood pressure, heart rate, respiratory rate and oxygen saturation were monitored over 1 hour. RESULTS: Three patients (8.1%) in the unilateral group and 5 (13.5%) in the conventional group developed ENTD hypotension ENTDEND , P= 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND  are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and ENTC angiotensin ENTCEND -converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, ENTC aspartate ENTCEND transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue ENTC malondialdehyde ENTCEND (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum ENTC lactate ENTCEND dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and ENTC nitric oxide ENTCEND levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05). Pretreatment with S. virgaurea extract for 5 weeks at a dose of 250 mg/kg followed by isoproterenol injection significantly prevented the observed alterations. ENTC Captopril ENTCEND (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, ENTC alanine ENTCEND transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total ENTC cholesterol ENTCEND , triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, ENTC creatine ENTCEND phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, ENTC triglycerides ENTCEND , free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on ENTC isoproterenol ENTCEND -induced cardiotoxicity in rats
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum ENTC fatty acid ENTCEND , cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of ENTC glutathione ENTCEND and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	Cardiovascular diseases ( ENTD CVDs ENTDEND ) are the major health problem of advanced as well as developing countries of the world. The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and ENTC superoxide ENTCEND dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and ENTC angiotensin ENTCEND -converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, ENTC aspartate ENTCEND transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue ENTC malondialdehyde ENTCEND (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum ENTC lactate ENTCEND dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and ENTC nitric oxide ENTCEND levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05). Pretreatment with S. virgaurea extract for 5 weeks at a dose of 250 mg/kg followed by isoproterenol injection significantly prevented the observed alterations. ENTC Captopril ENTCEND (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, ENTC alanine ENTCEND transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total ENTC cholesterol ENTCEND , triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, ENTC creatine ENTCEND phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, ENTC triglycerides ENTCEND , free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
1	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on ENTC isoproterenol ENTCEND -induced ENTD cardiotoxicity ENTDEND in rats
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum ENTC fatty acid ENTCEND , cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of ENTC glutathione ENTCEND and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0
0	The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced ENTD cardiotoxicity ENTDEND  in rats. The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and ENTC superoxide ENTCEND dismutase in cardiac tissue as compared to the normal control group (P < 0
0	We have described a patient with severe ENTD rheumatoid arthritis ENTDEND and a history of ENTC mefenamic acid ENTCEND nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	Hyperkalemia induced by indomethacin and ENTC naproxen ENTCEND  and reversed by fludrocortisone.We have described a patient with severe ENTD rheumatoid arthritis ENTDEND and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	Hyperkalemia induced by ENTC indomethacin ENTCEND  and naproxen and reversed by fludrocortisone.We have described a patient with severe ENTD rheumatoid arthritis ENTDEND and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	Hyperkalemia induced by indomethacin and naproxen and reversed by ENTC fludrocortisone ENTCEND .We have described a patient with severe ENTD rheumatoid arthritis ENTDEND and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	We have described a patient with severe ENTD rheumatoid arthritis ENTDEND  and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function. It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with ENTC prostaglandin ENTCEND synthetase inhibitors
0	We have described a patient with severe rheumatoid arthritis and a history of ENTC mefenamic acid ENTCEND  nephropathy in whom ENTD hyperkalemia ENTDEND and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
1	ENTD Hyperkalemia ENTDEND  induced by indomethacin and ENTC naproxen ENTCEND and reversed by fludrocortisone
1	ENTD Hyperkalemia ENTDEND  induced by ENTC indomethacin ENTCEND and naproxen and reversed by fludrocortisone
0	Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, ENTC fludrocortisone ENTCEND was added, correcting the ENTD hyperkalemia ENTDEND and allowing indomethacin therapy to be continued safely
0	It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with ENTC prostaglandin ENTCEND  synthetase inhibitors. Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the ENTD hyperkalemia ENTDEND and allowing indomethacin therapy to be continued safely
1	We have described a patient with severe rheumatoid arthritis and a history of ENTC mefenamic acid ENTCEND  ENTD nephropathy ENTDEND in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and ENTC naproxen ENTCEND  without major decline in renal function. It is likely that preexisting ENTD renal disease ENTDEND predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors
0	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid ENTD nephropathy ENTDEND  in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both ENTC indomethacin ENTCEND and naproxen, without major decline in renal function
0	Hyperkalemia induced by indomethacin and naproxen and reversed by ENTC fludrocortisone ENTCEND .We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid ENTD nephropathy ENTDEND in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function
0	It is likely that preexisting ENTD renal disease ENTDEND  predisposed this patient to type IV renal tubular acidosis with ENTC prostaglandin ENTCEND synthetase inhibitors
0	We have described a patient with severe rheumatoid arthritis and a history of ENTC mefenamic acid ENTCEND  nephropathy in whom hyperkalemia and inappropriate ENTD hypoaldosteronism ENTDEND were caused by both indomethacin and naproxen, without major decline in renal function
1	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate ENTD hypoaldosteronism ENTDEND  were caused by both indomethacin and ENTC naproxen ENTCEND , without major decline in renal function
1	We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate ENTD hypoaldosteronism ENTDEND  were caused by both ENTC indomethacin ENTCEND and naproxen, without major decline in renal function
0	It is likely that preexisting renal disease predisposed this patient to ENTD type IV renal tubular acidosis ENTDEND with prostaglandin synthetase inhibitors. Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, ENTC fludrocortisone ENTCEND was added, correcting the hyperkalemia and allowing indomethacin therapy to be continued safely
0	It is likely that preexisting renal disease predisposed this patient to ENTD type IV renal tubular acidosis ENTDEND  with ENTC prostaglandin ENTCEND synthetase inhibitors
1	C57BL/6J, chosen as a "prototypic" mouse strain, was used to determine behavioral responses to a broad range (5-500 mg/kg) of ENTC caffeine ENTCEND doses. Five phenotypic characteristics--locomotor activity, righting ability, ENTD clonic seizure ENTDEND induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions
0	By any single behavioral criterion or a combination of these criteria, marked differences in response to toxic ENTC caffeine ENTCEND doses were observed between strains. These results indicate that behavioral ENTD toxicity ENTDEND testing of alkylxanthines in a single mouse strain may be misleading and suggest that toxic responses of the central nervous system to this class of compounds are genetically influenced in mammals
1	The incidence of ENTD subependymal cysts ENTDEND in infants exposed to ENTC cocaine ENTCEND prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0
0	PURPOSE: Prenatal ENTC cocaine ENTCEND exposure has been linked with subependymal ENTD hemorrhage ENTDEND and the formation of cysts that are detectable on cranial sonography in neonates born at term
1	Prenatal cocaine exposure and cranial sonographic findings in ENTD preterm infants ENTDEND .PURPOSE: Prenatal ENTC cocaine ENTCEND exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term
1	The incidence of ENTD subependymal cysts ENTDEND in infants exposed to ENTC cocaine ENTCEND prenatally was 44% (8 of 18) compared with 8% (8 of 99) in the unexposed group (p < 0
0	Infants were assigned to the ENTC cocaine ENTCEND exposed group if there was a maternal history of ENTD cocaine abuse ENTDEND during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery
1	Acetaminophen (APAP) produces proximal ENTD tubular necrosis ENTDEND in Fischer 344 (F344) rats. Recently, ENTC p-aminophenol ENTCEND (PAP), a known potent nephrotoxicant, was identified as a metabolite of APAP in F344 rats
1	It is concluded that PAP formation, in vivo, accounts, at least in part, for ENTC APAP ENTCEND induced ENTD renal tubular necrosis ENTDEND
0	The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of ENTC bis(p-nitrophenyl) phosphate ENTCEND  on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.Acetaminophen (APAP) produces proximal ENTD tubular necrosis ENTDEND in Fischer 344 (F344) rats
0	Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and ENTC PAP ENTCEND ENTD nephrotoxicity ENTDEND and metabolism was determined
0	The purpose of this study was to determine if PAP formation is a requisite step in ENTC APAP ENTCEND induced ENTD nephrotoxicity ENTDEND
0	The role of p-aminophenol in acetaminophen-induced ENTD nephrotoxicity ENTDEND : effect of ENTC bis(p-nitrophenyl) phosphate ENTCEND on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats
1	Histamine antagonists and ENTC d-tubocurarine ENTCEND -induced ENTD hypotension ENTDEND in cardiac surgical patients
0	Histamine antagonists and d-tubocurarine-induced ENTD hypotension ENTDEND  in cardiac surgical patients.Hemodynamic effects and histamine release by bolus injection of 0.35 mg/kg of d-tubocurarine were studied in 24 patients. H1- and H2-histamine antagonists or placebo were given before dosing with d-tubocurarine in a randomized double-blind fashion to four groups: group 1--placebo; group 2--cimetidine, 4 mg/kg, plus placebo; group 3-- ENTC chlorpheniramine ENTCEND , 0
0	ENTC Histamine ENTCEND  antagonists and d-tubocurarine-induced ENTD hypotension ENTDEND in cardiac surgical patients
0	Histamine antagonists and d-tubocurarine-induced ENTD hypotension ENTDEND  in cardiac surgical patients.Hemodynamic effects and histamine release by bolus injection of 0.35 mg/kg of d-tubocurarine were studied in 24 patients. H1- and H2-histamine antagonists or placebo were given before dosing with d-tubocurarine in a randomized double-blind fashion to four groups: group 1--placebo; group 2-- ENTC cimetidine ENTCEND , 4 mg/kg, plus placebo; group 3--chlorpheniramine, 0
0	The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of ENTC metformin ENTCEND  Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), ENTD tumor ENTDEND necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Metfromin markedly lowered ENTC isoproterenol ENTCEND induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), ENTD tumor ENTDEND necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates ENTD left ventricular dysfunction ENTDEND  following myocardial infarction.Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of ENTC AMP ENTCEND -activated protein kinase (AMPK)
0	Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates ENTD left ventricular dysfunction ENTDEND  following myocardial infarction.Acute treatment with ENTC metformin ENTCEND has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK)
1	The ENTD left ventricular dysfunction ENTDEND was significantly lower in the groups treated with 25 and 50mg/kg of metformin. Metfromin markedly lowered ENTC isoproterenol ENTCEND -induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of ENTC AMP ENTCEND -activated protein kinase (AMPK). In the present study, the effect of chronic pre-treatment with metformin on ENTD cardiac dysfunction ENTDEND and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed
0	In the present study, the effect of chronic pre-treatment with ENTC metformin ENTCEND on ENTD cardiac dysfunction ENTDEND and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed
0	In the present study, the effect of chronic pre-treatment with metformin on ENTD cardiac dysfunction ENTDEND  and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed. Male Wistar rats were randomly assigned to one of 5 groups (n=6): normal control and groups were injected ENTC isoproterenol ENTCEND after chronic pre-treatment with 0, 25, 50, or 100mg/kg of metformin twice daily for 14 days
0	The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of ENTC metformin ENTCEND . Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor ENTD necrosis ENTDEND factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Metfromin markedly lowered ENTC isoproterenol ENTCEND -induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor ENTD necrosis ENTDEND factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues
0	Acute treatment with metformin has a protective effect in ENTD myocardial infarction ENTDEND by suppression of inflammatory responses due to activation of ENTC AMP ENTCEND -activated protein kinase (AMPK)
0	Chronic pre-treatment with ENTC metformin ENTCEND reduces post- ENTD myocardial infarction ENTDEND cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities
1	Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce ENTD acute myocardial infarction ENTDEND  ENTC Isoproterenol ENTCEND alone decreased left ventricular systolic pressure and myocardial contractility indexed as LVdp/dtmax and LVdp/dtmin
1	Flumazenil induces ENTD seizures ENTDEND  and death in mixed cocaine ENTC diazepam ENTCEND intoxications
1	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask ENTD seizures ENTDEND in mixed ENTC cocaine ENTCEND -benzodiazepine intoxication
0	STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask ENTD seizures ENTDEND  in mixed cocaine- ENTC benzodiazepine ENTCEND intoxication
1	ENTC Flumazenil ENTCEND  induces ENTD seizures ENTDEND and death in mixed cocaine-diazepam intoxications
0	CONCLUSION: This report describes the case of a woman with LACNP that developed after a ENTC steroid ENTCEND injection for the treatment of ENTD lateral epicondylitis ENTDEND
0	MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the paresthesia had occurred after a ENTC steroid ENTCEND injection in the right lateral epicondyle 3 months before. Her sensation of light touch and ENTD pain ENTDEND was diminished over the lateral side of the right forearm and wrist area
0	Lateral antebrachial cutaneous ENTD neuropathy ENTDEND  after ENTC steroid ENTCEND injection at lateral epicondyle
1	MATERIAL AND METHOD: A 40-year-old woman presented with decreased sensation and paresthesia over her right lateral forearm; the ENTD paresthesia ENTDEND had occurred after a ENTC steroid ENTCEND injection in the right lateral epicondyle 3 months before
1	Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of ENTC aminophylline ENTCEND until onset of maximal ENTD seizures ENTDEND which occurred after 28 and 30 minutes respectively
0	Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal ENTD seizures ENTDEND  which occurred after 28 and 30 minutes respectively. ENTC Theophylline ENTCEND concentrations at this endpoint in serum (total) and CSF were similar but serum (free) and brain concentrations were slightly different in pregnant rats
0	The purpose of this investigation was to determine whether the ENTD neurotoxicity ENTDEND of theophylline is altered in advanced pregnancy. Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of ENTC aminophylline ENTCEND until onset of maximal seizures which occurred after 28 and 30 minutes respectively
0	ENTC Theophylline ENTCEND ENTD neurotoxicity ENTDEND in pregnant rats
0	Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl ENTD seizure ENTDEND  testing. ENTC Monosodium glutamate ENTCEND (MSG) administration to neonatal rodents produces convulsions and results in numerous biochemical and behavioral deficits
0	ENTC Flurothyl ENTCEND ENTD seizure ENTDEND thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing
0	A flurothyl ENTC ether ENTCEND ENTD seizure ENTDEND screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g)
0	MSG treatment resulted in significant reductions in whole brain weight but did not alter ENTD seizure ENTDEND threshold. A ENTC naloxone ENTCEND (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice
0	A naloxone (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of ENTC MSG ENTCEND treated mice. Flurothyl ether produced ENTD hypothermia ENTDEND which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
1	ENTC Flurothyl ENTCEND ether produced ENTD hypothermia ENTDEND which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
0	Flurothyl ENTC ether ENTCEND produced ENTD hypothermia ENTDEND which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
0	A ENTC naloxone ENTCEND  (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice. Flurothyl ether produced ENTD hypothermia ENTDEND which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear
0	selectively inhibited the ENTD enlargement of pulse pressure ENTDEND and the tachycardia following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. atropine (3 mug) or hexamethonium (500 mug), and significantly reduced by i.c. ENTC chlorpromazine ENTCEND (50 mug) but significantly potentiated by i
0	) injection of ENTC guanethidine ENTCEND (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENTD enlargement of pulse pressure ENTDEND and the tachycardia following i
1	selectively inhibited the ENTD enlargement of pulse pressure ENTDEND  and the tachycardia following i.c. ENTC carbachol ENTCEND (1 mug)
0	) injection of guanethidine (5 mg), hexamethonium (10 mg) or ENTC phentolamine ENTCEND (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENTD enlargement of pulse pressure ENTDEND and the tachycardia following i
0	) injection of guanethidine (5 mg), ENTC hexamethonium ENTCEND (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENTD enlargement of pulse pressure ENTDEND and the tachycardia following i
1	ENTC desmethylimipramine ENTCEND (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the ENTD enlargement of pulse pressure ENTDEND and the tachycardia following i
0	selectively inhibited the ENTD enlargement of pulse pressure ENTDEND  and the tachycardia following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. ENTC atropine ENTCEND (3 mug) or hexamethonium (500 mug), and significantly reduced by i
0	3 mg), while ENTC propranolol ENTCEND (0.5 mg) i.v. selectively inhibited the ENTD enlargement of pulse pressure ENTDEND and the tachycardia following i
0	selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. atropine (3 mug) or hexamethonium (500 mug), and significantly reduced by i.c. ENTC chlorpromazine ENTCEND (50 mug) but significantly potentiated by i
0	) injection of ENTC guanethidine ENTCEND  (5 mg), hexamethonium (10 mg) or phentolamine (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND following i
1	selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND  following i.c. ENTC carbachol ENTCEND (1 mug)
0	) injection of guanethidine (5 mg), hexamethonium (10 mg) or ENTC phentolamine ENTCEND  (5 mg), and conversely, potentiated by i.v. desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND following i
0	selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND  following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. atropine (3 mug) or ENTC hexamethonium ENTCEND (500 mug), and significantly reduced by i
0	ENTC desmethylimipramine ENTCEND  (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND following i
0	selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND  following i.c. carbachol (1 mug). On the other hand, the pressor response to i.c. carbachol (1 mug) was almost completely blocked by i.c. ENTC atropine ENTCEND (3 mug) or hexamethonium (500 mug), and significantly reduced by i
0	3 mg), while ENTC propranolol ENTCEND  (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the ENTD tachycardia ENTDEND following i
1	Normoammonemic encephalopathy: solely ENTC valproate ENTCEND  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, auditory hallucinations and ENTD delusions ENTDEND
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, auditory hallucinations and ENTD delusions ENTDEND . In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENTC N-methyl-D-aspartate ENTCEND (NMDA) receptor antibodies were present in this patient
0	Normoammonemic encephalopathy: solely ENTC valproate ENTCEND  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, ENTD aggression ENTDEND , auditory hallucinations and delusions
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, ENTD aggression ENTDEND , auditory hallucinations and delusions. In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENTC N-methyl-D-aspartate ENTCEND (NMDA) receptor antibodies were present in this patient
0	In the preceding months, the patient had a number of admissions with transient unilateral ENTD hemiparesis ENTDEND with facial droop, and had been started on ENTC valproate ENTCEND for presumed hemiplegic migraine
0	In the preceding months, the patient had a number of admissions with transient unilateral ENTD hemiparesis ENTDEND  with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENTC N-methyl-D-aspartate ENTCEND (NMDA) receptor antibodies were present in this patient
1	Normoammonemic encephalopathy: solely ENTC valproate ENTCEND  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive ENTD confusion ENTDEND , aggression, auditory hallucinations and delusions
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive ENTD confusion ENTDEND , aggression, auditory hallucinations and delusions. In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENTC N-methyl-D-aspartate ENTCEND (NMDA) receptor antibodies were present in this patient
0	The possible aetiologies of ENTC valproate ENTCEND induced encephalopathy and NMDA receptor-associated ENTD encephalitis ENTDEND present a diagnostic dilemma
0	The possible aetiologies of valproate-induced encephalopathy and ENTC NMDA ENTCEND receptor-associated ENTD encephalitis ENTDEND present a diagnostic dilemma
0	In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed ENTD hemiplegic migraine ENTDEND  ENTC Valproate ENTCEND was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up
0	In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed ENTD hemiplegic migraine ENTDEND . Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENTC N-methyl-D-aspartate ENTCEND (NMDA) receptor antibodies were present in this patient
0	Normoammonemic ENTD encephalopathy ENTDEND : solely ENTC valproate ENTCEND induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, auditory hallucinations and delusions
0	The possible aetiologies of valproate-induced ENTD encephalopathy ENTDEND and ENTC NMDA ENTCEND receptor-associated encephalitis present a diagnostic dilemma
1	Normoammonemic encephalopathy: solely ENTC valproate ENTCEND  induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, ENTD auditory hallucinations ENTDEND and delusions
0	Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?A 77-year-old woman presented with subacute onset progressive confusion, aggression, ENTD auditory hallucinations ENTDEND  and delusions. In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine. Valproate was withdrawn soon after admission and her cognitive abilities have gradually improved over 3 months of follow-up. Valproate levels taken prior to withdrawal were subtherapeutic and the patient was normoammonaemic. EEG undertaken during inpatient stay showed changes consistent with encephalopathy, and low titre ENTC N-methyl-D-aspartate ENTCEND (NMDA) receptor antibodies were present in this patient
0	Four types of experimental ENTD arrhythmia ENTDEND are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine. The compound ENTC P11 ENTCEND is introduced in doses of 0
0	On the antiarrhythmic activity of one N-substituted ENTC piperazine ENTCEND  derivative of trans-2-amino-3-hydroxy-1, 2, 3, 4-tetrahydroanaphthalene.The antiarrhythmic activity of the compound N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine hydrochloride, referred to as P11, is studied on anaesthesized cats and Wistar albino rats, as well as on non-anaesthesized rabbits. Four types of experimental ENTD arrhythmia ENTDEND are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine
1	Four types of experimental ENTD arrhythmia ENTDEND  are used--with BaCl2, with chloroform-adrenaline, with ENTC strophantine G ENTCEND and with aconitine
1	Four types of experimental ENTD arrhythmia ENTDEND  are used--with ENTC BaCl2 ENTCEND , with chloroform-adrenaline, with strophantine G and with aconitine
1	The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the ENTD arrhythmia ENTDEND induced by ENTC chloroform ENTCEND -adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent)
1	The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the ENTD arrhythmia ENTDEND  induced by chloroform- ENTC adrenaline ENTCEND (in 90 per cent) and with BaCl2 (in 84 per cent)
1	Four types of experimental ENTD arrhythmia ENTDEND  are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with ENTC aconitine ENTCEND
0	009), and higher baseline plasma ENTC bilirubin ENTCEND value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001). CONCLUSIONS: Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation. Amoxicillin-clavulanate stands out as the most common drug related to ENTD DILI ENTDEND
1	ENTC Amoxicillin-clavulanate ENTCEND stands out as the most common drug related to ENTD DILI ENTDEND
0	009), and higher baseline plasma ENTC bilirubin ENTCEND  value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001). CONCLUSIONS: Patients with drug-induced hepatocellular ENTD jaundice ENTDEND have 11
1	CONCLUSIONS: Patients with drug-induced hepatocellular ENTD jaundice ENTDEND  have 11.7% chance of progressing to death or transplantation. ENTC Amoxicillin-clavulanate ENTCEND stands out as the most common drug related to DILI
0	Factors associated with the development of ENTD fulminant hepatic failure ENTDEND were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma ENTC bilirubin ENTCEND value (OR = 1
0	Factors associated with the development of ENTD fulminant hepatic failure ENTDEND  were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001). CONCLUSIONS: Patients with drug-induced hepatocellular jaundice have 11.7% chance of progressing to death or transplantation. ENTC Amoxicillin-clavulanate ENTCEND stands out as the most common drug related to DILI
0	The liver damage was characterized according to hepatocellular, ENTD cholestatic ENTDEND  and mixed laboratory criteria and to histologic criteria when available. Further evaluation of causality assessment was centrally performed. RESULTS: Since April 1994 to August 2004, 461 out of 570 submitted cases, involving 505 drugs, were deemed to be related to DILI. The antiinfective group of drugs was the more frequently incriminated, ENTC amoxicillin-clavulanate ENTCEND accounting for the 12
1	We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these ENTC levodopa ENTCEND induce ENTD ocular dyskinesias ENTDEND
0	Usually they occur simultaneously with limb peak-dose ENTD choreatic dyskinesias ENTDEND  We report on a patient with leftward and upward deviations of gaze during the peak effect of ENTC levodopa ENTCEND , and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias
0	Levodopa-induced ocular dyskinesias in ENTD Parkinson's disease ENTDEND . ENTC Levodopa ENTCEND -induced ocular dyskinesias are very uncommon
1	Reports that satisfy defined criteria were classified as ENTD acute kidney injury ENTDEND  kidney tubular dysfunction and Fanconi syndrome. Of the 407 Yellow Card records analysed, 106 satisfied criteria for ENTC TDF ENTCEND -related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome
0	The potential for ENTC tenofovir ENTCEND to cause a range of kidney syndromes has been established from mechanistic and randomised clinical trials. However, the exact pattern of kidney involvement is still uncertain. We undertook a descriptive analysis of Yellow Card records of 407 HIV-positive persons taking tenofovir disoproxil fumarate (TDF) as part of their antiretroviral therapy regimen and submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) with suspected kidney adverse effects. Reports that satisfy defined criteria were classified as ENTD acute kidney injury ENTDEND , kidney tubular dysfunction and Fanconi syndrome
1	Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had ENTD Fanconi syndrome ENTDEND  The median ENTC TDF ENTCEND exposure was 316 days (interquartile range 120-740)
0	The potential for ENTC tenofovir ENTCEND  to cause a range of kidney syndromes has been established from mechanistic and randomised clinical trials. However, the exact pattern of kidney involvement is still uncertain. We undertook a descriptive analysis of Yellow Card records of 407 HIV-positive persons taking tenofovir disoproxil fumarate (TDF) as part of their antiretroviral therapy regimen and submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA) with suspected kidney adverse effects. Reports that satisfy defined criteria were classified as acute kidney injury, kidney tubular dysfunction and ENTD Fanconi syndrome ENTDEND
0	Of the 407 Yellow Card records analysed, 106 satisfied criteria for ENTC TDF ENTCEND -related ENTD kidney disease ENTDEND , of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome
0	An investigation of the pattern of ENTD kidney injury ENTDEND  in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).The potential for ENTC tenofovir ENTCEND to cause a range of kidney syndromes has been established from mechanistic and randomised clinical trials
1	ENTC Neuroleptic ENTCEND -associated ENTD hyperprolactinemia ENTDEND
0	Neuroleptic-associated ENTD hyperprolactinemia ENTDEND . Can it be treated with ENTC bromocriptine ENTCEND ?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine
1	This suggests that bromocriptine should be further evaluated as potential therapy for ENTC neuroleptic ENTCEND associated hyperprolactinemia and ENTD amenorrhea ENTDEND /galactorrhea
0	Can it be treated with ENTC bromocriptine ENTCEND ?Six stable psychiatric outpatients with hyperprolactinemia and ENTD amenorrhea ENTDEND /oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine
1	Can it be treated with bromocriptine?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/ ENTD oligomenorrhea ENTDEND associated with their ENTC neuroleptic medications ENTCEND were treated with bromocriptine
0	Can it be treated with bromocriptine?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/ ENTD oligomenorrhea ENTDEND  associated with their neuroleptic medications were treated with ENTC bromocriptine ENTCEND
0	Can it be treated with bromocriptine?Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their ENTC neuroleptic medications ENTCEND  were treated with bromocriptine. Daily dosages of 5-10 mg corrected the hyperprolactinemia and restored menstruation in four of the six patients. One woman, however, developed worsened ENTD psychiatric symptoms ENTDEND while taking bromocriptine, and it was discontinued
1	One woman, however, developed worsened ENTD psychiatric symptoms ENTDEND  while taking ENTC bromocriptine ENTCEND , and it was discontinued
0	This suggests that bromocriptine should be further evaluated as potential therapy for ENTC neuroleptic ENTCEND -associated hyperprolactinemia and amenorrhea/ ENTD galactorrhea ENTDEND
0	This suggests that ENTC bromocriptine ENTCEND should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea ENTD galactorrhea ENTDEND
0	We propose that remoxipride and benzene may induce ENTD aplastic anemia ENTDEND via production of similar reactive metabolites and that the ability of NCQ436 and ENTC NCQ344 ENTCEND to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and ENTC FLA797 ENTCEND  and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive. Similarly, benzene-derived catechol and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENTD aplastic anemia ENTDEND via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the ENTC phenols ENTCEND  NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive. Similarly, benzene-derived catechol and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENTD aplastic anemia ENTDEND via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
1	We propose that remoxipride and ENTC benzene ENTCEND may induce ENTD aplastic anemia ENTDEND via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired ENTD aplastic anemia ENTDEND  We have examined the ability of remoxipride, three pyrrolidine ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor (HBMP) cells. Cells were treated for 0-24 h with each compound (0-200 microM). Apoptosis was assessed by fluorescence microscopy in ENTC Hoechst 33342 ENTCEND - and propidium iodide stained cell samples
0	Similarly, benzene-derived catechol and hydroquinone, but not ENTC phenol ENTCEND  induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENTD aplastic anemia ENTDEND via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired ENTD aplastic anemia ENTDEND . We have examined the ability of remoxipride, three pyrrolidine ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor (HBMP) cells. Cells were treated for 0-24 h with each compound (0-200 microM). Apoptosis was assessed by fluorescence microscopy in Hoechst 33342- and ENTC propidium iodide ENTCEND stained cell samples
1	Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to ENTC remoxipride ENTCEND -induced ENTD aplastic anemia ENTDEND
0	Similarly, benzene-derived ENTC catechol ENTCEND and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENTD aplastic anemia ENTDEND via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	We propose that remoxipride and benzene may induce ENTD aplastic anemia ENTDEND  via production of similar reactive metabolites and that the ability of ENTC NCQ436 ENTCEND and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	Similarly, benzene-derived catechol and ENTC hydroquinone ENTCEND  but not phenol, induce apoptosis in HBMP cells [Moran et al., Mol. Pharmacol., 50 (1996) 610-615]. We propose that remoxipride and benzene may induce ENTD aplastic anemia ENTDEND via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride
0	The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired ENTD aplastic anemia ENTDEND . We have examined the ability of remoxipride, three ENTC pyrrolidine ENTCEND ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor (HBMP) cells
0	No ENTD necrosis ENTDEND was observed in cells treated with NCQ436 but ENTC NCQ344 ENTCEND had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and ENTC FLA797 ENTCEND , and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENTD necrosis ENTDEND was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the ENTC phenols ENTCEND , NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENTD necrosis ENTDEND was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENTD necrosis ENTDEND at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive. Similarly, ENTC benzene ENTCEND -derived catechol and hydroquinone, but not phenol, induce apoptosis in HBMP cells [Moran et al
0	Apoptosis was assessed by fluorescence microscopy in ENTC Hoechst 33342 ENTCEND - and propidium iodide stained cell samples. Results were confirmed by determination of internucleosomal DNA fragmentation using gel electrophoresis for HL60 cell samples and terminal deoxynucleotidyl transferase assay in HBMP cells. The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENTD necrosis ENTDEND was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENTD necrosis ENTDEND  at higher concentrations. These data show that the catechol and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the ENTC phenol ENTCEND metabolites were inactive
0	Apoptosis was assessed by fluorescence microscopy in Hoechst 33342- and ENTC propidium iodide ENTCEND  stained cell samples. Results were confirmed by determination of internucleosomal DNA fragmentation using gel electrophoresis for HL60 cell samples and terminal deoxynucleotidyl transferase assay in HBMP cells. The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the pyrrolidine ring, FLA838, NCM001, and NCL118, had no effect. No ENTD necrosis ENTDEND was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENTD necrosis ENTDEND  at higher concentrations. These data show that the catechol and hydroquinone metabolites of ENTC remoxipride ENTCEND have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENTD necrosis ENTDEND  at higher concentrations. These data show that the ENTC catechol ENTCEND and hydroquinone metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive
0	No ENTD necrosis ENTDEND  was observed in cells treated with ENTC NCQ436 ENTCEND but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and ENTD necrosis ENTDEND  at higher concentrations. These data show that the catechol and ENTC hydroquinone ENTCEND metabolites of remoxipride have direct toxic effects in HL60 and HBMP cells, leading to apoptosis, while the phenol metabolites were inactive
0	The catechol and hydroquinone metabolites, NCQ436 and NCQ344, induced apoptosis in HL60 and HBMP cells in a time- and concentration dependent manner, while the phenols, NCR181, FLA873, and FLA797, and the derivatives formed by oxidation of the ENTC pyrrolidine ENTCEND ring, FLA838, NCM001, and NCL118, had no effect. No ENTD necrosis ENTDEND was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations
0	Left ventricular function (assessed by echocardiography) showed that PPA increased the ENTD stroke ENTDEND volume 30% (from 62.5 +/- 20.9 to 80.8 +/- 22.4 ml), the ejection fraction 9% (from 64% +/- 10% to 70% +/- 7%), and cardiac output 14% (from 3.6 +/- 0.6 to 4.1 +/- 1.0 L/min). Intravenous propranolol reversed these effects. Systemic vascular resistance was increased by PPA 28% (from 1710 +/- 200 to 2190 +/- 700 dyne X sec/cm5) and was further increased by propranolol 22% (to 2660 +/- 1200 dyne X sec/cm5). We conclude that PPA increases blood pressure by increasing systemic vascular resistance and cardiac output, and that propranolol antagonizes this increase by reversing the effect of PPA on cardiac output. That propranolol antagonizes the pressor effect of PPA is in contrast to the interaction in which propranolol enhances the pressor effect of ENTC norepinephrine ENTCEND
0	Left ventricular function (assessed by echocardiography) showed that ENTC PPA ENTCEND increased the ENTD stroke ENTDEND volume 30% (from 62
0	Intravenous ENTC propranolol ENTCEND after PPA also decreased blood pressure. Left ventricular function (assessed by echocardiography) showed that PPA increased the ENTD stroke ENTDEND volume 30% (from 62
1	Propranolol antagonism of phenylpropanolamine-induced ENTD hypertension ENTDEND . ENTC Phenylpropanolamine ENTCEND (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death
0	We studied the efficacy and safety of propranolol in the treatment of PPA-induced ENTD hypertension ENTDEND  Subjects received ENTC propranolol ENTCEND either by mouth for 48 hours before PPA or as a rapid intravenous infusion after PPA
0	Phenylpropanolamine ( ENTC PPA ENTCEND  ENTD overdose ENTDEND can cause severe hypertension, intracerebral hemorrhage, and death
0	ENTC Propranolol ENTCEND  antagonism of phenylpropanolamine-induced hypertension.Phenylpropanolamine (PPA) ENTD overdose ENTDEND can cause severe hypertension, intracerebral hemorrhage, and death
0	Phenylpropanolamine ( ENTC PPA ENTCEND ) overdose can cause severe hypertension, ENTD intracerebral hemorrhage ENTDEND , and death
0	Phenylpropanolamine (PPA) overdose can cause severe hypertension, ENTD intracerebral hemorrhage ENTDEND , and death. We studied the efficacy and safety of ENTC propranolol ENTCEND in the treatment of PPA-induced hypertension
0	From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive ENTD acute renal failure ENTDEND caused by ENTC desferrioxamine ENTCEND
0	Given the progressive deterioration of the symptoms and of the laboratory values, despite adequate medical treatment, a decision was made to introduce haemodialytical therapy in order to remove the drug and therapy reduce the ENTD nephrotoxicity ENTDEND  From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by ENTC desferrioxamine ENTCEND
0	A patient with transfusion-dependent ENTD thalassemia ENTDEND was undergoing home intravenous ENTC desferrioxamine ENTCEND (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy
1	A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine ( ENTC DFX ENTCEND  treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy. Due to an accidental malfunctioning of the infusion pump, the patient was inadvertently administered a toxic dosage of the drug which caused ENTD renal insufficiency ENTDEND
0	B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced ENTD weight loss ENTDEND  better preservation of kidney function, down regulation of inflammatory cytokines and less acute tubular necrosis. Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum ENTC creatinine ENTCEND and blood urea after cisplatin administration
0	B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced ENTD weight loss ENTDEND , better preservation of kidney function, down regulation of inflammatory cytokines and less acute tubular necrosis. Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood ENTC urea ENTCEND after cisplatin administration
1	Additionally, WT mice were treated with a B2 receptor antagonist after ENTC cisplatin ENTCEND administration. B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced ENTD weight loss ENTDEND , better preservation of kidney function, down regulation of inflammatory cytokines and less acute tubular necrosis
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of ENTC creatinine ENTCEND and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the inflammation process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the ENTD diabetic nephropathy ENTDEND status
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and ENTC urea ENTCEND  increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the inflammation process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the ENTD diabetic nephropathy ENTDEND status
0	The kinin B2 receptor has been associated with the inflammation process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the ENTD diabetic nephropathy ENTDEND  status. To examine the role of the kinin B2 receptor in ENTC cisplatin ENTCEND -induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of ENTC creatinine ENTCEND  and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the ENTD inflammation ENTDEND process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the diabetic nephropathy status
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and ENTC urea ENTCEND , increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a). The kinin B2 receptor has been associated with the ENTD inflammation ENTDEND process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the diabetic nephropathy status
0	The kinin B2 receptor has been associated with the ENTD inflammation ENTDEND  process, as well as the regulation of cytokine expression, and its deletion resulted in an improvement in the diabetic nephropathy status. To examine the role of the kinin B2 receptor in ENTC cisplatin ENTCEND -induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of ENTC creatinine ENTCEND  and urea, increase the ENTD acute tubular necrosis ENTDEND score and up-regulate cytokines (e
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and ENTC urea ENTCEND , increase the ENTD acute tubular necrosis ENTDEND score and up-regulate cytokines (e
1	B2 receptor-deficient mice were less sensitive to this drug than the WT mice, as shown by reduced weight loss, better preservation of kidney function, down regulation of inflammatory cytokines and less ENTD acute tubular necrosis ENTDEND  Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood urea after ENTC cisplatin ENTCEND administration
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum ENTC creatinine ENTCEND  and blood urea after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the ENTD necrotic ENTDEND process and the expression of inflammatory cytokines, thus resulting in declined renal function
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood ENTC urea ENTCEND  after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the ENTD necrotic ENTDEND process and the expression of inflammatory cytokines, thus resulting in declined renal function
0	Thus, our data suggest that the kinin B2 receptor is involved in ENTC cisplatin ENTCEND induced acute kidney injury by mediating the ENTD necrotic ENTDEND process and the expression of inflammatory cytokines, thus resulting in declined renal function
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum ENTC creatinine ENTCEND  and blood urea after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function. These results highlight the kinin B2 receptor antagonist treatment in amelioration of ENTD nephrotoxicity ENTDEND induced by cisplatin therapy
0	Moreover, treatment with the kinin B2 receptor antagonist effectively reduced the levels of serum creatinine and blood ENTC urea ENTCEND  after cisplatin administration. Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function. These results highlight the kinin B2 receptor antagonist treatment in amelioration of ENTD nephrotoxicity ENTDEND induced by cisplatin therapy
0	These results highlight the kinin B2 receptor antagonist treatment in amelioration of ENTD nephrotoxicity ENTDEND  induced by ENTC cisplatin ENTCEND therapy
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce ENTD acute kidney injury ENTDEND due its ability to negatively affect renal function, augment serum levels of ENTC creatinine ENTCEND and urea, increase the acute tubular necrosis score and up-regulate cytokines (e
0	Cisplatin treatment has been adopted in some chemotherapies; however, this drug can induce ENTD acute kidney injury ENTDEND  due its ability to negatively affect renal function, augment serum levels of creatinine and ENTC urea ENTCEND , increase the acute tubular necrosis score and up-regulate cytokines (e
1	Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced ENTD acute renal injury ENTDEND . ENTC Cisplatin ENTCEND treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated ENTC creatinine ENTCEND clearance and, possibly, female gender all increase the risk for nephrotoxicity. Other causes of ENTD acute renal failure ENTDEND , such as shock, appear to have an additive effect
0	Clinical trials of ENTC aminoglycosides ENTCEND in seriously ill patients indicate that the relative risk for developing ENTD acute renal failure ENTDEND during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated ENTC creatinine ENTCEND  clearance and, possibly, female gender all increase the risk for nephrotoxicity. Other causes of acute renal failure, such as ENTD shock ENTDEND , appear to have an additive effect
0	Further analysis of these data suggests that the duration of therapy, plasma ENTC aminoglycoside ENTCEND levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity. Other causes of acute renal failure, such as ENTD shock ENTDEND , appear to have an additive effect
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated ENTC creatinine ENTCEND  clearance and, possibly, female gender all increase the risk for ENTD nephrotoxicity ENTDEND
1	Studies of risk factors for ENTC aminoglycoside ENTCEND ENTD nephrotoxicity ENTDEND
0	Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, ENTD liver disease ENTDEND  advanced age, high initial estimated ENTC creatinine ENTCEND clearance and, possibly, female gender all increase the risk for nephrotoxicity
0	Further analysis of these data suggests that the duration of therapy, plasma ENTC aminoglycoside ENTCEND  levels, ENTD liver disease ENTDEND , advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity
0	Delayed ENTD anemia ENTDEND  after treatment with injectable ENTC artesunate ENTCEND in the Democratic Republic of the Congo: a manageable issue
0	6%] > 5 years of age) were followed-up after treatment with injectable ENTC artesunate ENTCEND for severe ENTD malaria ENTDEND in hospitals and health centers of the Democratic Republic of the Congo
1	Cases of delayed ENTD hemolytic anemia ENTDEND have been described after treatment with injectable ENTC artesunate ENTCEND , the current World Health Organization (WHO)-recommended first-line drug for the treatment of severe malaria
0	A 1-year-old female presented with neuroleptic malignant syndrome probably caused by ENTC methylphenidate ENTCEND  She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENTD multicystic encephalomalacia ENTDEND ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENTD multicystic encephalomalacia ENTDEND ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a ENTC dopamine ENTCEND agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENTD multicystic encephalomalacia ENTDEND ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative gamma-aminobutyric acid-ergic deficiency might occur because ENTC diazepam ENTCEND , a gamma-aminobutyric acid-mimetic agent, was strikingly effective
0	She had defects in the supratentorial brain including the basal ganglia and the striatum ( ENTD multicystic encephalomalacia ENTDEND ) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative ENTC gamma-aminobutyric acid ENTCEND -ergic deficiency might occur because diazepam, a gamma-aminobutyric acid-mimetic agent, was strikingly effective
1	ENTD Neuroleptic malignant syndrome ENTDEND  and ENTC methylphenidate ENTCEND
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal hypoxic-ischemic encephalopathy, which was considered to be a possible predisposing factor causing ENTD neuroleptic malignant syndrome ENTDEND  A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a ENTC dopamine ENTCEND agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome
0	A relative gamma-aminobutyric acid-ergic deficiency might occur because ENTC diazepam ENTCEND , a gamma-aminobutyric acid-mimetic agent, was strikingly effective. This is the first reported patient with ENTD neuroleptic malignant syndrome ENTDEND probably caused by methylphenidate
0	A relative gamma-aminobutyric acid-ergic deficiency might occur because diazepam, a ENTC gamma-aminobutyric acid ENTCEND mimetic agent, was strikingly effective. This is the first reported patient with ENTD neuroleptic malignant syndrome ENTDEND probably caused by methylphenidate
0	A 1-year-old female presented with neuroleptic malignant syndrome probably caused by ENTC methylphenidate ENTCEND . She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENTD hypoxic-ischemic encephalopathy ENTDEND , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENTD hypoxic-ischemic encephalopathy ENTDEND , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a ENTC dopamine ENTCEND agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENTD hypoxic-ischemic encephalopathy ENTDEND , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative gamma-aminobutyric acid-ergic deficiency might occur because ENTC diazepam ENTCEND , a gamma-aminobutyric acid-mimetic agent, was strikingly effective
0	She had defects in the supratentorial brain including the basal ganglia and the striatum (multicystic encephalomalacia) due to severe perinatal ENTD hypoxic-ischemic encephalopathy ENTDEND , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome. A dopaminergic blockade mechanism generally is accepted as the pathogenesis of this syndrome. However, methylphenidate is a dopamine agonist via the inhibition of uptake of dopamine, and therefore dopaminergic systems in the brainstem (mainly the midbrain) and the spinal cord were unlikely to participate in the onset of this syndrome. A relative ENTC gamma-aminobutyric acid ENTCEND -ergic deficiency might occur because diazepam, a gamma-aminobutyric acid-mimetic agent, was strikingly effective
0	Efficacy of ENTC olanzapine ENTCEND  in acute ENTD bipolar mania ENTDEND : a double-blind, placebo-controlled study
1	However, ENTC olanzapine ENTCEND treated patients had a statistically significant greater mean (+/- SD) ENTD weight gain ENTDEND than placebo-treated patients (2
0	There were no statistically significant differences in ENTD EPSs ENTDEND between groups. However, ENTC olanzapine ENTCEND -treated patients had a statistically significant greater mean (+/- SD) weight gain than placebo-treated patients (2
1	3 kg, respectively) and also experienced more treatment-emergent ENTD somnolence ENTDEND (21 patients [38.2%] vs 5 [8.3% ], respectively). CONCLUSION: ENTC Olanzapine ENTCEND demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated
0	Grade 3/4 nonhematologic ENTD toxicities ENTDEND were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9%) and 18 partial responses (53%) for an overall response rate of 62%. Of the 19 evaluable patients with prior ENTC doxorubicin ENTCEND exposure, 11 (58%) responded compared with nine of 15 (60%) without prior doxorubicin
0	ENTC Paclitaxel ENTCEND and 5-fluorouracil have additive ENTD cytotoxicity ENTDEND in MCF-7 cell lines
0	Paclitaxel and ENTC 5-fluorouracil ENTCEND have additive ENTD cytotoxicity ENTDEND in MCF-7 cell lines
0	Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required ENTC granulocyte colony-stimulating factor ENTCEND due to neutropenia; no patient required platelet transfusions. Grade 3/4 nonhematologic ENTD toxicities ENTDEND were uncommon
0	Paclitaxel and 5-fluorouracil have additive ENTD cytotoxicity ENTDEND  in MCF-7 cell lines. We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by ENTC folinic acid ENTCEND 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer
0	Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to ENTD neutropenia ENTDEND  no patient required platelet transfusions. Grade 3/4 nonhematologic toxicities were uncommon. Among the 34 patients evaluable for response, there were three complete responses (9%) and 18 partial responses (53%) for an overall response rate of 62%. Of the 19 evaluable patients with prior ENTC doxorubicin ENTCEND exposure, 11 (58%) responded compared with nine of 15 (60%) without prior doxorubicin
1	We performed a phase II trial of ENTC paclitaxel ENTCEND 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 ENTD neutropenia ENTDEND requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions
1	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before ENTC 5-fluorouracil ENTCEND 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 ENTD neutropenia ENTDEND requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions
0	Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required ENTC granulocyte colony-stimulating factor ENTCEND  due to ENTD neutropenia ENTDEND ; no patient required platelet transfusions
1	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by ENTC folinic acid ENTCEND  300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer. Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 ENTD neutropenia ENTDEND requiring hospitalization; seven (4%) cycles in two patients required granulocyte colony-stimulating factor due to neutropenia; no patient required platelet transfusions
0	Of the 19 evaluable patients with prior doxorubicin exposure, 11 (58%) responded compared with nine of 15 (60%) without prior ENTC doxorubicin ENTCEND  Plasma paclitaxel concentrations were measured at the completion of paclitaxel infusion and at 24 hours in 19 patients. TFL is an active, well-tolerated regimen in metastatic ENTD breast cancer ENTDEND
0	5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic ENTD breast cancer ENTDEND patients. ENTC Paclitaxel ENTCEND and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines
0	5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic ENTD breast cancer ENTDEND  patients. Paclitaxel and ENTC 5-fluorouracil ENTCEND have additive cytotoxicity in MCF-7 cell lines
0	We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic ENTD breast cancer ENTDEND  Analysis is reported on 37 patients with a minimum of 6 months follow-up who received a total of 192 cycles of TFL: nine cycles (5%) were associated with grade 3/4 neutropenia requiring hospitalization; seven (4%) cycles in two patients required ENTC granulocyte colony-stimulating factor ENTCEND due to neutropenia; no patient required platelet transfusions
0	Paclitaxel, 5-fluorouracil, and ENTC folinic acid ENTCEND  in metastatic ENTD breast cancer ENTDEND : BRE-26, a phase II trial
0	The dose-dependent effect of ENTC misoprostol ENTCEND  on indomethacin-induced ENTD renal dysfunction ENTDEND in well compensated cirrhosis
1	The dose-dependent effect of misoprostol on ENTC indomethacin ENTCEND -induced ENTD renal dysfunction ENTDEND in well compensated cirrhosis
0	Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced ENTD renal dysfunction ENTDEND in well compensated cirrhotic patients. The aim of this study was to determine if the prophylactic value of misoprostol was dose-dependent. Parameters of renal hemodynamics and tubular ENTC sodium ENTCEND and water handling were assessed by clearance techniques in 26 well compensated cirrhotic patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol
0	The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated ENTD cirrhosis ENTDEND . ENTC Misoprostol ENTCEND (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients
0	The dose-dependent effect of misoprostol on ENTC indomethacin ENTCEND -induced renal dysfunction in well compensated ENTD cirrhosis ENTDEND
0	Parameters of renal hemodynamics and tubular ENTC sodium ENTCEND  and water handling were assessed by clearance techniques in 26 well compensated ENTD cirrhotic ENTDEND patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENTC sulfamethoxazole ENTCEND  The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of ENTD anemia ENTDEND should be considered in patients with worse-than-expected anemia after chemotherapy
0	Drug studies using the indirect antiglobulin test were strongly positive with ENTC trimethoprim ENTCEND and trimethoprim-sulfamethoxazole but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of ENTD anemia ENTDEND should be considered in patients with worse-than-expected anemia after chemotherapy
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENTC trimethoprim-sulfamethoxazole ENTCEND but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of ENTD anemia ENTDEND should be considered in patients with worse-than-expected anemia after chemotherapy
0	During red cell transfusion, he developed ENTD hemoglobinuria ENTDEND  Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENTC sulfamethoxazole ENTCEND
0	ENTC Trimethoprim ENTCEND -induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.A 10-year-old male with acute leukemia presented with post-chemotherapy anemia. During red cell transfusion, he developed ENTD hemoglobinuria ENTDEND
0	During red cell transfusion, he developed ENTD hemoglobinuria ENTDEND . Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENTC trimethoprim-sulfamethoxazole ENTCEND but negative with sulfamethoxazole
0	Drug-induced immune ENTD hemolytic anemia ENTDEND was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENTC sulfamethoxazole ENTCEND
1	ENTC Trimethoprim ENTCEND -induced immune ENTD hemolytic anemia ENTDEND in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction
0	Drug-induced immune ENTD hemolytic anemia ENTDEND  was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENTC trimethoprim-sulfamethoxazole ENTCEND but negative with sulfamethoxazole
0	A 10-year-old male with ENTD acute leukemia ENTDEND presented with post-chemotherapy anemia. During red cell transfusion, he developed hemoglobinuria. Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENTC sulfamethoxazole ENTCEND
0	ENTC Trimethoprim ENTCEND -induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.A 10-year-old male with ENTD acute leukemia ENTDEND presented with post-chemotherapy anemia
0	A 10-year-old male with ENTD acute leukemia ENTDEND  presented with post-chemotherapy anemia. During red cell transfusion, he developed hemoglobinuria. Transfusion reaction workup was negative. Drug-induced immune hemolytic anemia was suspected because of positive direct antiglobulin test, negative eluate, and microspherocytes on smear pre- and post-transfusion. Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENTC trimethoprim-sulfamethoxazole ENTCEND but negative with sulfamethoxazole
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and trimethoprim-sulfamethoxazole but negative with ENTC sulfamethoxazole ENTCEND . The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of anemia should be considered in patients with worse-than-expected anemia after chemotherapy. Furthermore, ENTD hemolysis ENTDEND during transfusion is not always a transfusion reaction
0	Drug studies using the indirect antiglobulin test were strongly positive with ENTC trimethoprim ENTCEND  and trimethoprim-sulfamethoxazole but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of anemia should be considered in patients with worse-than-expected anemia after chemotherapy. Furthermore, ENTD hemolysis ENTDEND during transfusion is not always a transfusion reaction
0	Drug studies using the indirect antiglobulin test were strongly positive with trimethoprim and ENTC trimethoprim-sulfamethoxazole ENTCEND  but negative with sulfamethoxazole. The patient recovered after discontinuing the drug, with no recurrence in 2 years. Other causes of anemia should be considered in patients with worse-than-expected anemia after chemotherapy. Furthermore, ENTD hemolysis ENTDEND during transfusion is not always a transfusion reaction
0	She was admitted to our center for severe ENTD anemia ENTDEND due to menorrhagia and deterioration of renal function. She was infused three units of packed cells during a session of hemodialysis. ENTC Tranexamic acid ENTCEND (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum
0	Thus, the precipitating cause of convulsions was believed to be an ENTD overdose ENTDEND of ENTC TNA ENTCEND
0	ENTC Tranexamic acid ENTCEND  overdosage-induced generalized seizure in renal failure.We report a 45-year-old lady with chronic kidney disease stage 4 due to chronic ENTD tubulointerstial disease ENTDEND
0	ENTC Tranexamic acid ENTCEND  overdosage-induced generalized seizure in renal failure.We report a 45-year-old lady with ENTD chronic kidney disease ENTDEND stage 4 due to chronic tubulointerstial disease
0	ENTC Tranexamic acid ENTCEND  overdosage-induced generalized seizure in ENTD renal failure ENTDEND
0	Thus, the precipitating cause of ENTD convulsions ENTDEND was believed to be an overdose of ENTC TNA ENTCEND
0	She was admitted to our center for severe anemia due to ENTD menorrhagia ENTDEND and deterioration of renal function. She was infused three units of packed cells during a session of hemodialysis. ENTC Tranexamic acid ENTCEND (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum
0	ENTC TNA ENTCEND was discontinued. Investigations of the patient revealed no biochemical or structural central ENTD nervous system abnormalities ENTDEND that could have provoked the convulsions
0	Tranexamic acid (TNA) 1 g 8-hourly was administered to her to control ENTD bleeding ENTDEND per vaginum. Two hours after the sixth dose of ENTC TNA ENTCEND , she had an episode of generalized tonic clonic convulsions
1	Two hours after the sixth dose of TNA, she had an episode of generalized ENTD tonic clonic convulsions ENTDEND ENTC TNA ENTCEND was discontinued
0	Twenty carcinomas of the urinary bladder and one ENTD carcinoma of the prostate ENTDEND have been reported in association with its use. The present case is the first carcinoma of the renal pelvis reported in association with ENTC cyclophosphamide ENTCEND treatment
0	Invasive carcinoma of the renal pelvis following ENTC cyclophosphamide ENTCEND  therapy for nonmalignant disease.A 47-year-old woman with right ENTD hydroureteronephrosis ENTDEND due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis
1	Twenty ENTD carcinomas of the urinary bladder ENTDEND and one carcinoma of the prostate have been reported in association with its use. The present case is the first carcinoma of the renal pelvis reported in association with ENTC cyclophosphamide ENTCEND treatment
0	Invasive ENTD carcinoma of the renal pelvis ENTDEND  following ENTC cyclophosphamide ENTCEND therapy for nonmalignant disease
0	It is the third urinary tract cancer reported in association with ENTC cyclophosphamide ENTCEND treatment for nonmalignant disease. The association of the ENTD tumor ENTDEND with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide
0	The present case is the first carcinoma of the renal pelvis reported in association with ENTC cyclophosphamide ENTCEND  treatment. It is the third ENTD urinary tract cancer ENTDEND reported in association with cyclophosphamide treatment for nonmalignant disease
1	A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross ENTD hematuria ENTDEND after being treated for five years wtih ENTC cyclophosphamide ENTCEND for cerebral vasculitis
0	Although the ability of ENTC cyclophosphamide ENTCEND to cause ENTD hemorrhagic cystitis ENTDEND and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract
0	A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih ENTC cyclophosphamide ENTCEND  for ENTD cerebral vasculitis ENTDEND
0	Although the ability of ENTC cyclophosphamide ENTCEND  to cause ENTD hemorrhagic cystitis ENTDEND and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract
1	Although the ability of ENTC cyclophosphamide ENTCEND  to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade ENTD carcinoma ENTDEND is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract
0	Intradermal injections of glutamate and ENTC capsaicin ENTCEND are attractive to use in human experimental ENTD pain ENTDEND models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders
0	Intradermal injections of ENTC glutamate ENTCEND and capsaicin are attractive to use in human experimental ENTD pain ENTDEND models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders
0	Intradermal injections of glutamate and ENTC capsaicin ENTCEND  are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical ENTD pain disorders ENTDEND
0	Intradermal injections of ENTC glutamate ENTCEND  and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical ENTD pain disorders ENTDEND
1	In conclusion, glutamate and ENTC capsaicin ENTCEND yield reproducible ENTD hyperalgesic ENTDEND and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena
0	Intra-individual variability was generally lower for the VAS response to von Frey and brush compared with areas of secondary hyperalgesia and ENTD allodynia ENTDEND  In conclusion, ENTC glutamate ENTCEND and capsaicin yield reproducible hyperalgesic and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena
1	Protective effect of Terminalia chebula against experimental ENTD myocardial injury ENTDEND  induced by ENTC isoproterenol ENTCEND
0	Protective effect of ENTC Terminalia chebula ENTCEND  against experimental ENTD myocardial injury ENTDEND induced by isoproterenol
0	Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in isoproterenol (200 mg/kg body wt) induced ENTD myocardial damage ENTDEND in rats. In isoproterenol administered rats, the level of lipid ENTC peroxides ENTCEND increased significantly in the serum and heart
1	Histopathological examination was carried out to confirm the myocardial ENTD necrosis ENTDEND  T. chebula extract pretreatment was found to ameliorate the effect of ENTC isoproterenol ENTCEND on lipid peroxide formation and retained the activities of the diagnostic marker enzymes
0	Histopathological examination was carried out to confirm the myocardial ENTD necrosis ENTDEND . ENTC T. chebula extract ENTCEND pretreatment was found to ameliorate the effect of isoproterenol on lipid peroxide formation and retained the activities of the diagnostic marker enzymes
0	Histopathological examination was carried out to confirm the myocardial ENTD necrosis ENTDEND . T. chebula extract pretreatment was found to ameliorate the effect of isoproterenol on lipid ENTC peroxide ENTCEND formation and retained the activities of the diagnostic marker enzymes
0	5 mg/dL (44 micromol/L) in the serum ENTC creatinine ENTCEND level that is greater than 50% of baseline immediately after conditioning. Urine sediment score was the sum of the individual types of sediment identified on urine microscopy. RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan. Univariate analysis identified age, ENTD hypoalbuminemia ENTDEND , heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors
0	8% of the patients after high-dose ENTC melphalan ENTCEND  Univariate analysis identified age, ENTD hypoalbuminemia ENTDEND , heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors
0	Acute renal insufficiency ( ENTD ARI ENTDEND  after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum ENTC creatinine ENTCEND level that is greater than 50% of baseline immediately after conditioning
1	Ongoing tubular injury may be a prerequisite for ENTD renal injury ENTDEND by ENTC melphalan ENTCEND as evidenced by the active urinary sediment
0	METHODS: Consecutive ENTD AL ENTDEND patients who underwent PBSCT were studied retrospectively. Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum ENTC creatinine ENTCEND level that is greater than 50% of baseline immediately after conditioning
0	METHODS: Consecutive ENTD AL ENTDEND  patients who underwent PBSCT were studied retrospectively. Acute renal insufficiency (ARI) after high-dose ENTC melphalan ENTCEND was defined by a minimum increase of 0
0	Acute renal insufficiency after high-dose ENTC melphalan ENTCEND  in patients with ENTD primary systemic amyloidosis ENTDEND during stem cell transplantation
0	5 mg/dL (44 micromol/L) in the serum ENTC creatinine ENTCEND  level that is greater than 50% of baseline immediately after conditioning. Urine sediment score was the sum of the individual types of sediment identified on urine microscopy. RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan. Univariate analysis identified age, hypoalbuminemia, heavy ENTD proteinuria ENTDEND , diuretic use, and urine sediment score (>3) as risk factors
0	8% of the patients after high-dose ENTC melphalan ENTCEND . Univariate analysis identified age, hypoalbuminemia, heavy ENTD proteinuria ENTDEND , diuretic use, and urine sediment score (>3) as risk factors
0	It was possible to suppress the increased ENTC ornithine ENTCEND decarboxylase activity with both beta-blockers in ENTD hypertrophied hearts ENTDEND , but there was no effect on the heart mass
1	The studies were performed using an experimental model of ENTC isoproterenol ENTCEND induced ENTD heart hypertrophy ENTDEND in rats
0	Subacute effects of ENTC propranolol ENTCEND  and B 24/76 on isoproterenol-induced rat ENTD heart hypertrophy ENTDEND in correlation with blood pressure
0	Both beta-blockers influenced the development of ENTD hypertrophy ENTDEND to a different, but not reproducible extent. It was possible to suppress the increased ENTC ornithine ENTCEND decarboxylase activity with both beta-blockers in hypertrophied hearts, but there was no effect on the heart mass
0	Neither propranolol nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the ENTD hypertrophied ENTDEND rat heart. Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent ENTC isoproterenol ENTCEND from producing heart hypertrophy
0	Neither ENTC propranolol ENTCEND nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the ENTD hypertrophied ENTDEND rat heart
0	Quetiapine-induced neutropenia in a ENTD bipolar ENTDEND  patient with hepatocellular carcinoma.OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENTC clozapine ENTCEND , which has the highest risk of causing blood dyscrasias, especially neutropenia
0	ENTC Quetiapine ENTCEND -induced neutropenia in a ENTD bipolar ENTDEND patient with hepatocellular carcinoma
1	Hepatic dysfunction may be one of the possible risk factors, and concomitant ENTD fever ENTDEND may be a diagnostic marker for adverse reaction to ENTC quetiapine ENTCEND
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENTC clozapine ENTCEND , which has the highest risk of causing ENTD blood dyscrasias ENTDEND , especially neutropenia
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing ENTD blood dyscrasias ENTDEND , especially neutropenia. There are some case reports about this side effect of ENTC quetiapine ENTCEND , but possible risk factors are seldom discussed and identified
0	CONCLUSIONS: Although neutropenia is not a common side effect of ENTC quetiapine ENTCEND  physicians should be cautious about its presentation and associated risk factors. ENTD Hepatic dysfunction ENTDEND may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine
0	Quetiapine-induced neutropenia in a bipolar patient with ENTD hepatocellular carcinoma ENTDEND .OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENTC clozapine ENTCEND , which has the highest risk of causing blood dyscrasias, especially neutropenia
0	Quetiapine-induced neutropenia in a bipolar patient with ENTD hepatocellular carcinoma ENTDEND .OBJECTIVE: ENTC Quetiapine ENTCEND is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENTC clozapine ENTCEND , which has the highest risk of causing blood dyscrasias, especially neutropenia. There are some case reports about this side effect of quetiapine, but possible risk factors are seldom discussed and identified. A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here. CASE REPORT: A 62-year-old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60. She developed ENTD leucopenia ENTDEND after being treated with quetiapine
1	She developed ENTD leucopenia ENTDEND  after being treated with ENTC quetiapine ENTCEND
0	OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to ENTC clozapine ENTCEND , which has the highest risk of causing blood dyscrasias, especially ENTD neutropenia ENTDEND
1	ENTC Quetiapine ENTCEND -induced ENTD neutropenia ENTDEND in a bipolar patient with hepatocellular carcinoma
0	A 47-year-old man who had been taking ENTC minocycline ENTCEND for palmoplantar pustulosis developed fever, myalgias, ENTD polyneuropathy ENTDEND , and testicular pain, with elevated C-reactive protein (CRP)
0	A 47-year-old man who had been taking ENTC minocycline ENTCEND  for ENTD palmoplantar pustulosis ENTDEND developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)
0	A 47-year-old man who had been taking ENTC minocycline ENTCEND  for palmoplantar pustulosis developed ENTD fever ENTDEND , myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)
0	ENTC Minocycline ENTCEND -induced ENTD vasculitis ENTDEND fulfilling the criteria of polyarteritis nodosa
1	These manifestations met the American College of Rheumatology 1990 criteria for the classification of ENTD polyarteritis nodosa ENTDEND  Stopping ENTC minocycline ENTCEND led to amelioration of symptoms and normalization of CRP level
0	A 47-year-old man who had been taking ENTC minocycline ENTCEND  for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and ENTD testicular pain ENTDEND , with elevated C-reactive protein (CRP)
0	A 47-year-old man who had been taking ENTC minocycline ENTCEND  for palmoplantar pustulosis developed fever, ENTD myalgias ENTDEND , polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP)
1	001) ENTC Dex ENTCEND induced hypertension. LF prevented body ENTD weight loss ENTDEND and significantly reduced the elevated plasma H2O2 and increased FRAP values
0	LF prevented body ENTD weight loss ENTDEND  and significantly reduced the elevated plasma ENTC H2O2 ENTCEND and increased FRAP values
0	Dexamethasone- (Dex-) induced ENTD hypertension ENTDEND is associated with enhanced oxidative stress. Lactoferrin (LF) is an ENTC iron ENTCEND -binding glycoprotein with antihypertensive properties
1	In this study, we investigated the effect of chronic administration of LF on oxidative stress and ENTD hypertension ENTDEND upon ENTC Dex ENTCEND administration
0	001) Dex-induced ENTD hypertension ENTDEND  LF prevented body weight loss and significantly reduced the elevated plasma ENTC H2O2 ENTCEND and increased FRAP values
1	Early paracentral ENTD visual field loss ENTDEND  in patients taking ENTC hydroxychloroquine ENTCEND
0	Two cases of downbeat nystagmus and oscillopsia associated with ENTC carbamazepine ENTCEND . ENTD Downbeat nystagmus ENTDEND is often associated with structural lesions at the craniocervical junction, but has occasionally been reported as a manifestation of metabolic imbalance or drug intoxication
1	Two cases of downbeat nystagmus and ENTD oscillopsia ENTDEND  associated with ENTC carbamazepine ENTCEND
0	Milk-alkali syndrome induced by ENTC 1,25(OH)2D ENTCEND  in a patient with ENTD hypoparathyroidism ENTDEND
0	This article presents a patient with ENTD hypoparathyroidism ENTDEND who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENTC pamidronate ENTCEND on his first admission and with hydrocortisone on the second
0	This article presents a patient with ENTD hypoparathyroidism ENTDEND  who was treated with ENTC calcium carbonate ENTCEND and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENTD hypoparathyroidism ENTDEND .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENTC calcium ENTCEND and alkali
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENTD hypoparathyroidism ENTDEND .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and ENTC sucralfate ENTCEND ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENTD hypoparathyroidism ENTDEND .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, ENTC omeprazole ENTCEND , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	This article presents a patient with ENTD hypoparathyroidism ENTDEND  who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENTC hydrocortisone ENTCEND on the second
0	Milk-alkali syndrome induced by 1,25(OH)2D in a patient with ENTD hypoparathyroidism ENTDEND .Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENTC alkali ENTCEND
0	Milk-alkali syndrome induced by ENTC 1,25(OH)2D ENTCEND  in a patient with hypoparathyroidism.Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND with large amounts of calcium and alkali
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENTC pamidronate ENTCEND on his first admission and with hydrocortisone on the second
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENTC calcium carbonate ENTCEND and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND  with large amounts of ENTC calcium ENTCEND and alkali
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and ENTC sucralfate ENTCEND ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, ENTC omeprazole ENTCEND , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND  with large amounts of calcium and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENTC hydrocortisone ENTCEND on the second
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of ENTD peptic ulcer disease ENTDEND  with large amounts of calcium and ENTC alkali ENTCEND
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and ENTC calcitriol ENTCEND resulting in two admissions to the hospital for milk-alkali syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND  remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENTC pamidronate ENTCEND on his first admission and with hydrocortisone on the second
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND  remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENTC calcium carbonate ENTCEND and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENTC calcium ENTCEND  and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and ENTC sucralfate ENTCEND ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, ENTC omeprazole ENTCEND , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND  remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENTC hydrocortisone ENTCEND on the second
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENTC alkali ENTCEND . Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and ENTD renal impairment ENTDEND remains the hallmark of the syndrome
1	ENTD Milk-alkali syndrome ENTDEND  induced by ENTC 1,25(OH)2D ENTCEND in a patient with hypoparathyroidism
0	This illustrates intravenous ENTC pamidronate ENTCEND as a valuable therapeutic tool when ENTD milk-alkali syndrome ENTDEND presents as hypercalcemic emergency
1	This article presents a patient with hypoparathyroidism who was treated with ENTC calcium carbonate ENTCEND  and calcitriol resulting in two admissions to the hospital for ENTD milk-alkali syndrome ENTDEND
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENTC calcium ENTCEND  and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of ENTD milk-alkali syndrome ENTDEND has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and ENTC sucralfate ENTCEND ), the frequency of ENTD milk-alkali syndrome ENTDEND has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, ENTC omeprazole ENTCEND , and sucralfate), the frequency of ENTD milk-alkali syndrome ENTDEND has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	The patient was successfully treated with intravenous pamidronate on his first admission and with ENTC hydrocortisone ENTCEND  on the second. This illustrates intravenous pamidronate as a valuable therapeutic tool when ENTD milk-alkali syndrome ENTDEND presents as hypercalcemic emergency
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENTC alkali ENTCEND . Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of ENTD milk-alkali syndrome ENTDEND has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND  and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and ENTC calcitriol ENTCEND resulting in two admissions to the hospital for milk-alkali syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND , and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENTC pamidronate ENTCEND on his first admission and with hydrocortisone on the second
1	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND , and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENTC calcium carbonate ENTCEND and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENTC calcium ENTCEND  and alkali. Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND , and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and ENTC sucralfate ENTCEND ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND , and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, ENTC omeprazole ENTCEND , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND , and renal impairment remains the hallmark of the syndrome
0	Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND , and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENTC hydrocortisone ENTCEND on the second
1	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENTC alkali ENTCEND . Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, ENTD alkalosis ENTDEND , and renal impairment remains the hallmark of the syndrome
0	Milk-alkali syndrome induced by ENTC 1,25(OH)2D ENTCEND  in a patient with hypoparathyroidism.Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali. Although with current ENTD ulcer ENTDEND therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENTD ulcer ENTDEND  therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous ENTC pamidronate ENTCEND on his first admission and with hydrocortisone on the second
0	Although with current ENTD ulcer ENTDEND  therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with ENTC calcium carbonate ENTCEND and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of ENTC calcium ENTCEND  and alkali. Although with current ENTD ulcer ENTDEND therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENTD ulcer ENTDEND  therapy (H-2 blockers, omeprazole, and ENTC sucralfate ENTCEND ), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENTD ulcer ENTDEND  therapy (H-2 blockers, ENTC omeprazole ENTCEND , and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Although with current ENTD ulcer ENTDEND  therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome. Milk-alkali syndrome can present serious and occasionally life-threatening illness unless diagnosed and treated appropriately. This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome. The patient was successfully treated with intravenous pamidronate on his first admission and with ENTC hydrocortisone ENTCEND on the second
0	Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and ENTC alkali ENTCEND . Although with current ENTD ulcer ENTDEND therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome
0	Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in ENTC lamivudine ENTCEND untreated ENTD chronic hepatitis B ENTDEND patients
1	YMDD motif mutants were not detected in any of the patients despite the liver enzyme levels and the presence of ENTC HBeAg ENTCEND or anti-HBe. CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with ENTD chronic hepatitis B ENTDEND has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients
0	Recent studies show that the YMDD motif mutants (resistant ENTD hepatitis B ENTDEND virus) occur as natural genome variability in ENTC lamivudine ENTCEND -untreated chronic hepatitis B patients
0	Recent studies show that the YMDD motif mutants (resistant ENTD hepatitis B ENTDEND  virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients. In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran. PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study. Serum samples from patients were tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for detection of YMDD motif mutants. All patients were also tested for liver enzymes, anti-HCV, ENTC HBeAg ENTCEND , and anti-HBe
1	This study shows that 17alpha-ethinylestradiol ( ENTC EE ENTCEND -induced ENTD intrahepatic cholestasis ENTDEND in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis
0	This study shows that 17alpha-ethinylestradiol (EE)-induced ENTD intrahepatic cholestasis ENTDEND  in rats is associated with selective inhibition of the neutral pathway of ENTC bile salt ENTCEND (BS) synthesis
0	In addition, mRNA levels of ENTC sterol ENTCEND 12alpha-hydroxylase and lithocholate 6beta-hydroxylase were increased by bile diversion and suppressed by EE. This study shows that 17alpha-ethinylestradiol (EE)-induced ENTD intrahepatic cholestasis ENTDEND in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis
0	BACKGROUND: Thrombocytopenia in patients with end-stage liver disease is a common disorder caused mainly by ENTD portal hypertension ENTDEND  low levels of thrombopoetin, and endotoxemia. The impact of immune-mediated ENTC heparin ENTCEND -induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results
0	CONCLUSIONS: The incidence of HIT in patients with ENTD end-stage hepatic failure ENTDEND is, with about 1.95%, rare. For further reduction of HIT type II, the use of intravenous ENTC heparin ENTCEND should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count
1	Incidence of ENTC heparin ENTCEND -induced ENTD thrombocytopenia type II ENTDEND and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis
0	6%) of 205 patients had thrombocytopenia before transplantation, significantly influenced by Model of End-Stage Liver Disease score and ENTD liver cirrhosis ENTDEND  The platelet count exceeded 100,000/uL in most of the patients (n = 193) at a medium of 7 d. Regarding HIT II, there were four (1.95%) patients with a background of HIT type II. CONCLUSIONS: The incidence of HIT in patients with end-stage hepatic failure is, with about 1.95%, rare. For further reduction of HIT type II, the use of intravenous ENTC heparin ENTCEND should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count
0	BACKGROUND: Thrombocytopenia in patients with end-stage liver disease is a common disorder caused mainly by portal hypertension, low levels of thrombopoetin, and ENTD endotoxemia ENTDEND  The impact of immune-mediated ENTC heparin ENTCEND -induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results
0	The impact of immune-mediated ENTC heparin ENTCEND -induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results. The aim of our study was to demonstrate the perioperative course of thrombocytopenia after liver transplantation and determine the occurrence of clinical HIT type II. METHOD: We retrospectively evaluated the medical records of 205 consecutive adult patients who underwent full-size liver transplantation between January 2006 and December 2010 due to ENTD end-stage or malignant liver disease ENTDEND
0	Prominent white-matter hypertrophy may result from altered myelination and adaptive glial changes, including ENTD gliosis ENTDEND secondary to neuronal damage. These brain substrates may help account for the symptoms of ENTC MA ENTCEND abuse, providing therapeutic targets for drug-induced brain injury
0	On average, ENTC MA ENTCEND abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant white-matter ENTD hypertrophy ENTDEND (7
0	Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic ENTC MA ENTCEND abuse in human subjects and related these deficits to ENTD cognitive impairment ENTDEND
0	Prominent white-matter hypertrophy may result from altered myelination and adaptive glial changes, including gliosis secondary to ENTD neuronal damage ENTDEND  These brain substrates may help account for the symptoms of ENTC MA ENTCEND abuse, providing therapeutic targets for drug-induced brain injury
1	MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to ENTD impaired memory performance ENTDEND  ENTC MA ENTCEND may selectively damage the medial temporal lobe and, consistent with metabolic studies, the cingulate-limbic cortex, inducing neuroadaptation, neuropil reduction, or cell death
1	We visualize, for the first time, the profile of ENTD structural deficits in the human brain ENTDEND associated with chronic ENTC methamphetamine ENTCEND (MA) abuse
0	Studies of human subjects who have used ENTC MA ENTCEND chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral ENTD metabolic abnormalities ENTDEND
0	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by ENTC propofol ENTCEND remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT. ENTD Hemorrhage ENTDEND was measured and the visibility of the operative field was evaluated according to a six-point scale
0	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol- ENTC remifentanil ENTCEND TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT. ENTD Hemorrhage ENTDEND was measured and the visibility of the operative field was evaluated according to a six-point scale
1	METHODS: Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled ENTD hypotension ENTDEND anesthesia caused by ENTC propofol ENTCEND -remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT
1	CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced ENTD hypotension ENTDEND with low doses of ENTC remifentanil ENTCEND during TIVA in patients undergoing FESS
0	The participation of reactive oxygen species in aminoglycoside-induced ENTD ototoxicity ENTDEND has been deduced from observations that aminoglycoside- ENTC iron ENTCEND complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	The participation of reactive ENTC oxygen ENTCEND species in aminoglycoside-induced ENTD ototoxicity ENTDEND has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ENTD ototoxicity ENTDEND in vivo. We therefore hypothesized that overexpression of Cu/ ENTC Zn ENTCEND -superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity
0	The participation of reactive oxygen species in ENTC aminoglycoside ENTCEND induced ENTD ototoxicity ENTDEND has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	Overexpression of copper/zinc-superoxide dismutase protects from ENTC kanamycin ENTCEND -induced hearing loss.The participation of reactive oxygen species in aminoglycoside-induced ENTD ototoxicity ENTDEND has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ENTD ototoxicity ENTDEND  in vivo. We therefore hypothesized that overexpression of ENTC Cu ENTCEND /Zn-superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity
0	The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of ENTC superoxide ENTCEND radicals in vitro and that antioxidants attenuate ENTD ototoxicity ENTDEND in vivo
0	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced ENTD hearing loss ENTDEND .The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside ENTC iron ENTCEND complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced ENTD hearing loss ENTDEND .The participation of reactive ENTC oxygen ENTCEND species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
0	Overexpression of copper/ ENTC zinc ENTCEND -superoxide dismutase protects from kanamycin-induced ENTD hearing loss ENTDEND
0	Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced ENTD hearing loss ENTDEND .The participation of reactive oxygen species in ENTC aminoglycoside ENTCEND -induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo
1	Overexpression of copper/zinc-superoxide dismutase protects from ENTC kanamycin ENTCEND -induced ENTD hearing loss ENTDEND
0	Overexpression of ENTC copper ENTCEND /zinc-superoxide dismutase protects from kanamycin-induced ENTD hearing loss ENTDEND
0	Overexpression of copper/zinc- ENTC superoxide ENTCEND  dismutase protects from kanamycin-induced ENTD hearing loss ENTDEND
0	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti- ENTD tachycardial ENTDEND effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of ENTC bepridil ENTCEND in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by KCl microelectrodes) starting at doses of 5 X 10(-6) M
0	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti- ENTD tachycardial ENTDEND  effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of bepridil in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by ENTC KCl ENTCEND microelectrodes) starting at doses of 5 X 10(-6) M
0	ENTC Bepridil ENTCEND  a novel active compound for prophylactic treatment of ENTD anginal attacks ENTDEND , induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo
0	Bepridil, a novel active compound for prophylactic treatment of ENTD anginal attacks ENTDEND , induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of bepridil in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by ENTC KCl ENTCEND microelectrodes) starting at doses of 5 X 10(-6) M
1	Studies on the ENTD bradycardia ENTDEND  induced by ENTC bepridil ENTCEND
0	Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent ENTD bradycardia ENTDEND and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo. In vitro perfusion of bepridil in the life-support medium for isolated sino-atrial tissue from rabbit heart, caused a reduction in action potential (AP) spike frequency (recorded by ENTC KCl ENTCEND microelectrodes) starting at doses of 5 X 10(-6) M
0	Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact ENTC pentobarbital ENTCEND anesthetized rats. There was a significant decrease in the time to onset of ENTD arrhythmia ENTDEND as compared with control nonprogesterone-treated rats (6
1	Potentiation of ENTC bupivacaine ENTCEND ENTD arrhythmia ENTDEND in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level
1	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become ENTD arrhythmic ENTDEND , we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm. Each concentration of progesterone (6.25, 12.5, 25, and 50 micrograms/ml) caused a significant and concentration-dependent reduction in the AD50 for bupivacaine. ENTC Estradiol ENTCEND treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone
0	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become ENTD arrhythmic ENTDEND ), we determined the effect of 1-hour progesterone ENTC HCl ENTCEND exposure on myocyte contractile rhythm
1	After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become ENTD arrhythmic ENTDEND ), we determined the effect of 1-hour ENTC progesterone ENTCEND HCl exposure on myocyte contractile rhythm
0	Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by ENTC epinephrine ENTCEND  Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital-anesthetized rats. There was a significant decrease in the time to onset of ENTD arrhythmia ENTDEND as compared with control nonprogesterone-treated rats (6
1	ENTD Vasovagal syncope ENTDEND  and severe bradycardia following intranasal ENTC dexmedetomidine ENTCEND for pediatric procedural sedation
0	Vasovagal syncope and severe bradycardia following intranasal ENTC dexmedetomidine ENTCEND  for pediatric procedural sedation.We report ENTD syncope ENTDEND and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram
1	Vasovagal syncope and severe ENTD bradycardia ENTDEND  following intranasal ENTC dexmedetomidine ENTCEND for pediatric procedural sedation
0	CONCLUSION: Verapamil responsiveness is not a reliable finding for the differential diagnosis of ENTD hyperprolactinemia ENTDEND  However, ENTC verapamil ENTCEND unresponsiveness discriminates stalk effect (i
1	8%), and ENTC risperidone ENTCEND induced ENTD hyperprolactinemia ENTDEND (N
0	Here, we aimed to re-investigate the diagnostic value of verapamil in a population who were all screened for ENTD macroprolactinemia ENTDEND  Prolactin responses to ENTC verapamil ENTCEND in 65 female patients (age: 29
0	19, PRL: 21%), ENTD macroprolactinemia ENTDEND (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and ENTC risperidone ENTCEND -induced hyperprolactinemia (N
1	Rechallenge of patients who developed oral candidiasis or ENTD hoarseness ENTDEND  with ENTC beclomethasone dipropionate ENTCEND
0	We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop ENTD hoarseness ENTDEND should not be re-challenged. Concomitant use of oral ENTC prednisone ENTCEND and topical beclomethasone may increase the risk of developing hoarseness or candidiasis
1	Rechallenge of patients who developed ENTD oral candidiasis ENTDEND  or hoarseness with ENTC beclomethasone dipropionate ENTCEND
0	Oral ENTD thrush ENTDEND did not recur, but 60% (3/5) of patients with hoarseness had recurrence. We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop hoarseness should not be re-challenged. Concomitant use of oral ENTC prednisone ENTCEND and topical beclomethasone may increase the risk of developing hoarseness or candidiasis
0	Concomitant use of oral prednisone and topical ENTC beclomethasone ENTCEND may increase the risk of developing hoarseness or ENTD candidiasis ENTDEND
0	Concomitant use of oral ENTC prednisone ENTCEND  and topical beclomethasone may increase the risk of developing hoarseness or ENTD candidiasis ENTDEND
0	Rechallenge of patients who developed oral candidiasis or hoarseness with ENTC beclomethasone dipropionate ENTCEND .Of 158 ENTD asthmatic ENTDEND patients who were placed on inhaled beclomethasone, 15 (9
1	Stereological methods reveal the robust size and stability of ectopic hilar granule cells after ENTC pilocarpine ENTCEND -induced ENTD status epilepticus ENTDEND in the adult rat
0	Interestingly, the size of the population appears to be correlated with the frequency of behavioral seizures, because animals with more ectopic granule cells in the hilus have more frequent behavioral ENTD seizures ENTDEND  The hilar ectopic granule cell population does not appear to vary systematically across the septotemporal axis, although it is associated with an increase in volume of the hilus. The results provide new insight into the potential role of ectopic hilar granule cells in the ENTC pilocarpine ENTCEND model of temporal lobe epilepsy
1	The results provide new insight into the potential role of ectopic hilar granule cells in the ENTC pilocarpine ENTCEND  model of ENTD temporal lobe epilepsy ENTDEND
0	ENTC Phenytoin ENTCEND  induced fatal ENTD hepatic injury ENTDEND
1	The hematologic, biochemical and pathologic features indicate a mixed hepatocellular damage due to ENTD drug hypersensitivity ENTDEND  In a patient receiving ENTC phenytoin ENTCEND who presents a viral-like illness, early recognition and discontinuation of the drug are mandatory
1	A 61 year old female developed fatal ENTD hepatic failure ENTDEND after ENTC phenytoin ENTCEND administration
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and ENTC amitriptyline ENTCEND are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENTD depressive and psychotic symptoms ENTDEND
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors ENTC fluoxetine ENTCEND and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENTD depressive and psychotic symptoms ENTDEND
0	Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENTD depressive and psychotic symptoms ENTDEND . Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors. Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENTC dopamine ENTCEND release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	Five cases of paranoid exacerbation with the ENTC serotonin ENTCEND reuptake inhibitors fluoxetine and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENTD depressive and psychotic symptoms ENTDEND
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and ENTC amitriptyline ENTCEND  are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENTD depressive and psychotic symptoms ENTDEND
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors ENTC fluoxetine ENTCEND  and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENTD depressive and psychotic symptoms ENTDEND
0	Complicated ENTD depressive disorders ENTDEND (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors. Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENTC dopamine ENTCEND release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	Five cases of paranoid exacerbation with the ENTC serotonin ENTCEND  reuptake inhibitors fluoxetine and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of ENTD depressive and psychotic symptoms ENTDEND
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and ENTC amitriptyline ENTCEND  are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms. Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, ENTD psychosis ENTDEND , bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors
0	Five cases of paranoid exacerbation with the serotonin reuptake inhibitors ENTC fluoxetine ENTCEND  and amitriptyline are reported here. Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms. Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, ENTD psychosis ENTDEND , bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors
0	Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary ENTD psychosis ENTDEND  may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors. Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENTC dopamine ENTCEND release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary ENTD psychosis ENTDEND ) may present particular vulnerability to paranoid exacerbations associated with ENTC serotonin ENTCEND reuptake inhibitors
1	Five cases of ENTD paranoid ENTDEND exacerbation with the serotonin reuptake inhibitors fluoxetine and ENTC amitriptyline ENTCEND are reported here
1	Five cases of ENTD paranoid ENTDEND  exacerbation with the serotonin reuptake inhibitors ENTC fluoxetine ENTCEND and amitriptyline are reported here
0	Although the pharmacology and neurobiology of ENTD paranoia ENTDEND remain cryptic, several mechanisms, including 5HT3 receptor-mediated ENTC dopamine ENTCEND release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon
0	These cases call attention to possible ENTD paranoid ENTDEND exacerbations with ENTC serotonin ENTCEND reuptake blockers in select patients and raise neurobiological considerations regarding paranoia
0	Factors contributing to ENTC ribavirin ENTCEND -induced ENTD anemia ENTDEND
0	Factors contributing to ribavirin-induced ENTD anemia ENTDEND .BACKGROUND AND AIM: ENTC Interferon ENTCEND and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia
0	BACKGROUND AND AIM: Interferon and ENTC ribavirin ENTCEND combination therapy for ENTD chronic hepatitis C ENTDEND produces hemolytic anemia
0	METHODS: Eighty-eight patients with ENTD chronic hepatitis C ENTDEND who received ENTC interferon-alpha-2b ENTCEND at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study
1	BACKGROUND AND AIM: Interferon and ENTC ribavirin ENTCEND  combination therapy for chronic hepatitis C produces ENTD hemolytic anemia ENTDEND
1	BACKGROUND AND AIM: ENTC Interferon ENTCEND  and ribavirin combination therapy for chronic hepatitis C produces ENTD hemolytic anemia ENTDEND
1	The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities (arthralgia and ENTD sensory neuropathy ENTDEND . Therapeutic effects were noted at all dose levels, with objective responses in 17 (two complete and 15 partial regressions) of 41 previously untreated patients. Toxicities were compared with a cohort of patients in a phase I trial of ENTC paclitaxel ENTCEND alone at identical dose levels
0	The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities (arthralgia and ENTD sensory neuropathy ENTDEND ). Therapeutic effects were noted at all dose levels, with objective responses in 17 (two complete and 15 partial regressions) of 41 previously untreated patients. Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels. ENTC Carboplatin ENTCEND did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks
0	ENTD Toxicities ENTDEND were compared with a cohort of patients in a phase I trial of ENTC paclitaxel ENTCEND alone at identical dose levels
0	ENTD Toxicities ENTDEND  were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels. ENTC Carboplatin ENTCEND did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks
1	0 by the Calvert formula, whereas ENTC paclitaxel ENTCEND was escalated in patient cohorts from 150 mg/m2 (dose level I) to 175, 200, 225, and 250 mg/m2. The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities ( ENTD arthralgia ENTDEND and sensory neuropathy)
0	The 225 mg/m2 level was expanded for the phase II study since the highest level achieved (250 mg/m2) required modification because of nonhematologic toxicities ( ENTD arthralgia ENTDEND  and sensory neuropathy). Therapeutic effects were noted at all dose levels, with objective responses in 17 (two complete and 15 partial regressions) of 41 previously untreated patients. Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels. ENTC Carboplatin ENTCEND did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks
0	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with ENTD non-small cell lung cancer ENTDEND  Carboplatin was given at a fixed target area under the concentration-time curve of 6.0 by the Calvert formula, whereas ENTC paclitaxel ENTCEND was escalated in patient cohorts from 150 mg/m2 (dose level I) to 175, 200, 225, and 250 mg/m2
0	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with ENTD non-small cell lung cancer ENTDEND . ENTC Carboplatin ENTCEND was given at a fixed target area under the concentration-time curve of 6
1	Carboplatin did not appear to add to the ENTD hematologic toxicities ENTDEND observed, and the ENTC paclitaxel ENTCEND /carboplatin combination could be dosed every 3 weeks
0	Carboplatin did not appear to add to the ENTD hematologic toxicities ENTDEND  observed, and the paclitaxel/ ENTC carboplatin ENTCEND combination could be dosed every 3 weeks
0	ENTC Sulfadiazine ENTCEND acute nephrotoxicity is reviving specially because of its use in ENTD toxoplasmosis ENTDEND in HIV-positive patients
0	Under treatment with ENTC sulfadiazine ENTCEND they developed oliguria, ENTD abdominal pain ENTDEND , renal failure and showed multiple radiolucent renal calculi in echography
0	Under treatment with ENTC sulfadiazine ENTCEND  they developed oliguria, abdominal pain, ENTD renal failure ENTDEND and showed multiple radiolucent renal calculi in echography
0	Under treatment with ENTC sulfadiazine ENTCEND  they developed ENTD oliguria ENTDEND , abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography
1	Under treatment with ENTC sulfadiazine ENTCEND  they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent ENTD renal calculi ENTDEND in echography
1	Patterns of ENTC sulfadiazine ENTCEND ENTD acute nephrotoxicity ENTDEND
0	A nephrostomy tube had to be placed in one of the patients for ENTD ureteral lithiasis ENTDEND in a single functional kidney. None of them needed dialysis or a renal biopsy because of a typical benign course. Treatment with ENTC sulfadiazine ENTCEND requires exquisite control of renal function, an increase in water ingestion and possibly the alcalinization of the urine
0	Phase 2 trial of liposomal ENTC doxorubicin ENTCEND  (40 mg/m(2)) in platinum/paclitaxel-refractory ENTD ovarian and fallopian tube cancers ENTDEND and primary carcinoma of the peritoneum
0	Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and ENTC paclitaxel ENTCEND refractory ENTD ovarian cancer ENTDEND
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in ENTC platinum ENTCEND resistant ENTD ovarian cancer ENTDEND , with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis
1	CONCLUSION: This modified liposomal ENTC doxorubicin ENTCEND regimen results in less toxicity (stomatitis, ENTD hand-foot syndrome ENTDEND ) than the standard FDA-approved dose schedule
0	CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, ENTD hand-foot syndrome ENTDEND ) than the standard FDA-approved dose schedule. Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and ENTC paclitaxel ENTCEND -refractory ovarian cancer
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in ENTC platinum ENTCEND -resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe ENTD erythrodysesthesia ENTDEND ("hand-foot syndrome") and stomatitis
1	CONCLUSION: This modified liposomal ENTC doxorubicin ENTCEND  regimen results in less toxicity ( ENTD stomatitis ENTDEND , hand-foot syndrome) than the standard FDA-approved dose schedule
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and ENTD stomatitis ENTDEND  We wished to develop a more tolerable liposomal doxorubicin treatment regimen and document its level of activity in a well-defined patient population with platinum/ ENTC paclitaxel ENTCEND -refractory disease
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and ENTD stomatitis ENTDEND . We wished to develop a more tolerable liposomal doxorubicin treatment regimen and document its level of activity in a well-defined patient population with ENTC platinum ENTCEND /paclitaxel-refractory disease
0	CONCLUSION: This modified liposomal ENTC doxorubicin ENTCEND  regimen results in less ENTD toxicity ENTDEND (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule
0	CONCLUSION: This modified liposomal doxorubicin regimen results in less ENTD toxicity ENTDEND  (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule. Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and ENTC paclitaxel ENTCEND -refractory ovarian cancer
0	BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in ENTC platinum ENTCEND -resistant ovarian cancer, with dose limiting ENTD toxicity ENTDEND of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis
0	Phase 2 trial of liposomal ENTC doxorubicin ENTCEND  (40 mg/m(2)) in platinum/paclitaxel-refractory ENTD ovarian and fallopian tube cancers ENTDEND and primary carcinoma of the peritoneum
0	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/ ENTC paclitaxel ENTCEND -refractory ENTD ovarian and fallopian tube cancers ENTDEND and primary carcinoma of the peritoneum
0	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in ENTC platinum ENTCEND /paclitaxel-refractory ENTD ovarian and fallopian tube cancers ENTDEND and primary carcinoma of the peritoneum
0	Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary ENTD carcinoma of the peritoneum ENTDEND .BACKGROUND: Several studies have demonstrated liposomal ENTC doxorubicin ENTCEND (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia ("hand-foot syndrome") and stomatitis
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary ENTD peritoneal carcinoma ENTDEND with platinum/ ENTC paclitaxel ENTCEND -refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary ENTD peritoneal carcinoma ENTDEND  with ENTC platinum ENTCEND /paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks
1	One patient developed grade 3 ENTD diarrhea ENTDEND requiring hospitalization for hydration. Six (12%) individuals required dose reductions. The median number of courses of liposomal ENTC doxorubicin ENTCEND administered on this protocol was 2 (range: 1-12)
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/ ENTC paclitaxel ENTCEND -refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks. RESULTS: A total of 49 patients (median age: 60; range 41-81) entered this phase 2 trial. The median number of prior regimens was 2 (range: 1-6). Six (12%) and 4 (8%) patients experienced grade 2 hand-foot syndrome and stomatitis, respectively (no episodes of grade 3). One patient developed grade 3 ENTD diarrhea ENTDEND requiring hospitalization for hydration
0	METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with ENTC platinum ENTCEND /paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks. RESULTS: A total of 49 patients (median age: 60; range 41-81) entered this phase 2 trial. The median number of prior regimens was 2 (range: 1-6). Six (12%) and 4 (8%) patients experienced grade 2 hand-foot syndrome and stomatitis, respectively (no episodes of grade 3). One patient developed grade 3 ENTD diarrhea ENTDEND requiring hospitalization for hydration
0	Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and ENTC superoxide ENTCEND dismutase were determined. Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed ENTD cortical dysplasia ENTDEND group
0	This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous ENTC melatonin ENTCEND upon cerebellar BCNU-induced ENTD cortical dysplasia ENTDEND , using histological and biochemical analyses
0	Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of ENTC malondialdehyde ENTCEND and superoxide dismutase were determined. Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed ENTD cortical dysplasia ENTDEND group
1	Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of ENTC BCNU ENTCEND -induced ENTD cortical dysplasia ENTDEND
0	However, the bupivacaine/placebo group reported significantly more ENTD pain ENTDEND at 24 h and ENTC PGE2 ENTCEND levels during the first 4 h were significantly higher than the other three treatment groups
0	After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 ( ENTC TXB2 ENTCEND  measurements. RESULTS: The bupivacaine/rofecoxib group reported significantly less ENTD pain ENTDEND , as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h
0	The differential effects of bupivacaine and ENTC lidocaine ENTCEND  on prostaglandin E2 release, cyclooxygenase gene expression and ENTD pain ENTDEND in a clinical pain model
0	However, the ENTC bupivacaine ENTCEND placebo group reported significantly more ENTD pain ENTDEND at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups
0	RESULTS: The bupivacaine/ ENTC rofecoxib ENTCEND group reported significantly less ENTD pain ENTDEND , as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h
0	However, the bupivacaine/placebo group reported significantly more ENTD pain ENTDEND  at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. ENTC Thromboxane ENTCEND levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1
0	CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENTD tissue injury ENTDEND  which is associated with higher ENTC PGE2 ENTCEND production and pain after the local anesthetic effect dissipates
0	After extraction, a microdialysis probe was placed at the surgical site for PGE2 and thromboxane B2 ( ENTC TXB2 ENTCEND ) measurements. RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENTD tissue injury ENTDEND , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the ENTC lidocaine ENTCEND placebo group. Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENTD tissue injury ENTDEND , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	CONCLUSIONS: These results suggest that ENTC bupivacaine ENTCEND stimulates COX-2 gene expression after ENTD tissue injury ENTDEND , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	RESULTS: The bupivacaine/ ENTC rofecoxib ENTCEND  group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups. Moreover, bupivacaine significantly increased COX-2 gene expression at 48 h as compared with the lidocaine/placebo group. Thromboxane levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENTD tissue injury ENTDEND , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	ENTC Thromboxane ENTCEND  levels were not significantly affected by any of the treatments, indicating that the effects seen were attributable to inhibition of COX-2, but not COX-1. CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after ENTD tissue injury ENTDEND , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 ( ENTC PGE2 ENTCEND  production and cyclooxygenase (COX) gene expression that increases ENTD postoperative pain ENTDEND in human subjects
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENTD postoperative pain ENTDEND  in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. Oral mucosal biopsies were taken before surgery and 48 h after surgery. After extraction, a microdialysis probe was placed at the surgical site for PGE2 and ENTC thromboxane B2 ENTCEND (TXB2) measurements
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENTD postoperative pain ENTDEND  in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% ENTC lidocaine ENTCEND or 0
1	In the present study, we describe the proinflammatory effects of ENTC bupivacaine ENTCEND on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENTD postoperative pain ENTDEND in human subjects
0	In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases ENTD postoperative pain ENTDEND  in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either ENTC rofecoxib ENTCEND 50 mg or placebo orally 90 min before surgery and for the following 48 h
0	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENTD inflammation ENTDEND  In the present study, we describe the proinflammatory effects of bupivacaine on local ENTC prostaglandin E2 ENTCEND (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects
0	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENTD inflammation ENTDEND . In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either rofecoxib 50 mg or placebo orally 90 min before surgery and for the following 48 h. Oral mucosal biopsies were taken before surgery and 48 h after surgery. After extraction, a microdialysis probe was placed at the surgical site for PGE2 and ENTC thromboxane B2 ENTCEND (TXB2) measurements
0	The differential effects of bupivacaine and ENTC lidocaine ENTCEND  on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENTD inflammation ENTDEND
1	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENTD inflammation ENTDEND . In the present study, we describe the proinflammatory effects of ENTC bupivacaine ENTCEND on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects
0	BACKGROUND: In addition to blocking nociceptive input from surgical sites, long-acting local anesthetics might directly modulate ENTD inflammation ENTDEND . In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects. METHODS: Subjects (n = 114) undergoing extraction of impacted third molars received either 2% lidocaine or 0.5% bupivacaine before surgery and either ENTC rofecoxib ENTCEND 50 mg or placebo orally 90 min before surgery and for the following 48 h
0	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by ENTC trimethoprim-sulfomethoxazole ENTCEND  resulting in ENTD cerebral anoxia ENTDEND leading to permanent damage
1	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing ENTD hemolytic anemia ENTDEND crisis induced by ENTC trimethoprim-sulfomethoxazole ENTCEND , resulting in cerebral anoxia leading to permanent damage
0	We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by ENTC trimethoprim-sulfomethoxazole ENTCEND , resulting in cerebral anoxia leading to permanent damage. Magnetic Resonance imaging revealed cortical laminar ENTD necrosis ENTDEND in arterial border zones in both cerebral hemispheres, ischemic changes in subcortical white matter of left cerebral hemisphere, and in the left putamen